<SEC-DOCUMENT>0000882095-23-000017.txt : 20230503
<SEC-HEADER>0000882095-23-000017.hdr.sgml : 20230503
<ACCEPTANCE-DATETIME>20230503160640
ACCESSION NUMBER:		0000882095-23-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230503
DATE AS OF CHANGE:		20230503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		23883698

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>gild-20230331.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:c106b7c8-2bb1-4b42-ab62-c7781606086b,g:b0acd2cc-13f9-458d-8974-066f309efac0,d:78cdcb1572754b6c94699d07bd7f2fd4--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:gild="http://www.gilead.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF80LTEtMS0xLTI2OTM2Mg_0dd4da5b-994c-4fd0-8e58-e75b15e06671">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF81LTEtMS0xLTI2OTM2Mg_296ae9f7-768b-4817-a512-850e849f5d7f">12/31</ix:nonNumeric><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF85LTEtMS0xLTI2OTM2Mg_18b7c8e9-387b-4714-bf9b-1b81ead51b93">2023</ix:nonNumeric><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF8xMC0xLTEtMS0yNjkzNjI_08b0cf5f-87c7-46b5-8ff2-26b973746641">Q1</ix:nonNumeric><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF8xMy0xLTEtMS0yNjkzNjI_cd317410-055f-49df-a316-85c5f55a97c8">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26af3e763f447f8b473acbdaab865df_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id5b99939368b46f298d75ed65a8f6ded_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia4e928b3ebd744fc970718834da3534a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic500805e8441430185668274754bd251_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c45e712edc45518e23cd00b61fb12c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a67c68bd87541d7b8aeb32a510dddfe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2a96fc6d924f519f7d51951f05ff10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i093edc5755704a77a5d407997e7193c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca3647effb04f2ea342c2cdf2754864_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4ed4a6dfc4488183b0a1d002929bd4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624da2b108014e5d9432f6660170cd2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d7c8a4a8ea4f46b59abb6bce9ebca1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e6d18dd50a48cd905a0a5c55031f82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754e1e540f8743189803095cb0207810_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43db347832e437da36ad93d501ee972_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2117194be2466c95399cea80f46988_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e727936efcb4ba8ab5f6da9a5878ef5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd710db690d4726a106486c05547cc3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81eccef1dab414a9b030474788c13c4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba0cff47492f4decb13158e416e6a4a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if725c7c7814e4cf4a3317e39e252bdb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a853e0354f546ee8636eb887f31fb19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86bf5b7641ca44ddb2ad53d7bd36d254_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926df607944244f1a8641e0053d1d3b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i950969f530e94f1395cc3b19fdc321a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c4fc949dc9b4e8da603b9bafd8f0af1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49700eb36c934cf4aca1f0807d4295a8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief6b15b37c004ae0aeeafce457d5b708_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3dd718f446d4121a028b08422617832_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c3b3b01542f435fab6816bf508c9fe0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf32ea5502c43f99d1ebd15aff8ab22_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42aa0aa14db49ed9e43dfc6d3bb5d7e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70473ad0789b4b03b86eb8db467a296b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c694f02592405083bdaf13c4316671_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d19c32e455643b7b05ce940c7be0801_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a53598b2a34113a51cf1d6114c3cd5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4583fc82b7754ac98fc2a9af1773de2e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie597530e49e3466db13821646fdb7c32_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ab2be40e2f4be1931d2379972c1dcd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5290416165d4826bca76f94fb4de05d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b086ae57d3416c93424778ee7a4f09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db3222bd3a24a5792f21001e0ed9f4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b0c18878c845d39d2faca137c3daea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1f35c3663a4c68be7e9d1d6e2fcdbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43b59bee267497cb6c22732ff724eed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1d0155e0d845058e2dd8f560ef7b2d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a40544f07842abbbd26abe8bd230fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95cce301e0e44138eda0e51e00f4923_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i542b657a0c2744368808c312bbc5c2db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d4aaab1fff4ee3b95ab9943ea6d302_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67eba08e27714767a82df70e121e94cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d65f9df40f4dd5b0c639e53db4dd9e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee89668eca8340e4ad175cab099b67cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ad68b551814279bf5718118b152459_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee012c5d38d4893b3cb19e18351ab58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5d8f1357d074b21a89698ec5b723bea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58599254220a42feb444edc701be833b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b4e751a2264ec9bb98b846928280c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e42fc11fdc540d7ad0245cb8d39d2e2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41bb316ef34b4eaf906de30392736fed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df3944f730544d1996bddf0bf5a8db4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf12dba5416c42248c844b94f20ca082_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc3f768136e47c0936791b4392b8289_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666aecd5c047480a9babba6ea8039520_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d8b014f89141aba79e057fe12638a3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a79f1e6c45d4bb897c9a98013083049_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib04f6c7e78c647b1807546ae78fdc62b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50a21232d20463095b52d48490cc6b3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997dc50c936a478aac1cc176a14d9ef9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689fc87158304986aa89fae3a01ed245_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91e1f772d34742e8a8d2a4145828b021_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771add6d73314919a6dd20ce750a969c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c19b71fcc4402098fe7a9aa8fc8eed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010418975aea40d895ec2686ed330d28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450d6b2c88a24625a9c496cecdc5bf52_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7af1b22c3f847fe9bdfc0f5f119ae02_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3a66e75c7047d3aafef3137fa6445b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bdbd845c58c46e8adb8c44ae5684498_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591c01bce34640e58557c165d695cf0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6494ec78b3ce416bb07ce891ecf80d8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6b130e3bfb4d008f422f886fe3bc7c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56aa7d6f82f411ca07a2196837c3857_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792f4398c7264a34bbfbb2e0141d0569_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36284b9953e94a87b53a58bccfc5e336_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36cc56c685bc447bb351b98590992488_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086e12e3ad3e4741a380acf23831618d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30546a0c6b624dac91f3b66455061d66_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40dd460e84042629c0071805ed4729f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic729d8e783a647028632b5ba40064638_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ca1b72c6804ecbbc1b605f601091f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dda79e450e447408d931455f2f8f8cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b399c95ac1b4246aaa5c0aaef8cd353_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c92a43cc92a47a6ab65bfa263d351eb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf7898842ff5448ba66ef0de574a341f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344ba46eb7a04d56bd7de76ee16b62fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbe81d744b24ac3aadfd0def0c3af1d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b6d840cf5d4035a31088c19454672b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06a18873aa0490ba83b5bddcaea2946_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0b6766fa594a13aa0be791f84893f3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e710d7e374b479fb14aabe9b50fd5ea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd6c3585eea4f94b84aff749f526ac8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37160460cc94423a6e38cb49e84b00a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i458cd9c1bb9a44bab1804ab82add9ef0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d671c5a402543c6bc98a00e54b218e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78556fab5a594eaaab678aa5b2b70c92_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f7ccbb67b3412d94eb07273cf08f82_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6292c28980b643479da9447ce2a9f473_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21dec2a2b762423e9ef5905cf0aa9cf2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603cb3b83ce14179bf04d0aaf6a195a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f30cf0bd3dc4f13a115c97982ce981f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd48e1d614c42f89931926809fc82a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7848b323c65b46e5a5d0b843644615ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedfb95b671ed491e8b70938724cb0c56_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ccec38bc81487a98ac2ef0ac2fb11c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9988c03dff4e4d05a5ff6badc0ed5ccc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb5ff7d45f6422e846f8796c101b1cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic00e734d3ce3408487ef17422e54a433_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6054258e4b146609392bf5d13038e6d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f67ef40bc148158d12ec2015ed480e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571a1be950c440d789469a2f4d9abfcb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea41115ebe564139a2c8659237f58346_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25c20fa74df4d2ab27b7cc2ef3698aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a272399a10347cb814cac2d9dfd148e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if463eff382504416bd3b435b029bab84_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad37f88a40ad417181970ffd6d38fdb8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6291bcbf7f7c41b98bbe26c0e03a3cf6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e10e1edf06747de90b02b2363965434_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c62a110af374a069c05307a70eb674a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05d7b2dd54e4758b222f4b9c96c8dcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4fd84ea511b418294dcc7d568645af7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ff71600e3d4a11b42b8372471e63e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4043b3f894c487facfbfa869ed06140_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da02de1bdab404c87ddd583b9eebf85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic846202eb035474a90d6bbdfc1b15217_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbbe48385584bfea6852686c3b019de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a4c42583664db8b3c33c5f299a0f4b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if951dfcac7744054906c5125f638ce21_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5cc2f2b76bb4d9c97bc86237986d9bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ebd3767145342f6b367a0b7f6f1a976_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8bda10becdf41afb4989abe63dc2011_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4101dba088994abcb8f4d35c5096da8e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd92b5b8015467faac7b2902c0e722c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee92c1d69fa4915a73d1e059bcc2f3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d037e0f2be44b11b472e2b6432f4801_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f9879159314fdbb7fdea07bdf585a8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie367458dfc7842fdb07fd2fe4e10fc1e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d872aaca9d40a4b6c2a27ebb8bdf10_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8284ac9437543ccbc0d3d44daf70792_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43370509bfb4a8c8dab8123e63ab0c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06a6eb489854930ae0def7cc8f416de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ab588f4a7646b9ae2305375fa5467b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f37487da5e349a4b9f9f387d2dc5398_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3bdda941ff4e2aaa037ade8321f098_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee659a3e712243d09b54e37ca804067e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94069cf576394220a168bb924848e1d5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75383c9367af4d9d8f8715d238548742_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44a7f7348754553ae0be14f2f11c8a4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie934396b4aa24066a63d81e4824e6824_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia825fa36f2c54e59a199832f003b73a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c70a0df7936466e8f48c9d8037878b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66dde11c9ee7473ea0df48b2aaacf03e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1bbc6a669f486ebe51bb1dcae67739_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0905351e17b64009b3bd40c0e79e555e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ce5f719ea84854a0b758397c95d01f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3479eb78982346cc9b440b90ac343bf9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510d0822c2574545adb8841ba008ce9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fdc21dc65e4d558d42514d101c97b7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a865d0fddb8445cb031590f0a02a80a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22aa3af8d494dc292b57bdf0cdf041c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86087bf8b37a4b89acc6817bcef8e756_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf24591ef12a41fca5174331a00cbb13_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb45ab67b990486599a343f8415ee905_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id752540ccedb480fbbb6e2bba52c34bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc42e0840ef141c5b3850d98173d4730_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d455cccf9d4832870bcf4419271ea9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f80c600bf04228823d182e0cb43b1a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1b8b9d99b04cd189bf897215f84c36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5869ea468ec4ca5b87ad1783a18dc9d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0580a54e234bf585f865b90a530189_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54593f03c1114400935e76093c34b8bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13b67d77f6f242b0a1bf8ac4155be76a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba94b3090254d63ba7bd368d1a8f7dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a201f81fa334729abf7031166fd5577_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie743df4532ec46c6bec9c152ca1030fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37473f0485a746938a7f26a2dca59cf3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica72aa2509b04035b02393bb3aea5e1b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ebfed05406413eaff961e952191aa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b45a8b90a848269a2592fbe0b8c3ce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d3312dcce0438cb345232fa7454979_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0934fd0075be4cd6ada897ff651ce8db_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c40a0615861452596fcb9aa9d86e704_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib500e8ef8aa84616b40a2191594114a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38ddeb60ee2443f956e770d097710c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie640715ca03a42e99d7cd895fa05c7b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652bed5b638547f9898ab03fcfdd467a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7dbdd67bdd453791f731cc83851f41_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dfffbb1fb6e4e8ba4b2d0adc6f90600_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97d2219d4e940e8872b33598cbc3523_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe303d4e215044fa92f72f822bdc870e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad5d36685f64582b233de7a5239d698_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9ebab0b3a942d5bb672c1ea1985565_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16768b8c0bd467089b916f0150aea2d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a09533ea02b4970830e57cb8ed16e29_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfa66c376de4d50b8d621ce7a69fd00_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb6838b754224e3ea3f49755cfe56353_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257a0e1302984795b9ed79cd7d56fcb6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib68686e7167f4cd88f12024feac41469_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824131aaa9e9438885ebb6c2d9d58420_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97befe6960ea47c09105a9d2792b241c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743bad3f631549ee9b7e3300a3b32478_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d9b52ba975f47eea73b114711437ee0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia99677732ab64aee9be9eb6c9b9c5297_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ccc5abc96549b4a653a8ac7248fcf8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d5d887661194281a92f5d47aaec6008_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70bf852e632a47e287a6514f25d2979d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f4a76252494b24bc1f179124aa3124_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9560016efc024c89af4afc6834f04bbb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ab8727efc14325bd00acfb911c338c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090c47f3a0cf452181e6d5b006c0be6a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7a471ebca74147a9b0d6e1a6089d93_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8185dc8b7344db9a1038babf06db22b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59f825423194376b8da82fe0cec886d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324e13105ef44547bab1c5e86c934957_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e40c5875114f3cb760a0d82117e6a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f9f3277ed14717a540d49002edff04_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8748476ff814f45b9ccd6e290667fc9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f8220ccfd0447bcaabd55458b891968_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9a86b0b2a84281bb61ad1873a15c2b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if614c6aa1eab4885acbcc73189da7a93_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i278eb945039342f2a8bda078049ec2e0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40b401de87f42519456da4227ef431e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie855dc4b080941e6be062405849ca9c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d547a3fe84543cea7ac0386bbc34d72_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54cccadc5c6b497ca5b1f30e89955b7d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c6167454744e0fab7410239683ab45_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d9606c89db437788fc45ee2168e4c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb18acf634f467aaf5cdd7a65b62981_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia581f9570a6a44e4bf717b04c2b68cad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i447d2250e1b9434a90d57aa2babd8a63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a7971fda6a4d1cb7a5b0c93dc55aa8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63020427351e4e01a6c232cf97913837_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e51316888b41cbb03d3ddfc57bd840_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74791ed0e7b346e89fd234b7be9699a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc4e4dc9bea4ec58fd5ff7790b0b8f8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d418d346974c1fa0c17dcfcaead0d7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfbb92a2127b42db9046b0b7ec4dfa6a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809de751ef2f4f78b9b8f68cd8b8e109_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4daac1a0fe9747d9bcd85f6d82586020_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42331a4397a48faaaefc64df2f413e2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28d2efd45f141f6b1f1fc7d243542f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755f2b30cc6e4fa993c605e6808ad1cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i677d46617baf4cfc97770f40bdf350eb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i996bd5bfe4d44d25b7c4bf8273caf0cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb8a2eae2e8547a5b670d21ca58b3fef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823bfbd777c846ddaf6555202b8a7351_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b10cde4a9524c0ca62293060948f483_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie41089e89bd74f35ae3f87c7a56e2a19_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696fbe445270452f81e087d1fa89fe11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae81192d9324630ba4b365d1cddd5bf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie33f4fdb4c494428ba2b4a99560b4e08_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709a08a357b14493b12bf32a458f6f6f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i710096d16b5642718cafb5a22d815d0d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ab8aec39084c4eac102e0706a4b80b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9e5623132040899baea9cd2d5a764e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3092cbdd04d40b19aab266dd867a766_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib976d60772b24c27944ea6b8d54d2d67_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113772172baa40a0b615da596117cf5f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7656db9d0049259fec5c0b61f4a692_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79faa34465a4d6aa155b887531a618a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d5861845724cc7b45b2421fadc72b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c53f8feb0a94f6491489c44593b168b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f19798d09f947d2a629343bde19e62b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a4176549214367abc167a2ec593abb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978f5bf8cd9d416190509bc5959bef0d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a5ba2a8a1540749ed46ae7a6ed4e6c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ea35337c87402dbc1082ebd607e554_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3374213965c34c23a79853f9a29ba6a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7caa2c5fbd246269301ab23ea219e18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c91b5b81b3f49cc99ed4d965e15cb05_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb135539ed644e89e8a56f37e4ba61d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68170415b25f47b08de05015410863d5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6849a5ebac4c97924794143c774f0b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c99b6a3f2a472c83a2fa839f90b5ea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f79d1cff43c43df82a4363c05362740_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic87bba42a74544ebb4ed1b2216e3f687_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic7c4130e03624fd8bb9980194f507734_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida6333a62e4e40e5ac281c56d97e63c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1daf12df0648b786b4f70679a69ee3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibffab27044b141ed8332a4acb0c26f71_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a637640e90643ad807df7af76498cb0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67a08172f4f244a79d2b394f399f8b13_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40005adf52144ed85b05da90b6d2139_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a00bf2652604fbcbb4da1bec40896e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad1222097c644f09b1a2dccc64bd3c4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd34e7473d924c328deed5a6ccdd4afe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298a129b64b84c158f7a79bfaabebbd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic015d372c6774949bc85fa263970366a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6548e7eaf5d34e378990fe5c8218b3a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56bec9c2c9449778eb81057ceb9299b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2a9da409b6496bbc57ceb63bf60484_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4458d1d12cea4625bc7db11da9a09beb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070c48e01f814ffd907a7fd8f6047117_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c206f3d17b44385898e7a9f69b7aa12_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4efb718dc0824ded809922f135d14f72_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bac2a669a64335b1a9e1e221e2f25c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26e1c0f325d4ca1a67fba9811c45fc9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b123dc510a43d8802b50cccdeedbf5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c59bdf9e624122b0025c13c8932d5b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6307387519504abc927afabdd827d0b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268af442ad9045fb9d0047cc8514e705_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58be9bdcf7e4accbe91509935a9f362_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9741f7ff7a4abeaf85943e5f22418a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28bc6923927495f8c985d0973d926f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858d8c032c1640b58d8d8f45207568b6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7955dfb43224407190574461d49d9540_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3fc36306554f1bb30285803dfe875c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5eff8a38aa425682a7f90c9892125b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice046d59307c4fdcaf4be021a9c9b7e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca4682777694e579dd8d81c0230ccb7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i840cd602edc14d1cb641e5ee8c6a8fe5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea63a1d9c8d4b34a96c93940d35e22f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaecfcff27fd54e13b0ec19e65fbd5d36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41faaf40d4ef4d49b113b09bc17772bb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a8d5247fbb40ffac874f473b0f297a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e94173dabe647a398189e72561ab576_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1afce071943b4d26b76439f3846f3a8a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d03adc29c7a4123ae502213f7338c96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ab2341ad8e4ff6b616f6930e3a7edc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d8a928fd4e43259f12d46c9b3dd925_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75af3c4962e045198fbc3aa6ec6a75ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf023b197aa4118b56f642584f72530_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03efe7c49cbc4bdeb65025a874918ba9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17d4fe5710248bf903fa448d86c0f88_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fdbabb1243f4e86a5376c9000522492_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729aa6a63477475ba65321969802f159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2cff82341c4dc0a251e15da3bf13c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd142e2bf3c46ee91f4326b178cb28a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1426c184f5cc47f8aa80bfe34a607cb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2661abbc964a0784a010dbe6cc0fc6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id531a955cfb3413a82cad523850c21c3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia788273cc08946368efc543494d4d4e7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70479b2efa064ffe8d5a4badb47ed829_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcb1b9cdaeb47dca59a07a6ce2025fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f350e4b39bf43c491eedf1e18c2f29f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f658fc7bfbc42d1b7319bf162b933e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fd105c3a34541189ed7853f9bdedb46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d38171e17734505bf300a4f7261bb9e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed5c2cce176468cb88406a4ef218eaf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a26bf538c9e4b07a3f50fa63e16c09f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194f48cf31ad4461966915e642a9d349_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937e321648424380aac9aa46560540c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i364fe131316c482492c686531f316415_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09c87dcc4754dbaa6d7f3f7aff3a559_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic272024b44504e08aea2aef0e5cdce3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a0d1c94992b4e8985f62b27d61769f9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38fae61cd724739954724cab1029f06_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db06db2f1954bfb84f43e2df4db34f3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3c224d5aabd4662bf6225bef1d6c8ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087ba3741afd43baa98b28ac94fd7f20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4d3507260a4b689350205f27a8e97d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8939a2992d04a64a5ff7980f5f17203_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65251199ab8d406ca23824a7b9f69f93_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6234e16f3ffa4f09aa53750804bbe37b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2b1f2190c1428e8e5a1008b1913d19_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id26d3f89e113495fb08196ab4d44bcf7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6cde4baccb455a8d4849e1ae54b485_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d215506fdb4ac9b9fdd8a1a8900a0d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7611b09e98a14f48bbd2f62d557253e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i001dc783df3642e1ac6e1ae958df97e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic063218f12c54d03acf4ce07c47d4275_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe5e217a5b1140728f4602157db87e2c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b9f0b6b0b844305a53445354ae194cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib183b8cea0954d138ad44af200a84877_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ee26b0e08842a0b843c4ac42a50e93_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1d8684d26247aa83ef85ca707fbd8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d573c781b70449f9e9416cded0054a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic05635ce202a4083958412667e099ed2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b368b49d37a4ee69978906222ce4b5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86fea5742d1f445d9c563566784f0cd0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ee5a60fac74d60b76c288f2df853d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a06827286fe4c8183a9be9be74fe8f4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ac4e1620e6498cb5b443b7ad7d32d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bda1d98cbaf438cbb28ebe26c09665e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id927ab0d29884827bea7bcaf3d2dc398_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dde228737e648788d98fb2fc1d4ac58_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df8c0d093bf48b2b63cba32a6131249_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e78ed5854ff4c45958a4d133cd9890a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1f122ae8f14eae930697c79bf7af6d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69013ac8af5f45c896d0e14dc6876b0d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i825aac04e24b40208c807dce228c07fb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedc3b620a74946d7bac3bf26a9c4ce16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6385da92df654fb6967cea6114292f4f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb0e9387655417ea47e244e390930c8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad78bf4198534e099b1e1e8624534d02_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34a910c12f414900999d3b059f396d47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f1f58b1a04471faea6d3a37e5320fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0463a71817c4cca9f2913df58ccc458_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6d5fe3d48b4ebc8612932358fce8e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dcae5f616154d2bb06f9c392d252555_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c466bd362f400780c77e751afc2c34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800882dc4b244976915f007c452e0fe6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i064e703fbfd049878de89e2a1c5dc621_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c191e188eb0435a839aff2e83dc0b7f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfcf3730e7494e1eac9bdd409e112df2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed3bb87a65d43c99c02e4fc37036b3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1daea506fa054411b9fcccb4c301cc61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4162868d814a43e3aaf697b3f77e900a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i05b4776cc8f6409e92531b2b339c0031_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7670407a0204455084b40c8717c401e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb395164c844896b27f93a01db7e27f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i821c4ec6a7fd4cd4b53462e6dc41da64_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b15ded1f1714d829d737d7f8ba59153_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5beeadbee5b426383f472cd603bccb1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bffbfdebfe4c0a8714dfe49168e8a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f93855d6db44024b333d78df947f56c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97bd7f721914df1bcf6152d4c3d17b4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ecf657b38947f592054cba9b58c1a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a2868046c1c40f5b963d0310b6e2c28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2f1b96e4fb4f3689024f243694c650_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d45d1db32724a06802d1990305aee2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f822206ae424d6e8263029d09d73dd7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4044808fa02946568c1a7cda0f2b4105_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59af451f1a45414e92cb058f5ca094fb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5fd9b5b14e74c698f0940b3bf03463d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416dc4eb70914dd983bc1a04995857fd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied61cbd6414f453896de669cb79e2da9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9f4eec9e644776964e5a8b7a54bd46_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2e973c5db44ac4ae316708dcf05f82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510d5f78872c4535851a18295b4f79b6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ee9e4a34394e0981b4f0da01de2965_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87e5e8c32c24d6b861c84c1383d9257_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3d373c59d041b98c7a3bfed37f67b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba2356957a154f63a357aa595e78976a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6343117edb334debb880ca01f650cb9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic51b601fb20040c198873c13a12ac3d8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc9e7315e954128826864d8f2720166_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d904395d75449c6b4a29ead472571b4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d6353ae110f4676995da4b3e2534756_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5635d77dfe96415b8fb073a7a5cea4f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22760aef3ef40599b18170cf792b16b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i711389022cab421e9b3754a803e7423a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5acaacfcea4242ec9bbcbe69b9091425_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0206d1fc4e7644e2afbdb52420fef11b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i725217d7109d45ce87fd002dc195f7c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c6fdd16179f433088b6dc239a41cdd7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5853354bfe4cce8964c6ee51f3ad72_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb59ef088a34337a2c34aded0358835_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0273ef720045479f9a269b27d3e723bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b209667eea74724a7b9275aafea9399_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4ed3db406545adbb4af3cbdee68817_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f7dcb7986040429aa8c1583d69150a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7080bfe269540189101c2421e6675ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c00e7d8b1e4ef485fcb73e58436bd3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib882e81dd83841ac984af47ed8b513e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644b5cd4730b4d5982cd086b35235aeb_D20230222-20230222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506cbd3ce6ca465992effd4d69548672_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59389bcaac841308152584683c981e2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e7f985abe641bf816e52117d2bceef_D20230130-20230130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-30</xbrli:startDate><xbrli:endDate>2023-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7994adfb551a4093b62e6cfbc11bfe49_I20230130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie49fa68b1f2d482184e980aaa5e1c250_I20230130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:ArcellxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e1c0e3aad754d999d54e43dd7074379_I20200619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e84714994f54c519010f82389507cd7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d20ca09d0f5459abd1fc754af94d026_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6461839ec90348219c82e7f40c41cfd5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b6da4b585b4321a7ec80b7967fa580_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5526c08c2df4105af84704e07402cc8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9a928007a34088ae330d4ec7c5a37b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb30d25a05de4811a48616e9e844ea50_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30ff5746ef9a40388f4773379f847193_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1ddf57d6b34a6583488abad14ff60c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b40d58e2714e7ba69b19c7555c6750_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875d511da18240e9bc3567ad24abf2e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c429589ccdf4bfea176e02c0cac635a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if70af8c6a10b495e9247a23a7f7601b0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00d0aa9e5e94a278cb25a17dafeb1d9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263db7dcf6884988a0e0a6b78d1e1a18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52e3a2b0b3f4d21893074364d38ef63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399115e8a60144f3bb971ed4e82ff382_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4cdb4878a34e009c969cee15e38f5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de5de081bec4dd18128468f84151606_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9f2ddd7ebd4003a278244a23a11b71_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05fe8e63eff3469cb53503276158f5ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f13613183647b781938b7084edb764_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica3992c52c804cb987a0221a71af7bf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574633526e804738b0b65a58c499de43_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1126acbd5f41e5ba02e34d7f3b1994_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61611069f0d34b499f897eda986a5c12_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b010acb61941da9f9b3702c05299d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03775ab216e04b35b7ed6670a04e0399_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if226e46e81434b4fa5ad7d3f0467adc3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32affe91c7174503bb23d6ad77cb2f0f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89771330d55c448a92e44362a44f16e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe06128b3294a28a03f9d23d916dc3c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i088891cbdf314ce6b8fcd496558912a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb55cd4308343798ee15ab28060178f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf624d97eb3d4a40934c3c494fa763f1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169f8c04a26a42f5a0b60374d9b36c86_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e24c0141fe24d3d87e593b121853912_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf82b9ef3fed489896bcbd40c4d57784_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d81d540e4094ac484768eedff9edef5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8c353412dc437b91aace4b203357c8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b148329838748f6809e967fa7b82687_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d46f8e092244b26b34a459dc7f0c882_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c2aeb4935e4346aed2bcc659b68b5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbcd186911f94c619108ead92cb447d6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9297445f1f41d294ff95f5471d37d7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f118b76b09d48e4b614386c5bc45cd5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4ae268d228410b823829d0e1ed0bef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1142e4972ea45ddaafa04ee35493867_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63c8bcfa26754f4fa29fad75dea0ebca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc0d81cbb4140808a9a1e24ab2c3d24_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i945f98bdf3c64038b9ab71e096b3f268_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia87974f636664eaea5bcaeec0ab40f90_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1572140a5a8d4e83a9e6933296251621_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95602d00443e4029bb73f9109ee2f243_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed4f399902a463ea3fcf0a543273745_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f7c7fd53cb943fca75d8a9cca2d3665_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade8a85e37a04d2dbacdbfd5cb15f536_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091813ff4b0b4bba8dd45fbd21ee9c90_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide79ceb5e2244413ba088809663b461f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2273e9e92d64f43ac4633c496068250_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6515a317e7e49bb958a7c1cfb861802_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018b9520570d4bdb9a852a1dc0a67292_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb2412b199c42529e8362b7502e548d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c75b45dd0b494a9413038b43d87195_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88176a5b89454f6fb32288e4abf39fd2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7036db910ef7473694d4dc36eb796a6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708772249eff4b8db077ea95cb4df25d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d94e60ba65414383aad05e7c5d0ac4_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gild:patent</xbrli:measure></xbrli:unit><xbrli:context id="idcf147879c32413c88dcfab0f196e448_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="opposingparty"><xbrli:measure>gild:opposingParty</xbrli:measure></xbrli:unit><xbrli:context id="ie39ed308edf943f8974b315e8b36ca06_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>gild:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_1"></div><div style="min-height:33.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV84OA_3bc537a7-e1cc-4fa0-9db5-afcfad7330db">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6Y2VlYmVjZTQwMDI1NGQyYWFlMDYzYjJjYWU1MzkzYTUvdGFibGVyYW5nZTpjZWViZWNlNDAwMjU0ZDJhYWUwNjNiMmNhZTUzOTNhNV8wLTAtMS0xLTI2OTM2Mg_125bc0ea-1239-4479-9099-6b8c3359687b">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8zMjk4NTM0ODg1NDEy_d036f438-6de8-4d88-b1e5-754329a8c113">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MGQ1MzcwMjIyZTkzNDg1Nzg4NzEzNDVjMzZhOTVhNmUvdGFibGVyYW5nZTowZDUzNzAyMjJlOTM0ODU3ODg3MTM0NWMzNmE5NWE2ZV8wLTAtMS0xLTI2OTM2Mg_aee8c215-1b7c-430f-87be-606839b70f79">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the transition period from ________ to ________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8xODI_92350493-15b2-46db-ad86-a94e0c5b3960">0-19731</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8xOTA_dadab7e6-8fe8-4dae-938d-cd912eca6d8a">GILEAD SCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6NDE4MDIyNjZlNDNkNDBiYjk5MDI3NmYyY2EyYWQyNzIvdGFibGVyYW5nZTo0MTgwMjI2NmU0M2Q0MGJiOTkwMjc2ZjJjYTJhZDI3Ml8wLTAtMS0xLTI2OTM2Mg_6ad2a7c4-f5cd-4b8f-a120-d3f674bd24d8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6NDE4MDIyNjZlNDNkNDBiYjk5MDI3NmYyY2EyYWQyNzIvdGFibGVyYW5nZTo0MTgwMjI2NmU0M2Q0MGJiOTkwMjc2ZjJjYTJhZDI3Ml8wLTEtMS0xLTI2OTM2Mg_ba157c17-d165-4a02-94cb-e3244cbb6d41">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNTQ_880d42c4-8f68-4648-8cd2-459fb0858d4f">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNTg_d900207f-d1d8-48f8-b06b-6856d05c5b29">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNjI_de0af112-da5d-4cd1-943a-3b201997b6f2">California</ix:nonNumeric> <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNjU_98a3709c-7bae-443a-bfca-85af6a520703">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8zMjE_bb9fefd9-678d-4214-91fa-be32c5f12525">650</ix:nonNumeric>-<ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8zMjQ_8d44a737-ce9c-4205-b5a9-9a6dae3b38a0">574-3000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MmUxZmZiMjQwMTE5NDQyMzk3MjA1N2RmZDE4NGQ5OTUvdGFibGVyYW5nZToyZTFmZmIyNDAxMTk0NDIzOTcyMDU3ZGZkMTg0ZDk5NV8xLTAtMS0xLTI2OTM2Mg_21c07640-7c2d-4cc0-8bbe-80ec0610ba2c">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MmUxZmZiMjQwMTE5NDQyMzk3MjA1N2RmZDE4NGQ5OTUvdGFibGVyYW5nZToyZTFmZmIyNDAxMTk0NDIzOTcyMDU3ZGZkMTg0ZDk5NV8xLTItMS0xLTI2OTM2Mg_d6f08092-23bb-4370-9978-bdbef954845b">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MmUxZmZiMjQwMTE5NDQyMzk3MjA1N2RmZDE4NGQ5OTUvdGFibGVyYW5nZToyZTFmZmIyNDAxMTk0NDIzOTcyMDU3ZGZkMTg0ZDk5NV8xLTQtMS0xLTI2OTM2Mg_c5df3bc4-357d-443c-af97-85ddd7f72a8d">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV83OTI_7c720197-178a-4cc3-ac50-0f9569392480">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant&#160;has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8xMTEx_984bf53e-5a84-4b1e-98fd-d88c354cf898">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY1_e10163d6-66ce-4d19-af73-b4d73b4d09c1">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY2_7e3848e9-f364-48b6-8763-84027e8e2656">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY3_25e1e223-c8e7-4180-b2cf-7cb07cd097dd">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY5_34909910-6b7a-4bdb-80ac-b7696808d7a4">x</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock, par value $0.001 per share, as of April&#160;28, 2023: <ix:nonFraction unitRef="shares" contextRef="if26af3e763f447f8b473acbdaab865df_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDYy_79677cba-9cd1-4ed4-b65c-3b44e648771d">1,247,352,689</ix:nonFraction></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_10">PART&#160;I.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_13">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_13">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_16">Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_19">Condensed Consolidated Statements of Income for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_19">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_16">March 31, 2023</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_19"> and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_22">Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_28">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_28">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_73">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_73">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_88">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_88">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_91">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_91">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_94">PART&#160;II.</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_94">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_94">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_97">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_97">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_100">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_100">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_103">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_103">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_103">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_106">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_106">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_109">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_112">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_112">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_112">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_115">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_115">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_115">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78cdcb1572754b6c94699d07bd7f2fd4_121">50</a></span></div></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to various trademarks and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KITE&#8482;, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SUNLENCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This report also refers to trademarks, service marks and trade names of other companies, which are the property of their respective owners.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts and percentages in this Quarterly Report on Form 10-Q may not sum or recalculate due to rounding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q, including Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Part II, Item&#160;1A. Risk Factors, contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; &#8220;forecast&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends; operating cost and revenue trends; liquidity and capital needs; plans and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections and the use of capital; collaboration and licensing arrangements; patent protection and estimated loss of exclusivity for our products and product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ongoing litigation and investigation matters; statements regarding the anticipated future impact on our business of the coronavirus disease 2019 (&#8220;COVID-19&#8221;); and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part II, Item&#160;1A. Risk Factors. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of U.S. Securities and Exchange Commission, we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described in Part II, Item&#160;1A. Risk Factors of this Quarterly Report on Form 10-Q. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_13"></div><div style="margin-top:16.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_16"></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMy0yLTEtMS0yNjkzNjI_e2c3d3cb-beb9-4e3e-b194-c8d57ca487af">4,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMy00LTEtMS0yNjkzNjI_15d5156b-9649-4c2d-bd26-73d1dcd82aab">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNC0yLTEtMS0yNjkzNjI_73fec332-cb2a-42dd-beea-f18b057c5f00">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNC00LTEtMS0yNjkzNjI_f6bc2c6c-f55c-4379-84ec-0a705ec42183">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNS0yLTEtMS0yNjkzNjI_d86f7978-f2c3-4ee3-b89d-8f480062ef63">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNS00LTEtMS0yNjkzNjI_51ce4942-22c1-4af3-86ef-b71bb23856cc">4,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNi0yLTEtMS0yNjkzNjI_2c6d6327-5a9d-417b-a78b-c01fc4c0f7ab">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNi00LTEtMS0yNjkzNjI_79c783b1-9229-4d7b-a142-7552d6e060e3">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNy0yLTEtMS0yNjkzNjI_2f912cad-530a-41a5-99dc-c65ee1f7933f">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNy00LTEtMS0yNjkzNjI_67188fbc-3660-4b9c-8f91-0bf5026d778e">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOC0yLTEtMS0yNjkzNjI_806fad32-e678-43fc-893f-7faa173e0698">13,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOC00LTEtMS0yNjkzNjI_627b64dd-8bac-4b74-ba8f-c3a04d0069de">14,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOS0yLTEtMS0yNjkzNjI_5f2bec8c-54ee-4164-a16a-018321ff7310">5,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOS00LTEtMS0yNjkzNjI_de51d4e4-2161-4734-b900-219fec78c5e8">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTAtMi0xLTEtMjY5MzYy_13254f77-469c-43bd-a8ee-15aac726d8ae">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTAtNC0xLTEtMjY5MzYy_32e11568-121a-4a04-ac34-9e8074659785">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTEtMi0xLTEtMjY5MzYy_e86f5602-46b8-4dad-9c57-9c08887cf8d9">28,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTEtNC0xLTEtMjY5MzYy_6daf79df-8401-488d-b8d4-901d740f3ac1">28,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTItMi0xLTEtMjY5MzYy_485b0fca-6e8c-4d94-8169-4f7c444ea571">8,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTItNC0xLTEtMjY5MzYy_1c77279e-87c1-4251-a55e-99e93d0fba1f">8,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTMtMi0xLTEtMjY5MzYy_f8c610bf-ed95-44f7-ae0f-a70f5dd86f69">4,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTMtNC0xLTEtMjY5MzYy_20b37566-a294-4eee-abd0-5e24e5e72a72">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTQtMi0xLTEtMjY5MzYy_e50849d4-3841-4819-aba8-d0f1b55ef1cd">61,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTQtNC0xLTEtMjY5MzYy_fe4a04a6-fb75-41a2-8d82-457d73f968ea">63,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTctMi0xLTEtMjY5MzYy_63162f95-64d6-4a12-96a9-04d2e3c105cb">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTctNC0xLTEtMjY5MzYy_34c5ecc9-e32c-4722-a47f-77b474083dc3">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTgtMi0xLTEtMjY5MzYy_c1577064-e29e-4729-a7f6-15d1b1e62fe1">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTgtNC0xLTEtMjY5MzYy_eb16dafe-25e2-4684-8383-1ecb11369a73">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTktMi0xLTEtMjY5MzYy_fd5a7f52-1800-4fce-bc13-e0995a854302">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTktNC0xLTEtMjY5MzYy_8a17acd6-3ae0-44ab-9828-390ce2f640c8">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjAtMi0xLTEtMjY5MzYy_86b29042-906a-43eb-9dad-ee1ac621a45e">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjAtNC0xLTEtMjY5MzYy_e2d34dd4-f815-49be-a109-450db9181cae">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjEtMi0xLTEtMjY5MzYy_896ffbf1-8ee8-4cc5-adef-0cfe0662984c">10,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjEtNC0xLTEtMjY5MzYy_e61b7f12-8a1b-4817-9571-3268e19edcd7">11,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjItMi0xLTEtMjY5MzYy_5c28d2c4-4cb4-4e66-8220-0b4cc2ff6e91">22,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjItNC0xLTEtMjY5MzYy_f006d533-6e97-480e-99d5-e9cfccbfbae2">22,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjMtMi0xLTEtMjY5MzYy_b148dcc9-6c9f-4b0c-b12e-a7d12d59f0c3">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjMtNC0xLTEtMjY5MzYy_8b528031-d3b0-4055-bd73-a1c955f35f6f">3,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjQtMi0xLTEtMjY5MzYy_85fbe3b1-feb7-4b24-8951-cdb821900fe7">2,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjQtNC0xLTEtMjY5MzYy_9e27f60d-38a5-4521-900f-75a1d3244f45">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjUtMi0xLTEtMjY5MzYy_e187c359-b462-4e79-8953-de62cf53719f">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjUtNC0xLTEtMjY5MzYy_d56dc496-f6ba-4cb1-84c8-0c10b0635f72">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjYtMi0xLTEtMjY5MzYy_e0c347e3-d09d-4823-bcbb-6d1b331c1b6d"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjYtNC0xLTEtMjY5MzYy_826c3750-371f-4e47-98c3-f8b08323e275"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfMzE_2fec221b-a22a-464a-848b-f358bf16d1eb"><ix:nonFraction unitRef="usdPerShare" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfMzE_4af4f336-af92-4852-bd0a-5e345f17c18b">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNDU_22046ea0-1f8b-497d-aafc-d68757689cad"><ix:nonFraction unitRef="shares" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNDU_ffc9f965-19bb-4019-b362-d3e383fe7d89">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNjc_6bea6881-9fd4-4a1a-a9c0-d287cb98ae96"><ix:nonFraction unitRef="shares" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNjc_7b52bd00-1455-442f-88f6-a6b880b1e9ae">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMi0xLTEtMjY5MzYy_6a80cead-e7f5-462a-b806-1cd697bfc44f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtNC0xLTEtMjY5MzYy_62586a64-a092-4358-bdba-e8bee58961e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMjg_46deaf74-5816-4606-ba27-dd36415cfb12"><ix:nonFraction unitRef="usdPerShare" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMjg_616784ce-0e76-4755-b85c-0c7994aa0d70">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNDI_6365163d-e202-438d-bad9-8a71e8a0bfda"><ix:nonFraction unitRef="shares" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNDI_676c92fe-59d8-4b67-adcc-a8bfa0631390">5,600</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNjQ_8ba7fa5e-ed93-414e-97ae-87b861c0d8a0"><ix:nonFraction unitRef="shares" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNjQ_add2d48b-846b-423f-94d9-51b6797f888b">1,248</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMTA5OTUxMTYyNzg3OQ_359c4d07-1d92-4e7e-ae5e-28b7805e4d22"><ix:nonFraction unitRef="shares" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMTA5OTUxMTYyNzg3OQ_9e1f5a3f-2552-4526-9c12-fdfcb39eeae0">1,247</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMi0xLTEtMjY5MzYy_5839bf03-2502-4c0f-9ed2-ac283a98d877">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktNC0xLTEtMjY5MzYy_291c7d56-96ba-417f-b67c-9cd57c9edd3f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzAtMi0xLTEtMjY5MzYy_ce4189fa-0369-492a-b9c4-9e0beb790978">5,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzAtNC0xLTEtMjY5MzYy_6c691490-0d74-45f7-a2cf-9a5d8a8a5494">5,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzEtMi0xLTEtMjY5MzYy_266807f6-2bba-4a72-933c-02bf71d723cf">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzEtNC0xLTEtMjY5MzYy_d73d5d55-092d-4b71-a126-c3496d474c9d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzItMi0xLTEtMjY5MzYy_45731a73-f8e0-4e59-8e14-11a23070ed8f">15,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzItNC0xLTEtMjY5MzYy_4c32a8fb-5362-40c9-9abc-f00441db7bd5">15,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzMtMi0xLTEtMjY5MzYy_2ffa52b3-afce-49ed-9b2e-3051cb83e81b">20,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzMtNC0xLTEtMjY5MzYy_6109d04a-f159-474b-9654-c41b00c7aef5">21,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzQtMi0xLTEtMjY5MzYy_04090ee2-6ee6-4fe3-aff5-55af46e48bbc">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzQtNC0xLTEtMjY5MzYy_3727ffd9-5421-4e84-ad8f-aa616e792acf">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzUtMi0xLTEtMjY5MzYy_e2120439-a723-4bc0-818f-ff2c17712cfb">20,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzUtNC0xLTEtMjY5MzYy_653b8205-c872-49e4-9fa2-b23cf5fed74c">21,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzYtMi0xLTEtMjY5MzYy_a0081a96-5ca9-4a36-b3ce-700857caff11">61,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzYtNC0xLTEtMjY5MzYy_fde38e69-3cb6-48f7-86c5-44f03173cb4e">63,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e928b3ebd744fc970718834da3534a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNC0yLTEtMS0yNjkzNjI_4464b41f-1ed1-42e5-8765-fef6f12d519a">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic500805e8441430185668274754bd251_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNC00LTEtMS0yNjkzNjI_f92545ee-afb5-47e7-be82-2964e244d7f9">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c45e712edc45518e23cd00b61fb12c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNS0yLTEtMS0yNjkzNjI_1b7cc60e-ed44-4e1f-b900-5415f0668a1a">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a67c68bd87541d7b8aeb32a510dddfe_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNS00LTEtMS0yNjkzNjI_a6abdc57-36c0-4f91-952b-09b2b6590dcc">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNi0yLTEtMS0yNjkzNjI_9fdbf9ff-034b-4628-816b-d2b131aa6768">6,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNi00LTEtMS0yNjkzNjI_1645417d-61e8-49a8-95a2-7f0f47183d77">6,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOC0yLTEtMS0yNjkzNjI_fa0d89b4-ebb0-4630-8f41-7f0f929bfcfe">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOC00LTEtMS0yNjkzNjI_b7f89641-1209-40a8-b65c-830afe71a9fa">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOS0yLTEtMS0yNjkzNjI_57695b4c-2135-4c9f-9ca9-5502baded283">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOS00LTEtMS0yNjkzNjI_3a365b0f-fe9f-41a0-86c3-c569f225486d">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtMi0xLTEtMjg2NTYx_e1bc8734-1a48-497d-8e27-dbe98d9a2e24">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtNC0xLTEtMjg2NTYx_568e0f5a-9d2e-43cf-8b74-1a979798db79">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtMi0xLTEtMjY5MzYy_ac9525c5-4494-414d-bb1d-3c2c06fc50ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtNC0xLTEtMjY5MzYy_95b58607-485e-441f-a9d7-3826bbce496b">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTItMi0xLTEtMjY5MzYy_5994c9f3-616f-4fcd-a426-18359e290a72">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTItNC0xLTEtMjY5MzYy_19b3a29c-fee4-4977-af7b-6c7120baa08a">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTMtMi0xLTEtMjY5MzYy_9330c230-5fce-489e-852c-69f7c369a7a2">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTMtNC0xLTEtMjY5MzYy_86b18d32-c93b-48a0-82da-1fcb74a0befa">6,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTQtMi0xLTEtMjY5MzYy_dde7dfef-df46-4dc0-9154-1791e73b2dcb">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTQtNC0xLTEtMjY5MzYy_decdbb3d-8235-4940-9666-a3c65b5e45f1">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTUtMi0xLTEtMjY5MzYy_798630a0-9100-4aae-b1b9-5e6246e3c93e">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTUtNC0xLTEtMjY5MzYy_52fd7bad-37fa-493f-91dd-439f5c51d776">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTYtMi0xLTEtMjY5MzYy_848c10be-3540-4e62-bf0a-d95dbc7daf19">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTYtNC0xLTEtMjY5MzYy_470a826e-d422-4305-a1eb-69c8132fdb63">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTctMi0xLTEtMjY5MzYy_1d47ccbb-2de5-4c07-af0a-e6f7b65cd93d">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTctNC0xLTEtMjY5MzYy_2cb70953-42d6-4745-9662-bb70970a8ecd">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTgtMi0xLTEtMjY5MzYy_a5d4ac8d-c85a-4f8e-8ef9-73c6a6b9864b">316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTgtNC0xLTEtMjY5MzYy_da2f3fec-2076-453b-84c9-89bcbd08387b">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTktMi0xLTEtMjY5MzYy_c8514a7f-5d5e-4e84-a0e9-8e6ea423aa68">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTktNC0xLTEtMjY5MzYy_62a52438-37cf-4123-b87d-48ace425bdf2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjAtMi0xLTEtMjY5MzYy_be302631-5bd3-4069-80d3-a2e067b34007">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjAtNC0xLTEtMjY5MzYy_3134008b-2dd8-44a3-b911-8acef5013435">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjEtMi0xLTEtMjY5MzYy_5a396394-8fdf-4a84-9809-b0ac64c2329e">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjEtNC0xLTEtMjY5MzYy_d285cdd9-9efd-4222-ab88-33114d1e496d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjItMi0xLTEtMjY5MzYy_f5cda576-46bf-444e-9655-f627879c6bbe">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjItNC0xLTEtMjY5MzYy_13506a27-4899-4052-9adb-4b242a73f31d">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjMtMi0xLTEtMjY5MzYy_bec12beb-96a9-4f51-8841-771ec457a879">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjMtNC0xLTEtMjY5MzYy_7547cd03-7e29-4fd3-bf1b-0f7d53114dbf">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjQtMi0xLTEtMjY5MzYy_7cf7a139-10c0-4bd3-8c02-632406976621">0.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjQtNC0xLTEtMjY5MzYy_5594ee38-2021-4aea-ad00-c5ad1cbcee66">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjUtMi0xLTEtMjY5MzYy_f63ea940-d5d7-4a3d-b1fe-cae1cc47af32">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjUtNC0xLTEtMjY5MzYy_525c9933-4663-4ebc-ab9e-86311f374c60">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMy0yLTEtMS0yNjkzNjI_76bf0fc6-0ec5-4334-aae9-437edfa3a8ae">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMy00LTEtMS0yNjkzNjI_e6c15975-04d7-425f-8705-c47ab5699ad9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNS0yLTEtMS0yNjkzNjI_a18c366f-7b54-408b-8b26-284e02cb998a">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNS00LTEtMS0yNjkzNjI_03374f6b-2ca2-4edd-85fe-de8ded7829b9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjplMjU5MDQ3NzRkYmE0ZWVhYjMwYTlmN2Q0Yzk1MmFiM18xNjQ5MjY3NDQxNzQz_d502f880-b6b1-413b-8fbb-f223edef246d">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjplMjU5MDQ3NzRkYmE0ZWVhYjMwYTlmN2Q0Yzk1MmFiM181NDk3NTU4MTQwNjc_8cb9bdc1-c304-432f-abba-a383fb31cd01">0</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy0yLTEtMS0yNjkzNjI_3df08d35-ef62-4a97-977c-0d8a6ba3cc96">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy00LTEtMS0yNjkzNjI_93cf2695-ed33-4b6e-a5dc-045b028205e2">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjo3NzgxNWQ2NGE0MWM0Mzg3ODIwNzQ0MzIwODI5MjUxY18xNjQ5MjY3NDQxNzQ5_b854bb40-095e-4b71-913d-762f7d5f9ab7">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjo3NzgxNWQ2NGE0MWM0Mzg3ODIwNzQ0MzIwODI5MjUxY181NDk3NTU4MTQwNzY_3cbd8435-915f-4c5d-9049-06ea575834bb">0</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC0yLTEtMS0yNjkzNjI_b72c09ec-3a5a-46eb-b708-0bc14efd5860">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC00LTEtMS0yNjkzNjI_ce55c376-db75-44b6-bf41-2bc38c267c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOS0yLTEtMS0yNjkzNjI_7bde6c26-9018-4e4e-bf10-8470daad0799">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOS00LTEtMS0yNjkzNjI_ef4b8197-3a4d-44a9-888c-376033088481">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax impact of $(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZGQ4YjFkODFkYzk2NGI3YWIzOWYzZjE5NDU3ZWRjODdfMTY0OTI2NzQ0MTc2OQ_b63a02d1-24ee-45e2-9e29-c86fb2fa9f22">1</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZGQ4YjFkODFkYzk2NGI3YWIzOWYzZjE5NDU3ZWRjODdfMTY0OTI2NzQ0MTc2Mw_4198b0e4-e053-466c-80c8-5f1028ee9069">3</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtMi0xLTEtMjY5MzYy_2cd36906-1444-4c0f-b10c-7994030c7f58">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtNC0xLTEtMjY5MzYy_f8b084ff-2c61-4fc5-bb87-eb8720e26ba3">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to net income, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItMC0xLTEtMjY5MzYyL3RleHRyZWdpb246Y2ZlODYxMWRiOTA2NGEyNGI0NDczNTA2ZjY4NGU0NTlfMTY0OTI2NzQ0MTc0NQ_7c8c7e52-4146-4d29-bbcd-616bd4803422">3</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItMC0xLTEtMjY5MzYyL3RleHRyZWdpb246Y2ZlODYxMWRiOTA2NGEyNGI0NDczNTA2ZjY4NGU0NTlfMTY0OTI2NzQ0MTc2Mw_43bf1154-4e5b-4d58-aaee-a00a9b15ea5e">3</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItMi0xLTEtMjY5MzYy_48eb664e-1046-46b2-b029-6311d14091d5">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItNC0xLTEtMjY5MzYy_527cc896-d543-4faf-8c57-cd312978bdb0">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTMtMi0xLTEtMjY5MzYy_6c12ceb5-9159-4f6b-9f05-5f35a07310c7">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTMtNC0xLTEtMjY5MzYy_bc988238-1657-4cd0-928f-fe95708ecdac">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTQtMi0xLTEtMjY5MzYy_bba53812-ecd8-471b-85b7-9eab94aee91b">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTQtNC0xLTEtMjY5MzYy_8f780a60-12b1-4d8e-9240-89798f9c001c">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTUtMi0xLTEtMjY5MzYy_e9ddebc7-034f-4d03-af77-6bab36f00ab1">962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTUtNC0xLTEtMjY5MzYy_4fcd49ea-e481-4961-85a0-ab8098e153df">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTYtMi0xLTEtMjY5MzYy_aab1a8d4-4811-4370-be57-eaf0986276f7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTYtNC0xLTEtMjY5MzYy_68db213f-ae99-4585-9234-0c6db5e1dbea">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to Gilead, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTctMi0xLTEtMjY5MzYy_18399c7c-1565-44ea-b069-9ef378ec8cd2">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTctNC0xLTEtMjY5MzYy_2e70a27d-9717-44da-a356-3a0340e85c7d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica2a96fc6d924f519f7d51951f05ff10_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0yLTEtMS0yNjkzNjI_12a10c34-4224-4003-841d-13d3b03b4b7b">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2a96fc6d924f519f7d51951f05ff10_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC00LTEtMS0yNjkzNjI_e0a2493b-2467-4f8c-8fa6-974cff686c83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093edc5755704a77a5d407997e7193c9_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC02LTEtMS0yNjkzNjI_554305f8-cf9c-437e-8bda-5e75d2ff2d0c">5,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca3647effb04f2ea342c2cdf2754864_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC04LTEtMS0yNjkzNjI_4b2662f3-ae68-4407-b7b4-38e2ad0523c4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4ed4a6dfc4488183b0a1d002929bd4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0xMC0xLTEtMjY5MzYy_e66c079d-e92c-4c8a-9759-f54f3cd841a4">15,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i624da2b108014e5d9432f6660170cd2b_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0xMi0xLTEtMjY5MzYy_f7000af8-afa9-49ac-a982-884e5441eb7b">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0xNC0xLTEtMjY5MzYy_b1b3c9e1-85ec-4c16-82f5-be6b7be3a723">21,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNS0xMC0xLTEtMjY5MzYy_22c813f5-7fc6-4be6-a61b-b60c4aea32da">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55d7c8a4a8ea4f46b59abb6bce9ebca1_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNS0xMi0xLTEtMjY5MzYy_f6892a60-478b-4e85-a901-9d1d22f68d94">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNS0xNC0xLTEtMjY5MzYy_60fa48c8-5078-43da-afab-4fea7daaa302">985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e6d18dd50a48cd905a0a5c55031f82_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNi04LTEtMS0yNjkzNjI_c99c9d4c-afa1-408d-ad54-3d8c01f56688">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNi0xNC0xLTEtMjY5MzYy_180efcb8-fd5a-4c46-ae60-7109b80b9ca3">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNy0yLTEtMS0yNjkzNjI_6c812670-114c-4418-aebd-d3bde20718dd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNy02LTEtMS0yNjkzNjI_c6a2addc-1cff-4099-aded-8f0b1d9c8586">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNy0xNC0xLTEtMjY5MzYy_cf95b1be-b72d-4376-adef-4a052391ff30">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOC0yLTEtMS0yNjkzNjI_7ffd100a-c778-4016-8ef7-5a405fea95b3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOC02LTEtMS0yNjkzNjI_68974000-3339-4376-8a0a-9a8a809cbc8c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOC0xNC0xLTEtMjY5MzYy_10ca69e9-5214-4bf4-b2e4-27e748c22b02">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOS02LTEtMS0yNjkzNjI_25f10c9e-c3be-4e36-af4f-f1926d060380">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOS0xNC0xLTEtMjY5MzYy_8eb2b734-5a0f-48b5-b385-096e57840922">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock under repurchase programs ($<ix:nonFraction unitRef="usdPerShare" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZDg3NDYzMjQ5YWE1NDY3YWI5MzcyNWUwNGZjZTQ1ZGNfNTQ5NzU1ODEzOTg0_92acc8e9-81b3-4575-a318-a63a902e6828">82.29</ix:nonFraction> average price per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMi0xLTEtMjY5MzYy_76f709ef-9cf9-4161-a519-98fce919cb1b">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtNi0xLTEtMjY5MzYy_4a79feb0-6565-47d0-afbe-c50a046ef782">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMTAtMS0xLTI2OTM2Mg_72be2ec4-7ab7-4966-b076-d11690e50e76">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMTQtMS0xLTI2OTM2Mg_7e305572-09d9-46ba-9068-47a18943cc2a">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchases of common stock for employee tax withholding under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMi0xLTEtMjkwNDUy_64765102-c094-4fa5-bf00-24fd6e9705eb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTAtMS0xLTI5MDQ1Mg_a333ceb6-0f4d-4094-a5a4-cd7e2d5bf6da">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTQtMS0xLTI5MDQ1Mg_d20ab19a-121c-42da-b730-778a082d6075">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ODgxNzVkODMxNDljNDEyZmFiZGZiZjdmNjE0OWU4ZDFfMTA5OTUxMTYyNzgxNA_771290b5-e7d1-4749-8513-c26c923525e9">0.75</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTAtMS0xLTI2OTM2Mg_c64ae7dc-2be0-4850-8910-9ef3cc730ec2">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTQtMS0xLTI2OTM2Mg_0869a65f-f875-4fdb-b6b6-1d2f61d95526">957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie43db347832e437da36ad93d501ee972_I20230331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMi0xLTEtMjY5MzYy_5f9ac551-b1fa-4fe1-8357-7459203224b6">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43db347832e437da36ad93d501ee972_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItNC0xLTEtMjY5MzYy_f5544054-05a3-47a7-84bb-834fcab6d532">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2117194be2466c95399cea80f46988_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItNi0xLTEtMjY5MzYy_65465633-e7e6-4614-a35f-b3de0c6ea8ed">5,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e727936efcb4ba8ab5f6da9a5878ef5_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItOC0xLTEtMjY5MzYy_f6832192-2302-455f-ab58-bebe18a37bad">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd710db690d4726a106486c05547cc3_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMTAtMS0xLTI2OTM2Mg_839fa1b4-d528-4d87-b348-dc0f016aa3e4">15,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic81eccef1dab414a9b030474788c13c4_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMTItMS0xLTI2OTM2Mg_98a05fb8-50d2-4a89-8a32-0e5a5dae2e3a">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMTQtMS0xLTI2OTM2Mg_8e84def1-9949-4e3b-9549-08d0453a8fc3">20,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba0cff47492f4decb13158e416e6a4a3_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0yLTEtMS0yNjkzNjI_f010cadb-8dbf-4190-bf28-603593e437bf">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0cff47492f4decb13158e416e6a4a3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC00LTEtMS0yNjkzNjI_6ca6f59f-4dc4-4321-8b30-c2754ca4375e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if725c7c7814e4cf4a3317e39e252bdb9_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC02LTEtMS0yNjkzNjI_9ce3ed7c-bc65-4e40-83ed-75cc4c260c0e">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a853e0354f546ee8636eb887f31fb19_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC04LTEtMS0yNjkzNjI_07b9fc65-40d9-45da-8208-fcd772467d23">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bf5b7641ca44ddb2ad53d7bd36d254_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0xMC0xLTEtMjY5MzYy_29edce22-bca5-4951-bc4f-37db50c483bd">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926df607944244f1a8641e0053d1d3b1_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0xMi0xLTEtMjY5MzYy_9d76779d-07e4-477a-b70c-1f62c56a9e54">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950969f530e94f1395cc3b19fdc321a6_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0xNC0xLTEtMjY5MzYy_0edcb7bf-a602-4800-abac-6b367c9f1ae1">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNS0xMC0xLTEtMjY5MzYy_069fef97-422c-4947-815f-b6e71f4d9248">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4fc949dc9b4e8da603b9bafd8f0af1_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNS0xMi0xLTEtMjY5MzYy_0ff4d119-49f5-40a0-ba8e-5174be62e910">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNS0xNC0xLTEtMjY5MzYy_38ea8ace-8e66-4f59-8d05-4b3fc0b29e0a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49700eb36c934cf4aca1f0807d4295a8_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNi04LTEtMS0yNjkzNjI_c00c77ba-d6a6-4ad6-9ca8-3993082b4d3f">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNi0xNC0xLTEtMjY5MzYy_5a116070-35bd-4a57-a03a-0f9e6c17b4fe">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNy0yLTEtMS0yNjkzNjI_ab0e93bd-2f9e-44f5-bb2e-a83b73206d1c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNy02LTEtMS0yNjkzNjI_614aa8eb-d124-4f4b-b7dc-ccf940f50f24">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNy0xNC0xLTEtMjY5MzYy_a25b64b5-53de-4ef3-9849-2930d2a7cb70">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOC0yLTEtMS0yNjkzNjI_10951b6c-5975-4355-ab98-e3e6e61fb0b2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOC02LTEtMS0yNjkzNjI_e683d8be-8e31-493a-bdc8-395794c4441a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOC0xNC0xLTEtMjY5MzYy_944571b0-7531-4234-849b-9eb02b6f54e0">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOS02LTEtMS0yNjkzNjI_3f3e9410-3d60-4bbe-925d-c6e470f1d8e2">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOS0xNC0xLTEtMjY5MzYy_501ebc1c-379d-459a-b003-0e9227bdf2ca">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock under repurchase programs ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246OGIzZjg0OGIzN2M1NDY0YThmM2FlYWRhZDUyZWU2YzZfNTQ5NzU1ODEzOTg1_c551ec7f-51aa-4ddc-91e1-28f29a731f61">63.78</ix:nonFraction> average price per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMi0xLTEtMjY5MzYy_d2f78185-4161-46b4-b0b5-57e8a9e6087a">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtNi0xLTEtMjY5MzYy_9a33edf3-80a9-4c9a-b0e4-35fe2be733f7">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMTAtMS0xLTI2OTM2Mg_08093968-f2b9-4745-9070-5f98c7f4938e">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMTQtMS0xLTI2OTM2Mg_f99b08f8-c7e8-4882-8a62-dda5480d45c0">353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock for employee tax withholding under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331" decimals="-6" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMi0xLTEtMjkwNDYw_73e3e778-43f3-4637-8bc8-f66c4ae09a74">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTAtMS0xLTI5MDQ2MA_863eaa0e-af1e-4d61-8185-fab14f391693">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTQtMS0xLTI5MDQ2MA_32b07d7e-5ac1-40cf-a3d2-d7640b722f59">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246OGMwMDZlN2YwNWI3NDM0MzhjODExZTkxYjUxZTUxMTVfMTA5OTUxMTYyNzgxNA_6e17cbb4-50df-4b41-9087-2cb5e9525ce7">0.73</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTAtMS0xLTI2OTM2Mg_df9a51c5-371f-4898-96d5-bfe2e8d85f62">932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTQtMS0xLTI2OTM2Mg_55a7cca4-4898-492f-81af-3e20413219d9">932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief6b15b37c004ae0aeeafce457d5b708_I20220331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMi0xLTEtMjY5MzYy_c9957f62-7ff7-466c-99d2-9477b59c33ee">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6b15b37c004ae0aeeafce457d5b708_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItNC0xLTEtMjY5MzYy_699118ba-8896-4f4c-923c-ae22b2f3dc5f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3dd718f446d4121a028b08422617832_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItNi0xLTEtMjY5MzYy_ec477589-b9cd-4b01-8c21-3992d6b01402">4,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c3b3b01542f435fab6816bf508c9fe0_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItOC0xLTEtMjY5MzYy_5d8bb7de-43ac-45da-ac7a-349abbb8c0db">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf32ea5502c43f99d1ebd15aff8ab22_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMTAtMS0xLTI2OTM2Mg_5a92e958-e408-43ec-9c79-c1f14b3ae263">14,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie42aa0aa14db49ed9e43dfc6d3bb5d7e_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMTItMS0xLTI2OTM2Mg_70f5f62c-5595-40d2-8828-7a591e7ed07d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70473ad0789b4b03b86eb8db467a296b_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMTQtMS0xLTI2OTM2Mg_e7078953-5062-4571-9698-8c32113363c5">19,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNC0yLTEtMS0yNjkzNjI_75e6c0c7-48be-4f27-a94f-03178dbde37a">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNC00LTEtMS0yNjkzNjI_62a52438-37cf-4123-b87d-48ace425bdf2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNi0yLTEtMS0yNjkzNjI_7f167b46-d135-4586-a011-d6f9b6e61904">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNi00LTEtMS0yNjkzNjI_e7502f37-4ed4-4728-8a89-b34be40efc59">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNy0yLTEtMS0yNjkzNjI_2de473e6-f960-4455-bab1-7d3c97991821">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNy00LTEtMS0yNjkzNjI_20250f92-7392-458b-9798-c1c198558f3b">445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOC0yLTEtMS0yNjkzNjI_7093aab0-937e-400d-ba63-1b69a143c867">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOC00LTEtMS0yNjkzNjI_0c13f154-6dd6-45b4-8dd9-6fcc91d49bcc">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOS0yLTEtMS0yNjkzNjI_6bdce9c0-702b-43c3-ab70-5502b809a30d">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOS00LTEtMS0yNjkzNjI_7170d49d-e903-4a48-91de-a478f5afec01">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTAtMi0xLTEtMjY5MzYy_3482d105-8028-4c59-8b26-28ddee18e457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTAtNC0xLTEtMjY5MzYy_0efd1754-c365-4e84-833a-16c359babaf7">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTEtMi0xLTEtMjY5MzYy_86380142-4b23-4060-9574-5502a0f1f239">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTEtNC0xLTEtMjY5MzYy_80086ff9-d741-46ac-8d45-ada43844e79c">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss from equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTItMi0xLTEtMjY5MzYy_56e5451b-9c79-4dc5-b6e3-803caf1dbab7">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTItNC0xLTEtMjY5MzYy_bb60dbe6-3bf7-41e7-a864-daa712f321d3">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTMtMi0xLTEtMjY5MzYy_26db7455-2919-4957-b8a3-5cad462a6f41">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTMtNC0xLTEtMjY5MzYy_044f6f07-a9b9-4123-af6a-8420a13cc43e">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTUtMi0xLTEtMjY5MzYy_576287c3-ba57-4ce4-8f4c-8eb3228ebb84">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTUtNC0xLTEtMjY5MzYy_5b54d600-9dcb-41db-90e2-f940d27cf47b">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTYtMi0xLTEtMjY5MzYy_27d01f12-8d40-4f68-a91d-4a983063fbdb">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTYtNC0xLTEtMjY5MzYy_d31a55f3-f700-477c-8a19-4490fdb1e2d0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTctMi0xLTEtMjY5MzYy_301149a4-d12d-4036-affc-473c552c2736">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTctNC0xLTEtMjY5MzYy_bcf0a333-610b-47eb-ba9d-38d0e11b835f">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTgtMi0xLTEtMjY5MzYy_3a4e38d6-0726-438e-bb5e-ef4fa327c4ca">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTgtNC0xLTEtMjY5MzYy_a621d347-f6e6-4f40-b806-956ff9035061">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax assets and liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTktMi0xLTEtMjY5MzYy_c5bb151c-6dc7-4fbb-8b08-5a2f73a8e052">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTktNC0xLTEtMjY5MzYy_da2d6ff7-68b8-44d7-806a-2687c208d121">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjAtMi0xLTEtMjY5MzYy_5f47ae5d-d11c-48ff-80fe-d7019b04c7ab">543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjAtNC0xLTEtMjY5MzYy_921a7c0f-fafd-43df-b04b-30ce779e1185">1,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjEtMi0xLTEtMjY5MzYy_7934b5ec-847e-4aff-b0b5-b46d2b67c4c6">1,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjEtNC0xLTEtMjY5MzYy_56991fdb-e3e5-4fe9-b012-0f5d81f1b469">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjMtMi0xLTEtMjY5MzYy_fdfafcf8-5b9a-412d-8e9a-f85751ccad66">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjMtNC0xLTEtMjY5MzYy_f1b44007-121d-4628-974b-1d720b31844f">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjQtMi0xLTEtMjY5MzYy_5780b1d4-6ede-4cf9-b7ea-99af3a0c955d">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjQtNC0xLTEtMjY5MzYy_14ec158c-f7c9-4586-a233-22fc54224560">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjUtMi0xLTEtMjY5MzYy_1d64dd5c-f559-4f94-9670-0f48e93ed7a7">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjUtNC0xLTEtMjY5MzYy_9d9a8c6f-cfb5-4817-a9cb-8b87fa68dfd3">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjYtMi0xLTEtMjY5MzYy_6cdd30bc-aff1-4fde-afd5-150a0581031a">551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjYtNC0xLTEtMjY5MzYy_f6c81445-f681-4999-8b39-7e42ca775fd0">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjctMi0xLTEtMjY5MzYy_dd5edc5a-2ab4-4e9e-89be-bd610a3e2956">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjctNC0xLTEtMjY5MzYy_343061ba-7539-47a3-9cfb-cd388843e2b1">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjgtMi0xLTEtMjY5MzYy_e20b35e5-0547-4c48-b50e-a102d0e69cfe">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjgtNC0xLTEtMjY5MzYy_cb284359-724f-4556-b011-4ebd042507fe">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjktMi0xLTEtMjY5MzYy_dc91e8f4-8c18-4798-8029-28b1e1df837f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjktNC0xLTEtMjY5MzYy_bd06d9b2-a679-477b-a8f3-850c2a1c1d8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzAtMi0xLTEtMjY5MzYy_97fc5cb8-0777-4fe8-b66c-15978050063f">826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzAtNC0xLTEtMjY5MzYy_3f2aac8c-8196-4899-8278-b6979b95d78e">1,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzItMi0xLTEtMjY5MzYy_33998de1-e3bc-46ca-94ce-98f20858f71f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzItNC0xLTEtMjY5MzYy_3603e528-acae-4181-85b2-a4bb6d03e085">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repurchases of common stock under repurchase programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzMtMi0xLTEtMjY5MzYy_1d48a42b-5a4f-40cb-9cb7-283da15633d6">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzMtNC0xLTEtMjY5MzYy_b763ce7e-cea7-4865-840c-22fa0892f4f2">352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzQtMi0xLTEtMjY5MzYy_dc557444-5b73-421a-b9e3-eebea3de5966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzQtNC0xLTEtMjY5MzYy_2da1052b-7a6d-4937-80b4-e60449777980">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments of dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzUtMi0xLTEtMjY5MzYy_7c6ead32-e330-4634-8123-52a367a5227b">969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzUtNC0xLTEtMjY5MzYy_bf6ecb91-80ca-4c0e-a72c-5e3200db7941">945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzYtMi0xLTEtMjY5MzYy_b40b502e-f5bf-4f23-b92e-a48bde653089">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzYtNC0xLTEtMjY5MzYy_fa07f9c7-de07-4fba-9c85-e077f8957206">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzctMi0xLTEtMjY5MzYy_94063c6d-f199-49d9-9047-afe3605ecb9f">1,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzctNC0xLTEtMjY5MzYy_8a995b55-d687-4433-985e-2c5400cd133f">1,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzgtMi0xLTEtMjY5MzYy_9865ee03-93d0-49c4-ac85-d53e0fc81fae">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzgtNC0xLTEtMjY5MzYy_634d9f7d-ee54-40d0-bf3a-4969e068d7b0">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzktMi0xLTEtMjY5MzYy_0797ea18-059a-4bb9-952b-067bda4d25ee">476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzktNC0xLTEtMjY5MzYy_54c75eac-8666-4279-bcae-721535e90f87">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDAtMi0xLTEtMjY5MzYy_d3623b91-d30a-4848-bdb7-8523feb953b7">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950969f530e94f1395cc3b19fdc321a6_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDAtNC0xLTEtMjY5MzYy_7ee3c96e-e6c3-4997-839d-06a3a23b3ae5">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDEtMi0xLTEtMjY5MzYy_c86cedcd-eb2d-4499-b9b7-95b1a493e07e">4,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70473ad0789b4b03b86eb8db467a296b_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDEtNC0xLTEtMjY5MzYy_a099d8a6-3149-4aa1-8623-ad802c7d9543">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_34"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfMTgxMw_9482e165-ccde-40d0-bf0c-a6a3c0ea6960" continuedAt="i289f72d53e5e4a81bca82fe51cd3cad0" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i289f72d53e5e4a81bca82fe51cd3cad0" continuedAt="ibc14c3a99c7d4619a6f8425af78ff866"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfMTgxNw_f2b03de3-c820-4f5b-ba15-a7183320e0b6" continuedAt="i7b5c7b03fb534e189d566086044e944a" escape="true">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Condensed Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $<ix:nonFraction unitRef="usd" contextRef="i40c694f02592405083bdaf13c4316671_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfODI0NjMzNzIxNzI0OQ_781596d0-a22f-486b-9ed0-c26de67816de"><ix:nonFraction unitRef="usd" contextRef="i40c694f02592405083bdaf13c4316671_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInIncomeTaxes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfODI0NjMzNzIxNzI0OQ_96886b78-4808-4314-a704-418110b706da">34</ix:nonFraction></ix:nonFraction> million from Prepaid expenses and other for the three months ended March 31, 2022.</ix:nonNumeric></ix:continuation></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc14c3a99c7d4619a6f8425af78ff866"><ix:continuation id="i7b5c7b03fb534e189d566086044e944a">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.</ix:continuation></ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU5NA_f8235d6f-91d2-401c-9cae-b40515920231" continuedAt="i5343e8536ea84029bb33e8d450682eb7" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i5343e8536ea84029bb33e8d450682eb7" continuedAt="i8d74c97fc5b141759261131928b9735c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of Revenues</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU5MQ_f1e94614-7579-4844-a195-a8cd9e59cc8c" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d19c32e455643b7b05ce940c7be0801_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0yLTEtMS0yNjkzNjI_8a46b500-21f1-42cc-9a7e-8a867739098b">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a53598b2a34113a51cf1d6114c3cd5_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC00LTEtMS0yNjkzNjI_c876bd10-56e0-480a-ba4a-cc95167d8893">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4583fc82b7754ac98fc2a9af1773de2e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC02LTEtMS0yNjkzNjI_f82421ba-c0c7-4e01-bf0c-28eefc83c6d7">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie597530e49e3466db13821646fdb7c32_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC04LTEtMS0yNjkzNjI_8b681dac-fc65-4379-9fdd-c7b0ecfd441d">2,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ab2be40e2f4be1931d2379972c1dcd_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xMC0xLTEtMjY5MzYy_92c5f12e-e508-4664-bf72-cb19a909a48c">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5290416165d4826bca76f94fb4de05d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xMi0xLTEtMjY5MzYy_d7a97d17-63ac-4fc3-852e-fac68369f699">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b086ae57d3416c93424778ee7a4f09_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xNC0xLTEtMjY5MzYy_7b22e792-7f35-4cda-99c6-b960947ef9ad">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db3222bd3a24a5792f21001e0ed9f4a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xNi0xLTEtMjY5MzYy_f80a3bcc-3d5b-4d2f-893f-6a1a18216978">2,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b0c18878c845d39d2faca137c3daea_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0yLTEtMS0yNjkzNjI_4f591c45-542e-4a77-bdf3-cdca9e213c0e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1f35c3663a4c68be7e9d1d6e2fcdbd_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS00LTEtMS0yNjkzNjI_81c14b66-8cc2-4898-b7b9-313ecb750b94">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43b59bee267497cb6c22732ff724eed_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS02LTEtMS0yNjkzNjI_3bf4b5f9-bec3-405f-9e52-1831c57439af">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1d0155e0d845058e2dd8f560ef7b2d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS04LTEtMS0yNjkzNjI_9ee3f37e-2a00-45dc-84da-f8ae6f830302">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24a40544f07842abbbd26abe8bd230fd_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xMC0xLTEtMjY5MzYy_7bcdca06-bfcd-4050-8f91-438a05b281f0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95cce301e0e44138eda0e51e00f4923_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xMi0xLTEtMjY5MzYy_676079f3-cf9e-4f16-a1cb-6c0346b6a6a1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i542b657a0c2744368808c312bbc5c2db_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xNC0xLTEtMjY5MzYy_d45d6d25-ebc0-4b9e-803a-bc901db1156b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d4aaab1fff4ee3b95ab9943ea6d302_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xNi0xLTEtMjY5MzYy_10aa9e4d-0494-4dc9-b2b8-e26662dfac4a">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67eba08e27714767a82df70e121e94cb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0yLTEtMS0yNjkzNjI_b14b762c-fb00-4f4d-860e-598549e32b76">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d65f9df40f4dd5b0c639e53db4dd9e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi00LTEtMS0yNjkzNjI_7d16216a-3a57-49f9-bb3d-13f54ece53b2">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee89668eca8340e4ad175cab099b67cb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi02LTEtMS0yNjkzNjI_1fc47db1-a6a8-4115-a0f1-ec27cec1dab2">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ad68b551814279bf5718118b152459_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi04LTEtMS0yNjkzNjI_bcbe22bf-4c59-4c36-8b6c-68a108c12131">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee012c5d38d4893b3cb19e18351ab58_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xMC0xLTEtMjY5MzYy_e278c9fd-68f0-4466-b22f-14dd5b2268dc">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d8f1357d074b21a89698ec5b723bea_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xMi0xLTEtMjY5MzYy_d6e2d6ae-d3f5-46f7-80d7-94a5bfe57fe5">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58599254220a42feb444edc701be833b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xNC0xLTEtMjY5MzYy_2d538313-0d01-4212-8af8-e5c17c0427fc">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8b4e751a2264ec9bb98b846928280c0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xNi0xLTEtMjY5MzYy_744529e4-28c4-4ebb-ac49-8c62ab03cf5e">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e42fc11fdc540d7ad0245cb8d39d2e2_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0yLTEtMS0yNjkzNjI_1a028c69-aa53-49a5-a01a-f2b5d1e20869">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41bb316ef34b4eaf906de30392736fed_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy00LTEtMS0yNjkzNjI_a2b0931a-3cc2-4596-b313-f77afa2156ee">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df3944f730544d1996bddf0bf5a8db4_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy02LTEtMS0yNjkzNjI_83bd989f-ff2e-42f1-afd1-186f5e02ce2f">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf12dba5416c42248c844b94f20ca082_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy04LTEtMS0yNjkzNjI_f389dd8f-93e3-40b0-bceb-bdad2058c0cb">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc3f768136e47c0936791b4392b8289_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xMC0xLTEtMjY5MzYy_082469b7-576c-4199-8941-3b3ecdb0f3d3">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666aecd5c047480a9babba6ea8039520_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xMi0xLTEtMjY5MzYy_c04cb8b3-f030-4684-bcfe-1d2dc988c823">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d8b014f89141aba79e057fe12638a3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xNC0xLTEtMjY5MzYy_b7edb7f9-8b9f-40e9-b048-805936315dae">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a79f1e6c45d4bb897c9a98013083049_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xNi0xLTEtMjY5MzYy_68f7fca7-e7ee-4431-a054-baf6e3b8d4ea">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04f6c7e78c647b1807546ae78fdc62b_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0yLTEtMS0yNjkzNjI_06da9315-3fe9-4788-a7f9-ab3431a5f0be">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50a21232d20463095b52d48490cc6b3_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC00LTEtMS0yNjkzNjI_de950eec-db69-4f58-95d9-09611a606588">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997dc50c936a478aac1cc176a14d9ef9_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC02LTEtMS0yNjkzNjI_fb1dd7fc-e5df-4f55-86ba-215561056231">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689fc87158304986aa89fae3a01ed245_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC04LTEtMS0yNjkzNjI_c1645207-759a-4270-be22-1437ba3d6913">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e1f772d34742e8a8d2a4145828b021_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xMC0xLTEtMjY5MzYy_b5565e79-35c3-4f23-bc11-b887f52b7e26">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771add6d73314919a6dd20ce750a969c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xMi0xLTEtMjY5MzYy_a041e5fb-3a87-4aa1-bd88-09e64ef5bd52">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c19b71fcc4402098fe7a9aa8fc8eed_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xNC0xLTEtMjY5MzYy_eeb5e6a1-fa5d-4f14-9d20-bb33ada2596c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010418975aea40d895ec2686ed330d28_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xNi0xLTEtMjY5MzYy_b6267fc9-4917-473a-bfdc-1730fff68bbc">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450d6b2c88a24625a9c496cecdc5bf52_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0yLTEtMS0yNjkzNjI_96ca130e-4d3b-4bfa-8809-27bf1da580be">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7af1b22c3f847fe9bdfc0f5f119ae02_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS00LTEtMS0yNjkzNjI_60bada2e-f63f-4650-87e2-2d69970d860b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3a66e75c7047d3aafef3137fa6445b_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS02LTEtMS0yNjkzNjI_80c94a58-99fd-4970-9d37-f44c906816d0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdbd845c58c46e8adb8c44ae5684498_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS04LTEtMS0yNjkzNjI_cb2cc874-5074-47bf-aab2-9c38e1b1e337">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591c01bce34640e58557c165d695cf0b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xMC0xLTEtMjY5MzYy_5c80b9cd-c7ba-4b14-82d2-317b5747c30b">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6494ec78b3ce416bb07ce891ecf80d8a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xMi0xLTEtMjY5MzYy_9987373c-fd6b-4e24-88a4-8acd38eaa06d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6b130e3bfb4d008f422f886fe3bc7c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xNC0xLTEtMjY5MzYy_e464c1c7-c0cf-416d-b747-b2ec97e23578">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id56aa7d6f82f411ca07a2196837c3857_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xNi0xLTEtMjY5MzYy_ccd99c28-d6f4-40f3-90db-e1a3cc7f51e9">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i792f4398c7264a34bbfbb2e0141d0569_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMi0xLTEtMjY5MzYy_b752629b-1d23-4a95-af43-d0672e79be28">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36284b9953e94a87b53a58bccfc5e336_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtNC0xLTEtMjY5MzYy_fefdbeae-0312-4989-beed-d1d6ffcdd475">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36cc56c685bc447bb351b98590992488_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtNi0xLTEtMjY5MzYy_f7089b63-1a04-47d3-861c-5c32ad8a4ac3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086e12e3ad3e4741a380acf23831618d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtOC0xLTEtMjY5MzYy_b02accb0-b8a5-468b-b4ce-05f8682ac8f2">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30546a0c6b624dac91f3b66455061d66_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTAtMS0xLTI2OTM2Mg_f05165b8-477f-44d4-83fc-adeaa8fe218b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40dd460e84042629c0071805ed4729f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTItMS0xLTI2OTM2Mg_4d99554c-b5fe-4847-a613-0395457b2894">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic729d8e783a647028632b5ba40064638_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTQtMS0xLTI2OTM2Mg_68a72ecd-1854-4176-85f1-357eab2cf113">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ca1b72c6804ecbbc1b605f601091f0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTYtMS0xLTI2OTM2Mg_76133201-a885-4796-9dfd-64dc9df1a2c0">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dda79e450e447408d931455f2f8f8cc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMi0xLTEtMjY5MzYy_a6bf710b-1a5c-430c-b0d6-a22ca08a11fd">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b399c95ac1b4246aaa5c0aaef8cd353_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtNC0xLTEtMjY5MzYy_cc30bb4c-164f-4b92-a6b4-315fa4875dec">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c92a43cc92a47a6ab65bfa263d351eb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtNi0xLTEtMjY5MzYy_22453f8f-973d-4ae3-bf8e-b0a6f071d5e9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7898842ff5448ba66ef0de574a341f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtOC0xLTEtMjY5MzYy_18d6fc90-c9c9-4913-81b7-9c3fc5f21181">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344ba46eb7a04d56bd7de76ee16b62fe_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTAtMS0xLTI2OTM2Mg_466724cd-9020-43ce-abed-0e92b3c68dea">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbe81d744b24ac3aadfd0def0c3af1d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTItMS0xLTI2OTM2Mg_51ded9f6-8578-4007-a155-7040071da279">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b6d840cf5d4035a31088c19454672b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTQtMS0xLTI2OTM2Mg_bd32fcbc-2cf6-4c04-8421-2fc542deb9ec">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06a18873aa0490ba83b5bddcaea2946_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTYtMS0xLTI2OTM2Mg_d685f793-5622-40cd-83f3-1ddfe8a5be83">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0b6766fa594a13aa0be791f84893f3_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMi0xLTEtMjY5MzYy_5204e4a5-ec30-4159-852a-addfe1663597">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e710d7e374b479fb14aabe9b50fd5ea_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItNC0xLTEtMjY5MzYy_bcabb92d-e5ff-4f46-bdc8-2f4f0df8695e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd6c3585eea4f94b84aff749f526ac8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItNi0xLTEtMjY5MzYy_1dc3342a-9d27-44b0-b851-16aea9d433c7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37160460cc94423a6e38cb49e84b00a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItOC0xLTEtMjY5MzYy_c3727003-9ba1-46e7-b0eb-b29769e91e6a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i458cd9c1bb9a44bab1804ab82add9ef0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTAtMS0xLTI2OTM2Mg_8835b6b4-5350-4ec0-a6f1-97a8880567e5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d671c5a402543c6bc98a00e54b218e2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTItMS0xLTI2OTM2Mg_e8b99f9b-1827-4523-8adf-741bd51806a6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78556fab5a594eaaab678aa5b2b70c92_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTQtMS0xLTI2OTM2Mg_50ccf8a9-57a2-4193-a41a-81a6d6300dfb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f7ccbb67b3412d94eb07273cf08f82_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTYtMS0xLTI2OTM2Mg_dbd1fb5b-f17e-4a07-afb1-7171170f189a">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6292c28980b643479da9447ce2a9f473_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMi0xLTEtMjY5MzYy_41533a72-1127-4be3-8790-47a15e4e0b58">3,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21dec2a2b762423e9ef5905cf0aa9cf2_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtNC0xLTEtMjY5MzYy_76c120f6-f684-4018-9ce4-c1c6ec48426e">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603cb3b83ce14179bf04d0aaf6a195a1_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtNi0xLTEtMjY5MzYy_197f73f8-180c-454f-8e44-f4028abee0db">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f30cf0bd3dc4f13a115c97982ce981f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtOC0xLTEtMjY5MzYy_1b58c7c1-4a62-4a54-adad-3cbe00505d84">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd48e1d614c42f89931926809fc82a7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTAtMS0xLTI2OTM2Mg_d8657ce1-640e-416f-b403-6aef1e2fde3e">2,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7848b323c65b46e5a5d0b843644615ab_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTItMS0xLTI2OTM2Mg_3d63462c-ad9a-43ca-b2fc-dd679da29757">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfb95b671ed491e8b70938724cb0c56_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTQtMS0xLTI2OTM2Mg_73f28316-5753-439c-a9a6-b13e49001f63">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ccec38bc81487a98ac2ef0ac2fb11c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTYtMS0xLTI2OTM2Mg_04848d9e-46bc-48c9-bbfe-2809318b6a86">3,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9988c03dff4e4d05a5ff6badc0ed5ccc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMi0xLTEtMzAxMzk3_a2c84a75-6ac1-4926-9d80-c102a94119f2">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb5ff7d45f6422e846f8796c101b1cc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNC0xLTEtMzAxMzk3_9d1a980f-7ad4-4e3e-bcc4-50158458fec0">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic00e734d3ce3408487ef17422e54a433_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNi0xLTEtMzAxMzk3_4b97a454-8bd3-42d0-906b-ff867a36fc08">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6054258e4b146609392bf5d13038e6d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctOC0xLTEtMzAxMzk3_198b5a81-42d5-4dd4-ba48-43f2b238951e">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f67ef40bc148158d12ec2015ed480e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTAtMS0xLTMwMTM5Nw_8048dc41-16e9-4545-976b-0cd357ca1167">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571a1be950c440d789469a2f4d9abfcb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTItMS0xLTMwMTM5Nw_a7c2bd18-0583-4a76-99bc-2011f2b9eb44">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea41115ebe564139a2c8659237f58346_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTQtMS0xLTMwMTM5Nw_44bbab63-7a5c-4071-bae1-36caec96cf1c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25c20fa74df4d2ab27b7cc2ef3698aa_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTYtMS0xLTMwMTM5Nw_aa9a7058-0d1e-4daa-83fd-341142af78c1">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a272399a10347cb814cac2d9dfd148e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMi0xLTEtMzAxMzk3_6bacd194-6f74-4f08-be12-94d3aa12fd87">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if463eff382504416bd3b435b029bab84_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNC0xLTEtMzAxMzk3_3990aeaf-bb59-4345-b41c-e3542542778c">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad37f88a40ad417181970ffd6d38fdb8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNi0xLTEtMzAxMzk3_9ca8624f-33a9-4ea1-925b-f5a363110478">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6291bcbf7f7c41b98bbe26c0e03a3cf6_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtOC0xLTEtMzAxMzk3_c6244666-1904-41b3-90a5-d5466df2dabd">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e10e1edf06747de90b02b2363965434_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTAtMS0xLTMwMTM5Nw_89caad2a-9669-4bea-8874-039bec724d12">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c62a110af374a069c05307a70eb674a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTItMS0xLTMwMTM5Nw_52f085a6-6bf6-478a-98b3-490c4f4c2545">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05d7b2dd54e4758b222f4b9c96c8dcc_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTQtMS0xLTMwMTM5Nw_8eeffbd8-1bbf-4f12-bb06-d172a2c13f3f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fd84ea511b418294dcc7d568645af7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTYtMS0xLTMwMTM5Nw_7f382445-2341-4efd-ba78-91f520a32a87">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff71600e3d4a11b42b8372471e63e8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMi0xLTEtMzAxMzk3_f79de661-8bc9-4517-8b79-892ac8ce47ec">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4043b3f894c487facfbfa869ed06140_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNC0xLTEtMzAxMzk3_8ddcaddc-4598-498b-bc75-359fd417a8b1">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8da02de1bdab404c87ddd583b9eebf85_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNi0xLTEtMzAxMzk3_0ba1956c-70ab-4b33-8e5d-e4deae9fed63">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic846202eb035474a90d6bbdfc1b15217_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktOC0xLTEtMzAxMzk3_cfee8179-29b9-4cc0-b75b-c6231edc57fe">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccbbe48385584bfea6852686c3b019de_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTAtMS0xLTMwMTM5Nw_c57c018c-b563-4504-b61d-badc22a0e24f">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a4c42583664db8b3c33c5f299a0f4b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTItMS0xLTMwMTM5Nw_9e63cdac-7603-40f1-878d-394a52d6f817">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if951dfcac7744054906c5125f638ce21_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTQtMS0xLTMwMTM5Nw_d269ed16-d8be-4ce8-9a6e-aa4befd6b28c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5cc2f2b76bb4d9c97bc86237986d9bd_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTYtMS0xLTMwMTM5Nw_88ee2bb7-99b1-4a1f-be22-b749fa8defc7">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebd3767145342f6b367a0b7f6f1a976_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMi0xLTEtMzAxNDAz_bbd34d2a-5c2f-463c-895e-f6eb22123952">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bda10becdf41afb4989abe63dc2011_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtNC0xLTEtMzAxNDAz_52c2d0a6-e699-4ef6-a11d-44e4fb7d81e2">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4101dba088994abcb8f4d35c5096da8e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtNi0xLTEtMzAxNDAz_e693d04a-6af8-4a2f-83f6-2f11eaeb5381">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd92b5b8015467faac7b2902c0e722c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtOC0xLTEtMzAxNDAz_4f4b4552-a638-4515-aede-da6d823bcc8e">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee92c1d69fa4915a73d1e059bcc2f3e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTAtMS0xLTMwMTQwMw_4aeaaa2b-fd0b-49f1-a544-509e38efb1b1">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d037e0f2be44b11b472e2b6432f4801_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTItMS0xLTMwMTQwMw_4f901ee9-2151-4430-a6da-2ef5dfcf560f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f9879159314fdbb7fdea07bdf585a8_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTQtMS0xLTMwMTQwMw_66bb692d-4f74-4dc7-8c94-e961b8e66cef">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie367458dfc7842fdb07fd2fe4e10fc1e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTYtMS0xLTMwMTQwMw_cb65afe7-2eec-42b7-a52d-5ac7d329d0f9">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d872aaca9d40a4b6c2a27ebb8bdf10_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMi0xLTEtMzAxNDEx_839dae84-1401-4d78-a975-ee586d0847d3">431</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8284ac9437543ccbc0d3d44daf70792_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItNC0xLTEtMzAxNDEx_6a8f8722-922c-424c-89ba-2b753b96f6e0">202</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43370509bfb4a8c8dab8123e63ab0c8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItNi0xLTEtMzAxNDEx_392cb196-72c8-47eb-acb6-a1baa3019ed0">37</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06a6eb489854930ae0def7cc8f416de_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItOC0xLTEtMzAxNDEx_20389c15-603d-4ea8-9e47-baad14395764">670</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ab588f4a7646b9ae2305375fa5467b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTAtMS0xLTMwMTQxNQ_f6b992b5-d23d-433b-8a0a-ceac878fe68a">292</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f37487da5e349a4b9f9f387d2dc5398_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTItMS0xLTMwMTQxNQ_f8181fa9-2237-4ba9-8aa5-3861dc8df3a4">117</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3bdda941ff4e2aaa037ade8321f098_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTQtMS0xLTMwMTQxNQ_8a720fcf-013b-44e0-b78b-e4926544f02c">11</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee659a3e712243d09b54e37ca804067e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTYtMS0xLTMwMTQxNQ_d524196d-2bd3-4738-a498-d952a6541a36">420</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liver Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chronic hepatitis C virus (&#8220;HCV&#8221;)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94069cf576394220a168bb924848e1d5_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMi0xLTEtMjY5MzYy_490364f7-21d9-43a4-841f-f51b7fda0282">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75383c9367af4d9d8f8715d238548742_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNC0xLTEtMjY5MzYy_097141d3-4886-4de1-9fd2-635b444712ee">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44a7f7348754553ae0be14f2f11c8a4_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNi0xLTEtMjY5MzYy_8a0d4dae-7c17-48af-8977-f86690772048">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie934396b4aa24066a63d81e4824e6824_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctOC0xLTEtMjY5MzYy_475c0df3-5901-470b-bdf5-cac1a975177b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia825fa36f2c54e59a199832f003b73a0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTAtMS0xLTI2OTM2Mg_961969b3-a36e-4da5-bc8c-1e0fb6f164cd">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c70a0df7936466e8f48c9d8037878b1_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTItMS0xLTI2OTM2Mg_ab707ebd-9e5d-4efa-ac29-14142bdc01e9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dde11c9ee7473ea0df48b2aaacf03e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTQtMS0xLTI2OTM2Mg_fa37a0ea-3db9-4cec-ab4c-43d49edca875">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1bbc6a669f486ebe51bb1dcae67739_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTYtMS0xLTI2OTM2Mg_a0f8a45d-618d-4656-95f8-a3312de25067">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0905351e17b64009b3bd40c0e79e555e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMi0xLTEtMjY5MzYy_6283fb65-e821-4ebf-9642-c6b2fd442f70">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ce5f719ea84854a0b758397c95d01f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNC0xLTEtMjY5MzYy_b9df6665-642b-4d5b-b94e-01929e126a05">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3479eb78982346cc9b440b90ac343bf9_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNi0xLTEtMjY5MzYy_108bc714-c973-4280-8416-87f17f977e87">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510d0822c2574545adb8841ba008ce9b_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtOC0xLTEtMjY5MzYy_39829fe8-c53c-4a5a-8fc3-5ea3e68a00ce">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fdc21dc65e4d558d42514d101c97b7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTAtMS0xLTI2OTM2Mg_605b20a2-faa4-4296-89ce-056700b71a70">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a865d0fddb8445cb031590f0a02a80a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTItMS0xLTI2OTM2Mg_838b5e34-99dc-4e25-8db5-618802fcf0a8">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22aa3af8d494dc292b57bdf0cdf041c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTQtMS0xLTI2OTM2Mg_11d2aa5e-c749-4be0-9a98-99dfd9a24fee">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86087bf8b37a4b89acc6817bcef8e756_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTYtMS0xLTI2OTM2Mg_e76952e0-2d78-48f0-b6af-860ebc39a36a">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf24591ef12a41fca5174331a00cbb13_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMi0xLTEtMjY5MzYy_a00268ce-0528-4623-8b05-706a712e17ca">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb45ab67b990486599a343f8415ee905_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNC0xLTEtMjY5MzYy_bf7db8d1-b984-4d73-92f1-849bd63577c9">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id752540ccedb480fbbb6e2bba52c34bb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNi0xLTEtMjY5MzYy_cc143b28-7491-42a9-bb9a-0ffedd1486d1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc42e0840ef141c5b3850d98173d4730_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktOC0xLTEtMjY5MzYy_0943c147-1dd7-467e-be25-0a2cd37d99dd">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d455cccf9d4832870bcf4419271ea9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTAtMS0xLTI2OTM2Mg_d3bea8e7-7b74-4949-a4ca-a899987361d7">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f80c600bf04228823d182e0cb43b1a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTItMS0xLTI2OTM2Mg_1ce5ed1e-d723-44fe-a1fd-030423d6981b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1b8b9d99b04cd189bf897215f84c36_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTQtMS0xLTI2OTM2Mg_d6f93b77-3d64-41e9-8c53-c5698fb14293">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5869ea468ec4ca5b87ad1783a18dc9d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTYtMS0xLTI2OTM2Mg_d6ea831d-126e-4b29-9a73-52e9324c1402">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0580a54e234bf585f865b90a530189_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMi0xLTEtMjY5MzYy_89915a33-7288-4830-87a9-fffd00d0278d">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54593f03c1114400935e76093c34b8bd_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtNC0xLTEtMjY5MzYy_c0066e37-8d58-4db8-b43f-4667f7ed532c">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b67d77f6f242b0a1bf8ac4155be76a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtNi0xLTEtMjY5MzYy_239b77dc-ffc3-4d84-8e30-43ec29d6485f">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba94b3090254d63ba7bd368d1a8f7dc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtOC0xLTEtMjY5MzYy_109c0599-727b-4b98-a322-40fc17f2f83b">445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a201f81fa334729abf7031166fd5577_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTAtMS0xLTI2OTM2Mg_faf2cced-43ea-4ded-b5cd-140da33a90e5">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie743df4532ec46c6bec9c152ca1030fb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTItMS0xLTI2OTM2Mg_98fd9d09-05b8-42a1-8635-e5ae1064366f">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37473f0485a746938a7f26a2dca59cf3_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTQtMS0xLTI2OTM2Mg_482766f9-b9ec-439f-afaa-4329dea10a00">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica72aa2509b04035b02393bb3aea5e1b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTYtMS0xLTI2OTM2Mg_a4b718e0-919c-4049-a2e4-e4c202fd92f8">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chronic hepatitis B virus (&#8220;HBV&#8221;) / hepatitis delta virus (&#8220;HDV&#8221;)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ebfed05406413eaff961e952191aa4_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMi0xLTEtMjY5MzYy_e26c7d5a-460b-4193-9e7a-bed9ea4989b5">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b45a8b90a848269a2592fbe0b8c3ce_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtNC0xLTEtMjY5MzYy_84ecdbd6-ef6e-4757-aa16-560a51f682f1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d3312dcce0438cb345232fa7454979_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtNi0xLTEtMjY5MzYy_12e98e53-81a0-4cd3-8711-0ffbb814c321">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0934fd0075be4cd6ada897ff651ce8db_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtOC0xLTEtMjY5MzYy_8ddbe7d2-25c3-4248-a5f9-6061d824dabd">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c40a0615861452596fcb9aa9d86e704_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTAtMS0xLTI2OTM2Mg_9647ff0b-816f-4ab9-bbe4-a7d0a11be829">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib500e8ef8aa84616b40a2191594114a7_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTItMS0xLTI2OTM2Mg_fbbbc350-5c62-4faf-be87-a9aad2231c7b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38ddeb60ee2443f956e770d097710c9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTQtMS0xLTI2OTM2Mg_5d59c8c7-c051-48ec-8701-0602f2c01f66">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie640715ca03a42e99d7cd895fa05c7b4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTYtMS0xLTI2OTM2Mg_6fe2da28-432f-4113-b983-c86ad80d199b">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i652bed5b638547f9898ab03fcfdd467a_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMi0xLTEtMjY5MzYy_65f86001-67e8-413b-a64f-aa6d023fa65d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7dbdd67bdd453791f731cc83851f41_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtNC0xLTEtMjY5MzYy_f780f70a-f01b-4760-a3e9-27fc7c4b8b13">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dfffbb1fb6e4e8ba4b2d0adc6f90600_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtNi0xLTEtMjY5MzYy_d4fcb54b-6a99-4d43-9f65-a259b87443a3">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97d2219d4e940e8872b33598cbc3523_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtOC0xLTEtMjY5MzYy_0f96279a-fda7-472a-8bb9-8bf929b12c84">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe303d4e215044fa92f72f822bdc870e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTAtMS0xLTI2OTM2Mg_f37b3425-99f7-4192-b6de-3dc9e6636e7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad5d36685f64582b233de7a5239d698_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTItMS0xLTI2OTM2Mg_c96903f0-2232-44f6-a8bb-8352eaf98170">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9ebab0b3a942d5bb672c1ea1985565_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTQtMS0xLTI2OTM2Mg_81da6fb7-022c-45fa-ba7a-743d36a521d6">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic16768b8c0bd467089b916f0150aea2d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTYtMS0xLTI2OTM2Mg_4752a8e5-73e4-48ed-aeaf-85aea2c8b6d2">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a09533ea02b4970830e57cb8ed16e29_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMi0xLTEtMjY5MzYy_7bc5c86e-6d4e-469e-944f-bde9091d5284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfa66c376de4d50b8d621ce7a69fd00_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtNC0xLTEtMjY5MzYy_0e19ef40-da9a-445d-967b-69d00577a364">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6838b754224e3ea3f49755cfe56353_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtNi0xLTEtMjY5MzYy_d1758c1c-82d3-4c1d-95a8-de1bb1524e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257a0e1302984795b9ed79cd7d56fcb6_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtOC0xLTEtMjY5MzYy_10e7bb03-d7c2-4945-bc7d-15a0a06e2503">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68686e7167f4cd88f12024feac41469_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTAtMS0xLTI2OTM2Mg_e372ba3f-5160-49da-b4ad-1907ca9bf251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824131aaa9e9438885ebb6c2d9d58420_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTItMS0xLTI2OTM2Mg_4ef73fc3-ccd7-457d-a619-21e71e09c5cc">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97befe6960ea47c09105a9d2792b241c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTQtMS0xLTI2OTM2Mg_1f87866f-0bb9-4db3-91bc-eabf7aec3b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743bad3f631549ee9b7e3300a3b32478_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTYtMS0xLTI2OTM2Mg_0836ea3f-8d78-4d19-a453-a3b505c68154">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9b52ba975f47eea73b114711437ee0_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMi0xLTEtMjY5MzYy_3c3c4188-736e-4c5c-b009-6ed3c8ef4e51">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia99677732ab64aee9be9eb6c9b9c5297_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtNC0xLTEtMjY5MzYy_919d1e70-fd08-4843-af91-d0175f54c806">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ccc5abc96549b4a653a8ac7248fcf8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtNi0xLTEtMjY5MzYy_47e7d885-92f8-4aaf-bce6-8f872705b00a">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5d887661194281a92f5d47aaec6008_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtOC0xLTEtMjY5MzYy_dd2901e3-f372-4c79-96da-f08c0fe476af">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70bf852e632a47e287a6514f25d2979d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTAtMS0xLTI2OTM2Mg_4ae34acc-0894-465a-a58d-0b356cc3cc73">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f4a76252494b24bc1f179124aa3124_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTItMS0xLTI2OTM2Mg_0cfd4cad-9375-4910-ab6d-f205357497d4">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9560016efc024c89af4afc6834f04bbb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTQtMS0xLTI2OTM2Mg_d1872b75-0e7d-4351-816b-f8f275489b14">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ab8727efc14325bd00acfb911c338c_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTYtMS0xLTI2OTM2Mg_81e0440e-2d67-486d-9a03-5b59bb438deb">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liver Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090c47f3a0cf452181e6d5b006c0be6a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMi0xLTEtMzAxNDc3_da5f7e21-b9ef-4e03-9e88-ed2164ff5d8f">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7a471ebca74147a9b0d6e1a6089d93_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtNC0xLTEtMzAxNDc3_0c847761-0fa9-479e-85a0-7d00c3153e63">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8185dc8b7344db9a1038babf06db22b_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtNi0xLTEtMzAxNDc3_4ee7cd13-68d9-41e7-9797-e0b05fd312d0">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59f825423194376b8da82fe0cec886d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtOC0xLTEtMzAxNDc3_5619f8e0-eb53-4738-8915-f21066942dd7">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i324e13105ef44547bab1c5e86c934957_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTAtMS0xLTMwMTQ4Mg_5407b323-65d5-4488-b071-26d616677440">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e40c5875114f3cb760a0d82117e6a5_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTItMS0xLTMwMTQ4Mg_45e0ca52-9d75-4f7e-94bb-e4ad58585443">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f9f3277ed14717a540d49002edff04_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTQtMS0xLTMwMTQ4Mg_6def4a4e-d811-4622-b9cd-4ff9d718a79a">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8748476ff814f45b9ccd6e290667fc9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTYtMS0xLTMwMTQ4Mg_f609dfcd-6d96-4ee0-9d72-5bd2e64c9230">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8220ccfd0447bcaabd55458b891968_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMi0xLTEtMzAxMzY3_ac430736-f0d0-4a0a-b8d0-65a56f8111bf">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9a86b0b2a84281bb61ad1873a15c2b_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNC0xLTEtMzAxMzY3_1a7a7ff6-235f-4be7-a363-a9664223250b">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if614c6aa1eab4885acbcc73189da7a93_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNi0xLTEtMzAxMzY3_565256f4-9b66-41bf-8821-98187d539796">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278eb945039342f2a8bda078049ec2e0_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtOC0xLTEtMzAxMzY3_68eaff44-8fe5-4757-9daa-7f31bbd48983">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40b401de87f42519456da4227ef431e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTAtMS0xLTMwMTM2Nw_41110f89-5382-4f4f-8bb9-0269e32d08b2">801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie855dc4b080941e6be062405849ca9c9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTItMS0xLTMwMTM2Nw_95cffa84-fdd2-4207-8dbe-a96329a873f0">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d547a3fe84543cea7ac0386bbc34d72_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTQtMS0xLTMwMTM2Nw_84105703-998d-4cb4-b10f-5d4e76700332">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cccadc5c6b497ca5b1f30e89955b7d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTYtMS0xLTMwMTM2Nw_2321ca1d-0025-407f-974f-5747edd31c0b">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c6167454744e0fab7410239683ab45_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMi0xLTEtMjY5MzYy_05d6b1b2-69bf-4c6b-9f7d-3c6a864f7777">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d9606c89db437788fc45ee2168e4c8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNC0xLTEtMjY5MzYy_55c24af5-93b2-4ce9-9482-c31cb9ceba2b">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb18acf634f467aaf5cdd7a65b62981_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNi0xLTEtMjY5MzYy_2b62050d-8da7-44e8-8403-a7e42e89318f">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia581f9570a6a44e4bf717b04c2b68cad_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtOC0xLTEtMjY5MzYy_e8c5e968-8230-45c7-852d-b526b0b6ebb7">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447d2250e1b9434a90d57aa2babd8a63_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTAtMS0xLTI2OTM2Mg_8b981cdb-af9f-442e-94bb-f4e33cf77211">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a7971fda6a4d1cb7a5b0c93dc55aa8_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTItMS0xLTI2OTM2Mg_0cbaf404-3d2e-4cc0-bd5a-2d3caa700e92">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63020427351e4e01a6c232cf97913837_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTQtMS0xLTI2OTM2Mg_8a16096c-3713-4240-bec8-b56ddabfc5f2">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e51316888b41cbb03d3ddfc57bd840_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTYtMS0xLTI2OTM2Mg_4eb9f614-1a0d-4dac-ba4b-5a08270a1205">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74791ed0e7b346e89fd234b7be9699a7_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMi0xLTEtMjY5MzYy_6eff3c67-17fd-43be-86ca-47ae75bf1892">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc4e4dc9bea4ec58fd5ff7790b0b8f8_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctNC0xLTEtMjY5MzYy_3f75c4b5-23cb-438c-a5db-b0596b10bb3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d418d346974c1fa0c17dcfcaead0d7_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctNi0xLTEtMjY5MzYy_665d18cf-2814-4074-8e16-80cacd2136a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbb92a2127b42db9046b0b7ec4dfa6a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctOC0xLTEtMjY5MzYy_7d959edb-69a2-43cd-adac-83ccecfe85ca">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809de751ef2f4f78b9b8f68cd8b8e109_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTAtMS0xLTI2OTM2Mg_b1dc992c-7f13-4a1c-8774-edf2dc8fdf74">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4daac1a0fe9747d9bcd85f6d82586020_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTItMS0xLTI2OTM2Mg_6967ae4a-f854-4a63-980a-9dab04df3448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42331a4397a48faaaefc64df2f413e2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTQtMS0xLTI2OTM2Mg_443157d4-191b-4c41-ae0f-450a993a82c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28d2efd45f141f6b1f1fc7d243542f0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTYtMS0xLTI2OTM2Mg_317634e0-507c-4f25-a8f0-89df38542fd8">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755f2b30cc6e4fa993c605e6808ad1cd_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMi0xLTEtMjY5MzYy_cb29df55-069e-4b80-8cac-8d2c522909ab">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i677d46617baf4cfc97770f40bdf350eb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtNC0xLTEtMjY5MzYy_2fdba8bc-e7ce-416d-85de-513b47413b13">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996bd5bfe4d44d25b7c4bf8273caf0cc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtNi0xLTEtMjY5MzYy_b82bd0c2-284a-4bb8-8864-2fd6b2d39308">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8a2eae2e8547a5b670d21ca58b3fef_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtOC0xLTEtMjY5MzYy_f1e25392-7459-4efb-b842-4e349affe08b">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823bfbd777c846ddaf6555202b8a7351_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTAtMS0xLTI2OTM2Mg_cb652140-4ba8-4e76-b6b3-1df357b41d29">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b10cde4a9524c0ca62293060948f483_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTItMS0xLTI2OTM2Mg_df7ad31d-0675-4d5d-9c06-dfff12219d71">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie41089e89bd74f35ae3f87c7a56e2a19_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTQtMS0xLTI2OTM2Mg_bcf0ecab-2fa6-4535-9e7a-0eeb5b066eb5">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696fbe445270452f81e087d1fa89fe11_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTYtMS0xLTI2OTM2Mg_94d5e523-5614-4e2a-9dde-e74c4d1cd319">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae81192d9324630ba4b365d1cddd5bf_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMi0xLTEtMjY5MzYy_1fdeabf9-ff63-4cbc-9e0b-0925d9ce0635">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33f4fdb4c494428ba2b4a99560b4e08_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktNC0xLTEtMjY5MzYy_083225dc-5223-4aad-b026-e00bc5053fa7">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709a08a357b14493b12bf32a458f6f6f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktNi0xLTEtMjY5MzYy_3e072cba-da74-4417-b452-cc0adbf3376a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710096d16b5642718cafb5a22d815d0d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktOC0xLTEtMjY5MzYy_145bff26-b016-4c2c-bc7c-d39f8bf5ba85">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ab8aec39084c4eac102e0706a4b80b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTAtMS0xLTI2OTM2Mg_2140d72f-a4cd-4b7e-acd9-7ede339bacf5">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9e5623132040899baea9cd2d5a764e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTItMS0xLTI2OTM2Mg_69957008-5c14-443d-a26a-b32dd5ffbb67">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3092cbdd04d40b19aab266dd867a766_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTQtMS0xLTI2OTM2Mg_8b8a1127-c35b-4e3f-9d8c-e27819a3ae49">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib976d60772b24c27944ea6b8d54d2d67_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTYtMS0xLTI2OTM2Mg_cde47c52-19c8-4507-9de9-2c0723b8144b">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113772172baa40a0b615da596117cf5f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMi0xLTEtMjY5MzYy_73fe14ac-1f08-482c-8668-b831c4f3bf18">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7656db9d0049259fec5c0b61f4a692_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtNC0xLTEtMjY5MzYy_c07e084e-cf24-4937-ad05-7a331eabc859">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic79faa34465a4d6aa155b887531a618a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtNi0xLTEtMjY5MzYy_4861656e-436a-4154-ad67-fa87f79f8d51">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e928b3ebd744fc970718834da3534a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtOC0xLTEtMjY5MzYy_534c8c60-4584-4f6b-9db0-a210e827ae59">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d5861845724cc7b45b2421fadc72b4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTAtMS0xLTI2OTM2Mg_c674fa9c-1052-472b-919a-4e5eb47211ce">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c53f8feb0a94f6491489c44593b168b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTItMS0xLTI2OTM2Mg_bbbacbae-2dc8-4bc2-9bd9-8c4cc598000c">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f19798d09f947d2a629343bde19e62b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTQtMS0xLTI2OTM2Mg_f4eaafa5-9330-4d9e-96bd-bd16905cb62e">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic500805e8441430185668274754bd251_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTYtMS0xLTI2OTM2Mg_b632df50-51d8-4be7-94e2-24ff6629cdec">6,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a4176549214367abc167a2ec593abb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMi0xLTEtMjY5MzYy_cbe42ea1-ddc3-46ee-aa08-f6bb8acc7d3c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978f5bf8cd9d416190509bc5959bef0d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtNC0xLTEtMjY5MzYy_c3e28c80-f98c-4392-afa4-7217ded204e4">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a5ba2a8a1540749ed46ae7a6ed4e6c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtNi0xLTEtMjY5MzYy_64365531-031a-4e22-8711-45398a3848fe">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c45e712edc45518e23cd00b61fb12c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtOC0xLTEtMjY5MzYy_eb09f538-e9e5-4fc7-b537-89a65b88db27">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ea35337c87402dbc1082ebd607e554_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTAtMS0xLTI2OTM2Mg_6ae79360-1c93-44e1-b3f7-b5ec33a174eb">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3374213965c34c23a79853f9a29ba6a5_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTItMS0xLTI2OTM2Mg_3a808fcf-c2ed-41d1-b2b7-1129677a068f">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7caa2c5fbd246269301ab23ea219e18_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTQtMS0xLTI2OTM2Mg_646c4381-305e-4567-80e7-a3735171a515">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a67c68bd87541d7b8aeb32a510dddfe_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTYtMS0xLTI2OTM2Mg_46a5910c-0a29-42af-86ed-d6e2a52a9d68">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c91b5b81b3f49cc99ed4d965e15cb05_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMi0xLTEtMjY5MzYy_6f383511-a019-447e-8b9f-8bc3f65636f1">4,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb135539ed644e89e8a56f37e4ba61d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItNC0xLTEtMjY5MzYy_23a85c8b-3f43-42cd-a314-23164df6a48e">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68170415b25f47b08de05015410863d5_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItNi0xLTEtMjY5MzYy_6391635f-4f5f-4762-a18d-48085ac62738">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItOC0xLTEtMjY5MzYy_494d1e71-52da-4997-b66c-2b3c9870116e">6,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6849a5ebac4c97924794143c774f0b_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTAtMS0xLTI2OTM2Mg_5883dbf6-e157-45a0-bdcd-0f803636c5bb">4,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c99b6a3f2a472c83a2fa839f90b5ea_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTItMS0xLTI2OTM2Mg_bcf617b0-3a8f-4a80-83e0-9baafa8cf0ac">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f79d1cff43c43df82a4363c05362740_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTQtMS0xLTI2OTM2Mg_ee7d5b96-3322-4f94-81f2-c37302d94b48">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTYtMS0xLTI2OTM2Mg_20b4d2ad-905e-42e8-a120-47db807d9929">6,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Atripla, Emtriva, Sunlenca and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i8d74c97fc5b141759261131928b9735c"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues from Major Customers</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU4NQ_45b9fa08-fc41-4458-96d4-6588e9252b75" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic87bba42a74544ebb4ed1b2216e3f687_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfMy0yLTEtMS0yNjkzNjI_d4707fe4-d8a7-4966-afc0-9a22747030ea">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7c4130e03624fd8bb9980194f507734_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfMy00LTEtMS0yNjkzNjI_d2ec0635-5025-498f-ac6b-851c8b735792">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ida6333a62e4e40e5ac281c56d97e63c8_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNC0yLTEtMS0yNjkzNjI_707d0750-fd1b-40e9-b52d-b18babe41b52">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f1daf12df0648b786b4f70679a69ee3_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNC00LTEtMS0yNjkzNjI_a0030121-90e0-4ba1-9949-8a45837b00a1">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibffab27044b141ed8332a4acb0c26f71_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNS0yLTEtMS0yNjkzNjI_829941fd-f269-4b92-bc8b-0a6fd10b07f7">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a637640e90643ad807df7af76498cb0_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNS00LTEtMS0yNjkzNjI_67c91e68-8c9e-4c2b-b46b-8a6e01d9d3fc">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU4Ng_f19dc029-f5a2-4dd1-b0f0-d8aae155f4ae" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen and royalties for licenses of intellectual property</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfMy0yLTEtMS0yNjkzNjI_2b8ba31b-3475-4f42-90df-3c15408f70f9">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfMy00LTEtMS0yNjkzNjI_6e567e35-591c-44f4-904a-2fc6bb7be41f">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfNC0yLTEtMS0yNjkzNjI_b5779a41-aa64-440d-b33f-2a42b9d7fee3">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfNC00LTEtMS0yNjkzNjI_0fe5a8cb-fb28-4122-bf19-c730300c373d">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contract Balances </span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMzg0ODI5MDcwMTU0NQ_18a03fd2-0d0d-466e-b34c-48576fbd48cd" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMS0yLTEtMS0yOTcyODY_73ad654f-4f5c-4997-9876-f8c8cfbde10f">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMS00LTEtMS0yOTcyODY_9d4af536-7143-44f6-a6c3-3c16144a0468">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMi0yLTEtMS0yOTcyODY_f1076a6e-41cf-442c-b535-62588a0285d0">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMi00LTEtMS0yOTcyODY_63192298-3341-4020-9cbf-79f54f87524d">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Generally results from receipt of advance payment before our performance under the contract.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM3Mg_08fd81e9-6e35-4a32-b1c4-c94812a73b1f" continuedAt="i06e2fff5b4b347dc803db004cee06bdc" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i06e2fff5b4b347dc803db004cee06bdc" continuedAt="i9a76ab7e9203481ea29a4d65e9486809"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM2Nw_d556d88a-5e26-4e13-a9ff-c4973524b6e7" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a08172f4f244a79d2b394f399f8b13_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0yLTEtMS0yNjkzNjI_4c0e9730-5f1d-406d-8eef-7d62cdefa304">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40005adf52144ed85b05da90b6d2139_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC00LTEtMS0yNjkzNjI_77d9fd12-f51c-42b5-b42f-78b3127d9dbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a00bf2652604fbcbb4da1bec40896e6_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC02LTEtMS0yNjkzNjI_803ac608-c99d-4f3e-b377-ef0db6628428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad1222097c644f09b1a2dccc64bd3c4_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC04LTEtMS0yNjkzNjI_54f4864f-cadf-4677-8c59-cbc2dd72017f">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd34e7473d924c328deed5a6ccdd4afe_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xMC0xLTEtMjY5MzYy_2d151c3c-55f3-4baf-8fe9-0a42d0159705">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298a129b64b84c158f7a79bfaabebbd9_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xMi0xLTEtMjY5MzYy_f74e58e0-a3bc-440f-a897-8bf295edea97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic015d372c6774949bc85fa263970366a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xNC0xLTEtMjY5MzYy_9987e8a6-be3f-47e9-beff-c4ba2b2606b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6548e7eaf5d34e378990fe5c8218b3a6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xNi0xLTEtMjY5MzYy_e8638651-0ade-493c-a7e5-2fb829c6613e">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56bec9c2c9449778eb81057ceb9299b_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0yLTEtMS0yNjkzNjI_75db799e-38c6-4bd8-a9d2-3f614ce70b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2a9da409b6496bbc57ceb63bf60484_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS00LTEtMS0yNjkzNjI_9e3358da-de24-400e-9ce1-241a986d4d77">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4458d1d12cea4625bc7db11da9a09beb_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS02LTEtMS0yNjkzNjI_b46ebf44-b8d3-4a7b-b8f4-80ad7ea51814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070c48e01f814ffd907a7fd8f6047117_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS04LTEtMS0yNjkzNjI_6670cfa2-015e-49eb-82f4-91a34a0e1d75">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c206f3d17b44385898e7a9f69b7aa12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xMC0xLTEtMjY5MzYy_c3a65179-3169-4c5e-b5ca-d27e64d66e10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efb718dc0824ded809922f135d14f72_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xMi0xLTEtMjY5MzYy_44d5cb55-5128-43bf-ae9a-76e42b597bab">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bac2a669a64335b1a9e1e221e2f25c_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xNC0xLTEtMjY5MzYy_4bf2d871-f2ae-4f87-a203-57603c8c29fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26e1c0f325d4ca1a67fba9811c45fc9_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xNi0xLTEtMjY5MzYy_b322fd58-3ba3-4d75-a5da-5efc91142591">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b123dc510a43d8802b50cccdeedbf5_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0yLTEtMS0yNjkzNjI_9d658c89-7915-40a5-8ef5-5fddb7db8a34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c59bdf9e624122b0025c13c8932d5b_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi00LTEtMS0yNjkzNjI_18381d99-c14a-4c69-aa0a-8eb25ac8e33e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6307387519504abc927afabdd827d0b0_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi02LTEtMS0yNjkzNjI_22ba83c5-4f0f-4a1e-b46b-0210f35a8cf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268af442ad9045fb9d0047cc8514e705_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi04LTEtMS0yNjkzNjI_2ddbe466-1012-4153-90c9-dc7be8fdd0d5">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58be9bdcf7e4accbe91509935a9f362_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xMC0xLTEtMjY5MzYy_91f2d785-e88d-413d-a93d-f2c806a3bd02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9741f7ff7a4abeaf85943e5f22418a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xMi0xLTEtMjY5MzYy_7e84bf23-3121-4675-9bfd-3105f8a5a696">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib28bc6923927495f8c985d0973d926f0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xNC0xLTEtMjY5MzYy_5ffdd613-e7fb-4dba-b1c3-2ad9a54cee4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858d8c032c1640b58d8d8f45207568b6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xNi0xLTEtMjY5MzYy_afd3dd0c-ad1f-483e-8a50-b317a705b01d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7955dfb43224407190574461d49d9540_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0yLTEtMS0yNjkzNjI_8b3c7b90-fb33-46cb-ad35-95fb2c7dd233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3fc36306554f1bb30285803dfe875c_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy00LTEtMS0yNjkzNjI_e9749e5e-b329-4f1e-b37b-64a567a52591">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5eff8a38aa425682a7f90c9892125b_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy02LTEtMS0yNjkzNjI_4a61b91b-4bd3-4af4-94c7-ea4662980bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice046d59307c4fdcaf4be021a9c9b7e6_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy04LTEtMS0yNjkzNjI_912c6b66-5ea7-4688-987c-67f5eccf2a33">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca4682777694e579dd8d81c0230ccb7_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xMC0xLTEtMjY5MzYy_dad064ae-82ec-4daf-9cbf-c50fd863e022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i840cd602edc14d1cb641e5ee8c6a8fe5_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xMi0xLTEtMjY5MzYy_00c32a89-ee56-4204-adf3-3ba727e3932f">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea63a1d9c8d4b34a96c93940d35e22f_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xNC0xLTEtMjY5MzYy_09a54093-f8a1-47a5-a81a-af01ac96f86f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecfcff27fd54e13b0ec19e65fbd5d36_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xNi0xLTEtMjY5MzYy_c626a422-13b9-44bf-80a2-7ee858d697c6">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41faaf40d4ef4d49b113b09bc17772bb_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0yLTEtMS0yNjkzNjI_7ee75c48-474b-417b-ac3c-763c745ccf5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a8d5247fbb40ffac874f473b0f297a_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC00LTEtMS0yNjkzNjI_6fa4f15a-840a-4b7c-baaa-29b120f56514">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e94173dabe647a398189e72561ab576_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC02LTEtMS0yNjkzNjI_58e939f9-9c55-4581-8ac1-08a6898c6667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afce071943b4d26b76439f3846f3a8a_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC04LTEtMS0yNjkzNjI_baa3c576-98cf-41a8-a25b-7347d06e3513">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d03adc29c7a4123ae502213f7338c96_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xMC0xLTEtMjY5MzYy_1884da7b-4438-43a8-8c03-b133618db656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ab2341ad8e4ff6b616f6930e3a7edc_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xMi0xLTEtMjY5MzYy_d0ba6e79-8808-4a49-9860-7c4fa4e7ec81">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d8a928fd4e43259f12d46c9b3dd925_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xNC0xLTEtMjY5MzYy_ae896df0-8337-41d4-bbd7-e4ea2a474de3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75af3c4962e045198fbc3aa6ec6a75ee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xNi0xLTEtMjY5MzYy_e5b1b787-5de5-4923-991c-cd37f552d129">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf023b197aa4118b56f642584f72530_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0yLTEtMS0yNjkzNjI_b27bf3c4-593e-45e6-8ed2-9d4ca3539a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03efe7c49cbc4bdeb65025a874918ba9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS00LTEtMS0yNjkzNjI_9a011033-ce1b-4e88-bd8d-bfb7e3960e66">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia17d4fe5710248bf903fa448d86c0f88_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS02LTEtMS0yNjkzNjI_20e1cdff-9023-4c8b-a1bd-e41590aa51d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fdbabb1243f4e86a5376c9000522492_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS04LTEtMS0yNjkzNjI_6ff89c5d-a761-4d07-a835-d1604985bca3">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729aa6a63477475ba65321969802f159_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xMC0xLTEtMjY5MzYy_90ca1ca0-d09f-4e33-816e-00741a085c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2cff82341c4dc0a251e15da3bf13c8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xMi0xLTEtMjY5MzYy_930c2dd9-26e0-4604-9ead-c7a41363833e">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd142e2bf3c46ee91f4326b178cb28a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xNC0xLTEtMjY5MzYy_567e9131-d6e7-4f11-a67d-8f51f8fd536f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1426c184f5cc47f8aa80bfe34a607cb3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xNi0xLTEtMjY5MzYy_3ef47b3c-7e82-470f-86db-4451a3d8a5bb">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2661abbc964a0784a010dbe6cc0fc6_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMi0xLTEtMjY5MzYy_9593d4f0-18ff-4d11-afcf-a8988d49ff4c">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id531a955cfb3413a82cad523850c21c3_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtNC0xLTEtMjY5MzYy_01b3165c-a334-41fd-8f33-4c7ae04db626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia788273cc08946368efc543494d4d4e7_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtNi0xLTEtMjY5MzYy_e50502d3-3720-45db-86f8-7fdca678e6f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70479b2efa064ffe8d5a4badb47ed829_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtOC0xLTEtMjY5MzYy_8753b423-fbea-4e0c-9469-62004bdea904">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfcb1b9cdaeb47dca59a07a6ce2025fb_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTAtMS0xLTI2OTM2Mg_327ba69c-760f-43e8-8324-8bd90427b966">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f350e4b39bf43c491eedf1e18c2f29f_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTItMS0xLTI2OTM2Mg_0c2d1e38-795b-48b3-8c7b-3e030af79487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f658fc7bfbc42d1b7319bf162b933e8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTQtMS0xLTI2OTM2Mg_ee722ba0-933e-4967-8f98-c1dc5a8454a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd105c3a34541189ed7853f9bdedb46_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTYtMS0xLTI2OTM2Mg_3f213c75-3dbe-4d1a-a8a4-0dc8e4eedeb6">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d38171e17734505bf300a4f7261bb9e_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMi0xLTEtMjY5MzYy_c566e3ae-a49b-429c-bc0e-fe32ddc04111">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed5c2cce176468cb88406a4ef218eaf_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItNC0xLTEtMjY5MzYy_6c1baab1-8739-4839-9dc1-b37c6155cc9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a26bf538c9e4b07a3f50fa63e16c09f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItNi0xLTEtMjY5MzYy_6b1d979b-6322-414d-a91a-d9c49de9faa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194f48cf31ad4461966915e642a9d349_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItOC0xLTEtMjY5MzYy_81a16702-fda1-4456-b6d4-0e81dfd88aea">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i937e321648424380aac9aa46560540c5_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTAtMS0xLTI2OTM2Mg_7add42eb-4747-43d1-99fc-aa5c7916cfd7">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364fe131316c482492c686531f316415_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTItMS0xLTI2OTM2Mg_b62a5e9c-6a56-4dbf-95a0-624ba53c8d22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09c87dcc4754dbaa6d7f3f7aff3a559_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTQtMS0xLTI2OTM2Mg_32df9f7a-941d-45aa-a08a-156d2af59b78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic272024b44504e08aea2aef0e5cdce3b_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTYtMS0xLTI2OTM2Mg_870c2379-7108-4e1c-afcc-5e10dcbe91af">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0d1c94992b4e8985f62b27d61769f9_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMi0xLTEtMjY5MzYy_cd6be588-5cb5-4617-8884-36b7055641d3">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38fae61cd724739954724cab1029f06_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtNC0xLTEtMjY5MzYy_0f78f3cf-bd7d-4f2a-ac15-4d4040b94398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db06db2f1954bfb84f43e2df4db34f3_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtNi0xLTEtMjY5MzYy_ee1bcc3f-a6d3-41c9-8e9d-3b4146262964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c224d5aabd4662bf6225bef1d6c8ea_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtOC0xLTEtMjY5MzYy_30977af9-2f51-4866-8891-aa35cb1121f5">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087ba3741afd43baa98b28ac94fd7f20_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTAtMS0xLTI2OTM2Mg_d8b1dc2e-1ae8-437e-a4ec-f157e2801d7a">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4d3507260a4b689350205f27a8e97d_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTItMS0xLTI2OTM2Mg_4e17cb6f-9465-49e1-ad3f-fb900cf088ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8939a2992d04a64a5ff7980f5f17203_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTQtMS0xLTI2OTM2Mg_ffd7585e-15a2-422a-b14b-b8f27908fd81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65251199ab8d406ca23824a7b9f69f93_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTYtMS0xLTI2OTM2Mg_352359c6-a56a-49f9-b083-33e8576f5c0c">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6234e16f3ffa4f09aa53750804bbe37b_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMi0xLTEtMjY5MzYy_70b0259f-0060-48ea-be64-496a88554a9e">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2b1f2190c1428e8e5a1008b1913d19_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtNC0xLTEtMjY5MzYy_db32307e-2008-40f0-875d-7d1aee5203b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id26d3f89e113495fb08196ab4d44bcf7_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtNi0xLTEtMjY5MzYy_b502986d-decb-4b97-a9d9-7c23fc8befce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6cde4baccb455a8d4849e1ae54b485_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtOC0xLTEtMjY5MzYy_87e7ca65-8509-411c-b56b-a1101df99b7c">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d215506fdb4ac9b9fdd8a1a8900a0d_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTAtMS0xLTI2OTM2Mg_0d2e2089-be7d-4a38-8852-69ceea965ece">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7611b09e98a14f48bbd2f62d557253e6_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTItMS0xLTI2OTM2Mg_4e645356-56cd-4ff2-8000-7ee36e8f70d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001dc783df3642e1ac6e1ae958df97e1_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTQtMS0xLTI2OTM2Mg_a3fe6291-dbb4-4afe-ab13-5218110692cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic063218f12c54d03acf4ce07c47d4275_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTYtMS0xLTI2OTM2Mg_215151bc-e843-48f5-8823-ca353da4f3ae">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5e217a5b1140728f4602157db87e2c_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMi0xLTEtMjY5MzYy_49d138aa-0752-49e4-8f8a-04b4b6dfc0e6">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9f0b6b0b844305a53445354ae194cb_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtNC0xLTEtMjY5MzYy_d513b63f-fe49-4353-8ca0-c812d26dcea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib183b8cea0954d138ad44af200a84877_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtNi0xLTEtMjY5MzYy_8dcff600-3ef1-4605-b82d-547795750eba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee26b0e08842a0b843c4ac42a50e93_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtOC0xLTEtMjY5MzYy_26573d2c-b5a3-4a71-86fd-8052365da9e9">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1d8684d26247aa83ef85ca707fbd8a_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTAtMS0xLTI2OTM2Mg_963d27bc-91b1-4b72-a5bd-e384fc5e1aa9">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d573c781b70449f9e9416cded0054a7_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTItMS0xLTI2OTM2Mg_2c3618f7-7c5c-46e5-8bb2-1a72a76bb41c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05635ce202a4083958412667e099ed2_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTQtMS0xLTI2OTM2Mg_deb10669-b123-41b5-aac2-57237918e5b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b368b49d37a4ee69978906222ce4b5c_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTYtMS0xLTI2OTM2Mg_76b94432-b6d5-453b-b95a-d04782f214c7">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86fea5742d1f445d9c563566784f0cd0_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMi0xLTEtMjY5MzYy_93067e22-4fe4-484f-bc0e-e726bd65ba80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ee5a60fac74d60b76c288f2df853d3_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtNC0xLTEtMjY5MzYy_f063a71c-0500-4991-8980-217217c0ac49">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a06827286fe4c8183a9be9be74fe8f4_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtNi0xLTEtMjY5MzYy_420e05e6-1615-4bb8-9d68-65b16d539e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ac4e1620e6498cb5b443b7ad7d32d3_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtOC0xLTEtMjY5MzYy_01700d6e-455e-46a9-bb55-49a68a72de23">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bda1d98cbaf438cbb28ebe26c09665e_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTAtMS0xLTI2OTM2Mg_c97b63ab-848a-425f-885d-9e9043a2e612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id927ab0d29884827bea7bcaf3d2dc398_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTItMS0xLTI2OTM2Mg_f78ee8db-700a-4778-b916-86efe75bcfa4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dde228737e648788d98fb2fc1d4ac58_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTQtMS0xLTI2OTM2Mg_492dd3b3-886b-441e-ae6b-ec055c01ad00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df8c0d093bf48b2b63cba32a6131249_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTYtMS0xLTI2OTM2Mg_276a0388-315f-40cf-940b-d4e809daa6e4">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e78ed5854ff4c45958a4d133cd9890a_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMi0xLTEtMjY5MzYy_21a94469-a607-4bab-91fa-293892baf7d0">4,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1f122ae8f14eae930697c79bf7af6d_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctNC0xLTEtMjY5MzYy_81277617-bcfb-47e7-b452-96f4a24a6c54">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69013ac8af5f45c896d0e14dc6876b0d_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctNi0xLTEtMjY5MzYy_5aabe966-307f-412a-a1be-ed5463bc1442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i825aac04e24b40208c807dce228c07fb_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctOC0xLTEtMjY5MzYy_7c46be3c-888a-40ba-96b0-3530d7a446f3">6,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc3b620a74946d7bac3bf26a9c4ce16_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTAtMS0xLTI2OTM2Mg_d1d3be31-6c67-47ac-b7d5-abca6dcabc46">5,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6385da92df654fb6967cea6114292f4f_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTItMS0xLTI2OTM2Mg_ccf96aaa-3ac1-417c-ac70-9c0e393d5daf">1,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb0e9387655417ea47e244e390930c8_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTQtMS0xLTI2OTM2Mg_14040173-c78e-4d36-a983-49b78eb649d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad78bf4198534e099b1e1e8624534d02_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTYtMS0xLTI2OTM2Mg_a5ab9fa5-f79f-4934-a973-5fab0fe7ff2e">7,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a910c12f414900999d3b059f396d47_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMi0xLTEtMjY5MzYy_d24aeb24-1d3f-4bf0-a505-2a3bdc5251b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f1f58b1a04471faea6d3a37e5320fc_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktNC0xLTEtMjY5MzYy_f2d58104-be0c-4d24-8ef9-2f836ffe5eec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0463a71817c4cca9f2913df58ccc458_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktNi0xLTEtMjY5MzYy_cb533e10-6fa0-49ca-9429-dbc6a025c5b4">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6d5fe3d48b4ebc8612932358fce8e6_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktOC0xLTEtMjY5MzYy_84836dc9-d846-4256-9f83-f2c45af5003b">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dcae5f616154d2bb06f9c392d252555_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTAtMS0xLTI2OTM2Mg_0f00b736-a068-41a7-ad47-61bba7c3f0c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c466bd362f400780c77e751afc2c34_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTItMS0xLTI2OTM2Mg_372d154d-2473-4e57-8c7e-b04e253305b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800882dc4b244976915f007c452e0fe6_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTQtMS0xLTI2OTM2Mg_d17b7262-9338-4375-9499-9866795a96cf">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064e703fbfd049878de89e2a1c5dc621_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTYtMS0xLTI2OTM2Mg_899520d2-dbb4-4641-8baa-a5643862e538">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe5e217a5b1140728f4602157db87e2c_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMi0xLTEtMjY5MzYy_03e4f1f7-d28b-412f-980a-1f0b98915648">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b9f0b6b0b844305a53445354ae194cb_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtNC0xLTEtMjY5MzYy_4e232b7b-5e99-4abd-b2b6-89ee723fcde9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib183b8cea0954d138ad44af200a84877_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtNi0xLTEtMjY5MzYy_a8ebe701-f305-4e7d-851c-1357c3657e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ee26b0e08842a0b843c4ac42a50e93_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtOC0xLTEtMjY5MzYy_050ed7f2-6174-49dc-be7f-f72a3c92b47b">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1d8684d26247aa83ef85ca707fbd8a_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTAtMS0xLTI2OTM2Mg_45cc998b-8b57-411c-a4e5-af05edb0cd3d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d573c781b70449f9e9416cded0054a7_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTItMS0xLTI2OTM2Mg_5d66c134-5a72-44d8-b9ea-4fd641856d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05635ce202a4083958412667e099ed2_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTQtMS0xLTI2OTM2Mg_447a5078-18a5-432b-9ac6-07d458ce8a7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b368b49d37a4ee69978906222ce4b5c_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTYtMS0xLTI2OTM2Mg_f29a8f80-f95e-497d-95e3-5a0b0881d4ba">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86fea5742d1f445d9c563566784f0cd0_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMi0xLTEtMjY5MzYy_8d07e9f4-3ffc-4b69-a2b8-d71856ae25fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ee5a60fac74d60b76c288f2df853d3_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtNC0xLTEtMjY5MzYy_96d71aa5-3af6-4986-93fb-339b41014aa2">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a06827286fe4c8183a9be9be74fe8f4_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtNi0xLTEtMjY5MzYy_3e134989-2061-46d3-b409-358cce7f2daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ac4e1620e6498cb5b443b7ad7d32d3_I20230331" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtOC0xLTEtMjY5MzYy_45bd8a25-e0c3-4768-882c-d11d4fe953fb">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bda1d98cbaf438cbb28ebe26c09665e_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTAtMS0xLTI2OTM2Mg_26bf9274-e02f-46de-9cd9-99a3a14cd0ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id927ab0d29884827bea7bcaf3d2dc398_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTItMS0xLTI2OTM2Mg_9210e037-c904-4418-aee9-f612a722d2c8">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dde228737e648788d98fb2fc1d4ac58_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTQtMS0xLTI2OTM2Mg_8c84ae09-b4a3-4588-afb0-bdc094b805c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df8c0d093bf48b2b63cba32a6131249_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTYtMS0xLTI2OTM2Mg_4d7dffde-b7e9-468b-b239-871a31b08499">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e78ed5854ff4c45958a4d133cd9890a_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMi0xLTEtMjY5MzYy_ded4be3f-65c8-43a0-bc6a-d7f48c28d423">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1f122ae8f14eae930697c79bf7af6d_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItNC0xLTEtMjY5MzYy_114aebd0-55fa-4545-ba19-96ac26e6e74c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69013ac8af5f45c896d0e14dc6876b0d_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItNi0xLTEtMjY5MzYy_cf30a386-60e7-4709-afd3-c9260e6959c1">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i825aac04e24b40208c807dce228c07fb_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItOC0xLTEtMjY5MzYy_cb1565ec-1505-47ed-a1b4-a22fd79eae4b">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc3b620a74946d7bac3bf26a9c4ce16_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTAtMS0xLTI2OTM2Mg_024695ee-6ae7-461e-864f-9e42d00541e2">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6385da92df654fb6967cea6114292f4f_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTItMS0xLTI2OTM2Mg_b2634b2e-73b0-4234-94e1-b88fead56436">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb0e9387655417ea47e244e390930c8_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTQtMS0xLTI2OTM2Mg_5e20454c-2f8d-4b0f-82d3-0d4e4c493864">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad78bf4198534e099b1e1e8624534d02_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTYtMS0xLTI2OTM2Mg_d933f899-fd2e-488a-9a60-7b4f7ac54c4c">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM3OA_3f0972e0-69f2-4012-9345-5c4998dd1613" continuedAt="i83e3c4e7cd9344b8b4e5482d93e97eee" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an <ix:nonNumeric contextRef="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzI5ODUzNDg5NzUyNA_80298157-6c82-4ccd-bd4f-81b695d5d55e">18</ix:nonNumeric>-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9a76ab7e9203481ea29a4d65e9486809"><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="i6c191e188eb0435a839aff2e83dc0b7f_I20230331" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzgwMw_f71ea07d-9812-4205-9adb-f53667a7dbf0">22.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibfcf3730e7494e1eac9bdd409e112df2_I20221231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzgxMA_1c3d1639-c7e3-4f4e-b7c9-dc16699be88f">21.9</ix:nonFraction> billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and the carrying value was $<ix:nonFraction unitRef="usd" contextRef="i1ed3bb87a65d43c99c02e4fc37036b3e_I20230331" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzg4MA_20398b6c-8be6-45fa-bd49-9c9627914c97"><ix:nonFraction unitRef="usd" contextRef="i1daea506fa054411b9fcccb4c301cc61_I20221231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzg4MA_c20c1b08-1008-445a-b662-3534686cf740">24.1</ix:nonFraction></ix:nonFraction> billion as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><ix:continuation id="i83e3c4e7cd9344b8b4e5482d93e97eee"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="i4162868d814a43e3aaf697b3f77e900a_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTQ5NzU1ODI4MDI2_999402da-7b94-4e58-b61a-25f637f01557">300</ix:nonFraction> million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex until the related contingency is resolved.</span></div></ix:continuation><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM3MQ_b249aa41-3fac-4466-beac-049b2f487b43" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in fair value of our contingent consideration liability: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b4776cc8f6409e92531b2b339c0031_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfMy0yLTEtMS0yNjkzNjI_197b039f-e0d2-4f6d-a430-c0f52d5108cc">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7670407a0204455084b40c8717c401e5_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfMy00LTEtMS0yNjkzNjI_6528337e-4234-4129-9142-2603ea8e3068">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfb395164c844896b27f93a01db7e27f_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNS0yLTEtMS0yNjkzNjI_c5580b38-adc9-46d0-942a-a76eaac4ab5a">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821c4ec6a7fd4cd4b53462e6dc41da64_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNS00LTEtMS0yNjkzNjI_a00b262c-f035-4f2f-a78a-79e458f2c77f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb395164c844896b27f93a01db7e27f_D20230101-20230331" decimals="-6" name="gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNi0yLTEtMS0yNjkzNjI_b34fdb45-a045-46c7-85d6-511ccf13ebca">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i821c4ec6a7fd4cd4b53462e6dc41da64_D20220101-20220331" decimals="-6" sign="-" name="gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNi00LTEtMS0yNjkzNjI_7acbebc0-8382-4e94-958b-dde333f747da">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b15ded1f1714d829d737d7f8ba59153_I20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNy0yLTEtMS0yNjkzNjI_14c1ac6f-278a-40c5-8b03-49574db3bccd">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5beeadbee5b426383f472cd603bccb1_I20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNy00LTEtMS0yNjkzNjI_c0866e74-10db-4811-bc3a-6118d6d7f567">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Research and development expenses on our Condensed Consolidated Statements of Income. The change in 2023 primarily related to updated expected payment dates and the change in 2022 primarily related to updated probability rate estimates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair value of the liability related to future royalties was $<ix:nonFraction unitRef="usd" contextRef="if8bffbfdebfe4c0a8714dfe49168e8a0_I20230331" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNDk0OA_1db84b48-0adb-46f7-ba92-676b48c7632a"><ix:nonFraction unitRef="usd" contextRef="i3f93855d6db44024b333d78df947f56c_I20221231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNDk0OA_7840317b-c23a-42d9-9c39-3fa6a595d631">1.1</ix:nonFraction></ix:nonFraction>&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, and the carrying value was $<ix:nonFraction unitRef="usd" contextRef="ia97bd7f721914df1bcf6152d4c3d17b4_I20230331" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTAxNg_a3c2ccbb-ce77-4154-9ba4-368850ce83b5"><ix:nonFraction unitRef="usd" contextRef="i62ecf657b38947f592054cba9b58c1a8_I20221231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTAxNg_f0f942e9-2f5b-4479-94c9-40741c99842a">1.1</ix:nonFraction></ix:nonFraction>&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we recorded a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9a2868046c1c40f5b963d0310b6e2c28_D20220101-20220331" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMTA5OTUxMTYzNzYxMQ_e626da3f-80e0-4b84-b0e2-8b1cea28d944">2.7</ix:nonFraction> billion related to certain acquired in-process research and development (&#8220;IPR&amp;D&#8221;) assets. See Note 7. Intangible Assets for additional information. There were no indicators of impairment to IPR&amp;D assets noted during the three months ended March 31, 2023. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value Level Transfers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjEyNw_c36530ae-5165-4572-866a-63d8d48287be" continuedAt="i55dd55b311044466a53228fe4cf4e8e6" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i55dd55b311044466a53228fe4cf4e8e6" continuedAt="i6a5d925ea71c43249758102f24a6849f"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjExMw_75f1d359-6708-4b43-a865-3b0006d2209d" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0yLTEtMS0yNjkzNjI_f844891d-3b58-4c11-b01f-9950b59d5f9a">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi00LTEtMS0yNjkzNjI_cf334407-6ec5-4bc6-96f7-4756766da99a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi02LTEtMS0yNjkzNjI_d7852cbf-3369-4824-a3b9-3bb9b4044e69">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi04LTEtMS0yNjkzNjI_35781970-f43c-4b5f-8e3c-5245538c61ca">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xMC0xLTEtMjY5MzYy_85413941-a9e3-4bf5-9043-599950184692">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xMi0xLTEtMjY5MzYy_fded2b13-2843-4e6c-a597-b0a4e4cd4f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xNC0xLTEtMjY5MzYy_6d507cc2-05a0-408c-a737-03fcb93304fa">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xNi0xLTEtMjY5MzYy_76772c2b-8b2f-4e36-829b-47928f7645b0">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0yLTEtMS0yNjkzNjI_755c7427-b405-4284-8d5f-98ef932e6f13">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy00LTEtMS0yNjkzNjI_b5f19249-445f-4656-8f80-cbad722edeb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy02LTEtMS0yNjkzNjI_b3e2fc46-143e-4121-9154-fda379c3f715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy04LTEtMS0yNjkzNjI_c6fe21ae-0f88-4258-b85c-5c65519632ba">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xMC0xLTEtMjY5MzYy_4401c391-f619-4dcc-ae18-8c9d3d03e143">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xMi0xLTEtMjY5MzYy_c727839b-1ceb-4e04-b958-0878bbebb1d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xNC0xLTEtMjY5MzYy_b5f9e688-898a-47b3-97e3-653a22ef6cdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xNi0xLTEtMjY5MzYy_26426156-0487-4998-af18-0b823b2a01c3">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0yLTEtMS0yNjkzNjI_9bca3d32-faea-4f6d-a364-0121b06ac551">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC00LTEtMS0yNjkzNjI_fbcf0ed5-018d-4e6b-8600-614462bf8924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC02LTEtMS0yNjkzNjI_26f4024d-31e0-4bcd-ba6b-701662e006b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC04LTEtMS0yNjkzNjI_b15d8e2f-afab-4092-8fb4-ea7df2ea2ebf">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xMC0xLTEtMjY5MzYy_bb11ca0e-ca71-439e-a9a1-b3c11678e9b3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xMi0xLTEtMjY5MzYy_e945b14b-88e7-4ca7-aedc-8f32b96cf6e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xNC0xLTEtMjY5MzYy_afe88da8-70b6-429c-9cd5-c2b1ea068d3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xNi0xLTEtMjY5MzYy_0cd294a6-5f31-45da-9b7c-1771800c23de">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0yLTEtMS0yNjkzNjI_e9daac95-a17d-4c7d-a14b-f221e85f835c">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS00LTEtMS0yNjkzNjI_0c8906d0-1832-4d34-817d-d89365e85c30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS02LTEtMS0yNjkzNjI_20965dc0-881e-48f6-8ec2-638c3d5c0fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS04LTEtMS0yNjkzNjI_2ef99c1e-16bd-4de2-bc00-d5800c0c27fd">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xMC0xLTEtMjY5MzYy_8bdff428-7717-4071-b009-cea2600b6f1d">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xMi0xLTEtMjY5MzYy_62604674-7dbb-42d6-a1d1-2e002f2a0b05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xNC0xLTEtMjY5MzYy_e669b9e1-9855-40bb-b319-9bf6051fd240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xNi0xLTEtMjY5MzYy_417fd88a-f038-4947-b872-2a75b8ecd7b8">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0yLTEtMS0yNjkzNjI_1d62b0b2-99a1-485b-a4ed-84291d021d73">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi00LTEtMS0yNjkzNjI_8040c8a4-6ad3-4094-a257-2add176e3af2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi02LTEtMS0yNjkzNjI_bc35dd22-e197-4b26-b842-634bd00fc6ee">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi04LTEtMS0yNjkzNjI_75781ce7-637e-403d-a477-241ee342da5c">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xMC0xLTEtMjY5MzYy_e4bacb03-c4dd-4a05-921c-9969bb88230e">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xMi0xLTEtMjY5MzYy_49b25dab-5e5b-45c7-8f6e-a110a2090dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xNC0xLTEtMjY5MzYy_47f50990-c5fc-43dc-bf87-fae28ff397f7">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xNi0xLTEtMjY5MzYy_b4c86bfd-9d12-416d-bf73-bebbfdfe0066">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0yLTEtMS0yNjkzNjI_665e2e5a-618f-4244-a2f7-00355324e736">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy00LTEtMS0yNjkzNjI_6ab5377c-e1fc-4636-96cf-7c4b607b3456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy02LTEtMS0yNjkzNjI_8b29d7ae-42c8-4b57-8dbc-ac15683ef079">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy04LTEtMS0yNjkzNjI_3c165ff4-6868-4716-a74b-7ce7837dacd3">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xMC0xLTEtMjY5MzYy_ac10514f-0f5c-40a5-84c2-d8f9206b983f">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xMi0xLTEtMjY5MzYy_e657be81-8327-446a-8692-3c3705f83912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xNC0xLTEtMjY5MzYy_480c9375-93db-4166-b023-d6de105f3679">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xNi0xLTEtMjY5MzYy_811a5d15-4a01-49d3-a085-3c04d0e6b386">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0yLTEtMS0yNjkzNjI_90357f21-4c85-4687-917c-a564c50d1ab6">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC00LTEtMS0yNjkzNjI_7b82a91b-cc2c-4731-a2b3-fdb36a7bd79e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC02LTEtMS0yNjkzNjI_12cb1bef-0f2e-4b0b-ba45-e90898c8b750">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC04LTEtMS0yNjkzNjI_d884ce51-72c9-4242-bbfa-c0c0f53affe7">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xMC0xLTEtMjY5MzYy_5eecd519-9359-4729-9607-548e4051ad15">2,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xMi0xLTEtMjY5MzYy_7c13aba1-8655-4290-b6a8-9d44d1cb333f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xNC0xLTEtMjY5MzYy_2e02bc77-b40f-410b-acbf-0fbdfbf810eb">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xNi0xLTEtMjY5MzYy_e9ec2a0e-8bbb-4271-8eed-3a2d65b973f8">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfNDk0NzgwMjMzMjAxMA_d6752bb9-8ec7-4b96-9c48-c7935fa2bf7a" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:40.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy0yLTEtMS0yNzQ4NjI_f77874b6-56e9-43b9-ab8c-61f295b6196a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy00LTEtMS0yNzQ4NjI_7585a0f6-4048-4bb5-abfb-ac2a27205939">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy02LTEtMS0yNzQ4NjI_31174a0b-85a3-4704-8ca9-edef239c751f">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy04LTEtMS0yNzQ4NjI_bea630c6-0066-46d2-99cb-41d87ad01cc5">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy0xMC0xLTEtMjc0ODYy_901b09f6-9cd0-4ade-a05c-44446a2a7aed">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy0xMi0xLTEtMjc0ODYy_4619fa0b-56d8-4792-817c-5719889dbce9">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC0yLTEtMS0yNzQ4NjI_35cbdc3a-4497-4412-990a-eae3d2678334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC00LTEtMS0yNzQ4NjI_557c5de9-cb9a-4869-98b8-2f56cc54fe2e">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC02LTEtMS0yNzQ4NjI_4fb0bf02-ed74-4f1e-969a-c621ef3b7039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC04LTEtMS0yNzQ4NjI_74cf20bb-ac5e-4aa5-890d-02c0cccb0694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC0xMC0xLTEtMjc0ODYy_a9982bf6-b9f7-4614-be24-3d7ede297b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC0xMi0xLTEtMjc0ODYy_e327b5c6-49d8-4c41-8d3b-18f00b2ae420">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS0yLTEtMS0yNzQ4NjI_a1d8677b-4deb-4fab-964e-1f92556146d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS00LTEtMS0yNzQ4NjI_39f7cb6e-1395-412b-a958-740419455f68">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS02LTEtMS0yNzQ4NjI_e73a66f1-5157-488d-960f-7a6d5276d11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS04LTEtMS0yNzQ4NjI_e398b98b-ddcb-4233-b414-cb5f2104f44a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS0xMC0xLTEtMjc0ODYy_09870062-7e73-4f26-b575-808b9304a23d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS0xMi0xLTEtMjc0ODYy_ed236aeb-c333-4436-93fa-aa81cd344471">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy0yLTEtMS0yNzQ4NjI_2bf961d6-fce2-453f-acde-c34da6b3debd">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy00LTEtMS0yNzQ4NjI_099360f5-547f-4420-bb31-725b537a114a">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy02LTEtMS0yNzQ4NjI_8db8998c-9cf1-4780-9694-7da1d34869fb">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy04LTEtMS0yNzQ4NjI_93fac00d-64e2-44dd-b8cd-c9154225c295">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy0xMC0xLTEtMjc0ODYy_69aacde3-74bf-4edf-8ce3-8d0b182bccb8">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy0xMi0xLTEtMjc0ODYy_27f3ebdf-1b34-49ab-bf0e-cfef87de6ed1">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC0yLTEtMS0yNzQ4NjI_5180ba5c-a183-4038-8799-e14c81f796f4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC00LTEtMS0yNzQ4NjI_1725daef-88ae-408f-a447-0b45388df634">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC02LTEtMS0yNzQ4NjI_7459089d-cc8a-489b-b073-2585349f1df6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC04LTEtMS0yNzQ4NjI_50f2e0d0-9db6-4b41-bbb4-4cd613e1417a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC0xMC0xLTEtMjc0ODYy_257348a6-b342-4fc1-9b66-4380b9bd495e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC0xMi0xLTEtMjc0ODYy_8b838593-7ab8-4ab5-bcfa-1441ff1ad1ba">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS0yLTEtMS0yNzQ4NjI_9d638e5e-e93f-4926-955a-c5262876d72a">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS00LTEtMS0yNzQ4NjI_b2835814-3325-4c22-bb3c-6b4cf6257fd1">862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS02LTEtMS0yNzQ4NjI_495055cb-8f21-460f-a91b-0852276319d0">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS04LTEtMS0yNzQ4NjI_01cf50d2-6b03-47fa-9b8a-45c8a69fb647">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS0xMC0xLTEtMjc0ODYy_ecac2c69-b942-4776-86d4-5607289fae30">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS0xMi0xLTEtMjc0ODYy_ed2aa53e-4960-4d7a-87bb-4f4c0de6437c">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy0yLTEtMS0yNzQ4NjI_765f619a-a0e9-44bb-a46d-128abd494595">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy00LTEtMS0yNzQ4NjI_a7ae1c1c-45b8-4992-a949-86deff5d7610">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy02LTEtMS0yNzQ4NjI_4d9fabd1-b0cd-45a7-845e-81bb24b7e9b7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy04LTEtMS0yNzQ4NjI_fa4e0177-4d16-4bdb-9d32-1d60bda74762">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy0xMC0xLTEtMjc0ODYy_59193321-1925-4170-bd70-b1a2826b4139">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy0xMi0xLTEtMjc0ODYy_1afee0bb-3be4-4c4e-ade5-284873812bca">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC0yLTEtMS0yNzQ4NjI_ef2b28f2-7855-4a67-a924-c0fc6489678a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC00LTEtMS0yNzQ4NjI_9a0ae341-0343-4c84-8740-184bc5f02397">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC02LTEtMS0yNzQ4NjI_06d0da55-3a33-4232-9fa6-6e6ac0a9d2b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC04LTEtMS0yNzQ4NjI_679e9148-8737-435c-9c51-aded54f95e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC0xMC0xLTEtMjc0ODYy_a5d0a5de-ef06-4224-8a75-444d73a3076e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC0xMi0xLTEtMjc0ODYy_1f1f749a-a70e-4999-a0d5-d8cc530836c6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS0yLTEtMS0yNzQ4NjI_74c324bc-a8b8-4327-878d-e74825189f68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS00LTEtMS0yNzQ4NjI_2806deb0-0d5c-48fb-bd78-22b61766132a">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS02LTEtMS0yNzQ4NjI_0a32496a-f503-4fc3-8b7a-127d223a05d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS04LTEtMS0yNzQ4NjI_0f80680f-6892-4ca7-b644-759d34c01edf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS0xMC0xLTEtMjc0ODYy_83dbcfaa-1bbd-430d-b9e3-06dcdd1a8c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS0xMi0xLTEtMjc0ODYy_e1894d3f-143c-4d71-8d66-609afc9c268d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy0yLTEtMS0yNzQ4NjI_0f75a962-df21-4327-bfaa-5d4862e82ddc">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy00LTEtMS0yNzQ4NjI_bb4d4b77-bdc4-41ed-b0ab-392d4947ec7d">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy02LTEtMS0yNzQ4NjI_c371e1a6-b710-438b-b728-e7c44cb37024">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy04LTEtMS0yNzQ4NjI_99a3c106-bb70-42fb-84a6-c4ed2c40786e">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy0xMC0xLTEtMjc0ODYy_2b2a0998-af48-4e24-bfda-02e67b991113">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy0xMi0xLTEtMjc0ODYy_43e85479-3b94-4152-8b7c-78d24cfd6c7c">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC0yLTEtMS0yNzQ4NjI_af5ff988-11c1-40aa-9237-0068cd2d361a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC00LTEtMS0yNzQ4NjI_9f4d885f-80cb-4bdf-a6a3-3a275d043b70">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC02LTEtMS0yNzQ4NjI_aeffe6e2-d546-472e-8ced-04b62fe8411a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC04LTEtMS0yNzQ4NjI_0c43fb82-86df-42c3-ba74-8f68af14f4b4">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC0xMC0xLTEtMjc0ODYy_74e35433-ecb6-41c9-9258-3e883be10dad">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC0xMi0xLTEtMjc0ODYy_7330d13b-656f-4d28-8fa2-333f93a71549">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS0yLTEtMS0yNzQ4NjI_681278d5-e027-439a-96d6-2be10797bf46">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS00LTEtMS0yNzQ4NjI_7374ddad-1bbd-4796-a295-452e281d401e">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS02LTEtMS0yNzQ4NjI_197f8002-5230-449e-9383-f545d935ab27">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS04LTEtMS0yNzQ4NjI_e30e8b95-32fe-4812-98e0-3a03b0ed7adc">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS0xMC0xLTEtMjc0ODYy_5551e6d6-81ea-401b-b3e3-13dbfe559dd8">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS0xMi0xLTEtMjc0ODYy_84bee0de-42d2-4d5c-bbf2-6fd794e452fd">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTA5OTUxMTYzMDU4Mw_ec83a4de-f3df-4687-b22a-042cf6deb857">No</ix:nonFraction> allowance for credit losses was recognized for investments with unrealized losses as of March&#160;31, 2023 as the unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments. We do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases.</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjEyNQ_16a1f23f-fa08-487b-b626-ad5726422140" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9f4eec9e644776964e5a8b7a54bd46_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMS0yLTEtMS0yNjkzNjI_8a5f052a-dba0-40b4-9348-1e127cf8905e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2e973c5db44ac4ae316708dcf05f82_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMS00LTEtMS0yNjkzNjI_71b3e768-b992-4d31-b2c0-dc242a6ab1eb">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510d5f78872c4535851a18295b4f79b6_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMi0yLTEtMS0yNjkzNjI_b5f690a6-12f9-4601-9f61-230d267f12fd">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ee9e4a34394e0981b4f0da01de2965_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMi00LTEtMS0yNjkzNjI_259bb323-1b25-4abd-af07-6ef9e7fd4c9b">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87e5e8c32c24d6b861c84c1383d9257_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMy0yLTEtMS0yNjkzNjI_5289bd89-a6f3-44f3-b822-750331523241">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3d373c59d041b98c7a3bfed37f67b0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMy00LTEtMS0yNjkzNjI_b1630379-15c1-4e26-9846-e5569d92ffbf">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfNC0yLTEtMS0yNjkzNjI_aeba9180-bc55-47b7-894f-ae6e28c9800b">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfNC00LTEtMS0yNjkzNjI_eb996be0-b505-45c5-880c-89b03ebfe3cc">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6a5d925ea71c43249758102f24a6849f"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjEyMQ_cf1f6298-015e-4721-a50a-c98c8d7f7caf" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMi0yLTEtMS0yNjkzNjI_f105dece-c9c2-47ea-bf4f-ceb5d2061e31">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMi00LTEtMS0yNjkzNjI_62a0caf0-114b-450d-bfff-7b01e1fcd76a">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMy0yLTEtMS0yNjkzNjI_9e79c203-cecc-4590-9bdc-46390b4e0197">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMy00LTEtMS0yNjkzNjI_678ca2ce-84ae-487c-9209-4acefce9fb7d">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNC0yLTEtMS0yNjkzNjI_0f2b4b7d-def8-4e66-b2de-d485dbc982ad">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNC00LTEtMS0yNjkzNjI_0db4bf4e-f659-49b8-8b5d-7ff831c1ad7c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNS0yLTEtMS0yNjkzNjI_056b734d-29b0-4810-8ee3-2f75a361aaeb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNS00LTEtMS0yNjkzNjI_1b0804bf-ab83-4d1d-998d-773334c1d3fb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNi0yLTEtMS0yNjkzNjI_3cc7ba34-d35c-498c-9f47-9238f25b0d72">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNi00LTEtMS0yNjkzNjI_a86b7c82-1f37-4df5-beb2-cfe7334470a7">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Securities</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Measured at Fair Value</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjE0NQ_99d65e69-3a9a-41ba-a774-b42eecfa3e50" continuedAt="i3e52e55adc0749a7aa60270137796d89" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9f4eec9e644776964e5a8b7a54bd46_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMS0yLTEtMS0yNjkzNjI_6b857f45-89ec-43c8-a050-60a5cffccbfb">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2e973c5db44ac4ae316708dcf05f82_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMS00LTEtMS0yNjkzNjI_9b5c1bbc-7a6f-4d22-a2e5-75fb8e61c341">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2356957a154f63a357aa595e78976a_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMi0yLTEtMS0yNjkzNjI_9cbdcb34-7368-42bc-b2e8-ad2fbcfc6ecd">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6343117edb334debb880ca01f650cb9f_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMi00LTEtMS0yNjkzNjI_70389aa2-602f-400a-a8d7-446ff8d4c373">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51b601fb20040c198873c13a12ac3d8_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMy0yLTEtMS0yNjkzNjI_283f95e1-7464-4876-a795-72aa976d7fb1">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc9e7315e954128826864d8f2720166_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMy00LTEtMS0yNjkzNjI_89c36bef-3acf-485b-ad38-2f828fc7bec0">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d904395d75449c6b4a29ead472571b4_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfNC0yLTEtMS0yNjkzNjI_e575f6fe-527a-4101-9273-891b8a63b693">4,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6353ae110f4676995da4b3e2534756_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfNC00LTEtMS0yNjkzNjI_34aa8253-f40f-4a31-8129-778433601bbb">5,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i3e52e55adc0749a7aa60270137796d89" continuedAt="i704f829522cc4d8ca9813a427229bf27">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i704f829522cc4d8ca9813a427229bf27"> &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.</ix:continuation> </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTQzNg_c6f896a5-bcd4-4b02-acfa-a0b4ffb1d4ec">333</ix:nonFraction> million</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTQ0Mw_919e288d-ca5a-4f11-a0d6-2207c07d650d">423</ix:nonFraction> million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrealized Gains and Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized on equity securities were $<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTYwMA_4e5aae3c-b921-4585-8c2b-2de1cfb1f70e">256</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjE5OTAyMzI2MTgwMg_1323ca9e-b5ab-45a4-a9e8-6bd4b498ace2">96</ix:nonFraction>&#160;million for the three months ended March 31, 2023, and 2022, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjk5Mw_0695c3b0-51f7-433f-8291-27dc94eaa30f" continuedAt="i02b7291ad1c842a895e12eb2a8ff41db" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i02b7291ad1c842a895e12eb2a8ff41db" continuedAt="i0f620753c3b84421baa7cc43ca1ad2f9"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzNTQxMA_a9c84102-932f-4724-8a07-06e064e1e0be">18</ix:nonNumeric> months or less. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held foreign currency exchange contracts with outstanding notional amounts of $<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjI5MQ_777f61db-60c6-4922-ba41-4d99244c1c2d">2.9</ix:nonFraction> billion as of March&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjMwNw_f079eaa6-a770-4830-8836-6c8d43e43faf">3.0</ix:nonFraction> billion as of December&#160;31, 2022. </span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjk3Mw_8cb88ae9-0f7c-4f7c-a3a7-3baca6c9b4d6" continuedAt="i674cb310215b4eb6875806d06a75ba6a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 25.75pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5635d77dfe96415b8fb073a7a5cea4f6_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNC00LTEtMS0yNjkzNjI_76596b10-f186-4995-b465-b52b38b7de66">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22760aef3ef40599b18170cf792b16b_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNC04LTEtMS0yNjkzNjI_a49867ca-d964-4356-be8a-62444866bd1f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711389022cab421e9b3754a803e7423a_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNS00LTEtMS0yNjkzNjI_6caff572-4be3-474b-9230-e5c46c0b9a38">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acaacfcea4242ec9bbcbe69b9091425_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNS04LTEtMS0yNjkzNjI_ac4199bc-c433-4c11-bb45-495b59759d69">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0206d1fc4e7644e2afbdb52420fef11b_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNi00LTEtMS0yNjkzNjI_ddb81187-3f06-41f2-a263-13908e72853d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0206d1fc4e7644e2afbdb52420fef11b_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNi04LTEtMS0yNjkzNjI_4d919148-8ae0-427a-8371-df9a755c0912">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725217d7109d45ce87fd002dc195f7c6_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOC00LTEtMS0yNjkzNjI_577b622c-3a95-4838-bd14-1792071cee1b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6fdd16179f433088b6dc239a41cdd7_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOC04LTEtMS0yNjkzNjI_1cdf8e3e-797c-49f8-a910-6a3a5263f55d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5853354bfe4cce8964c6ee51f3ad72_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOS00LTEtMS0yNjkzNjI_7f03cb27-5f05-4ddd-ae60-65f7242550d5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5853354bfe4cce8964c6ee51f3ad72_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOS04LTEtMS0yNjkzNjI_940e6e62-eec6-40ea-bbbc-742a91ccab05">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTAtNC0xLTEtMjY5MzYy_43ae392b-6252-44b0-ba3d-750a4af37f74">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTAtOC0xLTEtMjY5MzYy_5378021a-5ce6-4bbe-9bdd-bae1cfcc62ba">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTMtNC0xLTEtMjc1NDAx_1859db4c-d5aa-4b8c-9d2b-c70386fa67d0">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTMtOC0xLTEtMjc1NDAx_81c9bf05-bf39-4b21-b19f-e217f1337908">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTQtNC0xLTEtMjc1NDAx_82d30df3-9f50-465a-885d-ccccc41455cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTQtOC0xLTEtMjc1NDAx_a7f0a02a-f570-40ba-bec8-8e1dd7e3f973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTUtNC0xLTEtMjc1NDAx_be46b34d-c546-48e0-8c49-069efccf557a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTUtOC0xLTEtMjc1NDAx_317266c9-d74a-4ff3-b46a-be8fb3bf6b3d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0f620753c3b84421baa7cc43ca1ad2f9"><div style="margin-top:4.5pt"><ix:continuation id="i674cb310215b4eb6875806d06a75ba6a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb59ef088a34337a2c34aded0358835_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNC00LTEtMS0yNjkzNjI_c4843b80-9e0a-41b1-a5c4-673d23d7e94e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0273ef720045479f9a269b27d3e723bc_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNC04LTEtMS0yNjkzNjI_32b8aaaa-30ed-4e6e-b5f5-8830750fbe09">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b209667eea74724a7b9275aafea9399_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNS00LTEtMS0yNjkzNjI_bbc146c3-206d-44b2-939e-8a16f19bfe88">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4ed3db406545adbb4af3cbdee68817_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNS04LTEtMS0yNjkzNjI_65cd4307-6948-4abd-8a4d-73754f9e79a1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f7dcb7986040429aa8c1583d69150a_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNi00LTEtMS0yNjkzNjI_70310f96-9718-45ed-a2c3-0a3ac2b8a568">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f7dcb7986040429aa8c1583d69150a_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNi04LTEtMS0yNjkzNjI_6dae1954-9f2a-4ea0-aa0c-8543de7ba4ff">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7080bfe269540189101c2421e6675ad_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOC00LTEtMS0yNjkzNjI_ac4dcc90-288a-4c76-b015-3f3d76a64fd6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c00e7d8b1e4ef485fcb73e58436bd3_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOC04LTEtMS0yNjkzNjI_aa770035-9706-42ed-b2e4-f119ad5866b7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib882e81dd83841ac984af47ed8b513e9_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOS00LTEtMS0yNjkzNjI_309c2964-4c4a-4ea1-adb4-f7c6c73b3eb4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib882e81dd83841ac984af47ed8b513e9_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOS04LTEtMS0yNjkzNjI_6dcead08-977f-43dc-ba97-69537bc3c9d5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTAtNC0xLTEtMjY5MzYy_b618ae0a-8d4f-407d-8bb9-24a7ced8f722">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTAtOC0xLTEtMjY5MzYy_2b338e58-a004-4b34-81cb-e34fe7bc385c">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTMtNC0xLTEtMjc1NDE4_a904e35b-f10a-4d84-9c17-cf7b052238b8">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTMtOC0xLTEtMjc1NDE4_a3c7eb51-1c1d-41e3-8406-078ee145239b">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTQtNC0xLTEtMjc1NDE4_0c5c4c89-0069-4eed-a39a-1a9194a59820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTQtOC0xLTEtMjc1NDE4_416c4ab2-0e12-4840-9b62-9d68b2e8ff4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTUtNC0xLTEtMjc1NDE4_78d4bc7b-34e4-461f-8122-00bcf51385e0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTUtOC0xLTEtMjc1NDE4_e85fc7aa-3e60-4017-81a9-61f3ffc2bda5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjk2NA_dba4e405-c3e6-46f2-9e80-1ab6bc9d8dd8" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) recognized in Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNC0yLTEtMS0yNjkzNjI_66a4871c-b467-4451-984f-967da07001e1">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNC00LTEtMS0yNjkzNjI_047d7010-f956-4668-b4fb-827a359fdbfe">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain reclassified from Accumulated other comprehensive income into Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNS0yLTEtMS0yNjkzNjI_9b2c8aca-9df2-4dba-b575-8fe761da5d2b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNS00LTEtMS0yNjkzNjI_97760705-5db5-4e85-8887-39939a7d2328">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNy0yLTEtMS0yNjkzNjI_41e5effb-bc64-4d37-852f-4279bef0eb32">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNy00LTEtMS0yNjkzNjI_5d7a445a-1207-4e46-b3bf-9c78830ff7e1">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of March&#160;31, 2023 are expected to be reclassified to Product sales within <ix:nonNumeric contextRef="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzMzUzNw_6d4f57ed-c879-427c-b215-9a355a4695d2">12</ix:nonNumeric> months. There were <ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-8" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzMzU1NA_12f0a02d-7d4e-4e22-8e6a-b16fa90c9e32"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-8" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzMzU1NA_263f4969-774e-4d33-9a2a-e488cc1d3b55">no</ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the three months ended March 31, 2023 and 2022 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div id="i78cdcb1572754b6c94699d07bd7f2fd4_549755814941"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzM4NDgyOTA3MDg0MTE_8c8694a6-586d-4048-aad9-e9a309a3376a" continuedAt="i2ca5c8228e894befaf645474047f5aaa" escape="true">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2ca5c8228e894befaf645474047f5aaa" continuedAt="i734e2a8858f9424299a351744fc4fb49">We enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i734e2a8858f9424299a351744fc4fb49"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tmunity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed an agreement to acquire Tmunity Therapeutics, Inc. (&#8220;Tmunity&#8221;), a clinical-stage, private biotechnology company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $<ix:nonFraction unitRef="usd" contextRef="i644b5cd4730b4d5982cd086b35235aeb_D20230222-20230222" decimals="-6" name="gild:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzEzMzM_6e60959c-9fc5-4390-ba9c-6a3edbdb1cc3">300</ix:nonFraction>&#160;million in cash consideration. As a result, Tmunity became our wholly-owned subsidiary.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition and recorded a $<ix:nonFraction unitRef="usd" contextRef="i506cbd3ce6ca465992effd4d69548672_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzIxOTkwMjMyNjIzNzA_7399c2ec-a1e6-462f-a85a-f7ec558eedd9">244</ix:nonFraction>&#160;million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income during the three months ended March 31, 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed, consisting primarily of deferred tax assets. Under the agreement, the former shareholders of Tmunity and the University of Pennsylvania are eligible to receive a mix of up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie59389bcaac841308152584683c981e2_I20230331" decimals="-8" name="gild:PotentialFutureMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzU0OTc1NTgyOTkzNQ_4cf0f006-5754-4e3a-860d-31123da206ad">1.0</ix:nonFraction> billion in potential future payments upon achievement of certain development, regulatory and sales-based milestones, as well as royalty payments on sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Collaborations and Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arcellx</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, Inc. (&#8220;Arcellx&#8221;) to co-develop and co-commercialize Arcellx&#8217;s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future next-generation autologous and non-autologous products. In conjunction with the collaboration agreement, we recorded a $<ix:nonFraction unitRef="usd" contextRef="if7e7f985abe641bf816e52117d2bceef_D20230130-20230130" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzgyNDYzMzcyMTk2OTU_845f7972-64cb-4d8c-aa8b-b22bcab42074">212</ix:nonFraction> million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income during the three months ended March 31, 2023, primarily related to an upfront payment, as well as a $<ix:nonFraction unitRef="usd" contextRef="if7e7f985abe641bf816e52117d2bceef_D20230130-20230130" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzM5NTE_15f8faee-0856-46f1-b040-74117dcd3ee9">115</ix:nonFraction>&#160;million equity investment, which is subject to lock-up provisions until July 2024, in Other long-term assets on our Condensed Consolidated Balance Sheets. The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits <ix:nonFraction unitRef="number" contextRef="i7994adfb551a4093b62e6cfbc11bfe49_I20230130" decimals="2" name="gild:RevenuePerformanceObligationPercentageOfUSProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzQxODQ_5a68e467-6388-4eba-a0b7-23806bc9e14b">50</ix:nonFraction>/<ix:nonFraction unitRef="number" contextRef="ie49fa68b1f2d482184e980aaa5e1c250_I20230130" decimals="2" name="gild:RevenuePerformanceObligationPercentageOfUSProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzQxODc_79217ab8-2858-4776-87db-e0515b75d045">50</ix:nonFraction>. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales. Arcellx is eligible to receive performance-based development and regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i7994adfb551a4093b62e6cfbc11bfe49_I20230130" decimals="-6" name="gild:PotentialFutureMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzc2OTY1ODE0MTIwMDE_2df020fa-0c38-4ebb-bc96-66572ae6227d">835</ix:nonFraction> million related to CART-ddBCMA, a potential future next-generation autologous product and a potential future non-autologous product, with further commercial milestone payments, profit split payments on co-promote products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts-in to co-promote on the future products. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promote products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts-in to co-promote these additional future products as well.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a transaction with Pionyr Immunotherapeutics (&#8220;Pionyr&#8221;), a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate agreements, one related to the initial acquisition of a <ix:nonFraction unitRef="number" contextRef="i9e1c0e3aad754d999d54e43dd7074379_I20200619" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzgyNDYzMzcyMjA5NzE_1a6e5c99-a74c-4eb5-843e-228a43f429b7">49.9</ix:nonFraction>% equity interest in Pionyr and the other providing us with the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (&#8220;Pionyr Merger and Option Agreements&#8221;). The exclusive option had an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i9e1c0e3aad754d999d54e43dd7074379_I20200619" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzU0OTc1NTgyODM5MQ_77e9380d-8dff-40de-919b-265e7be2c86e">70</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. In March 2023, we waived our exclusive option to acquire Pionyr and certain other rights under the Pionyr Merger and Option Agreements and recorded a $<ix:nonFraction unitRef="usd" contextRef="i3e84714994f54c519010f82389507cd7_D20230101-20230331" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzgyNDYzMzcyMjEwMjk_08f4f41e-cfdb-4043-8288-570c0875edc7">70</ix:nonFraction> million charge to Other income (expense), net on our Condensed Consolidated Statements of Income. We will retain our equity interest in Pionyr as well as the right, under certain conditions, to review new data as it emerges.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjk4Mg_983d6e9e-1de4-4315-818c-f0a96029de61" continuedAt="ie15e9d47fd354ce9b54f7106196f55d2" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="ie15e9d47fd354ce9b54f7106196f55d2" continuedAt="idb63941afd8747e3a7b3f84620bc57cd"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMzAwOQ_3f3c387b-3a00-4077-b88c-6f8f2744c712" escape="true"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMzAxMA_1746b239-f3c8-4f9b-b79a-80a192d13418" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0yLTEtMS0yNjkzNjI_503c0f3b-184a-4b39-9d0c-8a4ac30c680b">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy00LTEtMS0yNjkzNjI_1c5f6be9-c35f-4388-ab47-7579a58b0df4">6,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy02LTEtMS0yNjkzNjI_8de29ff6-de31-4585-9611-ad62fb722603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy04LTEtMS0yNjkzNjI_0f704781-ed11-4fee-a461-386b495ace54">4,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xMC0xLTEtMjY5MzYy_cb30e9d9-890e-453e-9a2b-498a5e53be62">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xMi0xLTEtMjY5MzYy_5276a731-d7af-4fb5-b36c-b34060872ff8">6,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xNC0xLTEtMjY5MzYy_2e8c9a28-7fe4-48b2-a677-973f82f49c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xNi0xLTEtMjY5MzYy_87a641e0-f9dd-476c-9b95-f64b34aa0916">4,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0yLTEtMS0yNjkzNjI_72a96777-974d-41ba-8a41-f48048387daa">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC00LTEtMS0yNjkzNjI_61fbb95b-df96-444b-9e68-dec23c0d527c">2,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC02LTEtMS0yNjkzNjI_06aa1a3e-91ce-4a2a-8cf5-a002cc590ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC04LTEtMS0yNjkzNjI_4e68e479-0a49-4d0a-b173-011e0c4b5aca">5,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xMC0xLTEtMjY5MzYy_0087d078-fe13-4dd0-82e2-21fe3ee7c12b">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xMi0xLTEtMjY5MzYy_3f384135-713a-454a-8529-483b73c127ac">1,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xNC0xLTEtMjY5MzYy_9ffb795f-ad1d-49e4-ba6a-0089bbdfa21b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xNi0xLTEtMjY5MzYy_afa250f8-1c0c-4b04-b886-15cbeb1f6830">5,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0yLTEtMS0yNjkzNjI_18246893-0112-4f66-ba0e-a8d21bd40d95">11,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS00LTEtMS0yNjkzNjI_3234a9ad-8caa-4e06-8abe-b02d9a888f70">1,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS02LTEtMS0yNjkzNjI_76543005-687d-49b3-b70b-8664f1fe5464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS04LTEtMS0yNjkzNjI_324d6e02-57c5-4557-b3e2-b287adda9726">10,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xMC0xLTEtMjY5MzYy_707bc35a-5b5e-47dc-a5e7-811fc2a8198b">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xMi0xLTEtMjY5MzYy_a9b48719-0e76-4b83-a874-4b351d893a65">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xNC0xLTEtMjY5MzYy_447d0a84-1488-4135-bffb-b832ed8f2060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xNi0xLTEtMjY5MzYy_c3127ce4-2ec7-4d98-a951-0224d09c0b7c">4,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0yLTEtMS0yNjkzNjI_4ff38d5f-bd13-4338-bb2d-1b0b9f5a7991">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi00LTEtMS0yNjkzNjI_27394688-a6a8-4728-91bc-46b87098d900">179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi02LTEtMS0yNjkzNjI_bb27fc26-538e-484f-8acd-96cc74101548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi04LTEtMS0yNjkzNjI_370549d7-0d9a-4496-81b0-fd4a1aeffcdf">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ff5746ef9a40388f4773379f847193_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xMC0xLTEtMjY5MzYy_4b1d86e9-6365-4508-beb3-6ca0b5d0a626">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30ff5746ef9a40388f4773379f847193_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xMi0xLTEtMjY5MzYy_acc3b624-d809-41d5-8527-6b1920e39bf7">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ff5746ef9a40388f4773379f847193_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xNC0xLTEtMjY5MzYy_d21e78c6-6387-4a1f-8b45-a007f4b3e397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30ff5746ef9a40388f4773379f847193_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xNi0xLTEtMjY5MzYy_241c5d19-8b2c-4c7b-bc22-27641b18f395">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0yLTEtMS0yNjkzNjI_a167f6ab-1ead-4885-8ee1-949bc619a504">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy00LTEtMS0yNjkzNjI_bbf67abb-c86b-467c-b910-3fd87cd4ddf0">762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy02LTEtMS0yNjkzNjI_827145ac-69e3-430b-ab82-ffd2da2158aa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy04LTEtMS0yNjkzNjI_323cd7ab-f8a7-4439-a546-48803e0a4574">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xMC0xLTEtMjY5MzYy_a82b4b3f-f63b-458d-bbeb-ffe89c175dc4">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xMi0xLTEtMjY5MzYy_8e1b4475-6897-4d34-90af-8b42c693c1e8">733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xNC0xLTEtMjY5MzYy_5ad8d79e-ffe1-4de0-9520-9e5163b689b9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xNi0xLTEtMjY5MzYy_fbc501cb-e9ac-4941-917c-a1aacf1f98ea">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0yLTEtMS0yNjkzNjI_431b10ec-27ad-4514-8925-0316ed308ad3">31,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC00LTEtMS0yNjkzNjI_2d3a2303-5c35-4b33-b047-125e5828371b">10,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC02LTEtMS0yNjkzNjI_217bb2aa-4dbf-432d-81bf-a242b886be6d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC04LTEtMS0yNjkzNjI_d9c2f5b3-6fc6-4f39-8608-9f64ffbbf50d">21,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xMC0xLTEtMjY5MzYy_812ca1c0-7349-46f2-8bfe-7b4501e70d3e">25,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xMi0xLTEtMjY5MzYy_6ba39272-2d16-401e-836b-9d08db007655">10,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xNC0xLTEtMjY5MzYy_671c6634-fa4f-456f-9a5f-efc68e2967ac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xNi0xLTEtMjY5MzYy_806c1b86-d206-4f41-8c09-68833f2265bc">15,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0yLTEtMS0yNjkzNjI_ecdc96f7-3115-4dc4-9025-06fc8131e904">7,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS02LTEtMS0yNjkzNjI_95048c05-552a-4e0b-bf4d-9cd1881cf1da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS04LTEtMS0yNjkzNjI_e3f9e80c-47e4-4554-9f44-0f5125246450">7,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875d511da18240e9bc3567ad24abf2e8_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0xMC0xLTEtMjY5MzYy_98978918-0821-46b0-93b2-0bca757e5715">13,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875d511da18240e9bc3567ad24abf2e8_I20221231" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0xNC0xLTEtMjY5MzYy_fb9471e7-686e-4e76-98ec-57ed114e35f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875d511da18240e9bc3567ad24abf2e8_I20221231" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0xNi0xLTEtMjY5MzYy_3ff4e641-1706-4b66-a835-a5308af193f6">13,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMi0xLTEtMjY5MzYy_1a1bd0b8-0d28-4059-b5d9-20fbd9bfb9c8">39,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtNC0xLTEtMjY5MzYy_90fa29ac-d51b-49a5-87a4-9bca774725c7">10,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtNi0xLTEtMjY5MzYy_8ffe3c08-204c-4481-a75c-e19d24136924">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtOC0xLTEtMjY5MzYy_c07de3e2-a6f3-466b-a0d9-acb0459cff94">28,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTAtMS0xLTI2OTM2Mg_fc804adc-1cd6-46d3-81a4-e653e9160235">39,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTItMS0xLTI2OTM2Mg_216531b3-b470-443d-94d4-88889a6a6bdc">10,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTQtMS0xLTI2OTM2Mg_f5dd1374-4ee6-4ddb-a4d6-9b5e615bf8fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTYtMS0xLTI2OTM2Mg_ad022e7c-c2d2-4c25-8bee-5e7a64d27bb2">28,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $<ix:nonFraction unitRef="usd" contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331" decimals="-8" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMTA5OTUxMTY0MTgzMQ_c125badd-bdea-4931-b962-954605efd0f0"><ix:nonFraction unitRef="usd" contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331" decimals="-8" sign="-" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMTA5OTUxMTY0MTgzMQ_c1efc07a-d6a8-47d1-9dda-1b5cad80cad7">6.1</ix:nonFraction></ix:nonFraction> billion was reclassified to finite-lived assets in the first quarter of 2023.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfNDI0_eabd8333-77da-43f6-958e-ae285208769b">546</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfNTQ5NzU1ODIyOTk3_251864c0-1ccd-4b15-ae5d-6f0a06f35014">445</ix:nonFraction> million for the three months ended March 31, 2023 and 2022, respectively, and is primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjk3Mg_9c02674d-3c8c-4894-93b6-03b00ca60aa7" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2023:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfMS0yLTEtMS0yNjkzNjI_97fc31c3-682b-4ebd-a36b-9a96a19b898e">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfMi0yLTEtMS0yNjkzNjI_c31e6569-48f0-4b3b-9bad-d88129942d53">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfMy0yLTEtMS0yNjkzNjI_ab5d6caf-7035-41c0-af69-dd750ef5f408">2,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNC0yLTEtMS0yNjkzNjI_272ddbc0-9f8c-453d-b49f-626c92d3afaa">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNS0yLTEtMS0yNjkzNjI_a6ae5f80-5979-4aea-b915-3a9ff6de1d47">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNi0yLTEtMS0yNjkzNjI_adaf61ba-6213-460b-835f-57d0a1b03762">9,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNy0yLTEtMS0yNjkzNjI_bbb20ff0-5ae8-4760-9a46-aaf6ed2573ac">21,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No indicators of impairment were noted for the three months ended March 31, 2023 and 2022, except as described under &#8220;2022 IPR&amp;D Impairment&#8221; below.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idb63941afd8747e3a7b3f84620bc57cd"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 IPR&amp;D Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $<ix:nonFraction unitRef="usd" contextRef="i7c429589ccdf4bfea176e02c0cac635a_I20201231" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfODUy_64da9105-b508-41d6-8733-5fbee0ea12b8">8.8</ix:nonFraction>&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $<ix:nonFraction unitRef="usd" contextRef="if70af8c6a10b495e9247a23a7f7601b0_I20220331" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMTU3Mg_a4cfd776-cc97-4543-8cb5-41da4ff83a4f">6.1</ix:nonFraction>&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of <ix:nonFraction unitRef="number" contextRef="ib00d0aa9e5e94a278cb25a17dafeb1d9_I20220331" decimals="4" name="gild:IndefiniteLivedIntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjQ3Ng_82a165e6-ac29-459b-9851-e72a2fc2cf97">6.75</ix:nonFraction>% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9a2868046c1c40f5b963d0310b6e2c28_D20220101-20220331" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjgzMQ_ade40d71-ddc1-4027-812f-b8d75b10a9f6">2.7</ix:nonFraction>&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022.</span></div></ix:continuation><div id="i78cdcb1572754b6c94699d07bd7f2fd4_55"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzI4_6ef7e1d1-fc39-495d-b370-168847d7bd77" continuedAt="i872ba54d0e354c14b82b75d81494002d" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i872ba54d0e354c14b82b75d81494002d" continuedAt="id6369d8c963746828fa069ac646c6c32"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts receivable, net</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzIw_2b110234-5516-4903-8a7e-62e2f961c8d3" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMS0yLTEtMS0yNjkzNjI_0a82476f-4830-4ee2-841c-ee9f88f969f7">4,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMS00LTEtMS0yNjkzNjI_81e33e93-e01f-498a-8d78-1594cf542ba9">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMi0yLTEtMS0yNjkzNjI_6bfb05f7-c759-44c0-982a-dcba011c2a8a">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMi00LTEtMS0yNjkzNjI_b35da719-c476-41f6-ae3f-733fa7962e64">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMy0yLTEtMS0yNjkzNjI_f4a7b312-829f-494e-a204-574cc259a36e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMy00LTEtMS0yNjkzNjI_ac4a6cab-0129-4b2c-9e90-330c2b50c260">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNC0yLTEtMS0yNjkzNjI_d42ff7b6-35b6-40f1-b9e6-846372906e46">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNC00LTEtMS0yNjkzNjI_8907e12e-d943-4fa8-b4a1-0f31e6dcef17">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNS0yLTEtMS0yNjkzNjI_d3f9cab0-66e4-4670-91d1-9589d61323b9">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNS00LTEtMS0yNjkzNjI_2493ed46-3969-4435-908e-a2cf3067904a">4,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our trade accounts receivable arises from product sales in the U.S. and Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzM3_38f7980c-772b-4c31-b31c-c358d3dda040" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMS0yLTEtMS0yNjkzNjI_799e9397-546d-4f15-a8b1-e2dba807bb48">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMS00LTEtMS0yNjkzNjI_a484b391-ae4f-4b09-b3f3-7b1d09addc78">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMi0yLTEtMS0yNjkzNjI_cd1dd0e7-7b10-49fb-a416-472c5e5e614a">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMi00LTEtMS0yNjkzNjI_b31fc13a-fa69-4ca9-a4ea-6da998a987b5">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMy0yLTEtMS0yNjkzNjI_164325b8-c83f-497d-911c-861fb51d70d4">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMy00LTEtMS0yNjkzNjI_f55aa11c-971d-4054-8857-20d145765150">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNC0yLTEtMS0yNjkzNjI_50491089-ad2d-4aa6-8c6a-962e316eb94f">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNC00LTEtMS0yNjkzNjI_eaa0fb86-dcfb-46f7-8fb6-0399b50a3840">2,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNi0yLTEtMS0yNjkzNjI_2c6d6327-5a9d-417b-a78b-c01fc4c0f7ab">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNi00LTEtMS0yNjkzNjI_79c783b1-9229-4d7b-a142-7552d6e060e3">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNy0yLTEtMS0yNjkzNjI_9751622d-a2dd-4007-8002-6c66fb6ca36d">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNy00LTEtMS0yNjkzNjI_39f3884b-9876-41ac-811c-7d120fcfadcb">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfOC0yLTEtMS0yNjkzNjI_8670b99a-e1b8-40aa-b174-94fc766287a5">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfOC00LTEtMS0yNjkzNjI_e737ff3a-7960-48fb-84ab-765842aec10a">2,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id6369d8c963746828fa069ac646c6c32"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other current liabilities</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzE3_382d49a2-806e-4306-979f-c0492215803f" continuedAt="i6ef99dbbe293484e9bfedcc0d23746c5" escape="true">The following table summarizes the components of Other current liabilities:</ix:nonNumeric></span></div><div style="margin-top:9pt"><ix:continuation id="i6ef99dbbe293484e9bfedcc0d23746c5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMS0yLTEtMS0yNjkzNjI_0a9a6966-a9c1-4192-93b3-7a6533a25215">707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMS00LTEtMS0yNjkzNjI_fd535fec-ca84-4207-b610-a41b77053931">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMi0yLTEtMS0yNjkzNjI_4ea1d461-5149-410e-8d09-e0054f515542">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMi00LTEtMS0yNjkzNjI_4afecc34-2d70-4db0-a4b6-f9db6e561051">959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMy0yLTEtMS0yNjkzNjI_51b5eddd-0f45-4bca-bf8a-b4203f190d4e">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMy00LTEtMS0yNjkzNjI_1373bc93-ede7-4bef-bd19-b695f540e80f">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNS0yLTEtMS0yNjkzNjI_b71c4908-d0dd-4d9e-acfb-cf32f74f6d33">1,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNS00LTEtMS0yNjkzNjI_4a097bcd-1660-443a-b380-f97e33c75895">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNi0yLTEtMS0yNjkzNjI_e4a27bcd-cfdc-4906-b289-9dc9dca8391d">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNi00LTEtMS0yNjkzNjI_990a302e-faef-44f0-8220-fe36fe8949dc">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accumulated other comprehensive income (loss)</span></div><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzg0ODI5MDY5OTA4NA_ca9c2438-d434-4464-9720-5225dd37d50a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263db7dcf6884988a0e0a6b78d1e1a18_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS0yLTEtMS0yOTY1OTE_d22e61f4-db63-4c74-b2ba-425646377f3e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52e3a2b0b3f4d21893074364d38ef63_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS00LTEtMS0yOTY1OTE_abdc5fb1-523c-44d1-bed2-5a330c9b58d2">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399115e8a60144f3bb971ed4e82ff382_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS02LTEtMS0yOTY1OTE_15d46502-6329-4756-acd1-c35776b3010a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca3647effb04f2ea342c2cdf2754864_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS04LTEtMS0yOTY1OTE_be4d7380-2deb-498d-946f-9d902f8309eb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi0yLTEtMS0yOTY1OTE_96bccb4c-eaaf-4695-974e-6dd1af8b87b2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi00LTEtMS0yOTY1OTE_5e3667bd-737f-4d01-9210-2d693d077b83">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi02LTEtMS0yOTY1OTE_285e598f-2ea1-4eaf-8fd3-7cfa76c4646c">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi04LTEtMS0yOTY1OTE_f3b349db-ad82-402a-ba6b-a22bb6bcf124">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy0yLTEtMS0yOTY1OTE_e7e9434f-15e7-4810-a8a6-2e1615dd4e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy00LTEtMS0yOTY1OTE_9b5b3754-28c0-4358-b7dc-e4f5922c36d7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy02LTEtMS0yOTY1OTE_729d2b94-02ec-4e2c-a09b-d0be7e3a5c42">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy04LTEtMS0yOTY1OTE_028d1d06-6e18-4d23-9ff1-fc62158ed1aa">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC0yLTEtMS0yOTY1OTE_97e77a04-8e50-4d6d-90d1-83ecfaff8891">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC00LTEtMS0yOTY1OTE_b764589c-5e20-4fd9-9a93-8149d6473ad1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC02LTEtMS0yOTY1OTE_07780860-f8cc-40b4-a0c1-6a715a1e521a">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC04LTEtMS0yOTY1OTE_1791dc8b-0e19-4a88-a319-e464c49d9f89">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad4cdb4878a34e009c969cee15e38f5c_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS0yLTEtMS0yOTY1OTE_06e6c3a3-70e1-4026-81ba-1b9fd5589ba4">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de5de081bec4dd18128468f84151606_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS00LTEtMS0yOTY1OTE_61459e66-a2b1-4d54-a514-f66acc900253">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9f2ddd7ebd4003a278244a23a11b71_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS02LTEtMS0yOTY1OTE_8a0276bf-8d85-4da1-8934-59396d13a66d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e727936efcb4ba8ab5f6da9a5878ef5_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS04LTEtMS0yOTY1OTE_9d75cc88-842f-4a8d-bcde-d5d9a9b46c21">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05fe8e63eff3469cb53503276158f5ce_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS0yLTEtMS0yOTY1OTE_720afee6-5033-4892-be3e-1ecfceeda820">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4f13613183647b781938b7084edb764_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS00LTEtMS0yOTY1OTE_a5eaebc4-8e88-456f-bcac-923229575d4d">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica3992c52c804cb987a0221a71af7bf0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS02LTEtMS0yOTY1OTE_1e85cf79-d5a3-4693-8f44-2bd2fe1dcd99">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a853e0354f546ee8636eb887f31fb19_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS04LTEtMS0yOTY1OTE_ba242636-a85a-4a3a-9c4a-1f8fd121c493">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574633526e804738b0b65a58c499de43_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi0yLTEtMS0yOTY1OTE_46ac8221-09d9-4728-a1ed-063f9057503e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi00LTEtMS0yOTY1OTE_6f2fc144-6be2-4e91-aa85-6299b1c2e2e1">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi02LTEtMS0yOTY1OTE_78779498-ba97-4eef-925c-635a0b024887">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi04LTEtMS0yOTY1OTE_8dc0b55a-3a11-4af5-a093-916ad0d8f484">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574633526e804738b0b65a58c499de43_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy0yLTEtMS0yOTY1OTE_65c2ca42-5c1a-4adb-89bf-a47619d783b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy00LTEtMS0yOTY1OTE_53336531-03e2-4e39-876a-98e8477ea199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy02LTEtMS0yOTY1OTE_06146866-a615-41df-b3e4-8c7856cf4654">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy04LTEtMS0yOTY1OTE_7bf2080c-a553-4378-9336-528bf189c451">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574633526e804738b0b65a58c499de43_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC0yLTEtMS0yOTY1OTE_53821e7d-8ce2-4e9d-8798-b2d25591e892">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC00LTEtMS0yOTY1OTE_5a80b13f-c05e-45e5-a11e-e1ee536660e4">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC02LTEtMS0yOTY1OTE_9f6ebf15-f31a-4acc-bfa7-54f74c0212c2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC04LTEtMS0yOTY1OTE_751dbdd6-677c-4322-8be4-055c62f1f704">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1126acbd5f41e5ba02e34d7f3b1994_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS0yLTEtMS0yOTY1OTE_689ec780-bc31-404a-b35b-b85cfb5d0378">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61611069f0d34b499f897eda986a5c12_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS00LTEtMS0yOTY1OTE_62324518-8cec-49c6-ba88-3e94a9cf4bd9">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b010acb61941da9f9b3702c05299d1_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS02LTEtMS0yOTY1OTE_19c01dc1-705c-490c-85be-74b1f6a0ef98">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c3b3b01542f435fab6816bf508c9fe0_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS04LTEtMS0yOTY1OTE_3a93c430-3ebf-457c-9bfe-22ea966e9239">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNzcy_fb30f1fd-0892-424b-8905-a63b595ceeb4" continuedAt="ie00b2f89f8074e69b16665be51775a2a" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="ie00b2f89f8074e69b16665be51775a2a"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNzgy_cdef9e19-8657-499a-be70-9eb76d071e72" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03775ab216e04b35b7ed6670a04e0399_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNC02LTEtMS0yNjkzNjI_931defa7-2b56-4e72-95f1-03ff2c09d7a2">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03775ab216e04b35b7ed6670a04e0399_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNC04LTEtMS0yNjkzNjI_14e7a695-7eaa-4d18-844d-d2a91cb75eea">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if226e46e81434b4fa5ad7d3f0467adc3_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNC0xMC0xLTEtMjY5MzYy_edd1bb73-c839-4bf2-8293-be29c8aaab16">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32affe91c7174503bb23d6ad77cb2f0f_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNS02LTEtMS0yNjkzNjI_86e205e4-5507-4ebb-bba2-3de784f9a162">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32affe91c7174503bb23d6ad77cb2f0f_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNS04LTEtMS0yNjkzNjI_9506777f-def1-49a4-bc01-04e23ac88ea9">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89771330d55c448a92e44362a44f16e3_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNS0xMC0xLTEtMjY5MzYy_a489c26b-a988-4094-95b0-087d3fded8cd">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfe06128b3294a28a03f9d23d916dc3c_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNi02LTEtMS0yNjkzNjI_9cb64fe1-8d37-438a-bc7c-e3c2c5e99f71">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe06128b3294a28a03f9d23d916dc3c_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNi04LTEtMS0yNjkzNjI_0c30606e-b5a3-4917-a9b9-6adef9838e71">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i088891cbdf314ce6b8fcd496558912a3_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNi0xMC0xLTEtMjY5MzYy_8dc2c744-5498-481a-a29e-aca8ac12f718">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cb55cd4308343798ee15ab28060178f_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNy02LTEtMS0yNjkzNjI_ccf39663-c6d2-4684-99f9-339d5004505a">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb55cd4308343798ee15ab28060178f_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNy04LTEtMS0yNjkzNjI_12ab14d1-a573-4d4b-8b27-254ce7674730">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf624d97eb3d4a40934c3c494fa763f1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNy0xMC0xLTEtMjY5MzYy_9811d369-3bb7-4d30-a245-dad75325e04c">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i169f8c04a26a42f5a0b60374d9b36c86_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOC02LTEtMS0yNjkzNjI_35d127b6-11f8-4afd-9923-1f8f45cd1a11">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169f8c04a26a42f5a0b60374d9b36c86_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOC04LTEtMS0yNjkzNjI_a7ca9af2-0550-4c9a-9d35-9eca042a797c">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e24c0141fe24d3d87e593b121853912_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOC0xMC0xLTEtMjY5MzYy_a5e1756a-2832-4cd2-8ed8-380f776456b6">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf82b9ef3fed489896bcbd40c4d57784_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOS02LTEtMS0yNjkzNjI_9747caf6-25a5-4d08-86f1-7ca5967a041c">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf82b9ef3fed489896bcbd40c4d57784_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOS04LTEtMS0yNjkzNjI_bb17c5e6-4c23-4757-a796-2e6566c83421">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d81d540e4094ac484768eedff9edef5_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOS0xMC0xLTEtMjY5MzYy_23379c8e-a3dc-4fc2-a86c-330319314c74">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1d8c353412dc437b91aace4b203357c8_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTAtNi0xLTEtMjY5MzYy_9063af43-1f5b-40c0-b667-e9ee3212d67e">1.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8c353412dc437b91aace4b203357c8_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTAtOC0xLTEtMjY5MzYy_5a15aa22-5fde-4d06-8521-cdaaad8ff6e3">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b148329838748f6809e967fa7b82687_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTAtMTAtMS0xLTI2OTM2Mg_2370a2d3-09b4-4044-a972-b6e0cc83f185">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d46f8e092244b26b34a459dc7f0c882_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTEtNi0xLTEtMjY5MzYy_3546f510-0d8c-432f-80fa-6ba6df6e7410">1.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d46f8e092244b26b34a459dc7f0c882_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTEtOC0xLTEtMjY5MzYy_ef4db5c3-0274-4c3b-ba6e-6456c44413c9">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c2aeb4935e4346aed2bcc659b68b5a_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTEtMTAtMS0xLTI2OTM2Mg_ce08b07e-1b27-499a-8ece-2476d33de80b">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbcd186911f94c619108ead92cb447d6_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTItNi0xLTEtMjY5MzYy_c829bcd1-d5b7-47b2-b7dc-360afe0930fc">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcd186911f94c619108ead92cb447d6_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTItOC0xLTEtMjY5MzYy_2bccf8a1-6eaf-426e-adfd-40268e099e8d">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9297445f1f41d294ff95f5471d37d7_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTItMTAtMS0xLTI2OTM2Mg_ba1e214c-389f-46e5-8779-85932f4a0597">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f118b76b09d48e4b614386c5bc45cd5_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTMtNi0xLTEtMjY5MzYy_32b8a8d1-660f-4f98-a2ca-e83592d60045">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f118b76b09d48e4b614386c5bc45cd5_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTMtOC0xLTEtMjY5MzYy_3531f3fd-ff0a-447c-8c91-cd19e181eda5">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4ae268d228410b823829d0e1ed0bef_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTMtMTAtMS0xLTI2OTM2Mg_7ba57ff0-ddbf-4e13-b4e2-a84c7d422e60">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1142e4972ea45ddaafa04ee35493867_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTQtNi0xLTEtMjY5MzYy_24f64431-8dd2-49a7-9af3-7ff96c59437e">2.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1142e4972ea45ddaafa04ee35493867_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTQtOC0xLTEtMjY5MzYy_a3cc0128-d663-47af-b8fe-310efea81548">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c8bcfa26754f4fa29fad75dea0ebca_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTQtMTAtMS0xLTI2OTM2Mg_b10ae50e-6ae4-4fe3-a59e-555faeb5d621">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdc0d81cbb4140808a9a1e24ab2c3d24_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTUtNi0xLTEtMjY5MzYy_a1dc6749-fcae-452e-82a4-1a2ed8a4fab2">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdc0d81cbb4140808a9a1e24ab2c3d24_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTUtOC0xLTEtMjY5MzYy_0a8f2024-e906-436a-a663-b85d9df21579">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945f98bdf3c64038b9ab71e096b3f268_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTUtMTAtMS0xLTI2OTM2Mg_f1b20715-c693-4ff9-8495-1b4148a4663a">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia87974f636664eaea5bcaeec0ab40f90_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTYtNi0xLTEtMjY5MzYy_29d2adce-65d5-4032-bfd0-12dbbab87bcd">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87974f636664eaea5bcaeec0ab40f90_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTYtOC0xLTEtMjY5MzYy_9cb23100-9a50-47cb-aa8f-208c067adc70">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1572140a5a8d4e83a9e6933296251621_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTYtMTAtMS0xLTI2OTM2Mg_eb4d86f0-71b5-40a2-b139-b41eb2911242">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95602d00443e4029bb73f9109ee2f243_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTctNi0xLTEtMjY5MzYy_4d8575b2-d1a8-4290-a6e4-ddb4b58131fa">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95602d00443e4029bb73f9109ee2f243_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTctOC0xLTEtMjY5MzYy_3b044a8e-206c-4010-baf8-97e6eb60ee89">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed4f399902a463ea3fcf0a543273745_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTctMTAtMS0xLTI2OTM2Mg_7c77ebcd-ac2a-4291-bb08-08a3769500ab">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f7c7fd53cb943fca75d8a9cca2d3665_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTgtNi0xLTEtMjY5MzYy_1823405f-5c48-4b0f-a9af-cee573fe3d13">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7c7fd53cb943fca75d8a9cca2d3665_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTgtOC0xLTEtMjY5MzYy_848b7f3b-74f7-45b8-89cf-34945a743d6e">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade8a85e37a04d2dbacdbfd5cb15f536_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTgtMTAtMS0xLTI2OTM2Mg_ac581972-a1fd-47cb-8d4b-9ce2153dd8b5">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i091813ff4b0b4bba8dd45fbd21ee9c90_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTktNi0xLTEtMjY5MzYy_eca73f7f-4d34-4506-a573-50e3acb374da">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091813ff4b0b4bba8dd45fbd21ee9c90_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTktOC0xLTEtMjY5MzYy_2845f8a2-e357-4ff8-953e-24e8fae33e74">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide79ceb5e2244413ba088809663b461f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTktMTAtMS0xLTI2OTM2Mg_52a42add-2770-41e6-89df-c3da671b7c70">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2273e9e92d64f43ac4633c496068250_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjAtNi0xLTEtMjY5MzYy_55b2ce8a-d003-42ae-ab56-6ec936c8892e">2.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2273e9e92d64f43ac4633c496068250_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjAtOC0xLTEtMjY5MzYy_2f1cac37-a1c9-4c86-b732-7f188e439d85">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6515a317e7e49bb958a7c1cfb861802_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjAtMTAtMS0xLTI2OTM2Mg_586f38e1-2850-406e-8bc6-207cedad8089">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018b9520570d4bdb9a852a1dc0a67292_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjEtOC0xLTEtMjY5MzYy_eec084d4-f0c5-4df0-a0b0-6cc4b6a4cbeb">24,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb2412b199c42529e8362b7502e548d_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjEtMTAtMS0xLTI2OTM2Mg_bee8d70e-e4c4-40f9-be58-e7ab0b08f2f3">24,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c75b45dd0b494a9413038b43d87195_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjItOC0xLTEtMjY5MzYy_56156461-bbb6-47a8-b0ef-299d7673f61b">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88176a5b89454f6fb32288e4abf39fd2_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjItMTAtMS0xLTI2OTM2Mg_1e2c2117-f242-4cc5-b408-4562624958e5">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjMtOC0xLTEtMjY5MzYy_4a7aff42-9a3f-4ef0-8c9e-2b9cfc39d0d5">25,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjMtMTAtMS0xLTI2OTM2Mg_7017fa11-df5f-44a4-a613-01893ddc8cd4">25,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjQtOC0xLTEtMjY5MzYy_7acc8084-7792-4fd0-ab77-d6547f6bce48">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjQtMTAtMS0xLTI2OTM2Mg_0e9b936b-5b0d-42fd-a626-924dbd85a1eb">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjUtOC0xLTEtMjY5MzYy_a5a93cd1-636a-4bf4-8f28-7f9f53fb42db">22,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjUtMTAtMS0xLTI2OTM2Mg_d2c87003-59a7-4e38-8360-c4638dccc0ad">22,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2023, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revolving Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="i7036db910ef7473694d4dc36eb796a6c_I20221231" decimals="-8" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjQy_861280ea-f39b-4b01-a80d-c75284a4d074"><ix:nonFraction unitRef="usd" contextRef="i708772249eff4b8db077ea95cb4df25d_I20230331" decimals="-8" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjQy_e249560f-cacf-4142-8d1f-474d84a32d81">no</ix:nonFraction></ix:nonFraction> amounts outstanding under our $<ix:nonFraction unitRef="usd" contextRef="i708772249eff4b8db077ea95cb4df25d_I20230331" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjc1_15b1d18b-04d9-4add-bfa0-db31f385769c"><ix:nonFraction unitRef="usd" contextRef="i7036db910ef7473694d4dc36eb796a6c_I20221231" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjc1_67754358-1ea6-44ed-863b-6bca54aa3298">2.5</ix:nonFraction></ix:nonFraction> billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div></ix:continuation><div id="i78cdcb1572754b6c94699d07bd7f2fd4_61"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMjM4Mzg_1a8204d4-b4af-470f-8495-cf834fb6584e" continuedAt="if5016c4ac37343419ce8e0af5fc29e19" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="if5016c4ac37343419ce8e0af5fc29e19" continuedAt="if63dccd2c4df44b18c41d2bac50bb0fa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December 31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if63dccd2c4df44b18c41d2bac50bb0fa" continuedAt="i0a259ca050994ec7a1b65ee7fd51bd8f"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, sold under the brand name Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision, and in March 2023, a three-judge panel of the Court of Appeals for the Federal Circuit affirmed the PTAB&#8217;s decision. The litigation in the U.S. District Court was dismissed in April 2023 after the University represented to the Court that it did not intend to pursue further appeals.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. The EPO subsequently held an appeal hearing in March 2023 and revoked the EP &#8217;190 patent, including the amended patent. We had also initiated proceedings to invalidate the U.K. counterparts of the EP &#8217;190 patent and a related patent, European Patent No. 3,904,365 (the EP &#8216;365 patent) in the High Court of England &amp; Wales. NuCana had filed counterclaims against us in the High Court of England &amp; Wales alleging patent infringement of the U.K. counterparts and seeking damages and other relief. The U.K. case was heard in early 2023, and the judge issued a judgment in March 2023 invalidating both patents.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. In April 2022, we filed an action for grant of a compulsory license before the Federal Patent Court in Germany. In July 2022, the D&#252;sseldorf court determined that NuCana&#8217;s German counterpart of the EP &#8217;190 patent is infringed and granted an injunction. In August 2022, Gilead filed a notice of appeal regarding the D&#252;sseldorf court&#8217;s decision, and a hearing is scheduled for August 2023. Following the revocation of the EP &#8217;190 patent by the EPO, we expect the injunction in Germany to be lifted.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a259ca050994ec7a1b65ee7fd51bd8f" continuedAt="ibfc78cb213fc4d5baec4c23d55bd40f9"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of <ix:nonFraction unitRef="agreement" contextRef="ic2d94e60ba65414383aad05e7c5d0ac4_I20200430" decimals="INF" name="gild:LossContingencyMaterialTransferAgreementsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTA5OTUxMTY4MTk4Ng_c444a421-b979-4339-addb-cd5991aab945">three</ix:nonFraction> material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and two clinical trial agreements (&#8220;CTAs&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the Court of Federal Claims was held in June 2022, and in November 2022, the Court determined that the government breached the three MTAs. The Court also made findings of fact relating to the CTAs but declined to issue a decision on breach of the CTAs until after trial in the Delaware District Court. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Delaware District Court has been set for May 2023. A separate trial at the Court of Federal Claims to determine the damages Gilead is owed based on the government&#8217;s breach has yet to be set.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. (&#8220;Lupin&#8221;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen (&#8220;Janssen&#8221;), filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. Trial has been scheduled for October 2023. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (&#8220;Apotex&#8221;) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Apotex asserting infringement of two additional patents in the same court. Trial has not yet been scheduled in the lawsuits against Apotex.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2022, we received letters from Lupin, Laurus Labs (&#8220;Laurus&#8221;) and Cipla Ltd. (&#8220;Cipla&#8221;), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTM0Nzg_8d2698f7-337d-4127-9069-470dad603cf3">three</ix:nonFraction> of the <ix:nonFraction unitRef="patent" contextRef="ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331" decimals="INF" name="gild:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTM0ODg_478f41ac-3468-494b-816d-080e67acbffd">five</ix:nonFraction> patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for December 2024.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing was held in November 2022, but a final decision regarding the validity of the claims has not yet been announced.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. The original opposing parties have appealed, requesting full revocation. The hearing for the appeal has been scheduled for September 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibfc78cb213fc4d5baec4c23d55bd40f9" continuedAt="i3209dcdd86b548778cb63908a7596a26"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. <ix:nonFraction unitRef="opposingparty" contextRef="idcf147879c32413c88dcfab0f196e448_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTQ3OTY_fe7b075e-e1c3-4ec0-84b9-d468bfd49fd4">Three</ix:nonFraction> parties have appealed this decision. The appeal hearing was held in March 2023 and the EPO affirmed the validity of the TAF hemifumarate patent.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process for sofosbuvir opposition proceedings may take several years . While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for sofosbuvir, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc., have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes. These cases have been coordinated with the class actions. Trial has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#8220;Cipla Defendants&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we, along with BMS and Teva Pharmaceutical Industries Ltd., were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="ie39ed308edf943f8974b315e8b36ca06_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTkwMjc_26651362-ac3e-4e2e-a3a5-d74755e94c87">one</ix:nonFraction> class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, and Missouri, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="ie39ed308edf943f8974b315e8b36ca06_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTk0MDA_839ae9aa-2f4c-482e-8fb1-3f1cb1c62584">25,000</ix:nonFraction> active plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed while the California First District Court of Appeal considers the merits of plaintiffs&#8217; theories of liability. The first bellwether trial in California federal court is scheduled to begin in January 2024. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3209dcdd86b548778cb63908a7596a26"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The lawsuit seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. This case was stayed in September 2021 pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above. Health Choice filed a motion to lift the stay, and in April 2023, the trial court granted Health Choice&#8217;s motion to lift the stay. Gilead has filed a motion to the Texas Court of Appeals requesting reinstatement of the stay until final judgment in the Eastern District of Pennsylvania lawsuit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. In June 2022, plaintiffs filed their Motion for Class Certification, and Immunomedics submitted its Opposition in July 2022. The parties have agreed to settle this litigation. A motion seeking preliminary approval of the settlement was granted in February 2023. The court has not yet entered a final order approving the settlement. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfOTg2_3e984b1f-d403-45b3-9c7c-cc9b58d2e599" continuedAt="i1b48920ba68d46cfbf77e6dcb7bc57a4" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i1b48920ba68d46cfbf77e6dcb7bc57a4"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfOTc1_36c055df-b02d-4b14-ac0b-f7e66496ae5c" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfMy0yLTEtMS0yNjkzNjI_73a15179-f95e-4dc6-8e1e-b4ea722275fa"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfMy0yLTEtMS0yNjkzNjI_b8035a5d-c6eb-48ae-b374-3ed328f99520">1,010</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfMy00LTEtMS0yNjkzNjI_017bd6a9-ceb0-4e81-a9a0-436ee50682a6">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNC0yLTEtMS0yNjkzNjI_29374399-5c60-450d-981d-f811d8632878">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNC00LTEtMS0yNjkzNjI_d31ae73c-65cb-47e0-9441-e600520fbf64">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNS0yLTEtMS0yNjkzNjI_cfa562ff-87ed-4e9f-8afd-09553eeeef5b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNS00LTEtMS0yNjkzNjI_35f910df-949d-4de3-b156-67b041270396">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNi0yLTEtMS0yNjkzNjI_028b07fb-63f6-4165-bfb8-11b4f09011a8">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNi00LTEtMS0yNjkzNjI_18df49ba-f0c8-4227-80d1-eabb9c18bcd5">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOC0yLTEtMS0yNjkzNjI_f5cda576-46bf-444e-9655-f627879c6bbe">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOC00LTEtMS0yNjkzNjI_b2880eda-e95e-44a7-98aa-471910d5c0fd">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOS0yLTEtMS0yNjkzNjI_7cf7a139-10c0-4bd3-8c02-632406976621">0.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOS00LTEtMS0yNjkzNjI_3c18f1b5-1bf6-4f24-a962-092aec70f2b6">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted earnings per share attributable to Gilead because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfOTE0_5c00fac1-1cdf-4a09-99d2-9166fd8a491d">3</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfMjE5OTAyMzI1NzI4OA_cdf6be10-1dde-4185-800a-ab081c3db611">16</ix:nonFraction> million for the three months ended March 31, 2023, and 2022, respectively.</span></div></ix:continuation><div id="i78cdcb1572754b6c94699d07bd7f2fd4_70"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTYwMQ_4442dcb4-e188-4fd7-a042-f6f4d7e95d2f" continuedAt="iac5dbd040fb04fa8810d2811c09cca7d" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="iac5dbd040fb04fa8810d2811c09cca7d"><ix:nonNumeric contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTU5OA_b9b8a7d5-7b8c-451b-932a-088a39b6385b" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfMy0yLTEtMS0yNjkzNjI_d6f00951-b667-4c50-8840-e8a6dfa8fd85">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfMy00LTEtMS0yNjkzNjI_2cb70953-42d6-4745-9662-bb70970a8ecd">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNC0yLTEtMS0yNjkzNjI_08a1c297-e921-4239-b84d-6601d71e3221">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNC00LTEtMS0yNjkzNjI_da2f3fec-2076-453b-84c9-89bcbd08387b">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNS0yLTEtMS0yNjkzNjI_a9cc45d3-aaad-4147-8afa-839cdc483be3">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNS00LTEtMS0yNjkzNjI_6e867960-a6d3-4cb8-8dc2-1de3ca5e014c">107.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfODc_7d22bb21-90e6-458f-b369-34fea9d98264">24.3</ix:nonFraction>% for the three months ended March 31, 2023 differed from the U.S. federal statutory rate of 21% primarily due to $<ix:nonFraction unitRef="usd" contextRef="i506cbd3ce6ca465992effd4d69548672_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMjc0ODc3OTA3MzU4OA_7399c2ec-a1e6-462f-a85a-f7ec558eedd9">244</ix:nonFraction> million of non-deductible Acquired in-process research and development expenses recorded in connection with our acquisition of Tmunity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of <ix:nonFraction unitRef="number" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTA5OTUxMTYzMDAzMA_6e867960-a6d3-4cb8-8dc2-1de3ca5e014c">107.9</ix:nonFraction>% for three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in state deferred tax liabilities associated with a partial IPR&amp;D impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331" decimals="-8" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTA5OTUxMTYzMDQ1Nw_3db38071-fdf4-497e-8318-2abd1c57437f">2.7</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis is intended to provide material information around events and uncertainties known to management relevant to an assessment of the financial condition and results of operations of Gilead and should therefore be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto and other disclosures included as part of our Annual Report on Form 10-K for the year ended December&#160;31, 2022 and our unaudited Condensed Consolidated Financial Statements for the three months ended March 31, 2023 and the related notes thereto and other disclosures (including the disclosures under Part II, Item&#160;1A. Risk Factors) included in this Quarterly Report on Form 10-Q where other material events and uncertainties not otherwise discussed below are disclosed.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Management Overview</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Business Updates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlights are based on press releases recently issued. Readers are encouraged to review all press releases available on our website at www.gilead.com. The content on the referenced website does not constitute a part of and is not incorporated by reference into this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Oncology</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2023, we completed the acquisition of Tmunity, a clinical stage private biotech company, which provides preclinical and clinical programs. This includes an &#8220;armored&#8221; CAR T technology platform that has the potential to be applied to a variety of CAR Ts to enhance anti-tumor activity, as well as rapid manufacturing processes. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, we announced primary overall survival results from the Phase 3 ZUMA-7 study for initial treatment of adult patients with relapsed or refractory (&#8220;R/R&#8221;) large B-cell lymphoma (&#8220;LBCL&#8221;), which showed a statistically significant improvement for Yescarta in overall survival versus historical treatment.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2023, we received FDA approval of Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inflammation</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, we exercised an option to license investigational targeted protein degrader molecule NX&#8209;0479 (&#8220;GS-6791&#8221;) from Nurix. GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Financial Results</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:70.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues decreased by 4% to $6.4 billion for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to lower sales of Veklury, partially offset by higher product sales in HIV, Cell Therapy and Trodelvy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead was $1.0 billion, or $0.80 diluted earnings per share, for the three months ended March 31, 2023, compared to $19 million, or $0.02 diluted earnings per share for the same period in 2022. The increase was primarily due to the following items net of their related tax effect: a $2.7&#160;billion in-process research and development (&#8220;IPR&amp;D&#8221;) impairment recorded in the first quarter of 2022, which did not repeat in 2023, partially offset by higher operating expenses and lower revenues in 2023.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_79"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liver Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chronic hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chronic hepatitis B virus (&#8220;HBV&#8221;) / hepatitis delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,452&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 2. Revenues of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for further disaggregation of revenue by product.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales increased by 13% to $4.2 billion for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to favorable pricing dynamics, higher demand for Biktarvy and Descovy for pre-exposure prophylaxis (&#8220;PrEP&#8221;) and lower inventory draw-downs, partially offset by unfavorable foreign currency exchange impact.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Oncology</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell Therapy product sales increased by 64% to $448 million the three months ended March 31, 2023, compared to the same period in 2022, primarily due to increased Yescarta demand for the treatment of R/R LBCL and increased Tecartus demand for R/R mantle cell lymphoma and R/R adult acute lymphoblastic leukemia.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy product sales increased by 52% to $222 million for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to increased adoption in metastatic triple-negative breast cancer in the U.S. and Europe as well as the launch of the indication for pre-treated HR+/HER2- metastatic breast cancer in the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liver Disease</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales increased by 12% to $445 million for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to favorable pricing dynamics and timing of purchases in the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HBV / HDV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales were $230 million during the three months ended March 31, 2023 and remained relatively flat compared to the same period in 2022.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury product sales decreased by 63% to $573 million for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to lower demand driven by reduced hospitalization rates in all regions. Sales of Veklury generally reflect COVID-19 related rates and severity of infections and hospitalizations as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19. As a result, future sales of Veklury are difficult to predict and may vary significantly from one period to the next.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales decreased by 16% to $199 million for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to lower demand for AmBisome and Letairis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Impact</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es, 30% and 34% we</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re generated outside the U.S. for the three months ended March 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Foreign currency exchange, net of hedges, had an unfavorable impact on our total product sales of $106 million for the three months ended March 31, 2023, based on a comparison using foreign currency exchange rates from three months ended March 31, 2022.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our costs and expenses:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">-42 bps</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin was 77.8% for the three months ended March 31, 2023 and remained relatively flat compared to the same period in 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses consist primarily of personnel costs including salaries, benefits and stock-based compensation expense, infrastructure, materials and supplies and other support costs, research and clinical studies performed by contract research organizations and our collaboration partners and other outside services.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our R&amp;D expenses by identifying the R&amp;D activities we expect to be performed during a given period and then prioritizing efforts based on scientific data, probability of successful technical development and regulatory approval, market potential, available human and capital resources and other considerations. We regularly review our R&amp;D activities based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities that we believe will best support the long-term growth of our business. We do not track total R&amp;D expenses by product candidate, therapeutic area or development phase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakout of expenses by major cost type:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, infrastructure and other support costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies and other costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by 23% to $1.4&#160;billion for the three months ended March 31, 2023, compared to the same period in 2022. Personnel, infrastructure and other support costs as well as Clinical studies and other costs both increased due to new study launches and clinical activities primarily related to oncology.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&amp;D projects.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expenses were $481 million for the three months ended March 31, 2023, primarily related to a $244 million charge associated with our acquisition of Tmunity in February 2023 and a $212 million upfront payment associated with the collaboration with Arcellx, which we entered into in January 2023. Expenses for the three months ended March 31, 2022 were minimal. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6. Acquisitions, Collaborations and Other Arrangements of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In-Process Research and Development Impairment </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development impairment was $2.7&#160;billion for the three months ended March 31, 2022 related to a partial impairment charge on our HR+/HER2- IPR&amp;D intangible asset. No IPR&amp;D impairment charges were recorded during the three months ended March 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs related to sales and marketing, finance, human resources, legal and other administrative activities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by 22% to $1.3&#160;billion for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to increased commercial activities, mainly in oncology, and increased corporate spend, including an increase in our allocation of the branded prescription drug fee and corporate grants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense and Other Income (Expense), Net</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in Interest expense and Other income (expense), net:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March 31, 2023 decreased by 4% to $230 million, compared to the same period in 2022, primarily due to lower outstanding debt balances.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Other income (expense), net for the three months ended March 31, 2023 compared to the same period in 2022, primarily reflect higher net unrealized losses from equity securities, partially offset by higher interest income due to rising interest rates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(83.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate decreased for the three months ended March 31, 2023 compared to the same period in 2022, primarily due to a partial IPR&amp;D impairment charge of $2.7&#160;billion recorded in the three months ended March 31, 2022.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_82"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate our liquidity and capital resources, including our access to external capital, so that we can adequately and efficiently finance our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable debt securities were $7.2 billion and $7.6 billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Cash and cash equivalents decreased by $476 million from December&#160;31, 2022 to March&#160;31, 2023. The following table summarizes our cash flow activities:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,406)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Net cash provided by operating activities was $1.7 billion for the three months ended March 31, 2023 compared to $1.8 billion for the same period in 2022. The change was primarily due to lower collections as well as higher inventory and operating spend in 2023, partially offset by the effect of the non-recurring payment of a $1.25 billion settlement related to bictegravir litigation in 2022.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $826 million for the three months ended March 31, 2023 compared to $1.1 billion for the same period in 2022. The change was primarily due to a decrease in acquisition spend, including acquired IPR&amp;D.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $1.4 billion for the three months ended March 31, 2023 compared to $1.8&#160;billion for the same period in 2022. During the three months ended March 31, 2023, we utilized cash of $969 million for dividend payments and $400&#160;million for common stock repurchases. During the three months ended March 31, 2022, we utilized cash of $500&#160;million for debt repayments, $945&#160;million for dividend payments and $352 million for common stock repurchases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources and Material Cash Requirements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our capital resources and material cash requirements is presented in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2022. See Notes 6. Acquisitions, Collaborations and Other Arrangements, 9. Debt and Credit Facilities, 10. Commitments and Contingencies and 12. Income Taxes of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for any material changes to our capital resources and material cash requirements during the three months ended March 31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Estimates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our critical accounting estimates is presented in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2022. There were no material changes to our critical accounting estimates during the three months ended March 31, 2023.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_88"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our market risk is presented in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2022. See Notes 3. Fair Value Measurements, 4. Available-For-Sale Debt Securities and Equity Securities and 5. Derivative Financial Instruments of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for any material changes to these disclosures.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_91"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of March&#160;31, 2023 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in U.S. Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2023, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_97"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, please see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. </span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_100"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Quarterly Report on Form 10-Q. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During the three months ended March 31, 2023, sales of our HIV products accounted for approximately 66% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products, including generics, or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, many of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), which belongs to the nucleoside class of antiviral therapeutics. If there are any changes to the treatment or prevention paradigm for HIV that cause nucleoside-based therapeutics to fall out of favor, our HIV product sales would be adversely impacted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our supply and sale of Veklury, which was approved by U.S. Food and Drug Administration (&#8220;FDA&#8221;) as a treatment for patients with coronavirus disease 2019 (&#8220;COVID-19&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While Veklury sales generally reflect COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccines and alternative treatments for COVID-19, we are unable to accurately predict our revenues or supply needs over the short- and long-term due to the dynamic nature of the COVID-19 pandemic. If we do not accurately forecast demand or manufacture Veklury at levels to align with actual demand, then we may experience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product shortages or build excess inventory that may need to be written off. We also remain subject to significant public attention and scrutiny over the complex decisions made regarding clinical data, supply, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Yescarta or Tecartus, which are chimeric antigen receptor (&#8220;CAR&#8221;) T-cell therapies, creates significant challenges, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of cell therapy;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. While FDA has approved some cell therapies, including Yescarta and Tecartus, we must continue to demonstrate to the medical community the potential advantages of cell therapy compared to existing and future therapeutics. For challenges related to the reimbursement of Yescarta and Tecartus, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Yescarta and Tecartus to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate an automated CAR T-cell therapy manufacturing facility in Frederick, Maryland. We have not previously manufactured our products in an automated facility on a commercial scale, and as a result, we may require additional time and resources in order to effectively increase manufacturing capacity. We also operate a new retroviral vector manufacturing facility in Oceanside, California, which received FDA approval for commercial production in October 2022. We also have not previously manufactured viral vectors on a commercial scale, and as a result, we may require additional time and resources in order to effectively increase manufacturing capacity. In addition, we may not be able to produce or otherwise obtain an amount of viral vector supply sufficient to satisfy demand for our finished products. If we are unable to meet product demand, we will have difficulty meeting sales forecasts for our finished products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products, our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the U.S., which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not mirror actual patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels, and we may continue to see this trend in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the U.S. exclusively through the wholesale channel. For the three months ended March 31, 2023, approximately 90% of our product sales in the U.S. were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end-user demand and may not be accurate in matching their inventory levels to actual end-user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end-user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end-user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of products and technologies that may be competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability and amount of third-party payer reimbursement for our products and related treatments and medical services in the markets where we sell our products. As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the European Union (&#8220;EU&#8221;) and other significant or potentially significant markets for our products and pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duct candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. The volume of drug pricing-related legislation has dramatically increased in recent years, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Congress has enacted laws requiring manufacturer refunds on certain amounts of discarded drug from single-use vials beginning in 2023 and eliminating the existing cap on Medicaid rebate amounts beginning in 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Congress has enacted the Inflation Reduction Act of 2022 (the &#8220;Act&#8221;), which, among other changes, (1) requires the Department of Health and Human Services to &#8220;negotiate&#8221; Medicare prices for certain drugs (starting with 10 drugs in 2026, adding 15 drugs in 2027 and 2028, and adding 20 drugs in 2029 and subsequent years), (2) imposes an inflation-based rebate on Medicare Part B utilization starting in 2023 and Part D utilization beginning October 1, 2022, and (3) restructures the Medicare Part D benefit to cap out-of-pocket expenses for Part D beneficiaries beginning in 2024 and, effective January 1, 2025, increases Part D plans&#8217; contributions in the catastrophic coverage phase and increases manufacturers&#8217; discount contributions across coverage phases such that manufacturers must pay a 10% discount in the initial coverage phase and a 20% discount in the catastrophic phase on drugs utilized by all Part D beneficiaries, including low income subsidy patients. We continue to evaluate the impact of the Act on our business but expect the Act will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) has recently issued a number of guidance documents but how certain provisions will be implemented remains unclear. There may be additional guidance, legislation or rulemaking issued that could reflect the government&#8217;s evolving views, and select provisions may become subject to legal challenges in the future. Therefore, the full impact of the Act on the profitability of our business and the pharmaceutical industry as a whole remains uncertain at this time.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices, establishing drug payment limits, and encouraging the use of generic drugs. These initiatives and such other legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many countries outside the U.S., including the EU member states, have established complex and lengthy procedures to obtain price approvals and coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of these reviews cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medical products in the EU member states. Reductions in the pricing of our medical products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to covered entities under Section 340B of the Public Health Service Act (&#8220;340B&#8221;). Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, the continued growth of the 340B program limits the prices we may charge on an increasing percentage of sales. Changes to the calculation of rebates under the Medicaid program could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B-covered entities. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we implemented a contract pharmacy integrity initiative for our branded hepatitis C virus (&#8220;HCV&#8221;) products. This integrity initiative does not involve any products from Asegua Therapeutics LLC. Our integrity initiative requires covered entities that enter into 340B bill to/ship to arrangements with contract pharmacies for our branded HCV products to provide claims level data for units dispensed from such contract pharmacies; covered entities without an in-house pharmacy that choose not to participate in the initiative can designate a single contract pharmacy for shipment. Certain manufacturers that have implemented other contract pharmacy integrity programs have received enforcement letters from the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) asserting that those programs violate the 340B statute, have been referred to the HHS Office of Inspector General for assessment of civil monetary penalties, and have been subject to administrative dispute resolution proceedings brought on behalf of covered entities. These manufacturers are currently challenging HHS&#8217; position in ongoing litigation. We believe that our integrity initiative complies with the requirements of the 340B statute. However, additional legal or legislative developments with respect to the 340B program, including potential litigation with HHS, may negatively impact our ability to implement or continue our integrity initiative. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity-adjusted diagnosis-related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T-cell products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the EU, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the U.S., actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience adverse impacts resulting from the importation of our products from lower price markets or the distribution of illegally diverted or counterfeit versions of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allow generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the U.S., the EU or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, we are required to permit products purchased in one EU member state to be sold in another member state. Purchases of our products in member states where our selling prices are relatively low for resale in member states in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the quality and/or efficacy of the products and could harm patients and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various suppliers around the world that, without Gilead&#8217;s authorization, purport to source our products and generic versions of our products and sell them for use in countries where those products have not been approved. As a result, patients may be at risk of taking unapproved medications that may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could harm patients and adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties have illegally distributed and sold, and may continue to illegally distribute and sell, illegally diverted and counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. For example, as part of a U.S. civil enforcement lawsuit in coordination with law enforcement, and pursuant to court order, we seized thousands of bottles of Gilead-labeled medication with counterfeit supply chain documentation. Our investigation revealed that pharmaceutical distributors that are not authorized by Gilead to sell Gilead medicine sold purportedly genuine Gilead medicine sourced from an illegal counterfeiting scheme to independent pharmacies nationwide.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illegally diverted and counterfeit versions of Gilead-branded medicines exist and may pose a serious risk to patient health and safety. Our actions to stop or prevent the distribution and sale of illegally diverted and counterfeit versions of our medicines around the world may be costly and unsuccessful, which may adversely affect patients and our reputation and business, including our product revenues and financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of product candidates that we develop for each intended use through extensive preclinical studies and clinical trials. The results from these studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face numerous risks and uncertainties with our clinical trials that could result in delays or prevent completion of the development and approval of our product candidates, including challenges in clinical trial protocol design, our ability to enroll patients in clinical trials, the possibility of unfavorable or inadequate trial results to support further development of our product candidates, including failure to meet a trial&#8217;s primary endpoint, safety issues arising from our clinical trials, and the need to modify or delay our clinical trials or to perform additional trials. For example, in October 2022, we announced that FDA issued a complete response letter for our Biologics License Application for bulevirtide for the treatment of adults with hepatitis delta virus infection. In addition, see Note 7. Intangible Assets of the Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q for a discussion of the partial in-process research and development impairment charge that we recognized during the three months ended March 31, 2022 related to assets we acquired from Immunomedics, Inc. (&#8220;Immunomedics&#8221;) in 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may be unable to successfully complete our clinical trials on our anticipated timelines, or at all. Based on trial results, it is possible that FDA and other regulatory authorities do not approve our product candidates, or that any market approvals include significant limitations on the products&#8217; use. In addition, clinical trials involving our commercial products can raise new safety issues for our existing products, which could adversely impact our business. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. Therefore, our product candidates may never be successfully commercialized, and we may be unable to recoup the significant R&amp;D and clinical trial expenses incurred. We expect to expend significant time and resources on our clinical trial activities without any assurance that we will recoup our investments or that our efforts will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also risks associated with the use of third parties in our clinical trial activities. We extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We have incurred, and will continue to incur, inventory write-off charges and other expenses for products that fail to meet specifications and quality standards, and we may need to undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our existing products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase enough of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers are interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the U.S. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the U.S. from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will continue to file, for marketing approval in additional countries and for additional indications and products. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities, may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines, suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the healthcare industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to various federal, state and international laws and regulations pertaining to drug approval, reimbursement, rebates, price reporting, healthcare fraud and abuse, and data privacy and security. In the U.S., these laws include anti-kickback and false claims laws, Federal Food, Drug, and Cosmetic Act, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, such as the Medicaid Rebate Statute and the 340B statute, laws that regulate written and verbal communications about our products, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state healthcare programs, including Medicare, Medicaid and U.S. Department of Veterans Affairs and U.S. Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance, alter one or more of our sales or marketing practices, or impact our ability to obtain or maintain regulatory approvals. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex, and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement and other patient support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted after obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or those taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the U.S. and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time after filing, we may not know if our competitors have filed applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents covering our existing compounds, products and processes, and those that we will likely file in the future, may not provide complete or adequate protection. Filing patent applications is a fact-intensive and complex process. We may file patent applications that ultimately do not result in patents or have patents that do not provide adequate protection for the related product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future litigation or other proceedings regarding the enforcement or validity of our existing patents or any future patents could result in the invalidation of our patents or substantially reduce their protection. In addition, we may face criticism as a result of our legitimate use of the patent systems to protect our investments in new and useful innovations in medicine.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. ANDA litigation and related settlement and license agreements, in some cases, may result in a loss of exclusivity for our patents sooner than we would otherwise expect. In addition, loss of exclusivity may be earlier than expected under these settlement and license agreements under certain circumstances. For example, settlement and license agreements with generic manufacturers typically include acceleration clauses that permit generic entry before the agreed-upon entry date in certain circumstances, and generic manufacturers may continue to challenge the patents protecting our products. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by other parties that such parties may claim to cover the use of our products and research activities. For a description of our pending patent litigation, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources. These matters could require us to pay significant monetary amounts, including royalty payments for past and future sales. For example, on February 1, 2022, we reached an agreement with ViiV Healthcare Company and related parties (collectively, &#8220;ViiV&#8221;) for a global resolution of all claims related to our sales of Biktarvy, pursuant to which (1) Gilead agreed to make a one-time payment of $1.25 billion and an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the U.S. until October 5, 2027, and (2) ViiV granted Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigation and other dispute-related matters, see Note 10. Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the effects from the COVID-19 pandemic.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, or other public health emergencies, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. As we have seen with the COVID-19 pandemic, outbreaks can result in global supply chain and logistics disruptions and distribution constraints. The impact of an outbreak or other public health crisis on our results of operations and financial condition would depend on numerous evolving factors, but could involve higher operating expenses, lower demand for our products as a result of governmental, business and individuals&#8217; actions taken in response to such an event (including quarantines, travel restrictions and interruptions to healthcare services, which can impact enrollment in or operation of our clinical trials or limit patients&#8217; ability or willingness to access and seek care), challenges associated with the safety of our employees and safe occupancy of our job sites, and financial market volatility and significant macroeconomic uncertainty in global markets. An outbreak or public health emergency also could amplify many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Currency Exchange: For the three months ended March 31, 2023, approximately 30% of our product sales were outside the U.S. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation. For example, see Part I, Item 2 of this Quarterly Report on Form 10-Q for a discussion of our exposure to movements in foreign currency exchange rates, primarily in the Euro, and the impacts from foreign currency exchange, net of hedges, for the three months ended March 31, 2023.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest Rates and Inflation: We hold interest-generating assets and interest-bearing liabilities, including our available-for-sale debt securities and our senior unsecured notes and credit facilities. Fluctuations in interest rates, including the U.S. Federal Reserve&#8217;s recent increases in interest rates, could expose us to increased financial risk. In addition, high inflation, such as what we are seeing in the current economic environment, has adversely impacted and may continue to adversely impact our business and financial results.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state-controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation, the imposition of compulsory licenses or similar actions, including waiver of intellectual property protections.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the U.S. or other governments.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires, extreme heat, drought or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we may not have sufficient insurance. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry sufficient earthquake insurance, and significant recovery time could be required to resume operations. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes, including in China, Russia and Ukraine. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to environmental, social and governance (&#8220;ESG&#8221;) matters expose us to numerous risks, including risks to our reputation and stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institutional and individual investors are increasingly using ESG screening criteria to determine whether Gilead qualifies for inclusion in their investment portfolios. We are frequently asked by investors and other stakeholders to set ambitious ESG goals and provide new and more robust disclosure on goals, progress toward goals and other matters of interest to ESG stakeholders. In response, we have adapted the tracking and reporting of our corporate responsibility program to various evolving ESG frameworks, and we have established and announced goals and other objectives related to ESG matters. These goal statements reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, any of which could have a material negative impact, including on our reputation and stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve any goal or objective, including with respect to environmental and diversity initiatives, is subject to numerous risks, many of which are outside of our control. Examples of such risks include: (1) the availability and cost of low- or non-carbon-based energy sources and technologies, (2) evolving regulatory requirements affecting ESG standards or disclosures, (3) the availability of suppliers that can meet our sustainability, diversity and other standards, (4) our ability to recruit, develop and retain diverse talent in our labor markets and (5) the impact of our organic growth and acquisitions or dispositions of businesses or operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. Our selection of disclosure frameworks that seek to align with various reporting standards may change from time to time and may result in a lack of consistent or meaningful comparative data from period to period. In addition, regulatory authorities may impose mandatory disclosure requirements with respect to ESG matters. For example, in March 2022, U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) proposed rule changes that would require companies to make certain climate-related disclosures, including information about climate-related risks, greenhouse gas emissions and certain climate-related financial statement metrics. Our processes and controls may not reflect evolving standards for identifying, measuring and reporting ESG matters, immediately or at all, our interpretation of reporting standards may differ from those of others, and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals. In addition, enhancements to our processes and controls to reflect evolving reporting standards may be costly and require additional resources. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our goals, targets and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to government enforcement actions and private litigation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant cybersecurity incidents could give rise to legal liability and regulatory action under data protection and privacy laws and adversely affect our business and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta and Tecartus. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and ransomware attack. Likewise, data privacy or cybersecurity incidents or breaches by employees or others can result in the exposure of sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners to unauthorized persons or to the public. Cybersecurity attacks and incidents are increasing in their frequency, sophistication and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intensity. Malicious actors seek to steal money, gain unauthorized access to, destroy or manipulate data, and disrupt operations, and some of their attacks may not be recognized or discovered until launched or after initial entry into the environment, such as novel or zero-day attacks that are launched before patches are available and defenses can be readied. Malicious actors are also increasingly developing methods to avoid prevention, detection and alerting capabilities, including employing counter-forensic tactics making response activities more difficult. Such attacks and incidents include, for example, the deployment of harmful malware, ransomware, denial-of-service, social engineering and other means to affect service reliability and operatio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ns and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many companies, we have experienced cybersecurity incidents, including data breaches and service interruptions. When cybersecurity incidents occur, our policy is to respond and address them in accordance with applicable governmental regulations and other legal requirements, including our cybersecurity protocols. There can be no assurance that our efforts in response to cybersecurity incidents, as well as our investments to protect our information technology infrastructure and data, will shield us from significant losses, brand and reputational harm and potential liability or prevent any future interruption or breach of our systems. Such cybersecurity incidents can cause the loss of critical or sensitive information, including personal information, and could give rise to legal liability and regulatory action under data protection and privacy laws. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act and the California Privacy Rights Act and other laws that have been or may be passed, similarly introduce requirements with respect to personal information, and non-compliance with such laws may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Other changes or new laws or regulations associated with the enhanced protection of personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, including the possibility that a governmental entity or regulatory body may delay or refuse to grant approval for the consummation of the transaction. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges related to the products, intellectual property and technologies that are acquired or licensed. For example, as a result of an impairment analysis we conducted following our receipt of data in March 2022 from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with hormone receptor-positive, human epidermal growth receptor 2-negative metastatic breast cancer, we recognized a partial in-process research and development impairment charge on our Condensed Consolidated Statements of Income during 2022. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic partners, such as in connection with our collaborations with Arcus Biosciences, Inc. and Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics in 2020, S&amp;P Global Ratings downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and various foreign jurisdictions. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. Our effective tax rates are affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, the introduction of new taxes, and changes in tax laws, regulations, administrative practices and interpretations, including in the U.S., Germany and Ireland.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the examination of our tax returns and other tax matters by the U.S. Internal Revenue Service and tax authorities in various foreign jurisdictions. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Issuer Purchases of Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), with no fixed expiration. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended March 31, 2023:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average<br/>Price Paid<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>as Part of a Publicly<br/>Announced Program (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maximum Fair<br/>Value of Shares<br/>that May Yet Be<br/>Purchased Under<br/>the 2020 Program (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.76&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,768&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 - February 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 - March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,862&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is due to shares of common stock withheld by us from employee restricted stock awards in order to satisfy applicable tax withholding obligations.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_106"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_109"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_112"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_115"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Exhibit Index included herein. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465923011167/tm235492d1_ex3-1.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Reference is made to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Exhibit 3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465923011167/tm235492d1_ex3-1.htm">Exhibit 3.2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note and Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2025 Note and Form of 2045 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Registrant</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000008/gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465922056435/tm2213708d1_ex10-1.htm">Gilead Sciences, Inc. 2022 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex1082022employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex1082022employe.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex1082022employe.htm"> in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm">Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm"> in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex10112023employ.htm">Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10172022non-ee.htm">Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10182022psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10182022psuagr.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10182022psuagr.htm"> in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex10222023psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10222022psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10222022psuagr.htm">made i</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10222022psuagr.htm">n 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex10262023psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10282022employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10282022employ.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10282022employ.htm"> in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">mad</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">e</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm"> </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gildq12023ex10332023employ.htm">Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants commencing in 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10342022non-ee.htm">Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10342022non-ee.htm">made </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10342022non-ee.htm">in 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1030.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1043.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex1049offerlette.htm">Offer Letter between Registrant and Deborah Telman, dated June 2, 2022</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex1050stockoptio.htm">Global stock option agreement for Deborah Telman under 2022 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex1051rsuagreeme.htm">Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (3 year vest)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex1052rsuagreeme.htm">Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (4 year vest)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(35)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(35)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(36)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(36)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(37)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.65</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(38)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.66</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.67</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex311ceocertific.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex312cfocertific.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gildq12023ex32section906ce.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule&#160;15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on February 6, 2023, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 5, 2022, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%">(20)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(36)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(37)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(38)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i78cdcb1572754b6c94699d07bd7f2fd4_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ANDREW D. DICKINSON</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>gildq12023ex10112023employ.htm
<DESCRIPTION>2023 EMPLOYEE STOCK OPTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie7479ec704de4be08f7071dd340d51c1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.11</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2022 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL STOCK OPTION AGREEMENT </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Global Stock Option Agreement (this &#8220;Agreement&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s grant of an option to the Participant set forth below (the &#8220;Optionee&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Capitalized terms not otherwise defined in this Agreement have the meanings set forth in the Plan.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby grants an option to Optionee named below upon the following terms and conditions&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby grants to Optionee a Non-statutory Stock Option to purchase shares of Common Stock under the Plan (the &#8220;Option&#8221;), subject to the terms and conditions set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPTION GRANT SPECIFICS</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Name of Optionee&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Number of Option Shares&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Paragraphs 4 and 5, the Option will vest and become exercisable as follows&#58; (i) 25% of the Option Shares on the first anniversary of the Grant Date and (ii) 6.25% of the Option Shares quarterly thereafter through the fourth anniversary of the Grant Date, in each case, subject to the Optionee&#8217;s Continuous Service through each vesting date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Expiration Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Option Term&#59; Exercisability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The term of the Option begins on the Grant Date and continues through the close of business on the last business day prior to the Expiration Date, unless sooner terminated in accordance with Paragraph 4 or 5 below (as applicable, the &#8220;Term&#8221;). The portion of the Option that has vested in accordance with the Vesting Schedule above will remain exercisable through the end of the Term. Upon the expiration of the Term, the Option will terminate and cease to be outstanding.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Option is not transferable or assignable by Optionee other than to Optionee&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Optionee&#8217;s estate following Optionee&#8217;s death and may be exercised, during Optionee&#8217;s lifetime, only by Optionee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Term will terminate (and the Option will cease to be outstanding) prior to bthe Expiration Date in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service as a result of Optionee&#8217;s death, then (i) the Option will immediately be fully vested and exercisable and (ii) the Option may be exercised by Optionee&#8217;s designated beneficiary (or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, the personal representative of Optionee&#8217;s estate) until the close of business on the last business day prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (A) the expiration of the 12-month period measured from the date of Optionee&#8217;s death or (B) the Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service as a result of Optionee&#8217;s Disability, then (i) the Option will immediately be fully vested and exercisable and (ii) the Option may be exercised by Optionee until the close of business on the last business day prior to the earlier of (A) expiration of the 12-month period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service (i) at least 12 months following the Grant Date and (ii) (x) after attaining age 55 and completing at least 10 years of Continuous Service or (y) after attaining age 65, then (I) the Option will continue to vest in accordance with the Vesting Schedule as if Optionee had remained in Continuous Service and (II) the Option may be exercised by Optionee until the close of business on the last business day prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of&#58; (A) expiration of the five-year period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date. Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment or legal development in Optionee&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Option pursuant to this Paragraph 4(c) being deemed unlawful or discriminatory, then the Company will not apply this favorable treatment at the time of Optionee&#8217;s cessation of Continuous Service, and the Option will be treated as otherwise set forth in this Paragraph 4, as applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">For Cause Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provision hereof, should Optionee&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Optionee is employed or under the terms of Optionee&#8217;s employment agreement, if any), or should Optionee engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then the Option will be immediately cancelled and forfeited, whether or not vested.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Other Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service for any reason other than as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the Option may be exercised by the Optionee until the close of business on the last business day prior to the expiration of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration of the three-month period measured from the date of such cessation of Continuous Service, or (ii) the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The period of post-service exercisability in effect pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will automatically be extended by an additional period of time equal in duration to any interval within such post-service exercise period during which the exercise of the Option or the immediate sale of the Option Shares acquired cannot be effected in compliance with applicable federal, state and foreign securities laws, but in no event will such an extension result in the continuation of the Option beyond the close of business on the last business day prior to the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During any period of post-service exercisability in effect pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Option may be exercisable only for the portion of the Option which is vested and exercisable (after giving effect to any accelerated vesting under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), and upon a cessation of Continuous Service, any portion of the Option which is not vested and exercisable will terminate and cease to be outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the time of a Change in Control, the Option may be (i) assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect, (ii) replaced with an economically-equivalent substitute equity award or (iii) replaced with a cash retention program of the successor corporation which preserves the spread existing at the time of the Change in Control on any Option Shares for which the Option is not vested and exercisable (the excess of the Fair Market Value of those Option Shares over the aggregate Exercise Price payable for such shares) and provides for the subsequent vesting and concurrent payout of that spread in accordance with the Vesting Schedule applicable to such Option Shares. In the event the Option is assumed or otherwise continued in effect, the Option will be adjusted immediately after the consummation of the Change in Control in accordance with Section 9 of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event of an assumption, continuation or replacement of the Option under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no accelerated vesting of the Option will occur at the time of the Change in Control. However, if Participant&#8217;s Continuous Service is terminated without Cause, or if Participant resigns from Continuous Service due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control and ending with the earlier of (A) the termination of that definitive agreement without the consummation of such Change in Control or (B) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, then&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  the Option (or any economically equivalent award) will immediately be fully vested and exercisable&#59; or</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:90.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the balance credited to Optionee under any replacement cash retention program will immediately be vested and paid to Optionee in a lump sum&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In the event all or any portion of the Option is not assumed, continued or replaced under Paragraph 5(a), the Option shall be fully vested and exercisable with adequate opportunity for Optionee to exercise the Option prior to the consummation of the Change in Control, and immediately following the consummation of the Change in Control, the Option will terminate and cease to be outstanding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee will not have any stockholder rights including voting, dividend or liquidation rights, with respect to the Option Shares until the Option is exercised, the Exercise Price is paid and Optionee becomes a holder of record of the Option Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Manner of Exercising Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In order to exercise all or any portion of the Option, Optionee must take the following actions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) Execute and deliver to the Company a notice of option exercise in the form authorized by the Company (the &#8220;Notice of Exercise&#8221;) as to the Option Shares for which the Option is to be exercised or comply with such other procedures as the Company may establish for notifying the Company of such exercise&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) Pay the aggregate Exercise Price in accordance with Section 7 of the Plan&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Furnish to the Company appropriate documentation that the person or persons exercising the Option (if other than Optionee) have the right to exercise the Option&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Make appropriate arrangements with the Company or the Related Entity employing or retaining Optionee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the satisfaction of all applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">As soon as practical after the date the Option is exercised, the Company will issue to or on behalf of Optionee (or any other person or persons exercising the Option) the purchased Option Shares, subject to appropriate restrictions, if any.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In no event may the Option be exercised for any fractional Option Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The exercise of the Option and the issuance of the Option Shares upon such exercise will be subject to compliance by the Company and Optionee with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Option will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee acknowledges that, regardless of any action the Company or the Employer may take with respect to any or all Withholding Taxes related to the Option, the ultimate liability for all such Withholding Taxes is and remains Optionee&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Optionee further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Option, including the grant, vesting or exercise of the Option, the subsequent sale of any shares of Common Stock acquired at exercise and the receipt of any dividends on those shares&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Option to reduce or eliminate Optionee&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Optionee is subject to Withholding Taxes in more than one jurisdiction, Optionee acknowledges that the Company or the Employer (or a former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Prior to the relevant taxable event, Optionee agrees to make arrangements satisfactory to the Company or the Employer to satisfy all Withholding Taxes. Optionee authorizes the Company or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following&#58;</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:60.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding of Shares otherwise deliverable upon exercise of the Option&#59;</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding from any other wages or other cash compensation paid to Optionee by the Company or the Employer&#59; or</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:54.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">payment through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Optionee&#8217;s jurisdiction, in which case Optionee may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Optionee may seek a refund from local tax authorities. In the event of under-withholding, Optionee may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer. If the obligation for </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Withholding Taxes is satisfied by withholding Shares, for tax purposes, Optionee is deemed to have been issued the full number of Shares subject to the exercised Option, notwithstanding that a number of Shares is held back solely for the purpose of paying the Withholding Taxes. The Company may refuse to deliver any purchased Option Shares or the proceeds of the sale of shares if Optionee fails to comply with Optionee&#8217;s obligations in connection with the Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Agreement, Optionee&#8217;s Continuous Service will not be deemed to cease during any period for which Optionee is on a military leave, sick leave or other personal leave approved by the Company. However, Optionee will not receive any Continuous Service credit, for purposes of vesting under the Vesting Schedule, for any period of such leave of absence, except to the extent otherwise required by employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any, or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee will receive Continuous Service credit for such vesting purposes for (i) the first three months of an approved personal leave of absence or (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In no event will Optionee be deemed to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration date of that leave of absence, unless Optionee returns to active Continuous Service on or before that date, or (ii) the date Optionee&#8217;s Continuous Service actually terminates by reason of Option&#8217;s voluntary or involuntary termination or by reason of Optionee&#8217;s death or Disability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee may be subject to insider trading restrictions or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Optionee&#8217;s country or Optionee&#8217;s broker&#8217;s country, if different, which may affect Optionee&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., options) or rights linked to the value of Shares during such times as Optionee is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Optionee placed before Optionee possessed inside information. Furthermore, Optionee could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Optionee acknowledges that it is Optionee&#8217;s responsibility to comply with any applicable restrictions and Optionee should speak with Optionee&#8217;s personal legal advisor on this matter.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee will be in writing and addressed to Optionee at the most current address then indicated for Optionee on the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company&#8217;s employee records or will be delivered electronically to Optionee through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect option exercises through the internet. All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except to the extent otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above, the provisions of this Agreement will inure to the benefit of and be binding upon the Company and its successors and assigns and Optionee, Optionee&#8217;s assigns, and the legal representatives, heirs and legatees of Optionee&#8217;s estate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the Option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Option. Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation. The word &#8220;or&#8221; is not exclusive. Words in the masculine gender include the feminine gender, and where appropriate, the plural includes the singular and the singular includes the plural. All references to &#8220;including&#8221; shall be construed as meaning &#8220;including without limitation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by the Option and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of the Option is made or to be performed.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Acknowledgment of Nature of Plan and Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the Option, Optionee acknowledges, understands and agrees that&#58;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future options, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Option and Optionee&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Optionee&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Option and the Option Shares, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Option and the Option Shares, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the Option Shares is unknown, indeterminable and cannot be predicted with any certainty&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if the Option Shares do not increase in value, the Option will have no value&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if Optionee exercises the Option, the value of the Option Shares acquired may increase or decrease, even below the Exercise Price&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from termination of Optionee&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any), and in consideration of the Award, Optionee irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives Optionee&#8217;s ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Optionee shall be deemed irrevocably to have agreed not to </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Option and the Option Shares, and the income and value of same, are not granted as consideration for, or in connection with, any service Optionee may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the Option and the benefits evidenced by this Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Option Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Optionee&#8217;s local currency and the United States Dollar that may affect the value of the Option or of any amounts due to Optionee pursuant to the exercise of the Option or the subsequent sale of any Option Shares acquired upon exercise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee&#8217;s participation in the Plan or Optionee&#8217;s acquisition or sale of the Option Shares. Optionee should consult with Optionee&#8217;s personal tax, legal and financial advisors regarding Optionee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Optionee acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Optionee or other Optionees.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Data Privacy.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Optionee is declaring that Optionee agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that Optionee needs to review the following information about the processing of Optionee's personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Optionee's consent. As regards the processing of Optionee&#8217;s Personal Data in connection with the Plan and this Agreement, Optionee understands that the Company is the controller of Optionee's Personal Data.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. The Company collects, uses and otherwise processes Personal Data about Optionee for the purposes of allocating shares of Common Stock and implementing, administering and managing the Plan. Optionee understands that this Personal Data may include Optionee's  name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Optionee&#8217;s favor. The legal basis for the processing of Optionee&#8217;s Personal Data, where required, will be Optionee's  consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company transfers Optionee's Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Optionee&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Optionee understands and acknowledges that the Company&#8217;s service provider will open an account for Optionee to receive and trade shares of Common Stock acquired under the Plan and that Optionee will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Optionee&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Optionee understands and acknowledges that Optionee&#8217;s country may have enacted data privacy laws that are different from the laws of the United States. The Company&#8217;s legal basis for the transfer of Optionee&#8217;s Personal Data is Optionee&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.03pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company will use Optionee&#8217;s Personal Data only as long as is necessary to implement, administer and manage Optionee&#8217;s participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Optionee understands and acknowledges that the Company&#8217;s legal basis for the processing of Optionee&#8217;s Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Optionee&#8217;s Personal Data for any of the above purposes, Optionee understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that Optionee&#8217;s participation in the Plan and Optionee&#8217;s consent is purely voluntary. Optionee may deny or later withdraw Optionee&#8217;s consent at any time, with future effect and for any or no reason. If Optionee denies or later withdraws Optionee&#8217;s consent, the Company can no longer offer Optionee participation in the Plan or offer other equity awards to Optionee or administer or maintain such awards and Optionee would no longer be able to participate in the Plan. Optionee further understands that denial or </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">withdrawal of Optionee&#8217;s consent would not affect Optionee&#8217;s status or salary as an employee or Optionee&#8217;s career and that Optionee would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Optionee is based and subject to the conditions set out in the Applicable Laws, Optionee may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Optionee and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Optionee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Optionee&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of Optionee&#8217;s Personal Data in certain situations where Optionee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Optionee&#8217;s Personal Data that Optionee has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Optionee&#8217;s employment and is carried out by automated means. In case of concerns, Optionee understands that Optionee may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Optionee&#8217;s rights, Optionee understands that Optionee should contact Optionee&#8217;s local human resources representative.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Optionee may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Optionee acknowledges that Optionee is sufficiently proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow Optionee to understand the terms and conditions of this Agreement. Further, if Optionee has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version differs in substance from the English version, the English version will control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through the electronic acceptance procedure established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Optionee Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event may the Option be exercised in the absence of such acceptance. An exercise of any portion of the shares subject to this Option shall be deemed to be an acceptance by Optionee of the terms and conditions of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Depending upon the country to which laws Optionee is subject, Optionee may have certain foreign asset or account reporting requirements that may affect Optionee&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Optionee&#8217;s country. Optionee&#8217;s country may require that Optionee report such accounts, assets or transactions to the applicable authorities in Optionee&#8217;s country. Optionee is responsible for knowledge of and compliance with any such regulations and should speak with Optionee&#8217;s own personal tax, legal and financial advisors regarding sam</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any provision herein, Optionee&#8217;s participation in the Plan shall be subject to any special terms and conditions as set forth in any addendum to this Agreement setting forth special terms and conditions for Optionee&#8217;s country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Moreover, if Optionee relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Optionee, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company reserves the right to impose other requirements on Optionee&#8217;s participation in the Plan, on the Option and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Optionee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:12pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the Option, Optionee agrees that the Option is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Optionee&#8217;s country. Optionee has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>gildq12023ex10222023psuagr.htm
<DESCRIPTION>2023 PSU AGREEMENT - TSR GOALS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8b55c922e25941249123d8958ea779df_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.22</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR PERFORMANCE GOAL</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">2022 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PERFORMANCE SHARE AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Performance Share Award Agreement (this &#8220;Agreement&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of Shares to the Participant thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Capitalized terms not otherwise defined in this Agreement or in the attached Appendix A have the meanings set forth in the Plan.    </font></div><div style="margin-top:12pt;text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, it is hereby agreed as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Performance Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby awards to Participant, as of the Grant Date indicated below, Performance Shares under the Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions set forth in this Agreement.  This Agreement provides the Participant with the right to receive one or more Shares on the designated issuance date for those shares, based upon the extent to which each Performance Share vests pursuant to the terms hereof</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD SUMMARY</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 10, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Number of Performance Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The actual number of Shares that may become issuable pursuant to the Performance Shares subject to this Agreement will be determined in accordance with the performance-vesting and Continuous Service vesting provisions of attached Schedule I. For purposes of the applicable calculations under Schedule I, the target number of Performance Shares to be utilized is _____ shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vesting Requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Performance Shares will be subject to the performance-vesting and Continuous Service vesting requirements set forth in attached Schedule I and will vest on the Certification Date</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Change in Control Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares underlying the Performance Shares may also vest on an accelerated basis in accordance with the applicable provisions of Paragraph 4 of this Agreement should a Change in Control occur after the start but prior to the completion of the Performance Period applicable to the Performance Shares or the Certification Date. </font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Shares which actually vest and become issuable pursuant to the Performance Shares will be issued in accordance with the provisions of this Agreement applicable to the particular circumstances under which such vesting occurs.</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the actual issuance of the Shares which vest hereunder, Participant may not transfer any interest in the Performance Shares subject to the Award or the underlying Shares or pledge or otherwise hedge the sale of those Performance Shares or underlying shares, including through any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares.  However, any Shares which vest hereunder but otherwise remain unissued at the time of Participant&#8217;s death will be transferred to Participant&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Participant&#8217;s estate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will not have any stockholder rights, including voting, dividend (except as provided in Paragraph 3(b)) or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to this Award on such record date have not been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account will be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution.  As such Shares subsequently vest hereunder, the dividend equivalents so credited to those Shares in the book account will vest, and those vested dividend equivalents will be distributed to Participant (in the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those dividend equivalents relate and correspondingly as such Shares are forfeited or cancelled under the Award (including in accordance with the Continuous Service vesting provisions), the dividend equivalents so credited to those Shares in the book account will be forfeited or cancelled. Settlement of dividend equivalents will be subject to the Company&#8217;s collection of applicable Withholding Taxes.  The Administrator will have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination will control. No dividend equivalent amount will be paid or distributed on Shares under this Award that are forfeited, cancelled or that otherwise are not issued or issuable under this Award. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The following provisions will apply only to the extent a Change in Control is consummated prior to the Certification Date and will have no force or effect if the effective date of the Change in Control occurs after the Certification Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should (i) the Change in Control occur within the first 12 months of the Performance Period and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant will immediately vest in that number of Shares equal to the Target Shares subject to this Award, without any measurement of Performance Goal attainment to date and without regard to the Continuous Service vesting provisions.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should (i) the Change in Control occur at any time on or after the completion of the first 12 months of the Performance Period but prior to the Certification Date and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant will immediately vest in that number of Shares equal to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">greater</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the Target Shares subject to the Award or (ii) the actual number of Performance-Qualified Shares determined by multiplying (A) the Target Shares subject to this Award by (B) the applicable percentage (determined in accordance with the payout slope set forth in attached Schedule I) for the level at which the TSR Performance Goal is attained over an abbreviated Performance Period ending with the close of the Company&#8217;s fiscal quarter coincident with or immediately preceding the effective date of the Change in Control, in either case, without regard to the Continuous Service vesting requirements. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The foregoing provisions of this Paragraph 4 will also apply if Participant&#8217;s Continuous Service is terminated without Cause or Participant resigns from Continuous Service due to Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the termination of the definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should Participant cease Continuous Service by reason of Participant&#8217;s Retirement at least twelve 12 months following the Grant Date but prior to the Certification Date and a Change in Control subsequently occurs prior to the Certification Date, then Participant will, at the time of such Change in Control, immediately vest in that number of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares equal to the Target Shares subject to this Award, without any measurement of Performance Goal attainment to date and without regard to the Continuous Service vesting provisions.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The number of Shares in which Participant vests determined in accordance with the foregoing provisions of this Paragraph 4 will be converted into the right to receive for each such Share the same consideration per share of Common Stock payable to the other stockholders of the Company in consummation of the Change in Control, and such consideration will be distributed to Participant on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) the 10th business day following the effective date of the Change in Control or (ii) the date those shares would have been issued to Participant in accordance with Paragraph 5 in the absence of such Change in Control.  Each issuance or distribution made under this Paragraph 4(e) will be subject to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Except for the actual number of Shares in which Participant vests in accordance with this Paragraph 4, Participant will cease to have any further right or entitlement to any additional Shares under this Agreement following the effective date of the Change in Control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Agreement will not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Settlement of Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in Paragraph 4, the Shares in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I will be issued in accordance with the following provisions&#58;  </font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">The issuance of the Shares will be effected during the period beginning on the first business day of February of the calendar year immediately succeeding the end of the Performance Period and ending no later than March 15 of that calendar year.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will, on the applicable issuance date, issue to or on behalf of Participant a certificate in electronic form for the Shares in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I and will concurrently settle with Participant any associated dividend equivalents. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in Paragraph 4 or this Paragraph 5, the settlement of all Performance Shares or Performance-Qualified Shares which vest under the Award will be made solely in Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in Paragraph 4, no Shares will be issued prior to the Certification Date.  No fractional Shares will be issued pursuant to the Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement will be rounded down to the next whole share.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The issuance of Shares pursuant to the Award will be subject to compliance by the Company and Participant with all Applicable Laws relating thereto. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Award will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained.  The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant acknowledges that, regardless of any action the Company or the applicable Related Entity employing or retaining the Participant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may take with respect to any or all Withholding Taxes related to the Award or Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all such Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Employer.  Participant further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares or other property in settlement of the Award, the subsequent sale of the Shares acquired pursuant to such issuance and the receipt of any dividends or dividend equivalents and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result.  Further, if Participant is or becomes subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and the Employer (or a former employer, as applicable) may withhold or account for Withholding Taxes in more than one jurisdiction.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this Agreement (including any Shares issued in settlement of any dividend equivalents) through an automatic share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless the Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides, in its sole discretion, to no longer utilize the Share Withholding Method and provides Participant with a corresponding notice. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of Shares subject to the vested Award, notwithstanding that a number of Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Share Withholding Method is not used, then the Withholding Taxes will be collected from Participant through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan. Participant will, promptly upon request from the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such broker-dealer sale and remittance transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no broker-dealer sale and remittance transaction will be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Company determines that such broker-dealer sale and remittance procedure is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such procedure can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of Participant&#8217;s separate check payable to the Company (or a wire transfer of funds to the Company) in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event will any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company will collect the Withholding Taxes with respect to dividend equivalents distributed in a form other than Shares by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Participant&#8217;s jurisdiction, in which case Participant may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Participant may seek a refund from local tax authorities.  In the event of under-withholding, Participant may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, to the extent Participant is subject to taxation in the United States, the Withholding Taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder will in all events be collected from Participant no later than the last business day of the calendar year in which those shares or other amounts vest (as determined under applicable tax laws).  Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those shares or other amounts vest, Participant will, if so requested by the Company, on or before the last business day of the calendar year in which such shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company ) in the dollar amount equal to the Withholding Taxes required to be withheld with respect to those shares or other amounts.  Alternatively, the Company may, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in its sole discretion, elect to withhold the dollar amount equal to the Withholding Taxes required to be withheld with respect to those shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.  The provisions of this Paragraph 6(g) will be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Section 3121(v) of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  For purposes of applying the various Continuous Service vesting provisions of this Agreement, Participant shall be deemed to cease Continuous Service on the commencement date of any leave of absence and not to remain in Continuous Service status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any, or pursuant to the following policy&#58;</font></div><div style="margin-bottom:0.12pt;text-indent:90pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will receive Continuous Service credit for vesting purposes for (i) the first three months of an approved personal leave of absence or (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In no event, however, will Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the earlier of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service on or before that date, or (ii) the date Participant&#8217;s Continuous Service actually terminates by reason of Participant&#8217;s voluntary or involuntary termination or by reason of Participant&#8217;s death or Disability. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In accepting this Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Participant is voluntarily participating in the Plan&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">no claim or entitlement to compensation or damages will arise from forfeiture of the Award resulting from the termination of Participant&#8217;s Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the grant of the Award to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against the Company, any Related Entity or the Employer, waives Participant&#8217;s ability, if any, to bring any such claim, and releases the Company, any Related Entity and the Employer from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant will be deemed irrevocably to have agreed not to pursue such claim and agreed to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise provided in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Performance Shares or of any amounts due to Participant pursuant to the settlement of the Performance Shares or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Data Privacy.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that Participant agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the Related Entities and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that Participant needs to review the following information about the processing of Participant&#8217;s personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Participant&#8217;s consent.  As regards the processing of Participant&#8217;s Personal Data in connection with the Plan and this Agreement, Participant understands that the Company is the controller of Participant&#8217;s Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan.  Participant understands that this Personal Data may include Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Shares or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant&#8217;s favor.  The legal basis for the processing of Participant&#8217;s Personal Data, where required, will be Participant&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company transfers Participant&#8217;s Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan.  In the future, the Company may select a different service provider and share Participant&#8217;s Personal Data with such different service provider that serves the Company in a similar manner.  Participant understands and acknowledges that the Company&#8217;s service provider will open an account for Participant to receive and trade Shares acquired under the Plan and that Participant will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States.  Participant understands and acknowledges that Participant&#8217;s country may have enacted data privacy laws that are different from the laws of the United States.  The Company&#8217;s legal basis for the transfer of Participant&#8217;s Personal Data is Participant&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.03pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company will use Participant&#8217;s Personal Data only as long as is necessary to implement, administer and manage Participant&#8217;s participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws.  In the latter case, Participant understands and acknowledges that the Company&#8217;s legal basis for the processing of Participant&#8217;s Personal Data would be compliance with the relevant laws or regulations.  When </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">the Company no longer needs Participant&#8217;s Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that Participant&#8217;s participation in the Plan and Participant&#8217;s consent is purely voluntary.  Participant may deny or later withdraw Participant&#8217;s consent at any time, with future effect and for any or no reason.  If Participant denies or later withdraws Participant&#8217;s consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan.  Participant further understands that denial or withdrawal of Participant&#8217;s consent would not affect Participant&#8217;s status or salary as an employee or Participant&#8217;s career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Participant is based and subject to the conditions set out in the Applicable Laws, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Participant and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Participant&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of Participant&#8217;s Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant&#8217;s Personal Data that Participant has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Participant&#8217;s employment and is carried out by automated means.  In case of concerns, Participant understands that Participant may also have the right to lodge a complaint with the competent local data protection authority.  Further, to receive clarification of, or to exercise any of, Participant&#8217;s rights, Participant understands that Participant should contact Participant&#8217;s local human resources representative.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying Shares.  Participant should consult with Participant&#8217;s own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">principal corporate offices.  Any notice required to be given or delivered to Participant will be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or will be delivered electronically to Participant through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect sales of the Shares issued hereunder.  All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, and the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A of the Code</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is the intention of the parties that the provisions of this Agreement will, to the maximum extent permissible, comply with the requirements of the short-term deferral exception to Section 409A of the Code and Treasury Regulations Section 1.409A-1(b)(4) with respect to one or more Shares underlying the Award.  Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the requirements or limitations of Section 409A of the Code applicable to such short-term deferral exception, then those provisions, as they apply to such Shares, will be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Section 409A of the Code and the Treasury Regulations thereunder that apply to such exception.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">However, to the extent this Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Section 409A of the Code with respect to one or more Shares underlying the Award, then the following provisions will apply with respect to those Shares, notwithstanding anything to the contrary set forth herein&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;None of those Shares or other amounts which become issuable or distributable with respect to those Shares by reason of Participant&#8217;s cessation of Continuous Service will actually be issued or distributed to Participant until or as soon as administratively practicable following the date of Participant&#8217;s Separation from Service, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the 15th day of the third calendar month following the date of such Separation from Service. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Participant&#8217;s cessation of Continuous Service that is considered a separation from service under Treasury Regulations Section 1.409A-1(h).</font></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;None of those Shares or other amounts which become issuable or distributable with respect to those Shares by reason of Participant&#8217;s cessation of Continuous Service will actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first day of the seventh  month following the date of Participant&#8217;s </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Section 409A of the Code, as determined by the Administrator, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Section 409A(a)(2) of the Code.  The deferred Shares or other distributable amount will be issued or distributed in a lump sum on the first day of the seventh month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction&#59; Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.  In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control.  All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Award.  Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation.  The word &#8220;or&#8221; is not exclusive.  Words in the masculine gender include the feminine gender, and where appropriate, the plural includes the singular and the singular includes the plural.  All references to &#8220;including&#8221; will be construed as meaning &#8220;including without limitation.&#8221;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The interpretation, performance and enforcement of this Agreement will be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules.  For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement or otherwise relating to or arising from this Agreement, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this grant is made or to be performed</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Agreement or in the Plan will confer upon Participant any right to remain in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Employer or of Participant, which rights are hereby expressly reserved by each, to terminate Participant&#8217;s Continuous Service at any time for any reason, with or without Cause.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents.  Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions will nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement will not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or Participant's broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares, rights to shares (e.g., Performance Shares) or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before Participant possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak with Participant's personal legal advisor on this matter.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event will any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance. By accepting the Award, Participant agrees that the Award is granted under and governed by the terms and conditions of the Plan and this Agreement. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"></td><td style="width:21.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature</font></td></tr></table></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i8b55c922e25941249123d8958ea779df_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions will be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Certification Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the date following the completion of the Performance Period on which the Administrator certifies the attained level of the TSR Performance Goal for such  Performance Period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the total shareholder return performance goal specified on attached Schedule I (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TSR Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that must be attained in order to satisfy the performance-vesting requirement for the Shares subject to this Award.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the period specified on attached Schedule I over which the attainment of the TSR Performance Goal is to be measured.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the maximum number of Shares in which Participant can vest based on the level at which the Performance Goal for the Performance Period is attained and will be calculated in accordance with the provisions of attached Schedule I.  In no event will the number of such Performance-Qualified Shares exceed two hundred percent (200%) of the Target Shares set forth in Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the Plan. Each Performance-Qualified Share that vests pursuant to the terms of the Award will entitle Participant to receive one share of Common Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i8b55c922e25941249123d8958ea779df_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE I</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PERFORMANCE GOAL AND PERFORMANCE PERIOD  </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Shares shall be the 34 month period beginning March 1, 2023 and ending December 31, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal  &#8211; Total Shareholder Return&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares subject to this Award shall be tied to the percentile level at which the total shareholder return (including stock price appreciation and reinvestment of any cash dividends or other stockholder distributions) to the Company&#8217;s stockholders over the Performance Period stands in relation to the total shareholder return realized for that period by the companies comprising the following three subsets of the S&#38;P Healthcare Index&#58; Biotechnology, Pharmaceuticals and Health Care Equipment (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">S&#38;P Healthcare Sub-Index&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For such purpose, the total shareholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be determined pursuant to the following formula&#58;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TSR  &#61;  (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Ending Stock Price* - Beginning Stock Price**) + Reinvested Dividends***</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                  Beginning Stock Price**</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*  Ending Stock Price is the average daily closing price per share of the Common Stock calculated for the last 60 consecutive trading days within the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">**  Beginning Stock Price is the average daily closing price per share of the Common Stock calculated for the last 60 consecutive trading days immediately preceding the commencement of the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*** Reinvested Dividends shall be calculated by multiplying (i) the aggregate number of shares (including fractional shares) that could have been purchased during the Performance Period had each cash dividend paid on a single share during that period been immediately reinvested in additional shares (or fractional shares) at the closing selling price per share of the Common Stock on the applicable dividend payment date by (ii) the average daily closing price per share calculated for the last 60 consecutive trading days within the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each of the foregoing amounts shall be equitably adjusted for stock splits, stock dividends, recapitalizations and other similar events affecting the shares in question without the issuer&#8217;s receipt of consideration.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For each company in the S&#38;P Healthcare Sub-Index, the TSR with respect to its common stock shall be calculated in the same manner as for the Common Stock.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the following parameters shall be in effect for purposes of measuring the total shareholder return for the S&#38;P Healthcare Sub-Index&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">a company will be included in the S&#38;P Healthcare Sub-Index only if that company is in existence both at the start of the Performance Period and at the end of the Performance Period, and the stock price performance of any company that is acquired, or otherwise ceases to exist as an independent publicly-owned entity, during the Performance Period shall not be taken into account in determining the relative total shareholder return of the companies comprising the S&#38;P Healthcare Sub-Index for the Performance Period&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">any distribution (other than a regular cash dividend), whether in cash, securities (other than shares of the distributing company&#8217;s common stock) or other property, made during the Performance Period by a company included in the S&#38;P Healthcare Sub-Index for that period shall be treated in the same manner as a regular cash dividend paid by such distributing company (in an amount per share of the distributing company&#8217;s common stock deemed equal to the cash amount or the fair market value of the securities or other property distributed per share of the distributing company&#8217;s common stock) that is immediately reinvested in the distributing company&#8217;s common stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided and only if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the amount distributed per share of the distributing company&#8217;s common stock (as determined in the manner set forth herein) is at least 10% of the closing price per share of the distributing company&#8217;s common stock on the effective date of such distribution&#59; otherwise, such distribution shall not be taken in effect in calculating the relative total shareholder return of the companies comprising the S&#38;P Healthcare Sub-Index&#59; and      </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">any spin-off distribution of shares of the common stock of one or more subsidiaries or other affiliated entities that is made during the Performance Period by a company included in the S&#38;P Healthcare Sub-Index for that period shall be treated in the same manner as a regular cash dividend paid by that distributing company (in an amount per share of the distributing company&#8217;s common stock deemed equal to the fair market value of the common stock (or fractional share thereof) of the spun-off entity distributed per share of the distributing company&#8217;s common stock) that is immediately reinvested in the distributing company&#8217;s common stock&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided and only if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the amount distributed per share of the distributing company&#8217;s common stock (as determined in the manner set forth herein) is at least 10% of the closing price per share of the distributing company&#8217;s common stock on the effective date of such distribution&#59; otherwise, such spin-off distribution shall not be taken in effect in calculating the relative total shareholder return of the companies comprising the S&#38;P Healthcare Sub-Index.         </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of measuring the total shareholder return of the Company for the Performance Period, the foregoing parameters governing distributions and spin-off transactions shall also apply to any distribution (other than a regular cash dividend) or spin-off transaction that is effected by the Company during the Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Should a Change in Control occur during the Performance Period, then the attained level of the Performance Goal shall be determined in accordance with the applicable Change in Control provisions of Paragraph 4 of this Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within 65 days after the completion of the Performance Period, the Administrator shall determine and certify the actual level at which the TSR Performance Goal is attained. The actual number of Performance-Qualified Shares that results from such certification may range from 0% to 200% of the Target Shares subject to this Award, as such number may be adjusted from time to time pursuant to the provisions of the Plan.  The actual percentage shall be determined on the basis of the percentile level at which the Administrator certifies that the TSR Performance Goal has been attained in relation to the total shareholder return realized for that period by the companies comprising the S&#38;P Healthcare Sub-Index&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) the maximum number of Shares that may qualify as Performance-Qualified Shares may not exceed 200% of the Target Shares, as such number may be adjusted from time to time pursuant to the provisions of the Plan, and (ii) in no event shall the number of Shares that may qualify as Performance-Qualified Shares pursuant to the Relative TSR Payout Slope below exceed 100% of the Target Shares (as such number may be adjusted from time to time pursuant to the provisions of the Plan) if the Company&#8217;s absolute TSR for the Performance Period is negative.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Levels of TSR Performance Goal&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares that may qualify as Performance-Qualified Shares on the basis of the certified percentile level of TSR Performance Goal attainment shall be calculated by multiplying the Target Shares (as such number may be adjusted from time to time pursuant to the provisions of the Plan) by the applicable percentage determined in accordance with the following payout slope for the TSR Performance Goal (with appropriate straight-line interpolation for any attained percentile level within two designated percentile levels in such slope)&#58; </font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TOTAL SHAREHOLDER RETURN PAYOUT SLOPE</font></div><div style="text-align:center"><img alt="a1022graph.jpg" src="a1022graph.jpg" style="height:334px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.955%"><tr><td style="width:1.0%"></td><td style="width:52.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Perce</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ntile</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">% of Target</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">20th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">0%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">30th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">25%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">40th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">63%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">50th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">100%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">60th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">125%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">70th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">150%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">80th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">175%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">81st</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">200%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">90th</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">200%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">100th</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">200%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CONTINUOUS SERVICE VESTING REQUIREMENT FOR PERFORMANCE-QUALIFIED SHARES </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares in which Participant may actually vest on the basis of the number of Performance-Qualified Shares certified by the Administrator in accordance with the performance vesting provisions of this Schedule I will be tied to Participant&#8217;s completion of the following Continuous Service vesting requirements&#58; </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">If Participant remains in Continuous Service through the Certification Date, Participant will vest in 100% of the Performance-Qualified Shares certified by the Administrator for the Performance Period.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant&#8217;s Continuous Service terminates prior to the Certification Date by reason of death or Disability, then Participant will, at the time of such termination of Continuous Service, immediately vest in the Target Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such termination occurs upon or following the end of the Performance Period, then Participant will instead vest in 100% of the Performance-Qualified Shares certified by the Administrator for the Performance Period.  The Shares that vest pursuant to this paragraph will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service , but in no event later than the later of (i) the close of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of the third calendar month following the date of such cessation of Continuous Service. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant&#8217;s Continuous Service terminates by reason of  Participant&#8217;s Retirement at least 12 months following the Grant Date but prior to the Certification Date, then Participant will, following the completion of the Performance Period and the Certification Date, vest in 100% of the Performance-Qualified Shares certified by the Administrator for the Performance Period as if Participant had remained in Continuous Service through the Certification Date. </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">In the event (i) Participant&#8217;s Continuous Service is terminated without Cause, or Participant resigns from Continuous Service due to a Constructive Termination, at any time after the completion of the Performance Period but prior to the Certification Date and (ii) such termination of Continuous Service also occurs during a period while there is in effect a definitive executed agreement for a Change in Control transaction, then Participant will vest in the number of Performance-Qualified Shares in which Participant could vest, based on the actual level at which the TSR Performance Goal is attained and certified for the Performance Period, had Participant remained in Continuous Service through such Certification Date.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">In the event Participant&#8217;s Continuous Service ceases for any other reason (including, without limitation, any deemed cessation of Continuous Service under Paragraph 8 of this Agreement) prior to the Certification Date, then Participant will not vest in any of the Performance-Qualified Shares, and all of Participant&#8217;s right, title and interest to the Shares subject to this Award will immediately terminate&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that should a Change in Control occur prior to the completion of the Performance Period, then the provisions of Paragraph 4 will govern the vesting of the Performance Shares subject to this Award. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>4
<FILENAME>gildq12023ex10262023psuagr.htm
<DESCRIPTION>2023 PSU AGREMENT - REVENUNE GOALS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic780221dfca44ec6ba81cd480f1ad925_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:0.24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.26</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> REVENUE PERFORMANCE GOAL</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2022 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:0.24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PERFORMANCE SHARE AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Performance Share Award Agreement (this &#8220;Agreement&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of Shares to the Participant thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Capitalized terms not otherwise defined in this Agreement or in the attached Appendix A have the meanings set forth in the Plan.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> it is hereby agreed as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant of Performance Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company hereby awards to Participant, as of the Grant Date indicated below, Performance Shares under the Plan (the &#8220;Award&#8221;), subject to the terms and conditions set forth in this Agreement. This Agreement provides the Participant with the right to receive one or more Shares on the designated issuance date for those shares, based upon the extent to which each Performance Share vests pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD SUMMARY</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">March 10, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Target Number of Performance Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The actual number of Shares that may become issuable pursuant to the Performance Shares subject to this Agreement will be determined in accordance with the performance-vesting and Continuous Service vesting provisions of attached Schedule I. For purposes of the applicable calculations under Schedule I, the target number of Performance Shares to be utilized is &#91;______&#93; shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Target Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;).</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Performance Shares will be divided into three separate Tranches with one third (1&#47;3) of the Target Shares allocated to each such Tranche.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Vesting Requirements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Each Tranche of Performance Shares will be subject to the performance-vesting and Continuous Service vesting requirements set forth for that particular Tranche in attached Schedule I and will vest on the Certification Date.</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Change in Control Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Shares underlying each Tranche of Performance Shares may also vest on an accelerated basis in accordance with the applicable provisions of Paragraph 4 of this Agreement should a Change in Control occur after the start but prior to the completion of the Performance Period applicable to that particular Tranche or the Certification Date.</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Issuance Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Shares which actually vest and become issuable pursuant to each Tranche of Performance Shares will be issued in accordance with the provisions of this Agreement applicable to the particular circumstances under which such vesting occurs.</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to the actual issuance of the Shares which vest hereunder, Participant may not transfer any interest in the Performance Shares subject to the Award or the underlying Shares or pledge or otherwise hedge the sale of those Performance Shares or underlying shares, including through any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares. However, any Shares which vest hereunder but otherwise remain unissued at the time of Participant&#8217;s death will be transferred to Participant&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Participant&#8217;s estate.</font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will not have any stockholder rights, including voting, dividend (except as provided in Paragraph 3(b)) or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that this Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to this Award on such record date have not been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account will be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to this Award had they been issued and outstanding and entitled to that dividend or distribution. As such Shares subsequently vest hereunder, the dividend equivalents so credited to those Shares in the book account will vest, and those vested dividend equivalents will be distributed to Participant (in the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those dividend equivalents relate and correspondingly as such Shares are forfeited or cancelled under this Award (including in accordance with the Continuous Service vesting provisions), the dividend equivalents so credited to those Shares in the book account will be forfeited or cancelled. Settlement of dividend equivalents will be subject to the Company&#8217;s collection of applicable Withholding Taxes. The Administrator will have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination will control. No dividend equivalent amount will be paid or distributed on Shares under this Award that are forfeited, cancelled or that otherwise are not issued or issuable under this Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The following provisions will apply only to the extent a Change in Control is consummated prior to the Certification Date and will have no force or effect if the effective date of the Change in Control occurs after the Certification Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Should (i) the Change in Control occur during a Performance Period that is in effect at the time with respect to a particular Tranche of Performance Shares but prior to the completion of that Performance Period and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant will immediately vest in that number of Shares equal to the Target Shares allocated to that particular Tranche, without any measurement of Performance Goal attainment to date with respect to that particular Tranche and without regard to the Continuous Service vesting provisions. To the extent a Performance Period for a particular Tranche of Performance Shares has not commenced prior to the effective date of the Change in Control, the Performance Shares allocated to that Tranche in accordance with Paragraph 1 of this Agreement and the provisions of attached Schedule I will be cancelled, and Participant will not have any further right or entitlement to receive any Shares with respect to those cancelled Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Should (i) the Change in Control occur at any time on or after the completion of the Performance Period applicable to a particular Tranche of Performance Shares but prior to the Certification Date and (ii) Participant remains in Continuous Service through the effective date of that Change in Control, then Participant will immediately vest in that number of Shares equal to the actual number of Performance-Qualified Shares (if any) at the time subject to that Tranche by reason of the level at which the Revenue Performance Goal for that Tranche was in fact attained for the Performance Period applicable to that Tranche, without regard to the Continuous Service vesting provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The foregoing provisions of this Paragraph 4 will also apply if Participant&#8217;s Continuous Service is terminated without Cause or Participant resigns from Continuous Service due to Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for the Change in Control transaction and ending with the earlier of (i) the termination of the definitive agreement without the consummation of such Change in Control or (ii) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Should Participant cease Continuous Service by reason of Participant&#8217;s Retirement at least twelve 12 months following the Grant Date but prior to the Certification Date and during one or more Service Periods that are, pursuant to the provisions of attached Schedule I, in effect at that time with respect to one or more Tranches of Performance Shares and a Change in Control subsequently occurs prior to the Certification Date, then Participant will, at the time of such Change in Control, immediately vest in that number of Shares equal to the Target Shares allocated to that particular Tranche, without any measurement of Performance Goal attainment to date with respect to that particular Tranche and without regard to the Continuous Service vesting provisions. To the extent a Performance Period for a particular Tranche of Performance Shares has not commenced prior to the effective date of the Change in Control, the Performance Shares allocated to that Tranche in accordance with Paragraph 1 of this Agreement and the provisions of attached Schedule I will be cancelled, and Participant will not have any further right or entitlement to receive any Shares with respect to those cancelled Performance Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The number of Shares in which Participant vests determined in accordance with the foregoing provisions of this Paragraph 4 will be converted into the right to receive for each such Share the same consideration per share of Common Stock payable to the other stockholders of the Company in consummation of the Change in Control, and such consideration will be distributed to Participant on the earlier of (i) the 10th business day following the effective date of the Change in Control or (ii) the date those shares would have been issued to Participant in accordance with Paragraph 5 in the absence of such Change in Control. Each issuance or distribution made under this Paragraph 4(e) will be subject to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Except for the actual number of Shares in which Participant vests in accordance with this Paragraph 4, Participant will cease to have any further right or entitlement to any additional Shares under this Agreement following the effective date of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;This Agreement will not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Settlement of Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4, the Shares in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I will be issued in accordance with the following provisions&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-&#160;&#160;&#160;&#160;The issuance of the Shares underlying each particular Tranche of Performance Shares will be effected during the period beginning on the first business day of February of the calendar year immediately succeeding the end of the Tranche Three Performance Period and ending no later than March 15 of that calendar year.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company will, on the applicable issuance date, issue to or on behalf of Participant a certificate in electronic form for the Shares in which Participant vests pursuant to the performance-vesting and Continuous Service vesting provisions of attached Schedule I and will concurrently settle with Participant any associated dividend equivalents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4 or this Paragraph 5, the settlement of all Performance Shares or Performance-Qualified Shares which vest under the Award will be made solely in Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Except as otherwise provided in Paragraph 4, no Shares will be issued prior to the Certification Date. No fractional Shares will be issued pursuant to the Award, and any fractional share resulting from any calculation made in accordance with the terms of this Agreement will be rounded down to the next whole share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The issuance of Shares pursuant to the Award will be subject to compliance by the Company and Participant with all Applicable Laws relating thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Award will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:0.12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant acknowledges that, regardless of any action the Company or the applicable Related Entity employing or retaining the Participant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may take with respect to any or all Withholding Taxes related to the Award or Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all such Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Employer.  Participant further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares or other property in settlement of the Award, the subsequent sale of the Shares acquired pursuant to such issuance and the receipt of any dividends or dividend equivalents and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result.  Further, if Participant is or becomes subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and the Employer (or a former employer, as applicable) may withhold or account for Withholding Taxes in more than one jurisdiction.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement (including any Shares issued in settlement of any dividend equivalents) through an automatic share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless the Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides, in its sole discretion, to no longer utilize the Share Withholding Method and provides Participant with a corresponding notice. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of Shares subject to the vested Award, notwithstanding that a number of Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Share Withholding Method is not used, then the Withholding Taxes will be collected from Participant through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan. Participant will, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such broker-dealer sale and remittance transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no broker-dealer sale and remittance transaction will be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Company determines that such broker-dealer sale and remittance procedure is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such procedure can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of Participant&#8217;s separate check payable to the Company (or a wire transfer of funds to the Company) in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event will any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company will collect the Withholding Taxes with respect to dividend equivalents distributed in a form other than Shares by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">withholding rates, including maximum applicable rates in Participant&#8217;s jurisdiction, in which case Participant may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Participant may seek a refund from local tax authorities.  In the event of under-withholding, Participant may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, to the extent Participant is subject to taxation in the United States, the Withholding Taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder will in all events be collected from Participant no later than the last business day of the calendar year in which those shares or other amounts vest (as determined under applicable tax laws).  Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those shares or other amounts vest, Participant will, if so requested by the Company, on or before the last business day of the calendar year in which such shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company ) in the dollar amount equal to the Withholding Taxes required to be withheld with respect to those shares or other amounts.  Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Withholding Taxes required to be withheld with respect to those shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.  The provisions of this Paragraph 6(g) will be applicable only to the extent necessary to comply with the applicable tax withholding requirements of Section 3121(v)  of the Code.</font></div><div style="text-align:justify;text-indent:90pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of applying the various Continuous Service vesting provisions of this Agreement, the Administrator may determine that Participant will be deemed to cease Continuous Service on the commencement date of any leave of absence and not to remain in Continuous Service status during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any, or pursuant to the following policy&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will receive Continuous Service credit for vesting purposes for (i) the first three months of an approved personal leave of absence or (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In no event, however, will Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service on or before that date, or (ii) the date Participant&#8217;s Continuous Service actually terminates by reason of Participant&#8217;s voluntary or involuntary termination or by reason of Participant&#8217;s death or Disability. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Nature of Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In accepting this award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Awards, or benefits in lieu of Awards, even if Awards have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages will arise from forfeiture of the Award resulting from the termination of Participant&#8217;s Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the grant of the Award to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against the Company, any Related Entity or the Employer, waives Participant&#8217;s ability, if any, to bring any such claim, and releases the Company, any Related Entity and the Employer from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant will be deemed irrevocably to have agreed not to pursue such claim and agreed to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;unless otherwise provided in the Plan or by the Company in its discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement to have the Award or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k) &#160;&#160;&#160;&#160;neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Performance Shares or of any amounts due to Participant pursuant to the settlement of the Performance Shares or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Data Privacy.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that Participant agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the Related Entities and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that Participant needs to review the following information about the processing of Participant&#8217;s personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Participant&#8217;s consent. As regards the processing of Participant&#8217;s Personal Data in connection with the Plan and this Agreement, Participant understands that the Company is the controller of Participant&#8217;s Personal Data.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan. Participant understands that this Personal Data may include Participant's  name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Shares or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant's favor. The legal basis for the processing of Participant's Personal Data, where required, will be Participant's consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that the Company transfers Participant's Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">different service provider and share Participant&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Participant understands and acknowledges that the Company&#8217;s service provider will open an account for Participant to receive and trade Shares acquired under the Plan and that Participant will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Participant understands and acknowledges that Participant&#8217;s country may have enacted data privacy laws that are different from the laws of the United States. The Company&#8217;s legal basis for the transfer of Participant&#8217;s Personal Data is Participant&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.03pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that the Company will use Participant&#8217;s Personal Data only as long as is necessary to implement, administer and manage Participant&#8217;s participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Participant understands and acknowledges that the Company&#8217;s legal basis for the processing of Participant&#8217;s Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Participant&#8217;s Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that Participant&#8217;s participation in the Plan and Participant&#8217;s consent is purely voluntary. Participant may deny or later withdraw Participant&#8217;s consent at any time, with future effect and for any or no reason. If Participant denies or later withdraws Participant&#8217;s consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan. Participant further understands that denial or withdrawal of Participant&#8217;s consent would not affect Participant&#8217;s status or salary as an employee or Participant&#8217;s career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:21.35pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Participant is based and subject to the conditions set out in the Applicable Laws, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Participant and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Participant&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">requirements, (iv) request the Company to restrict the processing of Participant&#8217;s Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant&#8217;s Personal Data that Participant has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Participant&#8217;s employment and is carried out by automated means. In case of concerns, Participant understands that Participant may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Participant&#8217;s rights, Participant understands that Participant should contact Participant&#8217;s local human resources representative.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the underlying Shares.  Participant should consult with Participant&#8217;s own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Award.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its principal corporate offices.  Any notice required to be given or delivered to Participant will be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or will be delivered electronically to Participant through the Company&#8217;s electronic mail system or through an on-line brokerage firm authorized by the Company to effect sales of the Shares issued hereunder.  All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except to the extent otherwise provided in this Agreement, the provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, and the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A of the Code</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is the intention of the parties that the provisions of this Agreement will, to the maximum extent permissible, comply with the requirements of the short-term deferral exception to Section 409A of the Code and Treasury Regulations Section 1.409A-1(b)(4) with respect to each Tranche of Performance Shares under this Award.  Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the requirements or limitations of Section 409A of the Code applicable to such short-term deferral exception, then those provisions, as they apply to each Tranche, will be interpreted and applied in a manner that does not result in a violation of the requirements or limitations of Section 409A of the Code and the Treasury Regulations thereunder that apply to such exception.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">However, to the extent this Agreement should be deemed to create a deferred compensation arrangement subject to the requirements of Section 409A of the Code with respect to one or more Tranches of the Performance Shares, then the following provisions will apply with respect to any such Tranche, notwithstanding anything to the contrary set forth herein&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No Shares or other amounts which become issuable or distributable with respect to such Tranche by reason of Participant&#8217;s cessation of Continuous Service will actually be issued or distributed to Participant until or as soon as administratively practicable following the date of Participant&#8217;s Separation from Service, but in no event later than the later of (i) the close of the calendar year in which such Separation from Service occurs or (ii) the 15th day of the third calendar month following the date of such Separation from Service. As used herein, &#8220;Separation from Service&#8221; means the Participant&#8217;s cessation of Continuous Service that is considered a separation from service under Treasury Regulations Section 1.409A-1(h).  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">No Shares or other amounts which become issuable or distributable with respect to such Tranche by reason of Participant&#8217;s cessation of Continuous Service will actually be issued or distributed to Participant prior to the earlier of (i) the first day of the seventh month following the date of Participant&#8217;s Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Section 409A of the Code, as determined by the Administrator, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Section 409A(a)(2) of the Code.  The deferred Shares or other distributable amount will be issued or distributed in a lump sum on the first day of the seventh month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt"> The Shares that are issuable pursuant to each Tranche of Performance Shares in accordance with the provisions of this Agreement and attached Schedule I will be deemed a separate payment for purposes of Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Construction&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.  In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control.  All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Award.  Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation.  The word &#8220;or&#8221; is not exclusive.  Words in the masculine gender include the feminine gender, and where appropriate, the plural </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">includes the singular and the singular includes the plural.  All references to &#8220;including&#8221; will be construed as meaning &#8220;including without limitation.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law&#47;Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The interpretation, performance and enforcement of this Agreement will be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules.  For purposes of any action, lawsuit or other proceedings brought to enforce this Agreement or otherwise relating to or arising from this Agreement, the parties hereby submit to and consent to the sole and exclusive jurisdiction of the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California, and no other courts, where this grant is made or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in this Agreement or in the Plan will confer upon Participant any right to remain in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Employer or of Participant, which rights are hereby expressly reserved by each, to terminate Participant&#8217;s Continuous Service at any time for any reason, with or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents.  Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions will nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement will not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant may be subject to insider trading restrictions and&#47;or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or Participant&#8217;s broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of shares, rights to shares (e.g., Performance Shares)  or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before Participant possessed inside information.  Furthermore, Participant could be prohibited from (i) disclosing the inside </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information to any third party, which may include fellow employees and (ii)  &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company.  Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions, and Participant should speak with Participant&#8217;s personal legal advisor on this matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Imposition of Other Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Participant Acceptance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event will any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance. By accepting the Award, Participant agrees that the Award is granted under and governed by the terms and conditions of the Plan and this Agreement. Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting this Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ic780221dfca44ec6ba81cd480f1ad925_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Gilead Sciences, Inc. has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.608%"><tr><td style="width:1.0%"></td><td style="width:21.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">EVP, Human Resources</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:7pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">PARTICIPANT</font></td></tr><tr style="height:41pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Signature</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="ic780221dfca44ec6ba81cd480f1ad925_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">APPENDIX A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following definitions will be in effect under the Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Certification Date </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Certification Date means the date following the completion of the Tranche Three Performance Period on which the Administrator certifies the attained level of the Performance Goal applicable to Tranche Three.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Performance Goa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l means, with respect to each separate Tranche of Performance Shares, the net product revenue performance goal established or to be established for that Tranche at one or more designated levels of attainment in accordance with the provisions of attached Schedule I (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that must be subsequently attained in order to satisfy the performance-vesting requirement for the Shares allocated to that particular Tranche.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7pt;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the one-year period specified on attached Schedule I for each separate Tranche of Performance Shares over which the attainment of the Revenue Performance Goal applicable to that particular Tranche is to be measured.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:6.34pt;text-decoration:underline">Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, with respect to each separate Tranche of Performance Shares,  the maximum number of Shares in which Participant can vest based on the level at which the Performance Goal applicable to that particular Tranche is in fact attained and will be calculated in accordance with the provisions of attached Schedule I.  Each Performance-Qualified Share that vests pursuant to the terms of the Award will entitle Participant to receive one Share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.67pt;text-decoration:underline">Service Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, with respect to each Tranche of Performance Shares, the applicable service period specified for that particular Tranche in attached Schedule I over which the Continuous Service vesting requirement in effect for that Tranche is to be measured.            </font></div><div style="margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.33pt;text-decoration:underline">Tranche</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the three separate tranches (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tranche One</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tranche Two</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tranche Three</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) into which the Performance Shares subject to this Award are divided in accordance with the provisions of Paragraph 1 of this Agreement and attached Schedule I.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="ic780221dfca44ec6ba81cd480f1ad925_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHEDULE I</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PERFORMANCE GOALS AND PERFORMANCE PERIODS FOR THE THREE TRANCHES OF PERFORMANCE SHARES </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">ESTABLISHMENT OF SEPARATE TRANCHES</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Target Shares subject to the Award have, in accordance with Paragraph 1 of this Agreement, been divided into three separate Tranches&#58; Tranche One, Tranche Two and Tranche Three.  Each such separate Tranche will cover one-third of the Target Shares and will have its own separate Performance Period and Service Period. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD FOR TRANCHE ONE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Goal for the Performance Shares allocated to Tranche One will be the one-year period coincident with the Company&#8217;s 2023 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche One Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SERVICE PERIOD FOR TRANCHE ONE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Service Period for the Continuous Service vesting condition for Tranche One will be the period beginning January 1, 2023 and ending on the Certification Date.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING FOR TRANCHE ONE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal for Tranche One&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares allocated to Tranche One will be tied to the Company&#8217;s recognition of net product revenue for the Tranche One Performance Period in a dollar amount ranging from $23.808 billion at 20% threshold level attainment to $26.453 billion at target level attainment and to $27.776 billion at maximum level attainment, with the net product revenue goal at any other point within such range to be in the dollar amount determined on a straight-line interpolated basis pursuant to the 2023 Fiscal Year Revenue Goal&#47;Revenue Payout Slope set forth below. For purposes of determining whether such Revenue Performance Goal is attained, the actual level of net product revenue recognized by the Company for the Tranche One Performance Period will be the net product revenue of the Company and its consolidated subsidiaries that is reported on a consolidated basis in the Company&#8217;s audited consolidated financial statements for the fiscal year coincident with the Tranche One Performance Period, adjusted, however, to factor out (i) the effect of any changes in applicable accounting principles that occur after the start of such period and (ii) any product revenue realized during the 2023 fiscal year by any entity acquired by the Company during that year.   </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within 65 days after the completion of the Tranche One Performance Period, the Administrator will determine and certify the actual dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche One Performance Period.  The actual number of Performance-Qualified Shares that results from such certification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche One Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may range from 0% to 200% of the Target Shares allocated to Tranche One in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of the Plan. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">actual percentage will be determined on the basis of the dollar amount of net product revenue that the Administrator certifies has in fact been recognized for the Tranche One Performance Period, as measured and reported on a consolidated basis with the Company&#8217;s subsidiaries in accordance with the Company&#8217;s audited consolidated financial statements for the Company&#8217;s fiscal year coincident with the Tranche One Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the maximum number of the Shares that may qualify as Tranche One Performance-Qualified Shares may not exceed 200% of the Target Shares allocated to Tranche One in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of the Plan.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Level of Tranche One Performance Goal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares that may qualify as Tranche One Performance-Qualified Shares on the basis of the certified dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche One Performance Period will be calculated by multiplying the number of Target Shares allocated to Tranche One in accordance with Paragraph 1 of this Agreement (as such number may be adjusted from time to time pursuant to the provisions of the Plan) by the applicable percentage determined in accordance with the following revenue goal&#47;payout slope for the Tranche One Performance Goal (with appropriate straight-line interpolation for any attained level within two otherwise designated levels in such slope)&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2023 FISCAL YEAR REVENUE GOAL&#47;REVENUE PAYOUT SLOPE</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><img alt="a1026grapha.jpg" src="a1026grapha.jpg" style="height:389px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.948%"><tr><td style="width:1.0%"></td><td style="width:36.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Net Product Revenue Achievement (in millions)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">% of Target</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Performance Shares Earned Under Tranche</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$23,808</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">90.0%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">20%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$26,453</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">100.0%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">100%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$27,114</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">102.5%</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">150%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$27,776</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">105.0%</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">200%</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD FOR TRANCHE TWO</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Goal for the Performance Shares allocated to Tranche Two will be the one-year period coincident with the Company&#8217;s 2024 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Two Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SERVICE PERIOD FOR TRANCHE TWO</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Service Period for the Continuous Service vesting condition for Tranche Two will be the period beginning January 1, 2024 and ending on the Certification Date.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING FOR TRANCHE TWO</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal for Tranche Two&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares allocated to Tranche Two will be tied to the Company&#8217;s recognition of net product revenue for the Tranche Two Performance Period in the dollar amounts (at threshold, target and maximum levels, with appropriate straight-line interpolation between any two such designated levels) to be set by the Administrator no later than 90 days after the start of that performance period.  The Performance Goal for the Tranche Two Performance Period will be the same as the Performance Goal for the Tranche One Performance Period for any Performance Share Award granted to you in 2024, unless you are notified otherwise in writing promptly following the Administrator&#8217;s establishment of the applicable Performance Goal for the Tranche Two Performance Period.  </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within 65 days after the completion of the Tranche Two Performance Period, the Administrator will determine and certify the actual dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Two Performance Period.  The actual number of Performance-Qualified Shares that results from such certification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Two Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may range from 0% to 200% of the Target Shares allocated to Tranche Two in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of the Plan. The actual percentage will be determined on the basis of the dollar amount of net product revenue that the Administrator certifies has in fact been recognized for the Tranche Two Performance Period, as measured and reported on a consolidated basis with the Company&#8217;s subsidiaries in accordance with the Company&#8217;s audited consolidated financial statements for the Company&#8217;s fiscal year coincident with the Tranche Two Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the maximum number of the Shares that may qualify as Tranche Two Performance-Qualified Shares may not exceed 200% of the Target Shares allocated to Tranche Two in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of the Plan.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Level of Tranche Two Performance Goal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares that may qualify as Tranche Two Performance-Qualified Shares on the basis of the certified dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Two Performance Period will be calculated by multiplying the number of Target Shares allocated to Tranche Two in accordance with Paragraph 1 of this Agreement (as such number may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">adjusted from time to time pursuant to the provisions of the Plan) by the applicable percentage determined in accordance with the payout slope (with appropriate straight-line interpolation for any attained level within two otherwise designated levels in such slope) approved by the Administrator at the same time it establishes the applicable Performance Goal for the Tranche Two Performance Period.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE PERIOD FOR TRANCHE THREE </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The measurement period for the Performance Goal for the Performance Shares allocated to Tranche Three will be the one-year period coincident with the Company&#8217;s 2025 fiscal year (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Three Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SERVICE PERIOD FOR TRANCHE THREE </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The applicable Service Period for the Continuous Service vesting condition for Tranche Three will be the period beginning January 1, 2025 and ending on the Certification Date.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PERFORMANCE GOAL FOR PERFORMANCE VESTING FOR TRANCHE THREE</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal for Tranche Three&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The performance-vesting requirement for the Performance Shares allocated to Tranche Three will be tied to the Company&#8217;s recognition of net product revenue for the Tranche Three Performance Period in the dollar amounts (at threshold, target and maximum levels, with appropriate straight-line interpolation between any two such designated levels) to be set by the Administrator no later than 90 days after the start of that performance period. The Performance Goal for the Tranche Three Performance Period will be the same as the Performance Goal for the Tranche One Performance Period for any Performance Share Award granted to you in 2025, unless you are notified otherwise in writing promptly following the Administrator&#8217;s establishment of the applicable Performance Goal for the Tranche Three Performance Period.</font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance-Qualified Shares&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within 65  days after the completion of the Tranche Three Performance Period, the Administrator will determine and certify the actual dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Three Performance Period. The actual number of Performance-Qualified Shares that results from such certification (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tranche Three Performance-Qualified Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may range from 0% to 200% of the Target Shares allocated to Tranche Three in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of the Plan.  The actual percentage will be determined on the basis of the dollar amount of net product revenue that the Administrator certifies has in fact been recognized for the Tranche Three Performance Period, as measured on a consolidated basis with the Company&#8217;s subsidiaries in accordance with the Company&#8217;s audited consolidated financial statements for the Company&#8217;s fiscal year coincident with the Tranche Three Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the maximum number of the Shares that may qualify as Tranche Three Performance-Qualified Shares may not exceed 200% of the Target Shares allocated to Tranche Three in accordance with Paragraph 1 of this Agreement, as such number may be adjusted from time to time pursuant to the provisions of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Slope for Determining Number of Performance-Qualified Shares Based on Attained Level of Tranche Three Performance Goal&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares that may qualify as Tranche Three Performance-Qualified Shares on the basis of the certified dollar amount of net product revenue recognized by the Company on a consolidated basis for the Tranche Three Performance Period will be calculated by multiplying the number of Target Shares allocated to Tranche Three in accordance with Paragraph 1 of this Agreement (as such number may be adjusted from time to time pursuant to the provisions of the Plan) by the applicable percentage determined in accordance with the payout slope (with appropriate straight-line interpolation for any attained level within two otherwise designated levels in such slope) approved by the Administrator at the same time it establishes the applicable Performance Goal for the Tranche Three Performance Period. </font></div><div style="margin-top:9pt;text-align:justify;text-indent:-0.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">CONTINUOUS SERVICE VESTING REQUIREMENT FOR PERFORMANCE-QUALIFIED SHARES </font></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The number of Shares in which Participant may actually vest on the basis of the number of Performance-Qualified Shares certified by the Administrator for each separate Tranche of Performance Shares in accordance with the foregoing provisions will be tied to his or her completion of the following Continuous Service vesting requirement applicable to each such Tranche&#58;</font></div><div style="margin-top:9pt;padding-left:108pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">If Participant remains in Continuous Service through the Certification Date, Participant will vest in 100% of the Performance-Qualified Shares certified by the Administrator for that Tranche.</font></div><div style="margin-top:9pt;padding-left:108pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant&#8217;s Continuous Service terminates prior to the Certification Date by reason of death or Disability, then&#58; (a) if such cessation  of Continuous Service occurs at any time on or after the completion of the Performance Period applicable to a particular Tranche of Performance Shares, Participant will immediately vest in the number of Shares equal to the actual number of Performance-Qualified Shares (if any) that was earned for the Performance Period applicable to that Tranche, and (b) if such cessation of Continuous Service occur prior to the completion of the Performance Period applicable to a particular Tranche of Performance Shares, Participant will immediately vest in the Target Shares allocated to that particular Tranche.  The Shares that vest pursuant to this paragraph will be issued or distributed on or as soon as administratively practicable after the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the later of (i) the close of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15th  day of the third calendar month following such Cessation of Continuous Service.</font></div><div style="margin-top:9pt;padding-left:108pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">If Participant&#8217;s Continuous Service terminates prior to the Certification Date but at least 12 months following the Grant Date by reason of Retirement, then Participant will, following the Certification Date, vest in 100%  of the Performance-Qualified Shares certified by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:9pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Administrator for that Tranche as if Participant had remained in Continuous Service through the Certification Date. </font></div><div style="margin-top:9pt;padding-left:108pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">In the event Participant&#8217;s Continuous Service ceases for any other reason (including, without limitation, any deemed cessation of Continuous Service under Paragraph 7 of this Agreement) prior to the Certification Date, then Participant will not vest in any of the Performance-Qualified Shares covered by any Tranche, and all of Participant&#8217;s right, title and interest to the Shares underlying each Tranche will immediately terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that should a Change in Control occur prior to the Certification Date, then the provisions of Paragraph 4 of the Agreement will govern the vesting of the Performance Shares (if any) allocated to each Tranche. </font></div><div style="margin-top:9pt;padding-left:108pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt">Notwithstanding anything to the contrary in the foregoing provisions of this Continuous Service section, should Participant&#8217;s Continuous Service cease for any reason (other than Participant&#8217;s death or Disability) prior to the start of the Service Period specified above for any particular Tranche of Performance Shares, then Participant will not vest in any of the Performance Shares allocated to that Tranche, and all of Participant&#8217;s right, title and interest to the Shares underlying that Tranche will immediately terminate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>5
<FILENAME>gildq12023ex10332023employ.htm
<DESCRIPTION>2023 RSU AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia381818f728041d5a8efd4e8172df3ae_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.33</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2022 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Restricted Stock Unit Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Capitalized terms not otherwise defined in this Agreement have the meanings set forth in the Plan.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby awards Restricted Stock Units to the Participant named below upon the following terms and conditions&#58;</font></div><div style="margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Grant Date indicated below, Restricted Stock Units under the Plan (the &#8220;Award&#8221;), subject to the terms and conditions set forth in this Agreement. Each Restricted Stock Unit that vests hereunder will entitle Participant to receive one share of Common Stock on the specified issuance date for that unit.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUMMARY</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares Subject to Award&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">shares of Common Stock (the &#8220;Shares&#8221;)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Shares will vest in as follows&#58; (i) 25% of the Shares on the first anniversary of the Grant Date and (ii) 6.25% of the Shares quarterly thereafter through the fourth anniversary of the Grant Date, in each case, subject to the Participant&#8217;s Continuous Service through each vesting date.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Schedule</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares that have become vested will be issued no later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which the Shares vest pursuant to the Vesting Schedule or (ii) the 15th day of the third calendar month following the applicable vesting date, in each case subject to the Company&#8217;s collection of applicable Withholding Taxes pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to actual receipt of the Shares which vest hereunder, Participant may not transfer any interest in the Award or the underlying Shares or pledge or otherwise hedge the sale of those Shares, including through any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares. However, any Shares which vest hereunder, but which otherwise remain unissued at the time of Participant&#8217;s death will be transferred to Participant&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Participant&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in this Paragraph 3 or in Paragraph 5, should Participant cease Continuous Service for any reason prior to vesting in one or more Shares pursuant to the Vesting Schedule, then the Award will be immediately cancelled and forfeited with respect to those unvested Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant ceases Continuous Service (i) at least 12 months following the Grant Date and (ii) (A) after attaining age 55 and completing at least 10 years of Continuous Service or (B) after attaining age 65, then Participant will continue to vest in unvested Shares granted hereunder in accordance with the Vesting Schedule as if such Participant had remained in Continuous Service. Any Shares which vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment or legal development in Participant&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Award pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> being deemed unlawful or discriminatory, then the Company will not apply this favorable treatment at the time of Participant&#8217;s cessation of Continuous Service, and the Award will be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Furthermore, if Participant is located in Hong Kong, the Netherlands, or Taiwan, Participant will not be eligible for the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Award will be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant ceases Continuous Service as a result of Participant&#8217;s death or Disability, then Participant will immediately vest in all unvested Shares at the time subject to the Award. The Shares that vest pursuant to this Paragraph 3(c) will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the later of (i) the close of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15th day of the third calendar month following the date of such cessation of Continuous Service.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">For Cause Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provision hereof, should Participant&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Participant is employed or under the terms of Participant&#8217;s employment agreement, if any), or should Participant engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company (or any Related Entity), as determined in the sole discretion of the Administrator, then the Award will be immediately cancelled and forfeited with respect to all Shares, whether or not vested at the time. Participant will thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will not have any stockholder rights, including voting, dividend (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that the Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to the Award on such record date have not been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account will be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to the Award had they been issued and outstanding and entitled to that dividend or distribution. As such Shares subsequently vest hereunder, the dividend equivalents so credited to those Shares in the book account will vest, and those vested dividend equivalents will be distributed to Participant (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those dividend equivalents relate, and correspondingly, as such Shares are forfeited or cancelled under the Award (including in accordance with Paragraph 3), the dividend equivalents so credited to those Shares in the book account will be forfeited or cancelled. Settlement of dividend equivalents will be subject to the Company&#8217;s collection of applicable Withholding Taxes. The Administrator will have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination will be controlling. No dividend equivalent amount will be paid or distributed on shares of Common Stock under the Award that are forfeited, cancelled or that otherwise are not issued or issuable under the Award.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:90pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the time of a Change in Control, the Award may be (i) assumed or otherwise continued in full force and effect by the surviving corporation, (ii) replaced with an economically-equivalent substitute award or (iii) replaced with a cash retention program of the successor corporation that is in a dollar amount equal to the Fair Market Value of the Shares underlying outstanding Restricted Stock Units under the Award (as measured immediately prior to the Change in Control) and provides for the subsequent vesting and payout of that dollar amount in accordance with the same vesting and issuance provisions that would otherwise be in effect for those Shares in the absence of the Change in Control. In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award will be adjusted immediately after the consummation of the Change in Control in accordance with Section 9 of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event of an assumption, continuation or replacement of the Award under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no accelerated vesting of the Restricted Stock Units will occur at the time of the Change in Control, and the Award will instead be subject to accelerated vesting as follows</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) If Participant&#8217;s Continuous Service is terminated without Cause, or if Participant resigns from Continuous Service due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control and ending with the earlier of (A) the termination of that definitive agreement without the consummation of such Change in Control or (B) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, then Participant will immediately vest in all unvested Shares (or any replacement securities or cash proceeds) at the time subject to the Award.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) The Shares (or any replacement securities or cash proceeds) that vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (I) the close of the calendar year in which such cessation of Continuous Service occurs or (I) the 15th day of the third calendar month following the date of such cessation of Continuous Service.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Award is not assumed, continued or replaced in under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the Award will fully vest immediately prior to the consummation of the Change in Control. The Shares subject to the vested Award will be converted into the right to receive for each such Share the same consideration per Share payable to the other stockholders of the Company upon consummation of that Change in Control, and such consideration per Share will be distributed to Participant by no later than the 10th business day following the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to occur of (i) the date the Share would have otherwise vested and been issued pursuant to the Vesting and Issuance Schedules set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the absence of such Change in Control, (ii) the date of Participant&#8217;s cessation of Continuous Service, or (iii) the first date following the Change in Control on which the distribution can be made without contravention of any applicable provisions of Section 409A of the Code.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Agreement will not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Settlement of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">On each date on which one or more Shares are to be issued in accordance with this Agreement, the Company will issue to or on behalf of Participant a certificate (which may be in electronic form) for those Shares and will concurrently distribute to Participant any dividend equivalents with respect to those Shares (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances), subject in each instance to the Company&#8217;s collection of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the settlement of all Restricted Stock Units which vest under the Award will be made solely in Shares. In no event, however, will any fractional Shares be issued. Accordingly, the total number of Shares to be issued at the time the Award vests (including any Shares issued in settlement of dividend equivalents) will, to the extent necessary, be rounded down to the next whole Share in order to avoid the issuance of a fractional Share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The issuance of Shares pursuant to the Award will be subject to compliance by the Company and Participant with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Award will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant acknowledges that, regardless of any action the Company or the applicable Related Entity employing or retaining the Participant (the &#8220;Employer&#8221;) may take with respect to any or all Withholding Taxes related to the Award or Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all such Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares (or other property) upon settlement of the Award, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends or dividend equivalents&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant has become subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and the Employer (or a former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this Agreement (including Shares issued in settlement of dividend equivalents) through an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless the Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides, in its sole discretion, to no longer utilize the Share Withholding Method and provides Participant with a corresponding notice. If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of Shares subject to the vested Award, notwithstanding that a number of the Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Share Withholding Method is not used , then the Withholding Taxes will be collected from Participant through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan. Participant will, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such broker-dealer sale and remittance transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes. However, no broker-dealer sale and remittance transaction will be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt"> If the Company determines that such broker-dealer sale and remittance procedure is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such procedure can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of Participant&#8217;s separate check payable to the Company (or a wire transfer of funds to the Company) in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant. In no event will any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company will collect the Withholding Taxes with respect to dividend equivalents distributed in a form other than Shares by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Participant&#8217;s jurisdiction, in which case Participant may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Participant may seek a refund from local tax authorities. In the event of under-withholding, Participant may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, to the extent Participant is subject to taxation in the United States, the Withholding Taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder will in all events be collected from Participant no later than the last business day of the calendar year in which those Shares or other amounts vest (as determined under applicable tax laws). Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those Shares or other amounts vest, Participant will, if so requested by the Company, on or before the last business day of the calendar year in which such Shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to Withholding Taxes required to be withheld with respect to those Shares or other amounts. Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Withholding Taxes required to be withheld with respect to those Shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion. The provisions of this Paragraph 7(g) are applicable only to the extent necessary to comply with the applicable tax withholding requirements of Section 3121(v) of the Code.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of applying the various vesting provisions of this Agreement, the Administrator, in its sole discretion, may determine that Participant will be deemed to cease Continuous Service on the commencement date of any leave of absence and not remain in Continuous Service during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">Participant will receive Continuous Service credit for such vesting purposes for (i) the first three months of an approved personal leave of absence and (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.52pt">In no event, however, will Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the earlier of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service on or before that date or (ii) the date Participant&#8217;s Continuous Service actually </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">terminates by reason of Participant&#8217;s voluntary or involuntary termination or by reason of Participant&#8217;s death or Disability.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or Participant&#8217;s broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before Participant possessed inside information. Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions and Participant should speak with Participant&#8217;s personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Deferred Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, to the extent Participant is subject to taxation in the United States and the Award may be deemed to create a deferred compensation arrangement under Section 409A of the Code, then the following limitations will apply&#58;</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">No Shares or other amounts which become issuable or distributable under this Agreement upon Participant&#8217;s Separation from Service will actually be issued or distributed to Participant prior to the earlier of (i) the first day of the seventh month following the date of such Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Section 409A of the Code, as determined by the Administrator, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Section 409A(a)(2) of the Code. The deferred Shares or other distributable amount will be issued or distributed in a lump sum on the first day of the seventh month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death. As used herein, &#8220;Separation from Service&#8221; means the Participant&#8217;s cessation of Continuous Service that is considered a separation from service under Treasury Regulations Section 1.409A-1(h).</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.52pt">To the extent there is any ambiguity as to whether any provision of this Agreement would otherwise contravene one or more requirements or limitations of Section 409A of the Code, such provisions shall be interpreted and applied in a manner that does not result in a violation of the applicable requirements or limitations of Code Section 409A of the Code and the Treasury Regulations thereunder.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">Each installment of Shares issuable pursuant to this Agreement shall be treated as a separate payment for purposes of Section 409A of the Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Participant will be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or will be delivered electronically to Participant through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect the sale of the Shares issued hereunder. All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, Participant&#8217;s assigns, and the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction&#59; Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Award. Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation. The word &#8220;or&#8221; is not exclusive. Words in the masculine gender include the feminine gender, and where appropriate, the plural includes the singular and the singular includes the plural. All references to &#8220;including&#8221; shall be construed as meaning &#8220;including without limitation.&#8221;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by the Award and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of the Restricted Stock Units is made or to be performed.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and Participant&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Participant&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with any certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from termination of Participant&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the Award, Participant irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives Participant&#8217;s ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan or Participant&#8217;s acquisition or sale of the underlying Shares. Participant should consult with Participant&#8217;s personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Restricted Stock Units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or other Participants.</font></div><div style="margin-top:12pt;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that Participant agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that Participant needs to review the following information about the processing of Participant's personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Participant's </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">consent. As regards the processing of Participant's Personal Data in connection with the Plan and this Agreement, Participant understands that the Company is the controller of Participant's Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan. Participant understands that this Personal Data may include Participant's name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant's favor. The legal basis for the processing of Participant's Personal Data, where required, will be Participant's consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that the Company transfers Participant's Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Participant's Personal Data with such different service provider that serves the Company in a similar manner. Participant understands and acknowledges that the Company&#8217;s service provider will open an account for Participant to receive and trade Shares acquired under the Plan and that Participant will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant's ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Participant understands and acknowledges that Participant's country may have enacted data privacy laws that are different from the laws of the United States. The Company&#8217;s legal basis for the transfer of Participant's Personal Data is Participant's consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that the Company will use Participant's Personal Data only as long as is necessary to implement, administer and manage Participant's participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Participant understands and acknowledges that the Company&#8217;s legal basis for the processing of Participant's Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Participant's Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that Participant's participation in the Plan and Participant's </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">consent is purely voluntary. Participant may deny or later withdraw Participant's consent at any time, with future effect and for any or no reason. If Participant denies or later withdraws Participant's consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan. Participant further understands that denial or withdrawal of Participant's consent would not affect Participant's status or salary as an employee or Participant's career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Participant understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Participant is based and subject to the conditions set out in the Applicable Laws, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Participant and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Participant's objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of Participant's Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant's Personal Data that Participant has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Participant's employment and is carried out by automated means. In case of concerns, Participant understands that Participant may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Participant's rights, Participant understands that Participant should contact Participant's local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Participant acknowledges that Participant is sufficiently proficient in English, or has consulted with an advisor who is sufficiently proficient in English so as to allow Participant, to understand the terms and conditions of this Agreement. Further, if Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version differs in substance from the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event will any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Depending upon the country to which laws Participant is subject, Participant may have certain foreign asset or account reporting requirements that may affect Participant&#8217;s ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends or dividend equivalents received or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside Participant&#8217;s country. Participant&#8217;s country may require that Participant report such accounts, assets or transactions to the applicable authorities in Participant&#8217;s country. Participant is responsible for knowledge of and compliance with any such regulations and should speak with Participant&#8217;s own personal tax, legal and financial advisors regarding same</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, the Award shall be subject to any special terms and conditions set forth in any addendum to this Agreement setting forth special terms and conditions for Participant&#8217;s country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Moreover, if Participant relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the Award, Participant agrees that the Award is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Participant&#8217;s country. Participant has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>6
<FILENAME>gildq12023ex1049offerlette.htm
<DESCRIPTION>OFFER LETTER (TELMAN)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i94313c1e1b78459fa0e4fa8f146e1ebf_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 10.49</font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:27px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REVISED June  2, 2022</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deborah Telman</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Deborah,</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (the &#8220;Company&#8221; or &#8220;Gilead&#8221;) is pleased to offer you the position of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVP, Corporate Affairs &#38; General Counsel </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">at a grade 37. In this role you will report to Gilead&#8217;s Chief Executive Officer (CEO) and Chairman, Daniel O&#8217;Day, and will have responsibility for Gilead&#8217;s Corporate Affairs &#38; General Counsel Functions. You will join Gilead&#8217;s Leadership Team and will be based in our Foster City, California headquarters. We would expect you to start on August 1, 2022 or such earlier date as may be agreed to by the CEO (such date, the &#8220;Start Date&#8221;).</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are very excited about the possibility of you joining our team, and we look forward to the prospect of working with you in our innovative company. The following outlines the specific terms of our offer&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Annual Compensation. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Your base salary on an annualized basis will be </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">$900,000</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, less taxes and withholdings, payable bi-weekly.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">eligible</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">participate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">annual</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">corporate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">program. Your target</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">bonus is </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">100% </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of annual salary. Your actual bonus payout, which for 2022 will be pro-rated based on the number of days between the Start Date and December 31, 2022, can range from 0% to 200% of this target based on your performance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">against your annual goals and objectives as established by the Compensation &#38; Talent Committee of Gilead&#8217;s Board of Directors (the &#8220;Board&#8221;).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the make whole and new hire equity awards described below, you will be eligible to participate in Gilead&#8217;s annual equity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">award program with the first grant to be awarded in March 2023. The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">current aggregate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">target</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">value</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for your</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">annual equity awards is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$3,250,000</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">target grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">values, and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">equity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">vehicles</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">are</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reviewed</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">an</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">annual</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">basis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">change</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">determined by the Compensation &#38; Talent Committee.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Make Whole Equity Grant. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will be awarded RSUs with a grant date value of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$1,500,000</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which amount</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reflects</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">value</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">equity</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">awards</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">granted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">current</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employer that</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forfeited</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(your &#34;Make-Whole</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RSUs&#34;). Your Make-Whole RSUs will vest annually over three years, commencing on the first anniversary of the grant date, subject to your continued service.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Hire Equity Awards. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">awarded</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">new</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hire</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">value</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$1,000,000 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and will be comprised of $500,000 in stock options and $500,000 RSUs (collectively, your &#8220;New</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hire</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Equity Awards&#8221;). The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">actual</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">number</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">each</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">these grants</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">based</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on the assumptions used by Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">at the time of grant to value equity awards for purposes of Gilead&#8217;s financial reporting.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.53pt">The exercise price for your stock options will be equal to the fair market value per share of Gilead common stock on the grant date. The fair market value per share for that date will be determined in accordance with the provisions of the equity plan governing your grant. Your options are scheduled to vest and become exercisable for 25% of the option shares upon your </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">completion</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">one</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">year of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead, measured</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">grant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date, and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:27px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">vest and become exercisable for the balance of the option shares in a series of successive equal quarterly installments upon your completion of each successive three-month period of continued</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">over the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">next</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">three</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">years. The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">options will have</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a maximum term of ten years, subject to earlier termination following your cessation of employment. You will be notified of the details after your options have been granted and your options will be subject to the additional terms and conditions set forth in the option agreement.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.53pt">Your RSUs are scheduled to vest 25% upon your completion of one year of employment with Gilead, measured from the grant date, and will vest in a series of successive equal quarterly installments upon your completion date of each successive three-month period of continued employment with Gilead over the next three years. Each RSU that vests will entitle you to one share of Gilead common stock. You will be notified of the details after your RSUs have been granted and your grant will be subject to the additional terms and conditions set forth in the RSU agreement.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sign-on Cash Bonus. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To offset the value of your annual bonus and certain unvested equity awards forfeited from your current employer and other economic</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">implications of your joining Gilead, you also will be eligible to receive a one-time bonus of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$1,200,000 </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">less applicable taxes and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">withholdings (the &#8220;Sign</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On Bonus&#8221;). Your Sign</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On Bonus will be advanced to you and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reflected on your first payroll check subsequent to your Start Date. The gross</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">amount of the Sign</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On Bonus, however, is not earned unless and until you have completed two years of service</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company, except, if prior to completing two years of service, your employment is terminated by the Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">result of a reduction in force or a merger or acquisition of the Company.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event that your employment is terminated by you without Good Reason (as defined below) or if your employment is terminated by the Company for Cause (as defined in the Company&#8217;s 2022 Equity Incentive Plan), and such termination occurs prior to your completion of two years of service, then a portion of the Sign On</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bonus advanced to you will not be earned, and a pro-rata amount of the Sign</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On Bonus must be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">repaid by you to the Company. Your repayment obligation amount, if applicable, will be equal to the Sign</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On Bonus advanced, prorated so that for each full month of service, the amount to be repaid shall be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reduced by 1&#47;24. Your repayment obligation, if</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">applicable,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">due</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">full</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ninety</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(90)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">days</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">immediately</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">following your employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">event</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a result</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your death or disability, you will not be required to repay any previously paid amounts.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event that during your first two years with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead, your employment is terminated by Gilead without</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cause (as defined in the Company&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 Equity Incentive Plan) or you terminate your employment for Good Reason (as defined below), you will become 100% vested in any of your remaining unvested New Hire Equity Awards, Make-Whole</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RSUs and the full Sign- on</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bonus, subject</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your execution</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">non-revocation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a waiver</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">general</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">claims</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">within the time period specified by and in the form then provided by Gilead. In</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such circumstances, any stock options granted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as part</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your New Hire</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Equity Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will remain</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">exercisable</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">until the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">first</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">anniversary of your termination date. Any unpaid portion of the Sign-On Bonus will be paid to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you within 60 days following such termination date.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The New</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hire Equity Awards and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Make-Whole RSUs will be subject, in all respects, to the terms and conditions of an award agreement that will be provided to you under separate cover.</font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:27px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">used</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">letter,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Good</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reason&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">occurrence</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">following events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> conditions&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) an adverse change in your employment status, title, position or primary responsibilities as EVP, Corporate Affairs and General Counsel (including reporting responsibilities)&#59; (ii) a reduction in your annual base compensation or any failure to pay you any compensation or benefits to which you are entitled</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30 days</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">due&#59;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or (iii)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">requires</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">relocate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any place</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">outside</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a 50 mile radius of the greater Foster City, California area, except for reasonably required travel on the business of Gilead or any subsidiary.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Relocation Assistance. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">role</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">requires</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">based</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">our</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Foster</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">City</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">headquarters,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead will provide you with certain relocation benefits to support your move to the San Francisco Bay Area. Subject to the following paragraph, Gilead will enroll you in our home marketing, Buyer Value Option (BVO) Program, administered by our relocation vendor, Weichert</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mobility. All</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">non-recurring transaction costs in connection with the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sale</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your current home</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and (if</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you so elect)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a new home</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will be covered by Gilead, through Weichert. This includes the real estate commission, typical seller closing costs, and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">typical purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">closing costs associated</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a new home. A complete</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">policy will be provided to you by Weichert, subject to the terms hereof.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead will provide you with up to twenty-four (24) months of temporary accommodations in a fully furnished corporate apartment. Gilead and its relocation vendors will assist you with the selection and billing for these accommodations. Following such period of temporary accommodations, you may elect to receive from Gilead either the mortgage subsidy or the rental subsidy described in the following two </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">paragraphs.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provide</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you assistance with either the purchase of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a home, as described in this paragraph, or a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rental</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">described</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">following</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">paragraph,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">election.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">elect</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">home, Gilead will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(as noted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">above) reimburse you for 100%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the transaction costs associated with your home purchase. All</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">non-recurring transaction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">costs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">connection</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">new</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">home</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">covered by Gilead, through the Ml Group. This includes the typical purchase closing costs associated with the purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">new</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">home.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">complete</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">policy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weichert.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">new</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">home</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purchase must</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">within</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">months of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">start</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date. In</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">addition,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provide</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mortgage</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy. The subsidy is an amount of money to be used only to help you purchase a home in the new location by reducing the mortgage's interest rate for a period of time so that you can transition into a higher cost area.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">cannot</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">use</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mortgage</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purpose</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">other</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">than</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reduce</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(temporarily)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">interest rate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">loan.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">order</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">most</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">advantageous</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">we</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">allow</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">configure</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">manner</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">choose,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">it</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">follows</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">legal</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">guidelines</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">tax-favored</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">treatment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The mortgage</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy is provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">exclusively through</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weichert</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for up</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ten</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">years. The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">annual distribution</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is set on a total subsidy amount capped at $450,000.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alternatively, if</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">elect</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rent</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">home,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provide</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rental</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy. The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rental</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subsidy you are eligible for is $200,000. The rental subsidy is considered taxable income and will be paid net of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">taxes.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weichert will arrange to have your household goods moved to your new location utilizing the company contracted carrier. Payment of these moving expenses will also include a payment to cover state and federal taxes incurred on this portion of your relocation expenses.</font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:27px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">miscellaneous</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">relocation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">allowance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$20,000,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">assoon</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">administratively</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">possible. This is intended to cover miscellaneous expenses such as utilities installation, auto license and registration, and any other expenses not provided elsewhere under Gilead's relocation policy.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If your employment should terminate within two (2) years of your Start Date, the full cash amount of this relocation package including, but not limited to, any moving allowance, temporary housing costs, transaction costs, lump</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sums</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and associated tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">gross-ups accepted by you is due</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and payable to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead within 90 days after your last date of employment, except that you will have no such repayment obligation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">if</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">terminated</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">without</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(as</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">defined</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 Equity Incentive Plan) or by you for Good Reason (as defined above).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Benefits. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provides a comprehensive company-paid benefits package including health, dental, vision, life insurance, and long-term disability insurance plans. You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">are eligible for health and welfare benefits if you are a full-time employee working 20 hours or more (unless otherwise specified). You will need to enroll for medical or dental&#47;vision within 31 days of your hire date, or you will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">eligible</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">enroll</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">until</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">next</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">open</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">enrollment, unless</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">have</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a qualifying life</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">event. Upon completion of enrollment, your coverage begins effective your date of hire.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the next enrollment date, you will be eligible to participate in our Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that offers you the opportunity to contribute up to 15% of your earnings, up to the IRS maximum, through</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">payroll</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">deductions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">stock</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">lower of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">closing price at the date of enrollment or purchase. ESPP enrollment occurs two times a year.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, we</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">offer a 401(k)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">plan, which provides you with the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">opportunity for Pre-tax,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Roth After-tax and Additional After-tax savings by deferring from 1-50% of your annual salary, subject to IRS maximums.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">match</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your Pre-tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and&#47;or Roth</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">After-tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contributions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">up</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to a maximum company contribution of $15,000 per year. More detailed information regarding your benefits will be provided at your New Employee Orientation, shortly after you begin employment.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As an employee, you are covered under Gilead&#8217;s Workers Compensation insurance policy. This policy applies</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employees</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">who</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">become</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ill</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or injured</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">on</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">job. Gilead&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Workers</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">carrier is XL Insurance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">America, Inc. Claims are handled by Sedgwick, a Third-Party Administrator, at 1-855-336-0983.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">entitled</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">severance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">accordance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">conditions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. Severance Plan.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For your information, we have enclosed a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Benefits Summary outlining Gilead's benefits programs.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We will arrange for you to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">meet with a member of our benefits staff to review your benefits package and enroll in the various programs. Please note that, as an executive, you will not accrue paid time-off but will instead have the flexibility of taking time off at your discretion in accordance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with the business needs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">corporation. Please</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">note</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">described</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">letter are</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subject</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">terms and conditions of all applicable Company plans and policies. In</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the event there is any discrepancy between</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">benefit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">description</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contained</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this letter and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">terms of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">applicable</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company plan or policy, the terms of the applicable plan and policy govern.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><img alt="image_1.jpg" src="image_1.jpg" style="height:27px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Terms. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">including</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">equity-based</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">compensation, will be subject to Gilead&#8217;s collection of applicable withholding taxes, and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead will not gross-up or make you whole for any such taxes.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You understand that the Company is hiring you because of your skills and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">abilities, and not because of your knowledge of any confidential, proprietary, or trade secret information of any prior employer or other third</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">party.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">signing below, you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">acknowledge</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">has</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">strictly</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prohibited</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from using or disclosing any confidential, proprietary, or trade secret information of any prior employer or third party. Upon starting employment with the Company, you will be required to sign the Company&#8217;s Confidential Information and Inventions Agreement (&#8220;CIIA&#8221;) for Employees indicating your agreement with</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this policy. At</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your employment, you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reminded</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your continuing duties under the CIIA. Please read this policy and the CIIA carefully.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">also</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">required</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">fill</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">out</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">electronic</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Eligibility</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Verification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Form I-9). This electronic form will be sent to you via email. On your first day of employment, please bring the necessary documents that establish your identity and employment eligibility.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You agree by signing below that the Company has</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">made no other promises other than what is outlined in this letter. It contains the entire offer the Company is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">making to you. Our agreement can only be modified by written agreement signed by you and the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s Representative. You also agree that should you accept a position at the Company, the employment relationship is based on the mutual consent of the employee and the Company. Accordingly, your employment with the Company is for no specific</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">time&#59;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">either you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">can</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">terminate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">relationship</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">at</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will, at any time, with or without cause or advance notice. You should also note that the Company may</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">modify wages and benefits from time to time at its discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">offer of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">employment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">effective</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for 7 days</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">letter. The</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">offer is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">also</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contingent upon</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">successful</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">background</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reference</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">checks. If</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">all</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">foregoing is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">satisfactory, please</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sign</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and date within 7 days.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">am</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">very</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">confident</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">you</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">are</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">right</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">leader for</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gilead&#8217;s</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affairs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#38;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Counsel</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">organization and look forward to working with you on the organization&#8217;s long-term success.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Daniel O&#8217;Day</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Daniel O'Day<br>CEO and Chairman</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foregoing terms and conditions hereby accepted&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Signature&#58;   &#47;s&#47; Deborah Telman                                </font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Name&#58;               Deborah Telman                                </font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Date&#58;                 June 8, 2022                                      </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                               </font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>7
<FILENAME>gildq12023ex1050stockoptio.htm
<DESCRIPTION>STOCK OPTION AGREEMENT (TELMAN)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if7c6bbd7086c49538eef3e21193d74e7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.50</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2022 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL STOCK OPTION AGREEMENT </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">This Global Stock Option Agreement (this &#8220;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">greemen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s grant of an option to the Participant set forth below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Optionee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">Capitalized terms not otherwise defined in this Agreement have the meanings set forth in the Plan.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereby grants an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the Optionee named below upon the following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and conditions&#58;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereby grants to Optionee a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-statutory Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to purchase shares of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> under the Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and conditions set forth in this Agreement. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPTION GRANT SPECIFICS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Name of Optionee&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">July 25, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Total Number of Option Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48,620 shares of Common Stock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exercise Price</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$60.75 per share</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Option will vest and become exercisable as follows&#58; (i) 25% of the Option Shares on the first anniversary of the Grant Date and (ii) 6.25% of the Option Shares quarterly thereafter through the fourth anniversary of the Grant Date, in each case, subject to the Optionee&#8217;s Continuous Service through each vesting date. </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Expiration Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">July 25, 2032</font></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Option Term&#59; Exercisability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The term of the Option begins on the Grant Date and continues through the close of business on the last business day prior to the Expiration Date, unless sooner terminated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below (as applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The portion of the Option that has vested in accordance with the Vesting Schedule above will remain exercisable through the end of the Term. Upon the expiration of the Term, the Option will terminate and cease to be outstanding.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Option is not transferable or assignable by Optionee other than to Optionee&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Optionee&#8217;s estate following Optionee&#8217;s death and may be exercised, during Optionee&#8217;s lifetime, only by Optionee.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Term will terminate (and the Option will cease to be outstanding) prior to the Expiration Date in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service as a result of Optionee&#8217;s death, then (i) the Option will immediately be fully vested and exercisable and (ii) the Option may be exercised by Optionee&#8217;s designated beneficiary (or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, the personal representative of Optionee&#8217;s estate) until the close of business on the last business day prior to the earlier of (A) the expiration of the 12-month period measured from the date of Optionee&#8217;s death or (B) the Ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">piration Date. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service as a result of Optionee&#8217;s Disability, then (i) the Option will immediately be fully vested and exercisable and (ii) the Option may be exercised by Optionee until the close of business on the last business day prior to the earlier of (A) expiration of the 12-month period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service (i) at least 12 months following the Grant Date and (ii) (x) after attaining age 55 and completing at least 10 years of Continuous Service or (y) after attaining age 65, then (I) the Option will continue to vest in accordance with the Vesting Schedule as if Optionee had remained in Continuous Service and (II) the Option may be exercised by Optionee until the close of business on the last business day prior to the earlier of&#58; (A) expiration of the five-year period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date. Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment or legal development in Optionee&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Option pursuant to this Paragraph 4(c) being deemed unlawful or discriminatory, then the Company will not apply this favorable treatment at the time of Optionee&#8217;s cessation of Continuous Service, and the Option will be treated as otherwise set forth in this Paragraph 4, as applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by the Company Without Cause or by Optionee for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee&#8217;s Continuous Service is terminated by the Company without Cause or by Optionee for Good Reason (as such term is defined in that certain offer letter by and between Optionee and the Company dated as of June 2, 2022) prior to Optionee completing two </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">years of Continuous Service then, subject to Optionee&#8217;s  execution and non-revocation of a waiver and general release of claims within the time period specified by and in the form then provided by the Company, (i) the Option will immediately be fully vested and exercisable and (ii) the Option may be exercised by Optionee until the close of business on the last business day prior to the earlier of (A) expiration of the 12-month period measured from the date of such cessation of Continuous Service, or (B) the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">For Cause Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Notwithstanding any other provision hereof, should Optionee&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Optionee is employed or under the terms of Optionee&#8217;s employment agreement, if any), or should Optionee engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then the Option will be immediately cancelled and forfeited, whether or not vested.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Other Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Optionee ceases Continuous Service for any reason other than as provided in Paragraphs 4(a) - 4(e), then the Option may be exercised by the Optionee until the close of business on the last business day prior to the expiration of the earlier of (i) the expiration of the three-month period measured from the date of such cessation of Continuous Service, or (ii) the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The period of post-service exercisability in effect pursuant to this Paragraph 4 will automatically be extended by an additional period of time equal in duration to any interval within such post-service exercise period during which the exercise of the Option or the immediate sale of the Option Shares acquired cannot be effected in compliance with applicable federal, state and foreign securities laws, but in no event will such an extension result in the continuation of the Option beyond the close of business on the last business day prior to the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During any period of post-service exercisability in effect pursuant to this Paragraph 4, the Option may be exercisable only for the portion of the Option which is vested and exercisable (after giving effect to any accelerated vesting under this Paragraph 4 or Paragraph 5), and upon a cessation of Continuous Service, any portion of the Option which is not vested and exercisable will terminate and cease to be outstanding.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the time of a Change in Control, the Option may be (i) assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect, (ii) replaced with an economically-equivalent substitute equity award or (iii) replaced with a cash retention program of the successor corporation which preserves the spread existing at the time of the Change in Control on any Option Shares for which the Option is not vested and exercisable (the excess of the Fair Market Value of those Option Shares over the aggregate Exercise Price payable for such shares) and provides for the subsequent vesting and concurrent payout of that spread in accordance with the Vesting Schedule applicable to such Option Shares. In the event </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Option is assumed or otherwise continued in effect, the Option will be adjusted immediately after the consummation of the Change in Control in accordance with Section 9 of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event of an assumption, continuation or replacement of the Option under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no accelerated vesting of the Option will occur at the time of the Change in Control. However, if Participant&#8217;s Continuous Service is terminated without Cause, or if Participant resigns from Continuous Service due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control and ending with the earlier of (A) the termination of that definitive agreement without the consummation of such Change in Control or (B) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control, then&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) the Option (or any economically equivalent award) will immediately be fully vested and exercisable&#59; or</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:90.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) the balance credited to Optionee under any replacement cash retention program will immediately be vested and paid to Optionee in a lump sum&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In the event all or any portion of the Option is not assumed, continued or replaced under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Option shall be fully vested and exercisable with adequate opportunity for Optionee to exercise the Option prior to the consummation of the Change in Control, and immediately following the consummation of the Change in Control, the Option will terminate and cease to be outstanding.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee will not have any stockholder rights including voting, dividend or liquidation rights, with respect to the Option Shares until the Option is exercised, the Exercise Price is paid and Optionee becomes a holder of record of the Option Shares.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Manner of Exercising Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In order to exercise all or any portion of the Option, Optionee must take the following actions&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i) Execute and deliver to the Company a notice of option exercise in the form authorized by the Company (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Notice of Exercise&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) as to the Option Shares for which the Option is to be exercised or comply with such other procedures as the Company may establish for notifying the Company of such exercise&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii) Pay the aggregate Exercise Price in accordance with Section 7 of the Plan&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) Furnish to the Company appropriate documentation that the person or persons exercising the Option (if other than Optionee) have the right to exercise the Option&#59; and</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv) Make appropriate arrangements with the Company or the Related Entity employing or retaining Optionee (the &#8220;Employer&#8221;) for the satisfaction of all applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">As soon as practical after the date the Option is exercised, the Company will issue to or on behalf of Optionee (or any other person or persons exercising the Option) the purchased Option Shares, subject to appropriate restrictions, if any.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In no event may the Option be exercised for any fractional Option Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The exercise of the Option and the issuance of the Option Shares upon such exercise will be subject to compliance by the Company and Optionee with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Option will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Optionee acknowledges that, regardless of any action the Company or the Employer may take with respect to any or all Withholding Taxes related to the Option, the ultimate liability for all such Withholding Taxes is and remains Optionee&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Optionee further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Option, including the grant, vesting or exercise of the Option, the subsequent sale of any shares of Common Stock acquired at exercise and the receipt of any dividends on those shares&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Option to reduce or eliminate Optionee&#8217;s liability for Withholding Taxes or achieve any particular tax result. Further, if Optionee is subject to Withholding Taxes in more than one jurisdiction, Optionee acknowledges that the Company or the Employer (or a former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Prior to the relevant taxable event, Optionee agrees to make arrangements satisfactory to the Company or the Employer to satisfy all Withholding Taxes. Optionee authorizes the Company or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Withholding Taxes by one or a combination of the following&#58;</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:60.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding of Shares otherwise deliverable upon exercise of the Option&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">withholding from any other wages or other cash compensation paid to Optionee by the Company or the Employer&#59; or</font></div><div style="margin-top:12pt;padding-left:112.5pt;text-align:justify;text-indent:54.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.5pt">payment through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Optionee&#8217;s jurisdiction, in which case Optionee may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Optionee may seek a refund from local tax authorities. In the event of under-withholding, Optionee may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer. If the obligation for Withholding Taxes is satisfied by withholding Shares, for tax purposes, Optionee is deemed to have been issued the full number of Shares subject to the exercised Option, notwithstanding that a number of Shares is held back solely for the purpose of paying the Withholding Taxes. The Company may refuse to deliver any purchased Option Shares or the proceeds of the sale of shares if Optionee fails to comply with Optionee&#8217;s obligations in connection with the Withholding Taxes.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Agreement, Optionee&#8217;s Continuous Service will not be deemed to cease during any period for which Optionee is on a military leave, sick leave or other personal leave approved by the Company. However, Optionee will not receive any Continuous Service credit, for purposes of vesting under the Vesting Schedule, for any period of such leave of absence, except to the extent otherwise required by employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any, or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.8pt">Optionee will receive Continuous Service credit for such vesting purposes for (i) the first three months of an approved personal leave of absence or (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">In no event will Optionee be deemed to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the expiration date of that leave of absence, unless Optionee returns to active Continuous Service on or before that date, or (ii) the date Optionee&#8217;s Continuous Service actually terminates by reason of Option&#8217;s voluntary or involuntary termination or by reason of Optionee&#8217;s death or Disability.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee may be subject to insider trading restrictions or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Optionee&#8217;s country or Optionee&#8217;s broker&#8217;s country, if different, which may affect Optionee&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., options) or rights linked to the value of Shares during such times as Optionee is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions). Local </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">insider trading laws and regulations may prohibit the cancellation or amendment of orders Optionee placed before Optionee possessed inside information. Furthermore, Optionee could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company. Optionee acknowledges that it is Optionee&#8217;s responsibility to comply with any applicable restrictions and Optionee should speak with Optionee&#8217;s personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee will be in writing and addressed to Optionee at the most current address then indicated for Optionee on the Company&#8217;s employee records or will be delivered electronically to Optionee through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect option exercises through the internet. All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except to the extent otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above, the provisions of this Agreement will inure to the benefit of and be binding upon the Company and its successors and assigns and Optionee, Optionee&#8217;s assigns, and the legal representatives, heirs and legatees of Optionee&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the Option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control. All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Option. Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation. The word &#8220;or&#8221; is not exclusive. Words in the masculine gender include the feminine gender, and where appropriate, the plural includes the singular and the singular includes the plural. All references to &#8220;including&#8221; shall be construed as meaning &#8220;including without limitation.&#8221;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by the Option and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of the Option is made or to be performed.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the Option, Optionee acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.8pt">all decisions with respect to future options, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">the Option and Optionee&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Optionee&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.8pt">Optionee&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.02pt">the Option and the Option Shares, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">the Option and the Option Shares, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">the future value of the Option Shares is unknown, indeterminable and cannot be predicted with any certainty&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.63pt">if the Option Shares do not increase in value, the Option will have no value&#59;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.63pt">if Optionee exercises the Option, the value of the Option Shares acquired may increase or decrease, even below the Exercise Price&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from termination of Optionee&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Optionee is employed or the terms of Optionee&#8217;s employment agreement, if any), and in consideration of the Award, Optionee irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives Optionee&#8217;s ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Optionee shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.63pt">unless otherwise agreed with the Company in writing, the Option and the Option Shares, and the income and value of same, are not granted as consideration for, or in connection with, any service Optionee may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.13pt">unless otherwise provided in the Plan or by the Company in its discretion, the Option and the benefits evidenced by this Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Option Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.18pt">neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Optionee&#8217;s local currency and the United States Dollar that may affect the value of the Option or of any amounts due to Optionee pursuant to the exercise of the Option or the subsequent sale of any Option Shares acquired upon exercise.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee&#8217;s participation in the Plan or Optionee&#8217;s acquisition or sale of the Option Shares. Optionee should consult with Optionee&#8217;s personal tax, legal and financial advisors regarding Optionee&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Optionee or other Optionees.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Optionee is declaring that Optionee agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the Related Entities and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that Optionee needs to review the following information about the processing of Optionee&#8217;s personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Optionee&#8217;s consent. As regards the processing of Optionee&#8217;s Personal Data in connection with the Plan and this Agreement, Optionee understands that the Company is the controller of Optionee&#8217;s Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> The Company collects, uses and otherwise processes Personal Data about Optionee for the purposes of allocating shares of Common Stock and implementing, administering and managing the Plan. Optionee understands that this Personal Data may include Optionee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Optionee&#8217;s favor. The legal basis for the processing of Optionee&#8217;s Personal Data, where required, will be Optionee&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company transfers Optionee&#8217;s Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Optionee&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Optionee understands and acknowledges that the Company&#8217;s service provider will open an account for Optionee to receive and trade shares of Common Stock acquired under the Plan and that Optionee will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Optionee&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Optionee understands and acknowledges that Optionee&#8217;s country may have enacted data privacy laws that are different from the laws of the United States. The Company&#8217;s legal basis for the transfer of Optionee&#8217;s Personal Data is Optionee&#8217;s consent.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.03pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that the Company will use Optionee&#8217;s Personal Data only as long as is necessary to implement, administer and manage Optionee&#8217;s participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Optionee understands and acknowledges that the Company&#8217;s legal basis for the processing of Optionee&#8217;s Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Optionee&#8217;s Personal Data for any of the above purposes, Optionee understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that Optionee&#8217;s participation in the Plan and Optionee&#8217;s consent is purely voluntary. Optionee may deny or later withdraw Optionee&#8217;s consent at any time, with future effect and for any or no reason. If Optionee denies or later withdraws Optionee&#8217;s consent, the Company can no longer offer Optionee participation in the Plan or offer other equity awards to Optionee or administer or maintain such awards and Optionee would no longer be able to participate in the Plan. Optionee further understands that denial or withdrawal of Optionee&#8217;s consent would not affect Optionee&#8217;s status or salary as an employee or Optionee&#8217;s career and that Optionee would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">. Optionee understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Optionee is based and subject to the conditions set out in the Applicable Laws, Optionee may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Optionee and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Optionee that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Optionee&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of Optionee&#8217;s Personal Data in certain situations where Optionee feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Optionee&#8217;s Personal Data that Optionee has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Optionee&#8217;s employment and is carried out by automated means. In case of concerns, Optionee understands that Optionee may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Optionee&#8217;s rights, Optionee understands that Optionee should contact Optionee&#8217;s local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Optionee may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Optionee acknowledges that Optionee is sufficiently proficient in the English language, or has consulted with an advisor who is sufficiently proficient in English, so as to allow Optionee to understand the terms and conditions of this Agreement. Further, if Optionee has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version differs in substance from the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Optionee hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through the electronic acceptance procedure established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Optionee Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Optionee must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company. In no event may the Option be exercised in the absence of such acceptance. An exercise of any portion of the shares subject to this Option shall be deemed to be an acceptance by Optionee of the terms and conditions of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Depending upon the country to which laws Optionee is subject, Optionee may have certain foreign asset or account reporting requirements that may affect Optionee&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Optionee&#8217;s country. Optionee&#8217;s country may require that Optionee report such accounts, assets or transactions to the applicable authorities in Optionee&#8217;s country. Optionee is responsible for knowledge of and compliance with any such regulations and should speak with Optionee&#8217;s own personal tax, legal and financial advisors regarding same.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any provision herein, Optionee&#8217;s participation in the Plan shall be subject to any special terms and conditions as set forth in any addendum to this Agreement setting forth special terms and conditions for Optionee&#8217;s country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Moreover, if Optionee relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Optionee, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons. The Addendum constitutes part of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company reserves the right to impose other requirements on Optionee&#8217;s participation in the Plan, on the Option and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Optionee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:12pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="margin-top:12pt;text-align:right;text-indent:36pt"><font><br></font></div><div style="margin-top:12pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPTIONEE&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Telman</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the Option, Optionee agrees that the Option is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Optionee&#8217;s country. Optionee has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.51
<SEQUENCE>8
<FILENAME>gildq12023ex1051rsuagreeme.htm
<DESCRIPTION>RSU AGREEMENT - 3 YEAR (TELMAN)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3b8e3c77fbf548f39f6eb24be7e703eb_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.51</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">2022 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Restricted Stock Unit Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Capitalized terms not otherwise defined in this Agreement have the meanings set forth in the Plan.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby awards Restricted Stock Units to the Participant named below upon the following terms and conditions&#58; </font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Award Date indicated below, Restricted Stock Units under the Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions set forth in this Agreement.  Each Restricted Stock Unit that vests hereunder will entitle Participant to receive one share of Common Stock on the specified issuance date for that unit.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUMMARY</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Award Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">July 25, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares Subject to Award&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24,690 shares of Common Stock (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraphs 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Shares will vest in three equal installments on the first three anniversaries of the Award Date, subject to the Participant&#8217;s Continuous Service through each vesting date.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Schedule</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares that have become vested will be issued no later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which the Shares vest pursuant to the Vesting Schedule or (ii) the 15th day of the third calendar month following the applicable vesting date, in each case subject to the Company&#8217;s collection of applicable Withholding Taxes pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div></td></tr></table></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to actual receipt of the Shares which vest hereunder, Participant may not transfer any interest in the Award or the underlying Shares or pledge or otherwise hedge the sale of those Shares, including through any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares.  However, any Shares which vest hereunder, but which otherwise remain unissued at the time of Participant&#8217;s death will be transferred to Participant&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Participant&#8217;s estate. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, should Participant cease Continuous Service for any reason prior to vesting in one or more Shares pursuant to the Vesting Schedule, then the Award will be immediately cancelled and forfeited with respect to those unvested Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event Participant ceases Continuous Service (i) at least 12 months following the Award Date and (ii) (A) after attaining age 55 and completing at least 10 years of Continuous Service or (B) after attaining age 65, then Participant will continue to vest in unvested Shares granted hereunder in accordance with the Vesting Schedule as if such Participant had remained in Continuous Service.  Any Shares which vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment or legal development in Participant&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Award pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> being deemed unlawful or discriminatory, then the Company will not apply this favorable treatment at the time of Participant&#8217;s cessation of Continuous Service, and the Award will be treated as set forth in Paragraph 3(a).  Furthermore, if Participant is located in Hong Kong, the Netherlands, or Taiwan, Participant will not be eligible for the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Award will be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event Participant ceases Continuous Service as a result of Participant&#8217;s death or Disability, then Participant will immediately vest in all unvested Shares at the time subject to the Award.  The Shares that vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15th day of the third calendar month following the date of such cessation of Continuous Service.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ermination by the Company Without Cause or by Participant for Good Reason.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    If Participant&#8217;s Continuous Service is terminated by the Company without Cause or by Participant for Good Reason (as such term is defined in that certain offer letter by and between Participant and the Company dated as of June 2, 2022) prior to Participant completing two years of Continuous Service, then Participant will immediately vest in all unvested Shares at the time subject to the Award, subject to Participant&#8217;s execution and non-</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">revocation of a waiver and general release of claims within the time period specified by and in the form then provided by the Company. The Shares that vest pursuant to this Paragraph 3(d) will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the later of (i) the close of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15th day of the third calendar month following the date of such cessation of Continuous Service. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">For Cause Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision hereof, should Participant&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Participant is employed or under the terms of Participant&#8217;s employment agreement, if any), or should Participant engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then the Award will be immediately cancelled and forfeited with respect to all Shares, whether or not vested at the time.  Participant will thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will not have any stockholder rights, including voting, dividend (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that the Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to the Award on such record date have not been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account will be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to the Award had they been issued and outstanding and entitled to that dividend or distribution.  As such Shares subsequently vest hereunder, the dividend equivalents so credited to those Shares in the book account will vest, and those vested dividend equivalents will be distributed to Participant (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those dividend equivalents relate, and correspondingly, as such Shares are forfeited or cancelled under the Award (including in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), the dividend equivalents so credited to those Shares in the book account will be forfeited or cancelled.  Settlement of dividend equivalents will be subject to the Company&#8217;s collection of applicable Withholding Taxes.  The Administrator will have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination will be controlling.  No dividend equivalent </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">amount will be paid or distributed on shares of Common Stock under the Award that are forfeited, cancelled or that otherwise are not issued or issuable under the Award.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the time of a Change in Control, the Award may be (i) assumed or otherwise continued in full force and effect by the surviving corporation, (ii) replaced with an economically-equivalent substitute award or (iii) replaced with a cash retention program of the successor corporation that is in a dollar amount equal to the Fair Market Value of the Shares underlying outstanding Restricted Stock Units under the Award (as measured immediately prior to the Change in Control) and provides for the subsequent vesting and payout of that dollar amount in accordance with the same vesting and issuance provisions that would otherwise be in effect for those Shares in the absence of the Change in Control.  In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award will be adjusted immediately after the consummation of the Change in Control in accordance with Section 9 of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event of an assumption, continuation or replacement of the Award under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no accelerated vesting of the Restricted Stock Units will occur at the time of the Change in Control, and the Award will instead be subject to accelerated vesting as follows&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">If Participant&#8217;s Continuous Service is terminated without Cause, or if Participant resigns from Continuous Service due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control and ending with the earlier of (A) the termination of that definitive agreement without the consummation of such Change in Control or (B) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control (or as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), then Participant will immediately vest in all unvested Shares (or any replacement securities or cash proceeds) at the time subject to the Award.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">The Shares (or any replacement securities or cash proceeds) that vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the later of (I) the close of the calendar year in which such cessation of Continuous Service occurs or (II) the 15th day of the third calendar month following the date of such cessation of Continuous Service.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Award is not assumed, continued or replaced in under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the Award will fully vest immediately prior to the consummation of the Change in Control.  The Shares subject to the vested Award will be converted into the right to receive for each such Share the same consideration per Share payable to the other stockholders of the Company upon consummation of that Change in Control, and such consideration per Share will be distributed to Participant by no later than the 10th business day following the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to occur of (i) the date the Share would have otherwise vested and been issued pursuant to the Vesting and Issuance Schedules set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the absence of such Change in </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Control, (ii) the date of Participant&#8217;s cessation of Continuous Service, or (iii) the first date following the Change in Control on which the distribution can be made without contravention of any applicable provisions of Section 409A of the Code.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Agreement will not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Settlement of Award.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">On each date on which one or more Shares are to be issued in accordance with this Agreement, the Company will issue to or on behalf of Participant a certificate (which may be in electronic form) for those Shares and will concurrently distribute to Participant any dividend equivalents with respect to those Shares (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances), subject in each instance to the Company&#8217;s collection of the applicable Withholding Taxes.  </font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in Paragraph 5, the settlement of all Restricted Stock Units which vest under the Award will be made solely in Shares.  In no event, however, will any fractional Shares be issued.  Accordingly, the total number of Shares to be issued at the time the Award vests (including any Shares issued in settlement of dividend equivalents) will, to the extent necessary, be rounded down to the next whole Share in order to avoid the issuance of a fractional Share.</font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The issuance of Shares pursuant to the Award will be subject to compliance by the Company and Participant with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Award will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained.  The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Withholding Taxes</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant acknowledges that, regardless of any action the Company or the applicable Related Entity employing or retaining the Participant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may take with respect to any or all Withholding Taxes related to the Award or Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all such Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer.  Participant further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares (or other property) upon </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">settlement of the Award, the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends or dividend equivalents&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result.  Further, if Participant has become subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and the Employer (or a former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this Agreement (including Shares issued in settlement of dividend equivalents) through an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless the Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides, in its sole discretion, to no longer utilize the Share Withholding Method and provides Participant with a corresponding notice.  If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of Shares subject to the vested Award, notwithstanding that a number of the Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Share Withholding Method is not used, then the Withholding Taxes will be collected from Participant through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan.  Participant will, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such broker-dealer sale and remittance transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes.  However, no broker-dealer sale and remittance transaction will be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Company determines that such broker-dealer sale and remittance procedure is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such procedure can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of Participant&#8217;s separate check payable to the Company (or a wire transfer of funds to the Company) in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant.  In no event will any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company will collect the Withholding Taxes with respect to dividend equivalents distributed in a form other than Shares by withholding a portion of that distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Participant&#8217;s jurisdiction, in which case Participant may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Participant may seek a refund from local tax authorities.  In the event of under-withholding, Participant may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, to the extent Participant is subject to taxation in the United States, the Withholding Taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder will in all events be collected from Participant no later than the last business day of the calendar year in which those Shares or other amounts vest (as determined under applicable tax laws).  Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those Shares or other amounts vest, Participant will, if so requested by the Company, on or before the last business day of the calendar year in which such Shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to Withholding Taxes required to be withheld with respect to those Shares or other amounts.  Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Withholding Taxes required to be withheld with respect to those Shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.  The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 7(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are applicable only to the extent necessary to comply with the applicable tax withholding requirements of Section 3121(v) of the Code.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of applying the various vesting provisions of this Agreement, the Administrator, in its sole discretion, may determine that Participant will be deemed to cease Continuous Service on the commencement date of any leave of absence and not remain in Continuous Service during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">Participant will receive Continuous Service credit for such vesting purposes for (i) the first three months of an approved personal leave of absence and (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.52pt">In no event, however, will Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the earlier of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service on or before that date or (ii) the date Participant&#8217;s Continuous Service actually terminates by reason of Participant&#8217;s voluntary or involuntary termination or by reason of Participant&#8217;s death or Disability.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or Participant&#8217;s broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before Participant possessed inside information.  Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company.  Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions and Participant should speak with Participant&#8217;s personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Deferred Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, to the extent Participant is subject to taxation in the United States and the Award may be deemed to create a deferred compensation arrangement under Section 409A of the Code, then the following limitations will apply&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">No Shares or other amounts which become issuable or distributable under this Agreement upon Participant&#8217;s Separation from Service will actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first day of the seventh month following the date of such Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Section 409A of the Code, as determined by the Administrator, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Section 409A(a)(2) of the Code.  The deferred Shares or other distributable amount will be issued or distributed in a lump sum on the first day of the seventh month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Participant&#8217;s cessation of Continuous Service that is considered a separation from service under Treasury Regulations Section 1.409A-1(h).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.52pt">To the extent there is any ambiguity as to whether any provision of this Agreement would otherwise contravene one or more requirements or limitations of Section </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">409A of the Code, such provisions shall be interpreted and applied in a manner that does not result in a violation of the applicable requirements or limitations of Code Section 409A of the Code and the Treasury Regulations thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.2pt">Each installment of Shares issuable pursuant to this Agreement shall be treated as a separate payment for purposes of Section 409A of the Code. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its principal corporate offices.  Any notice required to be given or delivered to Participant will be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or will be delivered electronically to Participant through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect the sale of the Shares issued hereunder.  All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, Participant&#8217;s assigns, and the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.  In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control.  All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Award.  Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation.  The word &#8220;or&#8221; is not exclusive.  Words in the masculine gender include the feminine gender, and where appropriate, the plural includes the singular and the singular includes the plural.  All references to &#8220;including&#8221; shall be construed as meaning &#8220;including without limitation.&#8221; </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by the Award and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or the federal courts for the Northern District of California, and no other courts where the grant of the Restricted Stock Units is made or to be performed. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.  </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and Participant&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Participant&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with any certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from termination of Participant&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the Award, Participant irrevocably agrees not to institute any claim against the Company, the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employer or any Related Entity, waives Participant&#8217;s ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan or Participant&#8217;s acquisition or sale of the underlying Shares.  Participant should consult with Participant&#8217;s personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Restricted Stock Units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or other Participants.</font></div><div style="text-align:justify;text-indent:94.5pt"><font><br></font></div><div style="text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that Participant agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the Related Entities and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that Participant needs to review the following information about the processing of Participant's personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Participant's consent. As regards the processing of Participant&#8217;s Personal Data in connection with the Plan and this Agreement, Participant understands that the Company is the controller of Participant's Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan. Participant understands that this Personal Data may include Participant's name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant&#8217;s favor. The legal basis for the processing of Participant&#8217;s Personal Data, where required, will be Participant's consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company transfers Participant's Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Participant&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Participant understands and acknowledges that the Company&#8217;s service provider will open an account for Participant to receive and trade Shares acquired under the Plan and that Participant will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Participant understands and acknowledges that Participant's country may have enacted data privacy laws that are different from the laws of the United States. The Company&#8217;s legal basis for the transfer of Participant&#8217;s Personal Data is Participant&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company will use Participant&#8217;s Personal Data only as long as is necessary to implement, administer and manage Participant&#8217;s participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Participant understands and acknowledges that the Company&#8217;s legal basis for the processing of Participant&#8217;s Personal Data would be compliance with the relevant laws or regulations. When </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">the Company no longer needs Participant&#8217;s Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that Participant&#8217;s participation in the Plan and Participant&#8217;s consent is purely voluntary. Participant may deny or later withdraw Participant&#8217;s consent at any time, with future effect and for any or no reason. If Participant denies or later withdraws Participant&#8217;s consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan. Participant further understands that denial or withdrawal of Participant&#8217;s consent would not affect Participant&#8217;s status or salary as an employee or Participant&#8217;s career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Participant is based and subject to the conditions set out in the Applicable Laws, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Participant and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Participant's objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of Participant's Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant&#8217;s Personal Data that Participant has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Participant's employment and is carried out by automated means. In case of concerns, Participant understands that Participant may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Participant&#8217;s rights, Participant understands that Participant should contact Participant's local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electing to accept this Agreement, Participant acknowledges that Participant is sufficiently proficient in English, or has consulted with an advisor who is sufficiently proficient in English so as to allow Participant, to understand the terms and conditions of this Agreement.  Further, if Participant has received this Agreement or </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any other document related to the Plan translated into a language other than English and if the translated version differs in substance from the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company.  In no event will any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Depending upon the country to which laws Participant is subject, Participant may have certain foreign asset or account reporting requirements that may affect Participant&#8217;s ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends or dividend equivalents received or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside Participant&#8217;s country.  Participant&#8217;s country may require that Participant report such accounts, assets or transactions to the applicable authorities in Participant&#8217;s country.  Participant is responsible for knowledge of and compliance with any such regulations and should speak with Participant&#8217;s own personal tax, legal and financial advisors regarding same.  </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, the Award shall be subject to any special terms and conditions set forth in any addendum to this Agreement setting forth special terms and conditions for Participant&#8217;s country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Moreover, if Participant relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons.  The Addendum constitutes part of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Telman</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the Award, Participant agrees that the Award is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Participant&#8217;s country.  Participant has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.  &#160;&#160;&#160;&#160;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.52
<SEQUENCE>9
<FILENAME>gildq12023ex1052rsuagreeme.htm
<DESCRIPTION>RSU AGREEMENT - 4 YEAR (TELMAN)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i02f45cfa8ddd4e3eb4ef6bb5f8309dd8_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.52</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">2022 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">GLOBAL RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;This Restricted Stock Unit Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s issuance of shares of Common Stock to Participant thereunder.</font></div><div style="margin-top:8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;Capitalized terms not otherwise defined in this Agreement have the meanings set forth in the Plan.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company hereby awards Restricted Stock Units to the Participant named below upon the following terms and conditions&#58; </font></div><div style="margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Grant of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company hereby awards to Participant, as of the Grant Date indicated below, Restricted Stock Units under the Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions set forth in this Agreement.  Each Restricted Stock Unit that vests hereunder will entitle Participant to receive one share of Common Stock on the specified issuance date for that unit.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AWARD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUMMARY</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">July 25, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Shares Subject to Award&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8,230 shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Paragraphs 3 and 5, the Shares will vest in as follows&#58; (i) 25% of the Shares on the first anniversary of the Grant Date and (ii) 6.25% of the Shares quarterly thereafter through the fourth anniversary of the Grant Date, in each case, subject to the Participant&#8217;s Continuous Service through each vesting date.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance Schedule</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares that have become vested will be issued no later than the later of (i) the close of the calendar year in which the Shares vest pursuant to the Vesting Schedule or (ii) the 15th day of the third calendar month following the applicable vesting date, in each case subject to the Company&#8217;s collection of applicable Withholding Taxes pursuant to Paragraph 7.</font></td></tr></table></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Limited Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to actual receipt of the Shares which vest hereunder, Participant may not transfer any interest in the Award or the underlying Shares or pledge or otherwise hedge the sale of those Shares, including through any short sale or any acquisition or disposition of any put or call option or other instrument tied to the value of the underlying Shares.  However, any Shares which vest hereunder, but which otherwise remain </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">unissued at the time of Participant&#8217;s death will be transferred to Participant&#8217;s designated beneficiary or, if none or if a beneficiary designation is not permitted by the Administrator or not valid under Applicable Laws, to Participant&#8217;s estate. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Cessation of Continuous Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Except as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, should Participant cease Continuous Service for any reason prior to vesting in one or more Shares pursuant to the Vesting Schedule, then the Award will be immediately cancelled and forfeited with respect to those unvested Shares.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event Participant ceases Continuous Service (i) at least 12 months following the Grant Date and (ii) (A) after attaining age 55 and completing at least 10 years of Continuous Service or (B) after attaining age 65, then Participant will continue to vest in unvested Shares granted hereunder in accordance with the Vesting Schedule as if such Participant had remained in Continuous Service.  Any Shares which vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment or legal development in Participant&#8217;s jurisdiction that would likely result in the favorable treatment applicable to the Award pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> being deemed unlawful or discriminatory, then the Company will not apply this favorable treatment at the time of Participant&#8217;s cessation of Continuous Service, and the Award will be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Furthermore, if Participant is located in Hong Kong, the Netherlands, or Taiwan, Participant will not be eligible for the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the Award will be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Death&#59; Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event Participant ceases Continuous Service as a result of Participant&#8217;s death or Disability, then Participant will immediately vest in all unvested Shares at the time subject to the Award.  The Shares that vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the close of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15th day of the third calendar month following the date of such cessation of Continuous Service.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by the Company Without Cause or by Participant for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.    If Participant&#8217;s Continuous Service is terminated by the Company without Cause or by Participant for Good Reason (as such term is defined in that certain offer letter by and between Participant and the Company dated as of June 2, 2022) prior to Participant completing two years of Continuous Service, then Participant will immediately vest in all unvested Shares at the time subject to the Award, subject to Participant&#8217;s execution and non-revocation of a waiver and general release of claims within the time period specified by and in the form then provided by the Company. The Shares that vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the later of (i) the close </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the calendar year in which such cessation of Continuous Service occurs or (ii) the 15th day of the third calendar month following the date of such cessation of Continuous Service. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">For Cause Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision hereof, should Participant&#8217;s Continuous Service be terminated for Cause (or for a reason that is comparable to termination for Cause under employment laws in the jurisdiction where Participant is employed or under the terms of Participant&#8217;s employment agreement, if any), or should Participant engage in any other conduct, while in Continuous Service or following cessation of Continuous Service, that is materially detrimental to the business or affairs of the Company (or any Related Entity), as determined in the sole discretion of the Administrator, then the Award will be immediately cancelled and forfeited with respect to all Shares, whether or not vested at the time.  Participant will thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Stockholder Rights and Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will not have any stockholder rights, including voting, dividend (except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) or liquidation rights, with respect to the Shares subject to the Award until Participant becomes the record holder of those Shares upon their actual issuance.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, if and to the extent that the Award is outstanding on the record date for any dividend or other distribution, whether regular or extraordinary and whether payable in cash, securities (other than Common Stock) or other property, and one or more Shares subject to the Award on such record date have not been delivered as of the payment date for such dividend or distribution and do not otherwise receive such dividend or distribution (i.e., those Shares are not otherwise treated as issued and outstanding for purposes of entitlement to the dividend or distribution pursuant to state law, the terms of such distribution or otherwise), then a special book account will be established for Participant and credited with a phantom dividend that is equivalent to the actual dividend or distribution which would have been paid on such Shares at the time subject to the Award had they been issued and outstanding and entitled to that dividend or distribution.  As such Shares subsequently vest hereunder, the dividend equivalents so credited to those Shares in the book account will vest, and those vested dividend equivalents will be distributed to Participant (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances) concurrently with the issuance of the vested Shares to which those dividend equivalents relate, and correspondingly, as such Shares are forfeited or cancelled under the Award (including in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), the dividend equivalents so credited to those Shares in the book account will be forfeited or cancelled.  Settlement of dividend equivalents will be subject to the Company&#8217;s collection of applicable Withholding Taxes.  The Administrator will have the sole discretion to determine the dollar value of any dividend or distribution paid other than in the form of cash, and its determination will be controlling.  No dividend equivalent amount will be paid or distributed on shares of Common Stock under the Award that are forfeited, cancelled or that otherwise are not issued or issuable under the Award.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">At the time of a Change in Control, the Award may be (i) assumed or otherwise continued in full force and effect by the surviving corporation, (ii) replaced with an economically-equivalent substitute award or (iii) replaced with a cash retention program of the successor corporation that is in a dollar amount equal to the Fair Market Value of the Shares underlying outstanding Restricted Stock Units under the Award (as measured immediately prior to the Change in Control) and provides for the subsequent vesting and payout of that dollar amount in accordance with the same vesting and issuance provisions that would otherwise be in effect for those Shares in the absence of the Change in Control.  In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award will be adjusted immediately after the consummation of the Change in Control in accordance with Section 9 of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event of an assumption, continuation or replacement of the Award under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no accelerated vesting of the Restricted Stock Units will occur at the time of the Change in Control, and the Award will instead be subject to accelerated vesting as follows&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">If Participant&#8217;s Continuous Service is terminated without Cause, or if Participant resigns from Continuous Service due to a Constructive Termination, at any time during the period beginning with the execution date of the definitive agreement for that Change in Control and ending with the earlier of (A) the termination of that definitive agreement without the consummation of such Change in Control or (B) the expiration of the Applicable Acceleration Period following the consummation of such Change in Control (or as otherwise provided in Paragraph 3(d)), then Participant will immediately vest in all unvested Shares (or any replacement securities or cash proceeds) at the time subject to the Award.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">The Shares (or any replacement securities or cash proceeds) that vest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be issued or distributed on or as soon as administratively practicable following the date of Participant&#8217;s cessation of Continuous Service, but in no event later than the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">later</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (I) the close of the calendar year in which such cessation of Continuous Service occurs or (II) the 15th day of the third calendar month following the date of such cessation of Continuous Service.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Award is not assumed, continued or replaced in under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the Award will fully vest immediately prior to the consummation of the Change in Control.  The Shares subject to the vested Award will be converted into the right to receive for each such Share the same consideration per Share payable to the other stockholders of the Company upon consummation of that Change in Control, and such consideration per Share will be distributed to Participant by no later than the 10th business day following the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earliest </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to occur of (i) the date the Share would have otherwise vested and been issued pursuant to the Vesting and Issuance Schedules set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the absence of such Change in Control, (ii) the date of Participant&#8217;s cessation of Continuous Service, or (iii) the first date </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">following the Change in Control on which the distribution can be made without contravention of any applicable provisions of Section 409A of the Code. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Agreement will not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Settlement of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">On each date on which one or more Shares are to be issued in accordance with this Agreement, the Company will issue to or on behalf of Participant a certificate (which may be in electronic form) for those Shares and will concurrently distribute to Participant any dividend equivalents with respect to those Shares (in the form of additional Shares or in such other form as the Administrator deems appropriate under the circumstances), subject in each instance to the Company&#8217;s collection of the applicable Withholding Taxes.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the settlement of all Restricted Stock Units which vest under the Award will be made solely in Shares.  In no event, however, will any fractional Shares be issued.  Accordingly, the total number of Shares to be issued at the time the Award vests (including any Shares issued in settlement of dividend equivalents) will, to the extent necessary, be rounded down to the next whole Share in order to avoid the issuance of a fractional Share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The issuance of Shares pursuant to the Award will be subject to compliance by the Company and Participant with all Applicable Laws relating thereto, as determined by counsel for the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to the Award will relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained.  The Company, however, will use its reasonable best efforts to obtain all such approvals.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant acknowledges that, regardless of any action the Company or the applicable Related Entity employing or retaining the Participant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may take with respect to any or all Withholding Taxes related to the Award or Participant&#8217;s participation in the Plan and legally applicable to Participant, the ultimate liability for all such Withholding Taxes is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Employer.  Participant further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Withholding Taxes in connection with any aspect of the Award, including the grant, vesting or settlement of the Award, the issuance of Shares (or other property) upon settlement of the Award, the subsequent sale of Shares acquired pursuant to such issuance and </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the receipt of any dividends or dividend equivalents&#59; and (ii) do not commit to, and are under no obligation to, structure the terms of the grant or any aspect of the Award to reduce or eliminate Participant&#8217;s liability for Withholding Taxes or achieve any particular tax result.  Further, if Participant has become subject to Withholding Taxes in more than one jurisdiction, Participant acknowledges that the Company and the Employer (or a former employer, as applicable) may be required to withhold or account for Withholding Taxes in more than one jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company will collect, and Participant hereby authorizes the Company to collect, the Withholding Taxes with respect to the Shares issued under this Agreement (including Shares issued in settlement of dividend equivalents) through an automatic Share withholding procedure pursuant to which the Company will withhold, immediately as the Shares are issued under the Award, a portion of those Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of such Withholding Taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Share Withholding Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), unless the Share Withholding Method is not permissible or advisable under local law or until the Company otherwise decides, in its sole discretion, to no longer utilize the Share Withholding Method and provides Participant with a corresponding notice.  If the obligation for Withholding Taxes is satisfied by using the Share Withholding Method, then Participant will, for tax purposes, be deemed to have been issued the full number of Shares subject to the vested Award, notwithstanding that a number of the Shares are withheld solely for the purpose of paying the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If the Share Withholding Method is not used, then the Withholding Taxes will be collected from Participant through a broker-dealer sale and remittance procedure in accordance with Section 7(d) of the Plan.  Participant will, promptly upon request from the Company, execute (whether manually or through electronic acceptance) an appropriate sales authorization (in form and substance reasonably satisfactory to the Company) that authorizes and directs the broker to effect such broker-dealer sale and remittance transactions and remit the sale proceeds, net of brokerage fees and other applicable charges, to the Company in satisfaction of the applicable Withholding Taxes.  However, no broker-dealer sale and remittance transaction will be effected unless (i) such a sale is at the time permissible under the Company&#8217;s insider trading policies governing the sale of Common Stock and (ii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">If the Company determines that such broker-dealer sale and remittance procedure is not permissible or advisable at the time or if Participant otherwise fails to effect a timely sales authorization as required by this Agreement, then the Company may, in its sole discretion, elect either to defer the issuance of the Shares until such procedure can be effected in accordance with Participant&#8217;s executed sale directive or to collect the applicable Withholding Taxes through Participant&#8217;s delivery of Participant&#8217;s separate check payable to the Company (or a wire transfer of funds to the Company) in the amount of such Withholding Taxes or by withholding such amount from other wages payable to Participant.  In no event will any Shares be issued in the absence of an arrangement reasonably satisfactory to the Company for the satisfaction of the applicable Withholding Taxes.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Company will collect the Withholding Taxes with respect to dividend equivalents distributed in a form other than Shares by withholding a portion of that </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">distribution equal to the amount of the applicable Withholding Taxes, with the cash portion of the distribution to be the first portion so withheld, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Company may withhold or account for Withholding Taxes by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Participant&#8217;s jurisdiction, in which case Participant may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, Participant may seek a refund from local tax authorities.  In the event of under-withholding, Participant may be required to pay any additional Withholding Taxes directly to the applicable tax authority or to the Company or the Employer.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding the foregoing, to the extent Participant is subject to taxation in the United States, the Withholding Taxes required to be withheld by the Company in connection with the vesting (as determined under applicable tax laws) of the Shares or any other amounts hereunder will in all events be collected from Participant no later than the last business day of the calendar year in which those Shares or other amounts vest (as determined under applicable tax laws).  Accordingly, to the extent the applicable issuance date for one or more vested Shares or the distribution date for such other amounts is to occur in a year subsequent to the calendar year in which those Shares or other amounts vest, Participant will, if so requested by the Company, on or before the last business day of the calendar year in which such Shares or other amounts vest, deliver to the Company a check payable to its order (or a wire transfer of funds to the Company) in the dollar amount equal to Withholding Taxes required to be withheld with respect to those Shares or other amounts.  Alternatively, the Company may, in its sole discretion, elect to withhold the dollar amount equal to the Withholding Taxes required to be withheld with respect to those Shares or other amounts from other wages payable to Participant, or through such other tax withholding arrangement as the Company deems appropriate, in its sole discretion.  The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paragraph 7(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are applicable only to the extent necessary to comply with the applicable tax withholding requirements of Section 3121(v) of the Code.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Leaves of Absence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of applying the various vesting provisions of this Agreement, the Administrator, in its sole discretion, may determine that Participant will be deemed to cease Continuous Service on the commencement date of any leave of absence and not remain in Continuous Service during the period of that leave, except to the extent otherwise required under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any or pursuant to the following policy&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant will receive Continuous Service credit for such vesting purposes for (i) the first three months of an approved personal leave of absence and (ii) the first seven months of any bona fide leave of absence (other than an approved personal leave), but in no event beyond the expiration date of such leave of absence.</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:22.02pt">In no event, however, will Participant be deemed, for vesting purposes hereunder, to remain in Continuous Service beyond the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">earlier </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">of (i) the expiration date of that leave of absence, unless Participant returns to active Continuous Service on or before that </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">date or (ii) the date Participant&#8217;s Continuous Service actually terminates by reason of Participant&#8217;s voluntary or involuntary termination or by reason of Participant&#8217;s death or Disability.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.5pt;text-decoration:underline">Insider Trading Restrictions&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant may be subject to insider trading restrictions or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions including the United States and Participant&#8217;s country or Participant&#8217;s broker&#8217;s country, if different, which may affect Participant&#8217;s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., Restricted Stock Units) or rights linked to the value of Shares (e.g., dividend equivalents) during such times as Participant is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws in applicable jurisdictions).  Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before Participant possessed inside information.  Furthermore, Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) &#8220;tipping&#8221; third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company.  Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable restrictions and Participant should speak with Participant&#8217;s personal legal advisor on this matter.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Deferred Issuance Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, to the extent Participant is subject to taxation in the United States and the Award may be deemed to create a deferred compensation arrangement under Section 409A of the Code, then the following limitations will apply&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">No Shares or other amounts which become issuable or distributable under this Agreement upon Participant&#8217;s Separation from Service will actually be issued or distributed to Participant prior to the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">earlier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of (i) the first day of the seventh month following the date of such Separation from Service or (ii) the date of Participant&#8217;s death, if Participant is deemed at the time of such Separation from Service to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations issued under Section 409A of the Code, as determined by the Administrator, and such delayed commencement is otherwise required in order to avoid a prohibited distribution under Section 409A(a)(2) of the Code.  The deferred Shares or other distributable amount will be issued or distributed in a lump sum on the first day of the seventh month following the date of Participant&#8217;s Separation from Service or, if earlier, the first day of the month immediately following the date the Company receives proof of Participant&#8217;s death.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Participant&#8217;s cessation of Continuous Service that is considered a separation from service under Treasury Regulations Section 1.409A-1(h).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">To the extent there is any ambiguity as to whether any provision of this Agreement would otherwise contravene one or more requirements or limitations of Section 409A of the Code, such provisions shall be interpreted and applied in a manner that does not result in a violation of the applicable requirements or limitations of Code Section 409A of the Code and the Treasury Regulations thereunder.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Each installment of Shares issuable pursuant to this Agreement shall be treated as a separate payment for purposes of Section 409A of the Code. </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required to be given or delivered to the Company under the terms of this Agreement will be in writing and addressed to the Company at its principal corporate offices.  Any notice required to be given or delivered to Participant will be in writing and addressed to Participant at the most current address then indicated for Participant on the Company&#8217;s employee records or will be delivered electronically to Participant through the Company&#8217;s electronic mail system or through the on-line brokerage firm authorized by the Company to effect the sale of the Shares issued hereunder.  All notices will be deemed effective upon personal delivery or delivery through the Company&#8217;s electronic mail system or upon deposit in the U.S. or local country mail, postage prepaid and properly addressed to the party to be notified.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except to the extent otherwise provided in this Agreement, the provisions of this Agreement will inure to the benefit of, and be binding upon, the Company and its successors and assigns and Participant, Participant&#8217;s assigns, and the legal representatives, heirs and legatees of Participant&#8217;s estate.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Construction&#59; Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.  In the event of any conflict between the provisions of this Agreement and the terms of the Plan, the terms of the Plan will control.  All decisions of the Administrator with respect to any question or issue arising under the Plan or this Agreement will be conclusive and binding on all persons having an interest in the Award.  Unless the context requires otherwise, all references to laws, regulations, contracts, agreements, plans and instruments refer to such laws, regulations, contracts, agreements, plans and instruments as they may be amended from time to time, and references to particular provisions of laws or regulations include a reference to the corresponding provisions of any succeeding law or regulation.  The word &#8220;or&#8221; is not exclusive.  Words in the masculine gender include the feminine gender, and where appropriate, the plural includes the singular and the singular includes the plural.  All references to &#8220;including&#8221; shall be construed as meaning &#8220;including without limitation.&#8221; </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Governing Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The interpretation, performance and enforcement of this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without resort to its conflict-of-laws rules.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by the Award and this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Mateo County, California, or the federal courts for the Northern District of California, and no other courts where the grant of the Restricted Stock Units is made or to be performed. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.  </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Acknowledgment of Nature of Plan and Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the Award, Participant acknowledges, understands and agrees that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future Awards or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and Participant&#8217;s participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company, the Employer or any Related Entity and shall not interfere with the ability of the Company, the Employer or any Related Entity, as applicable, to terminate Participant&#8217;s employment or service relationship (if any)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Participant&#8217;s participation in the Plan is voluntary&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the Award and the Shares subject to the Award, and the income and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Award and the Shares subject to the Award, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, holiday pay, bonuses, long-service awards, leave-related payments, pension or retirement or welfare benefits or similar payments&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with any certainty&#59; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Award resulting from termination of Participant&#8217;s Continuous Service by the Employer or the Company (or any Related Entity) (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#8217;s employment agreement, if any), and in consideration of the Award, Participant irrevocably agrees not to institute any claim against the Company, the Employer or any Related Entity, waives Participant&#8217;s ability, if any, to bring any such claim and releases the Company, the Employer and any Related Entity from any such claim&#59; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">unless otherwise agreed with the Company in writing, the Award and the Shares subject to the Award, and the income and value of same, are not granted as consideration for, or in connection with, any service Participant may provide as a director of the Company or a Related Entity&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock Units and the benefits evidenced by this Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">neither the Company, the Employer nor any Related Entity shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan or Participant&#8217;s acquisition or sale of the underlying Shares.  Participant should consult with Participant&#8217;s personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan or the Restricted Stock Units.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or other Participants.</font></div><div style="text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  By electing to participate in the Plan via the Company&#8217;s online acceptance procedure, Participant is declaring that Participant agrees with the data processing practices described herein and consents to the collection, processing and use of Personal Data (as defined below) by the Company and the Related Entities and the transfer of Personal Data to the recipients mentioned herein, including recipients located in countries which do not adduce an adequate level of protection from a European (or other) data protection law perspective, for the purposes described herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that Participant needs to review the following information about the processing of Participant&#8217;s personal data by or on behalf of the Company, the Employer or any Related Entity as described in the Agreement and any other Plan materials (the &#8220;Personal Data&#8221;) and declare Participant&#8217;s consent. As regards the processing of Participant&#8217;s Personal Data in connection with the Plan </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">and this Agreement, Participant understands that the Company is the controller of Participant&#8217;s Personal Data.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">Data Processing and Legal Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  The Company collects, uses and otherwise processes Personal Data about Participant for the purposes of allocating Shares and implementing, administering and managing the Plan. Participant understands that this Personal Data may include Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to shares of stock or equivalent benefits awarded, cancelled, exercised, vested, unvested or outstanding in Participant&#8217;s favor. The legal basis for the processing of Participant&#8217;s Personal Data, where required, will be Participant&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company transfers Participant&#8217;s Personal Data, or parts thereof, to E*TRADE Financial Services, Inc. (and its affiliated companies), an independent service provider based in the United States which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share Participant&#8217;s Personal Data with such different service provider that serves the Company in a similar manner. Participant understands and acknowledges that the Company&#8217;s service provider will open an account for Participant to receive and trade Shares acquired under the Plan and that Participant will be asked to agree on separate terms and data processing practices with the service provider, which is a condition of Participant&#8217;s ability to participate in the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.7pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company and, as of the date hereof, any third parties assisting in the implementation, administration and management of the Plan, such as E*TRADE Financial Services, Inc., are based in the United States. Participant understands and acknowledges that Participant&#8217;s country may have enacted data privacy laws that are different from the laws of the United States. The Company&#8217;s legal basis for the transfer of Participant&#8217;s Personal Data is Participant&#8217;s consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:24.69pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that the Company will use Participant&#8217;s Personal Data only as long as is necessary to implement, administer and manage Participant&#8217;s participation in the Plan, or to comply with legal or regulatory obligations, including under tax and securities laws. In the latter case, Participant understands and acknowledges that the Company&#8217;s legal basis for the processing of Participant&#8217;s Personal Data would be compliance with the relevant laws or regulations. When the Company no longer needs Participant&#8217;s Personal Data for any of the above purposes, Participant understands the Company will remove it from its systems.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Voluntariness and Consequences of Denial&#47;Withdrawal of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that Participant&#8217;s participation in the Plan and Participant&#8217;s consent is purely voluntary. Participant may deny or later withdraw Participant&#8217;s </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">consent at any time, with future effect and for any or no reason. If Participant denies or later withdraws Participant&#8217;s consent, the Company can no longer offer Participant participation in the Plan or offer other equity awards to Participant or administer or maintain such awards and Participant would no longer be able to participate in the Plan. Participant further understands that denial or withdrawal of Participant&#8217;s consent would not affect Participant&#8217;s status or salary as an employee or Participant&#8217;s career and that Participant would merely forfeit the opportunities associated with the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:22.02pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.  Participant understands that data subject rights regarding the processing of Personal Data vary depending on the Applicable Laws and that, depending on where Participant is based and subject to the conditions set out in the Applicable Laws, Participant may have, without limitation, the rights to (i) inquire whether and what kind of Personal Data the Company holds about Participant and how it is processed, and to access or request copies of such Personal Data, (ii) request the correction or supplementation of Personal Data about Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Personal Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of Participant&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request the Company to restrict the processing of Participant&#8217;s Personal Data in certain situations where Participant feels its processing is inappropriate, (v) object, in certain circumstances, to the processing of Personal Data for legitimate interests, and to (vi) request portability of Participant&#8217;s Personal Data that Participant has actively or passively provided to the Company (which does not include data derived or inferred from the collected data), where the processing of such Personal Data is based on consent or Participant&#8217;s employment and is carried out by automated means. In case of concerns, Participant understands that Participant may also have the right to lodge a complaint with the competent local data protection authority. Further, to receive clarification of, or to exercise any of, Participant&#8217;s rights, Participant understands that Participant should contact Participant&#8217;s local human resources representative.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Plan Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The official prospectus for the Plan is available on the Company&#8217;s intranet at&#58; GNet &#62; Employee Resources &#62; Stock Awards &#62; Plan Documents. Participant may also obtain a printed copy of the prospectus by contacting Stock Plan Services at stockplanservices&#64;gilead.com.&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. By electing to accept this Agreement, Participant acknowledges that Participant is sufficiently proficient in English, or has consulted with an advisor who is sufficiently proficient in English so as to allow Participant, to understand the terms and conditions of this Agreement.  Further, if Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the translated version differs in substance from the English version, the English version will control.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Participant Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant must accept the terms and conditions of this Agreement either electronically through the electronic acceptance procedure established by the Company or through a written acceptance delivered to the Company in a form satisfactory to the Company.  In no event will any Shares be issued (or other securities or property distributed) under this Agreement in the absence of such acceptance.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Account &#47; Assets Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Depending upon the country to which laws Participant is subject, Participant may have certain foreign asset or account reporting requirements that may affect Participant&#8217;s ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends or dividend equivalents received or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside Participant&#8217;s country.  Participant&#8217;s country may require that Participant report such accounts, assets or transactions to the applicable authorities in Participant&#8217;s country.  Participant is responsible for knowledge of and compliance with any such regulations and should speak with Participant&#8217;s own personal tax, legal and financial advisors regarding same.  </font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, the Award shall be subject to any special terms and conditions set forth in any addendum to this Agreement setting forth special terms and conditions for Participant&#8217;s country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Addendum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Moreover, if Participant relocates to one of the countries included in the Addendum, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary for legal or administrative reasons.  The Addendum constitutes part of this Agreement.</font></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company reserves the right to impose other requirements on Participant&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company has caused this Agreement to be executed on its behalf by its duly-authorized officer on the day and year first indicated above.</font></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.929%"><tr><td style="width:1.0%"></td><td style="width:21.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EVP, Human Resources</font></td></tr></table></div><div style="margin-top:24pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.250%"><tr><td style="width:1.0%"></td><td style="width:33.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.881%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARTICIPANT&#58;</font></td><td colspan="6" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="6" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deborah Telman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By electronically accepting the Award, Participant agrees that the Award is granted under and governed by the terms and conditions of the Plan and the Agreement, including the terms and conditions set forth in any Addendum to the Agreement for Participant&#8217;s country.  Participant has reviewed the Plan and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to accepting the Agreement and fully understands all provisions of the Plan and Agreement.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>gildq12023ex311ceocertific.htm
<DESCRIPTION>CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i42fae49f8cbf466981a3b36961aeb04d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;3, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:8pt;padding-left:288pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.959%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>gildq12023ex312cfocertific.htm
<DESCRIPTION>CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i87562a485552412ca8d7b4fddb464e4f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;3, 2023 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:11pt;padding-left:252pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>12
<FILENAME>gildq12023ex32section906ce.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i997e8220596240ff8cbefaf338688e99_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;3, 2023</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Day</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>gild-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c106b7c8-2bb1-4b42-ab62-c7781606086b,g:b0acd2cc-13f9-458d-8974-066f309efac0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.gilead.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical">
        <link:definition>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUES" roleURI="http://www.gilead.com/role/REVENUES">
        <link:definition>0000011 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000012 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES">
        <link:definition>0000013 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTS" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS">
        <link:definition>0000014 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS" roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS">
        <link:definition>0000015 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETS" roleURI="http://www.gilead.com/role/INTANGIBLEASSETS">
        <link:definition>0000016 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATION" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION">
        <link:definition>0000017 - Disclosure - OTHER FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIES" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES">
        <link:definition>0000018 - Disclosure - DEBT AND CREDIT FACILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARE" roleURI="http://www.gilead.com/role/EARNINGSPERSHARE">
        <link:definition>0000020 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.gilead.com/role/INCOMETAXES">
        <link:definition>0000021 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESTables" roleURI="http://www.gilead.com/role/REVENUESTables">
        <link:definition>0000023 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables">
        <link:definition>0000025 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSTables" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables">
        <link:definition>0000026 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSTables" roleURI="http://www.gilead.com/role/INTANGIBLEASSETSTables">
        <link:definition>0000027 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONTables" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables">
        <link:definition>0000028 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESTables" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables">
        <link:definition>0000029 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARETables" roleURI="http://www.gilead.com/role/EARNINGSPERSHARETables">
        <link:definition>0000030 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.gilead.com/role/INCOMETAXESTables">
        <link:definition>0000031 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>0000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESSummaryofDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails">
        <link:definition>0000033 - Disclosure - REVENUES - Summary of Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESSummaryofRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails">
        <link:definition>0000034 - Disclosure - REVENUES - Summary of Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESSummaryofPerformanceObligationsDetails" roleURI="http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails">
        <link:definition>0000035 - Disclosure - REVENUES - Summary of Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESSummaryofContractBalancesDetails" roleURI="http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails">
        <link:definition>0000036 - Disclosure - REVENUES - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>0000037 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
        <link:definition>0000038 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails">
        <link:definition>0000039 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>0000040 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails">
        <link:definition>0000041 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails">
        <link:definition>0000042 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>0000043 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>0000044 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails">
        <link:definition>0000045 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
        <link:definition>0000046 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>0000047 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>0000048 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails">
        <link:definition>0000049 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
        <link:definition>0000050 - Disclosure - INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1">
        <link:definition>0000050 - Disclosure - INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSAdditionalInformationDetails" roleURI="http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails">
        <link:definition>0000051 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails">
        <link:definition>0000052 - Disclosure - INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails">
        <link:definition>0000053 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails">
        <link:definition>0000054 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1">
        <link:definition>0000054 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>0000055 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000056 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
        <link:definition>0000057 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTANDCREDITFACILITIESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails">
        <link:definition>0000058 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>0000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails" roleURI="http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails">
        <link:definition>0000060 - Disclosure - EARNINGS PER SHARE - Schedule of the Calculation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREAdditionalInformationDetails" roleURI="http://www.gilead.com/role/EARNINGSPERSHAREAdditionalInformationDetails">
        <link:definition>0000061 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleDetails" roleURI="http://www.gilead.com/role/INCOMETAXESScheduleDetails">
        <link:definition>0000062 - Disclosure - INCOME TAXES - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetails" roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails">
        <link:definition>0000063 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsTecartusMember" abstract="true" name="CellTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A480SeniorUnsecuredNotesDueApril2044Member" abstract="true" name="A480SeniorUnsecuredNotesDueApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccruedRebates" abstract="false" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A350SeniorUnsecuredNotesDueFebruary2025Member" abstract="true" name="A350SeniorUnsecuredNotesDueFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GalapagosMember" abstract="true" name="GalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TmunityTherapeuticsMember" abstract="true" name="TmunityTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A365SeniorUnsecuredNotesDueMarch2026Member" abstract="true" name="A365SeniorUnsecuredNotesDueMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A475SeniorUnsecuredNotesDueMarch2046Member" abstract="true" name="A475SeniorUnsecuredNotesDueMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A250SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A250SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyMaterialTransferAgreementsNumber" abstract="false" name="LossContingencyMaterialTransferAgreementsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherHepatitisCVirusProductsMember" abstract="true" name="OtherHepatitisCVirusProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LiverDiseaseMember" abstract="true" name="LiverDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OncologyProductMember" abstract="true" name="OncologyProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsYescartaMember" abstract="true" name="CellTherapyProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HepcludexMember" abstract="true" name="HepcludexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_VekluryMember" abstract="true" name="VekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetMeasurementInput" abstract="false" name="IndefiniteLivedIntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_TrodelvyMember" abstract="true" name="TrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" abstract="true" name="InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A400SeniorUnsecuredNotesDueSeptember2036Member" abstract="true" name="A400SeniorUnsecuredNotesDueSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A295SeniorUnsecuredNotesDueMarch2027Member" abstract="true" name="A295SeniorUnsecuredNotesDueMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A415SeniorUnsecuredNotesDueMarch2047Member" abstract="true" name="A415SeniorUnsecuredNotesDueMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" abstract="false" name="EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ArcellxIncMember" abstract="true" name="ArcellxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorNotesAndMediumTermNotesMember" abstract="true" name="SeniorNotesAndMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsGrossReclassified" abstract="false" name="FiniteLivedIntangibleAssetsGrossReclassified" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AxicabtageneciloleucelDLBCLMember" abstract="true" name="AxicabtageneciloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PreExposureProphylaxisMember" abstract="true" name="PreExposureProphylaxisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyPartiesAppealedNumber" abstract="false" name="LossContingencyPartiesAppealedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialFutureMilestonePaymentsMaximum" abstract="false" name="PotentialFutureMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A450SeniorUnsecuredNotesDueFebruary2045Member" abstract="true" name="A450SeniorUnsecuredNotesDueFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PionyrImmunotherapeuticsIncMember" abstract="true" name="PionyrImmunotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A565SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="A565SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2032ExpirationMember" abstract="true" name="EuropeanPatentClaims2032ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A370SeniorUnsecuredNotesDueApril2024Member" abstract="true" name="A370SeniorUnsecuredNotesDueApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A460SeniorUnsecuredNotesDueSeptember2035Member" abstract="true" name="A460SeniorUnsecuredNotesDueSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GlobalStrategicCollaborationAgreementMember" abstract="true" name="GlobalStrategicCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_RevenuePerformanceObligationPercentageOfUSProfits" abstract="false" name="RevenuePerformanceObligationPercentageOfUSProfits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>gild-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c106b7c8-2bb1-4b42-ab62-c7781606086b,g:b0acd2cc-13f9-458d-8974-066f309efac0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7ec1c6e3-511f-45fd-873e-df08b0204c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:to="loc_us-gaap_AssetsCurrent_7ec1c6e3-511f-45fd-873e-df08b0204c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_415a10b5-95cd-4873-82bf-3f83d6d0525d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_415a10b5-95cd-4873-82bf-3f83d6d0525d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_91f51a28-be9b-4fc7-a63b-a30c2a91f8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_91f51a28-be9b-4fc7-a63b-a30c2a91f8d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8baa751-c237-4f92-8b0e-3b20e576a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8baa751-c237-4f92-8b0e-3b20e576a13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b39edca3-05e6-475a-a494-e17c95c2723c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:to="loc_us-gaap_Goodwill_b39edca3-05e6-475a-a494-e17c95c2723c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_23d72632-5634-4148-be50-37cdc9e534a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8c8d22ea-c17b-40d9-96e0-b535767cd292" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_23d72632-5634-4148-be50-37cdc9e534a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_65016031-2c9f-4398-a906-c91a23ac0acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3df351ea-cf2f-49eb-8e7b-2c640fb741f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65016031-2c9f-4398-a906-c91a23ac0acf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3df351ea-cf2f-49eb-8e7b-2c640fb741f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_68c5a126-d50a-495d-aef7-41365778894d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65016031-2c9f-4398-a906-c91a23ac0acf" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_68c5a126-d50a-495d-aef7-41365778894d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5fe0ccc1-4fee-4c94-865a-cd21f259ddaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65016031-2c9f-4398-a906-c91a23ac0acf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5fe0ccc1-4fee-4c94-865a-cd21f259ddaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_25ef509b-9986-4ff2-b4a3-1570b6c8dc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65016031-2c9f-4398-a906-c91a23ac0acf" xlink:to="loc_us-gaap_InventoryNet_25ef509b-9986-4ff2-b4a3-1570b6c8dc91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4f3e92c-3363-4319-a292-5e14f2a075cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65016031-2c9f-4398-a906-c91a23ac0acf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4f3e92c-3363-4319-a292-5e14f2a075cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1cc77cf9-f931-4fc0-b07f-72ab34779928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a48d737d-5224-48a4-a367-3a28706bb0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cc77cf9-f931-4fc0-b07f-72ab34779928" xlink:to="loc_us-gaap_AccountsPayableCurrent_a48d737d-5224-48a4-a367-3a28706bb0de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedRebates_18c2cb72-071c-4767-a265-175ba08fe4a0" xlink:href="gild-20230331.xsd#gild_AccruedRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cc77cf9-f931-4fc0-b07f-72ab34779928" xlink:to="loc_gild_AccruedRebates_18c2cb72-071c-4767-a265-175ba08fe4a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d3a89a90-e44d-4374-8deb-29c29b73e8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cc77cf9-f931-4fc0-b07f-72ab34779928" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d3a89a90-e44d-4374-8deb-29c29b73e8ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_dec521e9-6b8e-4601-bc4c-5161434f4fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1cc77cf9-f931-4fc0-b07f-72ab34779928" xlink:to="loc_us-gaap_DebtCurrent_dec521e9-6b8e-4601-bc4c-5161434f4fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49c44ce4-737b-4db3-b519-c85b4f329879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e7bbc8aa-f8a8-4976-bd4a-c8f08204f069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49c44ce4-737b-4db3-b519-c85b4f329879" xlink:to="loc_us-gaap_PreferredStockValue_e7bbc8aa-f8a8-4976-bd4a-c8f08204f069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c5f79010-c899-47c9-8153-c7cd6035b0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49c44ce4-737b-4db3-b519-c85b4f329879" xlink:to="loc_us-gaap_CommonStockValue_c5f79010-c899-47c9-8153-c7cd6035b0d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_71855bce-cf8c-4856-b2e9-8140af0192bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49c44ce4-737b-4db3-b519-c85b4f329879" xlink:to="loc_us-gaap_AdditionalPaidInCapital_71855bce-cf8c-4856-b2e9-8140af0192bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c27c9c5-fe8a-4d9e-88f7-4c2c5dd7cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49c44ce4-737b-4db3-b519-c85b4f329879" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c27c9c5-fe8a-4d9e-88f7-4c2c5dd7cbed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32b1e4f0-3b6b-4f4c-a5e4-97745d9b8dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49c44ce4-737b-4db3-b519-c85b4f329879" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32b1e4f0-3b6b-4f4c-a5e4-97745d9b8dcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a36bf3df-77f5-4664-a0d7-d2c12c9186c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c8395d5-88fa-41be-8a36-3f16cf3fd85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a36bf3df-77f5-4664-a0d7-d2c12c9186c0" xlink:to="loc_us-gaap_StockholdersEquity_9c8395d5-88fa-41be-8a36-3f16cf3fd85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e4c799b7-6a88-4dbd-8e22-ff7efacbed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a36bf3df-77f5-4664-a0d7-d2c12c9186c0" xlink:to="loc_us-gaap_MinorityInterest_e4c799b7-6a88-4dbd-8e22-ff7efacbed2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_17751433-832b-4f08-8835-536352e3314c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_17751433-832b-4f08-8835-536352e3314c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_85a294e8-c076-4728-9fac-3e8ac38084bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_85a294e8-c076-4728-9fac-3e8ac38084bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5a4041ef-7a65-409e-ad1f-b86d594c4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5a4041ef-7a65-409e-ad1f-b86d594c4b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_02ee7015-8c61-48d9-a7c8-4d4b0cbf2864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_CommitmentsAndContingencies_02ee7015-8c61-48d9-a7c8-4d4b0cbf2864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90998c27-552d-4d69-8d6e-c26523ec6f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90998c27-552d-4d69-8d6e-c26523ec6f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_75836c89-e3e6-4924-9d97-1f766c6dba66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_LiabilitiesCurrent_75836c89-e3e6-4924-9d97-1f766c6dba66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3da3fc77-1daa-49fc-b83e-008f4a2bebc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51b6d1f8-8fbe-4f98-a2a0-863ad0c8ab27" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3da3fc77-1daa-49fc-b83e-008f4a2bebc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fbbc7ffe-e9f5-430b-b332-086c00262c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00dba139-a2be-439e-8b88-b5f1981b457c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fbbc7ffe-e9f5-430b-b332-086c00262c4b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00dba139-a2be-439e-8b88-b5f1981b457c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2c3ef16d-bd67-4452-8583-dae000bb8ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fbbc7ffe-e9f5-430b-b332-086c00262c4b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2c3ef16d-bd67-4452-8583-dae000bb8ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_70b59e63-ce00-4f37-bc77-621052e98928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fbbc7ffe-e9f5-430b-b332-086c00262c4b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_70b59e63-ce00-4f37-bc77-621052e98928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_338b14e6-70a7-4be2-b4c8-cb8c050cf1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fbbc7ffe-e9f5-430b-b332-086c00262c4b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_338b14e6-70a7-4be2-b4c8-cb8c050cf1bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1e747052-7844-4cf4-b731-be77ff43fbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fbbc7ffe-e9f5-430b-b332-086c00262c4b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1e747052-7844-4cf4-b731-be77ff43fbe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7733c3b7-16f5-4f86-92f0-82d073af909f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_324702fd-bfb5-4377-98a4-b53d8b7fe0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7733c3b7-16f5-4f86-92f0-82d073af909f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_324702fd-bfb5-4377-98a4-b53d8b7fe0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_156d9dae-2488-44d6-a573-2cacc3551124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7733c3b7-16f5-4f86-92f0-82d073af909f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_156d9dae-2488-44d6-a573-2cacc3551124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_789022ed-e76f-4b9d-aabe-38566007910e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_db029e53-c4ac-443a-983f-e1e2aea0e819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_789022ed-e76f-4b9d-aabe-38566007910e" xlink:to="loc_us-gaap_CostsAndExpenses_db029e53-c4ac-443a-983f-e1e2aea0e819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_825503c6-88a4-438b-bd50-f5b9de756bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_789022ed-e76f-4b9d-aabe-38566007910e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_825503c6-88a4-438b-bd50-f5b9de756bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2706981-c1f3-4ad4-a202-03059afefb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ec0f1a30-7370-4a40-9829-c00d687284fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2706981-c1f3-4ad4-a202-03059afefb98" xlink:to="loc_us-gaap_OperatingIncomeLoss_ec0f1a30-7370-4a40-9829-c00d687284fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1b119f26-3a35-47aa-987c-56ea85f76a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2706981-c1f3-4ad4-a202-03059afefb98" xlink:to="loc_us-gaap_InterestExpense_1b119f26-3a35-47aa-987c-56ea85f76a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_020236bd-425f-41a9-a0c2-554d1b030990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e2706981-c1f3-4ad4-a202-03059afefb98" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_020236bd-425f-41a9-a0c2-554d1b030990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3c99aa7-5846-4245-9d7a-c5c9f7128b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c370e2d6-e13b-4090-a0a2-ca9b757d0184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f3c99aa7-5846-4245-9d7a-c5c9f7128b11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c370e2d6-e13b-4090-a0a2-ca9b757d0184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_887f88d6-90cb-4b81-a713-8c0f1b26f4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f3c99aa7-5846-4245-9d7a-c5c9f7128b11" xlink:to="loc_us-gaap_ProfitLoss_887f88d6-90cb-4b81-a713-8c0f1b26f4dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b7f3ef00-d8df-4b7d-beeb-d3e787e7dc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_546c0b86-053b-45c1-993f-2fa4d4c07c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b7f3ef00-d8df-4b7d-beeb-d3e787e7dc6c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_546c0b86-053b-45c1-993f-2fa4d4c07c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_aa6394c6-9655-44ea-8529-2b28b489ee31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b7f3ef00-d8df-4b7d-beeb-d3e787e7dc6c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_aa6394c6-9655-44ea-8529-2b28b489ee31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36a266be-519d-461f-9b2c-f2da4137f70a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0989ab38-8a01-4311-a894-200a3c338ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36a266be-519d-461f-9b2c-f2da4137f70a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0989ab38-8a01-4311-a894-200a3c338ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_14f30c5a-25a5-4a0f-a16a-21a4a1efabbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36a266be-519d-461f-9b2c-f2da4137f70a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_14f30c5a-25a5-4a0f-a16a-21a4a1efabbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3c6bd4e7-f75e-422f-b90b-5c8356e53976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36a266be-519d-461f-9b2c-f2da4137f70a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3c6bd4e7-f75e-422f-b90b-5c8356e53976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_510e93cc-f155-4340-8133-619ab8929e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_938abd87-a1dd-4867-9680-1af28d8f3175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_510e93cc-f155-4340-8133-619ab8929e41" xlink:to="loc_us-gaap_ProfitLoss_938abd87-a1dd-4867-9680-1af28d8f3175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1b308a0d-e240-4b01-b49a-135a17353cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_510e93cc-f155-4340-8133-619ab8929e41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1b308a0d-e240-4b01-b49a-135a17353cb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499b93f2-d8c9-4ab6-8461-cb7edbd1a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_063b001d-c496-4d2f-8da7-4e0bf371b399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499b93f2-d8c9-4ab6-8461-cb7edbd1a60c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_063b001d-c496-4d2f-8da7-4e0bf371b399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_87cdb8f7-fb6a-4183-9da0-f065f307a2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499b93f2-d8c9-4ab6-8461-cb7edbd1a60c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_87cdb8f7-fb6a-4183-9da0-f065f307a2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2cd4b839-35ab-4553-8915-023df4f68e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_185d5e3c-0ef0-4313-9f9d-6d42858de573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2cd4b839-35ab-4553-8915-023df4f68e81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_185d5e3c-0ef0-4313-9f9d-6d42858de573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_46fe679d-cdfa-401b-ba36-8f71596719a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2cd4b839-35ab-4553-8915-023df4f68e81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_46fe679d-cdfa-401b-ba36-8f71596719a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8f783d21-61c1-4c30-bc2e-b054d5b3d483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_Depreciation_8f783d21-61c1-4c30-bc2e-b054d5b3d483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4b2b5b41-a9ae-4611-bbb2-cd130271587b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4b2b5b41-a9ae-4611-bbb2-cd130271587b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7a656b2e-4907-450c-bc14-63a32075781b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_ProfitLoss_7a656b2e-4907-450c-bc14-63a32075781b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9a6c1e4c-28a3-45d5-844b-8dc757595b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9a6c1e4c-28a3-45d5-844b-8dc757595b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f615b498-a9f9-4c80-a0c6-7f6a2fdcff06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f615b498-a9f9-4c80-a0c6-7f6a2fdcff06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c5e215a3-5923-44d2-bd7d-986f08254d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c5e215a3-5923-44d2-bd7d-986f08254d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_81c3c2b8-dcda-4769-b283-eb67d5e18ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_81c3c2b8-dcda-4769-b283-eb67d5e18ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b98617b-d657-4597-9666-e21acee0c4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b98617b-d657-4597-9666-e21acee0c4f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a772c19c-a8c7-4591-962c-8d98c8831153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a772c19c-a8c7-4591-962c-8d98c8831153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_13a5d170-9e93-43a5-a06b-6f121310d086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_13a5d170-9e93-43a5-a06b-6f121310d086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_9976e5f9-211b-487c-b5d5-c65a2a60b87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_9976e5f9-211b-487c-b5d5-c65a2a60b87f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_9e01d347-d51a-4e9c-b781-acf8a71495de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_AdjustmentForAmortization_9e01d347-d51a-4e9c-b781-acf8a71495de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4699493d-49bc-40fd-bd05-7495040208dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4699493d-49bc-40fd-bd05-7495040208dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_73a068b8-62a0-4778-9b4e-83ecf97efd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_ShareBasedCompensation_73a068b8-62a0-4778-9b4e-83ecf97efd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_627fef7a-130e-4438-8e2f-a90a2fe6de5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3136941d-4f3f-4f0a-bb3b-d065621dfd05" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_627fef7a-130e-4438-8e2f-a90a2fe6de5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c64d3d5d-458f-4f49-8e89-90c0446ebfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e12ad431-1e95-4bc5-8d13-d27d070d5c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c64d3d5d-458f-4f49-8e89-90c0446ebfa8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e12ad431-1e95-4bc5-8d13-d27d070d5c06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56716301-a7c9-428e-b2d8-93b3b4e5e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c64d3d5d-458f-4f49-8e89-90c0446ebfa8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56716301-a7c9-428e-b2d8-93b3b4e5e8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24a63070-c4d8-4ee1-8501-89f2576d32f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c64d3d5d-458f-4f49-8e89-90c0446ebfa8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_24a63070-c4d8-4ee1-8501-89f2576d32f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe99539c-6e34-4aee-a31e-d9f80f9ba09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c64d3d5d-458f-4f49-8e89-90c0446ebfa8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe99539c-6e34-4aee-a31e-d9f80f9ba09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca2fe56d-1d23-4f24-9366-8770e2dfd462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4b05e457-eafb-4328-96f5-0d244997549f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca2fe56d-1d23-4f24-9366-8770e2dfd462" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4b05e457-eafb-4328-96f5-0d244997549f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_fe226c6b-c45b-4bd1-b5c9-ff112f29761f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca2fe56d-1d23-4f24-9366-8770e2dfd462" xlink:to="loc_us-gaap_PaymentsOfDividends_fe226c6b-c45b-4bd1-b5c9-ff112f29761f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d1947bd5-5935-49b5-931f-611414c24bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca2fe56d-1d23-4f24-9366-8770e2dfd462" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d1947bd5-5935-49b5-931f-611414c24bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4cb57f23-3f15-44f3-8308-33ef893cc5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca2fe56d-1d23-4f24-9366-8770e2dfd462" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_4cb57f23-3f15-44f3-8308-33ef893cc5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_372261e9-8762-4c23-b7e8-6bcd8f78c6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca2fe56d-1d23-4f24-9366-8770e2dfd462" xlink:to="loc_us-gaap_RepaymentsOfDebt_372261e9-8762-4c23-b7e8-6bcd8f78c6e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_2832ff2a-3853-4459-b111-361fe2ac954c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_2832ff2a-3853-4459-b111-361fe2ac954c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dfd88065-702b-402b-a170-5c49c40ecef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dfd88065-702b-402b-a170-5c49c40ecef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cdd3346a-68fa-496c-8870-71caabc94dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cdd3346a-68fa-496c-8870-71caabc94dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b59ecf64-3c29-4a7d-83ae-22a72ded4e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b59ecf64-3c29-4a7d-83ae-22a72ded4e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_085121d9-6054-43d5-b2d0-375c08db5697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_085121d9-6054-43d5-b2d0-375c08db5697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a6c18760-f2bb-4b9e-a3c7-bd943c89467c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_a6c18760-f2bb-4b9e-a3c7-bd943c89467c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_aa4dedc6-2511-4ef5-95ab-50ad34728063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1b00f8b2-e39f-4f67-9188-8c7e9cda3300" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_aa4dedc6-2511-4ef5-95ab-50ad34728063" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8e4f56a3-d0c7-4323-813d-d6561cc4c741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d2043ee1-3ffd-4bfe-b76c-0aa5d0eee7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8e4f56a3-d0c7-4323-813d-d6561cc4c741" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d2043ee1-3ffd-4bfe-b76c-0aa5d0eee7b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e07a57df-9485-43fa-a397-0435d6e507f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8e4f56a3-d0c7-4323-813d-d6561cc4c741" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e07a57df-9485-43fa-a397-0435d6e507f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_35d86563-4e6e-43fd-bc4d-002aaa52f44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8e4f56a3-d0c7-4323-813d-d6561cc4c741" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_35d86563-4e6e-43fd-bc4d-002aaa52f44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_16541087-2fde-4967-9599-f6652fbc3ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_27a2f7f5-7822-424f-886d-299a6da646dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_16541087-2fde-4967-9599-f6652fbc3ee9" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_27a2f7f5-7822-424f-886d-299a6da646dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_15947f8b-3728-4b27-8429-ea0782a21379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_16541087-2fde-4967-9599-f6652fbc3ee9" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_15947f8b-3728-4b27-8429-ea0782a21379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_22a94347-1934-4070-8549-ef7a009ddf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_16541087-2fde-4967-9599-f6652fbc3ee9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_22a94347-1934-4070-8549-ef7a009ddf3b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba2f5546-1c37-4c22-9b51-a661ce912b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2061280c-5ca2-46ad-b4d2-2bd7c7e8c149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba2f5546-1c37-4c22-9b51-a661ce912b4b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2061280c-5ca2-46ad-b4d2-2bd7c7e8c149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1ac32174-50ea-488a-911b-b1f33c4a84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba2f5546-1c37-4c22-9b51-a661ce912b4b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_1ac32174-50ea-488a-911b-b1f33c4a84b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97de0f82-14ca-4ae8-b5be-2d1f2b930241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba2f5546-1c37-4c22-9b51-a661ce912b4b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97de0f82-14ca-4ae8-b5be-2d1f2b930241" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_542d9851-f9f5-4d01-a1a2-9319c6669c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c81699de-0760-4288-a446-f9710926b4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_542d9851-f9f5-4d01-a1a2-9319c6669c6e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c81699de-0760-4288-a446-f9710926b4cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_57fbccf3-b63a-4b83-98ca-07a71b9d5d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_542d9851-f9f5-4d01-a1a2-9319c6669c6e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_57fbccf3-b63a-4b83-98ca-07a71b9d5d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d055b7c-4399-4444-b65d-a1d668ab849e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_50f510d5-98a7-455e-92ad-3983b3edeec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d055b7c-4399-4444-b65d-a1d668ab849e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_50f510d5-98a7-455e-92ad-3983b3edeec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b2feabc7-4d63-4967-8076-2cd090e2a1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1d055b7c-4399-4444-b65d-a1d668ab849e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b2feabc7-4d63-4967-8076-2cd090e2a1bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6dc69703-ccdf-446d-bc59-55e9ed02edc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3fc1fb71-81b0-49b2-91be-b42c2d3e114d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6dc69703-ccdf-446d-bc59-55e9ed02edc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3fc1fb71-81b0-49b2-91be-b42c2d3e114d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_6048c5dd-385e-4f60-b821-845bd5b6f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6dc69703-ccdf-446d-bc59-55e9ed02edc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_6048c5dd-385e-4f60-b821-845bd5b6f2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_e0d0cf57-220c-4dc3-91a4-b3028528f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6dc69703-ccdf-446d-bc59-55e9ed02edc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_e0d0cf57-220c-4dc3-91a4-b3028528f5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a6e89618-2d88-40e7-8f53-0a50eecfabfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6dc69703-ccdf-446d-bc59-55e9ed02edc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a6e89618-2d88-40e7-8f53-0a50eecfabfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_99fa3ea5-7b2a-4ed9-b002-42d55db443e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3083f99b-f2e1-4629-8e39-476580a959fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_99fa3ea5-7b2a-4ed9-b002-42d55db443e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_3083f99b-f2e1-4629-8e39-476580a959fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a5e14e85-b592-4463-b91d-8d7e95de7436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_99fa3ea5-7b2a-4ed9-b002-42d55db443e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_a5e14e85-b592-4463-b91d-8d7e95de7436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_74793322-7b32-4200-b536-61288641e89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_99fa3ea5-7b2a-4ed9-b002-42d55db443e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_74793322-7b32-4200-b536-61288641e89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_78ec1307-2ad2-4e3e-b5db-0bb2810db83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_99fa3ea5-7b2a-4ed9-b002-42d55db443e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_78ec1307-2ad2-4e3e-b5db-0bb2810db83f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b55777fc-0771-4a79-a32b-1afb18e17459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_21073a19-ae7b-4065-8f8c-1eacf7bc08b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b55777fc-0771-4a79-a32b-1afb18e17459" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_21073a19-ae7b-4065-8f8c-1eacf7bc08b6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_9b736f60-b195-42dc-abf1-5faa9d8fba8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e71415f0-084c-4191-b30c-0e5a5df9add6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_9b736f60-b195-42dc-abf1-5faa9d8fba8a" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e71415f0-084c-4191-b30c-0e5a5df9add6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9ff03d93-b5d9-4ce6-8da8-13f2fa3cc054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_9b736f60-b195-42dc-abf1-5faa9d8fba8a" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_9ff03d93-b5d9-4ce6-8da8-13f2fa3cc054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_5e4a2cf9-1bbe-410d-9885-5a8a77e0a008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_9b736f60-b195-42dc-abf1-5faa9d8fba8a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_5e4a2cf9-1bbe-410d-9885-5a8a77e0a008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3b157315-041e-462f-9318-fd3e8c4a5c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_9e45151c-f80b-418b-842c-ea5354d3300e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3b157315-041e-462f-9318-fd3e8c4a5c46" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_9e45151c-f80b-418b-842c-ea5354d3300e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f3ce1ba0-d4f4-42a6-8b2f-5419ecf625c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3b157315-041e-462f-9318-fd3e8c4a5c46" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f3ce1ba0-d4f4-42a6-8b2f-5419ecf625c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7e65a0ca-6a59-46e2-ab07-afde5c1a8147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3b157315-041e-462f-9318-fd3e8c4a5c46" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_7e65a0ca-6a59-46e2-ab07-afde5c1a8147" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ea8cdb0-5b9f-420d-a814-03d7d344c37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f818dbb-add4-486c-9c19-016de07e91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ea8cdb0-5b9f-420d-a814-03d7d344c37c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f818dbb-add4-486c-9c19-016de07e91e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a85a40ee-3989-4b48-ae2c-37db68c6082a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ea8cdb0-5b9f-420d-a814-03d7d344c37c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a85a40ee-3989-4b48-ae2c-37db68c6082a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_a22ab2df-334a-442c-a523-509961c73101" xlink:href="gild-20230331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ea8cdb0-5b9f-420d-a814-03d7d344c37c" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_a22ab2df-334a-442c-a523-509961c73101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_07e4d128-c759-4ca1-80c0-71bc22e151fd" xlink:href="gild-20230331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8a8eca97-396d-46ad-9e31-594f315c6351" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_07e4d128-c759-4ca1-80c0-71bc22e151fd" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8a8eca97-396d-46ad-9e31-594f315c6351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d9f72883-778e-49a0-bb78-30305797f05c" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_07e4d128-c759-4ca1-80c0-71bc22e151fd" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d9f72883-778e-49a0-bb78-30305797f05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef17e9aa-81e5-4266-8fc7-6952fa3b69f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f9f9ea9-e6cd-4d2c-8eb6-2d03069e589a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef17e9aa-81e5-4266-8fc7-6952fa3b69f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8f9f9ea9-e6cd-4d2c-8eb6-2d03069e589a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_f7f1689a-c328-4d28-a716-d84e432e4632" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef17e9aa-81e5-4266-8fc7-6952fa3b69f0" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_f7f1689a-c328-4d28-a716-d84e432e4632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_524a690c-a915-46cc-90d3-7d2ab588dda4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef17e9aa-81e5-4266-8fc7-6952fa3b69f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_524a690c-a915-46cc-90d3-7d2ab588dda4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a75135a2-ae88-4485-8e94-5b94205a68d8" xlink:href="gild-20230331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_69d4cc21-4602-4c66-85f4-c1c745041db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a75135a2-ae88-4485-8e94-5b94205a68d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_69d4cc21-4602-4c66-85f4-c1c745041db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4c1327be-7bcc-4338-8389-ecb3f6fb31db" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a75135a2-ae88-4485-8e94-5b94205a68d8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_4c1327be-7bcc-4338-8389-ecb3f6fb31db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4679cb44-ac89-4cf6-b314-142917a6851c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5bbef41f-aae1-4e3a-ade9-1b62c1a1c7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4679cb44-ac89-4cf6-b314-142917a6851c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5bbef41f-aae1-4e3a-ade9-1b62c1a1c7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d3e8411b-bb73-4b81-aa91-4a541b95ad94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4679cb44-ac89-4cf6-b314-142917a6851c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d3e8411b-bb73-4b81-aa91-4a541b95ad94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_71eaaf10-ef26-44c9-a4e3-2656af727bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1632a64c-22cc-4c3a-b4d4-6d951be28601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_71eaaf10-ef26-44c9-a4e3-2656af727bbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1632a64c-22cc-4c3a-b4d4-6d951be28601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_99172e1d-f251-4f96-97e0-1812619c2b09" xlink:href="gild-20230331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_71eaaf10-ef26-44c9-a4e3-2656af727bbd" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_99172e1d-f251-4f96-97e0-1812619c2b09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_18320411-9cb5-473f-86bb-df4a92780edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_18320411-9cb5-473f-86bb-df4a92780edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_34e342be-34de-47b6-974d-78ffcc34830c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_34e342be-34de-47b6-974d-78ffcc34830c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1391fa97-d95a-4a15-8cd2-b83a4f6f255e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1391fa97-d95a-4a15-8cd2-b83a4f6f255e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f4b63c1e-ff6b-4531-a4d8-0152348f0c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f4b63c1e-ff6b-4531-a4d8-0152348f0c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c6d224ef-4277-4987-a72b-158dd0d11e54" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:to="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c6d224ef-4277-4987-a72b-158dd0d11e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6f78b908-ed09-4955-9bef-b51fb179b8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f64e70cf-9649-4de1-91fe-9b15b787007a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6f78b908-ed09-4955-9bef-b51fb179b8b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e66bfcf2-27af-4d4e-b8ff-0ec1a35822ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3d4f579f-6f90-4ab0-a607-ac5292df356c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_e66bfcf2-27af-4d4e-b8ff-0ec1a35822ec" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3d4f579f-6f90-4ab0-a607-ac5292df356c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_b00a5ea4-b51e-46ed-8f85-9115748ac174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_e66bfcf2-27af-4d4e-b8ff-0ec1a35822ec" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_b00a5ea4-b51e-46ed-8f85-9115748ac174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_b3a1304f-ee35-492f-af9e-d15ea148f1c2" xlink:href="gild-20230331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_e66bfcf2-27af-4d4e-b8ff-0ec1a35822ec" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_b3a1304f-ee35-492f-af9e-d15ea148f1c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_1c9280f7-ac1b-4c53-9377-77520297898e" xlink:href="gild-20230331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_e66bfcf2-27af-4d4e-b8ff-0ec1a35822ec" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_1c9280f7-ac1b-4c53-9377-77520297898e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_b5af33ae-7022-47ac-976f-c0a4d1dead89" xlink:href="gild-20230331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_dc5c67de-ecd0-4a8b-b0da-6e955fa9bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_b5af33ae-7022-47ac-976f-c0a4d1dead89" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_dc5c67de-ecd0-4a8b-b0da-6e955fa9bcde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_87e94da5-d6f5-49b2-9140-75679f9b9fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_b5af33ae-7022-47ac-976f-c0a4d1dead89" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_87e94da5-d6f5-49b2-9140-75679f9b9fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e1a20533-b667-4c38-9d12-8362ccc6e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_b5af33ae-7022-47ac-976f-c0a4d1dead89" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e1a20533-b667-4c38-9d12-8362ccc6e1bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_c47d3cee-4c6e-46be-900e-1aa81a95317e" xlink:href="gild-20230331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_033b2120-f601-4d1e-8ff0-3144912fb08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_c47d3cee-4c6e-46be-900e-1aa81a95317e" xlink:to="loc_us-gaap_InventoryNet_033b2120-f601-4d1e-8ff0-3144912fb08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_3949dad6-7444-4456-86ef-5e9f3dcadf44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_c47d3cee-4c6e-46be-900e-1aa81a95317e" xlink:to="loc_us-gaap_InventoryNoncurrent_3949dad6-7444-4456-86ef-5e9f3dcadf44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b1976d19-437a-4213-ade4-966df5e1d208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0320f4a1-3de3-4214-bbeb-370e666bb9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b1976d19-437a-4213-ade4-966df5e1d208" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0320f4a1-3de3-4214-bbeb-370e666bb9e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_7c253368-5f04-4174-b833-5ecbb37d7488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b1976d19-437a-4213-ade4-966df5e1d208" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_7c253368-5f04-4174-b833-5ecbb37d7488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_23a765da-8006-4694-bfda-d6545790fb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b1976d19-437a-4213-ade4-966df5e1d208" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_23a765da-8006-4694-bfda-d6545790fb14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0b847a1a-0fb4-411b-be42-b2314dec08e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_b1976d19-437a-4213-ade4-966df5e1d208" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0b847a1a-0fb4-411b-be42-b2314dec08e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_dabfc0af-3ad2-4514-ad0d-9dabbb51bcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c5c56970-ac33-4d30-bf4e-861a180b91f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_dabfc0af-3ad2-4514-ad0d-9dabbb51bcfb" xlink:to="loc_us-gaap_LongTermDebtCurrent_c5c56970-ac33-4d30-bf4e-861a180b91f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_204b86fe-8786-4630-a92b-17e991c5c747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_dabfc0af-3ad2-4514-ad0d-9dabbb51bcfb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_204b86fe-8786-4630-a92b-17e991c5c747" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c33b8c5c-f376-41ea-9fc1-3460a8fb6d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f026b45-dfce-4489-b575-6fe60b120b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c33b8c5c-f376-41ea-9fc1-3460a8fb6d32" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6f026b45-dfce-4489-b575-6fe60b120b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_268fcdf9-c4bf-4f1b-b244-40d1c2cab39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c33b8c5c-f376-41ea-9fc1-3460a8fb6d32" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_268fcdf9-c4bf-4f1b-b244-40d1c2cab39e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>gild-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c106b7c8-2bb1-4b42-ab62-c7781606086b,g:b0acd2cc-13f9-458d-8974-066f309efac0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" xlink:type="extended" id="ib537e271895a445cb11e944e0644e573_CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e08f4d9d-d659-41b3-bcc7-32f6e0fe14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_RevenuesAbstract_e08f4d9d-d659-41b3-bcc7-32f6e0fe14e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_083ffd9c-fd1a-43a7-b20b-aafd6d9a67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e08f4d9d-d659-41b3-bcc7-32f6e0fe14e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_083ffd9c-fd1a-43a7-b20b-aafd6d9a67fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1abab8c0-5c86-4503-9eef-0f06b1432876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1abab8c0-5c86-4503-9eef-0f06b1432876" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c76d17e-5a67-4cc2-8c08-b82d72aabfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c76d17e-5a67-4cc2-8c08-b82d72aabfbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_edf3617b-17cd-4822-b527-7db740466f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_edf3617b-17cd-4822-b527-7db740466f2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3a751364-0e20-41e0-97ad-7de191749cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3a751364-0e20-41e0-97ad-7de191749cfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fcc3f4-fd57-4d16-b9b3-82852e7e38be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fcc3f4-fd57-4d16-b9b3-82852e7e38be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7745d5e4-9a2a-4482-a5da-571aa353f294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_CostsAndExpenses_7745d5e4-9a2a-4482-a5da-571aa353f294" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eda15d49-2677-4da3-a1cb-c043ba18e203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_OperatingIncomeLoss_eda15d49-2677-4da3-a1cb-c043ba18e203" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fa5a5a43-e0f1-4736-9734-1bea12b3986b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_InterestExpense_fa5a5a43-e0f1-4736-9734-1bea12b3986b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_11da8337-9902-4bcc-9c0d-e726c611e6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_11da8337-9902-4bcc-9c0d-e726c611e6f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0deb02db-2919-4e5d-8b8a-c7b51aea683a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0deb02db-2919-4e5d-8b8a-c7b51aea683a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_194f4248-dbb9-4267-9a41-f153e18d7136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_194f4248-dbb9-4267-9a41-f153e18d7136" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3dad7c30-02eb-4513-b1f9-09cb2cb13224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_ProfitLoss_3dad7c30-02eb-4513-b1f9-09cb2cb13224" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3a880fe-9d28-4c44-9772-1e1f7d86cc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3a880fe-9d28-4c44-9772-1e1f7d86cc34" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81432967-7916-4f8e-abab-9f1c4ddecd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_NetIncomeLoss_81432967-7916-4f8e-abab-9f1c4ddecd0b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1478b024-689b-432e-8a3d-7afbb49de0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_EarningsPerShareBasic_1478b024-689b-432e-8a3d-7afbb49de0a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9fcf806-28c6-4ea9-b344-cc1dd9c022cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9fcf806-28c6-4ea9-b344-cc1dd9c022cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e5b65f22-269f-4ec9-abc6-02b545518cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e5b65f22-269f-4ec9-abc6-02b545518cad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03447f95-abfb-4650-b081-7df5c49cd41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03447f95-abfb-4650-b081-7df5c49cd41e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:to="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:to="loc_srt_ProductsAndServicesDomain_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:to="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_31b894c5-68cf-4dd1-ba63-d9e94631b29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:to="loc_us-gaap_ProductMember_31b894c5-68cf-4dd1-ba63-d9e94631b29a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_f1f52ff5-b603-47bf-8c08-68f37e58548a" xlink:href="gild-20230331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:to="loc_gild_RoyaltyContractAndOtherMember_f1f52ff5-b603-47bf-8c08-68f37e58548a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended" id="i9e18941a2fae4cc0b23ecda3a6fc678e_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_47c2d947-4c11-4a6d-b27d-8943d4db16a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_47c2d947-4c11-4a6d-b27d-8943d4db16a4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6d8cf10-a1ac-4847-a760-26046e33a4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6d8cf10-a1ac-4847-a760-26046e33a4f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13c5788e-c0d9-4a12-adda-d1d39ca123fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13c5788e-c0d9-4a12-adda-d1d39ca123fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cffc5912-e90b-4637-864e-0add53972c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_ProfitLoss_cffc5912-e90b-4637-864e-0add53972c05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27ee4c1f-0b2c-40f8-b28e-1d7dfd6325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27ee4c1f-0b2c-40f8-b28e-1d7dfd6325a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69076b28-001b-48bd-b0ed-327e29bf200c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69076b28-001b-48bd-b0ed-327e29bf200c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0c9e42ea-f948-48f0-a62f-ad74a6a8f4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0c9e42ea-f948-48f0-a62f-ad74a6a8f4bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb708872-1ebe-461c-ae15-430abc460642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb708872-1ebe-461c-ae15-430abc460642" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1d08ff9-d334-4638-b5c4-73364544a41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1d08ff9-d334-4638-b5c4-73364544a41f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07be9fb0-5cf2-4443-9ed4-533a78162966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07be9fb0-5cf2-4443-9ed4-533a78162966" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ebf0f035-9c6c-47c4-8c01-3dbfc308a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ebf0f035-9c6c-47c4-8c01-3dbfc308a93f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_9eeb78ec-14a8-4b0b-b770-eedc10f2d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_9eeb78ec-14a8-4b0b-b770-eedc10f2d0a8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f622c53-849a-4dc7-a6c9-231a4a6cc47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f622c53-849a-4dc7-a6c9-231a4a6cc47e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f6b7a877-0240-4834-b2c9-e41a8f1842ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f6b7a877-0240-4834-b2c9-e41a8f1842ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_944b6a63-e0d2-4355-8445-129a1301dc88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_Dividends_944b6a63-e0d2-4355-8445-129a1301dc88" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4db9cb56-c701-4f7a-bf5f-ec67a13563bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78c68046-e423-4d8b-9c92-f73e8f416813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_47c2d947-4c11-4a6d-b27d-8943d4db16a4" xlink:to="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_876ccd2c-fc57-484d-8927-8ea04c4af8e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:to="loc_us-gaap_EquityComponentDomain_876ccd2c-fc57-484d-8927-8ea04c4af8e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:to="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6693d0a-11d4-4d11-94c6-f99d334964f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_CommonStockMember_d6693d0a-11d4-4d11-94c6-f99d334964f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_21ce1830-209f-46c4-b0a3-dfb3d8b9c529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_21ce1830-209f-46c4-b0a3-dfb3d8b9c529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f627a0c9-a334-41e7-a8d7-0475a8ba4b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f627a0c9-a334-41e7-a8d7-0475a8ba4b9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_437291a8-e018-4f19-8d15-0de757738b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_RetainedEarningsMember_437291a8-e018-4f19-8d15-0de757738b97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ef90f758-2fe9-4ce3-9a97-cc8ed230c613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ef90f758-2fe9-4ce3-9a97-cc8ed230c613" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="i365e4bb68f94433bb5d859488a48ff17_ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_70dba725-7ad9-4829-bce4-a36287cb9fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_70dba725-7ad9-4829-bce4-a36287cb9fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_c97101d6-255f-4739-9e20-c4a1e5a84c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_c97101d6-255f-4739-9e20-c4a1e5a84c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:to="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:to="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_1ba439aa-43dd-4422-91de-c3522943ac51_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:to="loc_srt_RestatementDomain_1ba439aa-43dd-4422-91de-c3522943ac51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_41ecf19f-d549-4bc1-b887-bc6569429e62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:to="loc_srt_RestatementDomain_41ecf19f-d549-4bc1-b887-bc6569429e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_030ac99c-ca8c-4811-bc14-4ceaa35b1323" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_41ecf19f-d549-4bc1-b887-bc6569429e62" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_030ac99c-ca8c-4811-bc14-4ceaa35b1323" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESSummaryofDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails" xlink:type="extended" id="i8998c62a53594b30831b47d7905da665_REVENUESSummaryofDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_16b7e99d-6315-444f-82f3-1bcb3f774817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ecdc80-3731-4092-8453-7678f578b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_16b7e99d-6315-444f-82f3-1bcb3f774817" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ecdc80-3731-4092-8453-7678f578b5de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_16b7e99d-6315-444f-82f3-1bcb3f774817" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:to="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_81421ff1-c086-4026-89fd-5189471ae030_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:to="loc_srt_ProductsAndServicesDomain_81421ff1-c086-4026-89fd-5189471ae030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:to="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:to="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:href="gild-20230331.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_65ea3dd9-7452-4595-972a-7d162532949a" xlink:href="gild-20230331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsBiktarvyMember_65ea3dd9-7452-4595-972a-7d162532949a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_4ecd5080-fafe-4450-bcc2-90e3fe37fac3" xlink:href="gild-20230331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_4ecd5080-fafe-4450-bcc2-90e3fe37fac3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_05c2e338-cb68-46e6-87e6-b6accfe3c595" xlink:href="gild-20230331.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsDescovyMember_05c2e338-cb68-46e6-87e6-b6accfe3c595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_934520b7-b3f2-4f84-a034-824ad1771abd" xlink:href="gild-20230331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsGenvoyaMember_934520b7-b3f2-4f84-a034-824ad1771abd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_d9c2555f-7373-4b51-9b2a-b976584d055c" xlink:href="gild-20230331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsOdefseyMember_d9c2555f-7373-4b51-9b2a-b976584d055c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_fac34f75-e49d-49b7-af95-f9062dda3ff2" xlink:href="gild-20230331.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsStribildMember_fac34f75-e49d-49b7-af95-f9062dda3ff2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_a9bd4743-f5db-4dcd-8e84-f25bd133f27a" xlink:href="gild-20230331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsTruvadaMember_a9bd4743-f5db-4dcd-8e84-f25bd133f27a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_9ca057c6-d3dd-4a90-a7a2-e0651fd2ddce" xlink:href="gild-20230331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_9ca057c6-d3dd-4a90-a7a2-e0651fd2ddce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_b4a3f895-3600-4cc5-b452-b8ec96c4af85" xlink:href="gild-20230331.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_ProductsOtherHIVMember_b4a3f895-3600-4cc5-b452-b8ec96c4af85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:href="gild-20230331.xsd#gild_OncologyProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_8bea6b7f-e9e3-4ce3-a3d2-2476ac8dc49a" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:to="loc_gild_CellTherapyProductsTecartusMember_8bea6b7f-e9e3-4ce3-a3d2-2476ac8dc49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_e8edf774-802a-42c3-9253-967702e45b34" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:to="loc_gild_CellTherapyProductsYescartaMember_e8edf774-802a-42c3-9253-967702e45b34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_d89752c6-410d-4519-a483-a5654e6a2499" xlink:href="gild-20230331.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:to="loc_gild_TrodelvyMember_d89752c6-410d-4519-a483-a5654e6a2499" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:href="gild-20230331.xsd#gild_LiverDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:href="gild-20230331.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:to="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_b9190368-b023-4a3d-a4f0-34bb029d63c5" xlink:href="gild-20230331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_b9190368-b023-4a3d-a4f0-34bb029d63c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_1e958dda-4fde-46f4-a0a3-1ca9a8ff9fe5" xlink:href="gild-20230331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_1e958dda-4fde-46f4-a0a3-1ca9a8ff9fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_876d0d38-aff4-4a2a-a528-8f2027325fe7" xlink:href="gild-20230331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_876d0d38-aff4-4a2a-a528-8f2027325fe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_c96c4fa8-b545-4783-87fa-29dbde99665b" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_c96c4fa8-b545-4783-87fa-29dbde99665b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_618bd5de-5d60-4a71-9f7a-bef289599060" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_618bd5de-5d60-4a71-9f7a-bef289599060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_84400ab6-483d-4401-be61-1736aead0572" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_84400ab6-483d-4401-be61-1736aead0572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_e8a51ae0-b8f4-4b42-abc4-bce8790449ee" xlink:href="gild-20230331.xsd#gild_VekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_VekluryMember_e8a51ae0-b8f4-4b42-abc4-bce8790449ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:href="gild-20230331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_a82ed849-b90b-49db-a36b-095f412463f5" xlink:href="gild-20230331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:to="loc_gild_OtherProductsAmBisomeMember_a82ed849-b90b-49db-a36b-095f412463f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_3dec4351-85c0-4655-8087-a3a6e85487ac" xlink:href="gild-20230331.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:to="loc_gild_OtherProductsLetairisMember_3dec4351-85c0-4655-8087-a3a6e85487ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_44d672d9-aa0f-43b7-907f-553d571121e5" xlink:href="gild-20230331.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:to="loc_gild_OtherProductsOtherMember_44d672d9-aa0f-43b7-907f-553d571121e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_c726cccd-536f-4de2-8fe6-d625e2785c13" xlink:href="gild-20230331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:to="loc_gild_RoyaltyContractAndOtherMember_c726cccd-536f-4de2-8fe6-d625e2785c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:to="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:to="loc_srt_SegmentGeographicalDomain_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:to="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2fcf6c1b-ffe4-4515-84a2-8ab58ffba975" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:to="loc_country_US_2fcf6c1b-ffe4-4515-84a2-8ab58ffba975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_1e53f8ff-b1fe-47ed-a079-cea232c30c79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:to="loc_srt_EuropeMember_1e53f8ff-b1fe-47ed-a079-cea232c30c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_d6300e7c-c40e-4c44-bb0c-36f2864092e5" xlink:href="gild-20230331.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:to="loc_gild_OtherInternationalMember_d6300e7c-c40e-4c44-bb0c-36f2864092e5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESSummaryofRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i87d713891cda42338e532af6af5b7acc_REVENUESSummaryofRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7afdf903-70ce-4409-8713-3960c38f26b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ec85673d-4e06-4b8d-9321-a441e8968646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7afdf903-70ce-4409-8713-3960c38f26b3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ec85673d-4e06-4b8d-9321-a441e8968646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7afdf903-70ce-4409-8713-3960c38f26b3" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb350708-551b-4e87-a692-2d855718cc23_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb350708-551b-4e87-a692-2d855718cc23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:to="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_91cbc247-43d1-42c4-82ef-091ffb3a8b0e" xlink:href="gild-20230331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:to="loc_gild_AmerisourcebergenCorpMember_91cbc247-43d1-42c4-82ef-091ffb3a8b0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_781d369e-db19-403a-95c9-47a4348ffc30" xlink:href="gild-20230331.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:to="loc_gild_CardinalHealthIncMember_781d369e-db19-403a-95c9-47a4348ffc30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_7e79e758-6210-4696-a84b-7a708c9bc476" xlink:href="gild-20230331.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:to="loc_gild_MckessonCorpMember_7e79e758-6210-4696-a84b-7a708c9bc476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5488afd0-4d09-4870-9fb6-aad10b833213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5488afd0-4d09-4870-9fb6-aad10b833213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46b9319a-1c92-412c-8cbb-a090a03ebf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46b9319a-1c92-412c-8cbb-a090a03ebf74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_47db9eb7-5372-4c94-8798-d6a74e5acfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46b9319a-1c92-412c-8cbb-a090a03ebf74" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_47db9eb7-5372-4c94-8798-d6a74e5acfc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c46cf19a-9ac6-4ddf-9d35-727eae7a663e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c46cf19a-9ac6-4ddf-9d35-727eae7a663e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f04d99cb-a29d-43fe-842b-55b756273d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f04d99cb-a29d-43fe-842b-55b756273d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_520051ca-5f8c-4dc1-8786-c71b5b8e74f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f04d99cb-a29d-43fe-842b-55b756273d79" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_520051ca-5f8c-4dc1-8786-c71b5b8e74f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i8016e3c0b77746b8a7020801e2e18ee8_FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a02aee44-974f-44c0-a0ce-646b3bda6283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a02aee44-974f-44c0-a0ce-646b3bda6283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_de61e4ae-73a8-4d89-a360-ef2f9a631de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_de61e4ae-73a8-4d89-a360-ef2f9a631de6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_38633b38-0e86-488b-b030-5313b7a22d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_38633b38-0e86-488b-b030-5313b7a22d0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_22222c88-7ccf-4903-9475-9b792c6c47d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_22222c88-7ccf-4903-9475-9b792c6c47d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e7b408c1-4501-4b7b-ad9e-c02962c8c6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e7b408c1-4501-4b7b-ad9e-c02962c8c6bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_34a24d80-6849-4f94-a468-a5fa6503c923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_34a24d80-6849-4f94-a468-a5fa6503c923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_df60fa5b-8f05-4e8f-b693-a8b0b41e5411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_df60fa5b-8f05-4e8f-b693-a8b0b41e5411" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_793f4285-6376-454a-8dad-9d892101a616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_793f4285-6376-454a-8dad-9d892101a616" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_42d8bfa6-f5a3-4447-9a8f-0f0135819922_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_42d8bfa6-f5a3-4447-9a8f-0f0135819922_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e87994b6-9fe8-4804-b9d7-66c8e9e412cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e87994b6-9fe8-4804-b9d7-66c8e9e412cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b0326de1-df6a-45fa-b55c-30b37191b539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e87994b6-9fe8-4804-b9d7-66c8e9e412cb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b0326de1-df6a-45fa-b55c-30b37191b539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_851be0d2-7102-44fb-ab9f-1642003cf527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_851be0d2-7102-44fb-ab9f-1642003cf527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dd341692-23ad-4e30-9246-28680a318078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dd341692-23ad-4e30-9246-28680a318078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_86dc04a9-8430-4b68-95d1-42e24543a86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_86dc04a9-8430-4b68-95d1-42e24543a86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_37360b53-ac1b-4476-aba9-4e72a3f19f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_37360b53-ac1b-4476-aba9-4e72a3f19f95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a6243e73-e8f1-4ada-b66b-669e9d25ddcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a6243e73-e8f1-4ada-b66b-669e9d25ddcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_05778da5-17ab-42f1-b79f-c04de3271eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_05778da5-17ab-42f1-b79f-c04de3271eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b9521315-60b5-40aa-9a0c-26bb766c3a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_05778da5-17ab-42f1-b79f-c04de3271eb0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b9521315-60b5-40aa-9a0c-26bb766c3a39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ee778bdf-0f18-4d26-bf05-8443c9172343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b9521315-60b5-40aa-9a0c-26bb766c3a39" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ee778bdf-0f18-4d26-bf05-8443c9172343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_df5a7b63-fdd6-4a7c-a146-afbb68709301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_df5a7b63-fdd6-4a7c-a146-afbb68709301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c86ce517-35e7-4342-8ba5-a4c68e2f4441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c86ce517-35e7-4342-8ba5-a4c68e2f4441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_24f951fd-93dc-4dd5-8d95-2a5ddc14f0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_24f951fd-93dc-4dd5-8d95-2a5ddc14f0dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_075271e0-f36a-46d2-94bf-ca9aa447cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_075271e0-f36a-46d2-94bf-ca9aa447cbda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a616bcb1-4fd0-469e-aaf3-3da48013d769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a616bcb1-4fd0-469e-aaf3-3da48013d769" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_02b39534-bc44-4582-8dc5-9659d6dd3015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_02b39534-bc44-4582-8dc5-9659d6dd3015" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_33858ec9-4130-4ce5-a6ec-9ee65c83166f" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_33858ec9-4130-4ce5-a6ec-9ee65c83166f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d820bf54-6630-4165-852e-3394f166f8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d820bf54-6630-4165-852e-3394f166f8dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e38a302c-79f5-49f4-b48f-3c472cb3598a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_EquitySecuritiesMember_e38a302c-79f5-49f4-b48f-3c472cb3598a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_40522f8b-a68f-418f-af13-7ea4270ae351" xlink:href="gild-20230331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_gild_DeferredCompensationPlanMember_40522f8b-a68f-418f-af13-7ea4270ae351" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_4cf92ef4-4917-4b91-8f2a-9265e7270011" xlink:href="gild-20230331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_4cf92ef4-4917-4b91-8f2a-9265e7270011" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f5876ade-231d-4368-a536-b21736a0fd9e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f5876ade-231d-4368-a536-b21736a0fd9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_149aeb9e-a781-4c94-b369-969905ff7b11" xlink:href="gild-20230331.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:to="loc_gild_GalapagosMember_149aeb9e-a781-4c94-b369-969905ff7b11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_3b0ea716-3160-4e34-b0c8-da43e7436dbd" xlink:href="gild-20230331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:to="loc_gild_ArcusBiosciencesIncMember_3b0ea716-3160-4e34-b0c8-da43e7436dbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9309314d-d711-4a34-babd-60b778250f94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9309314d-d711-4a34-babd-60b778250f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92015a3e-c5c6-4940-8279-103367234fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92015a3e-c5c6-4940-8279-103367234fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_45d37cb3-9a0c-42ea-a788-44d251624eff" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92015a3e-c5c6-4940-8279-103367234fc1" xlink:to="loc_gild_MYRGmbHMember_45d37cb3-9a0c-42ea-a788-44d251624eff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended" id="ie8689674145c45c393f03ce686be3145_FAIRVALUEMEASUREMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_8114e6a9-2654-4f28-bbf6-990a874bdfae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_8114e6a9-2654-4f28-bbf6-990a874bdfae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c832a21b-5f6a-43d1-a5da-f9fbea1aa321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_LongTermDebtFairValue_c832a21b-5f6a-43d1-a5da-f9fbea1aa321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b5227e8a-29f3-4406-8856-b8f0999c94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b5227e8a-29f3-4406-8856-b8f0999c94c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_76d8015d-3fad-437b-a939-420cc36b9ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_76d8015d-3fad-437b-a939-420cc36b9ff0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_4c2fdc6d-4df8-43c8-92e8-eaba7c4b5c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_4c2fdc6d-4df8-43c8-92e8-eaba7c4b5c9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b649ddd1-1862-4f9e-a614-4a587f096cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b649ddd1-1862-4f9e-a614-4a587f096cfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9ec517c2-31ad-4d5e-ac90-49f99f6702db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9ec517c2-31ad-4d5e-ac90-49f99f6702db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e8cbe8df-3e9a-4a30-ac4a-45af1eb7e58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e8cbe8df-3e9a-4a30-ac4a-45af1eb7e58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e8cbe8df-3e9a-4a30-ac4a-45af1eb7e58d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3a1bbfd-ae9a-40f4-994a-696ac0f8400a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3a1bbfd-ae9a-40f4-994a-696ac0f8400a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ebf64092-1b5e-4be2-a0b6-35fed98c67bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ebf64092-1b5e-4be2-a0b6-35fed98c67bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f651e909-489f-43f2-9890-40fc2240602f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f651e909-489f-43f2-9890-40fc2240602f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5e1ac890-8659-442e-ae4e-d65cfe2fad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5e1ac890-8659-442e-ae4e-d65cfe2fad3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d574698f-68ec-4415-bd19-266cc7727066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d574698f-68ec-4415-bd19-266cc7727066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_7da1c766-33e7-447b-9ffc-8268fdb5a437" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:to="loc_gild_MYRGmbHMember_7da1c766-33e7-447b-9ffc-8268fdb5a437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_acdaa274-ae61-4619-96e6-8802e0dfeee5" xlink:href="gild-20230331.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:to="loc_gild_ImmunomedicsIncMember_acdaa274-ae61-4619-96e6-8802e0dfeee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7c39b-c141-4071-a9ed-6db679f16729_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7c39b-c141-4071-a9ed-6db679f16729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186ae9f-4d9b-4652-972f-9578be7c4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186ae9f-4d9b-4652-972f-9578be7c4d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_b8617021-e67e-422f-bd3e-c668e4ffd6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186ae9f-4d9b-4652-972f-9578be7c4d13" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_b8617021-e67e-422f-bd3e-c668e4ffd6bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8016dbf8-a0a0-4716-a422-18e02234199e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8016dbf8-a0a0-4716-a422-18e02234199e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7465ea65-65a0-42b1-8145-5862098b202f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7465ea65-65a0-42b1-8145-5862098b202f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_0ac9f4ff-40b0-4f27-974b-d768986dbaa6" xlink:href="gild-20230331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7465ea65-65a0-42b1-8145-5862098b202f" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_0ac9f4ff-40b0-4f27-974b-d768986dbaa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89fa222c-5445-4daf-9fda-e6dc7e9745b8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:to="loc_srt_RangeMember_89fa222c-5445-4daf-9fda-e6dc7e9745b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af378191-540b-4005-9395-9ed948de0b9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:to="loc_srt_RangeMember_af378191-540b-4005-9395-9ed948de0b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76e0dbbb-5b31-4080-a9f1-e72244ed22d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af378191-540b-4005-9395-9ed948de0b9a" xlink:to="loc_srt_MaximumMember_76e0dbbb-5b31-4080-a9f1-e72244ed22d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="extended" id="ife9ea9886b6d4d898950292a8589c9c0_FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6bb5fcf-06b6-4a8f-8578-63f571a38478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6bb5fcf-06b6-4a8f-8578-63f571a38478" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7c7c5c4-3a28-4937-80a7-c57c10795598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7c7c5c4-3a28-4937-80a7-c57c10795598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_241d49e2-0037-4d9d-83b9-f871f9ba5c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_241d49e2-0037-4d9d-83b9-f871f9ba5c17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_99875c9e-66ad-4092-b7da-e0e0c43d8410" xlink:href="gild-20230331.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_99875c9e-66ad-4092-b7da-e0e0c43d8410" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d96d400f-4471-47f7-ad01-066dcfd10e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6bb5fcf-06b6-4a8f-8578-63f571a38478" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18eae9b0-fde7-45f7-bdbe-93d9f5116384_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_18eae9b0-fde7-45f7-bdbe-93d9f5116384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c22119ac-be6f-42e7-b69f-f35b6df2049b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c22119ac-be6f-42e7-b69f-f35b6df2049b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember_7aeadabe-16a4-49ac-a20f-b05847725cd8" xlink:href="gild-20230331.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c22119ac-be6f-42e7-b69f-f35b6df2049b" xlink:to="loc_gild_ContingentConsiderationLiabilityMember_7aeadabe-16a4-49ac-a20f-b05847725cd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7007d4fd-b700-43b3-8a1f-c91f861a435a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7007d4fd-b700-43b3-8a1f-c91f861a435a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04c7b773-9a43-43ba-a8b8-b0eace84ba0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04c7b773-9a43-43ba-a8b8-b0eace84ba0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_924ff913-b9e0-4c2a-99a2-5b868f8c6ea2" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04c7b773-9a43-43ba-a8b8-b0eace84ba0d" xlink:to="loc_gild_MYRGmbHMember_924ff913-b9e0-4c2a-99a2-5b868f8c6ea2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="i477c193dd2f7461085645c15b9b9a172_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8b2af284-275c-4efb-807d-c2e073290aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8b2af284-275c-4efb-807d-c2e073290aa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25acf288-5cb6-46bc-8a04-bc7484b8c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25acf288-5cb6-46bc-8a04-bc7484b8c1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b86ed139-32c1-42ae-bebb-8bac9af2979f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b86ed139-32c1-42ae-bebb-8bac9af2979f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8addae5c-8fc6-407b-8bb9-65e2d6469312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8addae5c-8fc6-407b-8bb9-65e2d6469312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_096197f1-b55b-46c8-9b74-0327e63cdf55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_096197f1-b55b-46c8-9b74-0327e63cdf55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c4132676-308d-476f-a480-868cbf2e04b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c4132676-308d-476f-a480-868cbf2e04b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1fa25360-63d5-4219-8c62-4d70a5caad20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1fa25360-63d5-4219-8c62-4d70a5caad20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_9865a675-405b-47fc-87b7-685dc708001d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_9865a675-405b-47fc-87b7-685dc708001d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_8f35d6e8-05a7-4899-96dd-f0f8b6df2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_8f35d6e8-05a7-4899-96dd-f0f8b6df2bcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52e51623-8310-4317-835d-ab507795b31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52e51623-8310-4317-835d-ab507795b31b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_cb53eae2-336f-4f32-9318-7c11ff320240" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_cb53eae2-336f-4f32-9318-7c11ff320240" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="extended" id="i09801da336ae42ee8d17f9491194c9e0_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_062b389c-38f8-49b9-a3a9-e378abcdafa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_062b389c-38f8-49b9-a3a9-e378abcdafa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f8c38040-c0fa-4587-bc73-9f86c1b386e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f8c38040-c0fa-4587-bc73-9f86c1b386e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_63a069e4-6aa9-481f-b48e-c50d2806a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_63a069e4-6aa9-481f-b48e-c50d2806a36b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a195ed0e-c8bb-46d6-8e27-28664ffdbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a195ed0e-c8bb-46d6-8e27-28664ffdbc76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8047b632-e493-4ced-8dca-83cf74a3becb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8047b632-e493-4ced-8dca-83cf74a3becb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e57aafbe-b124-4cbb-81fd-75bd726576b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e57aafbe-b124-4cbb-81fd-75bd726576b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54557853-fa62-4bbd-bcd6-d6fc151d1a38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_54557853-fa62-4bbd-bcd6-d6fc151d1a38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e62b3795-7f15-499c-a2cb-1f245ea33b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e62b3795-7f15-499c-a2cb-1f245ea33b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d1269d01-4f16-432f-b61a-c0666c8cb4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d1269d01-4f16-432f-b61a-c0666c8cb4c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4d656b0b-b766-468c-8982-faace99fa594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4d656b0b-b766-468c-8982-faace99fa594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_166b041c-ff38-4584-a01b-a9b1dcdb0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_166b041c-ff38-4584-a01b-a9b1dcdb0b50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bccf41f1-3375-4909-9b95-01fd13772776" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bccf41f1-3375-4909-9b95-01fd13772776" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i4d68c1e3cf6845568443b8519997ec57_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d568ecd-b82c-4ca6-935b-ab9850c229a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_970390b4-5690-43d3-bd15-11386573080e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d568ecd-b82c-4ca6-935b-ab9850c229a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_970390b4-5690-43d3-bd15-11386573080e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d568ecd-b82c-4ca6-935b-ab9850c229a5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_30e2edf5-36e0-4333-bb7e-55da641e4a10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_30e2edf5-36e0-4333-bb7e-55da641e4a10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_b0b4df9a-df0a-44eb-a71b-38f16460375e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_b0b4df9a-df0a-44eb-a71b-38f16460375e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_079761fc-2832-45aa-bf32-49f6b8edc75e" xlink:href="gild-20230331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_079761fc-2832-45aa-bf32-49f6b8edc75e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_f1248c74-f734-4906-bc9d-a5480f383800" xlink:href="gild-20230331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_f1248c74-f734-4906-bc9d-a5480f383800" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended" id="id39f1ceacedb47eba0f79637aa58e3cf_AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_98cdcd16-9740-4dd8-9fca-a668d399f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_98cdcd16-9740-4dd8-9fca-a668d399f72c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3f2d6637-82f1-480c-8d2c-c255a6c8c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3f2d6637-82f1-480c-8d2c-c255a6c8c1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_82f70c9c-379b-4841-839e-5edaf14a6fdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_82f70c9c-379b-4841-839e-5edaf14a6fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da7852b6-930c-4837-ac53-7588de744c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da7852b6-930c-4837-ac53-7588de744c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_47fa7d31-f13f-4d87-b217-a1bc5f1e474e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da7852b6-930c-4837-ac53-7588de744c3f" xlink:to="loc_us-gaap_EquitySecuritiesMember_47fa7d31-f13f-4d87-b217-a1bc5f1e474e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f1b8982f-33ad-4a6f-bee9-af6a655f2e03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f1b8982f-33ad-4a6f-bee9-af6a655f2e03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6e468734-f15b-4715-9345-3478a900f2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6e468734-f15b-4715-9345-3478a900f2fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c42dfdc7-20de-415e-8c96-b295e41ce41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c42dfdc7-20de-415e-8c96-b295e41ce41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_ab04f1e0-cbef-4afd-a200-f54a9b91624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_ab04f1e0-cbef-4afd-a200-f54a9b91624b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended" id="idcd9b222c182464ab2766cf0af91e881_DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_d50185b1-760a-4231-b7e4-229f7e55221f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_d50185b1-760a-4231-b7e4-229f7e55221f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9cec5545-55df-4336-8e6a-68e47549ff80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9cec5545-55df-4336-8e6a-68e47549ff80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_e333b9ab-8697-4540-afc6-8f8c680b336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_e333b9ab-8697-4540-afc6-8f8c680b336f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_03a42914-edbf-40b4-bd52-d10d5e534522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_03a42914-edbf-40b4-bd52-d10d5e534522" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:to="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6748c1e-72d3-4a8c-b42b-5c2189292dae_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:to="loc_srt_RangeMember_b6748c1e-72d3-4a8c-b42b-5c2189292dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41d311d6-970e-4284-98f9-a403ac79440c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:to="loc_srt_RangeMember_41d311d6-970e-4284-98f9-a403ac79440c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6fcc166a-a4a0-4d2e-87d0-65091ffdb59b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41d311d6-970e-4284-98f9-a403ac79440c" xlink:to="loc_srt_MaximumMember_6fcc166a-a4a0-4d2e-87d0-65091ffdb59b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="i24c7f337d2a542a786ef93ca4d428d6a_DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_21c8cabd-793c-4689-a727-c9b59f6eb9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_21c8cabd-793c-4689-a727-c9b59f6eb9ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_7ccdedde-60b6-4e1f-bb21-f2d994ce9f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_7ccdedde-60b6-4e1f-bb21-f2d994ce9f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_db86144b-8d13-4a0b-8d1b-2c1847d64a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_db86144b-8d13-4a0b-8d1b-2c1847d64a77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_313117fc-1464-423e-9cd1-847af5f3bf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_313117fc-1464-423e-9cd1-847af5f3bf7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ba53fd5c-7904-4b01-9834-a63ca6cd0d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ba53fd5c-7904-4b01-9834-a63ca6cd0d46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_c73b4e72-ee77-427e-b3e7-348353f8a85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_c73b4e72-ee77-427e-b3e7-348353f8a85d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_9e983141-3627-4dfd-a399-69f473afd769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_9e983141-3627-4dfd-a399-69f473afd769" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c4e96bc4-befd-4f43-804a-e6bb2f3f7f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c4e96bc4-befd-4f43-804a-e6bb2f3f7f6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:to="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_221dfc97-4a3a-46a4-b677-3855d9454e21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:to="loc_us-gaap_HedgingDesignationDomain_221dfc97-4a3a-46a4-b677-3855d9454e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:to="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_79d0ab6c-aeeb-45ab-bfc1-d61fb9c850a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_79d0ab6c-aeeb-45ab-bfc1-d61fb9c850a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6a9844c4-142d-4542-809b-96be46f365b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:to="loc_us-gaap_NondesignatedMember_6a9844c4-142d-4542-809b-96be46f365b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13714e58-716f-4528-ab08-63213a83e9ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_13714e58-716f-4528-ab08-63213a83e9ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f81f36e6-6562-4b27-a512-19975b7f6fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f81f36e6-6562-4b27-a512-19975b7f6fd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_865c9b94-93e0-49eb-852e-07829d855a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_865c9b94-93e0-49eb-852e-07829d855a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_521fbbd9-18d1-4d79-b683-7fdd79d5b71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_521fbbd9-18d1-4d79-b683-7fdd79d5b71e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5ae380d8-af79-424e-af86-1816692e655d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5ae380d8-af79-424e-af86-1816692e655d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended" id="i9163c7b040ba4fd99da726d5f7cc1bdf_ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions_0a185d10-0b98-4216-88ec-ea6358bd97d4" xlink:href="gild-20230331.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_gild_PaymentsForAssetAcquisitions_0a185d10-0b98-4216-88ec-ea6358bd97d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e05c5716-8559-4011-94d1-3650f110a179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e05c5716-8559-4011-94d1-3650f110a179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_de3a7178-d253-46e2-9089-1b2d1e038628" xlink:href="gild-20230331.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_de3a7178-d253-46e2-9089-1b2d1e038628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_1ea6b127-75b0-4e2d-a1fa-404768d3af28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_1ea6b127-75b0-4e2d-a1fa-404768d3af28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_2debc2cd-5624-4424-8a86-5aceb18e87f2" xlink:href="gild-20230331.xsd#gild_RevenuePerformanceObligationPercentageOfUSProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_2debc2cd-5624-4424-8a86-5aceb18e87f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_755eff51-c637-49c7-9fc3-ef145d2a1a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_755eff51-c637-49c7-9fc3-ef145d2a1a7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6c1cc8de-743e-4d91-b291-011439432bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6c1cc8de-743e-4d91-b291-011439432bfe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a52cbdc-b829-4770-9c52-1961be0dd34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9a52cbdc-b829-4770-9c52-1961be0dd34e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_984d342a-1619-4a6f-8675-1ae3b53f1faf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:to="loc_us-gaap_AssetAcquisitionDomain_984d342a-1619-4a6f-8675-1ae3b53f1faf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_aac52407-684d-4520-bffc-fa728c6d4ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:to="loc_us-gaap_AssetAcquisitionDomain_aac52407-684d-4520-bffc-fa728c6d4ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember_b187daee-d974-4c6f-8ab6-2e666a241fa1" xlink:href="gild-20230331.xsd#gild_TmunityTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_aac52407-684d-4520-bffc-fa728c6d4ba4" xlink:to="loc_gild_TmunityTherapeuticsMember_b187daee-d974-4c6f-8ab6-2e666a241fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a84f4f93-81d9-4de1-b72c-188416295937_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a84f4f93-81d9-4de1-b72c-188416295937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_18b20bfe-84a9-497c-ac24-723c50ed2c66" xlink:href="gild-20230331.xsd#gild_ArcellxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:to="loc_gild_ArcellxIncMember_18b20bfe-84a9-497c-ac24-723c50ed2c66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_ad3cdb3e-94ef-4edd-ac1b-3ff4df336f0d" xlink:href="gild-20230331.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_ad3cdb3e-94ef-4edd-ac1b-3ff4df336f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_64e9654b-4791-49c4-8c33-ad1ee838181f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_64e9654b-4791-49c4-8c33-ad1ee838181f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0b10980-9487-469f-a3a3-1578e89e15f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0b10980-9487-469f-a3a3-1578e89e15f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GlobalStrategicCollaborationAgreementMember_21f1222d-e921-47c7-9549-f2486a47d3d9" xlink:href="gild-20230331.xsd#gild_GlobalStrategicCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0b10980-9487-469f-a3a3-1578e89e15f8" xlink:to="loc_gild_GlobalStrategicCollaborationAgreementMember_21f1222d-e921-47c7-9549-f2486a47d3d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c7a2b13-6abb-4688-b23e-909c1c19164d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:to="loc_dei_EntityDomain_2c7a2b13-6abb-4688-b23e-909c1c19164d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76ea9d16-2f54-4431-922e-a40bed93e589" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:to="loc_dei_EntityDomain_76ea9d16-2f54-4431-922e-a40bed93e589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_b790d7bc-b385-4669-82b5-56cd31834ca7" xlink:href="gild-20230331.xsd#gild_ArcellxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_76ea9d16-2f54-4431-922e-a40bed93e589" xlink:to="loc_gild_ArcellxIncMember_b790d7bc-b385-4669-82b5-56cd31834ca7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended" id="icbeebd0ef7e44e58b3e5a7bea5692778_INTANGIBLEASSETSSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f242735-9c7b-4217-8524-3954b4eecc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f242735-9c7b-4217-8524-3954b4eecc5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_314d4405-a574-4d02-8904-bf59919961df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_314d4405-a574-4d02-8904-bf59919961df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cc28eebf-77c9-406c-b24d-6a056a4202b0" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cc28eebf-77c9-406c-b24d-6a056a4202b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9e1ddfe3-c9fb-4c0d-a76d-bd30eef4e54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9e1ddfe3-c9fb-4c0d-a76d-bd30eef4e54b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e06c1b5c-0114-4a1b-ab2f-259aa61f56c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e06c1b5c-0114-4a1b-ab2f-259aa61f56c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_b387bd9d-8982-47d5-854b-aafa20027a0c" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_b387bd9d-8982-47d5-854b-aafa20027a0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d20a7ad8-dd7c-44cd-b87b-b2b27cf45541" xlink:href="gild-20230331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d20a7ad8-dd7c-44cd-b87b-b2b27cf45541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b9be5254-60f9-431a-844e-07688368a03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b9be5254-60f9-431a-844e-07688368a03f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7960651d-5ffa-4cbb-b80b-dddc0c0ffcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1b2b4525-ae79-4591-81db-2903a21610f7" xlink:href="gild-20230331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1b2b4525-ae79-4591-81db-2903a21610f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c5471ce5-6c35-4668-92c9-ba8b8ebc472c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c5471ce5-6c35-4668-92c9-ba8b8ebc472c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_aa0dba89-b83b-4e47-9cad-44800a364954" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_aa0dba89-b83b-4e47-9cad-44800a364954" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5718061f-7e74-4fe0-aedd-eea506f044fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5718061f-7e74-4fe0-aedd-eea506f044fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_37806007-37a3-471e-8420-8553e3bac6ec" xlink:href="gild-20230331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_37806007-37a3-471e-8420-8553e3bac6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_2fb40740-594b-4e88-8f62-7b453d93bccd" xlink:href="gild-20230331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_2fb40740-594b-4e88-8f62-7b453d93bccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_6187c66d-d3d3-46d2-9ce6-b38bcb1df8a1" xlink:href="gild-20230331.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_TrodelvyMember_6187c66d-d3d3-46d2-9ce6-b38bcb1df8a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_b98b930b-bdc0-4000-805d-a84c4ab669b8" xlink:href="gild-20230331.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_HepcludexMember_b98b930b-bdc0-4000-805d-a84c4ab669b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_eba2192f-8a36-4965-b0b3-001962c878d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_eba2192f-8a36-4965-b0b3-001962c878d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ccc12b64-949f-4d72-a906-630ac434a7d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ccc12b64-949f-4d72-a906-630ac434a7d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09e2dcd0-c9e8-4538-abd3-49b87ff24ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09e2dcd0-c9e8-4538-abd3-49b87ff24ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9441243a-98ef-49f5-ab7e-0c07d0436b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09e2dcd0-c9e8-4538-abd3-49b87ff24ed8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9441243a-98ef-49f5-ab7e-0c07d0436b60" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended" id="i44dd3f92bad94dbebfb3ae7d3fbc171e_INTANGIBLEASSETSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2f8cc904-6985-4556-8fef-dbb5008ebe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2f8cc904-6985-4556-8fef-dbb5008ebe3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d97be3e2-3bc7-479d-a755-860b187bb7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d97be3e2-3bc7-479d-a755-860b187bb7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_f9841357-193e-4f83-9377-e3e16025d822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_f9841357-193e-4f83-9377-e3e16025d822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_ce524180-1c78-47f7-b20a-c33c54f85b00" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_ce524180-1c78-47f7-b20a-c33c54f85b00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a17c21b-c97e-4ef8-b188-c2351d9ee161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a17c21b-c97e-4ef8-b188-c2351d9ee161" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3bfe754-23f8-4767-aca7-2cc30af17a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3bfe754-23f8-4767-aca7-2cc30af17a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc96f94-8d59-46f9-8d44-35dae2138743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc96f94-8d59-46f9-8d44-35dae2138743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_573f9519-48f4-41d2-ac17-ebb6fd048f5d" xlink:href="gild-20230331.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc96f94-8d59-46f9-8d44-35dae2138743" xlink:to="loc_gild_ImmunomedicsIncMember_573f9519-48f4-41d2-ac17-ebb6fd048f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_375e6131-2072-43fa-82c1-a7b29f6b423c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_375e6131-2072-43fa-82c1-a7b29f6b423c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_b7ba8ca7-326c-4b71-bb32-1e9c86333a22" xlink:href="gild-20230331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_375e6131-2072-43fa-82c1-a7b29f6b423c" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_b7ba8ca7-326c-4b71-bb32-1e9c86333a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_811c128d-ce2e-4a3d-a981-263173241309_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_811c128d-ce2e-4a3d-a981-263173241309_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a4b6b86b-efec-43eb-b606-9e297fab5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a4b6b86b-efec-43eb-b606-9e297fab5d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_24894547-bf14-4f18-b469-feecaf3e5367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a4b6b86b-efec-43eb-b606-9e297fab5d54" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_24894547-bf14-4f18-b469-feecaf3e5367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_409b0287-abea-41ad-a733-e3263f79f627_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_409b0287-abea-41ad-a733-e3263f79f627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_87e49f8c-dbaa-4f40-9d27-9cc6025f1c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_87e49f8c-dbaa-4f40-9d27-9cc6025f1c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_18927ea6-936b-4aff-9441-3ffa8a57986b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_87e49f8c-dbaa-4f40-9d27-9cc6025f1c21" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_18927ea6-936b-4aff-9441-3ffa8a57986b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="if916eeaf6e7d469d86ea94f594c5c9f8_OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9f5002d0-9154-478e-ae8b-9bc1cca7da0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9f5002d0-9154-478e-ae8b-9bc1cca7da0a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d67129f2-a6ee-4f8d-9c9d-4c00cc4fdf48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d67129f2-a6ee-4f8d-9c9d-4c00cc4fdf48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5a85f502-37a4-4113-bd05-573b8f27331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5a85f502-37a4-4113-bd05-573b8f27331d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_cc0fcd08-a69b-4189-a263-5fe2658cf1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_cc0fcd08-a69b-4189-a263-5fe2658cf1a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ff8cbd6-899a-4912-a2be-c98bcd710453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ff8cbd6-899a-4912-a2be-c98bcd710453" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9281efbe-80e5-421f-87dc-403de32780bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9f5002d0-9154-478e-ae8b-9bc1cca7da0a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8dacded-cf70-46c9-9445-9913fb16e532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:to="loc_us-gaap_EquityComponentDomain_e8dacded-cf70-46c9-9445-9913fb16e532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87772af2-dad6-4391-933a-4c100438a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:to="loc_us-gaap_EquityComponentDomain_87772af2-dad6-4391-933a-4c100438a608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_87772af2-dad6-4391-933a-4c100438a608" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f3948f28-96ed-4448-b623-ef9e859de16d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f3948f28-96ed-4448-b623-ef9e859de16d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_893da5ff-9cc7-4a24-8ed8-2305b7931a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_893da5ff-9cc7-4a24-8ed8-2305b7931a41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d1ce8f-870a-4866-ad9a-5276ee90219b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d1ce8f-870a-4866-ad9a-5276ee90219b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="i98621051ad9b4bf18362212affbfcf16_DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7729c794-3ae1-40b1-9747-56352d160937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7729c794-3ae1-40b1-9747-56352d160937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3bc6a6a1-365f-4cf0-9c84-53f54f0ebbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_LongTermDebt_3bc6a6a1-365f-4cf0-9c84-53f54f0ebbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3a6b343f-0755-4fbd-b9d9-4f9be11ba07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3a6b343f-0755-4fbd-b9d9-4f9be11ba07b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6d9b8c1e-8fc8-4db2-b920-30aa84da1da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_LongTermDebtCurrent_6d9b8c1e-8fc8-4db2-b920-30aa84da1da1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1df925cb-6c72-4b74-8eee-0d3d2a81ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1df925cb-6c72-4b74-8eee-0d3d2a81ebed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01198a42-77cd-4285-87fe-d9842c3be7d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01198a42-77cd-4285-87fe-d9842c3be7d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_268f6b23-3b63-49e3-9e7c-a7b6c96ed8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:to="loc_us-gaap_SeniorNotesMember_268f6b23-3b63-49e3-9e7c-a7b6c96ed8a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_34853e48-c18d-46f4-ac9a-7aea94c9c655" xlink:href="gild-20230331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_34853e48-c18d-46f4-ac9a-7aea94c9c655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_996b857b-73cd-44bb-8bd7-44771a42b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_996b857b-73cd-44bb-8bd7-44771a42b33e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9e359d0-4132-4a87-80b4-0b8c58ead2fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9e359d0-4132-4a87-80b4-0b8c58ead2fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_8e378c49-7bad-48dc-9236-05d19d7ad183" xlink:href="gild-20230331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_8e378c49-7bad-48dc-9236-05d19d7ad183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_c447c039-89a6-4231-8e7e-4733deecbefb" xlink:href="gild-20230331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_c447c039-89a6-4231-8e7e-4733deecbefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_73b96322-e82a-40b9-bc1c-592fb4fab223" xlink:href="gild-20230331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_73b96322-e82a-40b9-bc1c-592fb4fab223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_4b2b2e8b-d6ae-4622-81e0-2dcb48d8988b" xlink:href="gild-20230331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_4b2b2e8b-d6ae-4622-81e0-2dcb48d8988b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_1b602ada-c94a-453c-808b-1e957bf0f9cd" xlink:href="gild-20230331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_1b602ada-c94a-453c-808b-1e957bf0f9cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_9456b6b3-ba84-4c06-aa0b-a57f13177fdf" xlink:href="gild-20230331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_9456b6b3-ba84-4c06-aa0b-a57f13177fdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_5b68cd09-ac1b-4127-9b8c-a082f3e0e21e" xlink:href="gild-20230331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_5b68cd09-ac1b-4127-9b8c-a082f3e0e21e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_1262fc38-431a-4f5d-bfff-91ff72d1d5cb" xlink:href="gild-20230331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_1262fc38-431a-4f5d-bfff-91ff72d1d5cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_f2d32b82-4716-4b24-b19c-8b667f1a7770" xlink:href="gild-20230331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_f2d32b82-4716-4b24-b19c-8b667f1a7770" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_55b35db1-1aa5-4f90-a31b-cfcd10b89b26" xlink:href="gild-20230331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_55b35db1-1aa5-4f90-a31b-cfcd10b89b26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_502e7176-0034-4882-8cb5-b99be4e71b80" xlink:href="gild-20230331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_502e7176-0034-4882-8cb5-b99be4e71b80" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_ca9491ca-ce9b-4ced-b97a-44b51dd73bdd" xlink:href="gild-20230331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_ca9491ca-ce9b-4ced-b97a-44b51dd73bdd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_d23adf7f-390a-4c5b-8bcb-8e5416f6368a" xlink:href="gild-20230331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_d23adf7f-390a-4c5b-8bcb-8e5416f6368a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_4ed96ac1-8465-47e1-9e1d-1a421ad2d71d" xlink:href="gild-20230331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_4ed96ac1-8465-47e1-9e1d-1a421ad2d71d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_9a01d355-68b3-4beb-88f9-6d15ca1f5656" xlink:href="gild-20230331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_9a01d355-68b3-4beb-88f9-6d15ca1f5656" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_a555f5a6-f7f4-4119-b2d7-b6719e47ace8" xlink:href="gild-20230331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_a555f5a6-f7f4-4119-b2d7-b6719e47ace8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_c5b349d6-78ef-47e6-ad1f-24bb98257048" xlink:href="gild-20230331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_c5b349d6-78ef-47e6-ad1f-24bb98257048" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended" id="i66c0bdab0af04381a30ee5f5598a7707_DEBTANDCREDITFACILITIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_65760222-c7e6-40fe-83ac-73908ccdda00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:to="loc_us-gaap_LineOfCredit_65760222-c7e6-40fe-83ac-73908ccdda00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_57369386-ea3e-46de-b470-1612a01a56c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_57369386-ea3e-46de-b470-1612a01a56c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:to="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc9da083-6be8-4f1f-b6f9-030388bb28cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc9da083-6be8-4f1f-b6f9-030388bb28cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e30e279a-d357-440c-895a-f5ff507dd46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc9da083-6be8-4f1f-b6f9-030388bb28cb" xlink:to="loc_us-gaap_LineOfCreditMember_e30e279a-d357-440c-895a-f5ff507dd46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_333ee788-df25-4925-8591-fc9e8cac3016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:to="loc_us-gaap_CreditFacilityDomain_333ee788-df25-4925-8591-fc9e8cac3016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dd377a9c-5402-4fc2-93e5-54caf31261f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:to="loc_us-gaap_CreditFacilityDomain_dd377a9c-5402-4fc2-93e5-54caf31261f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c3a1e68c-90af-4bb9-b159-8d2cdfad459d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dd377a9c-5402-4fc2-93e5-54caf31261f7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c3a1e68c-90af-4bb9-b159-8d2cdfad459d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_36198d31-ffe9-42d5-a944-8d2996d0c250_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_36198d31-ffe9-42d5-a944-8d2996d0c250_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_206be09f-fc50-40ef-bba9-08d1badd2260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_206be09f-fc50-40ef-bba9-08d1badd2260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_5b353da9-2a4c-4cf1-b850-6d763fd910d2" xlink:href="gild-20230331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_206be09f-fc50-40ef-bba9-08d1badd2260" xlink:to="loc_gild_CreditFacilityDueJune2025Member_5b353da9-2a4c-4cf1-b850-6d763fd910d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i96580ab3a9154a05b5c37aa09a5328f6_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_b0d449c9-813c-4bf6-b9d3-29c45386f7c1" xlink:href="gild-20230331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_b0d449c9-813c-4bf6-b9d3-29c45386f7c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_e6e8ab11-f434-441a-ba5f-16d8fcb91d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_e6e8ab11-f434-441a-ba5f-16d8fcb91d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents_84945dbd-489d-4560-8919-212a2c9fc7ed" xlink:href="gild-20230331.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_gild_LossContingencyNumberOfPatents_84945dbd-489d-4560-8919-212a2c9fc7ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_2cf78b6b-7f38-49b4-8ecb-47dd300dd418" xlink:href="gild-20230331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_2cf78b6b-7f38-49b4-8ecb-47dd300dd418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_3bdb367f-c95a-4dd1-aa5f-5ed5eec139b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_3bdb367f-c95a-4dd1-aa5f-5ed5eec139b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_907de7e1-0d60-4bec-b37f-bf45cd12751d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_907de7e1-0d60-4bec-b37f-bf45cd12751d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:to="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b50432ea-adb3-4578-8eef-8ff1833b4e72_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:to="loc_srt_LitigationCaseTypeDomain_b50432ea-adb3-4578-8eef-8ff1833b4e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:to="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_fdb8acda-e950-457d-936f-a29eac89ce13" xlink:href="gild-20230331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:to="loc_gild_PreExposureProphylaxisMember_fdb8acda-e950-457d-936f-a29eac89ce13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_17760119-33f8-42d4-b51a-3f0840d0ca46" xlink:href="gild-20230331.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_17760119-33f8-42d4-b51a-3f0840d0ca46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_efb003b8-cbdb-4a9c-a614-17413eb1bd69" xlink:href="gild-20230331.xsd#gild_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:to="loc_gild_ProductLiabilityMember_efb003b8-cbdb-4a9c-a614-17413eb1bd69" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended" id="i1f83bc423b22450faff9c60e43cd92a7_INCOMETAXESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ded6df5-a0b5-4625-87b3-c40a2aec444d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ded6df5-a0b5-4625-87b3-c40a2aec444d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_277ef25d-a68d-4f1f-8377-9ea025aac155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_277ef25d-a68d-4f1f-8377-9ea025aac155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2d68541f-1199-4060-8008-9c36079d21dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2d68541f-1199-4060-8008-9c36079d21dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:to="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_174d3e75-c80b-45b6-b5c8-2e3bd028802f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_174d3e75-c80b-45b6-b5c8-2e3bd028802f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c1675cee-40a5-453e-8983-d32742efbfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c1675cee-40a5-453e-8983-d32742efbfa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember_32c377d2-3887-42e7-94c6-ea3b6194cc3c" xlink:href="gild-20230331.xsd#gild_TmunityTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1675cee-40a5-453e-8983-d32742efbfa9" xlink:to="loc_gild_TmunityTherapeuticsMember_32c377d2-3887-42e7-94c6-ea3b6194cc3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>gild-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c106b7c8-2bb1-4b42-ab62-c7781606086b,g:b0acd2cc-13f9-458d-8974-066f309efac0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_53897866-df06-4ddc-b51e-c757c317db77_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20230331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_15639242-13c8-4e30-8ac0-6fa72093bfd8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f2a423c0-e019-4e70-9a93-e5820013f160_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_54ee5f12-aeb0-4a53-909f-d61fafdae5c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_b99aaa9b-e9b1-4595-8fbb-5338dfa9d400_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6badd1f1-1c4f-4e2c-9777-b3168d212c46_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d2ccc0fe-4733-4941-9395-5e8946479285_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_37a172dd-ef5b-4a44-a4d2-34604a001813_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e378b0fa-8c19-4864-bdea-82fccfd5283f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d0c45b02-e5e8-414d-b9bf-439b8e61d09a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt, carrying values</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_160dae68-2963-4e4b-a550-eed721b87e48_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total senior unsecured notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_a9211a4c-d974-406d-84f8-4e60a3cffea5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities in a Continuous Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3a9de613-70d2-4c03-9d4d-baf9d44b3694_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_73b9f773-246c-4e97-89cb-25c3bc468e33_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_acd65aa0-ef0b-4161-9960-0112dbe3370c_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cell Therapy</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TmunityTherapeuticsMember_7a90cd6f-7e15-4aa9-84f7-d79a29f4944f_terseLabel_en-US" xlink:label="lab_gild_TmunityTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tmunity Therapeutics</link:label>
    <link:label id="lab_gild_TmunityTherapeuticsMember_label_en-US" xlink:label="lab_gild_TmunityTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tmunity Therapeutics [Member]</link:label>
    <link:label id="lab_gild_TmunityTherapeuticsMember_documentation_en-US" xlink:label="lab_gild_TmunityTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tmunity Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember" xlink:href="gild-20230331.xsd#gild_TmunityTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TmunityTherapeuticsMember" xlink:to="lab_gild_TmunityTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_b3c144a3-a495-4674-b885-3954e05ea679_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material transfer agreements</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_label_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:href="gild-20230331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:to="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6bb1772a-5926-4c69-b435-e5800c0877a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_1d87803d-a807-414d-8610-0f0cfb0945e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cdd040fb-42ec-44c9-a113-80b3a6037c8d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_dd644dd7-bc1e-463a-8f85-5b4e6f64e1a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_5000dd24-c06e-4e29-b183-ea574edd72ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_64fc769e-e247-45a6-ad84-50c68561d2dc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_df6aab13-aa9f-4df2-8744-e33ef2abde01_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share with Janssen and royalties for licenses of intellectual property</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_105798c9-44c0-408d-bd91-facbb1b68858_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time estimate for gains (losses) to be reclassified from AOCI to product sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_457b6736-37aa-4226-a246-4d6b3dc6042f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_6f0dbe4d-d275-46db-ac4b-8218b62bb2f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_6f9386f0-4c2f-4774-a763-945300fbdba6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs involved</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_fd688735-4fe6-42ab-ba3f-8da143bd660a_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HBV/HBD</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_789b2740-6358-4225-9f99-a0699f60ca8c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_34848551-d7c7-429f-b556-ff925725f4ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d19e3fb3-97e7-4c9f-973a-2f8ff230ecbc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d9fbf581-63ea-4882-aac6-62c39dd820f1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_04046bd5-ba42-415f-9d40-de8cfdc7fd0a_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f65ad8ab-b9e7-4a6a-917d-736c00af10eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_86a06bd1-0a35-45d7-924c-ea41091f01ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ad8035e5-02fd-43c4-a600-5fbe7918852b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effect of Foreign Currency Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_53fdc393-1dba-4582-acfc-dd1212003c20_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_06373c7e-ea38-42a7-856d-df313b75e219_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_4aa020d0-b1c7-44b8-98c1-a99c7a79675b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d62d0142-f5e6-4e1a-bfb3-f6f6cb10bd27_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2e19d6a6-7b8a-41e5-878f-a3cc207dacbf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a1463d2b-ac5e-4946-9513-49f20fb5d5b4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1447ed07-25ee-473a-99c5-e48c8ed7ae22_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from earnings per share computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_cdfd0d19-6eb9-4c7f-9653-6f0242cf120b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_2ced7eec-172c-43d3-832a-c5be09278f28_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20230331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_c8738319-4566-46e8-9723-5f4ed1656b72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_e215b299-79f2-4998-9cca-ef04b4635ec0_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax impact of $0 and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_b9c88b40-c825-4bb5-9a58-49a29020ae8c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_30fee62d-3058-4768-bda0-053c132ce798_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_92870a50-500e-4024-ba82-81b7dfd6f4b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0779393e-adff-41d9-8340-1df50fbb7e3f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cebe9c3e-81c4-4fe4-92f0-1921fa274d42_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_ffe2e01e-7393-47b9-aa40-8fb37ae6ee59_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_7021562a-7119-4bab-b831-bb33e9a6933e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_052669a4-8cbe-4c8b-805c-a3fa43f9f94e_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20230331.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_75fa980b-babf-4571-a02b-f7baffdab628_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTable_57856f4a-4fca-4b15-80ff-6e5193c1c1e0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTable" xlink:to="lab_us-gaap_ReclassificationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_311803de-4034-45ea-95e3-3346313d46ff_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_4603e669-d749-4658-a3ff-9e7b6f90c50a_terseLabel_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_label_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026 [Member]</link:label>
    <link:label id="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member_documentation_en-US" xlink:label="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:href="gild-20230331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:to="lab_gild_A365SeniorUnsecuredNotesDueMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_39a356fe-9810-4eff-b556-07471965f982_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_dc176afc-4746-4f37-97ee-bb30d7a2a86b_terseLabel_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_label_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036 [Member]</link:label>
    <link:label id="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_documentation_en-US" xlink:label="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:href="gild-20230331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:to="lab_gild_A400SeniorUnsecuredNotesDueSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_0ee92c8e-701d-4ba9-be66-406a72eda8f7_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20230331.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_fcd1765c-7b03-4b56-ad50-120c7da85924_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a53215b6-96ac-4b42-9383-1a9b44f879fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_9e096fa4-7333-4512-97b0-9261dd82e08d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_15a512c7-af74-415f-944c-f8706322ab62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8b1bcec0-b090-4270-b01c-91554d44159b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ecc82333-768e-464f-a102-b5969bd297bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_2d670776-7ce9-47f1-b0bf-191f04e60ac9_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20230331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ae1b3e0d-7465-4aff-bcee-fead753f0f40_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c5a9feb8-92ea-4f4c-bd3c-45262f43c8dc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_779bfed3-93fa-4522-9aa1-daec88ed1e69_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_8da231eb-74d8-40ca-a6a8-44fd1351252e_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_178e8d85-da91-4bcf-a290-07d521b8b9c0_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_aa1b9ca3-6ef9-445b-a477-cef9b0f3a6a9_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20230331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_a8f41c3e-ddd7-472d-ae51-74110bd71cfa_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20230331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_bc985399-2ead-40e8-99f8-494aea1ac4f0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_abddfae6-9b0a-4abd-8f89-833ea31a1ac5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_db92eedd-8b06-4178-9ff2-631436360d2e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5a654458-49de-4103-bce6-3845aa1c1e5b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_bc405e49-83fb-4c80-8143-21080d6ecdf1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_3c1b1ea5-7384-4147-85f1-2ef73b4266bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain reclassified from Accumulated other comprehensive income into Product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_66c7a1d6-d28c-4791-8b2c-9fca8f0bcb07_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_65c2bd0e-63a0-4649-9b2b-0eb5b75885f8_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20230331.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_987c7811-85cc-41f5-b090-bee18d5ab471_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d81d1581-6139-480d-948f-07cf41102d4f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b91c53ed-cb52-4386-a6b5-9693aab85300_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_287d7ee1-eb1a-4fdc-9629-f494531b6bb9_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f63c90c4-fb0a-47bd-a33e-c1a081291498_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bac2e882-8ef4-4673-92dd-c0a15632a4b4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_8f825d99-2de8-4887-82eb-91be338f1edf_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ab767586-80ab-42d1-b1a1-fde49d5e390e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_c87bf81e-903b-48a3-abbd-4dac855b4dca_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b6fc0af2-98d3-44e2-aa60-e8a70cbd1c54_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc444291-9328-4278-95b1-8f261d1f3177_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4571c947-c667-4422-bd6c-b7b5b7de0348_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT AND CREDIT FACILITIES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_d2dbf060-1b5d-45a1-8460-a830ba340d77_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_eebdaa1f-1e94-4f2b-836a-78b26fc8fc7a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_50c28bce-41a0-4e32-8791-99cf5dbc16bb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_08cb4b10-183a-4909-bdcf-e13b918c8377_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_86662bd8-fc20-4599-b1dc-b27fff98a28e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_960eee86-eeb5-47fc-95ed-7c4a0806bdf6_terseLabel_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_label_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:label id="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member_documentation_en-US" xlink:label="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:href="gild-20230331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:to="lab_gild_A370SeniorUnsecuredNotesDueApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_3ad50672-3402-4274-b395-1649d7dc2340_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20230331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_e2983fcf-2e9b-482a-a7d7-8e1dde37b510_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4640c94d-3131-4b4f-ac7f-c230fa33efb0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_5e9fc61a-d467-4486-a856-5588f79f8070_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain (loss) recognized in Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyMember_5ec59d59-d0e6-47a9-b0d5-2f777efb2cce_terseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_42c9d7f0-12da-4622-ba45-1c11136df92d_verboseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_label_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy [Member]</link:label>
    <link:label id="lab_gild_TrodelvyMember_documentation_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember" xlink:href="gild-20230331.xsd#gild_TrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyMember" xlink:to="lab_gild_TrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_32d6bf37-abeb-4707-9d84-53de1700568c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fa8477dc-1d1b-4a67-b4d3-b4cc6b256f8e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_1c85450c-aea5-4d64-a6ca-02e2a26c54a2_terseLabel_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_label_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035 [Member]</link:label>
    <link:label id="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_documentation_en-US" xlink:label="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:href="gild-20230331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:to="lab_gild_A460SeniorUnsecuredNotesDueSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_87a2058d-9b2e-47f2-8689-1cc89398769c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_54602dbd-f424-455c-b1c8-54b38c2ba7e5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ff841d80-687c-4ea0-9d1e-ff19d698a356_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5a2e814b-a20e-4c4c-948c-871c2ecfbc9d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_dbf37b76-aaf9-4ea4-83d3-b3f8afffa46f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_36f36600-9e1a-4d1c-b8bf-9c536f042b1c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_20289324-fbb1-4b55-9161-70ad18c28e93_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_bf97ca14-aba6-4aaa-9db5-411404a7d275_terseLabel_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Liability [Member]</link:label>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember" xlink:href="gild-20230331.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ContingentConsiderationLiabilityMember" xlink:to="lab_gild_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_0c2bbc8f-9d9a-4ad2-b781-5537bba8d284_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a369e2ee-481a-481c-a0ab-96c2e8a7c172_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_f0ec7354-b9af-4c6e-8ece-e10401f0f9cc_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a5a1d229-f8a1-4113-8be8-433b9ab2fcec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_01d8cc9b-3e5f-48b6-a897-bc28cef65aae_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c3f70156-543c-4fd4-a533-9f464750001d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6afb1844-d7c9-406b-a535-fce716f286d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_edf49fc0-011c-45e1-9367-4da3e905281e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7c6e9b30-e34e-49d0-9012-c40b6df66ca7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9b9bf195-6cf1-4095-938e-c638dcadf12c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_846b1836-b632-48d1-924d-6d2969231cff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_cd6b7c30-a978-4250-b649-af8a148762f9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_c8a22b37-8e62-4d5d-bc7f-2c621c8c1b87_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20230331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ac9e7329-7956-4d71-a5e5-c8d27e8074c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_224dc201-8abb-4725-a9db-1368ea26a2eb_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20230331.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_21fd8e72-c5ec-43ef-a9d4-5a1fbd7a0b42_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income, net</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3207e023-b10f-46bf-88e8-09ccbf33f566_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_635056ce-70e5-429e-92f7-ed0cd887131a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification and Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_9627eac5-d7d1-4a0c-b4cd-80232d153694_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_7adb2028-9b10-4dfa-af52-e08be4c4a5f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_4814b2bb-ec4b-4aa8-ae59-059e065fbeb4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification into income tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_cbfff9ed-df03-405e-a9c0-8cb8bd8a33ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_50c883c7-ec18-4de2-b97e-a7c358fefeb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GlobalStrategicCollaborationAgreementMember_670f8181-bd23-42f9-8627-406b34b5b4e4_terseLabel_en-US" xlink:label="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration Agreement</link:label>
    <link:label id="lab_gild_GlobalStrategicCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_GlobalStrategicCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GlobalStrategicCollaborationAgreementMember" xlink:href="gild-20230331.xsd#gild_GlobalStrategicCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GlobalStrategicCollaborationAgreementMember" xlink:to="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_2cb80766-43bc-4189-8bb2-87f5ff5558b2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_2bdffc4c-5717-444a-ae84-7bc3a395710f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_36c80a70-5840-4a7d-bbbe-0835fd55f2c5_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20230331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_2748cb4a-712e-4304-b1d6-8816e968b2bc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_cb594515-b546-4ac2-83cd-99b0bfd6c422_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Equity Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_069048e6-f225-40ff-8850-41d54275c43d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_262c1c8a-f07c-4ed7-8b1d-7c31d85c8247_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecartus</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTecartusMember" xlink:to="lab_gild_CellTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c6344ea8-ba26-4523-b951-e9a8cd3c60a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_ed4b83ff-bb76-4bdf-8ea6-e31e0c34c513_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20230331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_337664ca-7d4e-4973-88b1-4c43937b68e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_f08079e0-5cc0-43be-8fcf-e9ce061f0967_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ea53e19-4f76-407d-9b38-872cc5c1d14c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f877df58-6518-4275-b641-49fb33f78def_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4a4fe367-4b9a-4596-bc3f-6381c0fad84a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4ce26717-ce30-44de-a54d-404c2e269f22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForAssetAcquisitions_ac56673f-8b01-4bab-b307-ece5294fb42d_terseLabel_en-US" xlink:label="lab_gild_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_gild_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_gild_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:label id="lab_gild_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_gild_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions" xlink:href="gild-20230331.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForAssetAcquisitions" xlink:to="lab_gild_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_6e49403d-4229-4c97-a56a-c95184790dc6_terseLabel_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_label_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products [Member]</link:label>
    <link:label id="lab_gild_OtherHepatitisCVirusProductsMember_documentation_en-US" xlink:label="lab_gild_OtherHepatitisCVirusProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hepatitis C Virus Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember" xlink:href="gild-20230331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHepatitisCVirusProductsMember" xlink:to="lab_gild_OtherHepatitisCVirusProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d79e6e9f-f98d-48e0-a661-0d1438aae19b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80934039-62bf-4322-b3ac-2806e0bd3954_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bc75cf97-ae4a-4c99-b3bf-9283b6a628b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bb8ab3cf-69f8-4d73-a654-63f151653f99_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a02be2a9-39ad-4b4f-a683-5a79ed576038_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_3e3b8a99-b4c3-4123-baf4-2f366e288c72_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_885959ce-784d-4407-bf59-dbcae5fbadd4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax impact of $(1) and $3, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_f21473c8-8ab2-4f7e-86e5-2f5134a83c3e_terseLabel_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20230331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A250SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductLiabilityMember_1ede25e2-e873-4aae-9fc9-8cfd64a1e7b9_terseLabel_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_label_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_documentation_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember" xlink:href="gild-20230331.xsd#gild_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductLiabilityMember" xlink:to="lab_gild_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1319eab5-a5e8-461c-b0d9-b956b5f0837b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8cc9c5ad-7121-4452-91b2-6b0e6b9b9d77_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_74555f7c-b0f2-49ec-b88a-ade1389b7f90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_08b6fc82-4217-4f48-b623-7930d179dc77_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_67a18245-aaa4-4bc9-8f7a-4200cc113958_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_90446d23-a0de-4426-a053-b6d75e44a431_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a77616dd-3bf8-44c4-bef7-f4ce7fc8e5f4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4b93c10f-ef5d-48e3-9924-7e2beccb04c8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_83c90a8a-91a5-4bf9-96a2-03e7da9fc032_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5ee9462d-26ba-47b3-bf40-2bdec801b559_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ab2389e1-a207-4faa-9cb3-5400e83d411b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest, net</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65252831-78b9-480f-b8e2-aa12a60fd0a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a54f943-2364-4eb3-bdb1-d74eef875ecc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LiverDiseaseMember_3ca4740b-d4b5-4237-a9bc-7a47a48879f4_terseLabel_en-US" xlink:label="lab_gild_LiverDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liver Disease</link:label>
    <link:label id="lab_gild_LiverDiseaseMember_label_en-US" xlink:label="lab_gild_LiverDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liver Disease [Member]</link:label>
    <link:label id="lab_gild_LiverDiseaseMember_documentation_en-US" xlink:label="lab_gild_LiverDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liver Disease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LiverDiseaseMember" xlink:href="gild-20230331.xsd#gild_LiverDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LiverDiseaseMember" xlink:to="lab_gild_LiverDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_069e9664-7c36-4590-bfb3-26643a34c66b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_badc42b1-d8f2-46fc-b93f-e180bec6bbe1_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HBV/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7a54f557-da57-4d0f-b10a-bb6643c028aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_ccaf7715-c518-4a12-9d7d-5c8fc1ff16f1_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20230331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_25a12971-926a-47b2-899d-594a37a7e39c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e0329cab-5423-496b-9442-e86f5f0005f1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5014f963-afa7-4365-beff-2bd5da21e03e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9b364ce2-b195-4c87-ac10-458ce335e173_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_188f6511-ebed-455c-8e42-c5f28aef3344_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2179726e-4d91-4bd3-b028-68c25a4dde7a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f9ef5e56-db5b-4524-afe3-3170fd024cdd_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e3126c8d-eb30-4f03-aac3-92424a7e951d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2f0dae6b-d673-47c1-a673-47cc0f39b691_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e97cfaf5-c6ba-4b10-9ff7-4b859af3ac74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_b6d2ca09-2c99-40bf-b4c1-e03bd6a08513_terseLabel_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20230331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_A565SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_b7f16a1c-1028-46cd-9726-ab270f97f609_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b13a5166-4057-4db7-9fe2-f8a24983996d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d25be2ab-bf01-4607-a72e-a9b8a22dbfb5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2a0626ea-d695-421a-88ca-06ddde27e97b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_14d874e6-63a4-4b2d-9338-f232ecd7c523_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2de6ad16-0d27-46a2-aeae-935ace77575a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Gilead (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_8cff0c07-1c8b-4b27-8ab9-9ea61b70dc99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcellxIncMember_ecc0c0ec-8efb-4379-9214-c039c03882a3_terseLabel_en-US" xlink:label="lab_gild_ArcellxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcellx, Inc</link:label>
    <link:label id="lab_gild_ArcellxIncMember_label_en-US" xlink:label="lab_gild_ArcellxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcellx, Inc [Member]</link:label>
    <link:label id="lab_gild_ArcellxIncMember_documentation_en-US" xlink:label="lab_gild_ArcellxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcellx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember" xlink:href="gild-20230331.xsd#gild_ArcellxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcellxIncMember" xlink:to="lab_gild_ArcellxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_44eeb549-be5e-4016-8e28-48759ba21241_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_692d0292-9f9e-44dc-8648-de17ea792292_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_b5d27e95-b7e0-4285-92d1-d72d8ec500f0_totalLabel_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:href="gild-20230331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:to="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_a2cb9421-fa76-4379-b774-33aa3e95e41f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b5029203-dbf4-40c4-818d-6bb5511f1578_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e35cdbe9-9577-4de5-a92e-d4302c14f083_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_bd0b5ab0-338f-4979-9b90-ee229f550faa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5f6209a6-b3c5-4cc0-bda4-060c85185100_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_520defb9-248d-4cc1-8afe-9a7118dcb6f6_terseLabel_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_label_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:label id="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_documentation_en-US" xlink:label="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:href="gild-20230331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:to="lab_gild_A450SeniorUnsecuredNotesDueFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_3c764164-3462-4210-8574-f14cf80e2b28_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_28f40247-bf5d-4718-ad06-8cf7d926a7cc_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified intangible assets</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:to="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_73f2b5b5-56f9-458b-9102-c6dc98bfe5c3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_c0a294e9-fe28-46b4-bf9c-65bd6c41ccac_terseLabel_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents" xlink:href="gild-20230331.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyNumberOfPatents" xlink:to="lab_gild_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0e236cac-9bb8-42a0-98ad-7db1a346750a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e3d1416-b314-42d7-bd6a-d8c38847497b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2f544347-7559-4800-91c0-ce6b66a2c8c1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1540a22b-c205-40d2-8f42-7711b6a3073a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c9346f5a-c9a6-4baa-b377-073bb376247f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_913b7b08-d0d3-4497-aef7-25096f9f6717_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yescarta</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsYescartaMember" xlink:to="lab_gild_CellTherapyProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_59a74c37-0225-4a6c-ac03-b2ef542df83b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_bee3b706-6a21-41b3-a240-722389550a40_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c8a370ac-dc15-4c72-8bf6-7920feca1bc6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_6f97590f-fb9f-4d0e-8af5-359df04bfc2c_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_28ab98ce-ced0-4a21-9cd2-8aa551ef0fa3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cb6fd43a-34b4-421b-ad65-c310a768c1a5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_8c60b2ae-31e3-46ff-8c6c-4986f0416d17_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20230331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_76bc5d08-88ef-48fb-926c-f34fd4a46243_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20230331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0918526a-5fcb-42cd-bd39-8aa7b2ec4678_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_392228c1-4ff7-4b27-917d-3313ef56749d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_785f86ee-ef78-4fad-adee-dd1ba79c0488_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock under repurchase programs</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_09dfebfb-176a-4974-be81-ef3e0eb05376_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e2d5af6d-5bed-4c74-b455-069f201f3949_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VekluryMember_e2661332-267d-4e54-9f06-561e2466a2fc_terseLabel_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_VekluryMember_label_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury [Member]</link:label>
    <link:label id="lab_gild_VekluryMember_documentation_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember" xlink:href="gild-20230331.xsd#gild_VekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VekluryMember" xlink:to="lab_gild_VekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8971cdce-ce91-45a6-8e4d-1ae132ede905_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e7f3b23d-f4e9-4cb9-a4f2-0e40ca5083b6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_98546d65-18e8-4c57-bdcd-3742ec9be0d3_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d39cd03e-cfc6-4dcd-8f40-7074af7639fd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_f313e23c-1525-4429-9c98-7ac276d45a4b_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20230331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1a4d33d9-a97d-406b-b302-b1741ddf5d11_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_6cb2369f-c244-4b0e-b33a-0673a530756c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_37739218-7877-41ce-baf6-94b40d0b6197_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1332e246-d289-4c29-803b-ef016fa7ca22_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8a21da36-9ff3-4edf-b020-64bc3db15d12_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_45860a67-349f-4532-8136-c55a642565bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2e875aac-a29d-4816-8fc5-779aa056e2b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d7b65b0a-8990-41f0-b01c-dded0cdf852e_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_100a4a03-3d59-4b69-ba58-e168c3f2a48d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_04f390fb-3adc-4f37-ac94-612101de880c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7a1e64f8-bf17-4b34-911c-0c82bf58ab9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_11136f13-aa79-45f4-836a-6d2b6269f193_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_b704e484-f6ea-4e3a-ac05-7d8b04e2bd42_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20230331.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_fafcd237-6bfe-474b-a9a5-b526d11d5219_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_01d72e00-daa7-499a-a534-c45e3fbb9664_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_d055e61d-a097-4bb8-84c1-ee7acfdbbb8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_40980cfe-1102-4b38-83f4-7de3c61198a2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19583e90-f5b4-4119-af1d-51a18c190bd4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_94ada075-9779-4b45-b4b0-69e4d6e823a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_64608050-1c60-448d-84b8-094e1a651625_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_197123f9-0882-4a42-8c50-56d52ef6c94c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_14cb764b-a19d-4045-8132-82a5a1fb7f8d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_51790d56-1515-42da-91e7-842dcb755f3f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28942d51-532a-42f8-a802-c090f223cf10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f384ef1f-1719-4d09-b3cd-b9ba75355fdf_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_3f4e2256-3147-4fc3-ba37-70fc423dc6e6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa8636b5-94c1-4611-812c-6f86e823b87b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_ea297f90-95e6-4750-9f08-d35d67cec04f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_dda26e30-e208-4e9a-af4f-3b1bd829b948_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_5ee175b4-373e-49bb-b8e6-f70747c414ad_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock under repurchase programs</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1c07ad42-82ac-449c-bfb5-319fc4070f59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_132546bd-4060-4fc6-aeb7-63fe0592bcc0_terseLabel_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_label_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:label id="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member_documentation_en-US" xlink:label="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:href="gild-20230331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:to="lab_gild_A480SeniorUnsecuredNotesDueApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_c0fa00d7-5109-46a0-920f-bf0cfe19e711_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20230331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_190a4d3f-d8b4-41e9-8878-d22c83ac1683_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f8f1d1cb-8b39-48ed-a172-7a688aca14d9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_639ab17a-ed8e-463f-8773-45a2285ce6da_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ff41da0d-af1a-42c9-8702-bb2269b5d136_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_49860bb8-de49-44df-8a66-028f3d886662_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e7346021-68cb-4b75-b000-e23af82ec33e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e26ad727-6a5c-4e5a-83b1-d05f2526ede3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ff43592e-705c-45b4-8ac0-4cca91cce5c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_55e383ff-1480-4f81-bb41-edda9876f2ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_08fced2f-50df-4531-8ac3-8cb2113a0a2d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_f290887c-dce6-401b-92e9-c0b0e8cfe55d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_cffb6538-c0d4-4c0e-8296-8952ae3a5217_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_0f409e7a-7b26-4fef-bcc8-377928134f0f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c7bb8c1c-bf9d-43c4-9abe-80343d256370_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock under repurchase programs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8648129a-7754-4aa9-ab2f-b9f89de82a26_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ba9e833c-4efb-48b0-99e7-a1c1945ef62c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_195b51a0-a875-4d2f-a271-14f177570be9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_95643f73-f0f3-4bd8-9a0a-89b4cf693f70_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d124e1b6-5a12-40ba-a838-03847159306b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_38c573cc-a97c-4c4a-90b7-7ce4d68e9b40_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_96dbaf04-42a3-4a74-bfb6-a845c54c6fc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_479779e3-346e-40a8-bf6b-72a4e9c17228_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_34bc992b-b68d-460a-a0f2-9b98864573e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_cd8780e6-0af5-4830-a3d0-b8b0c62a39fc_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4d85ecb0-6f5e-4f36-aa43-094571591c3e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d65753bb-520b-472f-8e2c-968ccc25667a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_631cee72-f70f-4a8c-8433-f3a2e327920c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_825911f0-37a9-4870-a4b4-44835b0c37e1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted earnings per share attributable to Gilead calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_20647704-aec2-48b2-b46b-ad5892c3a60d_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted earnings per share attributable to Gilead calculation</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_48b284b1-1f86-4a47-ac60-e2fd6bd0cd88_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received / pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3de10fd9-adf5-406b-ae72-8d31aa475622_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_5b9c41ec-adc7-4b7a-a41a-c3b5797b5e9f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f08a2bf-841d-451f-81f1-a8ee5cfd9ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5605a997-4b42-4ee9-828d-332ce813f8c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_6babb2ec-694d-4466-9611-d46c96aa2ac9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d858be75-1c4c-4d91-b24b-1fe716dd921a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,248 and 1,247 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ca0d1a16-2c60-40d6-82b9-4bab4fc30689_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_89a94f56-3c74-47b9-a11f-0f56cf4f5c90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c476c2a4-f152-4979-b777-d22c5cd8b665_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_42d5f9dc-69a6-47f6-a18d-9cfa5c82be06_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_15f9f2e0-eb89-41b9-a788-d52879ebbd6b_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_58b5951b-1ecf-4b5e-aad2-0a17ba227e86_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_acde7c49-c45b-49e1-97c8-efb45a1085b1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_71ed0d42-a2c1-48d5-bec4-b1e1bd92461f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedRebates_6f163020-c1a1-46f6-af88-2da31fe8c757_terseLabel_en-US" xlink:label="lab_gild_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_gild_AccruedRebates_label_en-US" xlink:label="lab_gild_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_gild_AccruedRebates_documentation_en-US" xlink:label="lab_gild_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedRebates" xlink:href="gild-20230331.xsd#gild_AccruedRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedRebates" xlink:to="lab_gild_AccruedRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49458dcb-a584-4e97-97b0-846af63c5698_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ee0a722-4075-4a9b-b62f-ac0dc5cd80cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_64e03be5-567f-4d85-a99c-a266ba64dc2d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_bd6172f0-87ef-4672-bf66-13578de3a393_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f7154a8c-fb1b-4a8c-858b-84df10451b0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6fb74b57-d68f-4fbb-9b6d-9b47f44687dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d991a0ec-983b-4d53-9471-127c95417691_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_673fb616-5777-426d-897e-d42e67dc9c19_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_6ff2a031-af1b-4943-9aa8-3dced3251266_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1ac848ff-4334-4a1c-9bf0-5c96bfd394ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b4a96bb2-392c-4d27-a174-7665068023a8_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_39ea3c76-f62c-41ad-bb9d-06bd819d1d01_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec901450-d2b6-443d-abbc-5d54e086cd02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_bb911627-9d06-4c00-bb62-b8b7d9e9ff08_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount (legal offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_11bdc9f0-aa19-485e-93e0-cf4d15748822_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class action lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_eb095420-31ae-48d7-afdf-d8b7368fdf11_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a515591d-e035-49d4-a90a-3eefd6169f54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6f5a4441-8318-467b-9e13-cad10e3a460d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_58cfc066-fdf7-48a2-8ac8-efa9e03f76a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5a4ef6fc-379d-4578-988d-419edc52bfdc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Gilead, net</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_d7960eb3-b221-4fea-a06e-5607fe12a5e1_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_120a87e0-ab84-403f-922c-461b2c6f1dc9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_78891fc0-cf4f-4b16-8a48-e6d33f9cabd7_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20230331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d99ed87e-9340-420a-a62a-f509e8a0553f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5aa6f4d9-2eab-4c80-b9e4-e7f5aac03e91_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6b9eb4ac-916c-4ae5-bef4-98a9c64960ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9b85532b-5af6-4b9e-ada1-71d120fa609c_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6c167fc7-4837-4939-929e-dcbd468f3de8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits_b2c89136-2071-4451-8c66-f2bd7fc2c1fc_terseLabel_en-US" xlink:label="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, performance obligation, percentage of U.S. profits</link:label>
    <link:label id="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits_label_en-US" xlink:label="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage Of U.S. Profits</link:label>
    <link:label id="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits_documentation_en-US" xlink:label="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage Of U.S. Profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:href="gild-20230331.xsd#gild_RevenuePerformanceObligationPercentageOfUSProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:to="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1296bd61-299f-425f-b4f2-70388a412648_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_56c875d6-32a5-41d1-940e-a8def79be1b5_netLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ee3a066d-362c-4ea3-bd62-eac7fa8a0d8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6f224ea3-747c-4694-866c-b6a634693ab9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_81e0fd02-5e42-42f8-9685-0406e1766a04_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value&#160;</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_be357aba-e8b1-4e3b-82a4-56fb874816a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_ef762a34-e5d3-4728-ad55-948eb8478ccf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e6260655-31d9-4213-8da6-5fb1fffa5d3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2819a8cd-7759-4fa4-82cc-80627499c1ca_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2fc9343c-667e-4e58-bb17-7bd456b45e7c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e56e7ff2-1804-4385-80ae-b93aa051f6d6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_96f7bbc9-e0ec-446f-937f-83b554d43578_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_547c2272-0009-4505-966f-2e8c69463f9e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_574a264c-c5ce-4ae4-a973-23597dc24d99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0df2db2b-6ea1-4a37-8bed-ef0795048134_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_5bf1dc5a-e0bb-4a33-8cd7-c359369cd346_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets, fair value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_a15db753-5678-4ad4-9b89-7626574ee523_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_41212478-b228-4fbb-a5ff-6e5c6d70e419_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_086ca391-0aab-4f32-b0e9-664e0f109483_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ed0718f4-9cf7-4488-aa28-50bbf713fc47_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_98bceafe-0d32-452e-b764-b2c27c22dc42_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_469fa5f6-f458-4d84-b01a-2726e08b756e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d69ffe05-9981-4c3f-aa96-8cbd1c528142_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_3a6becbe-e974-46c6-b5ca-e092bb2633f5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_21fbc5d5-3a5b-4c46-939b-0a3990871b38_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain (loss) recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_222bed54-1ce2-4990-8659-e23346262d81_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b7ed9837-4f0d-4711-b80d-65b76903b723_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8ef1c9a4-4079-4839-8805-588f4bc3c1ca_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_a3c8cce7-d4d0-437f-953c-7866d4178e3b_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bb24a97f-d54e-4da9-84e4-4e7c4521e3e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PreExposureProphylaxisMember_72d0789a-8dcc-4722-8e8f-71a3c1047311_terseLabel_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_label_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis [Member]</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_documentation_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember" xlink:href="gild-20230331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PreExposureProphylaxisMember" xlink:to="lab_gild_PreExposureProphylaxisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_2fa1a101-592f-4356-a6fe-c02b07b73750_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20230331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_5546eaf5-61f8-408b-9ec4-8acf41483215_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential future milestone payments</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_label_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:href="gild-20230331.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:to="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b6f029a6-0bf8-4cdf-9687-ea783b46cc59_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_2aff3d45-21c2-4a85-bece-5aef25fc1355_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedges:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_91551ceb-75ea-44f7-addc-cd33473d431b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_ad7caca1-2153-4aba-9c6b-814cc94b19c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_44af82ac-3b76-4550-a259-ae88a0c63a90_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20230331.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_42d5a4f6-82df-4ae1-8ac8-8126e6d5ec74_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_936a46c2-8210-4c42-9968-791023c581a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_f87545f8-aae5-474c-9c62-e49972b97465_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20230331.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_96c61118-ffe0-49f5-ab36-8d5b3996c3ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_5bad3e27-56d0-4f5e-a6fb-d158202cc82c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e296da6b-c82f-4c9f-97d3-d49041cb59a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f9946431-cef3-4597-b0b4-0bb844e0568d_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e22f8e6-7c2e-41de-b368-b7e3ebd3aa8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ec0007b4-c9cc-4674-9d8b-017f8b89b699_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ac120888-5165-4958-8610-fa2c5e0586d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ead31fd7-569f-41c1-8b57-8076ee5390b8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_cb55deb5-523e-4da2-95fe-69b028dc5e81_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate, measurement input</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6a1c77aa-ce4e-493b-b814-61f801931de0_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8806d034-d6a6-4d14-bd8f-1cd75dc2b3ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_60376a42-0c6b-4aed-9bac-4989dce125d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_eca7c9a8-16b1-4f24-bdbb-d72dc25153e3_terseLabel_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics Inc</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_label_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics Inc [Member]</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:href="gild-20230331.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:to="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_40b3c6ee-aa5e-4f10-8816-52cd371fed03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationLineItems_2242c5bf-89f0-4577-8ddb-f80d176a2225_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationLineItems" xlink:to="lab_us-gaap_ReclassificationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f34c2624-1452-4f52-8793-8f37832fbdbd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_eeae620c-1431-4b64-8737-be7d257d1e49_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_cd3aace9-67b3-45fc-8ad6-9515777a2d1f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_ba716677-5098-4042-9869-e7a93cb6323c_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vemlidy</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_90fdb61a-9e75-4b63-81be-4a01d2395aa2_terseLabel_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_label_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:label id="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member_documentation_en-US" xlink:label="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:href="gild-20230331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:to="lab_gild_A295SeniorUnsecuredNotesDueMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cf52c0ec-3218-4d34-b57d-3ad064cc6fcc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_409bcd95-176a-4ff1-8c2b-fa8c816cf309_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f620d014-9db3-41ea-a651-7569ec1a3252_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_84b70552-f057-42ce-ba18-0977ee575263_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0c34fc67-a0a1-4553-86d4-00c9922a7177_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_90fa149a-7b7f-4cd2-aa1e-25a6caef8062_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_a795e2c6-4152-4af6-b76f-396938927d27_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:href="gild-20230331.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f300c9f-4de1-4b75-9d11-f67cc16255e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_f3d49f43-3a08-4752-a93d-c90040315c10_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1b64cb75-fe39-4919-ac2e-6dea606db113_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_53b7187b-0533-4528-995a-fb2cb9921abc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_c0a61d1a-a519-4ade-b8d5-f3a7c96324e9_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20230331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_d4115084-a285-4194-ae3a-5e99b667a9f8_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20230331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6e0a6c9b-df14-42fc-9f56-3d6f9af57aea_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_36279b50-b7de-449a-9387-b924327e2511_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6505a24d-42f8-4ba1-9e10-02f576856308_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9639f84f-eb77-4b73-b143-73a1819f65d1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae11244c-49ee-40fd-aa51-ffc608525e06_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic earnings per share attributable to Gilead calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bca53337-cddd-4c2c-841b-f69025167a8b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic earnings per share attributable to Gilead calculation</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_ccde8450-bc2d-44d5-831e-b91f5dcff82e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f39c418d-be68-4d0e-a594-0b3508977f8c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_14d5bbaf-8f66-465f-a199-df9bcf78a10f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_77c00ad9-57b4-40e7-a596-7c9c2ad4bb63_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e82f109-1641-4350-ad5d-9083e462487a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_c5140599-9018-4def-9529-4c57983b0841_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments and equity method investments without readily determinable fair values</link:label>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</link:label>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:href="gild-20230331.xsd#gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_29ae7fe9-56fd-4dd1-9b2a-5c5a0efec93f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_033c2785-01ed-46f2-956e-aaa94e51e75a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_71813cc1-75c5-4817-927b-10964bdea523_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_9d54602f-6653-4fee-a743-7cce5b0a0a18_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount (legal offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_6730a769-6447-4477-8929-ba5bf4c45160_terseLabel_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2-</link:label>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_label_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2- [Member]</link:label>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_documentation_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2-</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:href="gild-20230331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:to="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_bc189806-f9c9-4f2f-997e-18fe925ad632_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_29b3f986-e3ae-448a-935b-b2b9951289c6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_6740f5da-3e47-4dab-b166-94a564f5f977_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to net income, net of tax impact of $3 and $3, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_81c33ed7-f031-47c4-b127-f6ad0c61427c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible IPR&amp;D charges</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_0b9a30ae-f0fc-4746-96cb-ded7d0a9c961_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Debt Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_d406649c-7ab3-4dbd-96ab-ffac34342166_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_203741a4-3e94-4927-b10c-71c321f69c6d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_e9a6583c-c361-4f08-812e-92e5c17e3891_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20230331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_cabbaaa2-d901-4045-bb9c-2cb3fe8af605_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_57b2ac02-72dd-42bb-94b5-319c4ff02379_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_63931193-6955-4e75-bd1c-72177fc64ede_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0c46b05e-93b1-4da3-8902-2155601856e2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ad312908-9962-45b7-af6d-8e60ec4edeaa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_aa61bb23-70ad-4954-af19-d71db011c0c9_terseLabel_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium-Term Notes</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_label_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium Term Notes [Member]</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_documentation_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:href="gild-20230331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:to="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_907a4052-cb87-4d7e-8f6e-9c76bed491e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_95feb53f-7f00-4808-968d-f0d701d32b3b_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20230331.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_20bcd581-01fa-4968-b3e9-855eb140c6f6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_85f6458f-e093-4ff5-863c-5b64a6e51240_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_c85514c2-153b-4cea-a791-f6917b6ec1e0_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20230331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_df90e6a1-4bc2-48df-93ea-b07158791aa1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosMember_5c8de29f-5e14-4e59-a028-5961daca0498_terseLabel_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos</link:label>
    <link:label id="lab_gild_GalapagosMember_label_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos [Member]</link:label>
    <link:label id="lab_gild_GalapagosMember_documentation_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos, a clinical-stage biotechnology company based in Belgium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember" xlink:href="gild-20230331.xsd#gild_GalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosMember" xlink:to="lab_gild_GalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c735f2e9-8515-4e92-a83a-0c48f61e9802_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_8ebbfc73-fddf-4f9b-a056-82bb09cce6cd_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20230331.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_716f640c-8794-4efc-ac8c-e64368224ee1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_044bce81-bf48-4358-aa1b-7aabb4a61f14_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_e55ba1fc-dbd6-4295-b75b-cd608ccde0ca_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_02dcce4d-524a-4605-8a65-062ca51d152e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2f912413-9383-4ae7-8b0f-4dadf8f3238d_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_10d30808-e2fb-44cf-9f2a-609fa1b59d11_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20230331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_95a1b9d5-d398-4b56-89ce-64eea7b38a80_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedges:</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2ec7d8d4-5e8d-4943-81d3-2f2658fcf012_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_28d58299-6fc0-4e55-8a0b-5cdbb148f7ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0a9c8845-ea92-433c-a4a3-ecb77e60166b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_117a70e4-4e9d-4ef3-af84-91346d986464_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_19db3ec9-827b-4322-8367-ff660839895c_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20230331.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9eead911-8bbb-4f45-ab19-df734803bd85_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_57b04cff-17c1-48ff-9ad0-2476ff40dc11_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ab0f1533-2e8f-419f-bc8b-e9b0bf7319ed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Gilead (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e60b52d4-7f71-47b4-9523-7b5ec92e88b2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1ebfee8c-f3e8-4498-b55a-db1ecf6aac77_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OncologyProductMember_6321d1a9-139a-4678-8609-d672a39836cd_terseLabel_en-US" xlink:label="lab_gild_OncologyProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Oncology</link:label>
    <link:label id="lab_gild_OncologyProductMember_label_en-US" xlink:label="lab_gild_OncologyProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology Product [Member]</link:label>
    <link:label id="lab_gild_OncologyProductMember_documentation_en-US" xlink:label="lab_gild_OncologyProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OncologyProductMember" xlink:href="gild-20230331.xsd#gild_OncologyProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OncologyProductMember" xlink:to="lab_gild_OncologyProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_f620fa4c-758e-4e76-87ab-cf09d6faebd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2baf854d-8b2a-4be4-9c5e-cfdea892dca3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_1e6084f7-d958-40f0-89d1-0d663140e499_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_af51e509-e172-41c9-b016-fc5ea099486b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepcludexMember_8e183990-eea9-4abc-9528-ce598c35b9f3_verboseLabel_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexMember_label_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex [Member]</link:label>
    <link:label id="lab_gild_HepcludexMember_documentation_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember" xlink:href="gild-20230331.xsd#gild_HepcludexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepcludexMember" xlink:to="lab_gild_HepcludexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_4fb0d6b7-69c1-4227-908a-aa6c209c6eec_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20230331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_7a38fa71-dae5-4878-9160-46de2da5c3b3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7c2fe0b5-ba35-4841-aaa4-b0c0c3decdb5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a4e69fc8-3026-4094-b49b-6155bd243a67_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_c427e1af-a3f4-4b06-a056-0c91ed0221d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c553fb55-abc0-43ce-ac9b-5ab8b78f8338_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_cb96a0d0-d854-4afb-b276-1d42d68cb1b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_16ae1fbf-70ec-489f-bf7a-aaf5213f47a3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_55c3f6d8-5ac3-4fe7-94fe-d776db5e79d6_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20230331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c0cda4e8-31a0-4dae-8cf7-ac53f3457012_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_fcbf1217-b5a2-45f5-837b-542a62f2ad7b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_59fa98fb-f3fb-48ff-8b2a-afb72f1e526b_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_f6555601-f20f-4965-ad89-7ad21cfbc8aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_76836b44-1601-4981-9c35-92413382636b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_b4280e2b-ec0c-4d78-b8b8-21cb2aa57485_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_4b2e2a22-ed67-453e-979b-ec9bead3d2db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenues from Major Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a42a9f84-b1a4-4aee-9a94-e4344c8935cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_845b3294-bab7-408a-b9df-fe09e7d54ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_56a16125-9d50-48d4-b770-0e687ab123c7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8752755-e7ff-4045-8bd3-8de17230c754_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ffcbcb15-ef9e-4297-bf57-7eef9f73a926_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_9afc8a72-e9fd-47df-a724-c988e4ef0e78_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_26e8309c-b6ad-488b-b3cc-f8145ba44293_terseLabel_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_label_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:label id="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member_documentation_en-US" xlink:label="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due March 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:href="gild-20230331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:to="lab_gild_A475SeniorUnsecuredNotesDueMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_fcdba318-6ccd-402f-8886-225cd8e96516_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received / pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3c2d4b65-2466-4173-8c42-aae2e9cb052d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_1dc7abce-e2f1-4dfd-a2df-bdc58d706e14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5613116b-69fe-428a-b7b6-80df51a38349_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_b759956c-f14b-408d-a463-85464ac79ff3_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viread</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_a1bf2a40-28fb-4292-8c4c-f583a12c9e17_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_042f1fd7-e434-45f2-8fa0-1e4efb07e215_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6d78a61e-6891-4d43-b58d-0b3d941c4ffd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax impact of $0 and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_f791f3e1-b02b-4d31-b6af-c0b1a9e72563_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5886a36d-1ebf-429d-bb33-9977ea2f8024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_d63cc885-5117-4b7a-81e0-85f9e2b9bb22_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20230331.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_e5a57815-2dd6-4e8e-bf8e-bb2e16b80501_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20230331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_813345eb-6bdb-4be2-b5c3-2ab1385990d0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_33db49fb-4f40-41a4-a832-d6998b89c5d9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_80a45fc8-4ba5-4099-8fda-5953ba704cb3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_bcf23ec0-b63c-4383-a62a-ac1bf1ded23f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_d34bd580-c85a-49c4-b930-7f98beacc737_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_05fbbdf8-3537-4d8c-8512-366835882a80_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Disaggregation of Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_bc0e833a-2c30-4d28-bc0e-a446803f25f3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_e9a2ab99-e8cd-41c5-a88b-853f712130b7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2306af53-3771-4c6c-8278-2a4b9a290f0d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_ce9f4302-a52c-49f8-ab33-9feacf419198_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties appealed</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber" xlink:href="gild-20230331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesAppealedNumber" xlink:to="lab_gild_LossContingencyPartiesAppealedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_c497b3ef-a422-4613-a66f-64cc67dc8411_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock for employee tax withholding under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2abf502f-9968-490c-91c7-c036e5868919_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_150f3cd0-a560-4d3e-897d-96d7b82e6872_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e794ae7a-7539-4d64-842a-f71c070ddacd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8c1cfedc-f7fb-4d0c-83c8-1f0d982ca207_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20230331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7cf85eab-ebab-4791-81ec-6ca6a8221914_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c1dd3f9e-a2f9-4291-9a67-b13197b75e31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e546380e-799d-4c48-9012-5b5bb2377d79_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_05d24907-ab22-461e-b3ba-8c827877dde3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock for employee tax withholding under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_56ae7b0b-a960-4d0c-a1ee-251b75f3872a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_af83ddf3-7ae2-4b52-959c-697a239de0fe_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_6dca5943-f179-4fad-981f-052d43faf126_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_97302a63-2ea1-4413-822a-48db202ab626_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_9df2fb31-0dc5-4444-a0c1-b527bd47ecb1_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; axicabtagene ciloleucel</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:href="gild-20230331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_aa12e404-2976-490a-856b-8fdae302ec79_terseLabel_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_label_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:label id="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member_documentation_en-US" xlink:label="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:href="gild-20230331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:to="lab_gild_A415SeniorUnsecuredNotesDueMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0af5a649-ace0-4731-b374-54df9bcc84cf_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4f3e389d-21be-443c-b91f-a441efd4b043_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c711c44e-bb59-4bca-9e85-33ad346706a2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_309275d0-7ebd-4a0d-aef4-64271679de7b_terseLabel_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange remeasurement</link:label>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_label_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</link:label>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_documentation_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:href="gild-20230331.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:to="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_41c41129-c2f2-4346-a042-7edcbfa68e13_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinuances of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_faf38c55-b3c9-437c-b4a0-729addc8962e_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20230331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_076bd7e6-19b3-4c5b-81d7-4ae3b8326425_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_f0244295-823f-4336-b3b5-7dfac12ecaae_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_45648cd8-2ab8-4c89-8920-6f2cdb92d080_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_224ec3f8-c9c4-434d-babf-59578abd3896_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6587fca0-31c1-4669-9267-cdbd2eb00c47_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3d65cba8-ba47-4422-b331-2865cca2e72c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_343d4ac0-a12a-442f-827a-4316bcfda554_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d967241e-61f8-424b-a45a-0257f82af4c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_2fba2d08-4b2b-496a-8141-d513e84e54c3_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20230331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_d4a7f71e-a4c9-443c-8bb1-ab6551d986aa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimates</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3d24981e-c362-486a-8a71-fc0f768ec70c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_39de8126-4c46-4aa0-ba76-d1621b5d4c81_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3ba99536-a719-4b34-9f33-960dfebfa38e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_f0e7e275-8f29-4894-a8e8-18e7a2404c3b_terseLabel_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_label_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:label id="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_documentation_en-US" xlink:label="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:href="gild-20230331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:to="lab_gild_A350SeniorUnsecuredNotesDueFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cf8b952d-fc2a-4645-bba0-2165a21f9b4b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_df71743c-5fef-4c75-aae0-368b1a73da3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Calculation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_44a70704-777f-43c7-9cfc-aa4970390365_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20230331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8cde4cd2-d135-457b-bb48-2648cf50d4fc_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>gild-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c106b7c8-2bb1-4b42-ab62-c7781606086b,g:b0acd2cc-13f9-458d-8974-066f309efac0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CoverPage" xlink:type="simple" xlink:href="gild-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_607c3827-1f7a-4f96-9f1a-46575f3fe8a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_DocumentType_607c3827-1f7a-4f96-9f1a-46575f3fe8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ac762756-2d15-484b-ac85-9b403bd93069" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_DocumentQuarterlyReport_ac762756-2d15-484b-ac85-9b403bd93069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_908362ed-9420-42db-9172-bff17d0e3488" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_DocumentPeriodEndDate_908362ed-9420-42db-9172-bff17d0e3488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_537852c8-d44c-477b-bcbf-52dd9cc37dc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_DocumentTransitionReport_537852c8-d44c-477b-bcbf-52dd9cc37dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8218ecae-a3ef-4401-a7d7-f5772dbb60c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityFileNumber_8218ecae-a3ef-4401-a7d7-f5772dbb60c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_44e7bdc4-d996-4a58-bb68-c3be7062571c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityRegistrantName_44e7bdc4-d996-4a58-bb68-c3be7062571c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_edd319fb-c6b9-4f94-aa94-c4c884b3d927" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_edd319fb-c6b9-4f94-aa94-c4c884b3d927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4cd803c7-07f6-4518-93bc-c106f169952d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityTaxIdentificationNumber_4cd803c7-07f6-4518-93bc-c106f169952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_48f240a7-5ba4-4054-82e5-cbdcabe6c8cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityAddressAddressLine1_48f240a7-5ba4-4054-82e5-cbdcabe6c8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_773076ad-7f49-49ad-b2e1-c67d5e0ce0ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityAddressCityOrTown_773076ad-7f49-49ad-b2e1-c67d5e0ce0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_858fa9a1-3ef3-4b0f-a7a2-e36fb60df01b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityAddressStateOrProvince_858fa9a1-3ef3-4b0f-a7a2-e36fb60df01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_00625c3f-2b2f-4204-9e3b-911ec94b0b64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityAddressPostalZipCode_00625c3f-2b2f-4204-9e3b-911ec94b0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4ab8641a-1e9b-4fdc-9da3-2e851b71329c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_CityAreaCode_4ab8641a-1e9b-4fdc-9da3-2e851b71329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bc373265-fa97-41ba-b948-5271413c0406" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_LocalPhoneNumber_bc373265-fa97-41ba-b948-5271413c0406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4cf0982c-2943-4bc3-8450-f82d1c921cbf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_Security12bTitle_4cf0982c-2943-4bc3-8450-f82d1c921cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_90883504-b630-4ed4-83fe-56b040490c07" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_TradingSymbol_90883504-b630-4ed4-83fe-56b040490c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9a191f11-21af-481d-99f8-b621b917644f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_SecurityExchangeName_9a191f11-21af-481d-99f8-b621b917644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_512bcf60-21bb-4258-876b-1456538affc3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityCurrentReportingStatus_512bcf60-21bb-4258-876b-1456538affc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7337cf04-7c5a-4d83-b7b3-6285440350b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityInteractiveDataCurrent_7337cf04-7c5a-4d83-b7b3-6285440350b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_202e79cb-ddd3-42b2-b669-20ebc60de12a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityFilerCategory_202e79cb-ddd3-42b2-b669-20ebc60de12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_10854e5d-f128-4308-ab7b-ce90198078b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntitySmallBusiness_10854e5d-f128-4308-ab7b-ce90198078b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_84e9002a-c8d8-4973-92a9-69b508c0dfac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityEmergingGrowthCompany_84e9002a-c8d8-4973-92a9-69b508c0dfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5b77e4c0-acae-4c63-8423-b49c36368673" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityShellCompany_5b77e4c0-acae-4c63-8423-b49c36368673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6d78ba13-1508-49b4-8be2-8fdd786ec2b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6d78ba13-1508-49b4-8be2-8fdd786ec2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_55d69071-71fb-4a92-bb73-875af810fe7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_EntityCentralIndexKey_55d69071-71fb-4a92-bb73-875af810fe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9ba79213-1273-4101-8ce9-44940bde0636" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_CurrentFiscalYearEndDate_9ba79213-1273-4101-8ce9-44940bde0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_87fc4c30-0e9b-457a-8e25-4f37281c3422" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_DocumentFiscalYearFocus_87fc4c30-0e9b-457a-8e25-4f37281c3422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8e44fe94-8210-4f25-9338-4eaa8d268286" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8e44fe94-8210-4f25-9338-4eaa8d268286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ef71291d-1b21-4b8b-90e7-0cead122dbd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_554542f9-9867-4560-9cdd-8883ed0d7d5e" xlink:to="loc_dei_AmendmentFlag_ef71291d-1b21-4b8b-90e7-0cead122dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17a81f8f-6c91-491e-b292-8f377b148b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17a81f8f-6c91-491e-b292-8f377b148b5e" xlink:to="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f82d508-0099-40e6-978a-6c105e5f1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5f82d508-0099-40e6-978a-6c105e5f1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_613c9998-5871-4b09-a38d-8b824bd244fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_613c9998-5871-4b09-a38d-8b824bd244fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0fc03153-0daf-4513-b3ec-77e0315601c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0fc03153-0daf-4513-b3ec-77e0315601c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0df45dbd-8643-45a9-995a-862882160e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:to="loc_us-gaap_InventoryNet_0df45dbd-8643-45a9-995a-862882160e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c448f013-8526-4b75-ac22-d9575f9ceb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c448f013-8526-4b75-ac22-d9575f9ceb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d08c55f7-cb32-40c2-a082-92f9d6c8bcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4383875f-cd0c-40b7-ba6d-03f93ac3a51f" xlink:to="loc_us-gaap_AssetsCurrent_d08c55f7-cb32-40c2-a082-92f9d6c8bcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0190f2bc-4a6a-4584-a42b-ac46b6911ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0190f2bc-4a6a-4584-a42b-ac46b6911ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_68469157-9469-4b90-a8f7-b4fe52ba86d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_68469157-9469-4b90-a8f7-b4fe52ba86d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_740ab752-0218-4855-9de7-e6d0649f4318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_740ab752-0218-4855-9de7-e6d0649f4318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_422b6e1d-1ae1-4b93-9330-06f186da9894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_Goodwill_422b6e1d-1ae1-4b93-9330-06f186da9894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9f821f82-58a9-4c1d-bbaf-c7a58cf337a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9f821f82-58a9-4c1d-bbaf-c7a58cf337a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f5a84eed-4ff8-41a7-9204-18ea4fc0fde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c72e119-2f02-4c41-8ec3-fcfd8114a1ae" xlink:to="loc_us-gaap_Assets_f5a84eed-4ff8-41a7-9204-18ea4fc0fde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17a81f8f-6c91-491e-b292-8f377b148b5e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3638ece0-08b1-4181-84cb-e6a8bbd60cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:to="loc_us-gaap_AccountsPayableCurrent_3638ece0-08b1-4181-84cb-e6a8bbd60cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedRebates_cb6f3020-c94e-4b62-aded-405390ecae0c" xlink:href="gild-20230331.xsd#gild_AccruedRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:to="loc_gild_AccruedRebates_cb6f3020-c94e-4b62-aded-405390ecae0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b0f64bdf-4074-4f78-9dad-5444ed772e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b0f64bdf-4074-4f78-9dad-5444ed772e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_a1a25782-54ba-4adc-929f-d01eb72cf7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:to="loc_us-gaap_DebtCurrent_a1a25782-54ba-4adc-929f-d01eb72cf7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d3c7c14e-e8f7-483d-b1fc-3db8c8f7310c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79b17ee4-25f0-496d-95fd-426ac4032234" xlink:to="loc_us-gaap_LiabilitiesCurrent_d3c7c14e-e8f7-483d-b1fc-3db8c8f7310c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3b3ec2e0-7272-4197-8169-f43ed9cb57a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3b3ec2e0-7272-4197-8169-f43ed9cb57a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e07f8f4b-115f-4c32-992b-8633467979c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_e07f8f4b-115f-4c32-992b-8633467979c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c0a9c2f2-3b71-4a22-bd1e-d793069bf2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c0a9c2f2-3b71-4a22-bd1e-d793069bf2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0c49afea-78b1-4eea-9d92-e1f6dbc9b08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0c49afea-78b1-4eea-9d92-e1f6dbc9b08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_765caef8-43b4-490f-b45f-e2b74347e8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_CommitmentsAndContingencies_765caef8-43b4-490f-b45f-e2b74347e8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6d0819a6-535b-45c1-9699-0361a0522f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_PreferredStockValue_6d0819a6-535b-45c1-9699-0361a0522f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e72f4314-f510-44e1-a76d-7ebf18d6f738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_CommonStockValue_e72f4314-f510-44e1-a76d-7ebf18d6f738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d41d233a-e1bd-4fb2-a95d-612e5b85d98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d41d233a-e1bd-4fb2-a95d-612e5b85d98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50ed0fda-d6b1-4559-8862-85297dcb4fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50ed0fda-d6b1-4559-8862-85297dcb4fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8ad7d494-dbe4-4f17-8bc6-1e0904a2c541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8ad7d494-dbe4-4f17-8bc6-1e0904a2c541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_17a0034e-26f8-48f9-aeb2-28445a5e19a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_StockholdersEquity_17a0034e-26f8-48f9-aeb2-28445a5e19a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62f1855d-92e5-49e9-8ada-50190f1b7363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_MinorityInterest_62f1855d-92e5-49e9-8ada-50190f1b7363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1dd9f8e-aba2-4362-901a-b95f56a1e027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1c7d3da2-036f-478f-8696-193f41d803dd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1dd9f8e-aba2-4362-901a-b95f56a1e027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9975b5cb-a617-4c82-acc0-62c86f0cde8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bc2cfc3d-56af-4cc6-a963-5ac23dffc953" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9975b5cb-a617-4c82-acc0-62c86f0cde8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c99a1df0-9619-4993-a795-3760be5de59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00137057-849a-4531-85a5-728b120d1af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c99a1df0-9619-4993-a795-3760be5de59a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00137057-849a-4531-85a5-728b120d1af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00137057-849a-4531-85a5-728b120d1af8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_70dfc757-3446-4261-9e8d-a3afa1c2aade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_70dfc757-3446-4261-9e8d-a3afa1c2aade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_17acab7a-ca45-48f0-9fd2-ec5041682a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_17acab7a-ca45-48f0-9fd2-ec5041682a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cb54b021-5fc9-4a5f-8c9c-4424f9c8ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cb54b021-5fc9-4a5f-8c9c-4424f9c8ed72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f76e705e-1624-40a6-93dc-42ad91dd390c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f76e705e-1624-40a6-93dc-42ad91dd390c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8ab089c9-7788-4871-a46d-14076e4a138e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8ab089c9-7788-4871-a46d-14076e4a138e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1a1433dd-9c75-4141-be02-b7b488f6d2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_CommonStockSharesIssued_1a1433dd-9c75-4141-be02-b7b488f6d2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f8aecd5e-28ed-4065-b501-2580761fcf91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_23c8dd99-7420-4490-b167-d5776676e595" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f8aecd5e-28ed-4065-b501-2580761fcf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_55050e19-9e2e-450c-b5d0-8ca01a533ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_55050e19-9e2e-450c-b5d0-8ca01a533ef4" xlink:to="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:to="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_80c22b6c-acdc-4c72-9eb2-9a03c801a9f6" xlink:to="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_31b894c5-68cf-4dd1-ba63-d9e94631b29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:to="loc_us-gaap_ProductMember_31b894c5-68cf-4dd1-ba63-d9e94631b29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_f1f52ff5-b603-47bf-8c08-68f37e58548a" xlink:href="gild-20230331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3c2cc0d3-2eb4-4b94-8b5e-6fad1022530b" xlink:to="loc_gild_RoyaltyContractAndOtherMember_f1f52ff5-b603-47bf-8c08-68f37e58548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_63a23a8c-336d-4dda-8fc1-390e5a98af35" xlink:to="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e08f4d9d-d659-41b3-bcc7-32f6e0fe14e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_RevenuesAbstract_e08f4d9d-d659-41b3-bcc7-32f6e0fe14e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_083ffd9c-fd1a-43a7-b20b-aafd6d9a67fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e08f4d9d-d659-41b3-bcc7-32f6e0fe14e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_083ffd9c-fd1a-43a7-b20b-aafd6d9a67fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1abab8c0-5c86-4503-9eef-0f06b1432876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1abab8c0-5c86-4503-9eef-0f06b1432876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c76d17e-5a67-4cc2-8c08-b82d72aabfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9c76d17e-5a67-4cc2-8c08-b82d72aabfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_edf3617b-17cd-4822-b527-7db740466f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_edf3617b-17cd-4822-b527-7db740466f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3a751364-0e20-41e0-97ad-7de191749cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3a751364-0e20-41e0-97ad-7de191749cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fcc3f4-fd57-4d16-b9b3-82852e7e38be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fcc3f4-fd57-4d16-b9b3-82852e7e38be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7745d5e4-9a2a-4482-a5da-571aa353f294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_37dd1b35-b6a0-46fa-bff2-609eaf7aee6e" xlink:to="loc_us-gaap_CostsAndExpenses_7745d5e4-9a2a-4482-a5da-571aa353f294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eda15d49-2677-4da3-a1cb-c043ba18e203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_OperatingIncomeLoss_eda15d49-2677-4da3-a1cb-c043ba18e203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fa5a5a43-e0f1-4736-9734-1bea12b3986b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_InterestExpense_fa5a5a43-e0f1-4736-9734-1bea12b3986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_11da8337-9902-4bcc-9c0d-e726c611e6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_11da8337-9902-4bcc-9c0d-e726c611e6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0deb02db-2919-4e5d-8b8a-c7b51aea683a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0deb02db-2919-4e5d-8b8a-c7b51aea683a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_194f4248-dbb9-4267-9a41-f153e18d7136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_194f4248-dbb9-4267-9a41-f153e18d7136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3dad7c30-02eb-4513-b1f9-09cb2cb13224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_ProfitLoss_3dad7c30-02eb-4513-b1f9-09cb2cb13224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3a880fe-9d28-4c44-9772-1e1f7d86cc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3a880fe-9d28-4c44-9772-1e1f7d86cc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81432967-7916-4f8e-abab-9f1c4ddecd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_NetIncomeLoss_81432967-7916-4f8e-abab-9f1c4ddecd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1478b024-689b-432e-8a3d-7afbb49de0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_EarningsPerShareBasic_1478b024-689b-432e-8a3d-7afbb49de0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9fcf806-28c6-4ea9-b344-cc1dd9c022cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9fcf806-28c6-4ea9-b344-cc1dd9c022cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e5b65f22-269f-4ec9-abc6-02b545518cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e5b65f22-269f-4ec9-abc6-02b545518cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03447f95-abfb-4650-b081-7df5c49cd41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1c57d1b2-4ef9-466e-88a3-0bb69834d2ef" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03447f95-abfb-4650-b081-7df5c49cd41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84455c7e-00df-4039-82ea-0a238e721f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_486e8f37-c6a2-4eed-9319-029d77b886fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84455c7e-00df-4039-82ea-0a238e721f29" xlink:to="loc_us-gaap_ProfitLoss_486e8f37-c6a2-4eed-9319-029d77b886fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c7c52a71-3767-496c-a1b0-86e34b03ea12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84455c7e-00df-4039-82ea-0a238e721f29" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c7c52a71-3767-496c-a1b0-86e34b03ea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8de7f1be-6e72-4b2b-a2e8-56e4e6eb90f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c7c52a71-3767-496c-a1b0-86e34b03ea12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8de7f1be-6e72-4b2b-a2e8-56e4e6eb90f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5972effb-dfe6-4057-b8d9-885ffb9c5e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c7c52a71-3767-496c-a1b0-86e34b03ea12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5972effb-dfe6-4057-b8d9-885ffb9c5e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7be2d130-6721-49fd-b1fa-8358109e0b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5972effb-dfe6-4057-b8d9-885ffb9c5e79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7be2d130-6721-49fd-b1fa-8358109e0b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4312efee-bc0b-4817-8f45-82b9389775d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5972effb-dfe6-4057-b8d9-885ffb9c5e79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_4312efee-bc0b-4817-8f45-82b9389775d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_80693e83-56f1-46c9-9a4e-4d0d0fcf35c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5972effb-dfe6-4057-b8d9-885ffb9c5e79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_80693e83-56f1-46c9-9a4e-4d0d0fcf35c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6e962482-be21-407b-aca1-135457c306fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c7c52a71-3767-496c-a1b0-86e34b03ea12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6e962482-be21-407b-aca1-135457c306fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6eae4011-49cc-49ae-a371-f21bce96e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6e962482-be21-407b-aca1-135457c306fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6eae4011-49cc-49ae-a371-f21bce96e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0026e78b-1246-41ea-87c7-4cde79f34523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6e962482-be21-407b-aca1-135457c306fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0026e78b-1246-41ea-87c7-4cde79f34523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6b8c6c27-970d-4952-ae38-7ec7eea14a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6e962482-be21-407b-aca1-135457c306fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_6b8c6c27-970d-4952-ae38-7ec7eea14a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_317963db-8e30-4e2b-8dd6-346d64b3cbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c7c52a71-3767-496c-a1b0-86e34b03ea12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_317963db-8e30-4e2b-8dd6-346d64b3cbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1ca900bf-0e6b-4319-a77d-fa93ea375ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84455c7e-00df-4039-82ea-0a238e721f29" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1ca900bf-0e6b-4319-a77d-fa93ea375ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d5c51e6c-b14b-40e4-9812-56144923a281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84455c7e-00df-4039-82ea-0a238e721f29" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d5c51e6c-b14b-40e4-9812-56144923a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6ccb4a8-ac80-4f0f-b8d9-de34bbdd8511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_84455c7e-00df-4039-82ea-0a238e721f29" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b6ccb4a8-ac80-4f0f-b8d9-de34bbdd8511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2026f35b-dcc2-433d-ad36-af48607bba39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_1a856a7b-9dc9-4941-ad44-7f09ccd9e4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2026f35b-dcc2-433d-ad36-af48607bba39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_1a856a7b-9dc9-4941-ad44-7f09ccd9e4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_e35521ea-8233-4e00-87db-01c28071fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_1a856a7b-9dc9-4941-ad44-7f09ccd9e4f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_e35521ea-8233-4e00-87db-01c28071fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_801a8e82-4c9b-4d0f-912d-7128d7816ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_1a856a7b-9dc9-4941-ad44-7f09ccd9e4f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_801a8e82-4c9b-4d0f-912d-7128d7816ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_0ff60b64-2c3f-4290-9397-5efd51218604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2026f35b-dcc2-433d-ad36-af48607bba39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_0ff60b64-2c3f-4290-9397-5efd51218604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_e917f0d7-5861-4795-bd96-2a8dcd427259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_0ff60b64-2c3f-4290-9397-5efd51218604" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_e917f0d7-5861-4795-bd96-2a8dcd427259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_53aba36d-c886-444f-9fab-6b42cd79ce0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_0ff60b64-2c3f-4290-9397-5efd51218604" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_53aba36d-c886-444f-9fab-6b42cd79ce0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b92d5d07-3750-4953-a637-e6769dea387f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b92d5d07-3750-4953-a637-e6769dea387f" xlink:to="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_876ccd2c-fc57-484d-8927-8ea04c4af8e1" xlink:to="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6693d0a-11d4-4d11-94c6-f99d334964f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_CommonStockMember_d6693d0a-11d4-4d11-94c6-f99d334964f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_21ce1830-209f-46c4-b0a3-dfb3d8b9c529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_21ce1830-209f-46c4-b0a3-dfb3d8b9c529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f627a0c9-a334-41e7-a8d7-0475a8ba4b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f627a0c9-a334-41e7-a8d7-0475a8ba4b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_437291a8-e018-4f19-8d15-0de757738b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_RetainedEarningsMember_437291a8-e018-4f19-8d15-0de757738b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ef90f758-2fe9-4ce3-9a97-cc8ed230c613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_728ff6c4-0f40-4edb-869d-c4b0ff253ab1" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ef90f758-2fe9-4ce3-9a97-cc8ed230c613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_47c2d947-4c11-4a6d-b27d-8943d4db16a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_972e72cb-ea48-4701-8462-b94ca59914c8" xlink:to="loc_us-gaap_StatementLineItems_47c2d947-4c11-4a6d-b27d-8943d4db16a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_47c2d947-4c11-4a6d-b27d-8943d4db16a4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6d8cf10-a1ac-4847-a760-26046e33a4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6d8cf10-a1ac-4847-a760-26046e33a4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13c5788e-c0d9-4a12-adda-d1d39ca123fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_13c5788e-c0d9-4a12-adda-d1d39ca123fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cffc5912-e90b-4637-864e-0add53972c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_ProfitLoss_cffc5912-e90b-4637-864e-0add53972c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27ee4c1f-0b2c-40f8-b28e-1d7dfd6325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27ee4c1f-0b2c-40f8-b28e-1d7dfd6325a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69076b28-001b-48bd-b0ed-327e29bf200c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69076b28-001b-48bd-b0ed-327e29bf200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0c9e42ea-f948-48f0-a62f-ad74a6a8f4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0c9e42ea-f948-48f0-a62f-ad74a6a8f4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb708872-1ebe-461c-ae15-430abc460642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb708872-1ebe-461c-ae15-430abc460642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1d08ff9-d334-4638-b5c4-73364544a41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c1d08ff9-d334-4638-b5c4-73364544a41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07be9fb0-5cf2-4443-9ed4-533a78162966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_07be9fb0-5cf2-4443-9ed4-533a78162966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ebf0f035-9c6c-47c4-8c01-3dbfc308a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ebf0f035-9c6c-47c4-8c01-3dbfc308a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_9eeb78ec-14a8-4b0b-b770-eedc10f2d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_9eeb78ec-14a8-4b0b-b770-eedc10f2d0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f622c53-849a-4dc7-a6c9-231a4a6cc47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9f622c53-849a-4dc7-a6c9-231a4a6cc47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f6b7a877-0240-4834-b2c9-e41a8f1842ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f6b7a877-0240-4834-b2c9-e41a8f1842ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_944b6a63-e0d2-4355-8445-129a1301dc88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_Dividends_944b6a63-e0d2-4355-8445-129a1301dc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4db9cb56-c701-4f7a-bf5f-ec67a13563bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4db9cb56-c701-4f7a-bf5f-ec67a13563bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78c68046-e423-4d8b-9c92-f73e8f416813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b627dfe0-bbc0-4b28-8b87-750090390ec4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_78c68046-e423-4d8b-9c92-f73e8f416813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_88f67850-526b-4f80-8fa2-f9a24ee17a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_04ff3202-c856-4dac-922a-39395791eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_88f67850-526b-4f80-8fa2-f9a24ee17a96" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_04ff3202-c856-4dac-922a-39395791eae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_f87073db-40a0-4934-873f-3f18df311cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_88f67850-526b-4f80-8fa2-f9a24ee17a96" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_f87073db-40a0-4934-873f-3f18df311cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c3833260-a7e8-40d5-b4a3-57744c462f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c3833260-a7e8-40d5-b4a3-57744c462f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff8f23a8-2af8-49ba-826c-d447f087d9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c3833260-a7e8-40d5-b4a3-57744c462f1d" xlink:to="loc_us-gaap_ProfitLoss_ff8f23a8-2af8-49ba-826c-d447f087d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c3833260-a7e8-40d5-b4a3-57744c462f1d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e4d9cd1e-c717-43ce-9cdc-2c80a79e1293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_Depreciation_e4d9cd1e-c717-43ce-9cdc-2c80a79e1293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_afa5f329-3de8-4fee-a3ac-1b2e1d911a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_AdjustmentForAmortization_afa5f329-3de8-4fee-a3ac-1b2e1d911a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3c7646a1-15bb-4739-8cee-2c587e45231b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_ShareBasedCompensation_3c7646a1-15bb-4739-8cee-2c587e45231b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7d021bb6-d2cb-4a90-9572-feadf42400d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7d021bb6-d2cb-4a90-9572-feadf42400d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b4c2d8b-51ab-4647-aecc-34f99be78dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8b4c2d8b-51ab-4647-aecc-34f99be78dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8bbb82c-6eeb-46c9-a8ce-a158347b5bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8bbb82c-6eeb-46c9-a8ce-a158347b5bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_85ef2be3-e5b2-4a3e-a94e-d74f362e9a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_85ef2be3-e5b2-4a3e-a94e-d74f362e9a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_387156cc-d76b-4085-945f-5acc7d381c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_387156cc-d76b-4085-945f-5acc7d381c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7ac181e8-9177-4f83-8ffe-bfdaa2729929" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cb473306-658f-4c0f-b60d-77f5015fe4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cb473306-658f-4c0f-b60d-77f5015fe4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7adf6b52-a3a1-4611-9f95-7e0f9a4fcc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7adf6b52-a3a1-4611-9f95-7e0f9a4fcc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_afbf876d-ac69-44ef-8333-14543a0809fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_afbf876d-ac69-44ef-8333-14543a0809fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2884af33-95f9-41c3-852d-f3f56039d046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2884af33-95f9-41c3-852d-f3f56039d046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_48b000bf-59cd-4eb0-a649-86613a8466e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_48b000bf-59cd-4eb0-a649-86613a8466e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9304bae5-25c4-4f00-a632-41adbd44f189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_76fe7074-2588-4b99-8951-9a0c0a3f96fc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9304bae5-25c4-4f00-a632-41adbd44f189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d004e6c9-9ed6-472f-8f39-4ddd5a2e3e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c3833260-a7e8-40d5-b4a3-57744c462f1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d004e6c9-9ed6-472f-8f39-4ddd5a2e3e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_974198dd-95b7-442c-b8e2-38c1ef098775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_974198dd-95b7-442c-b8e2-38c1ef098775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_35e2ccee-a78f-45ec-8ec9-358e1131cd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_35e2ccee-a78f-45ec-8ec9-358e1131cd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dff52277-86de-439c-b450-41c5d6708faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dff52277-86de-439c-b450-41c5d6708faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f0e1fd3-fef4-46c9-b68b-23c9253fc290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f0e1fd3-fef4-46c9-b68b-23c9253fc290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_1e634a92-57a5-41d3-8a72-4f0cc66cb0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_1e634a92-57a5-41d3-8a72-4f0cc66cb0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17e0b946-2fa3-49a0-a7e7-00c0fae646c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17e0b946-2fa3-49a0-a7e7-00c0fae646c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7cab7931-e4ce-40b7-b41e-d0c1e17effb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7cab7931-e4ce-40b7-b41e-d0c1e17effb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_154b5a4a-0516-4569-8016-b03b64b993fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_326d458b-171c-4dbe-95cd-e7726879787e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_154b5a4a-0516-4569-8016-b03b64b993fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_713fc5a7-3962-448d-8d51-c53b639598b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_713fc5a7-3962-448d-8d51-c53b639598b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9d58e910-a079-4304-b852-89063637aee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9d58e910-a079-4304-b852-89063637aee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ee5a819b-75dd-4e80-8046-062bdbacdb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:to="loc_us-gaap_RepaymentsOfDebt_ee5a819b-75dd-4e80-8046-062bdbacdb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_8969aaa4-36af-4ffb-88a3-b1b0521526fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:to="loc_us-gaap_PaymentsOfDividends_8969aaa4-36af-4ffb-88a3-b1b0521526fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c10235a0-5a3c-44b8-a4c5-b2b389d65b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c10235a0-5a3c-44b8-a4c5-b2b389d65b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc3b4903-52ee-4a58-8ce5-ed36270320bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d0af7e27-dffc-437c-9315-b692d76a4e79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc3b4903-52ee-4a58-8ce5-ed36270320bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_87656500-1686-48e5-90bb-e1c87e0cfd95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_87656500-1686-48e5-90bb-e1c87e0cfd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_496c4929-5f11-45ad-81d6-8edf44467574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_496c4929-5f11-45ad-81d6-8edf44467574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9afb2e74-8ad7-4940-aaa9-70f61abc45f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9afb2e74-8ad7-4940-aaa9-70f61abc45f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_448e15fa-6dbf-4228-a27b-d636f9749de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d37bb741-6119-4542-8599-e73d185abef4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_448e15fa-6dbf-4228-a27b-d636f9749de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="gild-20230331.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b228a292-9d1b-4433-bc2c-359572844ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_052590e4-5ce2-4b04-9351-e7b33177f8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b228a292-9d1b-4433-bc2c-359572844ff0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_052590e4-5ce2-4b04-9351-e7b33177f8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUES" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6e5ac2c9-a8c5-427a-a308-4624a7012ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5dc8294c-1dbf-4608-86e0-aaefff382f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6e5ac2c9-a8c5-427a-a308-4624a7012ba5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5dc8294c-1dbf-4608-86e0-aaefff382f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_09869649-2c5f-4e8b-992f-754075b68295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ab390b17-b8c1-4fe0-839f-fdcdc7f6d2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_09869649-2c5f-4e8b-992f-754075b68295" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ab390b17-b8c1-4fe0-839f-fdcdc7f6d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f932abb-7d8e-43f1-8fbe-dbd51859fd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1cbfbace-cb96-4147-a355-7f756544c1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_2f932abb-7d8e-43f1-8fbe-dbd51859fd25" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1cbfbace-cb96-4147-a355-7f756544c1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_74c78c16-e7e3-4111-9010-fa5e0d21bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dc8e80c4-fcc1-4bd7-80a5-c8df44975152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_74c78c16-e7e3-4111-9010-fa5e0d21bd0f" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dc8e80c4-fcc1-4bd7-80a5-c8df44975152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="simple" xlink:href="gild-20230331.xsd#ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_28e4191c-5ae0-4921-a149-98c4d8a79b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_95c9789e-28e4-49fa-816f-df9d8666f033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_28e4191c-5ae0-4921-a149-98c4d8a79b08" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_95c9789e-28e4-49fa-816f-df9d8666f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETS" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d996024-0960-471d-8c0d-a9814347639e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_966d80cc-d897-4f7c-a925-cea140990854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d996024-0960-471d-8c0d-a9814347639e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_966d80cc-d897-4f7c-a925-cea140990854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_8d272ad8-afd4-4a55-a6e0-403bc24f481d" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_374190b6-da86-49a7-8891-e5557e644c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_8d272ad8-afd4-4a55-a6e0-403bc24f481d" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_374190b6-da86-49a7-8891-e5557e644c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_570fff9c-1406-4d5f-a47b-4e7fccb51696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f88e77f0-f5a9-48ea-8704-71123de5095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_570fff9c-1406-4d5f-a47b-4e7fccb51696" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f88e77f0-f5a9-48ea-8704-71123de5095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="gild-20230331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_77174e02-9ba4-4f8a-8953-784923032fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_adaa85f7-0084-47e7-b904-d415d4d543d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_77174e02-9ba4-4f8a-8953-784923032fc5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_adaa85f7-0084-47e7-b904-d415d4d543d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EARNINGSPERSHARE" xlink:type="simple" xlink:href="gild-20230331.xsd#EARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aa4f5224-b4df-4f3e-8dda-a56bb2ba6427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6fbbb1d6-6ff3-4c5e-9be4-07d72582f092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aa4f5224-b4df-4f3e-8dda-a56bb2ba6427" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6fbbb1d6-6ff3-4c5e-9be4-07d72582f092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXES" xlink:type="simple" xlink:href="gild-20230331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7518a851-4faa-418a-9de4-2c7ae4579682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c0052b00-7a7f-4698-85cb-724513b4a1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7518a851-4faa-418a-9de4-2c7ae4579682" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c0052b00-7a7f-4698-85cb-724513b4a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="gild-20230331.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a4b93c4d-064d-4ac7-9937-dcdb590fc4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e37a3c4f-caff-4a91-a0b0-5fc71ac48cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a4b93c4d-064d-4ac7-9937-dcdb590fc4aa" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e37a3c4f-caff-4a91-a0b0-5fc71ac48cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d0854bd5-d6aa-4698-948b-c9f6250909fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a4b93c4d-064d-4ac7-9937-dcdb590fc4aa" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d0854bd5-d6aa-4698-948b-c9f6250909fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESTables" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_992be7eb-0f50-4b3e-a28b-3aed64849fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_25c8ba04-5146-4165-acd0-ab493115ef17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_992be7eb-0f50-4b3e-a28b-3aed64849fae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_25c8ba04-5146-4165-acd0-ab493115ef17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_cda32a1f-6b4b-4625-8f03-a7f5f55bc3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_992be7eb-0f50-4b3e-a28b-3aed64849fae" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_cda32a1f-6b4b-4625-8f03-a7f5f55bc3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_2552edca-2bc1-4a65-9023-ffd32a0f9223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_992be7eb-0f50-4b3e-a28b-3aed64849fae" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_2552edca-2bc1-4a65-9023-ffd32a0f9223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_30410dc0-346d-4886-8e0d-f3628e4b9e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_992be7eb-0f50-4b3e-a28b-3aed64849fae" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_30410dc0-346d-4886-8e0d-f3628e4b9e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_baae46ca-843b-4a8e-b6e5-644df48a28e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3bfa9f06-7933-4e75-b29a-2d74624d4060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baae46ca-843b-4a8e-b6e5-644df48a28e5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3bfa9f06-7933-4e75-b29a-2d74624d4060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ec7f8a13-0d8e-49f9-8d97-82449308d729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baae46ca-843b-4a8e-b6e5-644df48a28e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ec7f8a13-0d8e-49f9-8d97-82449308d729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_eb0dc482-eb10-42fd-b1ad-df9f489e9999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dbf9e1d9-0bdd-4e31-9329-4e3712d5dfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_eb0dc482-eb10-42fd-b1ad-df9f489e9999" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dbf9e1d9-0bdd-4e31-9329-4e3712d5dfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_7eb0bea5-4bea-4f1a-944f-b965710eff69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_eb0dc482-eb10-42fd-b1ad-df9f489e9999" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_7eb0bea5-4bea-4f1a-944f-b965710eff69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_07c0f3c6-0ad8-44de-b423-5b62aa2f3c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_eb0dc482-eb10-42fd-b1ad-df9f489e9999" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_07c0f3c6-0ad8-44de-b423-5b62aa2f3c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_cfd5a69d-4d54-4769-8528-a249ad51aabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_eb0dc482-eb10-42fd-b1ad-df9f489e9999" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_cfd5a69d-4d54-4769-8528-a249ad51aabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_4459ef78-9fcb-4f51-be05-920c990ecc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_eb0dc482-eb10-42fd-b1ad-df9f489e9999" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_4459ef78-9fcb-4f51-be05-920c990ecc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3ffe5c9f-8c19-4d89-9c9f-883819945199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4f1d8592-287d-4cf3-9e53-a5396a2265e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3ffe5c9f-8c19-4d89-9c9f-883819945199" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4f1d8592-287d-4cf3-9e53-a5396a2265e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5ceabbdb-866c-4e6b-80b2-15f9fd920411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3ffe5c9f-8c19-4d89-9c9f-883819945199" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5ceabbdb-866c-4e6b-80b2-15f9fd920411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSTables" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97681652-17ee-4ebc-bf9b-d873df60e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c0ccba76-093a-4059-b9fe-4c864c4f1eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97681652-17ee-4ebc-bf9b-d873df60e3c9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c0ccba76-093a-4059-b9fe-4c864c4f1eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8da48655-1c50-46f9-b42a-9697d1c03474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97681652-17ee-4ebc-bf9b-d873df60e3c9" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8da48655-1c50-46f9-b42a-9697d1c03474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f843fa97-f2de-4bcf-9922-fa82697f0800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_97681652-17ee-4ebc-bf9b-d873df60e3c9" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f843fa97-f2de-4bcf-9922-fa82697f0800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_25b8f705-2d59-4e19-944a-0498a6f23d3d" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f61ed955-82a2-400f-b997-e2d95e6fe2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_25b8f705-2d59-4e19-944a-0498a6f23d3d" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f61ed955-82a2-400f-b997-e2d95e6fe2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_28de0ddc-d93d-4a83-b2c0-be5ae6755f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_25b8f705-2d59-4e19-944a-0498a6f23d3d" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_28de0ddc-d93d-4a83-b2c0-be5ae6755f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_07b7a354-473f-469b-ae6d-08e04e193c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_25b8f705-2d59-4e19-944a-0498a6f23d3d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_07b7a354-473f-469b-ae6d-08e04e193c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_15286df8-1385-4529-9880-d8b0b0b50e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_25b8f705-2d59-4e19-944a-0498a6f23d3d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_15286df8-1385-4529-9880-d8b0b0b50e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5bf12407-787d-47ba-acb7-53a1393d33a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_e0354b77-8847-4623-9658-8f6c29fce0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5bf12407-787d-47ba-acb7-53a1393d33a7" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_e0354b77-8847-4623-9658-8f6c29fce0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EARNINGSPERSHARETables" xlink:type="simple" xlink:href="gild-20230331.xsd#EARNINGSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EARNINGSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_80e5dacb-c72c-4181-ae66-69b75a4ba1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e0d0d601-ad0c-4b7b-987e-f9cf1a96ab71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_80e5dacb-c72c-4181-ae66-69b75a4ba1d4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e0d0d601-ad0c-4b7b-987e-f9cf1a96ab71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="gild-20230331.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bad49760-6d74-42a8-a889-5b4b267ee068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d58a62f8-379d-4653-9fae-0a9d6132932f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bad49760-6d74-42a8-a889-5b4b267ee068" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d58a62f8-379d-4653-9fae-0a9d6132932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00a24cc9-f2c4-45b8-956d-755fec0756dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00a24cc9-f2c4-45b8-956d-755fec0756dd" xlink:to="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:to="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_41ecf19f-d549-4bc1-b887-bc6569429e62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1ba439aa-43dd-4422-91de-c3522943ac51" xlink:to="loc_srt_RestatementDomain_41ecf19f-d549-4bc1-b887-bc6569429e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_030ac99c-ca8c-4811-bc14-4ceaa35b1323" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_41ecf19f-d549-4bc1-b887-bc6569429e62" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_030ac99c-ca8c-4811-bc14-4ceaa35b1323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_03dd2d27-4434-4838-89f9-e6c7021c28fb" xlink:to="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_70dba725-7ad9-4829-bce4-a36287cb9fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_70dba725-7ad9-4829-bce4-a36287cb9fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_c97101d6-255f-4739-9e20-c4a1e5a84c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationLineItems_349fdfe6-1f23-4a23-b9b9-5525d5ccdb8b" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_c97101d6-255f-4739-9e20-c4a1e5a84c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESSummaryofDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a423ea57-7f93-421a-92b5-9cd1cb6bca51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a423ea57-7f93-421a-92b5-9cd1cb6bca51" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:to="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_81421ff1-c086-4026-89fd-5189471ae030" xlink:to="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:to="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:href="gild-20230331.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_65ea3dd9-7452-4595-972a-7d162532949a" xlink:href="gild-20230331.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsBiktarvyMember_65ea3dd9-7452-4595-972a-7d162532949a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_4ecd5080-fafe-4450-bcc2-90e3fe37fac3" xlink:href="gild-20230331.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_4ecd5080-fafe-4450-bcc2-90e3fe37fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_05c2e338-cb68-46e6-87e6-b6accfe3c595" xlink:href="gild-20230331.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsDescovyMember_05c2e338-cb68-46e6-87e6-b6accfe3c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_934520b7-b3f2-4f84-a034-824ad1771abd" xlink:href="gild-20230331.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsGenvoyaMember_934520b7-b3f2-4f84-a034-824ad1771abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_d9c2555f-7373-4b51-9b2a-b976584d055c" xlink:href="gild-20230331.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsOdefseyMember_d9c2555f-7373-4b51-9b2a-b976584d055c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_fac34f75-e49d-49b7-af95-f9062dda3ff2" xlink:href="gild-20230331.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsStribildMember_fac34f75-e49d-49b7-af95-f9062dda3ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_a9bd4743-f5db-4dcd-8e84-f25bd133f27a" xlink:href="gild-20230331.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_HIVProductsTruvadaMember_a9bd4743-f5db-4dcd-8e84-f25bd133f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_9ca057c6-d3dd-4a90-a7a2-e0651fd2ddce" xlink:href="gild-20230331.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_9ca057c6-d3dd-4a90-a7a2-e0651fd2ddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_b4a3f895-3600-4cc5-b452-b8ec96c4af85" xlink:href="gild-20230331.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_d21720d9-32e6-4fca-9cc3-9350678b6ba9" xlink:to="loc_gild_ProductsOtherHIVMember_b4a3f895-3600-4cc5-b452-b8ec96c4af85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:href="gild-20230331.xsd#gild_OncologyProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_8bea6b7f-e9e3-4ce3-a3d2-2476ac8dc49a" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:to="loc_gild_CellTherapyProductsTecartusMember_8bea6b7f-e9e3-4ce3-a3d2-2476ac8dc49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsYescartaMember_e8edf774-802a-42c3-9253-967702e45b34" xlink:href="gild-20230331.xsd#gild_CellTherapyProductsYescartaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d1a04a0-f91b-46df-adc0-830dcc3c92cc" xlink:to="loc_gild_CellTherapyProductsYescartaMember_e8edf774-802a-42c3-9253-967702e45b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_d89752c6-410d-4519-a483-a5654e6a2499" xlink:href="gild-20230331.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OncologyProductMember_f27ba71e-6030-4b6e-a15b-b88962951bd9" xlink:to="loc_gild_TrodelvyMember_d89752c6-410d-4519-a483-a5654e6a2499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:href="gild-20230331.xsd#gild_LiverDiseaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:href="gild-20230331.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:to="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_b9190368-b023-4a3d-a4f0-34bb029d63c5" xlink:href="gild-20230331.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_b9190368-b023-4a3d-a4f0-34bb029d63c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_1e958dda-4fde-46f4-a0a3-1ca9a8ff9fe5" xlink:href="gild-20230331.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_1e958dda-4fde-46f4-a0a3-1ca9a8ff9fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHepatitisCVirusProductsMember_876d0d38-aff4-4a2a-a528-8f2027325fe7" xlink:href="gild-20230331.xsd#gild_OtherHepatitisCVirusProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_e323917c-7d05-4f52-a7e2-ab656e20347c" xlink:to="loc_gild_OtherHepatitisCVirusProductsMember_876d0d38-aff4-4a2a-a528-8f2027325fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_LiverDiseaseMember_16de2cdb-6ca1-42a8-96a9-f3e4139d4912" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_c96c4fa8-b545-4783-87fa-29dbde99665b" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_c96c4fa8-b545-4783-87fa-29dbde99665b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_618bd5de-5d60-4a71-9f7a-bef289599060" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_618bd5de-5d60-4a71-9f7a-bef289599060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_84400ab6-483d-4401-be61-1736aead0572" xlink:href="gild-20230331.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_fb807106-82f5-492d-89c4-44732fe88341" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_84400ab6-483d-4401-be61-1736aead0572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_e8a51ae0-b8f4-4b42-abc4-bce8790449ee" xlink:href="gild-20230331.xsd#gild_VekluryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_VekluryMember_e8a51ae0-b8f4-4b42-abc4-bce8790449ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:href="gild-20230331.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6ad8b7ac-96ec-4cc5-b5ea-6041d0078042" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_a82ed849-b90b-49db-a36b-095f412463f5" xlink:href="gild-20230331.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:to="loc_gild_OtherProductsAmBisomeMember_a82ed849-b90b-49db-a36b-095f412463f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_3dec4351-85c0-4655-8087-a3a6e85487ac" xlink:href="gild-20230331.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:to="loc_gild_OtherProductsLetairisMember_3dec4351-85c0-4655-8087-a3a6e85487ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_44d672d9-aa0f-43b7-907f-553d571121e5" xlink:href="gild-20230331.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_120ce328-abe0-4671-b55f-ed589c78decc" xlink:to="loc_gild_OtherProductsOtherMember_44d672d9-aa0f-43b7-907f-553d571121e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_c726cccd-536f-4de2-8fe6-d625e2785c13" xlink:href="gild-20230331.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1633bca4-6b57-4f24-9a3d-11de420dbb17" xlink:to="loc_gild_RoyaltyContractAndOtherMember_c726cccd-536f-4de2-8fe6-d625e2785c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:to="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9b0eef18-6ae3-419c-b1f9-8ad1f6c46a50" xlink:to="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2fcf6c1b-ffe4-4515-84a2-8ab58ffba975" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:to="loc_country_US_2fcf6c1b-ffe4-4515-84a2-8ab58ffba975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_1e53f8ff-b1fe-47ed-a079-cea232c30c79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:to="loc_srt_EuropeMember_1e53f8ff-b1fe-47ed-a079-cea232c30c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_d6300e7c-c40e-4c44-bb0c-36f2864092e5" xlink:href="gild-20230331.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eecc2598-691c-45f7-b454-4a0fb0a91976" xlink:to="loc_gild_OtherInternationalMember_d6300e7c-c40e-4c44-bb0c-36f2864092e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_16b7e99d-6315-444f-82f3-1bcb3f774817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_98b0be15-dd25-461c-b4ce-8d249e10de6d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_16b7e99d-6315-444f-82f3-1bcb3f774817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ecdc80-3731-4092-8453-7678f578b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_16b7e99d-6315-444f-82f3-1bcb3f774817" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ecdc80-3731-4092-8453-7678f578b5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESSummaryofRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_48014294-0f1d-4e41-a519-46377dc4e8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_48014294-0f1d-4e41-a519-46377dc4e8b9" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_eb350708-551b-4e87-a692-2d855718cc23" xlink:to="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_91cbc247-43d1-42c4-82ef-091ffb3a8b0e" xlink:href="gild-20230331.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:to="loc_gild_AmerisourcebergenCorpMember_91cbc247-43d1-42c4-82ef-091ffb3a8b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_781d369e-db19-403a-95c9-47a4348ffc30" xlink:href="gild-20230331.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:to="loc_gild_CardinalHealthIncMember_781d369e-db19-403a-95c9-47a4348ffc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_7e79e758-6210-4696-a84b-7a708c9bc476" xlink:href="gild-20230331.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b0065a1-4f92-4c45-bda2-302d7c8d42d3" xlink:to="loc_gild_MckessonCorpMember_7e79e758-6210-4696-a84b-7a708c9bc476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46b9319a-1c92-412c-8cbb-a090a03ebf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5488afd0-4d09-4870-9fb6-aad10b833213" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46b9319a-1c92-412c-8cbb-a090a03ebf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_47db9eb7-5372-4c94-8798-d6a74e5acfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46b9319a-1c92-412c-8cbb-a090a03ebf74" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_47db9eb7-5372-4c94-8798-d6a74e5acfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f04d99cb-a29d-43fe-842b-55b756273d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c46cf19a-9ac6-4ddf-9d35-727eae7a663e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f04d99cb-a29d-43fe-842b-55b756273d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_520051ca-5f8c-4dc1-8786-c71b5b8e74f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f04d99cb-a29d-43fe-842b-55b756273d79" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_520051ca-5f8c-4dc1-8786-c71b5b8e74f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7afdf903-70ce-4409-8713-3960c38f26b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6cbc586c-5d00-4336-8c17-bc7b73d10590" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7afdf903-70ce-4409-8713-3960c38f26b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ec85673d-4e06-4b8d-9321-a441e8968646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7afdf903-70ce-4409-8713-3960c38f26b3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ec85673d-4e06-4b8d-9321-a441e8968646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESSummaryofPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31365447-c230-457a-911d-a4e60551ba0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a4cc3651-3d75-4eff-bf1d-13c3ea4d85d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31365447-c230-457a-911d-a4e60551ba0d" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_a4cc3651-3d75-4eff-bf1d-13c3ea4d85d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7d0d5b07-6fe1-4bff-8550-625c67790245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31365447-c230-457a-911d-a4e60551ba0d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_7d0d5b07-6fe1-4bff-8550-625c67790245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#REVENUESSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_600b46f5-029c-412e-a2ad-c27c325935df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_32f2799d-6c8b-49c9-aa86-f164f6230b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_600b46f5-029c-412e-a2ad-c27c325935df" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_32f2799d-6c8b-49c9-aa86-f164f6230b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_009ad04e-d360-4c55-b53a-73b7a59a50a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_600b46f5-029c-412e-a2ad-c27c325935df" xlink:to="loc_us-gaap_ContractWithCustomerLiability_009ad04e-d360-4c55-b53a-73b7a59a50a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6aa9abfc-fb92-4445-b005-68b3012efdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6aa9abfc-fb92-4445-b005-68b3012efdf3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e87994b6-9fe8-4804-b9d7-66c8e9e412cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_42d8bfa6-f5a3-4447-9a8f-0f0135819922" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e87994b6-9fe8-4804-b9d7-66c8e9e412cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b0326de1-df6a-45fa-b55c-30b37191b539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e87994b6-9fe8-4804-b9d7-66c8e9e412cb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b0326de1-df6a-45fa-b55c-30b37191b539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_851be0d2-7102-44fb-ab9f-1642003cf527" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dd341692-23ad-4e30-9246-28680a318078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dd341692-23ad-4e30-9246-28680a318078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_86dc04a9-8430-4b68-95d1-42e24543a86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_86dc04a9-8430-4b68-95d1-42e24543a86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_37360b53-ac1b-4476-aba9-4e72a3f19f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6382c402-7574-426e-b3b3-40de28487af9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_37360b53-ac1b-4476-aba9-4e72a3f19f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_05778da5-17ab-42f1-b79f-c04de3271eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a6243e73-e8f1-4ada-b66b-669e9d25ddcd" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_05778da5-17ab-42f1-b79f-c04de3271eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b9521315-60b5-40aa-9a0c-26bb766c3a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_05778da5-17ab-42f1-b79f-c04de3271eb0" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b9521315-60b5-40aa-9a0c-26bb766c3a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ee778bdf-0f18-4d26-bf05-8443c9172343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b9521315-60b5-40aa-9a0c-26bb766c3a39" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ee778bdf-0f18-4d26-bf05-8443c9172343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_df5a7b63-fdd6-4a7c-a146-afbb68709301" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c86ce517-35e7-4342-8ba5-a4c68e2f4441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c86ce517-35e7-4342-8ba5-a4c68e2f4441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_24f951fd-93dc-4dd5-8d95-2a5ddc14f0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_24f951fd-93dc-4dd5-8d95-2a5ddc14f0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_075271e0-f36a-46d2-94bf-ca9aa447cbda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_075271e0-f36a-46d2-94bf-ca9aa447cbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a616bcb1-4fd0-469e-aaf3-3da48013d769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a616bcb1-4fd0-469e-aaf3-3da48013d769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_02b39534-bc44-4582-8dc5-9659d6dd3015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_02b39534-bc44-4582-8dc5-9659d6dd3015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_33858ec9-4130-4ce5-a6ec-9ee65c83166f" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_33858ec9-4130-4ce5-a6ec-9ee65c83166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d820bf54-6630-4165-852e-3394f166f8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d820bf54-6630-4165-852e-3394f166f8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_e38a302c-79f5-49f4-b48f-3c472cb3598a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_us-gaap_EquitySecuritiesMember_e38a302c-79f5-49f4-b48f-3c472cb3598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_40522f8b-a68f-418f-af13-7ea4270ae351" xlink:href="gild-20230331.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_gild_DeferredCompensationPlanMember_40522f8b-a68f-418f-af13-7ea4270ae351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_4cf92ef4-4917-4b91-8f2a-9265e7270011" xlink:href="gild-20230331.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_51b4fcc8-10de-4a7a-9977-15dc3b826729" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_4cf92ef4-4917-4b91-8f2a-9265e7270011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f5876ade-231d-4368-a536-b21736a0fd9e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_149aeb9e-a781-4c94-b369-969905ff7b11" xlink:href="gild-20230331.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:to="loc_gild_GalapagosMember_149aeb9e-a781-4c94-b369-969905ff7b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_3b0ea716-3160-4e34-b0c8-da43e7436dbd" xlink:href="gild-20230331.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_77ea466f-af72-42c2-af9a-c070b333107f" xlink:to="loc_gild_ArcusBiosciencesIncMember_3b0ea716-3160-4e34-b0c8-da43e7436dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92015a3e-c5c6-4940-8279-103367234fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9309314d-d711-4a34-babd-60b778250f94" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92015a3e-c5c6-4940-8279-103367234fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_45d37cb3-9a0c-42ea-a788-44d251624eff" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_92015a3e-c5c6-4940-8279-103367234fc1" xlink:to="loc_gild_MYRGmbHMember_45d37cb3-9a0c-42ea-a788-44d251624eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f97ff490-916c-4a47-ba12-c899d0c5294d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a02aee44-974f-44c0-a0ce-646b3bda6283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a02aee44-974f-44c0-a0ce-646b3bda6283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_de61e4ae-73a8-4d89-a360-ef2f9a631de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_de61e4ae-73a8-4d89-a360-ef2f9a631de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_38633b38-0e86-488b-b030-5313b7a22d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_38633b38-0e86-488b-b030-5313b7a22d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_22222c88-7ccf-4903-9475-9b792c6c47d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_495ea2a4-26cd-4249-92f8-321fb5ae1425" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_22222c88-7ccf-4903-9475-9b792c6c47d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4d411e6-19bc-4352-8b3d-4c517784a25a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e7b408c1-4501-4b7b-ad9e-c02962c8c6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e7b408c1-4501-4b7b-ad9e-c02962c8c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_34a24d80-6849-4f94-a468-a5fa6503c923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_34a24d80-6849-4f94-a468-a5fa6503c923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_df60fa5b-8f05-4e8f-b693-a8b0b41e5411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_df60fa5b-8f05-4e8f-b693-a8b0b41e5411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_793f4285-6376-454a-8dad-9d892101a616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2543ade0-e3ad-4cec-8271-e2ffac8a95dd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_793f4285-6376-454a-8dad-9d892101a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9ddcbb56-f684-4976-bc2b-77ec39f6845e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9ddcbb56-f684-4976-bc2b-77ec39f6845e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e8cbe8df-3e9a-4a30-ac4a-45af1eb7e58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9ec517c2-31ad-4d5e-ac90-49f99f6702db" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e8cbe8df-3e9a-4a30-ac4a-45af1eb7e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e8cbe8df-3e9a-4a30-ac4a-45af1eb7e58d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3a1bbfd-ae9a-40f4-994a-696ac0f8400a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d3a1bbfd-ae9a-40f4-994a-696ac0f8400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ebf64092-1b5e-4be2-a0b6-35fed98c67bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da962cf0-aa00-47b8-8f72-1165e2637520" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ebf64092-1b5e-4be2-a0b6-35fed98c67bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f651e909-489f-43f2-9890-40fc2240602f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5e1ac890-8659-442e-ae4e-d65cfe2fad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5e1ac890-8659-442e-ae4e-d65cfe2fad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d574698f-68ec-4415-bd19-266cc7727066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11cb714b-f2e6-4727-8e27-afad12cbfeaa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d574698f-68ec-4415-bd19-266cc7727066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8ed17e02-7dd9-45d6-a02b-d8c24add9ff9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_7da1c766-33e7-447b-9ffc-8268fdb5a437" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:to="loc_gild_MYRGmbHMember_7da1c766-33e7-447b-9ffc-8268fdb5a437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_acdaa274-ae61-4619-96e6-8802e0dfeee5" xlink:href="gild-20230331.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d8cb005-ccd1-4ca1-8c9f-8f7567894928" xlink:to="loc_gild_ImmunomedicsIncMember_acdaa274-ae61-4619-96e6-8802e0dfeee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186ae9f-4d9b-4652-972f-9578be7c4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_09d7c39b-c141-4071-a9ed-6db679f16729" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186ae9f-4d9b-4652-972f-9578be7c4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_b8617021-e67e-422f-bd3e-c668e4ffd6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8186ae9f-4d9b-4652-972f-9578be7c4d13" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_b8617021-e67e-422f-bd3e-c668e4ffd6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7465ea65-65a0-42b1-8145-5862098b202f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8016dbf8-a0a0-4716-a422-18e02234199e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7465ea65-65a0-42b1-8145-5862098b202f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_0ac9f4ff-40b0-4f27-974b-d768986dbaa6" xlink:href="gild-20230331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7465ea65-65a0-42b1-8145-5862098b202f" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_0ac9f4ff-40b0-4f27-974b-d768986dbaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af378191-540b-4005-9395-9ed948de0b9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89fa222c-5445-4daf-9fda-e6dc7e9745b8" xlink:to="loc_srt_RangeMember_af378191-540b-4005-9395-9ed948de0b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76e0dbbb-5b31-4080-a9f1-e72244ed22d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af378191-540b-4005-9395-9ed948de0b9a" xlink:to="loc_srt_MaximumMember_76e0dbbb-5b31-4080-a9f1-e72244ed22d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0efb72e6-97d7-4757-8b62-f7420a5ed1f2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_8114e6a9-2654-4f28-bbf6-990a874bdfae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_8114e6a9-2654-4f28-bbf6-990a874bdfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c832a21b-5f6a-43d1-a5da-f9fbea1aa321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_LongTermDebtFairValue_c832a21b-5f6a-43d1-a5da-f9fbea1aa321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b5227e8a-29f3-4406-8856-b8f0999c94c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b5227e8a-29f3-4406-8856-b8f0999c94c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_76d8015d-3fad-437b-a939-420cc36b9ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_76d8015d-3fad-437b-a939-420cc36b9ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_4c2fdc6d-4df8-43c8-92e8-eaba7c4b5c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_4c2fdc6d-4df8-43c8-92e8-eaba7c4b5c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b649ddd1-1862-4f9e-a614-4a587f096cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1dbfcfc3-cef0-4104-ada0-b00b58538623" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b649ddd1-1862-4f9e-a614-4a587f096cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99d23df6-7750-489c-a885-af34a63a493a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99d23df6-7750-489c-a885-af34a63a493a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c22119ac-be6f-42e7-b69f-f35b6df2049b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_18eae9b0-fde7-45f7-bdbe-93d9f5116384" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c22119ac-be6f-42e7-b69f-f35b6df2049b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember_7aeadabe-16a4-49ac-a20f-b05847725cd8" xlink:href="gild-20230331.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c22119ac-be6f-42e7-b69f-f35b6df2049b" xlink:to="loc_gild_ContingentConsiderationLiabilityMember_7aeadabe-16a4-49ac-a20f-b05847725cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04c7b773-9a43-43ba-a8b8-b0eace84ba0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7007d4fd-b700-43b3-8a1f-c91f861a435a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04c7b773-9a43-43ba-a8b8-b0eace84ba0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_924ff913-b9e0-4c2a-99a2-5b868f8c6ea2" xlink:href="gild-20230331.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04c7b773-9a43-43ba-a8b8-b0eace84ba0d" xlink:to="loc_gild_MYRGmbHMember_924ff913-b9e0-4c2a-99a2-5b868f8c6ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6bb5fcf-06b6-4a8f-8578-63f571a38478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50c0b9dc-63bb-49cf-aa00-73a909c2245d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6bb5fcf-06b6-4a8f-8578-63f571a38478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6bb5fcf-06b6-4a8f-8578-63f571a38478" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7c7c5c4-3a28-4937-80a7-c57c10795598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e7c7c5c4-3a28-4937-80a7-c57c10795598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_241d49e2-0037-4d9d-83b9-f871f9ba5c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_241d49e2-0037-4d9d-83b9-f871f9ba5c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_99875c9e-66ad-4092-b7da-e0e0c43d8410" xlink:href="gild-20230331.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_99875c9e-66ad-4092-b7da-e0e0c43d8410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d96d400f-4471-47f7-ad01-066dcfd10e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_188722d7-cf48-47ce-a201-09653cd42284" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d96d400f-4471-47f7-ad01-066dcfd10e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_12013200-b840-457a-b6b2-565383d703b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_12013200-b840-457a-b6b2-565383d703b1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_096197f1-b55b-46c8-9b74-0327e63cdf55" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c4132676-308d-476f-a480-868cbf2e04b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c4132676-308d-476f-a480-868cbf2e04b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1fa25360-63d5-4219-8c62-4d70a5caad20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1fa25360-63d5-4219-8c62-4d70a5caad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_9865a675-405b-47fc-87b7-685dc708001d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_9865a675-405b-47fc-87b7-685dc708001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_8f35d6e8-05a7-4899-96dd-f0f8b6df2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_8f35d6e8-05a7-4899-96dd-f0f8b6df2bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52e51623-8310-4317-835d-ab507795b31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52e51623-8310-4317-835d-ab507795b31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_cb53eae2-336f-4f32-9318-7c11ff320240" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dd65b0f-3027-4bf0-87b5-63547213a62d" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_cb53eae2-336f-4f32-9318-7c11ff320240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f009647d-296a-4189-8b4d-5191ce25ebeb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8b2af284-275c-4efb-807d-c2e073290aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8b2af284-275c-4efb-807d-c2e073290aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25acf288-5cb6-46bc-8a04-bc7484b8c1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25acf288-5cb6-46bc-8a04-bc7484b8c1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b86ed139-32c1-42ae-bebb-8bac9af2979f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b86ed139-32c1-42ae-bebb-8bac9af2979f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8addae5c-8fc6-407b-8bb9-65e2d6469312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4894dfb0-be7c-4b09-8122-5059559ed5e5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_8addae5c-8fc6-407b-8bb9-65e2d6469312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c36a6c47-2e75-4e0a-ac14-05fa99a19342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c36a6c47-2e75-4e0a-ac14-05fa99a19342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_54557853-fa62-4bbd-bcd6-d6fc151d1a38" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e62b3795-7f15-499c-a2cb-1f245ea33b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e62b3795-7f15-499c-a2cb-1f245ea33b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d1269d01-4f16-432f-b61a-c0666c8cb4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d1269d01-4f16-432f-b61a-c0666c8cb4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4d656b0b-b766-468c-8982-faace99fa594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4d656b0b-b766-468c-8982-faace99fa594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_166b041c-ff38-4584-a01b-a9b1dcdb0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_166b041c-ff38-4584-a01b-a9b1dcdb0b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bccf41f1-3375-4909-9b95-01fd13772776" xlink:href="gild-20230331.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d076fb40-daef-48f3-b025-32234e7eacef" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bccf41f1-3375-4909-9b95-01fd13772776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2a6e28d8-d2ff-44b5-9051-bd2c37cdbaba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_062b389c-38f8-49b9-a3a9-e378abcdafa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_062b389c-38f8-49b9-a3a9-e378abcdafa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f8c38040-c0fa-4587-bc73-9f86c1b386e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f8c38040-c0fa-4587-bc73-9f86c1b386e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_63a069e4-6aa9-481f-b48e-c50d2806a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_53bfab63-c218-44ac-8525-3097e585789c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_63a069e4-6aa9-481f-b48e-c50d2806a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_4dbb5698-f52c-4607-94f0-4f37760c740a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a195ed0e-c8bb-46d6-8e27-28664ffdbc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_a195ed0e-c8bb-46d6-8e27-28664ffdbc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8047b632-e493-4ced-8dca-83cf74a3becb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_8047b632-e493-4ced-8dca-83cf74a3becb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e57aafbe-b124-4cbb-81fd-75bd726576b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_47138189-3835-4383-8dc1-e7f6154d0606" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e57aafbe-b124-4cbb-81fd-75bd726576b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_24bdcba6-3b56-47a1-aaca-96676bf4bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_4047ea2d-15ab-42e0-bb04-0633b3570ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_24bdcba6-3b56-47a1-aaca-96676bf4bbf6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_4047ea2d-15ab-42e0-bb04-0633b3570ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_8c4fb756-a755-4c27-9dcd-edc13026cf7f" xlink:href="gild-20230331.xsd#gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_24bdcba6-3b56-47a1-aaca-96676bf4bbf6" xlink:to="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_8c4fb756-a755-4c27-9dcd-edc13026cf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2691068b-037a-4f5a-9e2c-9c317f0e445c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_24bdcba6-3b56-47a1-aaca-96676bf4bbf6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2691068b-037a-4f5a-9e2c-9c317f0e445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c8cd33ec-1429-414d-9143-9173f4185da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_c8cd33ec-1429-414d-9143-9173f4185da8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_30e2edf5-36e0-4333-bb7e-55da641e4a10" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_b0b4df9a-df0a-44eb-a71b-38f16460375e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_b0b4df9a-df0a-44eb-a71b-38f16460375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_079761fc-2832-45aa-bf32-49f6b8edc75e" xlink:href="gild-20230331.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_079761fc-2832-45aa-bf32-49f6b8edc75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_f1248c74-f734-4906-bc9d-a5480f383800" xlink:href="gild-20230331.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_31a207ed-fbdb-4c2e-ad7c-1ff691929982" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_f1248c74-f734-4906-bc9d-a5480f383800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d568ecd-b82c-4ca6-935b-ab9850c229a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_35ffff91-d01c-496c-b1ac-3faef341a646" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d568ecd-b82c-4ca6-935b-ab9850c229a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_970390b4-5690-43d3-bd15-11386573080e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9d568ecd-b82c-4ca6-935b-ab9850c229a5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_970390b4-5690-43d3-bd15-11386573080e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec6183d6-b828-40e2-99fb-df11ffad281d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec6183d6-b828-40e2-99fb-df11ffad281d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4f25b2aa-1514-4b40-930a-b3c854a8dc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4f25b2aa-1514-4b40-930a-b3c854a8dc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_da8e91a2-f44f-4293-923b-e40ae5ba5344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_da8e91a2-f44f-4293-923b-e40ae5ba5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_4720dd35-aaba-4aba-ae35-0ad13a4af432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_4720dd35-aaba-4aba-ae35-0ad13a4af432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_02b4ba7b-0ba0-471e-a4d5-4cb61a30b368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_02b4ba7b-0ba0-471e-a4d5-4cb61a30b368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_98770593-7269-4c58-a397-140f0def9507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_2ec0f877-351d-4763-b890-dd1c13fe3e93" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_98770593-7269-4c58-a397-140f0def9507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ec6183d6-b828-40e2-99fb-df11ffad281d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5556e5de-05e3-4c3b-92f7-a0b43033da03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5556e5de-05e3-4c3b-92f7-a0b43033da03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6ac0004f-56b4-4eca-986d-a4df800e8bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6ac0004f-56b4-4eca-986d-a4df800e8bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f7136231-a262-4e15-902f-8726a6681552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_f7136231-a262-4e15-902f-8726a6681552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_7dfc5f94-68a8-4a3e-ab59-96e2218ef928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_7dfc5f94-68a8-4a3e-ab59-96e2218ef928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0065014c-1c52-408c-8b45-a8b5f8ddbcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bdf9a0d6-dde7-4147-a70b-7d52806362b5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0065014c-1c52-408c-8b45-a8b5f8ddbcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8d5a212e-3f49-418e-8143-74d148a4cefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8d5a212e-3f49-418e-8143-74d148a4cefa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da7852b6-930c-4837-ac53-7588de744c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_82f70c9c-379b-4841-839e-5edaf14a6fdd" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da7852b6-930c-4837-ac53-7588de744c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_47fa7d31-f13f-4d87-b217-a1bc5f1e474e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da7852b6-930c-4837-ac53-7588de744c3f" xlink:to="loc_us-gaap_EquitySecuritiesMember_47fa7d31-f13f-4d87-b217-a1bc5f1e474e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f1b8982f-33ad-4a6f-bee9-af6a655f2e03" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_6e468734-f15b-4715-9345-3478a900f2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_6e468734-f15b-4715-9345-3478a900f2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c42dfdc7-20de-415e-8c96-b295e41ce41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_c42dfdc7-20de-415e-8c96-b295e41ce41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_ab04f1e0-cbef-4afd-a200-f54a9b91624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2d09647f-bf66-43fa-b42c-1e88afc46bec" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_ab04f1e0-cbef-4afd-a200-f54a9b91624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e6ad4cc9-ba2a-43bf-a557-bcab7a0578cd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_98cdcd16-9740-4dd8-9fca-a668d399f72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_98cdcd16-9740-4dd8-9fca-a668d399f72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3f2d6637-82f1-480c-8d2c-c255a6c8c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc081476-fc78-42fe-8559-d043f2ba2999" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3f2d6637-82f1-480c-8d2c-c255a6c8c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e4f20daf-8701-48f7-9bcf-9d0d2af0d823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e4f20daf-8701-48f7-9bcf-9d0d2af0d823" xlink:to="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:to="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41d311d6-970e-4284-98f9-a403ac79440c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b6748c1e-72d3-4a8c-b42b-5c2189292dae" xlink:to="loc_srt_RangeMember_41d311d6-970e-4284-98f9-a403ac79440c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6fcc166a-a4a0-4d2e-87d0-65091ffdb59b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41d311d6-970e-4284-98f9-a403ac79440c" xlink:to="loc_srt_MaximumMember_6fcc166a-a4a0-4d2e-87d0-65091ffdb59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b086de9e-c973-44ab-87b7-98c1e8f4eac9" xlink:to="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_d50185b1-760a-4231-b7e4-229f7e55221f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_d50185b1-760a-4231-b7e4-229f7e55221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9cec5545-55df-4336-8e6a-68e47549ff80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9cec5545-55df-4336-8e6a-68e47549ff80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_e333b9ab-8697-4540-afc6-8f8c680b336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_e333b9ab-8697-4540-afc6-8f8c680b336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_03a42914-edbf-40b4-bd52-d10d5e534522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e962acea-5180-471b-986e-b785bfaaa1f3" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_03a42914-edbf-40b4-bd52-d10d5e534522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78f5c1bc-28ed-4af8-b83d-6f277e42e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78f5c1bc-28ed-4af8-b83d-6f277e42e2fe" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:to="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_221dfc97-4a3a-46a4-b677-3855d9454e21" xlink:to="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_79d0ab6c-aeeb-45ab-bfc1-d61fb9c850a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_79d0ab6c-aeeb-45ab-bfc1-d61fb9c850a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_6a9844c4-142d-4542-809b-96be46f365b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_16da07b5-541c-4a59-b02f-e88f5572970b" xlink:to="loc_us-gaap_NondesignatedMember_6a9844c4-142d-4542-809b-96be46f365b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_13714e58-716f-4528-ab08-63213a83e9ee" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f81f36e6-6562-4b27-a512-19975b7f6fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f81f36e6-6562-4b27-a512-19975b7f6fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_865c9b94-93e0-49eb-852e-07829d855a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_865c9b94-93e0-49eb-852e-07829d855a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_521fbbd9-18d1-4d79-b683-7fdd79d5b71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_521fbbd9-18d1-4d79-b683-7fdd79d5b71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5ae380d8-af79-424e-af86-1816692e655d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88c7865a-4277-48cd-8efc-a1651f148966" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5ae380d8-af79-424e-af86-1816692e655d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_98ae955c-a0e6-4248-807c-f11584c7dbdb" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_21c8cabd-793c-4689-a727-c9b59f6eb9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_21c8cabd-793c-4689-a727-c9b59f6eb9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_7ccdedde-60b6-4e1f-bb21-f2d994ce9f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_7ccdedde-60b6-4e1f-bb21-f2d994ce9f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_db86144b-8d13-4a0b-8d1b-2c1847d64a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_db86144b-8d13-4a0b-8d1b-2c1847d64a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_313117fc-1464-423e-9cd1-847af5f3bf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_313117fc-1464-423e-9cd1-847af5f3bf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ba53fd5c-7904-4b01-9834-a63ca6cd0d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ba53fd5c-7904-4b01-9834-a63ca6cd0d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_c73b4e72-ee77-427e-b3e7-348353f8a85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_c73b4e72-ee77-427e-b3e7-348353f8a85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_9e983141-3627-4dfd-a399-69f473afd769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_9e983141-3627-4dfd-a399-69f473afd769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c4e96bc4-befd-4f43-804a-e6bb2f3f7f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3d9a882d-14e3-4f31-ac0e-10fd445ff4f7" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_c4e96bc4-befd-4f43-804a-e6bb2f3f7f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1302a08b-5b80-4a1e-b939-b5d07f9a23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_07240357-2b49-4708-a731-81daee6d2336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1302a08b-5b80-4a1e-b939-b5d07f9a23b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_07240357-2b49-4708-a731-81daee6d2336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f0cd7745-1571-43e4-aa6e-b47309ed8309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1302a08b-5b80-4a1e-b939-b5d07f9a23b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f0cd7745-1571-43e4-aa6e-b47309ed8309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8c5f6f9f-2d29-44f0-aa57-202498ca778a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1302a08b-5b80-4a1e-b939-b5d07f9a23b1" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8c5f6f9f-2d29-44f0-aa57-202498ca778a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_266ff193-9af7-445d-9df7-19d9a62b436d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_266ff193-9af7-445d-9df7-19d9a62b436d" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_aac52407-684d-4520-bffc-fa728c6d4ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_984d342a-1619-4a6f-8675-1ae3b53f1faf" xlink:to="loc_us-gaap_AssetAcquisitionDomain_aac52407-684d-4520-bffc-fa728c6d4ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember_b187daee-d974-4c6f-8ab6-2e666a241fa1" xlink:href="gild-20230331.xsd#gild_TmunityTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_aac52407-684d-4520-bffc-fa728c6d4ba4" xlink:to="loc_gild_TmunityTherapeuticsMember_b187daee-d974-4c6f-8ab6-2e666a241fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a84f4f93-81d9-4de1-b72c-188416295937" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_18b20bfe-84a9-497c-ac24-723c50ed2c66" xlink:href="gild-20230331.xsd#gild_ArcellxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:to="loc_gild_ArcellxIncMember_18b20bfe-84a9-497c-ac24-723c50ed2c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_ad3cdb3e-94ef-4edd-ac1b-3ff4df336f0d" xlink:href="gild-20230331.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c40f6ed9-9c91-416b-a2c1-ec4caa84b2af" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_ad3cdb3e-94ef-4edd-ac1b-3ff4df336f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0b10980-9487-469f-a3a3-1578e89e15f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_64e9654b-4791-49c4-8c33-ad1ee838181f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0b10980-9487-469f-a3a3-1578e89e15f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GlobalStrategicCollaborationAgreementMember_21f1222d-e921-47c7-9549-f2486a47d3d9" xlink:href="gild-20230331.xsd#gild_GlobalStrategicCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a0b10980-9487-469f-a3a3-1578e89e15f8" xlink:to="loc_gild_GlobalStrategicCollaborationAgreementMember_21f1222d-e921-47c7-9549-f2486a47d3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76ea9d16-2f54-4431-922e-a40bed93e589" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2c7a2b13-6abb-4688-b23e-909c1c19164d" xlink:to="loc_dei_EntityDomain_76ea9d16-2f54-4431-922e-a40bed93e589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_b790d7bc-b385-4669-82b5-56cd31834ca7" xlink:href="gild-20230331.xsd#gild_ArcellxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_76ea9d16-2f54-4431-922e-a40bed93e589" xlink:to="loc_gild_ArcellxIncMember_b790d7bc-b385-4669-82b5-56cd31834ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_38185c7f-3826-418f-b995-86a629a94355" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions_0a185d10-0b98-4216-88ec-ea6358bd97d4" xlink:href="gild-20230331.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_gild_PaymentsForAssetAcquisitions_0a185d10-0b98-4216-88ec-ea6358bd97d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e05c5716-8559-4011-94d1-3650f110a179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e05c5716-8559-4011-94d1-3650f110a179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_de3a7178-d253-46e2-9089-1b2d1e038628" xlink:href="gild-20230331.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_de3a7178-d253-46e2-9089-1b2d1e038628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_1ea6b127-75b0-4e2d-a1fa-404768d3af28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_1ea6b127-75b0-4e2d-a1fa-404768d3af28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_2debc2cd-5624-4424-8a86-5aceb18e87f2" xlink:href="gild-20230331.xsd#gild_RevenuePerformanceObligationPercentageOfUSProfits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_2debc2cd-5624-4424-8a86-5aceb18e87f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_755eff51-c637-49c7-9fc3-ef145d2a1a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_755eff51-c637-49c7-9fc3-ef145d2a1a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6c1cc8de-743e-4d91-b291-011439432bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6c1cc8de-743e-4d91-b291-011439432bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9a52cbdc-b829-4770-9c52-1961be0dd34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_5ffc9754-04af-4274-b39c-6e1354b17ac5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9a52cbdc-b829-4770-9c52-1961be0dd34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0004164d-bcc1-4917-97fd-ce35b7bc8e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0004164d-bcc1-4917-97fd-ce35b7bc8e42" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5718061f-7e74-4fe0-aedd-eea506f044fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_37806007-37a3-471e-8420-8553e3bac6ec" xlink:href="gild-20230331.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_37806007-37a3-471e-8420-8553e3bac6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_2fb40740-594b-4e88-8f62-7b453d93bccd" xlink:href="gild-20230331.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_2fb40740-594b-4e88-8f62-7b453d93bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_6187c66d-d3d3-46d2-9ce6-b38bcb1df8a1" xlink:href="gild-20230331.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_TrodelvyMember_6187c66d-d3d3-46d2-9ce6-b38bcb1df8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_b98b930b-bdc0-4000-805d-a84c4ab669b8" xlink:href="gild-20230331.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_gild_HepcludexMember_b98b930b-bdc0-4000-805d-a84c4ab669b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_eba2192f-8a36-4965-b0b3-001962c878d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04a2545e-72de-4a80-bd6b-8614477ca13a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_eba2192f-8a36-4965-b0b3-001962c878d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09e2dcd0-c9e8-4538-abd3-49b87ff24ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ccc12b64-949f-4d72-a906-630ac434a7d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09e2dcd0-c9e8-4538-abd3-49b87ff24ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_9441243a-98ef-49f5-ab7e-0c07d0436b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09e2dcd0-c9e8-4538-abd3-49b87ff24ed8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_9441243a-98ef-49f5-ab7e-0c07d0436b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8bff339-938c-440b-a505-4df14d1ff04a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f242735-9c7b-4217-8524-3954b4eecc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f242735-9c7b-4217-8524-3954b4eecc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_314d4405-a574-4d02-8904-bf59919961df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_314d4405-a574-4d02-8904-bf59919961df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cc28eebf-77c9-406c-b24d-6a056a4202b0" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_cc28eebf-77c9-406c-b24d-6a056a4202b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9e1ddfe3-c9fb-4c0d-a76d-bd30eef4e54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9e1ddfe3-c9fb-4c0d-a76d-bd30eef4e54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e06c1b5c-0114-4a1b-ab2f-259aa61f56c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e06c1b5c-0114-4a1b-ab2f-259aa61f56c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_b387bd9d-8982-47d5-854b-aafa20027a0c" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_b387bd9d-8982-47d5-854b-aafa20027a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d20a7ad8-dd7c-44cd-b87b-b2b27cf45541" xlink:href="gild-20230331.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0b227b4e-d7b5-48a2-ab57-a847f89c66d8" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d20a7ad8-dd7c-44cd-b87b-b2b27cf45541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b9be5254-60f9-431a-844e-07688368a03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b9be5254-60f9-431a-844e-07688368a03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7960651d-5ffa-4cbb-b80b-dddc0c0ffcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7960651d-5ffa-4cbb-b80b-dddc0c0ffcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1b2b4525-ae79-4591-81db-2903a21610f7" xlink:href="gild-20230331.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1b2b4525-ae79-4591-81db-2903a21610f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c5471ce5-6c35-4668-92c9-ba8b8ebc472c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b1e8822a-f6ff-4a22-ae2a-d4c2aa7f47e4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c5471ce5-6c35-4668-92c9-ba8b8ebc472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_aa0dba89-b83b-4e47-9cad-44800a364954" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8e1f6647-d716-4cc2-86fe-a7230ab43823" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_aa0dba89-b83b-4e47-9cad-44800a364954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_121386cd-8c93-459c-b8db-872d5add3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_121386cd-8c93-459c-b8db-872d5add3dec" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc96f94-8d59-46f9-8d44-35dae2138743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f3bfe754-23f8-4767-aca7-2cc30af17a83" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc96f94-8d59-46f9-8d44-35dae2138743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_573f9519-48f4-41d2-ac17-ebb6fd048f5d" xlink:href="gild-20230331.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cdc96f94-8d59-46f9-8d44-35dae2138743" xlink:to="loc_gild_ImmunomedicsIncMember_573f9519-48f4-41d2-ac17-ebb6fd048f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_375e6131-2072-43fa-82c1-a7b29f6b423c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f4684e10-b9c8-4e8a-b250-b6a23d9a9af6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_375e6131-2072-43fa-82c1-a7b29f6b423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_b7ba8ca7-326c-4b71-bb32-1e9c86333a22" xlink:href="gild-20230331.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_375e6131-2072-43fa-82c1-a7b29f6b423c" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_b7ba8ca7-326c-4b71-bb32-1e9c86333a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a4b6b86b-efec-43eb-b606-9e297fab5d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_811c128d-ce2e-4a3d-a981-263173241309" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a4b6b86b-efec-43eb-b606-9e297fab5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_24894547-bf14-4f18-b469-feecaf3e5367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a4b6b86b-efec-43eb-b606-9e297fab5d54" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_24894547-bf14-4f18-b469-feecaf3e5367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_87e49f8c-dbaa-4f40-9d27-9cc6025f1c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409b0287-abea-41ad-a733-e3263f79f627" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_87e49f8c-dbaa-4f40-9d27-9cc6025f1c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_18927ea6-936b-4aff-9441-3ffa8a57986b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_87e49f8c-dbaa-4f40-9d27-9cc6025f1c21" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_18927ea6-936b-4aff-9441-3ffa8a57986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_778c758e-611a-4728-b932-197ed33f3eca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2f8cc904-6985-4556-8fef-dbb5008ebe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2f8cc904-6985-4556-8fef-dbb5008ebe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d97be3e2-3bc7-479d-a755-860b187bb7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d97be3e2-3bc7-479d-a755-860b187bb7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_f9841357-193e-4f83-9377-e3e16025d822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_f9841357-193e-4f83-9377-e3e16025d822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_ce524180-1c78-47f7-b20a-c33c54f85b00" xlink:href="gild-20230331.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_ce524180-1c78-47f7-b20a-c33c54f85b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a17c21b-c97e-4ef8-b188-c2351d9ee161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a7b75b6d-5101-4486-a025-50293dca8cb7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5a17c21b-c97e-4ef8-b188-c2351d9ee161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2f28d286-b615-4202-932f-df37b67fc919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2f28d286-b615-4202-932f-df37b67fc919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_aabad501-9ef4-439c-bd1c-7fa2febfb6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_aabad501-9ef4-439c-bd1c-7fa2febfb6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fb0c67a2-6b31-4a9f-9976-afdbdec3ad87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fb0c67a2-6b31-4a9f-9976-afdbdec3ad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_de75f761-f264-4150-993e-7c24e51653ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_de75f761-f264-4150-993e-7c24e51653ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3ff26399-70e4-4945-b963-480478d69382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3ff26399-70e4-4945-b963-480478d69382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_bbe10895-d52e-4f83-89a1-bb15c48752ac" xlink:href="gild-20230331.xsd#gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_bbe10895-d52e-4f83-89a1-bb15c48752ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4cf0e5f-b2ce-4b11-a21f-fb54a7ce9d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_58646a3f-179b-4d5d-8622-1a1660d8096c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4cf0e5f-b2ce-4b11-a21f-fb54a7ce9d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_80c9e8fa-707b-4ead-98d4-5e8c9b9dac2f" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_844803c8-32ef-4af9-9975-01dd42905899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_80c9e8fa-707b-4ead-98d4-5e8c9b9dac2f" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_844803c8-32ef-4af9-9975-01dd42905899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_fde83f44-8a53-429a-bb63-9f70cb8da525" xlink:href="gild-20230331.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_80c9e8fa-707b-4ead-98d4-5e8c9b9dac2f" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_fde83f44-8a53-429a-bb63-9f70cb8da525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_57b278bb-710b-4371-8412-d34c2040d2cc" xlink:href="gild-20230331.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_80c9e8fa-707b-4ead-98d4-5e8c9b9dac2f" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_57b278bb-710b-4371-8412-d34c2040d2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ce93b91e-320d-403c-aee5-c4a31e62007a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_80c9e8fa-707b-4ead-98d4-5e8c9b9dac2f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ce93b91e-320d-403c-aee5-c4a31e62007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a9b9e418-17c4-45cb-ae52-0840a9ed64a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_80c9e8fa-707b-4ead-98d4-5e8c9b9dac2f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a9b9e418-17c4-45cb-ae52-0840a9ed64a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_54fa83c3-3910-4f24-99b8-1319f9514c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_54fa83c3-3910-4f24-99b8-1319f9514c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5d789d18-057b-42d2-a9e7-7907b9c7e141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_5d789d18-057b-42d2-a9e7-7907b9c7e141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e7ef6dae-6094-4772-9fca-40244179dcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e7ef6dae-6094-4772-9fca-40244179dcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_28dd6284-0e69-434b-bc4a-222b9cee7c15" xlink:href="gild-20230331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:to="loc_gild_InventoryNetAndInventoryNoncurrent_28dd6284-0e69-434b-bc4a-222b9cee7c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2765491e-9a2c-4b77-ae60-32d44af03493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:to="loc_us-gaap_InventoryNet_2765491e-9a2c-4b77-ae60-32d44af03493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4b167116-5a01-42c0-8897-96cdad77fbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_7c4e9f67-b52d-4130-8beb-60f1032e431d" xlink:to="loc_us-gaap_InventoryNoncurrent_4b167116-5a01-42c0-8897-96cdad77fbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_63e4f612-b203-4b55-b531-dd5a1c291be7" xlink:href="gild-20230331.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_d224c79b-2397-46af-962a-6cd9ad90ccdd" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_37a06434-427b-4a22-822d-96fa4e79256c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d224c79b-2397-46af-962a-6cd9ad90ccdd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_37a06434-427b-4a22-822d-96fa4e79256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_67133dd2-bdde-4a73-8b70-b0b2bc06a150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d224c79b-2397-46af-962a-6cd9ad90ccdd" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_67133dd2-bdde-4a73-8b70-b0b2bc06a150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_b792f781-0a4b-4ca3-8322-50cd6ba28c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d224c79b-2397-46af-962a-6cd9ad90ccdd" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_b792f781-0a4b-4ca3-8322-50cd6ba28c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b925c3ca-29a1-47bb-ba66-2daf973f65ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d224c79b-2397-46af-962a-6cd9ad90ccdd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b925c3ca-29a1-47bb-ba66-2daf973f65ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8c37b999-5692-4f39-9625-6940bea416a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d224c79b-2397-46af-962a-6cd9ad90ccdd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8c37b999-5692-4f39-9625-6940bea416a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_c2360d4a-5dd1-45a4-bfe3-46c0031f6be2" xlink:href="gild-20230331.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_c2360d4a-5dd1-45a4-bfe3-46c0031f6be2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_87772af2-dad6-4391-933a-4c100438a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e8dacded-cf70-46c9-9445-9913fb16e532" xlink:to="loc_us-gaap_EquityComponentDomain_87772af2-dad6-4391-933a-4c100438a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_87772af2-dad6-4391-933a-4c100438a608" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f3948f28-96ed-4448-b623-ef9e859de16d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f3948f28-96ed-4448-b623-ef9e859de16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_893da5ff-9cc7-4a24-8ed8-2305b7931a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_893da5ff-9cc7-4a24-8ed8-2305b7931a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d1ce8f-870a-4866-ad9a-5276ee90219b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c20e549a-9e8f-4346-ab7e-47010f18945b" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_d4d1ce8f-870a-4866-ad9a-5276ee90219b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9f5002d0-9154-478e-ae8b-9bc1cca7da0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8d185a67-83ad-414e-a81f-541b75feb1d8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9f5002d0-9154-478e-ae8b-9bc1cca7da0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9f5002d0-9154-478e-ae8b-9bc1cca7da0a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d67129f2-a6ee-4f8d-9c9d-4c00cc4fdf48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d67129f2-a6ee-4f8d-9c9d-4c00cc4fdf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5a85f502-37a4-4113-bd05-573b8f27331d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_5a85f502-37a4-4113-bd05-573b8f27331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_cc0fcd08-a69b-4189-a263-5fe2658cf1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_cc0fcd08-a69b-4189-a263-5fe2658cf1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ff8cbd6-899a-4912-a2be-c98bcd710453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ff8cbd6-899a-4912-a2be-c98bcd710453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9281efbe-80e5-421f-87dc-403de32780bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_7185b037-51a9-4594-88e6-1898605c0bca" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9281efbe-80e5-421f-87dc-403de32780bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6b4e71fa-2285-475c-aa91-5c001ef49c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6b4e71fa-2285-475c-aa91-5c001ef49c25" xlink:to="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_01198a42-77cd-4285-87fe-d9842c3be7d8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_268f6b23-3b63-49e3-9e7c-a7b6c96ed8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:to="loc_us-gaap_SeniorNotesMember_268f6b23-3b63-49e3-9e7c-a7b6c96ed8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_34853e48-c18d-46f4-ac9a-7aea94c9c655" xlink:href="gild-20230331.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_34853e48-c18d-46f4-ac9a-7aea94c9c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_996b857b-73cd-44bb-8bd7-44771a42b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ad6486-6d2f-482a-83bb-43e55fcd064b" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_996b857b-73cd-44bb-8bd7-44771a42b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:to="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e9e359d0-4132-4a87-80b4-0b8c58ead2fb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_8e378c49-7bad-48dc-9236-05d19d7ad183" xlink:href="gild-20230331.xsd#gild_A250SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A250SeniorUnsecuredNotesDueSeptember2023Member_8e378c49-7bad-48dc-9236-05d19d7ad183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_c447c039-89a6-4231-8e7e-4733deecbefb" xlink:href="gild-20230331.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_c447c039-89a6-4231-8e7e-4733deecbefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_73b96322-e82a-40b9-bc1c-592fb4fab223" xlink:href="gild-20230331.xsd#gild_A370SeniorUnsecuredNotesDueApril2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A370SeniorUnsecuredNotesDueApril2024Member_73b96322-e82a-40b9-bc1c-592fb4fab223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_4b2b2e8b-d6ae-4622-81e0-2dcb48d8988b" xlink:href="gild-20230331.xsd#gild_A350SeniorUnsecuredNotesDueFebruary2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A350SeniorUnsecuredNotesDueFebruary2025Member_4b2b2e8b-d6ae-4622-81e0-2dcb48d8988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_1b602ada-c94a-453c-808b-1e957bf0f9cd" xlink:href="gild-20230331.xsd#gild_A365SeniorUnsecuredNotesDueMarch2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A365SeniorUnsecuredNotesDueMarch2026Member_1b602ada-c94a-453c-808b-1e957bf0f9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_9456b6b3-ba84-4c06-aa0b-a57f13177fdf" xlink:href="gild-20230331.xsd#gild_A295SeniorUnsecuredNotesDueMarch2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A295SeniorUnsecuredNotesDueMarch2027Member_9456b6b3-ba84-4c06-aa0b-a57f13177fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_5b68cd09-ac1b-4127-9b8c-a082f3e0e21e" xlink:href="gild-20230331.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_5b68cd09-ac1b-4127-9b8c-a082f3e0e21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_1262fc38-431a-4f5d-bfff-91ff72d1d5cb" xlink:href="gild-20230331.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_1262fc38-431a-4f5d-bfff-91ff72d1d5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_f2d32b82-4716-4b24-b19c-8b667f1a7770" xlink:href="gild-20230331.xsd#gild_A460SeniorUnsecuredNotesDueSeptember2035Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A460SeniorUnsecuredNotesDueSeptember2035Member_f2d32b82-4716-4b24-b19c-8b667f1a7770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_55b35db1-1aa5-4f90-a31b-cfcd10b89b26" xlink:href="gild-20230331.xsd#gild_A400SeniorUnsecuredNotesDueSeptember2036Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A400SeniorUnsecuredNotesDueSeptember2036Member_55b35db1-1aa5-4f90-a31b-cfcd10b89b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_502e7176-0034-4882-8cb5-b99be4e71b80" xlink:href="gild-20230331.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_502e7176-0034-4882-8cb5-b99be4e71b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_ca9491ca-ce9b-4ced-b97a-44b51dd73bdd" xlink:href="gild-20230331.xsd#gild_A565SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A565SeniorUnsecuredNotesDueDecember2041Member_ca9491ca-ce9b-4ced-b97a-44b51dd73bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_d23adf7f-390a-4c5b-8bcb-8e5416f6368a" xlink:href="gild-20230331.xsd#gild_A480SeniorUnsecuredNotesDueApril2044Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A480SeniorUnsecuredNotesDueApril2044Member_d23adf7f-390a-4c5b-8bcb-8e5416f6368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_4ed96ac1-8465-47e1-9e1d-1a421ad2d71d" xlink:href="gild-20230331.xsd#gild_A450SeniorUnsecuredNotesDueFebruary2045Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A450SeniorUnsecuredNotesDueFebruary2045Member_4ed96ac1-8465-47e1-9e1d-1a421ad2d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_9a01d355-68b3-4beb-88f9-6d15ca1f5656" xlink:href="gild-20230331.xsd#gild_A475SeniorUnsecuredNotesDueMarch2046Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A475SeniorUnsecuredNotesDueMarch2046Member_9a01d355-68b3-4beb-88f9-6d15ca1f5656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_a555f5a6-f7f4-4119-b2d7-b6719e47ace8" xlink:href="gild-20230331.xsd#gild_A415SeniorUnsecuredNotesDueMarch2047Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A415SeniorUnsecuredNotesDueMarch2047Member_a555f5a6-f7f4-4119-b2d7-b6719e47ace8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_c5b349d6-78ef-47e6-ad1f-24bb98257048" xlink:href="gild-20230331.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b35c6f-91e8-418a-8004-31f52572a4e2" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_c5b349d6-78ef-47e6-ad1f-24bb98257048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8ebae364-ea72-452e-888d-b4bb4a10a4e3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7729c794-3ae1-40b1-9747-56352d160937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7729c794-3ae1-40b1-9747-56352d160937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3bc6a6a1-365f-4cf0-9c84-53f54f0ebbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_LongTermDebt_3bc6a6a1-365f-4cf0-9c84-53f54f0ebbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3a6b343f-0755-4fbd-b9d9-4f9be11ba07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3a6b343f-0755-4fbd-b9d9-4f9be11ba07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6d9b8c1e-8fc8-4db2-b920-30aa84da1da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_LongTermDebtCurrent_6d9b8c1e-8fc8-4db2-b920-30aa84da1da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1df925cb-6c72-4b74-8eee-0d3d2a81ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_35b23cf6-6854-4a37-bff1-de2a9fbe604b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1df925cb-6c72-4b74-8eee-0d3d2a81ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#DEBTANDCREDITFACILITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e343c1f7-420b-4cbe-95a4-6e379b678aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e343c1f7-420b-4cbe-95a4-6e379b678aec" xlink:to="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc9da083-6be8-4f1f-b6f9-030388bb28cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b4fa93fa-58e9-491c-b043-3e1d5bfa5f3b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc9da083-6be8-4f1f-b6f9-030388bb28cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e30e279a-d357-440c-895a-f5ff507dd46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc9da083-6be8-4f1f-b6f9-030388bb28cb" xlink:to="loc_us-gaap_LineOfCreditMember_e30e279a-d357-440c-895a-f5ff507dd46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dd377a9c-5402-4fc2-93e5-54caf31261f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_333ee788-df25-4925-8591-fc9e8cac3016" xlink:to="loc_us-gaap_CreditFacilityDomain_dd377a9c-5402-4fc2-93e5-54caf31261f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c3a1e68c-90af-4bb9-b159-8d2cdfad459d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dd377a9c-5402-4fc2-93e5-54caf31261f7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c3a1e68c-90af-4bb9-b159-8d2cdfad459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_206be09f-fc50-40ef-bba9-08d1badd2260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_36198d31-ffe9-42d5-a944-8d2996d0c250" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_206be09f-fc50-40ef-bba9-08d1badd2260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_5b353da9-2a4c-4cf1-b850-6d763fd910d2" xlink:href="gild-20230331.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_206be09f-fc50-40ef-bba9-08d1badd2260" xlink:to="loc_gild_CreditFacilityDueJune2025Member_5b353da9-2a4c-4cf1-b850-6d763fd910d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_86571ee7-5126-4f06-9328-ba3886e68ae4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_65760222-c7e6-40fe-83ac-73908ccdda00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:to="loc_us-gaap_LineOfCredit_65760222-c7e6-40fe-83ac-73908ccdda00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_57369386-ea3e-46de-b470-1612a01a56c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7f1269c0-495c-4070-9f3c-6dcffd3a8de1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_57369386-ea3e-46de-b470-1612a01a56c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_74b146f7-538b-4672-b6aa-c9e71ada4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_74b146f7-538b-4672-b6aa-c9e71ada4c65" xlink:to="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:to="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b50432ea-adb3-4578-8eef-8ff1833b4e72" xlink:to="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_fdb8acda-e950-457d-936f-a29eac89ce13" xlink:href="gild-20230331.xsd#gild_PreExposureProphylaxisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:to="loc_gild_PreExposureProphylaxisMember_fdb8acda-e950-457d-936f-a29eac89ce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_17760119-33f8-42d4-b51a-3f0840d0ca46" xlink:href="gild-20230331.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_17760119-33f8-42d4-b51a-3f0840d0ca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_efb003b8-cbdb-4a9c-a614-17413eb1bd69" xlink:href="gild-20230331.xsd#gild_ProductLiabilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b9987ae8-0cac-4c96-b69e-2a9bfdb44c99" xlink:to="loc_gild_ProductLiabilityMember_efb003b8-cbdb-4a9c-a614-17413eb1bd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a9709c20-260f-4f83-b6fe-0c2f96c84bfc" xlink:to="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_b0d449c9-813c-4bf6-b9d3-29c45386f7c1" xlink:href="gild-20230331.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_b0d449c9-813c-4bf6-b9d3-29c45386f7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_e6e8ab11-f434-441a-ba5f-16d8fcb91d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_e6e8ab11-f434-441a-ba5f-16d8fcb91d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents_84945dbd-489d-4560-8919-212a2c9fc7ed" xlink:href="gild-20230331.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_gild_LossContingencyNumberOfPatents_84945dbd-489d-4560-8919-212a2c9fc7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_2cf78b6b-7f38-49b4-8ecb-47dd300dd418" xlink:href="gild-20230331.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_2cf78b6b-7f38-49b4-8ecb-47dd300dd418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_3bdb367f-c95a-4dd1-aa5f-5ed5eec139b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_3bdb367f-c95a-4dd1-aa5f-5ed5eec139b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_907de7e1-0d60-4bec-b37f-bf45cd12751d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5790ca81-19e0-49a6-bdde-bae6ff73484a" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_907de7e1-0d60-4bec-b37f-bf45cd12751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b640811-274d-45cb-8d76-9f1a25506aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:to="loc_us-gaap_NetIncomeLoss_4b640811-274d-45cb-8d76-9f1a25506aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed96a39b-8e8c-467d-becd-d5b52fa7c496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed96a39b-8e8c-467d-becd-d5b52fa7c496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b323e93f-c01b-4bf3-9f39-0e3df777134c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b323e93f-c01b-4bf3-9f39-0e3df777134c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_addf8062-56b5-426f-953d-3b79e8603576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_addf8062-56b5-426f-953d-3b79e8603576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f0388dac-f430-442f-bbb3-63972c1cb093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:to="loc_us-gaap_EarningsPerShareBasic_f0388dac-f430-442f-bbb3-63972c1cb093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_74ff8293-0b59-473a-bede-5eaa1047de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84fbae11-6565-4c13-8dc7-dddc65e62635" xlink:to="loc_us-gaap_EarningsPerShareDiluted_74ff8293-0b59-473a-bede-5eaa1047de8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EARNINGSPERSHAREAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#EARNINGSPERSHAREAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EARNINGSPERSHAREAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_26f2e6d6-767e-47f6-859c-7e1701e9e02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a637c12d-86b0-4f81-9915-62783e32cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_26f2e6d6-767e-47f6-859c-7e1701e9e02e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a637c12d-86b0-4f81-9915-62783e32cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESScheduleDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INCOMETAXESScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7c61abcb-4886-4727-a598-79c1aca6a708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f6eb9837-5a7e-4391-b313-3ba4dc39b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c61abcb-4886-4727-a598-79c1aca6a708" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f6eb9837-5a7e-4391-b313-3ba4dc39b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7b00d9f6-3258-4dc8-8578-e36a6d454dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c61abcb-4886-4727-a598-79c1aca6a708" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7b00d9f6-3258-4dc8-8578-e36a6d454dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dbd6b150-1d4c-4059-807b-1453642c83c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7c61abcb-4886-4727-a598-79c1aca6a708" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dbd6b150-1d4c-4059-807b-1453642c83c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20230331.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0aa2ff2-49dd-4c82-8a75-554710a91962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0aa2ff2-49dd-4c82-8a75-554710a91962" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:to="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c1675cee-40a5-453e-8983-d32742efbfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_174d3e75-c80b-45b6-b5c8-2e3bd028802f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c1675cee-40a5-453e-8983-d32742efbfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember_32c377d2-3887-42e7-94c6-ea3b6194cc3c" xlink:href="gild-20230331.xsd#gild_TmunityTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1675cee-40a5-453e-8983-d32742efbfa9" xlink:to="loc_gild_TmunityTherapeuticsMember_32c377d2-3887-42e7-94c6-ea3b6194cc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b0c22be3-5eb3-4387-82e6-feaf021ca783" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ded6df5-a0b5-4625-87b3-c40a2aec444d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ded6df5-a0b5-4625-87b3-c40a2aec444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_277ef25d-a68d-4f1f-8377-9ea025aac155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_277ef25d-a68d-4f1f-8377-9ea025aac155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2d68541f-1199-4060-8008-9c36079d21dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_3508fb38-a47d-446e-89b4-34a39597120d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2d68541f-1199-4060-8008-9c36079d21dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>a1022graph.jpg
<DESCRIPTION>EXHIBIT 10.22 GRAPHIC
<TEXT>
begin 644 a1022graph.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO;B!+<G5E
M9V5R   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,V,   DI(
M @    ,V,   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C R,SHP-3HP,2 Q-CHP-3HQ-P R,#(S.C U.C Q
M(#$V.C U.C$W    2@!O &X ( !+ '( =0!E &< 90!R    _^$+'FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S
M9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q
M.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^/'AM<#I#<F5A=&5$871E/C(P,C,M,#4M,#%4,38Z,#4Z,3<N-3DV/"]X
M;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD
M,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\
M<F1F.FQI/DIO;B!+<G5E9V5R/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D
M8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP
M;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG
M=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>
M)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<
M&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*O_  !$( A4#X@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH SM3_P"0AH__ %^-_P"D\M:-9VI_\A#1
M_P#K\;_TGEK1H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[0_
M^0?+_P!?EU_Z425HUG:'_P @^7_K\NO_ $HDH T:*** "BBB@ HHHH ****
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M.@-9.L^/OCUH6ARZ]JGAG3+;3X?GE C5C&N1R4$I<#GGT&2<=: /H@D $DX
MZDUE:+XIT'Q(9AX?UFQU,V^/-%I<++Y><XSM/&<'\J\[M_B7XA\:?!4^(_ V
MD03ZTL_V:YLI#O5"/OXY&?E96&3T/>O!?@MK/C_2+G5_^%<Z+;:J\JPB[$ZY
M$8!?9CYUQG+>O2@#Z,\<?&33_!'CS2_#%SI5W=S:@L3F:)@%C$CL@P.K'*]!
MZ]SQ7H]>)_%3XF:KX5^,7AS0+'3M*N+>[CMY&FNK8O,ADG>,[&##;PO''4FI
M+KXN^(-&_:$3P5K=M8IH]S.L5O,D;"4B1,QG<6P?G(4\>M 'M%%>2_''XKZG
M\.DT>T\.V]M<:AJ#NS+<1,X$:X  "L#DLPQ]#4/Q(^,6I^"K?1O#VGZ?%J'C
M'4K>%I(E1O)B=_EX7.6+.&"KGCJ3TR >P45\_:I\6/B=\.=4TZ;XDZ'ILND7
MI"%[(X9#U(!#'Y@.<$8/8]37OMO<17=K%<6[B2*9 Z..C*1D'\J //\ Q5\<
M?!O@[Q)<Z%K,]X+VU">:L5L64;D#CGOPPK'_ .&F/A[_ ,]]1_\  ,_XUZ'J
M?@[PSK5Z;S6/#NDZA<E0IGNK&*5R!T&YE)Q7SC\ /#NBZS\2?%EKK&CV%_;V
MZMY45U:I*D?[XCY0RX'''&* /=-)^*_A+5_!-YXLBOVM](LIC!/+<1%&#@*=
MH7DL3O7 &<YKBH_VI/ SZB(&M-8C@W%?M+6Z;?K@.6Q^&?:LW]I'PFMG\+]/
M7PSI4-IIMCJ!GN;>QMUCC3<A'F%5 [\9_P!JJWPK\>_"_7?!.F>$/$.FZ?97
MD<20O'?6R>5<R <R"3& S')^8@Y/&: /7]?\?:#X<\&0>*;^XD?2KA8GAEAB
M+&19!E"!UY!SS7$+^TO\/"P!N=04$]39GC]:J_M%6-MIGP+BL+")8;6UN;:&
M"->0B*"J@9]  *X[P;K'PRC_ &=+6R\7R:1-J*P71:#:C78?SI=F,?,K888/
M'!]* /?O#'BO1/&.CKJGAN_CO;4L49E!#(PY*LIP5/(X([@]ZV*^<_V3;#48
MK3Q%?2QR)IT[0QPLWW9)%W[MOT!&3[CTKZ,H \JO?VC? %C?SVDMS?M)!(T;
M%;0X)4X./RKHO!OQ9\'^.[MK/0-3W7JKO^RW$;12$>JYX;\"<=Z\#^ 5A9:A
M\;_$L.IVMO<P+973;+B-74$7,7.",=":I^(;32M,_:ITNW\ 1K'''J-J)(K)
M?W<;DCS54#@+MSNQP/F]* /KNBO)?&_C#XI'QM<Z%\/?"<<MI9B,OJ-ZN(YB
MR!OD9F5<#)4@;CD=JY[PC\9_&-A\3K?P;\3](M;*>\=(HI(5VE'<?)R&975C
M@9!X/Y  ][HKQ?P7\7O$%]\;-2\#^+;:PMUC>>.U:"-E9F0[ER2Q!#1@GH.U
M2_%'XLZ_X<^).B>#_!]M93W=\(_.:ZA:0*TC[4 VNO0 D^Q'- 'L=%>+_$WX
MUZIHOC./P7X!TI-3UUBJRO*C,J.P#!%4$9.TY+$X'X''-W/QJ^)7@#6K,?$_
MPS;KI]V#M^S!0YQC)5E=E)&?NG'7M0!]&45YC\7_ (EWW@WX<:7XE\*?8[H:
MA=PI&]PC.C120R2!@ PY.U?P-;D7BS4'^")\7-'!_:(T!M1V;#Y7FB R8QG.
MW(Z9Z=Z .R) !). .I-96B^*=!\2&8>']9L=3-OCS1:7"R^7G.,[3QG!_*O'
M?"OQ3\?^-?A-K&KZ/I6G7>M6M^MND$43!#"4!8X+\D9]?PKR/X+:SX_TBYU?
M_A7.BVVJO*L(NQ.N1& 7V8^=<9RWKTH ^TZY7QU\2/#GP[L([CQ%=.))\^1:
MP)OEFQUP. ![D@>]=57RK^T7:W&D_&72-?U33VOM(,5N0CC]W*(W)>'/3D=C
M_>H ]3\*_M%^#/%.O6^D)%J6GW-W,L-N;N!=LCL<*N49L$D@<\<]:D^(7QBN
M/!/Q*T7PK#HT=XFI1P.UPUP4*>9,T> H4]-N>O.?:I/"?B3X7?$ZZL9M.L[
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MT:SM3_Y"&C_]?C?^D\M:- !1110 4444 %%%% !1110 4444 %%%% !1110
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M<2'(MII%1&_WB@!/X$4 <9XGOM1U']C;1KC6'DDN/M:(LDH^9HUED5#[_*
M>XQU[YVC_!G2?$W[.-OXHTN&9/$:1W%PS+(S+<".:1=FP\ [%XQCD#U-?0WC
M/P!I/C7P>OAN\::RL8WC:,66U2@3A5&5( QQTJ[X0\*V/@OPC9>'M+>:6TLU
M8*UPP9VW.SL3@ =6/:@#S;]G'Q])XI\%S:-J4JOJ&CL%!VA3) V=AP !D$%3
M] 3R:]DKSSP7\&= \!^+[O7]"O-05KI)(S:2.GDHK,&P %!P,<<UZ'0!\6?#
MOX>V/Q)^*VNZ/J=W<6<4$=Q=![<+N+"=%QR.GSG\J^D?A]\%?"_P[O&O].%Q
M>ZBRE1=WC M&IZA H 'UY/)YQQ4G@CX/Z#X$\6:CX@TN[OY[N_C>)EN'0HBO
M('( 51W5>OI7?4 ?/?B#QUXV\:_&^Z\"^$M<B\.6EF7C:5H@7E*+EFY&2>N
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M#V((!%>8:%^S)X+TC4OM=Y<:AJ@4,$@NF3RQD8R0%&XC\O:@#&_99&?AYX@
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MGC(). >,U[K7E?@?]G[PQX'\1V^NVU[J-[?6NXPF>1 BDJ5)VJHSPQZFO5*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[4_^0AH_P#U
M^-_Z3RUHUG:G_P A#1_^OQO_ $GEK1H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L[0_\ D'R_]?EU_P"E$E:-9VA_\@^7_K\NO_2B2@#1HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\
M\9H T:*SO/UK_H'V'_@<_P#\9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_
M ('/_P#&://UK_H'V'_@<_\ \9H T:*SO/UK_H'V'_@<_P#\9H\_6O\ H'V'
M_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\ \9H T:*SO/UK
M_H'V'_@<_P#\9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://U
MK_H'V'_@<_\ \9H T:*SO/UK_H'V'_@<_P#\9H\_6O\ H'V'_@<__P 9H T:
M*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\ \9H T:*SO/UK_H'V'_@<_P#\
M9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\
M\9H T:*SO/UK_H'V'_@<_P#\9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_
M ('/_P#&://UK_H'V'_@<_\ \9H T:*SO/UK_H'V'_@<_P#\9H\_6O\ H'V'
M_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\ \9H T:*SO/UK
M_H'V'_@<_P#\9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://U
MK_H'V'_@<_\ \9H T:*SO/UK_H'V'_@<_P#\9H\_6O\ H'V'_@<__P 9H T:
M*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\ \9H T:*SO/UK_H'V'_@<_P#\
M9H\_6O\ H'V'_@<__P 9H T:*SO/UK_H'V'_ ('/_P#&://UK_H'V'_@<_\
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M?^%D>-O^B77_ /X'?_:JNE6YHWE^1AC\L=*ORT;6\Y+]6CTVBO,O^%D>-O\
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M+X<U!+KQ->>'VTR33])U+5M-2WU&8PP6\,ZP2.59(VX1PX*D="1D;>?3-6\
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M.[_Z =__ -]V_P#\=H_M.[_Z =__ -]V_P#\=K1HH SO[3N_^@'?_P#?=O\
M_':/[3N_^@'?_P#?=O\ _':T:* ,[^T[O_H!W_\ WW;_ /QVC^T[O_H!W_\
MWW;_ /QVM&B@#._M.[_Z =__ -]V_P#\=H_M.[_Z =__ -]V_P#\=K1HH SO
M[3N_^@'?_P#?=O\ _':/[3N_^@'?_P#?=O\ _':T:* ,[^T[O_H!W_\ WW;_
M /QVC^T[O_H!W_\ WW;_ /QVM&B@#._M.[_Z =__ -]V_P#\=H_M.[_Z =__
M -]V_P#\=K1HH SO[3N_^@'?_P#?=O\ _':/[3N_^@'?_P#?=O\ _':T:* ,
M[^T[O_H!W_\ WW;_ /QVC^T[O_H!W_\ WW;_ /QVM&B@#._M.[_Z =__ -]V
M_P#\=H_M.[_Z =__ -]V_P#\=K1HH SO[3N_^@'?_P#?=O\ _':/[3N_^@'?
M_P#?=O\ _':T:* ,[^T[O_H!W_\ WW;_ /QVC^T[O_H!W_\ WW;_ /QVM&B@
M#._M.[_Z =__ -]V_P#\=H_M.[_Z =__ -]V_P#\=K1HH SO[3N_^@'?_P#?
M=O\ _':/[3N_^@'?_P#?=O\ _':T:* ,[^T[O_H!W_\ WW;_ /QVC^T[O_H!
MW_\ WW;_ /QVM&B@#._M.[_Z =__ -]V_P#\=H_M.[_Z =__ -]V_P#\=K1H
MH SO[3N_^@'?_P#?=O\ _':/[3N_^@'?_P#?=O\ _':T:* ,[^T[O_H!W_\
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M.[_Z =__ -]V_P#\=H T:*SO[3N_^@'?_P#?=O\ _':/[3N_^@'?_P#?=O\
M_': -&BL[^T[O_H!W_\ WW;_ /QVC^T[O_H!W_\ WW;_ /QV@#1HK._M.[_Z
M =__ -]V_P#\=H_M.[_Z =__ -]V_P#\=H T:*SO[3N_^@'?_P#?=O\ _':/
M[3N_^@'?_P#?=O\ _': -&BL[^T[O_H!W_\ WW;_ /QVC^T[O_H!W_\ WW;_
M /QV@#1HK._M.[_Z =__ -]V_P#\=H_M.[_Z =__ -]V_P#\=H T:*SO[3N_
M^@'?_P#?=O\ _':/[3N_^@'?_P#?=O\ _': -&BL[^T[O_H!W_\ WW;_ /QV
MC^T[O_H!W_\ WW;_ /QV@#1HK._M.[_Z =__ -]V_P#\=H_M.[_Z =__ -]V
M_P#\=H T:*SO[3N_^@'?_P#?=O\ _':/[3N_^@'?_P#?=O\ _': -&BL[^T[
MO_H!W_\ WW;_ /QVC^T[O_H!W_\ WW;_ /QV@#1HK._M.[_Z =__ -]V_P#\
M=H_M.[_Z =__ -]V_P#\=H T:*SO[3N_^@'?_P#?=O\ _':KWWB+^S+*6\U'
M3+JVMHEW/++-;JJCZF6@:3;LC9KB/'?Q3T/P/"T,C_;=4*Y2RA;D>A=OX!^O
MH#7G/BSXV:IXFN%T/X=65TCW&%^T[,SOZA%&=H_VCS].M3^"/@T]G=?VIXXT
MJ\U.[+%Q:K+"T62<Y=C("Y]NGKFN=U7-\M/[SV*>!IX>*JXUV[16[_R,.QT+
MQM\;=474=8N&L=$1SL8J1$@](D_C/;<?SXQ7J-I\#O =O:1Q3Z3)=2(H#32W
M<H9SZD*P'Y 5UT=_<11K'%H%ZB( JJK6X"CT \VG?VG=_P#0#O\ _ONW_P#C
MM5&C%:RU9C6S*M.T:3Y(K9+3_ASE/^%*?#__ * '_D[<?_'*[RL[^T[O_H!W
M_P#WW;__ !VC^T[O_H!W_P#WW;__ !VM(QC'9'%4KU:MO:2;MW=S1HK._M.[
M_P"@'?\ _?=O_P#':/[3N_\ H!W_ /WW;_\ QVJ,31HK._M.[_Z =_\ ]]V_
M_P =H_M.[_Z =_\ ]]V__P =H T:*SO[3N_^@'?_ /?=O_\ ':/[3N_^@'?_
M /?=O_\ ': -&BL[^T[O_H!W_P#WW;__ !VC^T[O_H!W_P#WW;__ !V@#1HK
M._M.[_Z =_\ ]]V__P =H_M.[_Z =_\ ]]V__P =H T:*SO[3N_^@'?_ /?=
MO_\ ':/[3N_^@'?_ /?=O_\ ': -&BL[^T[O_H!W_P#WW;__ !VC^T[O_H!W
M_P#WW;__ !V@#1HK._M.[_Z =_\ ]]V__P =H_M.[_Z =_\ ]]V__P =H T:
M*SO[3N_^@'?_ /?=O_\ ':/[3N_^@'?_ /?=O_\ ': -&BFQL7B1V1HV902C
M8ROL<$C/T)IU &=J?_(0T?\ Z_&_])Y:T:SM3_Y"&C_]?C?^D\M:- !1110
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M/VB\5Y-[WY+%W$K'DAV.6 QD?+TXKJ'D2)"TKJBCJ6.!0TB( 7=5!. 2<9H
MY?7_  !I_B#5)+N:]O;6.YM4L[ZUMV017D*,65'#*2 "S#*E20Q!KJJ:\B1[
M?,=5W-M7<<9/H/>G4 %9VF?\A#6/^OQ?_2>*M&L[3/\ D(:Q_P!?B_\ I/%0
M!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBM&B@#._MRT_YY7_ /X+KC_XBC^W+3_GE?\ _@NN/_B*T:* ,[^W+3_GE?\
M_@NN/_B*/[<M/^>5_P#^"ZX_^(K1HH SO[<M/^>5_P#^"ZX_^(H_MRT_YY7_
M /X+KC_XBM&B@#._MRT_YY7_ /X+KC_XBC^W+3_GE?\ _@NN/_B*T:* ,[^W
M+3_GE?\ _@NN/_B*/[<M/^>5_P#^"ZX_^(K1HH SO[<M/^>5_P#^"ZX_^(H_
MMRT_YY7_ /X+KC_XBM&B@#._MRT_YY7_ /X+KC_XBC^W+3_GE?\ _@NN/_B*
MT:* ,[^W+3_GE?\ _@NN/_B*/[<M/^>5_P#^"ZX_^(K1HH SO[<M/^>5_P#^
M"ZX_^(H_MRT_YY7_ /X+KC_XBM&B@#._MRT_YY7_ /X+KC_XBC^W+3_GE?\
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M%:-% &=_;EI_SRO_ /P77'_Q%']N6G_/*_\ _!=<?_$5HT4 9W]N6G_/*_\
M_!=<?_$4?VY:?\\K_P#\%UQ_\16C10!G?VY:?\\K_P#\%UQ_\11_;EI_SRO_
M /P77'_Q%:-% &=_;EI_SRO_ /P77'_Q%']N6G_/*_\ _!=<?_$5HT4 9W]N
M6G_/*_\ _!=<?_$4?VY:?\\K_P#\%UQ_\16C10 V.02Q)(H8*ZA@&4J>?4'D
M'V-.HHH SM3_ .0AH_\ U^-_Z3RUHUG:G_R$-'_Z_&_])Y:T: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\
M^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\ ^"ZX_P#B*/[<
MM/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@N
MN/\ XB@#1HK._MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK.
M_MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\
M^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\ ^"ZX_P#B*/[<
MM/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@N
MN/\ XB@#1HK._MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK.
M_MRT_P">5_\ ^"ZX_P#B*/[<M/\ GE?_ /@NN/\ XB@#1HK._MRT_P">5_\
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M% &C16=_;EI_SRO_ /P77'_Q%']N6G_/*_\ _!=<?_$4 :-%9W]N6G_/*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#.U/_D(:/\ ]?C?^D\M:-9VI_\ (0T?_K\;_P!)Y:T: "BBB@ HHHH
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MC1_PD6B_]!BP_P# I/\ &M&B@#._X2+1?^@Q8?\ @4G^-'_"1:+_ -!BP_\
M I/\:T:* ,[_ (2+1?\ H,6'_@4G^-'_  D6B_\ 08L/_ I/\:T:* ,[_A(M
M%_Z#%A_X%)_C1_PD6B_]!BP_\"D_QK1HH SO^$BT7_H,6'_@4G^-'_"1:+_T
M&+#_ ,"D_P :T:* ,[_A(M%_Z#%A_P"!2?XT?\)%HO\ T&+#_P "D_QK1HH
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M_A'=%_Z ]A_X"I_A6C10!G?\([HO_0'L/_ 5/\*/^$=T7_H#V'_@*G^%:-%
M&=_PCNB_] >P_P# 5/\ "C_A'=%_Z ]A_P" J?X5HT4 9W_".Z+_ - >P_\
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M85S).L[OX?S/:E.&6P=.GK5>[_E\EYE*+PQH,$*10Z+IZ1HH55%JG 'X4_\
MX1W1?^@/8?\ @*G^%:-%=1X3;>K,[_A'=%_Z ]A_X"I_A1_PCNB_] >P_P#
M5/\ "M&B@#._X1W1?^@/8?\ @*G^%'_".Z+_ - >P_\  5/\*T:* ,[_ (1W
M1?\ H#V'_@*G^%'_  CNB_\ 0'L/_ 5/\*T:* ,[_A'=%_Z ]A_X"I_A1_PC
MNB_] >P_\!4_PK1HH SO^$=T7_H#V'_@*G^%'_".Z+_T![#_ ,!4_P *T:*
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MV'_@*G^%'_".Z+_T![#_ ,!4_P *T:* ,[_A'=%_Z ]A_P" J?X4?\([HO\
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M6=_PCNB_] >P_P# 5/\ "C_A'=%_Z ]A_P" J?X4 :-%9W_".Z+_ - >P_\
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M :-%9W_".Z+_ - >P_\  5/\*/\ A'=%_P"@/8?^ J?X4 :-%9W_  CNB_\
M0'L/_ 5/\*/^$=T7_H#V'_@*G^% &C138XTAB2.)%CC10JHHP% Z #L*=0!G
M:G_R$-'_ .OQO_2>6M&L[4_^0AH__7XW_I/+6C0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY[7_ /X,;C_XNM&B@#._L.T_Y[7_ /X,;C_XNC^P[3_GM?\ _@QN/_BZT:*
M,[^P[3_GM?\ _@QN/_BZ/[#M/^>U_P#^#&X_^+K1HH SO[#M/^>U_P#^#&X_
M^+H_L.T_Y[7_ /X,;C_XNM&B@#._L.T_Y[7_ /X,;C_XNC^P[3_GM?\ _@QN
M/_BZT:* ,[^P[3_GM?\ _@QN/_BZ/[#M/^>U_P#^#&X_^+K1HH SO[#M/^>U
M_P#^#&X_^+H_L.T_Y[7_ /X,;C_XNM&B@#._L.T_Y[7_ /X,;C_XNC^P[3_G
MM?\ _@QN/_BZT:* ,[^P[3_GM?\ _@QN/_BZ/[#M/^>U_P#^#&X_^+K1HH S
MO[#M/^>U_P#^#&X_^+H_L.T_Y[7_ /X,;C_XNM&B@#._L.T_Y[7_ /X,;C_X
MNC^P[3_GM?\ _@QN/_BZT:* ,[^P[3_GM?\ _@QN/_BZ/[#M/^>U_P#^#&X_
M^+K1HH SO[#M/^>U_P#^#&X_^+H_L.T_Y[7_ /X,;C_XNM&B@#._L.T_Y[7_
M /X,;C_XNC^P[3_GM?\ _@QN/_BZT:* ,[^P[3_GM?\ _@QN/_BZ/[#M/^>U
M_P#^#&X_^+K1HH SO[#M/^>U_P#^#&X_^+H_L.T_Y[7_ /X,;C_XNM&B@!L<
M8BB2-2Q5%"@LQ8\>I/)/N:=110!G:G_R$-'_ .OQO_2>6M&L[4_^0AH__7XW
M_I/+6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VA_\ (/E_
MZ_+K_P!*)*T:SM#_ .0?+_U^77_I1)0!HT444 %%%% !1110 5P7B_QYX@\(
M0W>KWOA>-_#ME,D<UR+\&X9&8+YJQ!"-N6Z%@>_%=[7C'BSQYX;\6>-9?#&L
M:W9:7X?T2Z5M2^U3*KZA<1L"L*KU\M67YR0,L !W- '=Z]XMU"'Q%!X?\*Z7
M!JFIO:_;9C<W7D0V\.[:I+!6)9B"  .Q.:P(/BQ>:I;16^C:# ^LPK>G4+&Z
MO_+6U:U95D02*C;F)D7;D 8.3BEO?$&F>%_B]+K&N7L=KI&M:)"MI?ROB R1
M2.QCW= 2L@8>O-<]::?I%]X3UWQ-KFF7DSZOKER^BVT%Q-;3W:2K'"D8*%6V
MR^4&(/R[<$\+F@#T"T\;IK.I:#::#;?:3J5FFI73.2HL[5TRA; ^^S$!5[X8
M]!75UX7J$^M>!;Z\M/[=6VUAK"'4(8(H8PNL7C2NIMEWJQ,<:+&BHA4@-N)[
MU[I0 5G:9_R$-8_Z_%_])XJT:P[:SGN-5U=XM1NK51=J-D*Q$']Q%S\R,<_C
MVH W**SO[,N_^@Y?_P#?%O\ _&J/[,N_^@Y?_P#?%O\ _&J -&BL[^S+O_H.
M7_\ WQ;_ /QJC^S+O_H.7_\ WQ;_ /QJ@#1HK._LR[_Z#E__ -\6_P#\:H_L
MR[_Z#E__ -\6_P#\:H T:*SO[,N_^@Y?_P#?%O\ _&J/[,N_^@Y?_P#?%O\
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M0!HT5G?V9=_]!R__ .^+?_XU1_9EW_T'+_\ [XM__C5 &C16=_9EW_T'+_\
M[XM__C5']F7?_0<O_P#OBW_^-4 :-%9W]F7?_0<O_P#OBW_^-4?V9=_]!R__
M .^+?_XU0!HT5G?V9=_]!R__ .^+?_XU1_9EW_T'+_\ [XM__C5 &C16=_9E
MW_T'+_\ [XM__C5']F7?_0<O_P#OBW_^-4 :-%9W]F7?_0<O_P#OBW_^-4?V
M9=_]!R__ .^+?_XU0!HT5G?V9=_]!R__ .^+?_XU1_9EW_T'+_\ [XM__C5
M&C16=_9EW_T'+_\ [XM__C5']F7?_0<O_P#OBW_^-4 :-%9W]F7?_0<O_P#O
MBW_^-4?V9=_]!R__ .^+?_XU0!HT5G?V9=_]!R__ .^+?_XU1_9EW_T'+_\
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M?^D\M:-9VI_\A#1_^OQO_2>6M&@ HHHH **** "BBB@ HHHH **** "BBB@
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M'2O</!_@/0_!-CY.CVP,[*!-=RX,LOU/8>PXKH8HHX(4B@C6.- %5$7 4>@
MZ4^KA247=ZLY<5CYUH^S@N6"V2_7N%%%%;'GA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G:G_R$-'_Z
M_&_])Y:T:SM3_P"0AH__ %^-_P"D\M:- !1110 4444 %%%% !1110 4444
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M_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\
MH.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\
MQJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[
M_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O
M_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\
MH.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\
MQJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[
M_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O
M_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\
MH.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\
MQJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[
M_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O
M_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\
MH.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\
MQJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[
M_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O
M_P#&J/[,N_\ H.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\
MH.7_ /WQ;_\ QJM&B@#._LR[_P"@Y?\ _?%O_P#&J/[,N_\ H.7_ /WQ;_\
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MZP0X:YFQPN>BJ.K,> /P! (-,^(^AZAX/U'Q%-]HLH-*FDM[ZWN(_P!]!,A
M,952<MDJ!@G)(I=#\>1ZKK\>C:CH>JZ'>W%NUS:IJ$<8%Q&I ;!1V 89&5."
M,BN%U[0!X=^#%[<75Y!J%Y)K%OK&MSVP#JS&YC>3 Y.U5 P/1?>M[Q3)IWB'
MXK>"+.T:"^:&*_NK@H5<);/;^5R?1V=1[X]A0!N:[X\LM-\!:QXFTN/^T(]*
M:6-XB3%NDC?8ZY(.,,#S@]*ZL$'.#TZ^U?/3:'X>T[X'^/+C3+*RM]12YU"U
M=HE D$277RH<<[0-F!]*[:+PQIG@SXO^%XO#T+VPU2QOUU!C(SM>&/RF5Y"<
M[GW.QW'GD\]J /3ZY3Q1XY;PPUU(WAO6+^RL8?/N[VVCC$4*8W$C>ZE\#D[0
M<5U=>>?$RT;7= UB"R\;Q:5!:6CQW]@5A:-_EW%96_UB;E8 X8<'WH W=4\=
M:=8:3I%Y96]UJLNMJK:=:62 RW"E-^[YBH50I!))&,U#I_Q%TBZTN\N]0AO-
M)EL+V.PN[2\B_>PS2%1&#L+ AMZX8$C!SQ7':5JL+>)/AEJU[9QZ19WFB7%K
M;V^,1V\I2)EC!/(RB';GTQWYYCQQI^BZ[KWC;6Y;6UN;.WU/1+,W3JI4R+(H
MG^;V254)/N.@H ]HUCQ&=*\4>'M(%KYHUJ:>(R^9M\GRX6ESC'S9VXZC&<UN
M @@$'(/0BO+/&/AC0KOQ%\/?#]M;1QZ,UY>K]GM'*(5%M(S)\I^Z2"&'<$@]
M:TOAS86^A^+_ !OH6EI]GTNQOK9[6U4G9!YMLCN%'8%B3CI0!Z#7*ZO\0=*T
MCQUI7A1XKB>_U'J\*@QV^0Q7S"3P6"/@#)^4UTUS))%:RR01&:1$+)$" 7('
M R>F>E>"R3ZYI.I>&;O6/!VJC6KWQ"U]>R^;;$7,IMI56&,B7A43 7=M&%)Z
MGD ]2UWQ[%I.L7.F:=H>JZY<V4*SWJZ='&1;(P)4,7=<L0"0JY./PK0TOQEH
MNL'2!8W3.VL6CWEFIC8;XUV[B>, C>HP>?RKE_"VIV6D?$#Q_'J]S':3&YM[
M[,Y"9MS;(H;/< HP/7!'OSYQX*\*>&YM0\"RZ[I%BD6I:?JEVJ7,:KE?M"R0
M>V5C?(] 30![=IWB3[?XSUS06MA$-)AM91/YF?-\\2<;<<8\OU.<]JW:\K?P
M9H?C#XQ>,(_$=G]MA@L=/$<+NPC#.LPW[0<;@!@-U&YL=:Z+X1WESJ'PC\.7
M-],\\[V:AI)#EFP2!D]^ .: -_Q)KMOX9\-:AK=[')+!80-/(D6-S #H,D#/
MXUF:3XON;U[IM7\,ZKH-K;6[3R7>H&'R\+C(^21CG&3TQ@'GIF]XKTW3M9\*
MW^EZU=_8[*^B^S2S"18RN\[1AFXR20!G/)KROQA+K=I+KGA&P\1W7B6WOO#5
MY<R1W21--:,H 3YXT4$/EEP1G(XH [?2_B9::CJ6F07&AZQIUIK#%=-O[N%!
M%<G:6 PKED+*"5W 9 K=D\2V)@US[&QGGT0$7,1!7#^4) N2.<J1R,]:X#Q-
MJNE^(/#?PZMM'FANI[S6-/N;58]I:-(AYDCXZKM16!XX)QZU2T;PYX:L?$?Q
M'DM].L8-0LY&6U*J!)&DEBK,%[X)+G\Z /4?#>L?\)!X6TK6#"(#J%E#=F'?
MN\OS$#;<X&<9QG SBM.O#-&\,:9X<\/?"K7](A>'5=1N;*"[N_,9GGBEM'9H
MV)SE1L4*.BA0!C%>YT <_P")/%UMX=N;.Q2RO-4U.^W?9K"Q16D=5QN<EB%5
M1D9+$#FH[SQG%I7A>/5]9TG4+*:686\6FLJ27$TK-A$0(Q4ENH^;&.3C!KCO
M$UC)=_'VVCE\07F@QW'AS;;S6ODAIF2X9I$5I$;:<&-C@ D >E8B:_?7MIX>
MU/7[\7VG:1XTELH]4:-5%Q#Y;QQ3-M '^L8H6  R,^] 'I?A[QK!K>H7^FWF
MEW^C:E81)/+:7RIN:)L[9%9&96&5(ZY!&*CU'QU9P^'="UK2HOM]GK5_:6D+
MEC%A)Y @DP1GC.=I _"N:U.TTSQ/\:+^$P07]K:>%VMK_P"574M)<!XXV/KB
M-FQVS[FN+L-!T)_@?X,338H;:;5-5TE;^:R?RY68S;=Q93D,,M@]0?I0!]!
M@]#FBO-_"^B:?X3^,NIZ-X=MEL-,GT*WO'M(B?+\[SY(]X'8E5 /KCG->D4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5G:'_ ,@^7_K\NO\ THDK1K.T/_D'R_\
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MXL;-8X%46Y8$-LP/ER&(..N35F"PM+:\N;JWM88KB[96N)40!IBJA5+'J<
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MAH__ %^-_P"D\M:- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-[&$FMW'9@"1@]B#7DFH_#'Q+_PAOP]NETF6\O/#T4D-_I4.H?9I663NDRL
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M=0W+,PW$!OFVYQ@YZ&N0\%> _$FE_$3P9J>H:8T5IIOA5;"ZE,T9\J<-(=F
MQ)X8<CCFJWQ#\'^.O$'BOQ+ =.OM6TR^M$CT=H=7^RVUF=A#F2(,-[9SP00>
M.QX -OQ]\8[CP^_A*?PYI%[J-AK<MO*UPEF9%F@D/^IB^8'[01R%([C\-35/
MC/I6GWD5C:^'_$6I:A]D2\N[*SL0TM@C*&"S@L-CX/W>?U&>8UWP5XL3X6_#
MQ=+T<7FK>&KRUN[C3VN$0MY8Y7>3MZ@#@]ZD@LO'WA?QWK?BG3/!RZH/$UE;
MR2V@U&)6L+A(]OELS$!U!)Y7C&.F* -_5?CIX5TO1=!U18M0O;;7EG^R_98
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M "L[0_\ D'R_]?EU_P"E$E:-9VA_\@^7_K\NO_2B2@#1HHHH **** "BBB@
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M ,[4_P#D(:/_ -?C?^D\M:-9VI_\A#1_^OQO_2>6M&@ HHHH **** "BBB@
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M_P#X]0!HT5G>1K7_ $$+#_P!?_X]1Y&M?]!"P_\  %__ (]0 :G_ ,A#1_\
MK\;_ -)Y:T:S!8:A->VDU[>VLD=M*90D-JR%B49.ID;CYR>G:M.@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"CK>JP:#H&H:O>)(]OI]K)=2K$ 7
M944L0H) S@<9(K)_X2C5_P#H1/$'_?\ T_\ ^2J/B/\ \DL\5_\ 8%O/_1#U
MTE '-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R57244 <W
M_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5=)10!S?_  E&
MK_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E5TE% '-_\ "4:O_P!"
M)X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R57244 <W_P )1J__ $(GB#_O
M_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\
MR51_PE&K_P#0B>(/^_\ I_\ \E5TE% '-_\ "4:O_P!")X@_[_Z?_P#)5'_"
M4:O_ -")X@_[_P"G_P#R57244 <W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\
MT(GB#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/
M^_\ I_\ \E5TE% '-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G
M_P#R57244 <W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5
M=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E5TE% '
M-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R57244 <W_P )
M1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB#_O_ *?_ /)5=)10!S?_  E&K_\
M0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\ I_\ \E5TE% '-_\ "4:O_P!")X@_
M[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R57244 <W_P )1J__ $(GB#_O_I__
M ,E4?\)1J_\ T(GB#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_
MPE&K_P#0B>(/^_\ I_\ \E5TE% '-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_
M -")X@_[_P"G_P#R57244 <W_P )1J__ $(GB#_O_I__ ,E4?\)1J_\ T(GB
M#_O_ *?_ /)5=)10!S?_  E&K_\ 0B>(/^_^G_\ R51_PE&K_P#0B>(/^_\
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M0?\ ?_3_ /Y*H_X2C5_^A$\0?]_]/_\ DJNDHH YO_A*-7_Z$3Q!_P!_]/\
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M>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\
MZ?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4:O\ ]")X@_[_ .G_ /R5
M1_PE&K_]")X@_P"_^G__ "57244 <W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J_
M_0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_
M +_Z?_\ )5=)10!S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__
M "57244 <W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE%
M '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)10!S?_"4
M:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "57244 <W_PE&K_ /0B
M>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N/^+7_)(?%'_8.E_]
M!KL*YOX@Z+J?B3P+JFB:,MI]HU"!H-]W,T:1AN"WRHQ./3 ^M '@6@:/XD\;
M?LX:+X2\.^'9)EFNI)9-4N9XHX(@L\AX&[>3T!^7H3UKUB[GUKP/9^%?#=IB
MVT&UL/+U+Q!*Z8MO+CPOW_EY8#J.AXZ5I?"7PGK/@?P':^'M<-C(]J\C)-9S
M.X<.Y?D,BXQN]ZR_B+X'\6>(_'GAG6O#M]I8L])9G>UU)7:,2$X\W8OWSM/
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M(R@9'*<-AF."O.1SQ0!H^$_B!J>K:QXR\,:HT0U3P\[M!>0Q_+-#SL+*>-W
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MG_\ D.NDHH YO[=XW_Z%[P__ .#Z?_Y#H^W>-_\ H7O#_P#X/I__ )#KI**
M.;^W>-_^A>\/_P#@^G_^0Z/MWC?_ *%[P_\ ^#Z?_P"0ZZ2B@#D[\>+=4TZX
ML-0\+^'+BUN8VBFB?79RKJ1@@_Z'530=,\1>&-*33M"\(^'+2UCQA%U^X8G
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MR52V -V'MC@X &1Z"O1** .;^W>-_P#H7O#_ /X/I_\ Y#H^W>-_^A>\/_\
M@^G_ /D.NDHH YO[=XW_ .A>\/\ _@^G_P#D.C[=XW_Z%[P__P"#Z?\ ^0ZZ
M2B@#F_MWC?\ Z%[P_P#^#Z?_ .0Z/MWC?_H7O#__ (/I_P#Y#KI** .;^W>-
M_P#H7O#_ /X/I_\ Y#H^W>-_^A>\/_\ @^G_ /D.NDHH YO[=XW_ .A>\/\
M_@^G_P#D.C[=XW_Z%[P__P"#Z?\ ^0ZZ2B@#F_MWC?\ Z%[P_P#^#Z?_ .0Z
M/MWC?_H7O#__ (/I_P#Y#KI** .;^W>-_P#H7O#_ /X/I_\ Y#H^W>-_^A>\
M/_\ @^G_ /D.NDHH YO[=XW_ .A>\/\ _@^G_P#D.C[=XW_Z%[P__P"#Z?\
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M_P#^#Z?_ .0Z/MWC?_H7O#__ (/I_P#Y#KI** .;^W>-_P#H7O#_ /X/I_\
MY#H^W>-_^A>\/_\ @^G_ /D.NDHH YO[=XW_ .A>\/\ _@^G_P#D.C[=XW_Z
M%[P__P"#Z?\ ^0ZZ2B@#F_MWC?\ Z%[P_P#^#Z?_ .0Z/MWC?_H7O#__ (/I
M_P#Y#KI** .;^W>-_P#H7O#_ /X/I_\ Y#J+P_::^?&FL:IK^G6=DEQI]E;P
M&SO3<HYCDN6;):.-@1YJ\;<<C!/('4T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>a1026grapha.jpg
<DESCRIPTION>EXHIBIT 10.26 GRAPHIC
<TEXT>
begin 644 a1026grapha.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO;B!+<G5E
M9V5R   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,T-   DI(
M @    ,T-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( D$#G0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M#UK5+:VCT;7+>UNYEA@OYK(B"1F.!A@3U)[BMSQI\4M \$W,5G>_:+S49O\
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MG+9$6Y]\YS^E=/XO^*.A>#M'T_5+T3W-GJ#A8Y+=00 >YR1Q7C-AX)U7Q/\
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MN^'=3\$W'BFZ^T:;IT#;,W2#<Y[;0I.:^:CXDU+POX/USX;S*_VJ:^$$8'0
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M?A3QAKZ:QK5I*]VH4923:&V],C'M74W6C6%[H[:7=6R2V;1^68F&05QBKU%
M'F\7P'\$17GGK:W6,Y\HW!\O_OG%=#XD^'N@>*M+L]/U6WD^S63!X4B?;M(K
MIZ* .=\2^!]%\6>&XM#UB*1[*%E=%1]I!4$#G\:DO_!FBZIX7C\/WUKYUA$@
M1%8\KCH<^M;U% 'G47P+\$1Z7/8&QF>.;@N\V749SA3CBNEO_!&A:GX9M]!O
M[,3V-N@2)7.64 8'/K7044 >?:5\$O!ND7R74%K<2O&P95GG+J"/:O0:** .
M8?X?Z%)XW'BMHI?[4  #^9\O'MBNGHHH X/6/@UX.UO6GU2ZLYH[B1MTGD2[
M%<^X[UI^%OAUX=\&ZG=7V@VSP37:!) 7R, YX'X5U-% 'SG<>$IO%W[3CWAT
MFYMM-L9-\LTL)5)F7N"1@Y.#7ONL:)I^O:7)IVJVR7%M(,,C"K]% 'G5E\"_
M!%E?+=+9W$NQMRQ33[HP?]W%=?K'AG2==T)M'U&T22R*@",#&W'3'I6M10!Y
MU!\#/!$.FW%E]AFDCG&"TDVYD&<_*<<=*ZF7P?H\_A1/#D]N9=.2,1B-SDX'
M3FMRB@#E/!_PX\/^!YIY-!CG1IP WFR[P!Z#TZUJ>)/"^E>*].%EK4!FA!RN
M#@J?4&M>B@#S[2O@EX+TF_2[CLY[ET.Y5N9C(H/TQ6UXD^'V@^*M4T^_U:&1
MI].(,'EOM P<CC%=/10!SOBCP)H'C"V2'7+/S?+&$D4[77Z&LOPY\(_"7AC4
M%O;"RDEN4^Y)<R>84^E=M10!\^?$GPM<Z]^T=X?\_2[BYTMA$L\@B8QA>^6Z
M"O2_#_P@\(^&]<75K"SE>[0DHT\N\(?;TKN** .;\5^ ?#_C2-%UVS\QX_N2
MQMM=?H:H>&/A5X7\):DE_I5M,UU&"$DN)2Y3(P<?@2*[.B@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y\_[+)]C$9GVGR_,)"Y[9(!
MXKSOX?7&NVWBOQ1:^(]3^WS6Y1\(,1QDC)"@]J]%N7ECMI'MXA-*JDI&6V[C
MZ9P<5Y[X=L/%5MXVU?4-1T"WAM-6*!BFH;FA &,XV#=^E &(XU;7/ >M>,TU
MFZMKVVEN9+2%'Q$BPNRA67OG9S]:-7UK[=XEL;O7;O6++2YM/67.GQR,H?:#
MR45JO#PMXLL?#VJ^#[&VM9--OIYO*U-I\-#%,Q9LQ8^8C<?XAG%=-<_\)'H<
M::=HFC6NI6"0+'$\EUY+(<8.1M;</RH V?#<UA/H%M)I-[)>VC+E)Y'W,WU/
M'-<(D=]XPOO$MV^JW=DNF3206<=N^T IGEO7.*UM#T#Q%X4\,V-GI7V.YN);
MX2WHDRJ1Q/)F0(!W )Q5(Z#XHT#4]>BT.RMKZSUF1I4DDN/*-LS_ 'LKM.X#
M/J* .5N_$.MZIH]I<WLVHQ@6,HMI-/C9Q+=KPH? . >>N![UU>E^)3K^M6$=
MSJL5C:6( ;?,J->SXP54$\JN3GU)'I6BOAC5=-\%V?A_2;A%>5@MW>9P8T/+
ME1ZGH.>,YK!U[X?7ZZI+%HVGVES97-O!#'+-)M:R,;[F91@[MWL1TH ]2'3B
MBHK6(P6L43'<40*3ZU+0 4444 %%%% !1110 4444 %%%% !1110 444V0.8
MV$1"OCY21D T .HKS?6)?$'A;Q'H3GQ)<ZF=2O3!/I\T,0C"'G='M0.-O'5F
MZTUKWQ!XINM>O-.UZXTF#2IG@MK>VBB*RLGWC(71B<G/W2O% 'I5%>5Z1XKU
MOQO-HVF6^HOI#2V;7%Y<V<:&1F5V3"^8&4 E"3P>M4I?%FOVRWNB:AJ\T2Z?
MJ9M9]8BB3SA"0&1B"I3=@@$A<>PH ]AHKR_2_%^K:IHMIH\&H :C<%M^I2(J
MF*$,0)""-N\CIQC/:O3HL>4N'\P8^_Q\WOQ0 ZBD9@HRQ 'J33/M$/\ SVC_
M .^A0!)135EC;[KJ?H:7>O\ >'YT +12;U_O#\Z-Z_WA^= "T4F]?[P_.C>O
M]X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_P!X?G0 M%)O7^\/SHWK_>'Y
MT +12;U_O#\Z-Z_WA^= "T4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_ 'A^= "T
M4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_WA^= "T4F]?[
MP_.C>O\ >'YT +12;U_O#\Z-Z_WA^= "T4F]?[P_.C>O]X?G0 M%)O7^\/SH
MWK_>'YT +12;U_O#\Z-Z_P!X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_W
MA^= "T4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_ 'A^= "T4F]?[P_.C>O]X?G0
M M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_WA^= "T4F]?[P_.C>O\ >'YT +12
M;U_O#\Z-Z_WA^= "T4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_>'YT +12;U_O#
M\Z-Z_P!X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_WA^= "T4F]?[P_.C>
MO]X?G0 M%)O7^\/SHWK_ 'A^= "T4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_>'
MYT +12;U_O#\Z-Z_WA^= "T4F]?[P_.C>O\ >'YT +12;U_O#\Z-Z_WA^= "
MT4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_P!X?G0 M%)O
M7^\/SHWK_>'YT +12;U_O#\Z-Z_WA^= "T5%/<PVUN\T\BI'&I9F)Z 5X5X1
M^+4U_P#%>Y6]E*Z;?2>5"C'B/'"UG.HH-)]3LP^$J8B,Y0^RKGO5%)O7^\/S
MHWK_ 'A^=:'&+12;U_O#\Z-Z_P!X?G0 M%)O7^\/SI0<].: "BBB@ HHHH *
M*** "BBB@ HHHH **** "H[AWBMY'BC,CJI*H/XCZ5)10!Y;H<NO3^*Y=9\3
M>&+^6[WF&T"E?*M8L]1[GJ3]/2IHK+Q!X:O-?L;+1Y;^#5)WGM[B,C$9?DAO
MH2:],HH \JTWPMK/@C4-'U"RL7U18[)K>ZAA/S*Q=GR,]LN:V-!TK5;"QU_6
M[G30]_JUP9X[)L'8,80-[X S7>T4 >5:KX)O+6WTZ[N-.;67=VDU&"/@NQ'R
MX]E/;VKN/!5A>:7X-TRSU,M]IB@575FW%3CIGVK=HH CGMXKF$Q3H'1NJGO6
M!J>BZ='J6DI':1JLERRN!_$/*<X_,"NCK*U;_D*Z+_U]-_Z)DH M0:796P(@
MMD0'K@5-]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:T?98/^>:U+10
M!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:T?98/^>:U+
M10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:T?98/^>:
MU+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:T?98/^
M>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:T?98
M/^>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:T?
M98/^>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^>:
MT?98/^>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98/^
M>:T?98/^>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?98
M/^>:T?98/^>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4 1?
M98/^>:T?98/^>:U+10!%]E@_YYK1]E@_YYK4M% $7V6#_GFM'V6#_GFM2T4
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M>:T?98/^>:U+15&1%]E@_P">:U(J*BX08'I2T4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !111F@ HHS1F@ HHS10 5E:M_P A71?^OIO_ $3)6K65
MJW_(5T7_ *^F_P#1,E &K1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR:/M</J?^^34U% $/VN'U/\ WR:/M</J?^^34U% $/VN'U/_ 'R:/M</J?\
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M%. *F1Q(NY>GTIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5E:M_R%=%_P"OIO\ T3)6K65JW_(5T7_KZ;_T3)0!JT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <IX[\:
MGP=IJRP:=/J%PX+".-2%500"S-T'WA[U)JGC$:;X6LM3^R^9=7P58+<-]YV[
M9]*I_%+5]-T_P/J%M?7D,$]Q#B&.1@&DPPS@=ZY?6=1M;[P3X9U+3IDO+?3+
MB-KIH3N\H;<'./2@#JM,\7ZJOB1M!\1:5#;7\EK]JMOLLID2502"N2!@@X_,
M5"/&.NZ=K>G6WB/1K>TMM2<I"\,Y=T;T<8X_#-9O]KV.O?%2RUK2KA;G3-*T
MR47%W'S&&<@A<^H"Y(]Q5#2/%6A^-/&4.L7VJVMM:V<ACTZSDE DD;IO9>HS
MV!H ]!\6:VWAOPCJ>LQPB=K&V>81,<!RHSC-9VB:SXDN;47VMZ=I]M8F'SMU
MO<,[XQGH5%-UGQ#X<U2PU_2-5:1K:RC\K408F"JK*"><<C!ZBN3T9=+A\>:;
M;^!KZ2^TYHBM^J2F6)%[9/0'IQ0!NZ#X^NK[4575[*WL[*XBDFMYTGW?(F22
M^?N\"N@\-:W-K]@U^UH;>UD<FU+Y#21]G([9'.*\]U#PO8W.LW\7ANRD:UM%
M9KP[R1,W7R5'N>OL:TOAIKM[J-]]G.K?VK;?8TDD8)C[/*0/W?\ /B@#TFBB
MO/\ XB?%/3?!UF]M;2+<ZHXPD*'.SW;TJ9245=FU&C4KS4*:NS<\9>-]*\&:
M4]SJ$RF8C$4"G+.?I7RWXU\=:KXVU+SM0E*V\9/DVX/RI_\ 7KL?"?@C7_BA
MKAUCQ$\L=ANR7?C=[**]YL/!7A[3[*.VATJV9(Q@%XP2:Y&IUUV1]!3J87*I
M6:YZG7R/DOP;X@E\,^*K/4H20(WP^.ZGJ*^R=-OHM3TVWO;9@T4Z!U(]ZI_\
M(MH7_0)L_P#OR*TH88K:%88(UCC085%& !6M&DZ>C9P9ECJ>-<91C9H?1117
M0>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$^/
MM7\:6DUI8^!M(@NI;@,9;NXDQ'!C&,CJ<Y_2N*/A/XSZAB>7Q;I-N^<F* OM
M'L?EKU'Q;/K%MX7O)?#=O'<:BJ?NHY#@'UKP'P=K?Q<L_P"TEL=)AF,ER3(+
MJ;!5O1<]J .YTF]^+WAS4H(M;MM+\06#R!'DLI2LD0]3N S]*]>4DH"PP2,D
M>E>=_"71?%-A#K&H>,G1;C4;A9([=)-ZQ #!QZ9_I7HC*'0J>A&#0!F0>)='
MNM?ET2VU"*7488Q+) F254G&2>G;IG-1ZQXLT70KA8-3O#',PR(XX7E8#U(1
M21^-<;IFB6.B?'!HM.A\M9=*\V0DY+,9&R2:R["3Q&WB[Q?J6F_V;NMIPC"^
M5BQ14& N.@QZT >BW_B[1-+L;>[OKPQQ7(S$/)D9W_X %+?I41\;>'O[%751
MJ2FS9R@98W+;@<%=@&[/MBN(\-ZTGBGXD:9J-S"(Q)I.^.)NBN'97Q_WS^54
M]/\ #UQJ?BGQ/)I%S!;'3]8,\/GJ3"6*#?D#WS^- 'I@\3Z.=!_MD7R?V?MW
M>=M;\MN,Y]L9K41@Z!EZ,,CC%>(Z;/<V]SI\)M3J]NL[M!!$PB6ZE!)9QN_A
M';Z5Z[X?UF'Q!H-IJ=O&\27$8?RWZKGL: -*LK5O^0KHO_7TW_HF2M"YDEB@
M9X(3,XZ(&"Y_$USNIW^HMJ6DE])966Y8J//4[CY3\>W'/X4 =/15*WN[R4'S
M]/:$CH#*IS^53>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=
M-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[
MG_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL
M4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-
M_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^
MY_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[
M% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]
M%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=
M-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[
MG_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL
M4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-
M_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^
MY_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[
M% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]
M%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% $]%0>=
M-_S[G_OL4>=-_P ^Y_[[% $]%0>=-_S[G_OL4>=-_P ^Y_[[% #IK:"XQ]H@
MCEQTWH&Q^="6MO'&8T@C5&ZJ$ !_"F^=-_S[G_OL4>=-_P ^Y_[[% #H[:"%
M"D4$:*W550 &F+I]DK!EM( PZ$1+_A2^=-_S[G_OL4>=-_S[G_OL4 /,$)WY
MB0^9]_*CYOKZTD-M!;Y\B".+/78@&?RIOG3?\^Y_[[%'G3?\^Y_[[% $JQHF
M=BJNXY.!C-,C@M[96:**.$=6*J%_.H+G4!96[SW:+#$@RSO(  *\&\>?%O4/
M%%Z= \'12"*1O+:1/O2_3T%9U*D8+4[<)@ZF*G:&RW?1'1?$CXS1:=YNC>%?
M])OF^1KA1E8S[>IK#^'?P@O=:OU\0>-BWELWF);N<O*?5O0>U;OPX^$']B21
MZMXB@%U??>2,L"$/OZFO6Q),!@6V .VX5C&G*H^:I]QZ%;&4L+!T,'\Y=7Z#
M[>VAM(%AMHUBC0855& !4E0>=-_S[G_OL4>=-_S[G_OL5U'A;D]%0>=-_P ^
MY_[[%'G3?\^Y_P"^Q0!/14'G3?\ /N?^^Q1YTW_/N?\ OL4 3T5!YTW_ #[G
M_OL4>=-_S[G_ +[% $]%0>=-_P ^Y_[[%'G3?\^Y_P"^Q0!/14'G3?\ /N?^
M^Q1YTW_/N?\ OL4 3T5!YTW_ #[G_OL4>=-_S[G_ +[% $]%0>=-_P ^Y_[[
M%2H69<LNT^F<T .HHHH **** "BBB@ HHHH **** $<D1L0,D#@>M?*=UXCU
M";XG)>ZGK;V^S5_L[6F=BQQ8)W'UZ5]5R-LC9O[H)KYDU77O!/BWQE<_\)=X
M5FB:.[^S'4+60JF>VX>M 'IGP;URXU2^\5VPO'OM.M=1'V2X<YR&7YE!] 0/
MSKU!AN4C)&1C([5X9H7Q)TCP9XQ/A'0- 6#0HKA(7O Y),KKN!.>O KW-6#*
M&'0C(H X\?#>R'B'^VCK>M&\QLW&X3&S).S&SIDU9U7P!INJZE/>_:[^SDN5
M"W*VLP19P!CY@5/;CC%=110!S%]X!T>[BL5MWNM/DL(_+@FLY CJOID@YJS:
M^#M-L] GTF![A8[DEKB;S!YLS,<L6;'4Y]*WJ* .>U/P5IFI65E;H]Q8_81B
MWEM'".@Q@C)!Z_2M72=+MM%TFVTZQ5E@MHQ&FXY. ,<GUJY10 5E:M_R%=%_
MZ^F_]$R5JUE:M_R%=%_Z^F_]$R4 :M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ^\F8?,Y^M=!3ITK/FGJR,7CU*'L,.N6"^]^H4445T'D!1110 4444 %%%%
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M%% !1110 4444 %%%-DD2&-I)6"(HR23P* '5YQ\1_BQ8^$8'LM.9+K4V'"
MY6/ZUS'Q'^,K^;)H7@[]Y.QV272C)!]%_P :K?#CX-O>2KKGC17E>0[UMI"3
MN]V]:YI57)\E/[SW,/@:="'UC&:+I'JSQ/5M5O-;U2?4-1E,MQ.VYV->S_L^
M^+%CDG\.W)4;B9(#C&?4>]>QCP?X: Q_8&F?^ B?X5-:^&M#L;A;BRT>QMYD
M^[)%;(K#Z$"HIX>4)\USHQ>;T,10='V;7;R-.BBBNP^;"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K
MWMY!9Q W$Z0F0[$+G&6["ODGQ#X?C.K7VM:[I]Q=K;ZWLNR5)S 5/3VSBO8/
MVAYKBV\+Z+-8Q":X358FCC;HS8; K)_X6#\69;58I/ 6FRQ%0-KB0@CZ;J +
MW[/-O;1V_B:;2K%[;2YKY3:-(I#,NWD'V']:]F.,'=T[YKB?AKK7B;5K&\7Q
M5X?M=$\EE%O':J55P<YX)^E=J0&4A@"#P0>] 'G2W>GQ?'-1!-;HG]D!<(P
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M.HH **** "BBB@ HHHH **** "BBB@##\2^'-*\2I9P:OS]GN%N(5W8)=?\
M]=;,138%C8,%&.#G%>=?%'P=XEUO4M(UKPA>1PWFF^9F*7[KA@/PSQ7F'A*/
MXS6 U'[*([?S+DE_M^U=S>J;^WTH ^EZ*XSX=_\ ";_9;P^/OLYD++]F\@KT
MYSG'X5V= !1110 4444 %%%% !65JW_(5T7_ *^F_P#1,E:M96K?\A71?^OI
MO_1,E &K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K_3[75+)[2^B$T$@
MPR'O5FB@#GM'\">&M O3=Z1I,-K.<Y=,\Y_&G6W@?PW::Q_:EMI%O'>>8T@D
M"]&/4XZ9YK?HH Y_6/ GAK7[S[5K&E0W<W]^3/\ C5J/POHT36+)81;M/8M:
MDC)B)!!(_ D5K44 <\? ?AEM4&HMI$!NM_F;R#][UQTK7ETRRFOH+R6W1[BW
M!$3D<IG@XJRS!%+,0%49)/85\X^-_C#JT/C6\7P]=?Z+'$UL@!RN2>6 Z9XX
M-9U*D::NSMP>"JXR3C3Z'>?$KQ'X2\*WPU(V-M=>(<?NB.60]F/YUYQX=\)^
M(OBWKC:KKLTJ6*MR[<#']U16Q\._A'?>(+T:_P"-?,,4AWI#*3OE/JWM7OEI
M:06-JEO:1+##&,*B#  K!1E6=YZ+L>G.O1RZ+I8?WI]9=O0H^'O#NG>&=)CT
M_2K=88D') Y8^I-:E%%=222LCP92E.3E)W;"BBBF2%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ".2J,0,D#(%?.6C^%+#XE>*?$EYXLUZ:WFLKDQ0P+<>7L7UQFOHZO.
M_$_P4\+^)]7?4IDEM;F48E:!L!_J* ,KX%WUR(?$.AO>OJ%EI-XL=I<LV[<K
M+D@'V(_6O6&.U"0"<#.!WK#\(^#])\%:*-,T.#RH2Y=R3DNQ &2?PK<9@JEC
MG &>!F@#@M#\7Z]J'Q,N-&U+3Q8V M/.@1Q^\;#E=Q] <=*L>+[_ ,5Z1;WN
MK65U9Q6-J RV\D89I !S\W8UAGQ' _QD745TW6_L8T\6GG'1KH+Y@D8XSY?3
MD<]/>F^+_$1UCQ2=%U'3M:@T2U*M++#I-S,+MNN%*1D;1TH V;CQ9JVLZEI6
ME>'S%:7-W9+>333IN$2D<#'OS61_PG^MA9M'N)+>VU2WU%K*6\9!Y0&,J^.V
M015B\NCH_CK3_$T6F:C+HUQIXMOW%A,\L)4G&Z$+O'7^[2:+IWF6/B?7M9T.
M>XM]4NS/;6,UL3)(H 5"8R,J2 #A@",\XH LV'CC4M2T.UM+,0S:Y=.T:,@R
M@4$@RD>G&:]!0,$ <Y;')'>O'=0\-W6D0Z;?:C:WT<5T2;Q-)BD=[=>J1JL8
M+8!QG ]:]%\$C41X+TS^V?-%Y]G7S!,,../XAZ^M &]65JW_ "%=%_Z^F_\
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M]E3^])_WT:/LJ?WI/^^C0!/14'V5/[TG_?1H^RI_>D_[Z- $]%0?94_O2?\
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M)8>QQD\U]#OG8VW[V./K7S;H%CX,U#Q9XI?XD3-_:*W)$2SR%0(^?NT >O\
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M?R&!^E=G;VT%K&([6&.%!_#&H4?I4M%;QC&.R/+JUZM9WJ2;"BBBJ,0HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_?!H^T_],9?^^#4]% $'VG_ *8R_P#?!H^T_P#3&7_O@U/10!!]I_Z8R_\
M?!H^T_\ 3&7_ +X-3T4 0?:?^F,O_?!H^T_],9?^^#4]% $'VG_IC+_WP:/M
M/_3&7_O@U/10!!]I_P"F,O\ WP:/M/\ TQE_[X-3T4 0?:?^F,O_ 'P:/M/_
M $QE_P"^#4]% $'VG_IC+_WP:/M/_3&7_O@U/10!!]I_Z8R_]\&C[3_TQE_[
MX-3T4 0?:?\ IC+_ -\&C[3_ -,9?^^#4]% $'VG_IC+_P!\&C[3_P!,9?\
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M @^T_P#3&7_O@T?:?^F,O_?!J>B@"#[3_P!,9?\ O@T?:?\ IC+_ -\&IZ*
M(/M/_3&7_O@T?:?^F,O_ 'P:GHH @^T_],9?^^#1]I_Z8R_]\&IZ* (/M/\
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MM.MYH!:,JMYJ$9W9Z9^E=E52SU*QOI)X[&YAF>W;9,L; F,^A':K= !1110
M4444 %%%% !65JW_ "%=%_Z^F_\ 1,E:M96K?\A71?\ KZ;_ -$R4 :M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M07T,$^GW$5YC[.\;"3=TVXYJ>B@#PZ]T_2]7.G^'O!WB2YUA%O89FM(Y!)%:
MQQR*[%B.@^7 SW(K9\8'P)]JU7SKC[+XB4>6BI,R2RR #:54'YN?ZUZN% Z
M#\*-H)S@9^E '&Z-XA>TTG0]$U_SAJ^I6[! 8SU"D_,>QQ7#Z=K]GI?PYU/P
MC>-Y>O?:YH8K _ZV7>^]65>I&&Z^QKVO%)M&<X&?I0!Y=J_ANPCLM$L!IXE\
M036Z(&!(\M5ZNPZ<=LUD:?>WOAWQ1_8MIJDL5S'J<<2Z<1G[3"T89YSW/SDC
M/;;BO::,#.<<T  Z#-%,EFB@C,D\B1H.K.P 'XFN.U[XK^$] W)-J4=S,O\
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M=**I8>.\M2*F;UVN6BE!>1S6A?#[PUX>4?8-,AW@<R.H8G\ZZ15"*%4!0.@
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M 3T5!FZ_N1?]]G_"C-U_<B_[[/\ A0!/14&;K^Y%_P!]G_"C-U_<B_[[/^%
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MV?\ "@">BH,W7]R+_OL_X49NO[D7_?9_PH GHJ#-U_<B_P"^S_A1FZ_N1?\
M?9_PH GHJ#-U_<B_[[/^%&;K^Y%_WV?\* )Z*@S=?W(O^^S_ (49NO[D7_?9
M_P * )Z*@S=?W(O^^S_A1FZ_N1?]]G_"@">BH,W7]R+_ +[/^%&;K^Y%_P!]
MG_"@">BH,W7]R+_OL_X49NO[D7_?9_PH GHJ#-U_<B_[[/\ A1FZ_N1?]]G_
M  H GHJ#-U_<B_[[/^%&;K^Y%_WV?\* )Z*@S=?W(O\ OL_X49NO[D7_ 'V?
M\* )Z*@S=?W(O^^S_A1FZ_N1?]]G_"@">BH,W7]R+_OL_P"%&;K^Y%_WV?\
M"@">BH,W7]R+_OL_X49NO[D7_?9_PH GHJ#-U_<B_P"^S_A1FZ_N1?\ ?9_P
MH GHJ#-U_<B_[[/^%&;K^Y%_WV?\* )Z*@S=?W(O^^S_ (49NO[D7_?9_P *
M )Z*@S=?W(O^^S_A1FZ_N1?]]G_"@">BH,W7]R+_ +[/^%&;K^Y%_P!]G_"@
M">BH,W7]R+_OL_X49NO[D7_?9_PH GHJ#-U_<B_[[/\ A1FZ_N1?]]G_  H
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M%&!L0 _G5^BBM[6/+E)R=VPHHHH$%%%% !1110 4444 %%%% !1110 4444
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M:9HQCA406=X(6XB>7,BD$=LA5_*LU[B[LC<V%W$I@>[W7D.G'(=OX8D/KW-
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M_DO^%344 0^0_P#S\R_DO^%'D/\ \_,OY+_A4U% $/D/_P _,OY+_A1Y#_\
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M;N<;;2' '_ CD_K7K>@?!_PEH:JQT]+R8<^9<?/S[9Z5VT%M!:QB.WA2)%&
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ME1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\
MGDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T
M5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\
MGDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[
M?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4
M3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_
M^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]C
MM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY
M4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]C
MM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY
M4?8[?_GDOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GD
MOY4 3T5!]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!
M]CM_^>2_E1]CM_\ GDOY4 3T5!]CM_\ GDOY4?8[?_GDOY4 3T5!]CM_^>2_
ME1]CM_\ GDOY4 3T5!]CM_\ GDOY5*B+&NU  /04 .HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH @O+&UU"W\B^MXKB(G.R5 PS]#
M7EOQ:T#2;*'PQ]CTVU@\W7;>.3RX57<ISD''45ZS7FWQC_U'A3_L8+;^M954
MN1GH9?.2Q$4GIK^1W%CH.DZ?,L]CIMK;S;<>9%$JG!]Q6C2+]T?2EK1:'#*3
MD[MC9)%BB:1^%4%C]!5'1-<L?$&GF]TR1I(1(T>YD*_,.O!KA/CAINNZEX/M
MX]#BN)X5G#7L-LVV1X_:L/X16GAV32M8TGPQJ.H6-Q+&/.L[PGS;=L$%QGZT
MR3V>BOGS3/"@T+XV6%GX.U*]O?+@WZQ,\Q= Y)X)Z9[XK!^)\-CI_C5GCN];
M36?M:M]OG#+:QH3PH/3B@#ZAHK.M7D?PS Z7*R2&T4BXSPQV_>S^M?*$2,OB
M*"6>^U!-<_M,I)JK2L;5D#= U 'V!17S_J6@M\3/B%XG@UC4KE;?1+=!9I!*
M0 Q0'=QUY.:Y6YUO4?$/PR\,R:S>W5Q8QSO;7-K;N?/N K$ @#D]* /JJBO'
M?@!A;'5X[>\F-FLY$%E<L3+ /]H'I7L5 !1110 4444 %%%% !1110 4444
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M<LV#@XA?@_\ ?- &K169_P )'IG_ #W?_OQ)_P#$T?\ "1Z9_P ]W_[\2?\
MQ- &G169_P )'IG_ #W?_OQ)_P#$T?\ "1Z9_P ]W_[\2?\ Q- &G169_P )
M'IG_ #W?_OQ)_P#$T?\ "1Z9_P ]W_[\2?\ Q- &G169_P )'IG_ #W?_OQ)
M_P#$T?\ "1Z9_P ]W_[\2?\ Q- &G169_P )'IG_ #W?_OQ)_P#$T?\ "1Z9
M_P ]W_[\2?\ Q- &G166WB72D4LURRJ!DDPO@?\ CM \1Z61D7#D?]<)/_B:
M -2BLS_A(],_Y[O_ -^)/_B:/^$CTS_GN_\ WXD_^)H TZ*S/^$CTS_GN_\
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M_OQ)_P#$T?\ "1Z9_P ]W_[\2?\ Q- &G169_P )'IG_ #W?_OQ)_P#$T?\
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MU8Z_<VNF/HRWEFUO9VUQ(S29_O/DG'TS6B8M<\6)X=TJZT&\TQ=.N$N;VXN
M A\M3A8R"<Y;;UQQF@"GH?CW48]:AGU;5!+;RI.US9M$%^R[?N@'KD^]=WX4
MN]2U&"YO]3E4)<.#;VJ@9AC'KWR<_I6+JWAVX\0ZY=(VG1VEC9J6C;RP#=S8
MX)(_A'ZUE?#S1=5L?$R2W&GWUC%'8R1WCW,FY+F<R(59!D\!0WI0!Z?1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH "<#)KYM^(?B?Q3J'C+6M<\.ZQ?VNE>&I+>!X+>=TB
MFSN9RR@X)&0.?:O=_&&K_P!A>$=0OP&+10G8%&26QQ7A/A+X3>+-=\ 7%XOB
MB;3;?6VEN;C3S'G<23U^N!0![+>_$'2-)\!VGB>_D(MKB%)$5>68D9P*X^_^
M)MOXP\$>(+3^Q[_3)?[/EDB^U+@2KM/(.*\NBM]<U/X20Z4UI-<7'A?5&\V+
M:<O&#D8'<5Z._P 1+7QIX&U>STO1KJ+[/I3K+-) 5",$^Z.* ,'X=_&;2_"W
MP_T2PO=,OI+>.-8I;Y5Q%&W0C..<5V^M:W;R?%WP[%'JNK1B[@62.V@N-MM(
M#R"Z=ZX#6+"0?LF64:VS>;Y*$J$^;.>M:4<%S)\4? CO'(=NG1AF*GCY>] '
M7>(?C9I>C:U=Z?8Z3?:M]B8K=36JY2$CKDX[593XQZ)+?Z##!;S/!KD@CAN,
M@*C'L17@]UX;TK0/&.OVOCJ#7(FN+MVMGL"^R923C..N:[;Q%X-2'X%VE_H>
MGW=I<:5,MW#'<9,JJ#D_I0!ZEJ?Q,TK2_&S^'9XI"\-HUW<7 8;(4 SS]>E<
MW#\?='>^B$^CZA!ITL@C3477]TQ)P.U<+X5T+5?'WA#QQXEEMG2_U* 6UHC
MAMBL&*C_ +Y%<AH6A>&9K6UTK4=/\1RZVD@W6:L_E;@>OH* /??$WQATKPUX
MD719-/N[NYEMO/@^SC=YIX^4#UQD_A6+#^T+HUQ9RF'1-2>_A8B6Q5,N@'\1
M..*J0Z>8OVDM, MV\J+1R 77.T\=_6J7PULG7XI?$9Y;8A6@0(S)U^_TH [V
MS^+'A^Z\!-XJ9GBM5<Q-$WWQ)_=^M9OA[XTZ;K6N0Z7?:1?Z3+<C-LUVN!,/
M;BO%;?PQJVM_!;4H;2UN)#::Y]H>%%(9DPP./S%:O@;1O">I^*=*DTFS\0W-
M_9L&D-TS^7 0.>O;- 'I-_\ 'K2K34-1L8-$U"\N=/F,<J0#/ _BSC@5E_$#
MXTSQ?"^Q\0>"XID>^FV>>8E=;?:<,K!@1D]JB^&=FPUCXDO+;G+W1",R=1L/
M2N+T[1]1O_V9]8MH+:5I(=9:41[3D(IR<"@#W7X<>+[KQCX7AO;[3KFRG"@.
M9TV^:?[P&!P:X;Q0Q\3_ +1V@Z-*0]GI4)NVC)X$H&X''Y5V?PK\2V_B+P39
M_98)XOLL2POYT97+ 8.,UQ!0:=^U@CSG OK!C'D<<)C^E &'JWB?6X]7N;HZ
MSJ$.LPZSY*6"W+B(6^_'^JSM(V]R*[_3=2U#Q[XX2[L+VYM/#VDS9'DRM&+V
M53T."-R9ZCH:;XX:7Q'XCC\*Z';)'+( U_?"(;HX^X#8ZD5YUXIL&T:^UW38
M1<07UO%&F@I$6&6R.5 X)SUH ^B[FXBM+66XN'"11(7=CV &37E%Q^T#I$4S
MR0Z)J4^F1OL?447]TO.,]*[C7].O=5^'=[8C)O9K(K[EMO2O!=/\9?V7\)KO
MX?W'A^\.N2QO;I&+<[26XW9QU'6@"_\ '?QS%K8\/Z;96E[<Z3=LETTD#E5N
ME.1Y8QW%>Q^$],MG^'<%AI<%YH\,L)6-'D;SH<CJ&/.:\8\3^&]0T+P_\,M-
MNX7:XM[C]ZJJ3L.0<5](1?ZE/]T4 ?-/BCPOXAT3XK>'O"\'Q"\4O;ZQYADE
M;4I-T>T9^7!Q7>'QP?ABK^'I;7Q%XJEMCOEOIF,C 'GEB.U4?B!;S/\ M&^!
M94B=HU$VY@O ^7UKB_B(;BX^)>KVWB[^V?LS1C^S8[#<%<X[X[4 >NW/QAT2
M'X>)XNB@FFM/M'V>2($!HW[@_2JT7QKTEM$N=5N-+OK:VC<+;F1,?:LC(V<5
MX]IMC.G[--Q;FVF#?\)&?W;H=V-J]:[GXUO%8_"OP\F!"0T>&0?/'A1RH[F@
M#<T/XZVNL^++70)/#6IV5Q<88M/@!$_OD8Z4EY\?=&M[Z7[/H^H7>FPRF)]2
MB7]T"#@GI7GWP[OM"U7Q/</?Z]?:AXAN[0VMHUY"8OEQPHSUKC=$\.:%I=C+
MH?B^R\0KK4<KI]FM2_E2?,<<#CTH ]4^(/QIU?1_&6B0>'K>XDTV?;)(J0JW
MVM3V0D$@_2I/B??R0:IX&\=V]K+87#7,<$\4HPZ1ORRM[\XK(^(FGR>&9O F
MJKI]T-/TW:9$VEWC ['WK8^-NJP^(_"7A$6J2(VJZA$8HW&' ;&,B@#VZ*02
MPI(O1E!%/J&SC,-C!&W5(U4_@*FH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N4\2^ K3Q
M%XGT?7OM<UG>Z5*'5X@#YJYSL;/:NKHH **** "BBB@ HHHH **** "N3\>?
M#[3O'UC;17UQ<6DUJY>"XMVPT;>HKK** /-_#/P;L=$\10:WJVMZEK]]:_\
M'O)J$N[ROI7I%%% !7*:YX"L]?\ &NE>(=0NI7_LM3Y-I@>66ZACWR*ZNB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_1.jpg
<DESCRIPTION>EXHIBIT 10.49 GRAPHIC
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  I )8# 2(  A$! Q$!_\0
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M;7XF>88C#5\35RW)X*G1I0G*4H_%)PBW\6[5]-]=]58^BZ**\>_:4_:2T?\
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AV'P@4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386877424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247,352,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999387756128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,936<span></span>
</td>
<td class="nump">$ 5,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,162<span></span>
</td>
<td class="nump">4,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,576<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">13,456<span></span>
</td>
<td class="nump">14,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">5,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">28,348<span></span>
</td>
<td class="nump">28,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,314<span></span>
</td>
<td class="nump">8,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,952<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">61,876<span></span>
</td>
<td class="nump">63,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">3,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,140<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,528<span></span>
</td>
<td class="nump">11,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">22,956<span></span>
</td>
<td class="nump">22,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">3,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 shares authorized; 1,248 and 1,247 shares issued and outstanding, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">5,793<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">15,223<span></span>
</td>
<td class="nump">15,687<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">20,997<span></span>
</td>
<td class="nump">21,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">20,939<span></span>
</td>
<td class="nump">21,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 61,876<span></span>
</td>
<td class="nump">$ 63,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386832448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600,000,000<span></span>
</td>
<td class="nump">5,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,248,000,000<span></span>
</td>
<td class="nump">1,247,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,248,000,000<span></span>
</td>
<td class="nump">1,247,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999387733840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,352<span></span>
</td>
<td class="nump">$ 6,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">4,647<span></span>
</td>
<td class="nump">6,393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(316)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic earnings per share attributable to Gilead calculation (in shares)</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted earnings per share attributable to Gilead calculation (in shares)</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,306<span></span>
</td>
<td class="nump">$ 6,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386627312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss), net of tax impact of $0 and $0, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income, net of tax impact of $0 and $0, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain (loss), net of tax impact of $(1) and $3, respectively</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassification to net income, net of tax impact of $3 and $3, respectively</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss, net</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income, net</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest, net</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Gilead, net</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386801648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax impact of net unrealized gain (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Tax impact of reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Tax impact of net unrealized gain (loss)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Tax impact of reclassifications to net income</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999381307728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4,661<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 16,324<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss, net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock under repurchase programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock under repurchase programs</a></td>
<td class="num">(353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchases of common stock for employee tax withholding under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchases of common stock for employee tax withholding under equity incentive plans</a></td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 19,915<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">14,986<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 21,209<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">15,687<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss, net</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock under repurchase programs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock under repurchase programs</a></td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchases of common stock for employee tax withholding under equity incentive plans (in shares)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchases of common stock for employee tax withholding under equity incentive plans</a></td>
<td class="num">$ (135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 20,939<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5,793<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 15,223<span></span>
</td>
<td class="num">$ (58)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999390124960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 82.29<span></span>
</td>
<td class="nump">$ 63.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386714880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net loss from equity securities</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(227)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">26<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(272)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Income tax assets and liabilities, net</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(543)<span></span>
</td>
<td class="num">(1,657)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">1,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable debt securities</a></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(551)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(826)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock under repurchase programs</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payments of dividends</a></td>
<td class="num">(969)<span></span>
</td>
<td class="num">(945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(1,794)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(476)<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,412<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 4,936<span></span>
</td>
<td class="nump">$ 4,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389834336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Condensed Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $34 million from Prepaid expenses and other for the three months ended March 31, 2022.These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386648320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of Revenues</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liver Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chronic hepatitis C virus (&#8220;HCV&#8221;)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chronic hepatitis B virus (&#8220;HBV&#8221;) / hepatitis delta virus (&#8220;HDV&#8221;)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liver Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Atripla, Emtriva, Sunlenca and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues from Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen and royalties for licenses of intellectual property</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Generally results from receipt of advance payment before our performance under the contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386648320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,895&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $22.6 billion and $21.9 billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and the carrying value was $24.1 billion as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to &#8364;300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex until the related contingency is resolved.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in fair value of our contingent consideration liability: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Research and development expenses on our Condensed Consolidated Statements of Income. The change in 2023 primarily related to updated expected payment dates and the change in 2022 primarily related to updated probability rate estimates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair value of the liability related to future royalties was $1.1&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, and the carrying value was $1.1&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we recorded a partial impairment charge of $2.7 billion related to certain acquired in-process research and development (&#8220;IPR&amp;D&#8221;) assets. See Note 7. Intangible Assets for additional information. There were no indicators of impairment to IPR&amp;D assets noted during the three months ended March 31, 2023. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value Level Transfers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385638912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No allowance for credit losses was recognized for investments with unrealized losses as of March&#160;31, 2023 as the unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments. We do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Securities</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Measured at Fair Value</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024. </span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $333 million</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $423 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrealized Gains and Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized on equity securities were $256 million and $96&#160;million for the three months ended March 31, 2023, and 2022, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999391200832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE FINANCIAL INSTRUMENTS</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTS<div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held foreign currency exchange contracts with outstanding notional amounts of $2.9 billion as of March&#160;31, 2023 and $3.0 billion as of December&#160;31, 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 25.75pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:79.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) recognized in Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain reclassified from Accumulated other comprehensive income into Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of March&#160;31, 2023 are expected to be reclassified to Product sales within 12 months. There were no discontinuances of cash flow hedges for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the three months ended March 31, 2023 and 2022 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385750320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</a></td>
<td class="text">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTSWe enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tmunity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed an agreement to acquire Tmunity Therapeutics, Inc. (&#8220;Tmunity&#8221;), a clinical-stage, private biotechnology company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $300&#160;million in cash consideration. As a result, Tmunity became our wholly-owned subsidiary.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition and recorded a $244&#160;million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income during the three months ended March 31, 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed, consisting primarily of deferred tax assets. Under the agreement, the former shareholders of Tmunity and the University of Pennsylvania are eligible to receive a mix of up to approximately $1.0 billion in potential future payments upon achievement of certain development, regulatory and sales-based milestones, as well as royalty payments on sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Collaborations and Other Arrangements</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arcellx</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, Inc. (&#8220;Arcellx&#8221;) to co-develop and co-commercialize Arcellx&#8217;s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future next-generation autologous and non-autologous products. In conjunction with the collaboration agreement, we recorded a $212 million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income during the three months ended March 31, 2023, primarily related to an upfront payment, as well as a $115&#160;million equity investment, which is subject to lock-up provisions until July 2024, in Other long-term assets on our Condensed Consolidated Balance Sheets. The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales. Arcellx is eligible to receive performance-based development and regulatory milestone payments of up to $835 million related to CART-ddBCMA, a potential future next-generation autologous product and a potential future non-autologous product, with further commercial milestone payments, profit split payments on co-promote products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts-in to co-promote on the future products. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promote products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts-in to co-promote these additional future products as well.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a transaction with Pionyr Immunotherapeutics (&#8220;Pionyr&#8221;), a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate agreements, one related to the initial acquisition of a 49.9% equity interest in Pionyr and the other providing us with the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (&#8220;Pionyr Merger and Option Agreements&#8221;). The exclusive option had an estimated fair value of $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. In March 2023, we waived our exclusive option to acquire Pionyr and certain other rights under the Pionyr Merger and Option Agreements and recorded a $70 million charge to Other income (expense), net on our Condensed Consolidated Statements of Income. We will retain our equity interest in Pionyr as well as the right, under certain conditions, to review new data as it emerges.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385678096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,894&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,667)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,228&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,794&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,667)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $546 million and $445 million for the three months ended March 31, 2023 and 2022, respectively, and is primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2023:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No indicators of impairment were noted for the three months ended March 31, 2023 and 2022, except as described under &#8220;2022 IPR&amp;D Impairment&#8221; below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 IPR&amp;D Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $6.1&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385512352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">OTHER FINANCIAL INFORMATION</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our trade accounts receivable arises from product sales in the U.S. and Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other current liabilities</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other current liabilities:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accumulated other comprehensive income (loss)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385444320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT AND CREDIT FACILITIES</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,092&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,238&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,229&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2023, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revolving Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385471776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December 31, 2022.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, sold under the brand name Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision, and in March 2023, a three-judge panel of the Court of Appeals for the Federal Circuit affirmed the PTAB&#8217;s decision. The litigation in the U.S. District Court was dismissed in April 2023 after the University represented to the Court that it did not intend to pursue further appeals.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. The EPO subsequently held an appeal hearing in March 2023 and revoked the EP &#8217;190 patent, including the amended patent. We had also initiated proceedings to invalidate the U.K. counterparts of the EP &#8217;190 patent and a related patent, European Patent No. 3,904,365 (the EP &#8216;365 patent) in the High Court of England &amp; Wales. NuCana had filed counterclaims against us in the High Court of England &amp; Wales alleging patent infringement of the U.K. counterparts and seeking damages and other relief. The U.K. case was heard in early 2023, and the judge issued a judgment in March 2023 invalidating both patents.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. In April 2022, we filed an action for grant of a compulsory license before the Federal Patent Court in Germany. In July 2022, the D&#252;sseldorf court determined that NuCana&#8217;s German counterpart of the EP &#8217;190 patent is infringed and granted an injunction. In August 2022, Gilead filed a notice of appeal regarding the D&#252;sseldorf court&#8217;s decision, and a hearing is scheduled for August 2023. Following the revocation of the EP &#8217;190 patent by the EPO, we expect the injunction in Germany to be lifted.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of three material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and two clinical trial agreements (&#8220;CTAs&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the Court of Federal Claims was held in June 2022, and in November 2022, the Court determined that the government breached the three MTAs. The Court also made findings of fact relating to the CTAs but declined to issue a decision on breach of the CTAs until after trial in the Delaware District Court. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Delaware District Court has been set for May 2023. A separate trial at the Court of Federal Claims to determine the damages Gilead is owed based on the government&#8217;s breach has yet to be set.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. (&#8220;Lupin&#8221;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen (&#8220;Janssen&#8221;), filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. Trial has been scheduled for October 2023. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (&#8220;Apotex&#8221;) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Apotex asserting infringement of two additional patents in the same court. Trial has not yet been scheduled in the lawsuits against Apotex.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2022, we received letters from Lupin, Laurus Labs (&#8220;Laurus&#8221;) and Cipla Ltd. (&#8220;Cipla&#8221;), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of three of the five patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for December 2024.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing was held in November 2022, but a final decision regarding the validity of the claims has not yet been announced.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. The original opposing parties have appealed, requesting full revocation. The hearing for the appeal has been scheduled for September 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. The appeal hearing was held in March 2023 and the EPO affirmed the validity of the TAF hemifumarate patent.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process for sofosbuvir opposition proceedings may take several years . While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for sofosbuvir, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc., have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes. These cases have been coordinated with the class actions. Trial has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#8220;Cipla Defendants&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we, along with BMS and Teva Pharmaceutical Industries Ltd., were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, and Missouri, involve more than 25,000 active plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed while the California First District Court of Appeal considers the merits of plaintiffs&#8217; theories of liability. The first bellwether trial in California federal court is scheduled to begin in January 2024. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The lawsuit seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. This case was stayed in September 2021 pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above. Health Choice filed a motion to lift the stay, and in April 2023, the trial court granted Health Choice&#8217;s motion to lift the stay. Gilead has filed a motion to the Texas Court of Appeals requesting reinstatement of the stay until final judgment in the Eastern District of Pennsylvania lawsuit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. In June 2022, plaintiffs filed their Motion for Class Certification, and Immunomedics submitted its Opposition in July 2022. The parties have agreed to settle this litigation. A motion seeking preliminary approval of the settlement was granted in February 2023. The court has not yet entered a final order approving the settlement. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385463200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:79.866%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted earnings per share attributable to Gilead because their effect would have been antidilutive were 3 million and 16 million for the three months ended March 31, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385448112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 24.3% for the three months ended March 31, 2023 differed from the U.S. federal statutory rate of 21% primarily due to $244 million of non-deductible Acquired in-process research and development expenses recorded in connection with our acquisition of Tmunity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate of 107.9% for three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in state deferred tax liabilities associated with a partial IPR&amp;D impairment charge of $2.7&#160;billion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385447680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Condensed Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $34 million from Prepaid expenses and other for the three months ended March 31, 2022.These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to &#8364;300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex until the related contingency is resolved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386703568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregation of Revenues</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,862&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 12.25pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liver Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chronic hepatitis C virus (&#8220;HCV&#8221;)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chronic hepatitis B virus (&#8220;HBV&#8221;) / hepatitis delta virus (&#8220;HDV&#8221;)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liver Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,534&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Atripla, Emtriva, Sunlenca and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Summary of Revenues from Major Customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen and royalties for licenses of intellectual property</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Balances</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Generally results from receipt of advance payment before our performance under the contract.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385613248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,895&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,909&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in fair value of our contingent consideration liability: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Research and development expenses on our Condensed Consolidated Statements of Income. The change in 2023 primarily related to updated expected payment dates and the change in 2022 primarily related to updated probability rate estimates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389834896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Estimated Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Available-for-Sale Debt Securities in a Continuous Loss Position</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:40.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Equity Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div>(1) &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385441856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Value of Derivative Instruments</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 25.75pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Effect of Foreign Currency Exchange Contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:79.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) recognized in Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain reclassified from Accumulated other comprehensive income into Product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999384806640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,894&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,667)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,228&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,794&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,667)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,525)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,009)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,894&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,667)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,228&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,794&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,667)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Estimated Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2023:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining nine months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389867504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of Accounts Receivable</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Other Accrued Liabilities</a></td>
<td class="text">The following table summarizes the components of Other current liabilities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Accumulated Other Comprehensive Income (loss)</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385736688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Debt Carrying Amount</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,092&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,238&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,229&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385449776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of the Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:79.866%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999385688848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of the Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Income tax benefit (expense):</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386687696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Reclassification out of prepaid expenses and other</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Reclassification into income tax assets and liabilities, net</a></td>
<td class="num">$ (161)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Reclassification Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Reclassification out of prepaid expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Reclassification into income tax assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999374678768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 6,352<span></span>
</td>
<td class="nump">$ 6,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,452<span></span>
</td>
<td class="nump">4,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,306<span></span>
</td>
<td class="nump">6,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="nump">4,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,190<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="nump">2,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,677<span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OncologyProductMember', window );">Total Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OncologyProductMember', window );">Total Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OncologyProductMember', window );">Total Oncology | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OncologyProductMember', window );">Total Oncology | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember', window );">Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_LiverDiseaseMember', window );">Total Liver Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_LiverDiseaseMember', window );">Total Liver Disease | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_LiverDiseaseMember', window );">Total Liver Disease | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_LiverDiseaseMember', window );">Total Liver Disease | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HBV/HBD | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OncologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OncologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_LiverDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_LiverDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_VekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_VekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386689728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Summary of Revenues from Major Customers (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=gild_MckessonCorpMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999387767184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Summary of Performance Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue share with Janssen and royalties for licenses of intellectual property</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Changes in estimates</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999390149632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUES - Summary of Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999373735920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,326<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,551<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,909<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,175<span></span>
</td>
<td class="nump">3,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Estimate of Fair Value Measurement | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,895<span></span>
</td>
<td class="nump">5,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">639<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,175<span></span>
</td>
<td class="nump">3,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | MYR GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386823280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturities of derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR GmbH | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Market value | Level 3 | Immunomedics | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt, carrying values</a></td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 3 | Immunomedics | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999386676496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details) - Contingent Consideration - MYR GmbH - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in valuation assumptions</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement', window );">Effect of foreign exchange remeasurement</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=gild_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=gild_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999373695280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="nump">$ 2,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">2,326<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 335<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999381286512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">1,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or longer</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or longer</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389737664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount', window );">Equity investments and equity method investments without readily determinable fair values</a></td>
<td class="nump">333,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 423,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net unrealized loss on investment of equity securities</a></td>
<td class="nump">$ 256,000,000<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999380192288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,326<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999374460272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">After five years through ten years</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">After ten years</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,350<span></span>
</td>
<td class="nump">$ 2,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">After five years through ten years</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">After ten years</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value&#160;</a></td>
<td class="nump">$ 2,326<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999373425968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 3,175<span></span>
</td>
<td class="nump">$ 3,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 4,551<span></span>
</td>
<td class="nump">$ 5,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999380338704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Discontinuances of cash flow hedges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturities of derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Time estimate for gains (losses) to be reclassified from AOCI to product sales</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999380640768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative financial instruments</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received / pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amount (legal offset)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative financial instruments</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received / pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amount (legal offset)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated as hedges: | Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedges:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedges: | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives not designated as hedges: | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999387653504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Net gain (loss) recognized in Accumulated other comprehensive income</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Net gain reclassified from Accumulated other comprehensive income into Product sales</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Net gain (loss) recognized in Other income (expense), net</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999381292480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Jan. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 19, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">$ (111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember', window );">Arcellx, Inc | Global Strategic Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_RevenuePerformanceObligationPercentageOfUSProfits', window );">Revenue, performance obligation, percentage of U.S. profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember', window );">Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_RevenuePerformanceObligationPercentageOfUSProfits', window );">Revenue, performance obligation, percentage of U.S. profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr Immunotherapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember', window );">Tmunity Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsForAssetAcquisitions', window );">Cash consideration</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_RevenuePerformanceObligationPercentageOfUSProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage Of U.S. Profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_RevenuePerformanceObligationPercentageOfUSProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gild_ArcellxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gild_ArcellxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999380308000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">$ 31,894<span></span>
</td>
<td class="nump">$ 25,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,667)<span></span>
</td>
<td class="num">(10,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">21,228<span></span>
</td>
<td class="nump">15,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">39,014<span></span>
</td>
<td class="nump">39,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,667)<span></span>
</td>
<td class="num">(10,121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">28,348<span></span>
</td>
<td class="nump">28,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">7,120<span></span>
</td>
<td class="nump">13,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">7,120<span></span>
</td>
<td class="nump">13,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="num">(6,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset &#8211; sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,525)<span></span>
</td>
<td class="num">(6,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,195<span></span>
</td>
<td class="nump">4,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,525)<span></span>
</td>
<td class="num">(6,350)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember', window );">Intangible asset &#8211; axicabtagene ciloleucel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(1,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,101<span></span>
</td>
<td class="nump">5,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(1,908)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Intangible asset &#8211; Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">11,730<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,192)<span></span>
</td>
<td class="num">(973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">10,538<span></span>
</td>
<td class="nump">4,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,192)<span></span>
</td>
<td class="num">(973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember', window );">Intangible asset &#8211; Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(762)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (762)<span></span>
</td>
<td class="num">$ (733)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Reclassified</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999374465088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived intangible assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2- | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics | In Process Research And Development Trodelvy For HR+/HER2- | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetMeasurementInput', window );">Discount rate, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389619072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 (remaining nine months)</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 21,228<span></span>
</td>
<td class="nump">$ 15,674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999390243376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 4,933<span></span>
</td>
<td class="nump">$ 5,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: allowances for chargebacks</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: allowances for cash discounts and other</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,162<span></span>
</td>
<td class="nump">$ 4,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999380377440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Summary of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,157<span></span>
</td>
<td class="nump">$ 1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_InventoryNetAndInventoryNoncurrent', window );">Total</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,576<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Net And Inventory Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389842192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">$ 1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="nump">2,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="nump">$ 4,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999387636896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 21,209<span></span>
</td>
<td class="nump">$ 21,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">20,939<span></span>
</td>
<td class="nump">19,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999380146896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 25,238<span></span>
</td>
<td class="nump">$ 25,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total Long-term debt, net</a></td>
<td class="nump">$ 22,956<span></span>
</td>
<td class="nump">22,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.50% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 0.75% Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,499<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.70% Senior Unsecured Notes Due April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.50% Senior Unsecured Notes Due February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.65% Senior Unsecured Notes Due March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.95% Senior Unsecured Notes Due March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.60% Senior Unsecured Notes Due September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.00% Senior Unsecured Notes Due September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.65% Senior Unsecured Notes Due December 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.80% Senior Unsecured Notes Due April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Unsecured Notes Due February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,734<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Unsecured Notes Due March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">2,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.15% Senior Unsecured Notes Due March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,728<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember', window );">Senior Notes and Medium-Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total senior unsecured notes</a></td>
<td class="nump">24,092<span></span>
</td>
<td class="nump">24,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,146<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A250SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A370SeniorUnsecuredNotesDueApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A350SeniorUnsecuredNotesDueFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A365SeniorUnsecuredNotesDueMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A295SeniorUnsecuredNotesDueMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A460SeniorUnsecuredNotesDueSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A400SeniorUnsecuredNotesDueSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A565SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A480SeniorUnsecuredNotesDueApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A450SeniorUnsecuredNotesDueFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A475SeniorUnsecuredNotesDueMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A415SeniorUnsecuredNotesDueMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999390149632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT AND CREDIT FACILITIES - Additional Information (Details) - Line of Credit - Revolving Credit Facility - Credit Facility Due June 2025 - USD ($)<br> $ in Billions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under revolving credit facilities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389545504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>plaintiff </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>opposingParty</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents challenged</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyNumberOfPatents', window );">Number of patents</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember', window );">Pre-Exposure Prophylaxis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyMaterialTransferAgreementsNumber', window );">Number of material transfer agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember', window );">European Patent Claims 2032 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember', window );">Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of class action lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs involved | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMaterialTransferAgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Material Transfer Agreements, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMaterialTransferAgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389799456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Schedule of the Calculation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic earnings per share attributable to Gilead calculation</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted earnings per share attributable to Gilead calculation</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389808944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Additional Information (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from earnings per share computation (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999390149760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="num">$ (152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">$ (316)<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">107.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139999389519536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">107.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Non-deductible IPR&amp;D charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember', window );">Tmunity Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>gild-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:gild="http://www.gilead.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20230331.xsd" xlink:type="simple"/>
    <context id="icd6c59c571494a02a71ad883d5631309_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if26af3e763f447f8b473acbdaab865df_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="if8f2633fb3c542d2b3573b60b6456dd2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5b99939368b46f298d75ed65a8f6ded_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4e928b3ebd744fc970718834da3534a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic500805e8441430185668274754bd251_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19c45e712edc45518e23cd00b61fb12c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a67c68bd87541d7b8aeb32a510dddfe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9df0d41627834bad8a580aa95611df74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica2a96fc6d924f519f7d51951f05ff10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i093edc5755704a77a5d407997e7193c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idca3647effb04f2ea342c2cdf2754864_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c4ed4a6dfc4488183b0a1d002929bd4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i624da2b108014e5d9432f6660170cd2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i55d7c8a4a8ea4f46b59abb6bce9ebca1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i69e6d18dd50a48cd905a0a5c55031f82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i754e1e540f8743189803095cb0207810_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie43db347832e437da36ad93d501ee972_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e2117194be2466c95399cea80f46988_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e727936efcb4ba8ab5f6da9a5878ef5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idcd710db690d4726a106486c05547cc3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic81eccef1dab414a9b030474788c13c4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iba0cff47492f4decb13158e416e6a4a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if725c7c7814e4cf4a3317e39e252bdb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a853e0354f546ee8636eb887f31fb19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86bf5b7641ca44ddb2ad53d7bd36d254_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i926df607944244f1a8641e0053d1d3b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i950969f530e94f1395cc3b19fdc321a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c4fc949dc9b4e8da603b9bafd8f0af1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i49700eb36c934cf4aca1f0807d4295a8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief6b15b37c004ae0aeeafce457d5b708_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3dd718f446d4121a028b08422617832_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4c3b3b01542f435fab6816bf508c9fe0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifbf32ea5502c43f99d1ebd15aff8ab22_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie42aa0aa14db49ed9e43dfc6d3bb5d7e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i70473ad0789b4b03b86eb8db467a296b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i40c694f02592405083bdaf13c4316671_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d19c32e455643b7b05ce940c7be0801_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i15a53598b2a34113a51cf1d6114c3cd5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4583fc82b7754ac98fc2a9af1773de2e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie597530e49e3466db13821646fdb7c32_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i77ab2be40e2f4be1931d2379972c1dcd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id5290416165d4826bca76f94fb4de05d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i12b086ae57d3416c93424778ee7a4f09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4db3222bd3a24a5792f21001e0ed9f4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45b0c18878c845d39d2faca137c3daea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d1f35c3663a4c68be7e9d1d6e2fcdbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id43b59bee267497cb6c22732ff724eed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b1d0155e0d845058e2dd8f560ef7b2d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i24a40544f07842abbbd26abe8bd230fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie95cce301e0e44138eda0e51e00f4923_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i542b657a0c2744368808c312bbc5c2db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97d4aaab1fff4ee3b95ab9943ea6d302_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67eba08e27714767a82df70e121e94cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia1d65f9df40f4dd5b0c639e53db4dd9e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iee89668eca8340e4ad175cab099b67cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i57ad68b551814279bf5718118b152459_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifee012c5d38d4893b3cb19e18351ab58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5d8f1357d074b21a89698ec5b723bea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58599254220a42feb444edc701be833b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie8b4e751a2264ec9bb98b846928280c0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e42fc11fdc540d7ad0245cb8d39d2e2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i41bb316ef34b4eaf906de30392736fed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5df3944f730544d1996bddf0bf5a8db4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icf12dba5416c42248c844b94f20ca082_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7cc3f768136e47c0936791b4392b8289_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i666aecd5c047480a9babba6ea8039520_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6d8b014f89141aba79e057fe12638a3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7a79f1e6c45d4bb897c9a98013083049_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib04f6c7e78c647b1807546ae78fdc62b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia50a21232d20463095b52d48490cc6b3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i997dc50c936a478aac1cc176a14d9ef9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i689fc87158304986aa89fae3a01ed245_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i91e1f772d34742e8a8d2a4145828b021_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i771add6d73314919a6dd20ce750a969c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25c19b71fcc4402098fe7a9aa8fc8eed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i010418975aea40d895ec2686ed330d28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i450d6b2c88a24625a9c496cecdc5bf52_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib7af1b22c3f847fe9bdfc0f5f119ae02_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibd3a66e75c7047d3aafef3137fa6445b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6bdbd845c58c46e8adb8c44ae5684498_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i591c01bce34640e58557c165d695cf0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6494ec78b3ce416bb07ce891ecf80d8a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf6b130e3bfb4d008f422f886fe3bc7c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id56aa7d6f82f411ca07a2196837c3857_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i792f4398c7264a34bbfbb2e0141d0569_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i36284b9953e94a87b53a58bccfc5e336_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i36cc56c685bc447bb351b98590992488_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i086e12e3ad3e4741a380acf23831618d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i30546a0c6b624dac91f3b66455061d66_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id40dd460e84042629c0071805ed4729f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic729d8e783a647028632b5ba40064638_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81ca1b72c6804ecbbc1b605f601091f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4dda79e450e447408d931455f2f8f8cc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8b399c95ac1b4246aaa5c0aaef8cd353_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2c92a43cc92a47a6ab65bfa263d351eb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idf7898842ff5448ba66ef0de574a341f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i344ba46eb7a04d56bd7de76ee16b62fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7cbe81d744b24ac3aadfd0def0c3af1d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia1b6d840cf5d4035a31088c19454672b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if06a18873aa0490ba83b5bddcaea2946_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d0b6766fa594a13aa0be791f84893f3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4e710d7e374b479fb14aabe9b50fd5ea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7fd6c3585eea4f94b84aff749f526ac8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie37160460cc94423a6e38cb49e84b00a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i458cd9c1bb9a44bab1804ab82add9ef0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d671c5a402543c6bc98a00e54b218e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i78556fab5a594eaaab678aa5b2b70c92_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i11f7ccbb67b3412d94eb07273cf08f82_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6292c28980b643479da9447ce2a9f473_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i21dec2a2b762423e9ef5905cf0aa9cf2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i603cb3b83ce14179bf04d0aaf6a195a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f30cf0bd3dc4f13a115c97982ce981f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7bd48e1d614c42f89931926809fc82a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7848b323c65b46e5a5d0b843644615ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iedfb95b671ed491e8b70938724cb0c56_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15ccec38bc81487a98ac2ef0ac2fb11c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9988c03dff4e4d05a5ff6badc0ed5ccc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3cb5ff7d45f6422e846f8796c101b1cc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic00e734d3ce3408487ef17422e54a433_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6054258e4b146609392bf5d13038e6d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i61f67ef40bc148158d12ec2015ed480e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i571a1be950c440d789469a2f4d9abfcb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea41115ebe564139a2c8659237f58346_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib25c20fa74df4d2ab27b7cc2ef3698aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1a272399a10347cb814cac2d9dfd148e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if463eff382504416bd3b435b029bab84_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad37f88a40ad417181970ffd6d38fdb8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6291bcbf7f7c41b98bbe26c0e03a3cf6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5e10e1edf06747de90b02b2363965434_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c62a110af374a069c05307a70eb674a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia05d7b2dd54e4758b222f4b9c96c8dcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4fd84ea511b418294dcc7d568645af7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie7ff71600e3d4a11b42b8372471e63e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id4043b3f894c487facfbfa869ed06140_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8da02de1bdab404c87ddd583b9eebf85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic846202eb035474a90d6bbdfc1b15217_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iccbbe48385584bfea6852686c3b019de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i71a4c42583664db8b3c33c5f299a0f4b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if951dfcac7744054906c5125f638ce21_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5cc2f2b76bb4d9c97bc86237986d9bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ebd3767145342f6b367a0b7f6f1a976_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib8bda10becdf41afb4989abe63dc2011_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4101dba088994abcb8f4d35c5096da8e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1fd92b5b8015467faac7b2902c0e722c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaee92c1d69fa4915a73d1e059bcc2f3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d037e0f2be44b11b472e2b6432f4801_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9f9879159314fdbb7fdea07bdf585a8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie367458dfc7842fdb07fd2fe4e10fc1e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i99d872aaca9d40a4b6c2a27ebb8bdf10_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia8284ac9437543ccbc0d3d44daf70792_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib43370509bfb4a8c8dab8123e63ab0c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if06a6eb489854930ae0def7cc8f416de_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i21ab588f4a7646b9ae2305375fa5467b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f37487da5e349a4b9f9f387d2dc5398_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4b3bdda941ff4e2aaa037ade8321f098_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee659a3e712243d09b54e37ca804067e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OncologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i94069cf576394220a168bb924848e1d5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i75383c9367af4d9d8f8715d238548742_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic44a7f7348754553ae0be14f2f11c8a4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie934396b4aa24066a63d81e4824e6824_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia825fa36f2c54e59a199832f003b73a0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c70a0df7936466e8f48c9d8037878b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i66dde11c9ee7473ea0df48b2aaacf03e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b1bbc6a669f486ebe51bb1dcae67739_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0905351e17b64009b3bd40c0e79e555e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i79ce5f719ea84854a0b758397c95d01f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3479eb78982346cc9b440b90ac343bf9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i510d0822c2574545adb8841ba008ce9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i58fdc21dc65e4d558d42514d101c97b7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a865d0fddb8445cb031590f0a02a80a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia22aa3af8d494dc292b57bdf0cdf041c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i86087bf8b37a4b89acc6817bcef8e756_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf24591ef12a41fca5174331a00cbb13_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idb45ab67b990486599a343f8415ee905_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id752540ccedb480fbbb6e2bba52c34bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icc42e0840ef141c5b3850d98173d4730_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34d455cccf9d4832870bcf4419271ea9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i98f80c600bf04228823d182e0cb43b1a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e1b8b9d99b04cd189bf897215f84c36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie5869ea468ec4ca5b87ad1783a18dc9d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHepatitisCVirusProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b0580a54e234bf585f865b90a530189_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i54593f03c1114400935e76093c34b8bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13b67d77f6f242b0a1bf8ac4155be76a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7ba94b3090254d63ba7bd368d1a8f7dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3a201f81fa334729abf7031166fd5577_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie743df4532ec46c6bec9c152ca1030fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i37473f0485a746938a7f26a2dca59cf3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ica72aa2509b04035b02393bb3aea5e1b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i23ebfed05406413eaff961e952191aa4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i82b45a8b90a848269a2592fbe0b8c3ce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if2d3312dcce0438cb345232fa7454979_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0934fd0075be4cd6ada897ff651ce8db_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c40a0615861452596fcb9aa9d86e704_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib500e8ef8aa84616b40a2191594114a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if38ddeb60ee2443f956e770d097710c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie640715ca03a42e99d7cd895fa05c7b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i652bed5b638547f9898ab03fcfdd467a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5b7dbdd67bdd453791f731cc83851f41_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5dfffbb1fb6e4e8ba4b2d0adc6f90600_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie97d2219d4e940e8872b33598cbc3523_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibe303d4e215044fa92f72f822bdc870e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1ad5d36685f64582b233de7a5239d698_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa9ebab0b3a942d5bb672c1ea1985565_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic16768b8c0bd467089b916f0150aea2d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a09533ea02b4970830e57cb8ed16e29_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8dfa66c376de4d50b8d621ce7a69fd00_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icb6838b754224e3ea3f49755cfe56353_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i257a0e1302984795b9ed79cd7d56fcb6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib68686e7167f4cd88f12024feac41469_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i824131aaa9e9438885ebb6c2d9d58420_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97befe6960ea47c09105a9d2792b241c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i743bad3f631549ee9b7e3300a3b32478_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d9b52ba975f47eea73b114711437ee0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia99677732ab64aee9be9eb6c9b9c5297_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i18ccc5abc96549b4a653a8ac7248fcf8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d5d887661194281a92f5d47aaec6008_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70bf852e632a47e287a6514f25d2979d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i20f4a76252494b24bc1f179124aa3124_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9560016efc024c89af4afc6834f04bbb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57ab8727efc14325bd00acfb911c338c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i090c47f3a0cf452181e6d5b006c0be6a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f7a471ebca74147a9b0d6e1a6089d93_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if8185dc8b7344db9a1038babf06db22b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie59f825423194376b8da82fe0cec886d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i324e13105ef44547bab1c5e86c934957_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia3e40c5875114f3cb760a0d82117e6a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59f9f3277ed14717a540d49002edff04_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if8748476ff814f45b9ccd6e290667fc9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:LiverDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8f8220ccfd0447bcaabd55458b891968_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaa9a86b0b2a84281bb61ad1873a15c2b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if614c6aa1eab4885acbcc73189da7a93_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i278eb945039342f2a8bda078049ec2e0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie40b401de87f42519456da4227ef431e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie855dc4b080941e6be062405849ca9c9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d547a3fe84543cea7ac0386bbc34d72_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i54cccadc5c6b497ca5b1f30e89955b7d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58c6167454744e0fab7410239683ab45_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i99d9606c89db437788fc45ee2168e4c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1eb18acf634f467aaf5cdd7a65b62981_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia581f9570a6a44e4bf717b04c2b68cad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i447d2250e1b9434a90d57aa2babd8a63_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9a7971fda6a4d1cb7a5b0c93dc55aa8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i63020427351e4e01a6c232cf97913837_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2e51316888b41cbb03d3ddfc57bd840_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74791ed0e7b346e89fd234b7be9699a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3dc4e4dc9bea4ec58fd5ff7790b0b8f8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i93d418d346974c1fa0c17dcfcaead0d7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibfbb92a2127b42db9046b0b7ec4dfa6a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i809de751ef2f4f78b9b8f68cd8b8e109_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4daac1a0fe9747d9bcd85f6d82586020_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic42331a4397a48faaaefc64df2f413e2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if28d2efd45f141f6b1f1fc7d243542f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i755f2b30cc6e4fa993c605e6808ad1cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i677d46617baf4cfc97770f40bdf350eb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i996bd5bfe4d44d25b7c4bf8273caf0cc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb8a2eae2e8547a5b670d21ca58b3fef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i823bfbd777c846ddaf6555202b8a7351_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b10cde4a9524c0ca62293060948f483_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie41089e89bd74f35ae3f87c7a56e2a19_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i696fbe445270452f81e087d1fa89fe11_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ae81192d9324630ba4b365d1cddd5bf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie33f4fdb4c494428ba2b4a99560b4e08_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i709a08a357b14493b12bf32a458f6f6f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i710096d16b5642718cafb5a22d815d0d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic1ab8aec39084c4eac102e0706a4b80b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf9e5623132040899baea9cd2d5a764e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3092cbdd04d40b19aab266dd867a766_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib976d60772b24c27944ea6b8d54d2d67_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i113772172baa40a0b615da596117cf5f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac7656db9d0049259fec5c0b61f4a692_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic79faa34465a4d6aa155b887531a618a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i89d5861845724cc7b45b2421fadc72b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c53f8feb0a94f6491489c44593b168b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f19798d09f947d2a629343bde19e62b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64a4176549214367abc167a2ec593abb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i978f5bf8cd9d416190509bc5959bef0d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i34a5ba2a8a1540749ed46ae7a6ed4e6c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib5ea35337c87402dbc1082ebd607e554_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3374213965c34c23a79853f9a29ba6a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib7caa2c5fbd246269301ab23ea219e18_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c91b5b81b3f49cc99ed4d965e15cb05_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6eb135539ed644e89e8a56f37e4ba61d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i68170415b25f47b08de05015410863d5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b6849a5ebac4c97924794143c774f0b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id9c99b6a3f2a472c83a2fa839f90b5ea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f79d1cff43c43df82a4363c05362740_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic87bba42a74544ebb4ed1b2216e3f687_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic7c4130e03624fd8bb9980194f507734_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ida6333a62e4e40e5ac281c56d97e63c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f1daf12df0648b786b4f70679a69ee3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibffab27044b141ed8332a4acb0c26f71_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a637640e90643ad807df7af76498cb0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i67a08172f4f244a79d2b394f399f8b13_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id40005adf52144ed85b05da90b6d2139_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2a00bf2652604fbcbb4da1bec40896e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ad1222097c644f09b1a2dccc64bd3c4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd34e7473d924c328deed5a6ccdd4afe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i298a129b64b84c158f7a79bfaabebbd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic015d372c6774949bc85fa263970366a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6548e7eaf5d34e378990fe5c8218b3a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie56bec9c2c9449778eb81057ceb9299b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c2a9da409b6496bbc57ceb63bf60484_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4458d1d12cea4625bc7db11da9a09beb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i070c48e01f814ffd907a7fd8f6047117_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5c206f3d17b44385898e7a9f69b7aa12_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4efb718dc0824ded809922f135d14f72_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i39bac2a669a64335b1a9e1e221e2f25c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia26e1c0f325d4ca1a67fba9811c45fc9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2b123dc510a43d8802b50cccdeedbf5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57c59bdf9e624122b0025c13c8932d5b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6307387519504abc927afabdd827d0b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i268af442ad9045fb9d0047cc8514e705_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic58be9bdcf7e4accbe91509935a9f362_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc9741f7ff7a4abeaf85943e5f22418a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib28bc6923927495f8c985d0973d926f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i858d8c032c1640b58d8d8f45207568b6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7955dfb43224407190574461d49d9540_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1b3fc36306554f1bb30285803dfe875c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d5eff8a38aa425682a7f90c9892125b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice046d59307c4fdcaf4be021a9c9b7e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ca4682777694e579dd8d81c0230ccb7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i840cd602edc14d1cb641e5ee8c6a8fe5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ea63a1d9c8d4b34a96c93940d35e22f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaecfcff27fd54e13b0ec19e65fbd5d36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41faaf40d4ef4d49b113b09bc17772bb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i52a8d5247fbb40ffac874f473b0f297a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2e94173dabe647a398189e72561ab576_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1afce071943b4d26b76439f3846f3a8a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d03adc29c7a4123ae502213f7338c96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1ab2341ad8e4ff6b616f6930e3a7edc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6d8a928fd4e43259f12d46c9b3dd925_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75af3c4962e045198fbc3aa6ec6a75ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icaf023b197aa4118b56f642584f72530_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i03efe7c49cbc4bdeb65025a874918ba9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia17d4fe5710248bf903fa448d86c0f88_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8fdbabb1243f4e86a5376c9000522492_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i729aa6a63477475ba65321969802f159_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a2cff82341c4dc0a251e15da3bf13c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccd142e2bf3c46ee91f4326b178cb28a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1426c184f5cc47f8aa80bfe34a607cb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c2661abbc964a0784a010dbe6cc0fc6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id531a955cfb3413a82cad523850c21c3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia788273cc08946368efc543494d4d4e7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i70479b2efa064ffe8d5a4badb47ed829_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfcb1b9cdaeb47dca59a07a6ce2025fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f350e4b39bf43c491eedf1e18c2f29f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f658fc7bfbc42d1b7319bf162b933e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3fd105c3a34541189ed7853f9bdedb46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d38171e17734505bf300a4f7261bb9e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0ed5c2cce176468cb88406a4ef218eaf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a26bf538c9e4b07a3f50fa63e16c09f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i194f48cf31ad4461966915e642a9d349_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i937e321648424380aac9aa46560540c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i364fe131316c482492c686531f316415_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id09c87dcc4754dbaa6d7f3f7aff3a559_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic272024b44504e08aea2aef0e5cdce3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4a0d1c94992b4e8985f62b27d61769f9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic38fae61cd724739954724cab1029f06_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7db06db2f1954bfb84f43e2df4db34f3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib3c224d5aabd4662bf6225bef1d6c8ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i087ba3741afd43baa98b28ac94fd7f20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife4d3507260a4b689350205f27a8e97d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8939a2992d04a64a5ff7980f5f17203_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i65251199ab8d406ca23824a7b9f69f93_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6234e16f3ffa4f09aa53750804bbe37b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifc2b1f2190c1428e8e5a1008b1913d19_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id26d3f89e113495fb08196ab4d44bcf7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec6cde4baccb455a8d4849e1ae54b485_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i17d215506fdb4ac9b9fdd8a1a8900a0d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7611b09e98a14f48bbd2f62d557253e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i001dc783df3642e1ac6e1ae958df97e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic063218f12c54d03acf4ce07c47d4275_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe5e217a5b1140728f4602157db87e2c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b9f0b6b0b844305a53445354ae194cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib183b8cea0954d138ad44af200a84877_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6ee26b0e08842a0b843c4ac42a50e93_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5f1d8684d26247aa83ef85ca707fbd8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d573c781b70449f9e9416cded0054a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic05635ce202a4083958412667e099ed2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b368b49d37a4ee69978906222ce4b5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86fea5742d1f445d9c563566784f0cd0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i99ee5a60fac74d60b76c288f2df853d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a06827286fe4c8183a9be9be74fe8f4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9ac4e1620e6498cb5b443b7ad7d32d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6bda1d98cbaf438cbb28ebe26c09665e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id927ab0d29884827bea7bcaf3d2dc398_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7dde228737e648788d98fb2fc1d4ac58_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7df8c0d093bf48b2b63cba32a6131249_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e78ed5854ff4c45958a4d133cd9890a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe1f122ae8f14eae930697c79bf7af6d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i69013ac8af5f45c896d0e14dc6876b0d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i825aac04e24b40208c807dce228c07fb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iedc3b620a74946d7bac3bf26a9c4ce16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6385da92df654fb6967cea6114292f4f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibfb0e9387655417ea47e244e390930c8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad78bf4198534e099b1e1e8624534d02_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34a910c12f414900999d3b059f396d47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i22f1f58b1a04471faea6d3a37e5320fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie0463a71817c4cca9f2913df58ccc458_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2e6d5fe3d48b4ebc8612932358fce8e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1dcae5f616154d2bb06f9c392d252555_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35c466bd362f400780c77e751afc2c34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i800882dc4b244976915f007c452e0fe6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i064e703fbfd049878de89e2a1c5dc621_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6c191e188eb0435a839aff2e83dc0b7f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfcf3730e7494e1eac9bdd409e112df2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ed3bb87a65d43c99c02e4fc37036b3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1daea506fa054411b9fcccb4c301cc61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4162868d814a43e3aaf697b3f77e900a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05b4776cc8f6409e92531b2b339c0031_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7670407a0204455084b40c8717c401e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfb395164c844896b27f93a01db7e27f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i821c4ec6a7fd4cd4b53462e6dc41da64_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b15ded1f1714d829d737d7f8ba59153_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia5beeadbee5b426383f472cd603bccb1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if8bffbfdebfe4c0a8714dfe49168e8a0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3f93855d6db44024b333d78df947f56c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia97bd7f721914df1bcf6152d4c3d17b4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i62ecf657b38947f592054cba9b58c1a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a2868046c1c40f5b963d0310b6e2c28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb2f1b96e4fb4f3689024f243694c650_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d45d1db32724a06802d1990305aee2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f822206ae424d6e8263029d09d73dd7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4044808fa02946568c1a7cda0f2b4105_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59af451f1a45414e92cb058f5ca094fb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5fd9b5b14e74c698f0940b3bf03463d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i416dc4eb70914dd983bc1a04995857fd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied61cbd6414f453896de669cb79e2da9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e9f4eec9e644776964e5a8b7a54bd46_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec2e973c5db44ac4ae316708dcf05f82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i510d5f78872c4535851a18295b4f79b6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic5ee9e4a34394e0981b4f0da01de2965_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id87e5e8c32c24d6b861c84c1383d9257_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c3d373c59d041b98c7a3bfed37f67b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba2356957a154f63a357aa595e78976a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6343117edb334debb880ca01f650cb9f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic51b601fb20040c198873c13a12ac3d8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfc9e7315e954128826864d8f2720166_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d904395d75449c6b4a29ead472571b4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7d6353ae110f4676995da4b3e2534756_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5635d77dfe96415b8fb073a7a5cea4f6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie22760aef3ef40599b18170cf792b16b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i711389022cab421e9b3754a803e7423a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5acaacfcea4242ec9bbcbe69b9091425_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0206d1fc4e7644e2afbdb52420fef11b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i725217d7109d45ce87fd002dc195f7c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3c6fdd16179f433088b6dc239a41cdd7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc5853354bfe4cce8964c6ee51f3ad72_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idbb59ef088a34337a2c34aded0358835_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0273ef720045479f9a269b27d3e723bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b209667eea74724a7b9275aafea9399_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b4ed3db406545adbb4af3cbdee68817_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i17f7dcb7986040429aa8c1583d69150a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7080bfe269540189101c2421e6675ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73c00e7d8b1e4ef485fcb73e58436bd3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib882e81dd83841ac984af47ed8b513e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i644b5cd4730b4d5982cd086b35235aeb_D20230222-20230222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="i506cbd3ce6ca465992effd4d69548672_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie59389bcaac841308152584683c981e2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7e7f985abe641bf816e52117d2bceef_D20230130-20230130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="i7994adfb551a4093b62e6cfbc11bfe49_I20230130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-30</instant>
        </period>
    </context>
    <context id="ie49fa68b1f2d482184e980aaa5e1c250_I20230130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-30</instant>
        </period>
    </context>
    <context id="i9e1c0e3aad754d999d54e43dd7074379_I20200619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-19</instant>
        </period>
    </context>
    <context id="i3e84714994f54c519010f82389507cd7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5d20ca09d0f5459abd1fc754af94d026_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6461839ec90348219c82e7f40c41cfd5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia3b6da4b585b4321a7ec80b7967fa580_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5526c08c2df4105af84704e07402cc8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3c9a928007a34088ae330d4ec7c5a37b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb30d25a05de4811a48616e9e844ea50_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i30ff5746ef9a40388f4773379f847193_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd1ddf57d6b34a6583488abad14ff60c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia2b40d58e2714e7ba69b19c7555c6750_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i875d511da18240e9bc3567ad24abf2e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c429589ccdf4bfea176e02c0cac635a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if70af8c6a10b495e9247a23a7f7601b0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib00d0aa9e5e94a278cb25a17dafeb1d9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i263db7dcf6884988a0e0a6b78d1e1a18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib52e3a2b0b3f4d21893074364d38ef63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i399115e8a60144f3bb971ed4e82ff382_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad4cdb4878a34e009c969cee15e38f5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6de5de081bec4dd18128468f84151606_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b9f2ddd7ebd4003a278244a23a11b71_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i05fe8e63eff3469cb53503276158f5ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4f13613183647b781938b7084edb764_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica3992c52c804cb987a0221a71af7bf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i574633526e804738b0b65a58c499de43_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icd1126acbd5f41e5ba02e34d7f3b1994_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i61611069f0d34b499f897eda986a5c12_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if0b010acb61941da9f9b3702c05299d1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i03775ab216e04b35b7ed6670a04e0399_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if226e46e81434b4fa5ad7d3f0467adc3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A250SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32affe91c7174503bb23d6ad77cb2f0f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89771330d55c448a92e44362a44f16e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idfe06128b3294a28a03f9d23d916dc3c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i088891cbdf314ce6b8fcd496558912a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A370SeniorUnsecuredNotesDueApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cb55cd4308343798ee15ab28060178f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf624d97eb3d4a40934c3c494fa763f1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A350SeniorUnsecuredNotesDueFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i169f8c04a26a42f5a0b60374d9b36c86_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7e24c0141fe24d3d87e593b121853912_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A365SeniorUnsecuredNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf82b9ef3fed489896bcbd40c4d57784_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d81d540e4094ac484768eedff9edef5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A295SeniorUnsecuredNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1d8c353412dc437b91aace4b203357c8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8b148329838748f6809e967fa7b82687_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d46f8e092244b26b34a459dc7f0c882_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i34c2aeb4935e4346aed2bcc659b68b5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifbcd186911f94c619108ead92cb447d6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibb9297445f1f41d294ff95f5471d37d7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A460SeniorUnsecuredNotesDueSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f118b76b09d48e4b614386c5bc45cd5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ife4ae268d228410b823829d0e1ed0bef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A400SeniorUnsecuredNotesDueSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1142e4972ea45ddaafa04ee35493867_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i63c8bcfa26754f4fa29fad75dea0ebca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdc0d81cbb4140808a9a1e24ab2c3d24_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i945f98bdf3c64038b9ab71e096b3f268_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A565SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia87974f636664eaea5bcaeec0ab40f90_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1572140a5a8d4e83a9e6933296251621_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A480SeniorUnsecuredNotesDueApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95602d00443e4029bb73f9109ee2f243_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7ed4f399902a463ea3fcf0a543273745_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A450SeniorUnsecuredNotesDueFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f7c7fd53cb943fca75d8a9cca2d3665_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iade8a85e37a04d2dbacdbfd5cb15f536_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A475SeniorUnsecuredNotesDueMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i091813ff4b0b4bba8dd45fbd21ee9c90_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide79ceb5e2244413ba088809663b461f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A415SeniorUnsecuredNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2273e9e92d64f43ac4633c496068250_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6515a317e7e49bb958a7c1cfb861802_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i018b9520570d4bdb9a852a1dc0a67292_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifcb2412b199c42529e8362b7502e548d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18c75b45dd0b494a9413038b43d87195_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i88176a5b89454f6fb32288e4abf39fd2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7036db910ef7473694d4dc36eb796a6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i708772249eff4b8db077ea95cb4df25d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2d94e60ba65414383aad05e7c5d0ac4_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idcf147879c32413c88dcfab0f196e448_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie39ed308edf943f8974b315e8b36ca06_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="patent">
        <measure>gild:patent</measure>
    </unit>
    <unit id="opposingparty">
        <measure>gild:opposingParty</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gild:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF80LTEtMS0xLTI2OTM2Mg_0dd4da5b-994c-4fd0-8e58-e75b15e06671">0000882095</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF81LTEtMS0xLTI2OTM2Mg_296ae9f7-768b-4817-a512-850e849f5d7f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF85LTEtMS0xLTI2OTM2Mg_18b7c8e9-387b-4714-bf9b-1b81ead51b93">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF8xMC0xLTEtMS0yNjkzNjI_08b0cf5f-87c7-46b5-8ff2-26b973746641">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80L2ZyYWc6NDlhYmNkODk2YjVjNDIxNzkyNjBkMTVkNjQ5M2ZlY2IvdGFibGU6OTI5NzE3YmFjOTcyNDQyYTgzYzZhMjJjZDQ5ZDUzOTAvdGFibGVyYW5nZTo5Mjk3MTdiYWM5NzI0NDJhODNjNmEyMmNkNDlkNTM5MF8xMy0xLTEtMS0yNjkzNjI_cd317410-055f-49df-a316-85c5f55a97c8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV84OA_3bc537a7-e1cc-4fa0-9db5-afcfad7330db">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6Y2VlYmVjZTQwMDI1NGQyYWFlMDYzYjJjYWU1MzkzYTUvdGFibGVyYW5nZTpjZWViZWNlNDAwMjU0ZDJhYWUwNjNiMmNhZTUzOTNhNV8wLTAtMS0xLTI2OTM2Mg_125bc0ea-1239-4479-9099-6b8c3359687b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8zMjk4NTM0ODg1NDEy_d036f438-6de8-4d88-b1e5-754329a8c113">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MGQ1MzcwMjIyZTkzNDg1Nzg4NzEzNDVjMzZhOTVhNmUvdGFibGVyYW5nZTowZDUzNzAyMjJlOTM0ODU3ODg3MTM0NWMzNmE5NWE2ZV8wLTAtMS0xLTI2OTM2Mg_aee8c215-1b7c-430f-87be-606839b70f79">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8xODI_92350493-15b2-46db-ad86-a94e0c5b3960">0-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8xOTA_dadab7e6-8fe8-4dae-938d-cd912eca6d8a">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6NDE4MDIyNjZlNDNkNDBiYjk5MDI3NmYyY2EyYWQyNzIvdGFibGVyYW5nZTo0MTgwMjI2NmU0M2Q0MGJiOTkwMjc2ZjJjYTJhZDI3Ml8wLTAtMS0xLTI2OTM2Mg_6ad2a7c4-f5cd-4b8f-a120-d3f674bd24d8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6NDE4MDIyNjZlNDNkNDBiYjk5MDI3NmYyY2EyYWQyNzIvdGFibGVyYW5nZTo0MTgwMjI2NmU0M2Q0MGJiOTkwMjc2ZjJjYTJhZDI3Ml8wLTEtMS0xLTI2OTM2Mg_ba157c17-d165-4a02-94cb-e3244cbb6d41">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNTQ_880d42c4-8f68-4648-8cd2-459fb0858d4f">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNTg_d900207f-d1d8-48f8-b06b-6856d05c5b29">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNjI_de0af112-da5d-4cd1-943a-3b201997b6f2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yNjU_98a3709c-7bae-443a-bfca-85af6a520703">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8zMjE_bb9fefd9-678d-4214-91fa-be32c5f12525">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8zMjQ_8d44a737-ce9c-4205-b5a9-9a6dae3b38a0">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MmUxZmZiMjQwMTE5NDQyMzk3MjA1N2RmZDE4NGQ5OTUvdGFibGVyYW5nZToyZTFmZmIyNDAxMTk0NDIzOTcyMDU3ZGZkMTg0ZDk5NV8xLTAtMS0xLTI2OTM2Mg_21c07640-7c2d-4cc0-8bbe-80ec0610ba2c">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MmUxZmZiMjQwMTE5NDQyMzk3MjA1N2RmZDE4NGQ5OTUvdGFibGVyYW5nZToyZTFmZmIyNDAxMTk0NDIzOTcyMDU3ZGZkMTg0ZDk5NV8xLTItMS0xLTI2OTM2Mg_d6f08092-23bb-4370-9978-bdbef954845b">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGFibGU6MmUxZmZiMjQwMTE5NDQyMzk3MjA1N2RmZDE4NGQ5OTUvdGFibGVyYW5nZToyZTFmZmIyNDAxMTk0NDIzOTcyMDU3ZGZkMTg0ZDk5NV8xLTQtMS0xLTI2OTM2Mg_c5df3bc4-357d-443c-af97-85ddd7f72a8d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV83OTI_7c720197-178a-4cc3-ac50-0f9569392480">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8xMTEx_984bf53e-5a84-4b1e-98fd-d88c354cf898">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY1_e10163d6-66ce-4d19-af73-b4d73b4d09c1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY2_7e3848e9-f364-48b6-8763-84027e8e2656">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY3_25e1e223-c8e7-4180-b2cf-7cb07cd097dd">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDY5_34909910-6b7a-4bdb-80ac-b7696808d7a4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if26af3e763f447f8b473acbdaab865df_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xL2ZyYWc6ZDRkNGE1N2FkOGZiNDY5NmFiNDJkZDYzZjFhOWViMzUvdGV4dHJlZ2lvbjpkNGQ0YTU3YWQ4ZmI0Njk2YWI0MmRkNjNmMWE5ZWIzNV8yMDYy_79677cba-9cd1-4ed4-b65c-3b44e648771d"
      unitRef="shares">1247352689</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMy0yLTEtMS0yNjkzNjI_e2c3d3cb-beb9-4e3e-b194-c8d57ca487af"
      unitRef="usd">4936000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMy00LTEtMS0yNjkzNjI_15d5156b-9649-4c2d-bd26-73d1dcd82aab"
      unitRef="usd">5412000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNC0yLTEtMS0yNjkzNjI_73fec332-cb2a-42dd-beea-f18b057c5f00"
      unitRef="usd">936000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNC00LTEtMS0yNjkzNjI_f6bc2c6c-f55c-4379-84ec-0a705ec42183"
      unitRef="usd">973000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNS0yLTEtMS0yNjkzNjI_d86f7978-f2c3-4ee3-b89d-8f480062ef63"
      unitRef="usd">4162000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNS00LTEtMS0yNjkzNjI_51ce4942-22c1-4af3-86ef-b71bb23856cc"
      unitRef="usd">4777000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNi0yLTEtMS0yNjkzNjI_2c6d6327-5a9d-417b-a78b-c01fc4c0f7ab"
      unitRef="usd">1576000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNi00LTEtMS0yNjkzNjI_79c783b1-9229-4d7b-a142-7552d6e060e3"
      unitRef="usd">1507000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNy0yLTEtMS0yNjkzNjI_2f912cad-530a-41a5-99dc-c65ee1f7933f"
      unitRef="usd">1846000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfNy00LTEtMS0yNjkzNjI_67188fbc-3660-4b9c-8f91-0bf5026d778e"
      unitRef="usd">1774000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOC0yLTEtMS0yNjkzNjI_806fad32-e678-43fc-893f-7faa173e0698"
      unitRef="usd">13456000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOC00LTEtMS0yNjkzNjI_627b64dd-8bac-4b74-ba8f-c3a04d0069de"
      unitRef="usd">14443000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOS0yLTEtMS0yNjkzNjI_5f2bec8c-54ee-4164-a16a-018321ff7310"
      unitRef="usd">5479000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfOS00LTEtMS0yNjkzNjI_de51d4e4-2161-4734-b900-219fec78c5e8"
      unitRef="usd">5475000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTAtMi0xLTEtMjY5MzYy_13254f77-469c-43bd-a8ee-15aac726d8ae"
      unitRef="usd">1327000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTAtNC0xLTEtMjY5MzYy_32e11568-121a-4a04-ac34-9e8074659785"
      unitRef="usd">1245000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTEtMi0xLTEtMjY5MzYy_e86f5602-46b8-4dad-9c57-9c08887cf8d9"
      unitRef="usd">28348000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTEtNC0xLTEtMjY5MzYy_6daf79df-8401-488d-b8d4-901d740f3ac1"
      unitRef="usd">28894000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTItMi0xLTEtMjY5MzYy_485b0fca-6e8c-4d94-8169-4f7c444ea571"
      unitRef="usd">8314000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTItNC0xLTEtMjY5MzYy_1c77279e-87c1-4251-a55e-99e93d0fba1f"
      unitRef="usd">8314000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTMtMi0xLTEtMjY5MzYy_f8c610bf-ed95-44f7-ae0f-a70f5dd86f69"
      unitRef="usd">4952000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTMtNC0xLTEtMjY5MzYy_20b37566-a294-4eee-abd0-5e24e5e72a72"
      unitRef="usd">4800000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTQtMi0xLTEtMjY5MzYy_e50849d4-3841-4819-aba8-d0f1b55ef1cd"
      unitRef="usd">61876000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTQtNC0xLTEtMjY5MzYy_fe4a04a6-fb75-41a2-8d82-457d73f968ea"
      unitRef="usd">63171000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTctMi0xLTEtMjY5MzYy_63162f95-64d6-4a12-96a9-04d2e3c105cb"
      unitRef="usd">627000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTctNC0xLTEtMjY5MzYy_34c5ecc9-e32c-4722-a47f-77b474083dc3"
      unitRef="usd">905000000</us-gaap:AccountsPayableCurrent>
    <gild:AccruedRebates
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTgtMi0xLTEtMjY5MzYy_c1577064-e29e-4729-a7f6-15d1b1e62fe1"
      unitRef="usd">3477000000</gild:AccruedRebates>
    <gild:AccruedRebates
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTgtNC0xLTEtMjY5MzYy_eb16dafe-25e2-4684-8383-1ecb11369a73"
      unitRef="usd">3479000000</gild:AccruedRebates>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTktMi0xLTEtMjY5MzYy_fd5a7f52-1800-4fce-bc13-e0995a854302"
      unitRef="usd">4140000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMTktNC0xLTEtMjY5MzYy_8a17acd6-3ae0-44ab-9828-390ce2f640c8"
      unitRef="usd">4580000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjAtMi0xLTEtMjY5MzYy_86b29042-906a-43eb-9dad-ee1ac621a45e"
      unitRef="usd">2283000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjAtNC0xLTEtMjY5MzYy_e2d34dd4-f815-49be-a109-450db9181cae"
      unitRef="usd">2273000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjEtMi0xLTEtMjY5MzYy_896ffbf1-8ee8-4cc5-adef-0cfe0662984c"
      unitRef="usd">10528000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjEtNC0xLTEtMjY5MzYy_e61b7f12-8a1b-4817-9571-3268e19edcd7"
      unitRef="usd">11237000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjItMi0xLTEtMjY5MzYy_5c28d2c4-4cb4-4e66-8220-0b4cc2ff6e91"
      unitRef="usd">22956000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjItNC0xLTEtMjY5MzYy_f006d533-6e97-480e-99d5-e9cfccbfbae2"
      unitRef="usd">22957000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjMtMi0xLTEtMjY5MzYy_b148dcc9-6c9f-4b0c-b12e-a7d12d59f0c3"
      unitRef="usd">3775000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjMtNC0xLTEtMjY5MzYy_8b528031-d3b0-4055-bd73-a1c955f35f6f"
      unitRef="usd">3916000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjQtMi0xLTEtMjY5MzYy_85fbe3b1-feb7-4b24-8951-cdb821900fe7"
      unitRef="usd">2401000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjQtNC0xLTEtMjY5MzYy_9e27f60d-38a5-4521-900f-75a1d3244f45"
      unitRef="usd">2673000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjUtMi0xLTEtMjY5MzYy_e187c359-b462-4e79-8953-de62cf53719f"
      unitRef="usd">1277000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjUtNC0xLTEtMjY5MzYy_d56dc496-f6ba-4cb1-84c8-0c10b0635f72"
      unitRef="usd">1179000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjYtMi0xLTEtMjY5MzYy_e0c347e3-d09d-4823-bcbb-6d1b331c1b6d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjYtNC0xLTEtMjY5MzYy_826c3750-371f-4e47-98c3-f8b08323e275"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfMzE_2fec221b-a22a-464a-848b-f358bf16d1eb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfMzE_4af4f336-af92-4852-bd0a-5e345f17c18b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNDU_22046ea0-1f8b-497d-aafc-d68757689cad"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNDU_ffc9f965-19bb-4019-b362-d3e383fe7d89"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNjc_6bea6881-9fd4-4a1a-a9c0-d287cb98ae96"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246MmYwODA0Yjg2ZTc3NGIxZDhkYTFiOTI5NmY4NzJlM2FfNjc_7b52bd00-1455-442f-88f6-a6b880b1e9ae"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtMi0xLTEtMjY5MzYy_6a80cead-e7f5-462a-b806-1cd697bfc44f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjgtNC0xLTEtMjY5MzYy_62586a64-a092-4358-bdba-e8bee58961e6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMjg_46deaf74-5816-4606-ba27-dd36415cfb12"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMjg_616784ce-0e76-4755-b85c-0c7994aa0d70"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNDI_6365163d-e202-438d-bad9-8a71e8a0bfda"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNDI_676c92fe-59d8-4b67-adcc-a8bfa0631390"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNjQ_8ba7fa5e-ed93-414e-97ae-87b861c0d8a0"
      unitRef="shares">1248000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfNjQ_add2d48b-846b-423f-94d9-51b6797f888b"
      unitRef="shares">1248000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMTA5OTUxMTYyNzg3OQ_359c4d07-1d92-4e7e-ae5e-28b7805e4d22"
      unitRef="shares">1247000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZWY3NWI5ODU4YTgwNDZmMTgxOGJiNjQyZmE1MDA5YTZfMTA5OTUxMTYyNzg3OQ_9e1f5a3f-2552-4526-9c12-fdfcb39eeae0"
      unitRef="shares">1247000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktMi0xLTEtMjY5MzYy_5839bf03-2502-4c0f-9ed2-ac283a98d877"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMjktNC0xLTEtMjY5MzYy_291c7d56-96ba-417f-b67c-9cd57c9edd3f"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzAtMi0xLTEtMjY5MzYy_ce4189fa-0369-492a-b9c4-9e0beb790978"
      unitRef="usd">5793000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzAtNC0xLTEtMjY5MzYy_6c691490-0d74-45f7-a2cf-9a5d8a8a5494"
      unitRef="usd">5550000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzEtMi0xLTEtMjY5MzYy_266807f6-2bba-4a72-933c-02bf71d723cf"
      unitRef="usd">-20000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzEtNC0xLTEtMjY5MzYy_d73d5d55-092d-4b71-a126-c3496d474c9d"
      unitRef="usd">2000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzItMi0xLTEtMjY5MzYy_45731a73-f8e0-4e59-8e14-11a23070ed8f"
      unitRef="usd">15223000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzItNC0xLTEtMjY5MzYy_4c32a8fb-5362-40c9-9abc-f00441db7bd5"
      unitRef="usd">15687000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzMtMi0xLTEtMjY5MzYy_2ffa52b3-afce-49ed-9b2e-3051cb83e81b"
      unitRef="usd">20997000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzMtNC0xLTEtMjY5MzYy_6109d04a-f159-474b-9654-c41b00c7aef5"
      unitRef="usd">21240000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzQtMi0xLTEtMjY5MzYy_04090ee2-6ee6-4fe3-aff5-55af46e48bbc"
      unitRef="usd">-58000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzQtNC0xLTEtMjY5MzYy_3727ffd9-5421-4e84-ad8f-aa616e792acf"
      unitRef="usd">-31000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzUtMi0xLTEtMjY5MzYy_e2120439-a723-4bc0-818f-ff2c17712cfb"
      unitRef="usd">20939000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzUtNC0xLTEtMjY5MzYy_653b8205-c872-49e4-9fa2-b23cf5fed74c"
      unitRef="usd">21209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzYtMi0xLTEtMjY5MzYy_a0081a96-5ca9-4a36-b3ce-700857caff11"
      unitRef="usd">61876000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xNi9mcmFnOjViODY4MDIyNzFmNzRhMjhhODdmOGI1YTk2ZGZjOWVjL3RhYmxlOjc4ODMyMTVlYTFhODQ1NzBhZmIzYTEyNmQxN2JmOTRhL3RhYmxlcmFuZ2U6Nzg4MzIxNWVhMWE4NDU3MGFmYjNhMTI2ZDE3YmY5NGFfMzYtNC0xLTEtMjY5MzYy_fde38e69-3cb6-48f7-86c5-44f03173cb4e"
      unitRef="usd">63171000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4e928b3ebd744fc970718834da3534a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNC0yLTEtMS0yNjkzNjI_4464b41f-1ed1-42e5-8765-fef6f12d519a"
      unitRef="usd">6306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic500805e8441430185668274754bd251_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNC00LTEtMS0yNjkzNjI_f92545ee-afb5-47e7-be82-2964e244d7f9"
      unitRef="usd">6534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19c45e712edc45518e23cd00b61fb12c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNS0yLTEtMS0yNjkzNjI_1b7cc60e-ed44-4e1f-b900-5415f0668a1a"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a67c68bd87541d7b8aeb32a510dddfe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNS00LTEtMS0yNjkzNjI_a6abdc57-36c0-4f91-952b-09b2b6590dcc"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNi0yLTEtMS0yNjkzNjI_9fdbf9ff-034b-4628-816b-d2b131aa6768"
      unitRef="usd">6352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfNi00LTEtMS0yNjkzNjI_1645417d-61e8-49a8-95a2-7f0f47183d77"
      unitRef="usd">6590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOC0yLTEtMS0yNjkzNjI_fa0d89b4-ebb0-4630-8f41-7f0f929bfcfe"
      unitRef="usd">1401000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOC00LTEtMS0yNjkzNjI_b7f89641-1209-40a8-b65c-830afe71a9fa"
      unitRef="usd">1424000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOS0yLTEtMS0yNjkzNjI_57695b4c-2135-4c9f-9ca9-5502baded283"
      unitRef="usd">1447000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfOS00LTEtMS0yNjkzNjI_3a365b0f-fe9f-41a0-86c3-c569f225486d"
      unitRef="usd">1178000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtMi0xLTEtMjg2NTYx_e1bc8734-1a48-497d-8e27-dbe98d9a2e24"
      unitRef="usd">481000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtNC0xLTEtMjg2NTYx_568e0f5a-9d2e-43cf-8b74-1a979798db79"
      unitRef="usd">8000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtMi0xLTEtMjY5MzYy_ac9525c5-4494-414d-bb1d-3c2c06fc50ed"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTAtNC0xLTEtMjY5MzYy_95b58607-485e-441f-a9d7-3826bbce496b"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTItMi0xLTEtMjY5MzYy_5994c9f3-616f-4fcd-a426-18359e290a72"
      unitRef="usd">1319000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTItNC0xLTEtMjY5MzYy_19b3a29c-fee4-4977-af7b-6c7120baa08a"
      unitRef="usd">1083000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTMtMi0xLTEtMjY5MzYy_9330c230-5fce-489e-852c-69f7c369a7a2"
      unitRef="usd">4647000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTMtNC0xLTEtMjY5MzYy_86b18d32-c93b-48a0-82da-1fcb74a0befa"
      unitRef="usd">6393000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTQtMi0xLTEtMjY5MzYy_dde7dfef-df46-4dc0-9154-1791e73b2dcb"
      unitRef="usd">1705000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTQtNC0xLTEtMjY5MzYy_decdbb3d-8235-4940-9666-a3c65b5e45f1"
      unitRef="usd">197000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTUtMi0xLTEtMjY5MzYy_798630a0-9100-4aae-b1b9-5e6246e3c93e"
      unitRef="usd">230000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTUtNC0xLTEtMjY5MzYy_52fd7bad-37fa-493f-91dd-439f5c51d776"
      unitRef="usd">238000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTYtMi0xLTEtMjY5MzYy_848c10be-3540-4e62-bf0a-d95dbc7daf19"
      unitRef="usd">-174000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTYtNC0xLTEtMjY5MzYy_470a826e-d422-4305-a1eb-69c8132fdb63"
      unitRef="usd">-111000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTctMi0xLTEtMjY5MzYy_1d47ccbb-2de5-4c07-af0a-e6f7b65cd93d"
      unitRef="usd">1300000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTctNC0xLTEtMjY5MzYy_2cb70953-42d6-4745-9662-bb70970a8ecd"
      unitRef="usd">-152000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTgtMi0xLTEtMjY5MzYy_a5d4ac8d-c85a-4f8e-8ef9-73c6a6b9864b"
      unitRef="usd">316000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTgtNC0xLTEtMjY5MzYy_da2f3fec-2076-453b-84c9-89bcbd08387b"
      unitRef="usd">-164000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTktMi0xLTEtMjY5MzYy_c8514a7f-5d5e-4e84-a0e9-8e6ea423aa68"
      unitRef="usd">985000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMTktNC0xLTEtMjY5MzYy_62a52438-37cf-4123-b87d-48ace425bdf2"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjAtMi0xLTEtMjY5MzYy_be302631-5bd3-4069-80d3-a2e067b34007"
      unitRef="usd">-26000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjAtNC0xLTEtMjY5MzYy_3134008b-2dd8-44a3-b911-8acef5013435"
      unitRef="usd">-7000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjEtMi0xLTEtMjY5MzYy_5a396394-8fdf-4a84-9809-b0ac64c2329e"
      unitRef="usd">1010000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjEtNC0xLTEtMjY5MzYy_d285cdd9-9efd-4222-ab88-33114d1e496d"
      unitRef="usd">19000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjItMi0xLTEtMjY5MzYy_f5cda576-46bf-444e-9655-f627879c6bbe"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjItNC0xLTEtMjY5MzYy_13506a27-4899-4052-9adb-4b242a73f31d"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjMtMi0xLTEtMjY5MzYy_bec12beb-96a9-4f51-8841-771ec457a879"
      unitRef="shares">1248000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjMtNC0xLTEtMjY5MzYy_7547cd03-7e29-4fd3-bf1b-0f7d53114dbf"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjQtMi0xLTEtMjY5MzYy_7cf7a139-10c0-4bd3-8c02-632406976621"
      unitRef="usdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjQtNC0xLTEtMjY5MzYy_5594ee38-2021-4aea-ad00-c5ad1cbcee66"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjUtMi0xLTEtMjY5MzYy_f63ea940-d5d7-4a3d-b1fe-cae1cc47af32"
      unitRef="shares">1261000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8xOS9mcmFnOmVlNTc0MWUxZjRkMjQ1YmI5YjY3NDEyYzMxZDkzNDdmL3RhYmxlOjhkNGE1OWIyODdhZjQ5ZTdhNWM3MmFlNDI0OWRkNjc5L3RhYmxlcmFuZ2U6OGQ0YTU5YjI4N2FmNDllN2E1YzcyYWU0MjQ5ZGQ2NzlfMjUtNC0xLTEtMjY5MzYy_525c9933-4663-4ebc-ab9e-86311f374c60"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMy0yLTEtMS0yNjkzNjI_76bf0fc6-0ec5-4334-aae9-437edfa3a8ae"
      unitRef="usd">985000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMy00LTEtMS0yNjkzNjI_e6c15975-04d7-425f-8705-c47ab5699ad9"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNS0yLTEtMS0yNjkzNjI_a18c366f-7b54-408b-8b26-284e02cb998a"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNS00LTEtMS0yNjkzNjI_03374f6b-2ca2-4edd-85fe-de8ded7829b9"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjplMjU5MDQ3NzRkYmE0ZWVhYjMwYTlmN2Q0Yzk1MmFiM18xNjQ5MjY3NDQxNzQz_d502f880-b6b1-413b-8fbb-f223edef246d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjplMjU5MDQ3NzRkYmE0ZWVhYjMwYTlmN2Q0Yzk1MmFiM181NDk3NTU4MTQwNjc_8cb9bdc1-c304-432f-abba-a383fb31cd01"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy0yLTEtMS0yNjkzNjI_3df08d35-ef62-4a97-977c-0d8a6ba3cc96"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfNy00LTEtMS0yNjkzNjI_93cf2695-ed33-4b6e-a5dc-045b028205e2"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjo3NzgxNWQ2NGE0MWM0Mzg3ODIwNzQ0MzIwODI5MjUxY18xNjQ5MjY3NDQxNzQ5_b854bb40-095e-4b71-913d-762f7d5f9ab7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC0wLTEtMS0yNjkzNjIvdGV4dHJlZ2lvbjo3NzgxNWQ2NGE0MWM0Mzg3ODIwNzQ0MzIwODI5MjUxY181NDk3NTU4MTQwNzY_3cbd8435-915f-4c5d-9049-06ea575834bb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC0yLTEtMS0yNjkzNjI_b72c09ec-3a5a-46eb-b708-0bc14efd5860"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOC00LTEtMS0yNjkzNjI_ce55c376-db75-44b6-bf41-2bc38c267c3c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOS0yLTEtMS0yNjkzNjI_7bde6c26-9018-4e4e-bf10-8470daad0799"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfOS00LTEtMS0yNjkzNjI_ef4b8197-3a4d-44a9-888c-376033088481"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZGQ4YjFkODFkYzk2NGI3YWIzOWYzZjE5NDU3ZWRjODdfMTY0OTI2NzQ0MTc2OQ_b63a02d1-24ee-45e2-9e29-c86fb2fa9f22"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZGQ4YjFkODFkYzk2NGI3YWIzOWYzZjE5NDU3ZWRjODdfMTY0OTI2NzQ0MTc2Mw_4198b0e4-e053-466c-80c8-5f1028ee9069"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtMi0xLTEtMjY5MzYy_2cd36906-1444-4c0f-b10c-7994030c7f58"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTEtNC0xLTEtMjY5MzYy_f8b084ff-2c61-4fc5-bb87-eb8720e26ba3"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItMC0xLTEtMjY5MzYyL3RleHRyZWdpb246Y2ZlODYxMWRiOTA2NGEyNGI0NDczNTA2ZjY4NGU0NTlfMTY0OTI2NzQ0MTc0NQ_7c8c7e52-4146-4d29-bbcd-616bd4803422"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItMC0xLTEtMjY5MzYyL3RleHRyZWdpb246Y2ZlODYxMWRiOTA2NGEyNGI0NDczNTA2ZjY4NGU0NTlfMTY0OTI2NzQ0MTc2Mw_43bf1154-4e5b-4d58-aaee-a00a9b15ea5e"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItMi0xLTEtMjY5MzYy_48eb664e-1046-46b2-b029-6311d14091d5"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTItNC0xLTEtMjY5MzYy_527cc896-d543-4faf-8c57-cd312978bdb0"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTMtMi0xLTEtMjY5MzYy_6c12ceb5-9159-4f6b-9f05-5f35a07310c7"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTMtNC0xLTEtMjY5MzYy_bc988238-1657-4cd0-928f-fe95708ecdac"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTQtMi0xLTEtMjY5MzYy_bba53812-ecd8-471b-85b7-9eab94aee91b"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTQtNC0xLTEtMjY5MzYy_8f780a60-12b1-4d8e-9240-89798f9c001c"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTUtMi0xLTEtMjY5MzYy_e9ddebc7-034f-4d03-af77-6bab36f00ab1"
      unitRef="usd">962000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTUtNC0xLTEtMjY5MzYy_4fcd49ea-e481-4961-85a0-ab8098e153df"
      unitRef="usd">2000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTYtMi0xLTEtMjY5MzYy_aab1a8d4-4811-4370-be57-eaf0986276f7"
      unitRef="usd">-26000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTYtNC0xLTEtMjY5MzYy_68db213f-ae99-4585-9234-0c6db5e1dbea"
      unitRef="usd">-7000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTctMi0xLTEtMjY5MzYy_18399c7c-1565-44ea-b069-9ef378ec8cd2"
      unitRef="usd">988000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yMi9mcmFnOmQ4OWVkY2MzOWEwNTQ5MDdiZTUyMDYyZDc2ZjhiNWI2L3RhYmxlOmQ0YjMyOTYyMDVhODRiYWY4YjhhNTVjYmY0MGUzM2E3L3RhYmxlcmFuZ2U6ZDRiMzI5NjIwNWE4NGJhZjhiOGE1NWNiZjQwZTMzYTdfMTctNC0xLTEtMjY5MzYy_2e70a27d-9717-44da-a356-3a0340e85c7d"
      unitRef="usd">9000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ica2a96fc6d924f519f7d51951f05ff10_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0yLTEtMS0yNjkzNjI_12a10c34-4224-4003-841d-13d3b03b4b7b"
      unitRef="shares">1247000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica2a96fc6d924f519f7d51951f05ff10_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC00LTEtMS0yNjkzNjI_e0a2493b-2467-4f8c-8fa6-974cff686c83"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i093edc5755704a77a5d407997e7193c9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC02LTEtMS0yNjkzNjI_554305f8-cf9c-437e-8bda-5e75d2ff2d0c"
      unitRef="usd">5550000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idca3647effb04f2ea342c2cdf2754864_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC04LTEtMS0yNjkzNjI_4b2662f3-ae68-4407-b7b4-38e2ad0523c4"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c4ed4a6dfc4488183b0a1d002929bd4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0xMC0xLTEtMjY5MzYy_e66c079d-e92c-4c8a-9759-f54f3cd841a4"
      unitRef="usd">15687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i624da2b108014e5d9432f6660170cd2b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0xMi0xLTEtMjY5MzYy_f7000af8-afa9-49ac-a982-884e5441eb7b"
      unitRef="usd">-31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNC0xNC0xLTEtMjY5MzYy_b1b3c9e1-85ec-4c16-82f5-be6b7be3a723"
      unitRef="usd">21209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNS0xMC0xLTEtMjY5MzYy_22c813f5-7fc6-4be6-a61b-b60c4aea32da"
      unitRef="usd">1010000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i55d7c8a4a8ea4f46b59abb6bce9ebca1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNS0xMi0xLTEtMjY5MzYy_f6892a60-478b-4e85-a901-9d1d22f68d94"
      unitRef="usd">-26000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNS0xNC0xLTEtMjY5MzYy_60fa48c8-5078-43da-afab-4fea7daaa302"
      unitRef="usd">985000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i69e6d18dd50a48cd905a0a5c55031f82_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNi04LTEtMS0yNjkzNjI_c99c9d4c-afa1-408d-ad54-3d8c01f56688"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNi0xNC0xLTEtMjY5MzYy_180efcb8-fd5a-4c46-ae60-7109b80b9ca3"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNy0yLTEtMS0yNjkzNjI_6c812670-114c-4418-aebd-d3bde20718dd"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNy02LTEtMS0yNjkzNjI_c6a2addc-1cff-4099-aded-8f0b1d9c8586"
      unitRef="usd">67000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfNy0xNC0xLTEtMjY5MzYy_cf95b1be-b72d-4376-adef-4a052391ff30"
      unitRef="usd">67000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOC0yLTEtMS0yNjkzNjI_7ffd100a-c778-4016-8ef7-5a405fea95b3"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOC02LTEtMS0yNjkzNjI_68974000-3339-4376-8a0a-9a8a809cbc8c"
      unitRef="usd">27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOC0xNC0xLTEtMjY5MzYy_10ca69e9-5214-4bf4-b2e4-27e748c22b02"
      unitRef="usd">27000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOS02LTEtMS0yNjkzNjI_25f10c9e-c3be-4e36-af4f-f1926d060380"
      unitRef="usd">165000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfOS0xNC0xLTEtMjY5MzYy_8eb2b734-5a0f-48b5-b385-096e57840922"
      unitRef="usd">165000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ZDg3NDYzMjQ5YWE1NDY3YWI5MzcyNWUwNGZjZTQ1ZGNfNTQ5NzU1ODEzOTg0_92acc8e9-81b3-4575-a318-a63a902e6828"
      unitRef="usdPerShare">82.29</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i57c0fe8f3fe44ca1bb3d42d60548e92f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMi0xLTEtMjY5MzYy_76f709ef-9cf9-4161-a519-98fce919cb1b"
      unitRef="shares">5000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i754e1e540f8743189803095cb0207810_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtNi0xLTEtMjY5MzYy_4a79feb0-6565-47d0-afbe-c50a046ef782"
      unitRef="usd">17000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMTAtMS0xLTI2OTM2Mg_72be2ec4-7ab7-4966-b076-d11690e50e76"
      unitRef="usd">383000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTAtMTQtMS0xLTI2OTM2Mg_7e305572-09d9-46ba-9068-47a18943cc2a"
      unitRef="usd">400000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMi0xLTEtMjkwNDUy_64765102-c094-4fa5-bf00-24fd6e9705eb"
      unitRef="shares">2000000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTAtMS0xLTI5MDQ1Mg_a333ceb6-0f4d-4094-a5a4-cd7e2d5bf6da"
      unitRef="usd">135000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTQtMS0xLTI5MDQ1Mg_d20ab19a-121c-42da-b730-778a082d6075"
      unitRef="usd">135000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246ODgxNzVkODMxNDljNDEyZmFiZGZiZjdmNjE0OWU4ZDFfMTA5OTUxMTYyNzgxNA_771290b5-e7d1-4749-8513-c26c923525e9"
      unitRef="usdPerShare">0.75</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i54c13baf41784270bd9bbe04beeb0864_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTAtMS0xLTI2OTM2Mg_c64ae7dc-2be0-4850-8910-9ef3cc730ec2"
      unitRef="usd">957000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTEtMTQtMS0xLTI2OTM2Mg_0869a65f-f875-4fdb-b6b6-1d2f61d95526"
      unitRef="usd">957000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie43db347832e437da36ad93d501ee972_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMi0xLTEtMjY5MzYy_5f9ac551-b1fa-4fe1-8357-7459203224b6"
      unitRef="shares">1248000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie43db347832e437da36ad93d501ee972_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItNC0xLTEtMjY5MzYy_f5544054-05a3-47a7-84bb-834fcab6d532"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e2117194be2466c95399cea80f46988_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItNi0xLTEtMjY5MzYy_65465633-e7e6-4614-a35f-b3de0c6ea8ed"
      unitRef="usd">5793000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e727936efcb4ba8ab5f6da9a5878ef5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItOC0xLTEtMjY5MzYy_f6832192-2302-455f-ab58-bebe18a37bad"
      unitRef="usd">-20000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcd710db690d4726a106486c05547cc3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMTAtMS0xLTI2OTM2Mg_839fa1b4-d528-4d87-b348-dc0f016aa3e4"
      unitRef="usd">15223000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic81eccef1dab414a9b030474788c13c4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMTItMS0xLTI2OTM2Mg_98a05fb8-50d2-4a89-8a32-0e5a5dae2e3a"
      unitRef="usd">-58000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOmE1MGEyNDM3YThhOTQzYmFiODUwNzNlZmYxMTc2YzVlL3RhYmxlcmFuZ2U6YTUwYTI0MzdhOGE5NDNiYWI4NTA3M2VmZjExNzZjNWVfMTItMTQtMS0xLTI2OTM2Mg_8e84def1-9949-4e3b-9549-08d0453a8fc3"
      unitRef="usd">20939000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iba0cff47492f4decb13158e416e6a4a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0yLTEtMS0yNjkzNjI_f010cadb-8dbf-4190-bf28-603593e437bf"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba0cff47492f4decb13158e416e6a4a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC00LTEtMS0yNjkzNjI_6ca6f59f-4dc4-4321-8b30-c2754ca4375e"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if725c7c7814e4cf4a3317e39e252bdb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC02LTEtMS0yNjkzNjI_9ce3ed7c-bc65-4e40-83ed-75cc4c260c0e"
      unitRef="usd">4661000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a853e0354f546ee8636eb887f31fb19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC04LTEtMS0yNjkzNjI_07b9fc65-40d9-45da-8208-fcd772467d23"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86bf5b7641ca44ddb2ad53d7bd36d254_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0xMC0xLTEtMjY5MzYy_29edce22-bca5-4951-bc4f-37db50c483bd"
      unitRef="usd">16324000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i926df607944244f1a8641e0053d1d3b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0xMi0xLTEtMjY5MzYy_9d76779d-07e4-477a-b70c-1f62c56a9e54"
      unitRef="usd">-5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i950969f530e94f1395cc3b19fdc321a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNC0xNC0xLTEtMjY5MzYy_0edcb7bf-a602-4800-abac-6b367c9f1ae1"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNS0xMC0xLTEtMjY5MzYy_069fef97-422c-4947-815f-b6e71f4d9248"
      unitRef="usd">19000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2c4fc949dc9b4e8da603b9bafd8f0af1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNS0xMi0xLTEtMjY5MzYy_0ff4d119-49f5-40a0-ba8e-5174be62e910"
      unitRef="usd">-7000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNS0xNC0xLTEtMjY5MzYy_38ea8ace-8e66-4f59-8d05-4b3fc0b29e0a"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i49700eb36c934cf4aca1f0807d4295a8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNi04LTEtMS0yNjkzNjI_c00c77ba-d6a6-4ad6-9ca8-3993082b4d3f"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNi0xNC0xLTEtMjY5MzYy_5a116070-35bd-4a57-a03a-0f9e6c17b4fe"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNy0yLTEtMS0yNjkzNjI_ab0e93bd-2f9e-44f5-bb2e-a83b73206d1c"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNy02LTEtMS0yNjkzNjI_614aa8eb-d124-4f4b-b7dc-ccf940f50f24"
      unitRef="usd">73000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfNy0xNC0xLTEtMjY5MzYy_a25b64b5-53de-4ef3-9849-2930d2a7cb70"
      unitRef="usd">73000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOC0yLTEtMS0yNjkzNjI_10951b6c-5975-4355-ab98-e3e6e61fb0b2"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOC02LTEtMS0yNjkzNjI_e683d8be-8e31-493a-bdc8-395794c4441a"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOC0xNC0xLTEtMjY5MzYy_944571b0-7531-4234-849b-9eb02b6f54e0"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOS02LTEtMS0yNjkzNjI_3f3e9410-3d60-4bbe-925d-c6e470f1d8e2"
      unitRef="usd">131000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfOS0xNC0xLTEtMjY5MzYy_501ebc1c-379d-459a-b003-0e9227bdf2ca"
      unitRef="usd">131000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246OGIzZjg0OGIzN2M1NDY0YThmM2FlYWRhZDUyZWU2YzZfNTQ5NzU1ODEzOTg1_c551ec7f-51aa-4ddc-91e1-28f29a731f61"
      unitRef="usdPerShare">63.78</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMi0xLTEtMjY5MzYy_d2f78185-4161-46b4-b0b5-57e8a9e6087a"
      unitRef="shares">6000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id3933d5fdf9e45f9a4cc67b6bdeb6967_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtNi0xLTEtMjY5MzYy_9a33edf3-80a9-4c9a-b0e4-35fe2be733f7"
      unitRef="usd">19000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMTAtMS0xLTI2OTM2Mg_08093968-f2b9-4745-9070-5f98c7f4938e"
      unitRef="usd">334000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTAtMTQtMS0xLTI2OTM2Mg_f99b08f8-c7e8-4882-8a62-dda5480d45c0"
      unitRef="usd">353000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ic20990f3ec3a4ef298f8ba761aebedc7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMi0xLTEtMjkwNDYw_73e3e778-43f3-4637-8bc8-f66c4ae09a74"
      unitRef="shares">2000000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTAtMS0xLTI5MDQ2MA_863eaa0e-af1e-4d61-8185-fab14f391693"
      unitRef="usd">91000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTQtMS0xLTI5MDQ2MA_32b07d7e-5ac1-40cf-a3d2-d7640b722f59"
      unitRef="usd">91000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMC0xLTEtMjY5MzYyL3RleHRyZWdpb246OGMwMDZlN2YwNWI3NDM0MzhjODExZTkxYjUxZTUxMTVfMTA5OTUxMTYyNzgxNA_6e17cbb4-50df-4b41-9087-2cb5e9525ce7"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i2fba1405a85445909b8adba0046a89ad_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTAtMS0xLTI2OTM2Mg_df9a51c5-371f-4898-96d5-bfe2e8d85f62"
      unitRef="usd">932000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTEtMTQtMS0xLTI2OTM2Mg_55a7cca4-4898-492f-81af-3e20413219d9"
      unitRef="usd">932000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ief6b15b37c004ae0aeeafce457d5b708_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMi0xLTEtMjY5MzYy_c9957f62-7ff7-466c-99d2-9477b59c33ee"
      unitRef="shares">1255000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief6b15b37c004ae0aeeafce457d5b708_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItNC0xLTEtMjY5MzYy_699118ba-8896-4f4c-923c-ae22b2f3dc5f"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3dd718f446d4121a028b08422617832_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItNi0xLTEtMjY5MzYy_ec477589-b9cd-4b01-8c21-3992d6b01402"
      unitRef="usd">4867000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c3b3b01542f435fab6816bf508c9fe0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItOC0xLTEtMjY5MzYy_5d8bb7de-43ac-45da-ac7a-349abbb8c0db"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbf32ea5502c43f99d1ebd15aff8ab22_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMTAtMS0xLTI2OTM2Mg_5a92e958-e408-43ec-9c79-c1f14b3ae263"
      unitRef="usd">14986000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie42aa0aa14db49ed9e43dfc6d3bb5d7e_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMTItMS0xLTI2OTM2Mg_70f5f62c-5595-40d2-8828-7a591e7ed07d"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70473ad0789b4b03b86eb8db467a296b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yNS9mcmFnOjc1N2IwNTk5Yjk0MDQ2NzY5YjYzMjNmZDMxNDJjMDg4L3RhYmxlOjM4NTk1Njc2MTBlMDRmMjA5ZWZkNDUxOWIxNzA1ZGM4L3RhYmxlcmFuZ2U6Mzg1OTU2NzYxMGUwNGYyMDllZmQ0NTE5YjE3MDVkYzhfMTItMTQtMS0xLTI2OTM2Mg_e7078953-5062-4571-9698-8c32113363c5"
      unitRef="usd">19915000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNC0yLTEtMS0yNjkzNjI_75e6c0c7-48be-4f27-a94f-03178dbde37a"
      unitRef="usd">985000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNC00LTEtMS0yNjkzNjI_62a52438-37cf-4123-b87d-48ace425bdf2"
      unitRef="usd">12000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNi0yLTEtMS0yNjkzNjI_7f167b46-d135-4586-a011-d6f9b6e61904"
      unitRef="usd">94000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNi00LTEtMS0yNjkzNjI_e7502f37-4ed4-4728-8a89-b34be40efc59"
      unitRef="usd">80000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNy0yLTEtMS0yNjkzNjI_2de473e6-f960-4455-bab1-7d3c97991821"
      unitRef="usd">546000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNy00LTEtMS0yNjkzNjI_20250f92-7392-458b-9798-c1c198558f3b"
      unitRef="usd">445000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOC0yLTEtMS0yNjkzNjI_7093aab0-937e-400d-ba63-1b69a143c867"
      unitRef="usd">165000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOC00LTEtMS0yNjkzNjI_0c13f154-6dd6-45b4-8dd9-6fcc91d49bcc"
      unitRef="usd">130000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOS0yLTEtMS0yNjkzNjI_6bdce9c0-702b-43c3-ab70-5502b809a30d"
      unitRef="usd">481000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfOS00LTEtMS0yNjkzNjI_7170d49d-e903-4a48-91de-a478f5afec01"
      unitRef="usd">8000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTAtMi0xLTEtMjY5MzYy_3482d105-8028-4c59-8b26-28ddee18e457"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTAtNC0xLTEtMjY5MzYy_0efd1754-c365-4e84-833a-16c359babaf7"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTEtMi0xLTEtMjY5MzYy_86380142-4b23-4060-9574-5502a0f1f239"
      unitRef="usd">-303000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTEtNC0xLTEtMjY5MzYy_80086ff9-d741-46ac-8d45-ada43844e79c"
      unitRef="usd">-651000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTItMi0xLTEtMjY5MzYy_56e5451b-9c79-4dc5-b6e3-803caf1dbab7"
      unitRef="usd">-256000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTItNC0xLTEtMjY5MzYy_bb60dbe6-3bf7-41e7-a864-daa712f321d3"
      unitRef="usd">-96000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTMtMi0xLTEtMjY5MzYy_26db7455-2919-4957-b8a3-5cad462a6f41"
      unitRef="usd">-63000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTMtNC0xLTEtMjY5MzYy_044f6f07-a9b9-4123-af6a-8420a13cc43e"
      unitRef="usd">-182000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTUtMi0xLTEtMjY5MzYy_576287c3-ba57-4ce4-8f4c-8eb3228ebb84"
      unitRef="usd">-635000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTUtNC0xLTEtMjY5MzYy_5b54d600-9dcb-41db-90e2-f940d27cf47b"
      unitRef="usd">-699000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTYtMi0xLTEtMjY5MzYy_27d01f12-8d40-4f68-a91d-4a983063fbdb"
      unitRef="usd">227000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTYtNC0xLTEtMjY5MzYy_d31a55f3-f700-477c-8a19-4490fdb1e2d0"
      unitRef="usd">-53000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTctMi0xLTEtMjY5MzYy_301149a4-d12d-4036-affc-473c552c2736"
      unitRef="usd">-26000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTctNC0xLTEtMjY5MzYy_bcf0a333-610b-47eb-ba9d-38d0e11b835f"
      unitRef="usd">54000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTgtMi0xLTEtMjY5MzYy_3a4e38d6-0726-438e-bb5e-ef4fa327c4ca"
      unitRef="usd">-272000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTgtNC0xLTEtMjY5MzYy_a621d347-f6e6-4f40-b806-956ff9035061"
      unitRef="usd">-91000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTktMi0xLTEtMjY5MzYy_c5bb151c-6dc7-4fbb-8b08-5a2f73a8e052"
      unitRef="usd">-161000000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMTktNC0xLTEtMjY5MzYy_da2d6ff7-68b8-44d7-806a-2687c208d121"
      unitRef="usd">-112000000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjAtMi0xLTEtMjY5MzYy_5f47ae5d-d11c-48ff-80fe-d7019b04c7ab"
      unitRef="usd">-543000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjAtNC0xLTEtMjY5MzYy_921a7c0f-fafd-43df-b04b-30ce779e1185"
      unitRef="usd">-1657000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjEtMi0xLTEtMjY5MzYy_7934b5ec-847e-4aff-b0b5-b46d2b67c4c6"
      unitRef="usd">1744000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjEtNC0xLTEtMjY5MzYy_56991fdb-e3e5-4fe9-b012-0f5d81f1b469"
      unitRef="usd">1840000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjMtMi0xLTEtMjY5MzYy_fdfafcf8-5b9a-412d-8e9a-f85751ccad66"
      unitRef="usd">527000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjMtNC0xLTEtMjY5MzYy_f1b44007-121d-4628-974b-1d720b31844f"
      unitRef="usd">613000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjQtMi0xLTEtMjY5MzYy_5780b1d4-6ede-4cf9-b7ea-99af3a0c955d"
      unitRef="usd">167000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjQtNC0xLTEtMjY5MzYy_14ec158c-f7c9-4586-a233-22fc54224560"
      unitRef="usd">119000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjUtMi0xLTEtMjY5MzYy_1d64dd5c-f559-4f94-9670-0f48e93ed7a7"
      unitRef="usd">324000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjUtNC0xLTEtMjY5MzYy_9d9a8c6f-cfb5-4817-a9cb-8b87fa68dfd3"
      unitRef="usd">506000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjYtMi0xLTEtMjY5MzYy_6cdd30bc-aff1-4fde-afd5-150a0581031a"
      unitRef="usd">551000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjYtNC0xLTEtMjY5MzYy_f6c81445-f681-4999-8b39-7e42ca775fd0"
      unitRef="usd">807000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjctMi0xLTEtMjY5MzYy_dd5edc5a-2ab4-4e9e-89be-bd610a3e2956"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjctNC0xLTEtMjY5MzYy_343061ba-7539-47a3-9cfb-cd388843e2b1"
      unitRef="usd">28000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjgtMi0xLTEtMjY5MzYy_e20b35e5-0547-4c48-b50e-a102d0e69cfe"
      unitRef="usd">109000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjgtNC0xLTEtMjY5MzYy_cb284359-724f-4556-b011-4ebd042507fe"
      unitRef="usd">247000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjktMi0xLTEtMjY5MzYy_dc91e8f4-8c18-4798-8029-28b1e1df837f"
      unitRef="usd">5000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMjktNC0xLTEtMjY5MzYy_bd06d9b2-a679-477b-a8f3-850c2a1c1d8f"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzAtMi0xLTEtMjY5MzYy_97fc5cb8-0777-4fe8-b66c-15978050063f"
      unitRef="usd">-826000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzAtNC0xLTEtMjY5MzYy_3f2aac8c-8196-4899-8278-b6979b95d78e"
      unitRef="usd">-1070000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzItMi0xLTEtMjY5MzYy_33998de1-e3bc-46ca-94ce-98f20858f71f"
      unitRef="usd">97000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzItNC0xLTEtMjY5MzYy_3603e528-acae-4181-85b2-a4bb6d03e085"
      unitRef="usd">94000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzMtMi0xLTEtMjY5MzYy_1d48a42b-5a4f-40cb-9cb7-283da15633d6"
      unitRef="usd">400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzMtNC0xLTEtMjY5MzYy_b763ce7e-cea7-4865-840c-22fa0892f4f2"
      unitRef="usd">352000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzQtMi0xLTEtMjY5MzYy_dc557444-5b73-421a-b9e3-eebea3de5966"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzQtNC0xLTEtMjY5MzYy_2da1052b-7a6d-4937-80b4-e60449777980"
      unitRef="usd">500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzUtMi0xLTEtMjY5MzYy_7c6ead32-e330-4634-8123-52a367a5227b"
      unitRef="usd">969000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzUtNC0xLTEtMjY5MzYy_bf6ecb91-80ca-4c0e-a72c-5e3200db7941"
      unitRef="usd">945000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzYtMi0xLTEtMjY5MzYy_b40b502e-f5bf-4f23-b92e-a48bde653089"
      unitRef="usd">-135000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzYtNC0xLTEtMjY5MzYy_fa07f9c7-de07-4fba-9c85-e077f8957206"
      unitRef="usd">-91000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzctMi0xLTEtMjY5MzYy_94063c6d-f199-49d9-9047-afe3605ecb9f"
      unitRef="usd">-1406000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzctNC0xLTEtMjY5MzYy_8a995b55-d687-4433-985e-2c5400cd133f"
      unitRef="usd">-1794000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzgtMi0xLTEtMjY5MzYy_9865ee03-93d0-49c4-ac85-d53e0fc81fae"
      unitRef="usd">13000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzgtNC0xLTEtMjY5MzYy_634d9f7d-ee54-40d0-bf3a-4969e068d7b0"
      unitRef="usd">-18000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzktMi0xLTEtMjY5MzYy_0797ea18-059a-4bb9-952b-067bda4d25ee"
      unitRef="usd">-476000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfMzktNC0xLTEtMjY5MzYy_54c75eac-8666-4279-bcae-721535e90f87"
      unitRef="usd">-1042000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDAtMi0xLTEtMjY5MzYy_d3623b91-d30a-4848-bdb7-8523feb953b7"
      unitRef="usd">5412000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i950969f530e94f1395cc3b19fdc321a6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDAtNC0xLTEtMjY5MzYy_7ee3c96e-e6c3-4997-839d-06a3a23b3ae5"
      unitRef="usd">5338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDEtMi0xLTEtMjY5MzYy_c86cedcd-eb2d-4499-b9b7-95b1a493e07e"
      unitRef="usd">4936000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i70473ad0789b4b03b86eb8db467a296b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8yOC9mcmFnOjMxMzQ5MjliNzdjNTQ0NmY4YzNkOGJjN2UwYjI0NGYxL3RhYmxlOjBlMmYwNWQ1NjBjYTQwMTk5YTBiYmY2OTI1NDZiODQxL3RhYmxlcmFuZ2U6MGUyZjA1ZDU2MGNhNDAxOTlhMGJiZjY5MjU0NmI4NDFfNDEtNC0xLTEtMjY5MzYy_a099d8a6-3149-4aa1-8623-ad802c7d9543"
      unitRef="usd">4296000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfMTgxMw_9482e165-ccde-40d0-bf0c-a6a3c0ea6960">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Condensed Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $34 million from Prepaid expenses and other for the three months ended March 31, 2022.These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfMTgxNw_f2b03de3-c820-4f5b-ba15-a7183320e0b6">The accompanying Condensed Consolidated Financial Statements and related Notes to Condensed Consolidated Financial Statements of Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2022, included in our Annual Report on Form 10-K filed with U.S. Securities and Exchange Commission. There have been no material changes to our organization or summary of significant accounting policies as disclosed in that filing. Beginning in the first quarter of 2023, we reclassified changes in income taxes prepaid and receivable from Prepaid expenses and other to combine with changes in income taxes payable as Income tax assets and liabilities, net within Operating Activities on our Condensed Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand cash flow movements. Prior periods have been revised to reflect this change, resulting in a reclassification of $34 million from Prepaid expenses and other for the three months ended March 31, 2022.These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and include all adjustments consisting of normal recurring adjustments that the management of Gilead believes are necessary for a fair presentation of the periods presented and are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period. Certain amounts and percentages in these Condensed Consolidated Financial Statements and accompanying notes may not sum or recalculate due to rounding.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i40c694f02592405083bdaf13c4316671_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfODI0NjMzNzIxNzI0OQ_781596d0-a22f-486b-9ed0-c26de67816de"
      unitRef="usd">-34000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="i40c694f02592405083bdaf13c4316671_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNC9mcmFnOjVjODY3ODRiY2FlMzQ1MWQ4MjY0NTIyNzk0NjZhNzk4L3RleHRyZWdpb246NWM4Njc4NGJjYWUzNDUxZDgyNjQ1MjI3OTQ2NmE3OThfODI0NjMzNzIxNzI0OQ_96886b78-4808-4314-a704-418110b706da"
      unitRef="usd">34000000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU5NA_f8235d6f-91d2-401c-9cae-b40515920231">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liver Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Chronic hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Chronic hepatitis B virus (&#x201c;HBV&#x201d;) / hepatitis delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Liver Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Atripla, Emtriva, Sunlenca and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revenues from Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues recognized from performance obligations satisfied in prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue share with Janssen and royalties for licenses of intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Generally results from receipt of advance payment before our performance under the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU5MQ_f1e94614-7579-4844-a195-a8cd9e59cc8c">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liver Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Chronic hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Chronic hepatitis B virus (&#x201c;HBV&#x201d;) / hepatitis delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Liver Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:23.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Atripla, Emtriva, Sunlenca and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston, Jyseleca, Ranexa and Zydelig.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d19c32e455643b7b05ce940c7be0801_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0yLTEtMS0yNjkzNjI_8a46b500-21f1-42cc-9a7e-8a867739098b"
      unitRef="usd">2161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15a53598b2a34113a51cf1d6114c3cd5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC00LTEtMS0yNjkzNjI_c876bd10-56e0-480a-ba4a-cc95167d8893"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4583fc82b7754ac98fc2a9af1773de2e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC02LTEtMS0yNjkzNjI_f82421ba-c0c7-4e01-bf0c-28eefc83c6d7"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie597530e49e3466db13821646fdb7c32_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC04LTEtMS0yNjkzNjI_8b681dac-fc65-4379-9fdd-c7b0ecfd441d"
      unitRef="usd">2677000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77ab2be40e2f4be1931d2379972c1dcd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xMC0xLTEtMjY5MzYy_92c5f12e-e508-4664-bf72-cb19a909a48c"
      unitRef="usd">1706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5290416165d4826bca76f94fb4de05d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xMi0xLTEtMjY5MzYy_d7a97d17-63ac-4fc3-852e-fac68369f699"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12b086ae57d3416c93424778ee7a4f09_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xNC0xLTEtMjY5MzYy_7b22e792-7f35-4cda-99c6-b960947ef9ad"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4db3222bd3a24a5792f21001e0ed9f4a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNC0xNi0xLTEtMjY5MzYy_f80a3bcc-3d5b-4d2f-893f-6a1a18216978"
      unitRef="usd">2151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45b0c18878c845d39d2faca137c3daea_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0yLTEtMS0yNjkzNjI_4f591c45-542e-4a77-bdf3-cdca9e213c0e"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d1f35c3663a4c68be7e9d1d6e2fcdbd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS00LTEtMS0yNjkzNjI_81c14b66-8cc2-4898-b7b9-313ecb750b94"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id43b59bee267497cb6c22732ff724eed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS02LTEtMS0yNjkzNjI_3bf4b5f9-bec3-405f-9e52-1831c57439af"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b1d0155e0d845058e2dd8f560ef7b2d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS04LTEtMS0yNjkzNjI_9ee3f37e-2a00-45dc-84da-f8ae6f830302"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24a40544f07842abbbd26abe8bd230fd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xMC0xLTEtMjY5MzYy_7bcdca06-bfcd-4050-8f91-438a05b281f0"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie95cce301e0e44138eda0e51e00f4923_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xMi0xLTEtMjY5MzYy_676079f3-cf9e-4f16-a1cb-6c0346b6a6a1"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i542b657a0c2744368808c312bbc5c2db_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xNC0xLTEtMjY5MzYy_d45d6d25-ebc0-4b9e-803a-bc901db1156b"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97d4aaab1fff4ee3b95ab9943ea6d302_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNS0xNi0xLTEtMjY5MzYy_10aa9e4d-0494-4dc9-b2b8-e26662dfac4a"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67eba08e27714767a82df70e121e94cb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0yLTEtMS0yNjkzNjI_b14b762c-fb00-4f4d-860e-598549e32b76"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1d65f9df40f4dd5b0c639e53db4dd9e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi00LTEtMS0yNjkzNjI_7d16216a-3a57-49f9-bb3d-13f54ece53b2"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee89668eca8340e4ad175cab099b67cb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi02LTEtMS0yNjkzNjI_1fc47db1-a6a8-4115-a0f1-ec27cec1dab2"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57ad68b551814279bf5718118b152459_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi04LTEtMS0yNjkzNjI_bcbe22bf-4c59-4c36-8b6c-68a108c12131"
      unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifee012c5d38d4893b3cb19e18351ab58_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xMC0xLTEtMjY5MzYy_e278c9fd-68f0-4466-b22f-14dd5b2268dc"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5d8f1357d074b21a89698ec5b723bea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xMi0xLTEtMjY5MzYy_d6e2d6ae-d3f5-46f7-80d7-94a5bfe57fe5"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58599254220a42feb444edc701be833b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xNC0xLTEtMjY5MzYy_2d538313-0d01-4212-8af8-e5c17c0427fc"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8b4e751a2264ec9bb98b846928280c0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNi0xNi0xLTEtMjY5MzYy_744529e4-28c4-4ebb-ac49-8c62ab03cf5e"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e42fc11fdc540d7ad0245cb8d39d2e2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0yLTEtMS0yNjkzNjI_1a028c69-aa53-49a5-a01a-f2b5d1e20869"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41bb316ef34b4eaf906de30392736fed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy00LTEtMS0yNjkzNjI_a2b0931a-3cc2-4596-b313-f77afa2156ee"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5df3944f730544d1996bddf0bf5a8db4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy02LTEtMS0yNjkzNjI_83bd989f-ff2e-42f1-afd1-186f5e02ce2f"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf12dba5416c42248c844b94f20ca082_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy04LTEtMS0yNjkzNjI_f389dd8f-93e3-40b0-bceb-bdad2058c0cb"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cc3f768136e47c0936791b4392b8289_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xMC0xLTEtMjY5MzYy_082469b7-576c-4199-8941-3b3ecdb0f3d3"
      unitRef="usd">457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i666aecd5c047480a9babba6ea8039520_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xMi0xLTEtMjY5MzYy_c04cb8b3-f030-4684-bcfe-1d2dc988c823"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6d8b014f89141aba79e057fe12638a3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xNC0xLTEtMjY5MzYy_b7edb7f9-8b9f-40e9-b048-805936315dae"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a79f1e6c45d4bb897c9a98013083049_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNy0xNi0xLTEtMjY5MzYy_68f7fca7-e7ee-4431-a054-baf6e3b8d4ea"
      unitRef="usd">582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib04f6c7e78c647b1807546ae78fdc62b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0yLTEtMS0yNjkzNjI_06da9315-3fe9-4788-a7f9-ab3431a5f0be"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia50a21232d20463095b52d48490cc6b3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC00LTEtMS0yNjkzNjI_de950eec-db69-4f58-95d9-09611a606588"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i997dc50c936a478aac1cc176a14d9ef9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC02LTEtMS0yNjkzNjI_fb1dd7fc-e5df-4f55-86ba-215561056231"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i689fc87158304986aa89fae3a01ed245_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC04LTEtMS0yNjkzNjI_c1645207-759a-4270-be22-1437ba3d6913"
      unitRef="usd">317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91e1f772d34742e8a8d2a4145828b021_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xMC0xLTEtMjY5MzYy_b5565e79-35c3-4f23-bc11-b887f52b7e26"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i771add6d73314919a6dd20ce750a969c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xMi0xLTEtMjY5MzYy_a041e5fb-3a87-4aa1-bd88-09e64ef5bd52"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25c19b71fcc4402098fe7a9aa8fc8eed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xNC0xLTEtMjY5MzYy_eeb5e6a1-fa5d-4f14-9d20-bb33ada2596c"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i010418975aea40d895ec2686ed330d28_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOC0xNi0xLTEtMjY5MzYy_b6267fc9-4917-473a-bfdc-1730fff68bbc"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i450d6b2c88a24625a9c496cecdc5bf52_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0yLTEtMS0yNjkzNjI_96ca130e-4d3b-4bfa-8809-27bf1da580be"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7af1b22c3f847fe9bdfc0f5f119ae02_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS00LTEtMS0yNjkzNjI_60bada2e-f63f-4650-87e2-2d69970d860b"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd3a66e75c7047d3aafef3137fa6445b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS02LTEtMS0yNjkzNjI_80c94a58-99fd-4970-9d37-f44c906816d0"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bdbd845c58c46e8adb8c44ae5684498_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS04LTEtMS0yNjkzNjI_cb2cc874-5074-47bf-aab2-9c38e1b1e337"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i591c01bce34640e58557c165d695cf0b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xMC0xLTEtMjY5MzYy_5c80b9cd-c7ba-4b14-82d2-317b5747c30b"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6494ec78b3ce416bb07ce891ecf80d8a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xMi0xLTEtMjY5MzYy_9987373c-fd6b-4e24-88a4-8acd38eaa06d"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf6b130e3bfb4d008f422f886fe3bc7c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xNC0xLTEtMjY5MzYy_e464c1c7-c0cf-416d-b747-b2ec97e23578"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id56aa7d6f82f411ca07a2196837c3857_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfOS0xNi0xLTEtMjY5MzYy_ccd99c28-d6f4-40f3-90db-e1a3cc7f51e9"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i792f4398c7264a34bbfbb2e0141d0569_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMi0xLTEtMjY5MzYy_b752629b-1d23-4a95-af43-d0672e79be28"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36284b9953e94a87b53a58bccfc5e336_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtNC0xLTEtMjY5MzYy_fefdbeae-0312-4989-beed-d1d6ffcdd475"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36cc56c685bc447bb351b98590992488_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtNi0xLTEtMjY5MzYy_f7089b63-1a04-47d3-861c-5c32ad8a4ac3"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i086e12e3ad3e4741a380acf23831618d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtOC0xLTEtMjY5MzYy_b02accb0-b8a5-468b-b4ce-05f8682ac8f2"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30546a0c6b624dac91f3b66455061d66_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTAtMS0xLTI2OTM2Mg_f05165b8-477f-44d4-83fc-adeaa8fe218b"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id40dd460e84042629c0071805ed4729f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTItMS0xLTI2OTM2Mg_4d99554c-b5fe-4847-a613-0395457b2894"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic729d8e783a647028632b5ba40064638_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTQtMS0xLTI2OTM2Mg_68a72ecd-1854-4176-85f1-357eab2cf113"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81ca1b72c6804ecbbc1b605f601091f0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTAtMTYtMS0xLTI2OTM2Mg_76133201-a885-4796-9dfd-64dc9df1a2c0"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dda79e450e447408d931455f2f8f8cc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMi0xLTEtMjY5MzYy_a6bf710b-1a5c-430c-b0d6-a22ca08a11fd"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b399c95ac1b4246aaa5c0aaef8cd353_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtNC0xLTEtMjY5MzYy_cc30bb4c-164f-4b92-a6b4-315fa4875dec"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c92a43cc92a47a6ab65bfa263d351eb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtNi0xLTEtMjY5MzYy_22453f8f-973d-4ae3-bf8e-b0a6f071d5e9"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf7898842ff5448ba66ef0de574a341f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtOC0xLTEtMjY5MzYy_18d6fc90-c9c9-4913-81b7-9c3fc5f21181"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i344ba46eb7a04d56bd7de76ee16b62fe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTAtMS0xLTI2OTM2Mg_466724cd-9020-43ce-abed-0e92b3c68dea"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cbe81d744b24ac3aadfd0def0c3af1d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTItMS0xLTI2OTM2Mg_51ded9f6-8578-4007-a155-7040071da279"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1b6d840cf5d4035a31088c19454672b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTQtMS0xLTI2OTM2Mg_bd32fcbc-2cf6-4c04-8421-2fc542deb9ec"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06a18873aa0490ba83b5bddcaea2946_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTEtMTYtMS0xLTI2OTM2Mg_d685f793-5622-40cd-83f3-1ddfe8a5be83"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d0b6766fa594a13aa0be791f84893f3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMi0xLTEtMjY5MzYy_5204e4a5-ec30-4159-852a-addfe1663597"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e710d7e374b479fb14aabe9b50fd5ea_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItNC0xLTEtMjY5MzYy_bcabb92d-e5ff-4f46-bdc8-2f4f0df8695e"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fd6c3585eea4f94b84aff749f526ac8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItNi0xLTEtMjY5MzYy_1dc3342a-9d27-44b0-b851-16aea9d433c7"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie37160460cc94423a6e38cb49e84b00a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItOC0xLTEtMjY5MzYy_c3727003-9ba1-46e7-b0eb-b29769e91e6a"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i458cd9c1bb9a44bab1804ab82add9ef0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTAtMS0xLTI2OTM2Mg_8835b6b4-5350-4ec0-a6f1-97a8880567e5"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d671c5a402543c6bc98a00e54b218e2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTItMS0xLTI2OTM2Mg_e8b99f9b-1827-4523-8adf-741bd51806a6"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78556fab5a594eaaab678aa5b2b70c92_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTQtMS0xLTI2OTM2Mg_50ccf8a9-57a2-4193-a41a-81a6d6300dfb"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11f7ccbb67b3412d94eb07273cf08f82_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTItMTYtMS0xLTI2OTM2Mg_dbd1fb5b-f17e-4a07-afb1-7171170f189a"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6292c28980b643479da9447ce2a9f473_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMi0xLTEtMjY5MzYy_41533a72-1127-4be3-8790-47a15e4e0b58"
      unitRef="usd">3364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21dec2a2b762423e9ef5905cf0aa9cf2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtNC0xLTEtMjY5MzYy_76c120f6-f684-4018-9ce4-c1c6ec48426e"
      unitRef="usd">528000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i603cb3b83ce14179bf04d0aaf6a195a1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtNi0xLTEtMjY5MzYy_197f73f8-180c-454f-8e44-f4028abee0db"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f30cf0bd3dc4f13a115c97982ce981f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtOC0xLTEtMjY5MzYy_1b58c7c1-4a62-4a54-adad-3cbe00505d84"
      unitRef="usd">4190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bd48e1d614c42f89931926809fc82a7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTAtMS0xLTI2OTM2Mg_d8657ce1-640e-416f-b403-6aef1e2fde3e"
      unitRef="usd">2862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7848b323c65b46e5a5d0b843644615ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTItMS0xLTI2OTM2Mg_3d63462c-ad9a-43ca-b2fc-dd679da29757"
      unitRef="usd">550000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedfb95b671ed491e8b70938724cb0c56_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTQtMS0xLTI2OTM2Mg_73f28316-5753-439c-a9a6-b13e49001f63"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15ccec38bc81487a98ac2ef0ac2fb11c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTMtMTYtMS0xLTI2OTM2Mg_04848d9e-46bc-48c9-bbfe-2809318b6a86"
      unitRef="usd">3707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9988c03dff4e4d05a5ff6badc0ed5ccc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMi0xLTEtMzAxMzk3_a2c84a75-6ac1-4926-9d80-c102a94119f2"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cb5ff7d45f6422e846f8796c101b1cc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNC0xLTEtMzAxMzk3_9d1a980f-7ad4-4e3e-bcc4-50158458fec0"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic00e734d3ce3408487ef17422e54a433_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNi0xLTEtMzAxMzk3_4b97a454-8bd3-42d0-906b-ff867a36fc08"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6054258e4b146609392bf5d13038e6d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctOC0xLTEtMzAxMzk3_198b5a81-42d5-4dd4-ba48-43f2b238951e"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61f67ef40bc148158d12ec2015ed480e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTAtMS0xLTMwMTM5Nw_8048dc41-16e9-4545-976b-0cd357ca1167"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i571a1be950c440d789469a2f4d9abfcb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTItMS0xLTMwMTM5Nw_a7c2bd18-0583-4a76-99bc-2011f2b9eb44"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea41115ebe564139a2c8659237f58346_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTQtMS0xLTMwMTM5Nw_44bbab63-7a5c-4071-bae1-36caec96cf1c"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib25c20fa74df4d2ab27b7cc2ef3698aa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTYtMS0xLTMwMTM5Nw_aa9a7058-0d1e-4daa-83fd-341142af78c1"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a272399a10347cb814cac2d9dfd148e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMi0xLTEtMzAxMzk3_6bacd194-6f74-4f08-be12-94d3aa12fd87"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if463eff382504416bd3b435b029bab84_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNC0xLTEtMzAxMzk3_3990aeaf-bb59-4345-b41c-e3542542778c"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad37f88a40ad417181970ffd6d38fdb8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNi0xLTEtMzAxMzk3_9ca8624f-33a9-4ea1-925b-f5a363110478"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6291bcbf7f7c41b98bbe26c0e03a3cf6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtOC0xLTEtMzAxMzk3_c6244666-1904-41b3-90a5-d5466df2dabd"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e10e1edf06747de90b02b2363965434_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTAtMS0xLTMwMTM5Nw_89caad2a-9669-4bea-8874-039bec724d12"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c62a110af374a069c05307a70eb674a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTItMS0xLTMwMTM5Nw_52f085a6-6bf6-478a-98b3-490c4f4c2545"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia05d7b2dd54e4758b222f4b9c96c8dcc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTQtMS0xLTMwMTM5Nw_8eeffbd8-1bbf-4f12-bb06-d172a2c13f3f"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4fd84ea511b418294dcc7d568645af7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTYtMS0xLTMwMTM5Nw_7f382445-2341-4efd-ba78-91f520a32a87"
      unitRef="usd">211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7ff71600e3d4a11b42b8372471e63e8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMi0xLTEtMzAxMzk3_f79de661-8bc9-4517-8b79-892ac8ce47ec"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4043b3f894c487facfbfa869ed06140_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNC0xLTEtMzAxMzk3_8ddcaddc-4598-498b-bc75-359fd417a8b1"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8da02de1bdab404c87ddd583b9eebf85_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNi0xLTEtMzAxMzk3_0ba1956c-70ab-4b33-8e5d-e4deae9fed63"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic846202eb035474a90d6bbdfc1b15217_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktOC0xLTEtMzAxMzk3_cfee8179-29b9-4cc0-b75b-c6231edc57fe"
      unitRef="usd">448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccbbe48385584bfea6852686c3b019de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTAtMS0xLTMwMTM5Nw_c57c018c-b563-4504-b61d-badc22a0e24f"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71a4c42583664db8b3c33c5f299a0f4b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTItMS0xLTMwMTM5Nw_9e63cdac-7603-40f1-878d-394a52d6f817"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if951dfcac7744054906c5125f638ce21_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTQtMS0xLTMwMTM5Nw_d269ed16-d8be-4ce8-9a6e-aa4befd6b28c"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5cc2f2b76bb4d9c97bc86237986d9bd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTYtMS0xLTMwMTM5Nw_88ee2bb7-99b1-4a1f-be22-b749fa8defc7"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ebd3767145342f6b367a0b7f6f1a976_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMi0xLTEtMzAxNDAz_bbd34d2a-5c2f-463c-895e-f6eb22123952"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8bda10becdf41afb4989abe63dc2011_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtNC0xLTEtMzAxNDAz_52c2d0a6-e699-4ef6-a11d-44e4fb7d81e2"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4101dba088994abcb8f4d35c5096da8e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtNi0xLTEtMzAxNDAz_e693d04a-6af8-4a2f-83f6-2f11eaeb5381"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fd92b5b8015467faac7b2902c0e722c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtOC0xLTEtMzAxNDAz_4f4b4552-a638-4515-aede-da6d823bcc8e"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaee92c1d69fa4915a73d1e059bcc2f3e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTAtMS0xLTMwMTQwMw_4aeaaa2b-fd0b-49f1-a544-509e38efb1b1"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d037e0f2be44b11b472e2b6432f4801_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTItMS0xLTMwMTQwMw_4f901ee9-2151-4430-a6da-2ef5dfcf560f"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9f9879159314fdbb7fdea07bdf585a8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTQtMS0xLTMwMTQwMw_66bb692d-4f74-4dc7-8c94-e961b8e66cef"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie367458dfc7842fdb07fd2fe4e10fc1e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjEtMTYtMS0xLTMwMTQwMw_cb65afe7-2eec-42b7-a52d-5ac7d329d0f9"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d872aaca9d40a4b6c2a27ebb8bdf10_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMi0xLTEtMzAxNDEx_839dae84-1401-4d78-a975-ee586d0847d3"
      unitRef="usd">431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8284ac9437543ccbc0d3d44daf70792_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItNC0xLTEtMzAxNDEx_6a8f8722-922c-424c-89ba-2b753b96f6e0"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib43370509bfb4a8c8dab8123e63ab0c8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItNi0xLTEtMzAxNDEx_392cb196-72c8-47eb-acb6-a1baa3019ed0"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06a6eb489854930ae0def7cc8f416de_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItOC0xLTEtMzAxNDEx_20389c15-603d-4ea8-9e47-baad14395764"
      unitRef="usd">670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21ab588f4a7646b9ae2305375fa5467b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTAtMS0xLTMwMTQxNQ_f6b992b5-d23d-433b-8a0a-ceac878fe68a"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f37487da5e349a4b9f9f387d2dc5398_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTItMS0xLTMwMTQxNQ_f8181fa9-2237-4ba9-8aa5-3861dc8df3a4"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b3bdda941ff4e2aaa037ade8321f098_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTQtMS0xLTMwMTQxNQ_8a720fcf-013b-44e0-b78b-e4926544f02c"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee659a3e712243d09b54e37ca804067e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjItMTYtMS0xLTMwMTQxNQ_d524196d-2bd3-4738-a498-d952a6541a36"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94069cf576394220a168bb924848e1d5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMi0xLTEtMjY5MzYy_490364f7-21d9-43a4-841f-f51b7fda0282"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75383c9367af4d9d8f8715d238548742_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNC0xLTEtMjY5MzYy_097141d3-4886-4de1-9fd2-635b444712ee"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic44a7f7348754553ae0be14f2f11c8a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctNi0xLTEtMjY5MzYy_8a0d4dae-7c17-48af-8977-f86690772048"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie934396b4aa24066a63d81e4824e6824_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctOC0xLTEtMjY5MzYy_475c0df3-5901-470b-bdf5-cac1a975177b"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia825fa36f2c54e59a199832f003b73a0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTAtMS0xLTI2OTM2Mg_961969b3-a36e-4da5-bc8c-1e0fb6f164cd"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c70a0df7936466e8f48c9d8037878b1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTItMS0xLTI2OTM2Mg_ab707ebd-9e5d-4efa-ac29-14142bdc01e9"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66dde11c9ee7473ea0df48b2aaacf03e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTQtMS0xLTI2OTM2Mg_fa37a0ea-3db9-4cec-ab4c-43d49edca875"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b1bbc6a669f486ebe51bb1dcae67739_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTctMTYtMS0xLTI2OTM2Mg_a0f8a45d-618d-4656-95f8-a3312de25067"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0905351e17b64009b3bd40c0e79e555e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMi0xLTEtMjY5MzYy_6283fb65-e821-4ebf-9642-c6b2fd442f70"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79ce5f719ea84854a0b758397c95d01f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNC0xLTEtMjY5MzYy_b9df6665-642b-4d5b-b94e-01929e126a05"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3479eb78982346cc9b440b90ac343bf9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtNi0xLTEtMjY5MzYy_108bc714-c973-4280-8416-87f17f977e87"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i510d0822c2574545adb8841ba008ce9b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtOC0xLTEtMjY5MzYy_39829fe8-c53c-4a5a-8fc3-5ea3e68a00ce"
      unitRef="usd">385000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58fdc21dc65e4d558d42514d101c97b7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTAtMS0xLTI2OTM2Mg_605b20a2-faa4-4296-89ce-056700b71a70"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a865d0fddb8445cb031590f0a02a80a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTItMS0xLTI2OTM2Mg_838b5e34-99dc-4e25-8db5-618802fcf0a8"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia22aa3af8d494dc292b57bdf0cdf041c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTQtMS0xLTI2OTM2Mg_11d2aa5e-c749-4be0-9a98-99dfd9a24fee"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86087bf8b37a4b89acc6817bcef8e756_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTgtMTYtMS0xLTI2OTM2Mg_e76952e0-2d78-48f0-b6af-860ebc39a36a"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf24591ef12a41fca5174331a00cbb13_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMi0xLTEtMjY5MzYy_a00268ce-0528-4623-8b05-706a712e17ca"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb45ab67b990486599a343f8415ee905_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNC0xLTEtMjY5MzYy_bf7db8d1-b984-4d73-92f1-849bd63577c9"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id752540ccedb480fbbb6e2bba52c34bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktNi0xLTEtMjY5MzYy_cc143b28-7491-42a9-bb9a-0ffedd1486d1"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc42e0840ef141c5b3850d98173d4730_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktOC0xLTEtMjY5MzYy_0943c147-1dd7-467e-be25-0a2cd37d99dd"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34d455cccf9d4832870bcf4419271ea9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTAtMS0xLTI2OTM2Mg_d3bea8e7-7b74-4949-a4ca-a899987361d7"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f80c600bf04228823d182e0cb43b1a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTItMS0xLTI2OTM2Mg_1ce5ed1e-d723-44fe-a1fd-030423d6981b"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e1b8b9d99b04cd189bf897215f84c36_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTQtMS0xLTI2OTM2Mg_d6f93b77-3d64-41e9-8c53-c5698fb14293"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5869ea468ec4ca5b87ad1783a18dc9d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMTktMTYtMS0xLTI2OTM2Mg_d6ea831d-126e-4b29-9a73-52e9324c1402"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b0580a54e234bf585f865b90a530189_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMi0xLTEtMjY5MzYy_89915a33-7288-4830-87a9-fffd00d0278d"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54593f03c1114400935e76093c34b8bd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtNC0xLTEtMjY5MzYy_c0066e37-8d58-4db8-b43f-4667f7ed532c"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13b67d77f6f242b0a1bf8ac4155be76a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtNi0xLTEtMjY5MzYy_239b77dc-ffc3-4d84-8e30-43ec29d6485f"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ba94b3090254d63ba7bd368d1a8f7dc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtOC0xLTEtMjY5MzYy_109c0599-727b-4b98-a322-40fc17f2f83b"
      unitRef="usd">445000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a201f81fa334729abf7031166fd5577_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTAtMS0xLTI2OTM2Mg_faf2cced-43ea-4ded-b5cd-140da33a90e5"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie743df4532ec46c6bec9c152ca1030fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTItMS0xLTI2OTM2Mg_98fd9d09-05b8-42a1-8635-e5ae1064366f"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37473f0485a746938a7f26a2dca59cf3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTQtMS0xLTI2OTM2Mg_482766f9-b9ec-439f-afaa-4329dea10a00"
      unitRef="usd">105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica72aa2509b04035b02393bb3aea5e1b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjAtMTYtMS0xLTI2OTM2Mg_a4b718e0-919c-4049-a2e4-e4c202fd92f8"
      unitRef="usd">399000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23ebfed05406413eaff961e952191aa4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMi0xLTEtMjY5MzYy_e26c7d5a-460b-4193-9e7a-bed9ea4989b5"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82b45a8b90a848269a2592fbe0b8c3ce_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtNC0xLTEtMjY5MzYy_84ecdbd6-ef6e-4757-aa16-560a51f682f1"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2d3312dcce0438cb345232fa7454979_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtNi0xLTEtMjY5MzYy_12e98e53-81a0-4cd3-8711-0ffbb814c321"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0934fd0075be4cd6ada897ff651ce8db_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtOC0xLTEtMjY5MzYy_8ddbe7d2-25c3-4248-a5f9-6061d824dabd"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c40a0615861452596fcb9aa9d86e704_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTAtMS0xLTI2OTM2Mg_9647ff0b-816f-4ab9-bbe4-a7d0a11be829"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib500e8ef8aa84616b40a2191594114a7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTItMS0xLTI2OTM2Mg_fbbbc350-5c62-4faf-be87-a9aad2231c7b"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if38ddeb60ee2443f956e770d097710c9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTQtMS0xLTI2OTM2Mg_5d59c8c7-c051-48ec-8701-0602f2c01f66"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie640715ca03a42e99d7cd895fa05c7b4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjMtMTYtMS0xLTI2OTM2Mg_6fe2da28-432f-4113-b983-c86ad80d199b"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i652bed5b638547f9898ab03fcfdd467a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMi0xLTEtMjY5MzYy_65f86001-67e8-413b-a64f-aa6d023fa65d"
      unitRef="usd">-1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b7dbdd67bdd453791f731cc83851f41_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtNC0xLTEtMjY5MzYy_f780f70a-f01b-4760-a3e9-27fc7c4b8b13"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dfffbb1fb6e4e8ba4b2d0adc6f90600_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtNi0xLTEtMjY5MzYy_d4fcb54b-6a99-4d43-9f65-a259b87443a3"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie97d2219d4e940e8872b33598cbc3523_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtOC0xLTEtMjY5MzYy_0f96279a-fda7-472a-8bb9-8bf929b12c84"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe303d4e215044fa92f72f822bdc870e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTAtMS0xLTI2OTM2Mg_f37b3425-99f7-4192-b6de-3dc9e6636e7a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ad5d36685f64582b233de7a5239d698_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTItMS0xLTI2OTM2Mg_c96903f0-2232-44f6-a8bb-8352eaf98170"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa9ebab0b3a942d5bb672c1ea1985565_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTQtMS0xLTI2OTM2Mg_81da6fb7-022c-45fa-ba7a-743d36a521d6"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic16768b8c0bd467089b916f0150aea2d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjQtMTYtMS0xLTI2OTM2Mg_4752a8e5-73e4-48ed-aeaf-85aea2c8b6d2"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a09533ea02b4970830e57cb8ed16e29_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMi0xLTEtMjY5MzYy_7bc5c86e-6d4e-469e-944f-bde9091d5284"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8dfa66c376de4d50b8d621ce7a69fd00_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtNC0xLTEtMjY5MzYy_0e19ef40-da9a-445d-967b-69d00577a364"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb6838b754224e3ea3f49755cfe56353_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtNi0xLTEtMjY5MzYy_d1758c1c-82d3-4c1d-95a8-de1bb1524e78"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i257a0e1302984795b9ed79cd7d56fcb6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtOC0xLTEtMjY5MzYy_10e7bb03-d7c2-4945-bc7d-15a0a06e2503"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib68686e7167f4cd88f12024feac41469_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTAtMS0xLTI2OTM2Mg_e372ba3f-5160-49da-b4ad-1907ca9bf251"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i824131aaa9e9438885ebb6c2d9d58420_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTItMS0xLTI2OTM2Mg_4ef73fc3-ccd7-457d-a619-21e71e09c5cc"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97befe6960ea47c09105a9d2792b241c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTQtMS0xLTI2OTM2Mg_1f87866f-0bb9-4db3-91bc-eabf7aec3b3e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i743bad3f631549ee9b7e3300a3b32478_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjUtMTYtMS0xLTI2OTM2Mg_0836ea3f-8d78-4d19-a453-a3b505c68154"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d9b52ba975f47eea73b114711437ee0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMi0xLTEtMjY5MzYy_3c3c4188-736e-4c5c-b009-6ed3c8ef4e51"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia99677732ab64aee9be9eb6c9b9c5297_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtNC0xLTEtMjY5MzYy_919d1e70-fd08-4843-af91-d0175f54c806"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18ccc5abc96549b4a653a8ac7248fcf8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtNi0xLTEtMjY5MzYy_47e7d885-92f8-4aaf-bce6-8f872705b00a"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d5d887661194281a92f5d47aaec6008_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtOC0xLTEtMjY5MzYy_dd2901e3-f372-4c79-96da-f08c0fe476af"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70bf852e632a47e287a6514f25d2979d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTAtMS0xLTI2OTM2Mg_4ae34acc-0894-465a-a58d-0b356cc3cc73"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20f4a76252494b24bc1f179124aa3124_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTItMS0xLTI2OTM2Mg_0cfd4cad-9375-4910-ab6d-f205357497d4"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9560016efc024c89af4afc6834f04bbb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTQtMS0xLTI2OTM2Mg_d1872b75-0e7d-4351-816b-f8f275489b14"
      unitRef="usd">128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57ab8727efc14325bd00acfb911c338c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMjYtMTYtMS0xLTI2OTM2Mg_81e0440e-2d67-486d-9a03-5b59bb438deb"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i090c47f3a0cf452181e6d5b006c0be6a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMi0xLTEtMzAxNDc3_da5f7e21-b9ef-4e03-9e88-ed2164ff5d8f"
      unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f7a471ebca74147a9b0d6e1a6089d93_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtNC0xLTEtMzAxNDc3_0c847761-0fa9-479e-85a0-7d00c3153e63"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8185dc8b7344db9a1038babf06db22b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtNi0xLTEtMzAxNDc3_4ee7cd13-68d9-41e7-9797-e0b05fd312d0"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie59f825423194376b8da82fe0cec886d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtOC0xLTEtMzAxNDc3_5619f8e0-eb53-4738-8915-f21066942dd7"
      unitRef="usd">675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i324e13105ef44547bab1c5e86c934957_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTAtMS0xLTMwMTQ4Mg_5407b323-65d5-4488-b071-26d616677440"
      unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3e40c5875114f3cb760a0d82117e6a5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTItMS0xLTMwMTQ4Mg_45e0ca52-9d75-4f7e-94bb-e4ad58585443"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59f9f3277ed14717a540d49002edff04_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTQtMS0xLTMwMTQ4Mg_6def4a4e-d811-4622-b9cd-4ff9d718a79a"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8748476ff814f45b9ccd6e290667fc9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzUtMTYtMS0xLTMwMTQ4Mg_f609dfcd-6d96-4ee0-9d72-5bd2e64c9230"
      unitRef="usd">635000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f8220ccfd0447bcaabd55458b891968_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMi0xLTEtMzAxMzY3_ac430736-f0d0-4a0a-b8d0-65a56f8111bf"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa9a86b0b2a84281bb61ad1873a15c2b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNC0xLTEtMzAxMzY3_1a7a7ff6-235f-4be7-a363-a9664223250b"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if614c6aa1eab4885acbcc73189da7a93_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNi0xLTEtMzAxMzY3_565256f4-9b66-41bf-8821-98187d539796"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i278eb945039342f2a8bda078049ec2e0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtOC0xLTEtMzAxMzY3_68eaff44-8fe5-4757-9daa-7f31bbd48983"
      unitRef="usd">573000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie40b401de87f42519456da4227ef431e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTAtMS0xLTMwMTM2Nw_41110f89-5382-4f4f-8bb9-0269e32d08b2"
      unitRef="usd">801000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie855dc4b080941e6be062405849ca9c9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTItMS0xLTMwMTM2Nw_95cffa84-fdd2-4207-8dbe-a96329a873f0"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d547a3fe84543cea7ac0386bbc34d72_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTQtMS0xLTMwMTM2Nw_84105703-998d-4cb4-b10f-5d4e76700332"
      unitRef="usd">430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54cccadc5c6b497ca5b1f30e89955b7d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTYtMS0xLTMwMTM2Nw_2321ca1d-0025-407f-974f-5747edd31c0b"
      unitRef="usd">1535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58c6167454744e0fab7410239683ab45_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMi0xLTEtMjY5MzYy_05d6b1b2-69bf-4c6b-9f7d-3c6a864f7777"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d9606c89db437788fc45ee2168e4c8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNC0xLTEtMjY5MzYy_55c24af5-93b2-4ce9-9482-c31cb9ceba2b"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eb18acf634f467aaf5cdd7a65b62981_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtNi0xLTEtMjY5MzYy_2b62050d-8da7-44e8-8403-a7e42e89318f"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia581f9570a6a44e4bf717b04c2b68cad_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtOC0xLTEtMjY5MzYy_e8c5e968-8230-45c7-852d-b526b0b6ebb7"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i447d2250e1b9434a90d57aa2babd8a63_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTAtMS0xLTI2OTM2Mg_8b981cdb-af9f-442e-94bb-f4e33cf77211"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9a7971fda6a4d1cb7a5b0c93dc55aa8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTItMS0xLTI2OTM2Mg_0cbaf404-3d2e-4cc0-bd5a-2d3caa700e92"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63020427351e4e01a6c232cf97913837_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTQtMS0xLTI2OTM2Mg_8a16096c-3713-4240-bec8-b56ddabfc5f2"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2e51316888b41cbb03d3ddfc57bd840_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzYtMTYtMS0xLTI2OTM2Mg_4eb9f614-1a0d-4dac-ba4b-5a08270a1205"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74791ed0e7b346e89fd234b7be9699a7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMi0xLTEtMjY5MzYy_6eff3c67-17fd-43be-86ca-47ae75bf1892"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dc4e4dc9bea4ec58fd5ff7790b0b8f8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctNC0xLTEtMjY5MzYy_3f75c4b5-23cb-438c-a5db-b0596b10bb3a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93d418d346974c1fa0c17dcfcaead0d7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctNi0xLTEtMjY5MzYy_665d18cf-2814-4074-8e16-80cacd2136a0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfbb92a2127b42db9046b0b7ec4dfa6a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctOC0xLTEtMjY5MzYy_7d959edb-69a2-43cd-adac-83ccecfe85ca"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i809de751ef2f4f78b9b8f68cd8b8e109_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTAtMS0xLTI2OTM2Mg_b1dc992c-7f13-4a1c-8774-edf2dc8fdf74"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4daac1a0fe9747d9bcd85f6d82586020_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTItMS0xLTI2OTM2Mg_6967ae4a-f854-4a63-980a-9dab04df3448"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic42331a4397a48faaaefc64df2f413e2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTQtMS0xLTI2OTM2Mg_443157d4-191b-4c41-ae0f-450a993a82c4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if28d2efd45f141f6b1f1fc7d243542f0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzctMTYtMS0xLTI2OTM2Mg_317634e0-507c-4f25-a8f0-89df38542fd8"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i755f2b30cc6e4fa993c605e6808ad1cd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMi0xLTEtMjY5MzYy_cb29df55-069e-4b80-8cac-8d2c522909ab"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i677d46617baf4cfc97770f40bdf350eb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtNC0xLTEtMjY5MzYy_2fdba8bc-e7ce-416d-85de-513b47413b13"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i996bd5bfe4d44d25b7c4bf8273caf0cc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtNi0xLTEtMjY5MzYy_b82bd0c2-284a-4bb8-8864-2fd6b2d39308"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb8a2eae2e8547a5b670d21ca58b3fef_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtOC0xLTEtMjY5MzYy_f1e25392-7459-4efb-b842-4e349affe08b"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i823bfbd777c846ddaf6555202b8a7351_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTAtMS0xLTI2OTM2Mg_cb652140-4ba8-4e76-b6b3-1df357b41d29"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b10cde4a9524c0ca62293060948f483_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTItMS0xLTI2OTM2Mg_df7ad31d-0675-4d5d-9c06-dfff12219d71"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie41089e89bd74f35ae3f87c7a56e2a19_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTQtMS0xLTI2OTM2Mg_bcf0ecab-2fa6-4535-9e7a-0eeb5b066eb5"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i696fbe445270452f81e087d1fa89fe11_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzgtMTYtMS0xLTI2OTM2Mg_94d5e523-5614-4e2a-9dde-e74c4d1cd319"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ae81192d9324630ba4b365d1cddd5bf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMi0xLTEtMjY5MzYy_1fdeabf9-ff63-4cbc-9e0b-0925d9ce0635"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie33f4fdb4c494428ba2b4a99560b4e08_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktNC0xLTEtMjY5MzYy_083225dc-5223-4aad-b026-e00bc5053fa7"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i709a08a357b14493b12bf32a458f6f6f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktNi0xLTEtMjY5MzYy_3e072cba-da74-4417-b452-cc0adbf3376a"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i710096d16b5642718cafb5a22d815d0d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktOC0xLTEtMjY5MzYy_145bff26-b016-4c2c-bc7c-d39f8bf5ba85"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1ab8aec39084c4eac102e0706a4b80b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTAtMS0xLTI2OTM2Mg_2140d72f-a4cd-4b7e-acd9-7ede339bacf5"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf9e5623132040899baea9cd2d5a764e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTItMS0xLTI2OTM2Mg_69957008-5c14-443d-a26a-b32dd5ffbb67"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3092cbdd04d40b19aab266dd867a766_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTQtMS0xLTI2OTM2Mg_8b8a1127-c35b-4e3f-9d8c-e27819a3ae49"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib976d60772b24c27944ea6b8d54d2d67_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfMzktMTYtMS0xLTI2OTM2Mg_cde47c52-19c8-4507-9de9-2c0723b8144b"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113772172baa40a0b615da596117cf5f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMi0xLTEtMjY5MzYy_73fe14ac-1f08-482c-8668-b831c4f3bf18"
      unitRef="usd">4434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac7656db9d0049259fec5c0b61f4a692_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtNC0xLTEtMjY5MzYy_c07e084e-cf24-4937-ad05-7a331eabc859"
      unitRef="usd">1053000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic79faa34465a4d6aa155b887531a618a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtNi0xLTEtMjY5MzYy_4861656e-436a-4154-ad67-fa87f79f8d51"
      unitRef="usd">819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4e928b3ebd744fc970718834da3534a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtOC0xLTEtMjY5MzYy_534c8c60-4584-4f6b-9db0-a210e827ae59"
      unitRef="usd">6306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89d5861845724cc7b45b2421fadc72b4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTAtMS0xLTI2OTM2Mg_c674fa9c-1052-472b-919a-4e5eb47211ce"
      unitRef="usd">4329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c53f8feb0a94f6491489c44593b168b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTItMS0xLTI2OTM2Mg_bbbacbae-2dc8-4bc2-9bd9-8c4cc598000c"
      unitRef="usd">1174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f19798d09f947d2a629343bde19e62b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTQtMS0xLTI2OTM2Mg_f4eaafa5-9330-4d9e-96bd-bd16905cb62e"
      unitRef="usd">1031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic500805e8441430185668274754bd251_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDAtMTYtMS0xLTI2OTM2Mg_b632df50-51d8-4be7-94e2-24ff6629cdec"
      unitRef="usd">6534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64a4176549214367abc167a2ec593abb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMi0xLTEtMjY5MzYy_cbe42ea1-ddc3-46ee-aa08-f6bb8acc7d3c"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i978f5bf8cd9d416190509bc5959bef0d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtNC0xLTEtMjY5MzYy_c3e28c80-f98c-4392-afa4-7217ded204e4"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34a5ba2a8a1540749ed46ae7a6ed4e6c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtNi0xLTEtMjY5MzYy_64365531-031a-4e22-8711-45398a3848fe"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19c45e712edc45518e23cd00b61fb12c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtOC0xLTEtMjY5MzYy_eb09f538-e9e5-4fc7-b537-89a65b88db27"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5ea35337c87402dbc1082ebd607e554_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTAtMS0xLTI2OTM2Mg_6ae79360-1c93-44e1-b3f7-b5ec33a174eb"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3374213965c34c23a79853f9a29ba6a5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTItMS0xLTI2OTM2Mg_3a808fcf-c2ed-41d1-b2b7-1129677a068f"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7caa2c5fbd246269301ab23ea219e18_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTQtMS0xLTI2OTM2Mg_646c4381-305e-4567-80e7-a3735171a515"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a67c68bd87541d7b8aeb32a510dddfe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDEtMTYtMS0xLTI2OTM2Mg_46a5910c-0a29-42af-86ed-d6e2a52a9d68"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c91b5b81b3f49cc99ed4d965e15cb05_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMi0xLTEtMjY5MzYy_6f383511-a019-447e-8b9f-8bc3f65636f1"
      unitRef="usd">4452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6eb135539ed644e89e8a56f37e4ba61d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItNC0xLTEtMjY5MzYy_23a85c8b-3f43-42cd-a314-23164df6a48e"
      unitRef="usd">1079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68170415b25f47b08de05015410863d5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItNi0xLTEtMjY5MzYy_6391635f-4f5f-4762-a18d-48085ac62738"
      unitRef="usd">821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItOC0xLTEtMjY5MzYy_494d1e71-52da-4997-b66c-2b3c9870116e"
      unitRef="usd">6352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b6849a5ebac4c97924794143c774f0b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTAtMS0xLTI2OTM2Mg_5883dbf6-e157-45a0-bdcd-0f803636c5bb"
      unitRef="usd">4355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9c99b6a3f2a472c83a2fa839f90b5ea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTItMS0xLTI2OTM2Mg_bcf617b0-3a8f-4a80-83e0-9baafa8cf0ac"
      unitRef="usd">1202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f79d1cff43c43df82a4363c05362740_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTQtMS0xLTI2OTM2Mg_ee7d5b96-3322-4f94-81f2-c37302d94b48"
      unitRef="usd">1033000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjM0YmZjZGZhZTRhMzQ5MWZhNGI3ZjRiMjM0MGVkMjU5L3RhYmxlcmFuZ2U6MzRiZmNkZmFlNGEzNDkxZmE0YjdmNGIyMzQwZWQyNTlfNDItMTYtMS0xLTI2OTM2Mg_20b4d2ad-905e-42e8-a120-47db807d9929"
      unitRef="usd">6590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU4NQ_45b9fa08-fc41-4458-96d4-6588e9252b75">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic87bba42a74544ebb4ed1b2216e3f687_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfMy0yLTEtMS0yNjkzNjI_d4707fe4-d8a7-4966-afc0-9a22747030ea"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic7c4130e03624fd8bb9980194f507734_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfMy00LTEtMS0yNjkzNjI_d2ec0635-5025-498f-ac6b-851c8b735792"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ida6333a62e4e40e5ac281c56d97e63c8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNC0yLTEtMS0yNjkzNjI_707d0750-fd1b-40e9-b52d-b18babe41b52"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6f1daf12df0648b786b4f70679a69ee3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNC00LTEtMS0yNjkzNjI_a0030121-90e0-4ba1-9949-8a45837b00a1"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibffab27044b141ed8332a4acb0c26f71_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNS0yLTEtMS0yNjkzNjI_829941fd-f269-4b92-bc8b-0a6fd10b07f7"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a637640e90643ad807df7af76498cb0_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjA1ZjdlNWQyMzE4ODQ1MjA4NzJlM2FkMGI2NGI2NWVjL3RhYmxlcmFuZ2U6MDVmN2U1ZDIzMTg4NDUyMDg3MmUzYWQwYjY0YjY1ZWNfNS00LTEtMS0yNjkzNjI_67c91e68-8c9e-4c2b-b46b-8a6e01d9d3fc"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMTU4Ng_f19dc029-f5a2-4dd1-b0f0-d8aae155f4ae">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues recognized from performance obligations satisfied in prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue share with Janssen and royalties for licenses of intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfMy0yLTEtMS0yNjkzNjI_2b8ba31b-3475-4f42-90df-3c15408f70f9"
      unitRef="usd">192000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfMy00LTEtMS0yNjkzNjI_6e567e35-591c-44f4-904a-2fc6bb7be41f"
      unitRef="usd">184000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfNC0yLTEtMS0yNjkzNjI_b5779a41-aa64-440d-b33f-2a42b9d7fee3"
      unitRef="usd">160000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOmFlNzMwNGUyZDg4ZDRkM2I5NWNiZmFiODRjYTZlMzZhL3RhYmxlcmFuZ2U6YWU3MzA0ZTJkODhkNGQzYjk1Y2JmYWI4NGNhNmUzNmFfNC00LTEtMS0yNjkzNjI_0fe5a8cb-fb28-4122-bf19-c730300c373d"
      unitRef="usd">230000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RleHRyZWdpb246NzU4YzBkNDliYzdhNGNjZTlkZmJiOWM5ODNiNjY1NTdfMzg0ODI5MDcwMTU0NQ_18a03fd2-0d0d-466e-b34c-48576fbd48cd">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Generally results from receipt of advance payment before our performance under the contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMS0yLTEtMS0yOTcyODY_73ad654f-4f5c-4997-9876-f8c8cfbde10f"
      unitRef="usd">164000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMS00LTEtMS0yOTcyODY_9d4af536-7143-44f6-a6c3-3c16144a0468"
      unitRef="usd">171000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMi0yLTEtMS0yOTcyODY_f1076a6e-41cf-442c-b535-62588a0285d0"
      unitRef="usd">93000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF8zNy9mcmFnOjc1OGMwZDQ5YmM3YTRjY2U5ZGZiYjljOTgzYjY2NTU3L3RhYmxlOjRlMjM0ZDI1ZWFkODRlMGQ4ZDE1MzdiOGUxOTA3Y2JkL3RhYmxlcmFuZ2U6NGUyMzRkMjVlYWQ4NGUwZDhkMTUzN2I4ZTE5MDdjYmRfMi00LTEtMS0yOTcyODY_63192298-3341-4020-9cbf-79f54f87524d"
      unitRef="usd">102000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM3Mg_08fd81e9-6e35-4a32-b1c4-c94812a73b1f">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Derivative Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $22.6 billion and $21.9 billion as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and the carrying value was $24.1 billion as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to &#x20ac;300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex until the related contingency is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in fair value of our contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation assumptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Research and development expenses on our Condensed Consolidated Statements of Income. The change in 2023 primarily related to updated expected payment dates and the change in 2022 primarily related to updated probability rate estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair value of the liability related to future royalties was $1.1&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022, and the carrying value was $1.1&#160;billion as of March&#160;31, 2023 and December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, we recorded a partial impairment charge of $2.7 billion related to certain acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) assets. See Note 7. Intangible Assets for additional information. There were no indicators of impairment to IPR&amp;amp;D assets noted during the three months ended March 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Fair Value Level Transfers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM2Nw_d556d88a-5e26-4e13-a9ff-c4973524b6e7">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i67a08172f4f244a79d2b394f399f8b13_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0yLTEtMS0yNjkzNjI_4c0e9730-5f1d-406d-8eef-7d62cdefa304"
      unitRef="usd">344000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id40005adf52144ed85b05da90b6d2139_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC00LTEtMS0yNjkzNjI_77d9fd12-f51c-42b5-b42f-78b3127d9dbd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2a00bf2652604fbcbb4da1bec40896e6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC02LTEtMS0yNjkzNjI_803ac608-c99d-4f3e-b377-ef0db6628428"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4ad1222097c644f09b1a2dccc64bd3c4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC04LTEtMS0yNjkzNjI_54f4864f-cadf-4677-8c59-cbc2dd72017f"
      unitRef="usd">344000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifd34e7473d924c328deed5a6ccdd4afe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xMC0xLTEtMjY5MzYy_2d151c3c-55f3-4baf-8fe9-0a42d0159705"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i298a129b64b84c158f7a79bfaabebbd9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xMi0xLTEtMjY5MzYy_f74e58e0-a3bc-440f-a897-8bf295edea97"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic015d372c6774949bc85fa263970366a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xNC0xLTEtMjY5MzYy_9987e8a6-be3f-47e9-beff-c4ba2b2606b8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6548e7eaf5d34e378990fe5c8218b3a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNC0xNi0xLTEtMjY5MzYy_e8638651-0ade-493c-a7e5-2fb829c6613e"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie56bec9c2c9449778eb81057ceb9299b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0yLTEtMS0yNjkzNjI_75db799e-38c6-4bd8-a9d2-3f614ce70b05"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4c2a9da409b6496bbc57ceb63bf60484_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS00LTEtMS0yNjkzNjI_9e3358da-de24-400e-9ce1-241a986d4d77"
      unitRef="usd">155000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4458d1d12cea4625bc7db11da9a09beb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS02LTEtMS0yNjkzNjI_b46ebf44-b8d3-4a7b-b8f4-80ad7ea51814"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i070c48e01f814ffd907a7fd8f6047117_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS04LTEtMS0yNjkzNjI_6670cfa2-015e-49eb-82f4-91a34a0e1d75"
      unitRef="usd">155000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5c206f3d17b44385898e7a9f69b7aa12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xMC0xLTEtMjY5MzYy_c3a65179-3169-4c5e-b5ca-d27e64d66e10"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4efb718dc0824ded809922f135d14f72_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xMi0xLTEtMjY5MzYy_44d5cb55-5128-43bf-ae9a-76e42b597bab"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i39bac2a669a64335b1a9e1e221e2f25c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xNC0xLTEtMjY5MzYy_4bf2d871-f2ae-4f87-a203-57603c8c29fd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia26e1c0f325d4ca1a67fba9811c45fc9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNS0xNi0xLTEtMjY5MzYy_b322fd58-3ba3-4d75-a5da-5efc91142591"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if2b123dc510a43d8802b50cccdeedbf5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0yLTEtMS0yNjkzNjI_9d658c89-7915-40a5-8ef5-5fddb7db8a34"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i57c59bdf9e624122b0025c13c8932d5b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi00LTEtMS0yNjkzNjI_18381d99-c14a-4c69-aa0a-8eb25ac8e33e"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6307387519504abc927afabdd827d0b0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi02LTEtMS0yNjkzNjI_22ba83c5-4f0f-4a1e-b46b-0210f35a8cf8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i268af442ad9045fb9d0047cc8514e705_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi04LTEtMS0yNjkzNjI_2ddbe466-1012-4153-90c9-dc7be8fdd0d5"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic58be9bdcf7e4accbe91509935a9f362_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xMC0xLTEtMjY5MzYy_91f2d785-e88d-413d-a93d-f2c806a3bd02"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idc9741f7ff7a4abeaf85943e5f22418a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xMi0xLTEtMjY5MzYy_7e84bf23-3121-4675-9bfd-3105f8a5a696"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib28bc6923927495f8c985d0973d926f0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xNC0xLTEtMjY5MzYy_5ffdd613-e7fb-4dba-b1c3-2ad9a54cee4c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i858d8c032c1640b58d8d8f45207568b6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNi0xNi0xLTEtMjY5MzYy_afd3dd0c-ad1f-483e-8a50-b317a705b01d"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7955dfb43224407190574461d49d9540_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0yLTEtMS0yNjkzNjI_8b3c7b90-fb33-46cb-ad35-95fb2c7dd233"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1b3fc36306554f1bb30285803dfe875c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy00LTEtMS0yNjkzNjI_e9749e5e-b329-4f1e-b37b-64a567a52591"
      unitRef="usd">90000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7d5eff8a38aa425682a7f90c9892125b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy02LTEtMS0yNjkzNjI_4a61b91b-4bd3-4af4-94c7-ea4662980bfc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ice046d59307c4fdcaf4be021a9c9b7e6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy04LTEtMS0yNjkzNjI_912c6b66-5ea7-4688-987c-67f5eccf2a33"
      unitRef="usd">90000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5ca4682777694e579dd8d81c0230ccb7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xMC0xLTEtMjY5MzYy_dad064ae-82ec-4daf-9cbf-c50fd863e022"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i840cd602edc14d1cb641e5ee8c6a8fe5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xMi0xLTEtMjY5MzYy_00c32a89-ee56-4204-adf3-3ba727e3932f"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6ea63a1d9c8d4b34a96c93940d35e22f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xNC0xLTEtMjY5MzYy_09a54093-f8a1-47a5-a81a-af01ac96f86f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaecfcff27fd54e13b0ec19e65fbd5d36_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfNy0xNi0xLTEtMjY5MzYy_c626a422-13b9-44bf-80a2-7ee858d697c6"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i41faaf40d4ef4d49b113b09bc17772bb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0yLTEtMS0yNjkzNjI_7ee75c48-474b-417b-ac3c-763c745ccf5c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i52a8d5247fbb40ffac874f473b0f297a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC00LTEtMS0yNjkzNjI_6fa4f15a-840a-4b7c-baaa-29b120f56514"
      unitRef="usd">1379000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2e94173dabe647a398189e72561ab576_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC02LTEtMS0yNjkzNjI_58e939f9-9c55-4581-8ac1-08a6898c6667"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1afce071943b4d26b76439f3846f3a8a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC04LTEtMS0yNjkzNjI_baa3c576-98cf-41a8-a25b-7347d06e3513"
      unitRef="usd">1379000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9d03adc29c7a4123ae502213f7338c96_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xMC0xLTEtMjY5MzYy_1884da7b-4438-43a8-8c03-b133618db656"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if1ab2341ad8e4ff6b616f6930e3a7edc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xMi0xLTEtMjY5MzYy_d0ba6e79-8808-4a49-9860-7c4fa4e7ec81"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if6d8a928fd4e43259f12d46c9b3dd925_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xNC0xLTEtMjY5MzYy_ae896df0-8337-41d4-bbd7-e4ea2a474de3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i75af3c4962e045198fbc3aa6ec6a75ee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOC0xNi0xLTEtMjY5MzYy_e5b1b787-5de5-4923-991c-cd37f552d129"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icaf023b197aa4118b56f642584f72530_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0yLTEtMS0yNjkzNjI_b27bf3c4-593e-45e6-8ed2-9d4ca3539a9b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i03efe7c49cbc4bdeb65025a874918ba9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS00LTEtMS0yNjkzNjI_9a011033-ce1b-4e88-bd8d-bfb7e3960e66"
      unitRef="usd">335000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia17d4fe5710248bf903fa448d86c0f88_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS02LTEtMS0yNjkzNjI_20e1cdff-9023-4c8b-a1bd-e41590aa51d4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8fdbabb1243f4e86a5376c9000522492_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS04LTEtMS0yNjkzNjI_6ff89c5d-a761-4d07-a835-d1604985bca3"
      unitRef="usd">335000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i729aa6a63477475ba65321969802f159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xMC0xLTEtMjY5MzYy_90ca1ca0-d09f-4e33-816e-00741a085c11"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2a2cff82341c4dc0a251e15da3bf13c8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xMi0xLTEtMjY5MzYy_930c2dd9-26e0-4604-9ead-c7a41363833e"
      unitRef="usd">333000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iccd142e2bf3c46ee91f4326b178cb28a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xNC0xLTEtMjY5MzYy_567e9131-d6e7-4f11-a67d-8f51f8fd536f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1426c184f5cc47f8aa80bfe34a607cb3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfOS0xNi0xLTEtMjY5MzYy_3ef47b3c-7e82-470f-86db-4451a3d8a5bb"
      unitRef="usd">333000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6c2661abbc964a0784a010dbe6cc0fc6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMi0xLTEtMjY5MzYy_9593d4f0-18ff-4d11-afcf-a8988d49ff4c"
      unitRef="usd">3175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id531a955cfb3413a82cad523850c21c3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtNC0xLTEtMjY5MzYy_01b3165c-a334-41fd-8f33-4c7ae04db626"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia788273cc08946368efc543494d4d4e7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtNi0xLTEtMjY5MzYy_e50502d3-3720-45db-86f8-7fdca678e6f6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i70479b2efa064ffe8d5a4badb47ed829_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtOC0xLTEtMjY5MzYy_8753b423-fbea-4e0c-9469-62004bdea904"
      unitRef="usd">3175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibfcb1b9cdaeb47dca59a07a6ce2025fb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTAtMS0xLTI2OTM2Mg_327ba69c-760f-43e8-8324-8bd90427b966"
      unitRef="usd">3831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0f350e4b39bf43c491eedf1e18c2f29f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTItMS0xLTI2OTM2Mg_0c2d1e38-795b-48b3-8c7b-3e030af79487"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5f658fc7bfbc42d1b7319bf162b933e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTQtMS0xLTI2OTM2Mg_ee722ba0-933e-4967-8f98-c1dc5a8454a1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3fd105c3a34541189ed7853f9bdedb46_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTEtMTYtMS0xLTI2OTM2Mg_3f213c75-3dbe-4d1a-a8a4-0dc8e4eedeb6"
      unitRef="usd">3831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6d38171e17734505bf300a4f7261bb9e_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMi0xLTEtMjY5MzYy_c566e3ae-a49b-429c-bc0e-fe32ddc04111"
      unitRef="usd">639000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0ed5c2cce176468cb88406a4ef218eaf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItNC0xLTEtMjY5MzYy_6c1baab1-8739-4839-9dc1-b37c6155cc9e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4a26bf538c9e4b07a3f50fa63e16c09f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItNi0xLTEtMjY5MzYy_6b1d979b-6322-414d-a91a-d9c49de9faa0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i194f48cf31ad4461966915e642a9d349_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItOC0xLTEtMjY5MzYy_81a16702-fda1-4456-b6d4-0e81dfd88aea"
      unitRef="usd">639000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i937e321648424380aac9aa46560540c5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTAtMS0xLTI2OTM2Mg_7add42eb-4747-43d1-99fc-aa5c7916cfd7"
      unitRef="usd">736000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i364fe131316c482492c686531f316415_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTItMS0xLTI2OTM2Mg_b62a5e9c-6a56-4dbf-95a0-624ba53c8d22"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id09c87dcc4754dbaa6d7f3f7aff3a559_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTQtMS0xLTI2OTM2Mg_32df9f7a-941d-45aa-a08a-156d2af59b78"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic272024b44504e08aea2aef0e5cdce3b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTItMTYtMS0xLTI2OTM2Mg_870c2379-7108-4e1c-afcc-5e10dcbe91af"
      unitRef="usd">736000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4a0d1c94992b4e8985f62b27d61769f9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMi0xLTEtMjY5MzYy_cd6be588-5cb5-4617-8884-36b7055641d3"
      unitRef="usd">252000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic38fae61cd724739954724cab1029f06_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtNC0xLTEtMjY5MzYy_0f78f3cf-bd7d-4f2a-ac15-4d4040b94398"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7db06db2f1954bfb84f43e2df4db34f3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtNi0xLTEtMjY5MzYy_ee1bcc3f-a6d3-41c9-8e9d-3b4146262964"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib3c224d5aabd4662bf6225bef1d6c8ea_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtOC0xLTEtMjY5MzYy_30977af9-2f51-4866-8891-aa35cb1121f5"
      unitRef="usd">252000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i087ba3741afd43baa98b28ac94fd7f20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTAtMS0xLTI2OTM2Mg_d8b1dc2e-1ae8-437e-a4ec-f157e2801d7a"
      unitRef="usd">286000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ife4d3507260a4b689350205f27a8e97d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTItMS0xLTI2OTM2Mg_4e17cb6f-9465-49e1-ad3f-fb900cf088ec"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia8939a2992d04a64a5ff7980f5f17203_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTQtMS0xLTI2OTM2Mg_ffd7585e-15a2-422a-b14b-b8f27908fd81"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i65251199ab8d406ca23824a7b9f69f93_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTMtMTYtMS0xLTI2OTM2Mg_352359c6-a56a-49f9-b083-33e8576f5c0c"
      unitRef="usd">286000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6234e16f3ffa4f09aa53750804bbe37b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMi0xLTEtMjY5MzYy_70b0259f-0060-48ea-be64-496a88554a9e"
      unitRef="usd">235000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifc2b1f2190c1428e8e5a1008b1913d19_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtNC0xLTEtMjY5MzYy_db32307e-2008-40f0-875d-7d1aee5203b9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id26d3f89e113495fb08196ab4d44bcf7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtNi0xLTEtMjY5MzYy_b502986d-decb-4b97-a9d9-7c23fc8befce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iec6cde4baccb455a8d4849e1ae54b485_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtOC0xLTEtMjY5MzYy_87e7ca65-8509-411c-b56b-a1101df99b7c"
      unitRef="usd">235000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i17d215506fdb4ac9b9fdd8a1a8900a0d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTAtMS0xLTI2OTM2Mg_0d2e2089-be7d-4a38-8852-69ceea965ece"
      unitRef="usd">175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7611b09e98a14f48bbd2f62d557253e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTItMS0xLTI2OTM2Mg_4e645356-56cd-4ff2-8000-7ee36e8f70d1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i001dc783df3642e1ac6e1ae958df97e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTQtMS0xLTI2OTM2Mg_a3fe6291-dbb4-4afe-ab13-5218110692cd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic063218f12c54d03acf4ce07c47d4275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTQtMTYtMS0xLTI2OTM2Mg_215151bc-e843-48f5-8823-ca353da4f3ae"
      unitRef="usd">175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibe5e217a5b1140728f4602157db87e2c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMi0xLTEtMjY5MzYy_49d138aa-0752-49e4-8f8a-04b4b6dfc0e6"
      unitRef="usd">249000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2b9f0b6b0b844305a53445354ae194cb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtNC0xLTEtMjY5MzYy_d513b63f-fe49-4353-8ca0-c812d26dcea0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib183b8cea0954d138ad44af200a84877_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtNi0xLTEtMjY5MzYy_8dcff600-3ef1-4605-b82d-547795750eba"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib6ee26b0e08842a0b843c4ac42a50e93_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtOC0xLTEtMjY5MzYy_26573d2c-b5a3-4a71-86fd-8052365da9e9"
      unitRef="usd">249000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5f1d8684d26247aa83ef85ca707fbd8a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTAtMS0xLTI2OTM2Mg_963d27bc-91b1-4b72-a5bd-e384fc5e1aa9"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9d573c781b70449f9e9416cded0054a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTItMS0xLTI2OTM2Mg_2c3618f7-7c5c-46e5-8bb2-1a72a76bb41c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic05635ce202a4083958412667e099ed2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTQtMS0xLTI2OTM2Mg_deb10669-b123-41b5-aac2-57237918e5b8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5b368b49d37a4ee69978906222ce4b5c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTUtMTYtMS0xLTI2OTM2Mg_76b94432-b6d5-453b-b95a-d04782f214c7"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i86fea5742d1f445d9c563566784f0cd0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMi0xLTEtMjY5MzYy_93067e22-4fe4-484f-bc0e-e726bd65ba80"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i99ee5a60fac74d60b76c288f2df853d3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtNC0xLTEtMjY5MzYy_f063a71c-0500-4991-8980-217217c0ac49"
      unitRef="usd">32000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i9a06827286fe4c8183a9be9be74fe8f4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtNi0xLTEtMjY5MzYy_420e05e6-1615-4bb8-9d68-65b16d539e11"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia9ac4e1620e6498cb5b443b7ad7d32d3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtOC0xLTEtMjY5MzYy_01700d6e-455e-46a9-bb55-49a68a72de23"
      unitRef="usd">32000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6bda1d98cbaf438cbb28ebe26c09665e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTAtMS0xLTI2OTM2Mg_c97b63ab-848a-425f-885d-9e9043a2e612"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="id927ab0d29884827bea7bcaf3d2dc398_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTItMS0xLTI2OTM2Mg_f78ee8db-700a-4778-b916-86efe75bcfa4"
      unitRef="usd">60000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i7dde228737e648788d98fb2fc1d4ac58_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTQtMS0xLTI2OTM2Mg_492dd3b3-886b-441e-ae6b-ec055c01ad00"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i7df8c0d093bf48b2b63cba32a6131249_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTYtMTYtMS0xLTI2OTM2Mg_276a0388-315f-40cf-940b-d4e809daa6e4"
      unitRef="usd">60000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e78ed5854ff4c45958a4d133cd9890a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMi0xLTEtMjY5MzYy_21a94469-a607-4bab-91fa-293892baf7d0"
      unitRef="usd">4895000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe1f122ae8f14eae930697c79bf7af6d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctNC0xLTEtMjY5MzYy_81277617-bcfb-47e7-b452-96f4a24a6c54"
      unitRef="usd">2014000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69013ac8af5f45c896d0e14dc6876b0d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctNi0xLTEtMjY5MzYy_5aabe966-307f-412a-a1be-ed5463bc1442"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i825aac04e24b40208c807dce228c07fb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctOC0xLTEtMjY5MzYy_7c46be3c-888a-40ba-96b0-3530d7a446f3"
      unitRef="usd">6909000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iedc3b620a74946d7bac3bf26a9c4ce16_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTAtMS0xLTI2OTM2Mg_d1d3be31-6c67-47ac-b7d5-abca6dcabc46"
      unitRef="usd">5658000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6385da92df654fb6967cea6114292f4f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTItMS0xLTI2OTM2Mg_ccf96aaa-3ac1-417c-ac70-9c0e393d5daf"
      unitRef="usd">1943000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfb0e9387655417ea47e244e390930c8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTQtMS0xLTI2OTM2Mg_14040173-c78e-4d36-a983-49b78eb649d2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad78bf4198534e099b1e1e8624534d02_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTctMTYtMS0xLTI2OTM2Mg_a5ab9fa5-f79f-4934-a973-5fab0fe7ff2e"
      unitRef="usd">7600000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i34a910c12f414900999d3b059f396d47_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMi0xLTEtMjY5MzYy_d24aeb24-1d3f-4bf0-a505-2a3bdc5251b1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i22f1f58b1a04471faea6d3a37e5320fc_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktNC0xLTEtMjY5MzYy_f2d58104-be0c-4d24-8ef9-2f836ffe5eec"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie0463a71817c4cca9f2913df58ccc458_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktNi0xLTEtMjY5MzYy_cb533e10-6fa0-49ca-9429-dbc6a025c5b4"
      unitRef="usd">277000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2e6d5fe3d48b4ebc8612932358fce8e6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktOC0xLTEtMjY5MzYy_84836dc9-d846-4256-9f83-f2c45af5003b"
      unitRef="usd">277000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1dcae5f616154d2bb06f9c392d252555_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTAtMS0xLTI2OTM2Mg_0f00b736-a068-41a7-ad47-61bba7c3f0c9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i35c466bd362f400780c77e751afc2c34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTItMS0xLTI2OTM2Mg_372d154d-2473-4e57-8c7e-b04e253305b5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i800882dc4b244976915f007c452e0fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTQtMS0xLTI2OTM2Mg_d17b7262-9338-4375-9499-9866795a96cf"
      unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i064e703fbfd049878de89e2a1c5dc621_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMTktMTYtMS0xLTI2OTM2Mg_899520d2-dbb4-4641-8baa-a5643862e538"
      unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ibe5e217a5b1140728f4602157db87e2c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMi0xLTEtMjY5MzYy_03e4f1f7-d28b-412f-980a-1f0b98915648"
      unitRef="usd">249000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i2b9f0b6b0b844305a53445354ae194cb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtNC0xLTEtMjY5MzYy_4e232b7b-5e99-4abd-b2b6-89ee723fcde9"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ib183b8cea0954d138ad44af200a84877_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtNi0xLTEtMjY5MzYy_a8ebe701-f305-4e7d-851c-1357c3657e85"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ib6ee26b0e08842a0b843c4ac42a50e93_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtOC0xLTEtMjY5MzYy_050ed7f2-6174-49dc-be7f-f72a3c92b47b"
      unitRef="usd">249000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i5f1d8684d26247aa83ef85ca707fbd8a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTAtMS0xLTI2OTM2Mg_45cc998b-8b57-411c-a4e5-af05edb0cd3d"
      unitRef="usd">220000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i9d573c781b70449f9e9416cded0054a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTItMS0xLTI2OTM2Mg_5d66c134-5a72-44d8-b9ea-4fd641856d7f"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ic05635ce202a4083958412667e099ed2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTQtMS0xLTI2OTM2Mg_447a5078-18a5-432b-9ac6-07d458ce8a7c"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i5b368b49d37a4ee69978906222ce4b5c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjAtMTYtMS0xLTI2OTM2Mg_f29a8f80-f95e-497d-95e3-5a0b0881d4ba"
      unitRef="usd">220000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i86fea5742d1f445d9c563566784f0cd0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMi0xLTEtMjY5MzYy_8d07e9f4-3ffc-4b69-a2b8-d71856ae25fa"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i99ee5a60fac74d60b76c288f2df853d3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtNC0xLTEtMjY5MzYy_96d71aa5-3af6-4986-93fb-339b41014aa2"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i9a06827286fe4c8183a9be9be74fe8f4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtNi0xLTEtMjY5MzYy_3e134989-2061-46d3-b409-358cce7f2daa"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia9ac4e1620e6498cb5b443b7ad7d32d3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtOC0xLTEtMjY5MzYy_45bd8a25-e0c3-4768-882c-d11d4fe953fb"
      unitRef="usd">49000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6bda1d98cbaf438cbb28ebe26c09665e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTAtMS0xLTI2OTM2Mg_26bf9274-e02f-46de-9cd9-99a3a14cd0ef"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="id927ab0d29884827bea7bcaf3d2dc398_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTItMS0xLTI2OTM2Mg_9210e037-c904-4418-aee9-f612a722d2c8"
      unitRef="usd">42000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i7dde228737e648788d98fb2fc1d4ac58_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTQtMS0xLTI2OTM2Mg_8c84ae09-b4a3-4588-afb0-bdc094b805c4"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i7df8c0d093bf48b2b63cba32a6131249_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjEtMTYtMS0xLTI2OTM2Mg_4d7dffde-b7e9-468b-b239-871a31b08499"
      unitRef="usd">42000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2e78ed5854ff4c45958a4d133cd9890a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMi0xLTEtMjY5MzYy_ded4be3f-65c8-43a0-bc6a-d7f48c28d423"
      unitRef="usd">249000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibe1f122ae8f14eae930697c79bf7af6d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItNC0xLTEtMjY5MzYy_114aebd0-55fa-4545-ba19-96ac26e6e74c"
      unitRef="usd">49000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i69013ac8af5f45c896d0e14dc6876b0d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItNi0xLTEtMjY5MzYy_cf30a386-60e7-4709-afd3-c9260e6959c1"
      unitRef="usd">277000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i825aac04e24b40208c807dce228c07fb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItOC0xLTEtMjY5MzYy_cb1565ec-1505-47ed-a1b4-a22fd79eae4b"
      unitRef="usd">575000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iedc3b620a74946d7bac3bf26a9c4ce16_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTAtMS0xLTI2OTM2Mg_024695ee-6ae7-461e-864f-9e42d00541e2"
      unitRef="usd">220000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6385da92df654fb6967cea6114292f4f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTItMS0xLTI2OTM2Mg_b2634b2e-73b0-4234-94e1-b88fead56436"
      unitRef="usd">42000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibfb0e9387655417ea47e244e390930c8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTQtMS0xLTI2OTM2Mg_5e20454c-2f8d-4b0f-82d3-0d4e4c493864"
      unitRef="usd">275000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iad78bf4198534e099b1e1e8624534d02_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjFkYjdiNmJlNThlMzQzMjY4YTFkNWY0OTU1MTJiYTMwL3RhYmxlcmFuZ2U6MWRiN2I2YmU1OGUzNDMyNjhhMWQ1ZjQ5NTUxMmJhMzBfMjItMTYtMS0xLTI2OTM2Mg_d933f899-fd2e-488a-9a60-7b4f7ac54c4c"
      unitRef="usd">538000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM3OA_3f0972e0-69f2-4012-9345-5c4998dd1613">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Derivative Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we are subject to a potential contingent consideration payment of up to &#x20ac;300 million, subject to customary adjustments, which is revalued each reporting period using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex until the related contingency is resolved.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzI5ODUzNDg5NzUyNA_80298157-6c82-4ccd-bd4f-81b695d5d55e">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6c191e188eb0435a839aff2e83dc0b7f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzgwMw_f71ea07d-9812-4205-9adb-f53667a7dbf0"
      unitRef="usd">22600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ibfcf3730e7494e1eac9bdd409e112df2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzgxMA_1c3d1639-c7e3-4f4e-b7c9-dc16699be88f"
      unitRef="usd">21900000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1ed3bb87a65d43c99c02e4fc37036b3e_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzg4MA_20398b6c-8be6-45fa-bd49-9c9627914c97"
      unitRef="usd">24100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1daea506fa054411b9fcccb4c301cc61_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMzg4MA_c20c1b08-1008-445a-b662-3534686cf740"
      unitRef="usd">24100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4162868d814a43e3aaf697b3f77e900a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTQ5NzU1ODI4MDI2_999402da-7b94-4e58-b61a-25f637f01557"
      unitRef="eur">300000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTM3MQ_b249aa41-3fac-4466-beac-049b2f487b43">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in fair value of our contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation assumptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Research and development expenses on our Condensed Consolidated Statements of Income. The change in 2023 primarily related to updated expected payment dates and the change in 2022 primarily related to updated probability rate estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i05b4776cc8f6409e92531b2b339c0031_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfMy0yLTEtMS0yNjkzNjI_197b039f-e0d2-4f6d-a430-c0f52d5108cc"
      unitRef="usd">275000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7670407a0204455084b40c8717c401e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfMy00LTEtMS0yNjkzNjI_6528337e-4234-4129-9142-2603ea8e3068"
      unitRef="usd">317000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ibfb395164c844896b27f93a01db7e27f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNS0yLTEtMS0yNjkzNjI_c5580b38-adc9-46d0-942a-a76eaac4ab5a"
      unitRef="usd">-3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i821c4ec6a7fd4cd4b53462e6dc41da64_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNS00LTEtMS0yNjkzNjI_a00b262c-f035-4f2f-a78a-79e458f2c77f"
      unitRef="usd">10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement
      contextRef="ibfb395164c844896b27f93a01db7e27f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNi0yLTEtMS0yNjkzNjI_b34fdb45-a045-46c7-85d6-511ccf13ebca"
      unitRef="usd">5000000</gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement>
    <gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement
      contextRef="i821c4ec6a7fd4cd4b53462e6dc41da64_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNi00LTEtMS0yNjkzNjI_7acbebc0-8382-4e94-958b-dde333f747da"
      unitRef="usd">-6000000</gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9b15ded1f1714d829d737d7f8ba59153_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNy0yLTEtMS0yNjkzNjI_14c1ac6f-278a-40c5-8b03-49574db3bccd"
      unitRef="usd">277000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia5beeadbee5b426383f472cd603bccb1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RhYmxlOjM5OThkMzc0NzEwYzRmMTlhMDAxNjdjNDhlN2FmMzUwL3RhYmxlcmFuZ2U6Mzk5OGQzNzQ3MTBjNGYxOWEwMDE2N2M0OGU3YWYzNTBfNy00LTEtMS0yNjkzNjI_c0866e74-10db-4811-bc3a-6118d6d7f567"
      unitRef="usd">322000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="if8bffbfdebfe4c0a8714dfe49168e8a0_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNDk0OA_1db84b48-0adb-46f7-ba92-676b48c7632a"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i3f93855d6db44024b333d78df947f56c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNDk0OA_7840317b-c23a-42d9-9c39-3fa6a595d631"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ia97bd7f721914df1bcf6152d4c3d17b4_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTAxNg_a3c2ccbb-ce77-4154-9ba4-368850ce83b5"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i62ecf657b38947f592054cba9b58c1a8_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfNTAxNg_f0f942e9-2f5b-4479-94c9-40741c99842a"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i9a2868046c1c40f5b963d0310b6e2c28_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80MC9mcmFnOjNmNjgzYWZjM2VmNzQ1OTY5NGJjOTc1OTU3MTdkY2I1L3RleHRyZWdpb246M2Y2ODNhZmMzZWY3NDU5Njk0YmM5NzU5NTcxN2RjYjVfMTA5OTUxMTYzNzYxMQ_e626da3f-80e0-4b84-b0e2-8b1cea28d944"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjEyNw_c36530ae-5165-4572-866a-63d8d48287be">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No allowance for credit losses was recognized for investments with unrealized losses as of March&#160;31, 2023 as the unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments. We do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments and other equity investments without readily determinable fair values were $333 million&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $423 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrealized Gains and Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net unrealized losses recognized on equity securities were $256 million and $96&#160;million for the three months ended March 31, 2023, and 2022, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjExMw_75f1d359-6708-4b43-a865-3b0006d2209d">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0yLTEtMS0yNjkzNjI_f844891d-3b58-4c11-b01f-9950b59d5f9a"
      unitRef="usd">346000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi00LTEtMS0yNjkzNjI_cf334407-6ec5-4bc6-96f7-4756766da99a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi02LTEtMS0yNjkzNjI_d7852cbf-3369-4824-a3b9-3bb9b4044e69"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi04LTEtMS0yNjkzNjI_35781970-f43c-4b5f-8e3c-5245538c61ca"
      unitRef="usd">344000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xMC0xLTEtMjY5MzYy_85413941-a9e3-4bf5-9043-599950184692"
      unitRef="usd">415000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xMi0xLTEtMjY5MzYy_fded2b13-2843-4e6c-a597-b0a4e4cd4f8b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xNC0xLTEtMjY5MzYy_6d507cc2-05a0-408c-a737-03fcb93304fa"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMi0xNi0xLTEtMjY5MzYy_76772c2b-8b2f-4e36-829b-47928f7645b0"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0yLTEtMS0yNjkzNjI_755c7427-b405-4284-8d5f-98ef932e6f13"
      unitRef="usd">156000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy00LTEtMS0yNjkzNjI_b5f19249-445f-4656-8f80-cbad722edeb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy02LTEtMS0yNjkzNjI_b3e2fc46-143e-4121-9154-fda379c3f715"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy04LTEtMS0yNjkzNjI_c6fe21ae-0f88-4258-b85c-5c65519632ba"
      unitRef="usd">155000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xMC0xLTEtMjY5MzYy_4401c391-f619-4dcc-ae18-8c9d3d03e143"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xMi0xLTEtMjY5MzYy_c727839b-1ceb-4e04-b958-0878bbebb1d9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xNC0xLTEtMjY5MzYy_b5f9e688-898a-47b3-97e3-653a22ef6cdf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfMy0xNi0xLTEtMjY5MzYy_26426156-0487-4998-af18-0b823b2a01c3"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0yLTEtMS0yNjkzNjI_9bca3d32-faea-4f6d-a364-0121b06ac551"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC00LTEtMS0yNjkzNjI_fbcf0ed5-018d-4e6b-8600-614462bf8924"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC02LTEtMS0yNjkzNjI_26f4024d-31e0-4bcd-ba6b-701662e006b8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC04LTEtMS0yNjkzNjI_b15d8e2f-afab-4092-8fb4-ea7df2ea2ebf"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xMC0xLTEtMjY5MzYy_bb11ca0e-ca71-439e-a9a1-b3c11678e9b3"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xMi0xLTEtMjY5MzYy_e945b14b-88e7-4ca7-aedc-8f32b96cf6e9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xNC0xLTEtMjY5MzYy_afe88da8-70b6-429c-9cd5-c2b1ea068d3d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNC0xNi0xLTEtMjY5MzYy_0cd294a6-5f31-45da-9b7c-1771800c23de"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0yLTEtMS0yNjkzNjI_e9daac95-a17d-4c7d-a14b-f221e85f835c"
      unitRef="usd">90000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS00LTEtMS0yNjkzNjI_0c8906d0-1832-4d34-817d-d89365e85c30"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS02LTEtMS0yNjkzNjI_20965dc0-881e-48f6-8ec2-638c3d5c0fca"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i59af451f1a45414e92cb058f5ca094fb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS04LTEtMS0yNjkzNjI_2ef99c1e-16bd-4de2-bc00-d5800c0c27fd"
      unitRef="usd">90000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xMC0xLTEtMjY5MzYy_8bdff428-7717-4071-b009-cea2600b6f1d"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xMi0xLTEtMjY5MzYy_62604674-7dbb-42d6-a1d1-2e002f2a0b05"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xNC0xLTEtMjY5MzYy_e669b9e1-9855-40bb-b319-9bf6051fd240"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id5fd9b5b14e74c698f0940b3bf03463d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNS0xNi0xLTEtMjY5MzYy_417fd88a-f038-4947-b872-2a75b8ecd7b8"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0yLTEtMS0yNjkzNjI_1d62b0b2-99a1-485b-a4ed-84291d021d73"
      unitRef="usd">1400000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi00LTEtMS0yNjkzNjI_8040c8a4-6ad3-4094-a257-2add176e3af2"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi02LTEtMS0yNjkzNjI_bc35dd22-e197-4b26-b842-634bd00fc6ee"
      unitRef="usd">21000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi04LTEtMS0yNjkzNjI_75781ce7-637e-403d-a477-241ee342da5c"
      unitRef="usd">1379000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xMC0xLTEtMjY5MzYy_e4bacb03-c4dd-4a05-921c-9969bb88230e"
      unitRef="usd">1452000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xMi0xLTEtMjY5MzYy_49b25dab-5e5b-45c7-8f6e-a110a2090dfb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xNC0xLTEtMjY5MzYy_47f50990-c5fc-43dc-bf87-fae28ff397f7"
      unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNi0xNi0xLTEtMjY5MzYy_b4c86bfd-9d12-416d-bf73-bebbfdfe0066"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0yLTEtMS0yNjkzNjI_665e2e5a-618f-4244-a2f7-00355324e736"
      unitRef="usd">336000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy00LTEtMS0yNjkzNjI_6ab5377c-e1fc-4636-96cf-7c4b607b3456"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy02LTEtMS0yNjkzNjI_8b29d7ae-42c8-4b57-8dbc-ac15683ef079"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy04LTEtMS0yNjkzNjI_3c165ff4-6868-4716-a74b-7ce7837dacd3"
      unitRef="usd">335000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xMC0xLTEtMjY5MzYy_ac10514f-0f5c-40a5-84c2-d8f9206b983f"
      unitRef="usd">335000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xMi0xLTEtMjY5MzYy_e657be81-8327-446a-8692-3c3705f83912"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xNC0xLTEtMjY5MzYy_480c9375-93db-4166-b023-d6de105f3679"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfNy0xNi0xLTEtMjY5MzYy_811a5d15-4a01-49d3-a085-3c04d0e6b386"
      unitRef="usd">333000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0yLTEtMS0yNjkzNjI_90357f21-4c85-4687-917c-a564c50d1ab6"
      unitRef="usd">2350000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC00LTEtMS0yNjkzNjI_7b82a91b-cc2c-4731-a2b3-fdb36a7bd79e"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC02LTEtMS0yNjkzNjI_12cb1bef-0f2e-4b0b-ba45-e90898c8b750"
      unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC04LTEtMS0yNjkzNjI_d884ce51-72c9-4242-bbfa-c0c0f53affe7"
      unitRef="usd">2326000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xMC0xLTEtMjY5MzYy_5eecd519-9359-4729-9607-548e4051ad15"
      unitRef="usd">2325000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xMi0xLTEtMjY5MzYy_7c13aba1-8655-4290-b6a8-9d44d1cb333f"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xNC0xLTEtMjY5MzYy_2e02bc77-b40f-410b-acbf-0fbdfbf810eb"
      unitRef="usd">34000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjdkM2NhMWM4MjkxZTQxNzhhNTE5Njk4NGZhM2RmMDg0L3RhYmxlcmFuZ2U6N2QzY2ExYzgyOTFlNDE3OGE1MTk2OTg0ZmEzZGYwODRfOC0xNi0xLTEtMjY5MzYy_e9ec2a0e-8bbb-4271-8eed-3a2d65b973f8"
      unitRef="usd">2293000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfNDk0NzgwMjMzMjAxMA_d6752bb9-8ec7-4b96-9c48-c7935fa2bf7a">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy0yLTEtMS0yNzQ4NjI_f77874b6-56e9-43b9-ab8c-61f295b6196a"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy00LTEtMS0yNzQ4NjI_7585a0f6-4048-4bb5-abfb-ac2a27205939"
      unitRef="usd">89000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy02LTEtMS0yNzQ4NjI_31174a0b-85a3-4704-8ca9-edef239c751f"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy04LTEtMS0yNzQ4NjI_bea630c6-0066-46d2-99cb-41d87ad01cc5"
      unitRef="usd">177000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy0xMC0xLTEtMjc0ODYy_901b09f6-9cd0-4ade-a05c-44446a2a7aed"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="icb2f1b96e4fb4f3689024f243694c650_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfMy0xMi0xLTEtMjc0ODYy_4619fa0b-56d8-4792-817c-5719889dbce9"
      unitRef="usd">266000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC0yLTEtMS0yNzQ4NjI_35cbdc3a-4497-4412-990a-eae3d2678334"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC00LTEtMS0yNzQ4NjI_557c5de9-cb9a-4869-98b8-2f56cc54fe2e"
      unitRef="usd">108000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC02LTEtMS0yNzQ4NjI_4fb0bf02-ed74-4f1e-969a-c621ef3b7039"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC04LTEtMS0yNzQ4NjI_74cf20bb-ac5e-4aa5-890d-02c0cccb0694"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC0xMC0xLTEtMjc0ODYy_a9982bf6-b9f7-4614-be24-3d7ede297b1b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3f822206ae424d6e8263029d09d73dd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNC0xMi0xLTEtMjc0ODYy_e327b5c6-49d8-4c41-8d3b-18f00b2ae420"
      unitRef="usd">108000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS0yLTEtMS0yNzQ4NjI_a1d8677b-4deb-4fab-964e-1f92556146d4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS00LTEtMS0yNzQ4NjI_39f7cb6e-1395-412b-a958-740419455f68"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS02LTEtMS0yNzQ4NjI_e73a66f1-5157-488d-960f-7a6d5276d11e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS04LTEtMS0yNzQ4NjI_e398b98b-ddcb-4233-b414-cb5f2104f44a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS0xMC0xLTEtMjc0ODYy_09870062-7e73-4f26-b575-808b9304a23d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i00b41ed9bf3a4f918f3b1b96cc347487_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNS0xMi0xLTEtMjc0ODYy_ed236aeb-c333-4436-93fa-aa81cd344471"
      unitRef="usd">23000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy0yLTEtMS0yNzQ4NjI_2bf961d6-fce2-453f-acde-c34da6b3debd"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy00LTEtMS0yNzQ4NjI_099360f5-547f-4420-bb31-725b537a114a"
      unitRef="usd">451000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy02LTEtMS0yNzQ4NjI_8db8998c-9cf1-4780-9694-7da1d34869fb"
      unitRef="usd">16000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy04LTEtMS0yNzQ4NjI_93fac00d-64e2-44dd-b8cd-c9154225c295"
      unitRef="usd">651000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy0xMC0xLTEtMjc0ODYy_69aacde3-74bf-4edf-8ce3-8d0b182bccb8"
      unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i416dc4eb70914dd983bc1a04995857fd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfNy0xMi0xLTEtMjc0ODYy_27f3ebdf-1b34-49ab-bf0e-cfef87de6ed1"
      unitRef="usd">1102000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC0yLTEtMS0yNzQ4NjI_5180ba5c-a183-4038-8799-e14c81f796f4"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC00LTEtMS0yNzQ4NjI_1725daef-88ae-408f-a447-0b45388df634"
      unitRef="usd">192000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC02LTEtMS0yNzQ4NjI_7459089d-cc8a-489b-b073-2585349f1df6"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC04LTEtMS0yNzQ4NjI_50f2e0d0-9db6-4b41-bbb4-4cd613e1417a"
      unitRef="usd">53000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC0xMC0xLTEtMjc0ODYy_257348a6-b342-4fc1-9b66-4380b9bd495e"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ied61cbd6414f453896de669cb79e2da9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOC0xMi0xLTEtMjc0ODYy_8b838593-7ab8-4ab5-bcfa-1441ff1ad1ba"
      unitRef="usd">245000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS0yLTEtMS0yNzQ4NjI_9d638e5e-e93f-4926-955a-c5262876d72a"
      unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS00LTEtMS0yNzQ4NjI_b2835814-3325-4c22-bb3c-6b4cf6257fd1"
      unitRef="usd">862000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS02LTEtMS0yNzQ4NjI_495055cb-8f21-460f-a91b-0852276319d0"
      unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS04LTEtMS0yNzQ4NjI_01cf50d2-6b03-47fa-9b8a-45c8a69fb647"
      unitRef="usd">880000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS0xMC0xLTEtMjc0ODYy_ecac2c69-b942-4776-86d4-5607289fae30"
      unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjA3Y2Y2YzA0ZDgyMzQ3YTBhMWIwNjY2NjY4MWQ1NjJiL3RhYmxlcmFuZ2U6MDdjZjZjMDRkODIzNDdhMGExYjA2NjY2NjgxZDU2MmJfOS0xMi0xLTEtMjc0ODYy_ed2aa53e-4960-4d7a-87bb-4f4c0de6437c"
      unitRef="usd">1743000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy0yLTEtMS0yNzQ4NjI_765f619a-a0e9-44bb-a46d-128abd494595"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy00LTEtMS0yNzQ4NjI_a7ae1c1c-45b8-4992-a949-86deff5d7610"
      unitRef="usd">174000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy02LTEtMS0yNzQ4NjI_4d9fabd1-b0cd-45a7-845e-81bb24b7e9b7"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy04LTEtMS0yNzQ4NjI_fa4e0177-4d16-4bdb-9d32-1d60bda74762"
      unitRef="usd">206000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy0xMC0xLTEtMjc0ODYy_59193321-1925-4170-bd70-b1a2826b4139"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7d45d1db32724a06802d1990305aee2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfMy0xMi0xLTEtMjc0ODYy_1afee0bb-3be4-4c4e-ade5-284873812bca"
      unitRef="usd">379000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC0yLTEtMS0yNzQ4NjI_ef2b28f2-7855-4a67-a924-c0fc6489678a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC00LTEtMS0yNzQ4NjI_9a0ae341-0343-4c84-8740-184bc5f02397"
      unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC02LTEtMS0yNzQ4NjI_06d0da55-3a33-4232-9fa6-6e6ac0a9d2b4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC04LTEtMS0yNzQ4NjI_679e9148-8737-435c-9c51-aded54f95e8b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC0xMC0xLTEtMjc0ODYy_a5d0a5de-ef06-4224-8a75-444d73a3076e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4044808fa02946568c1a7cda0f2b4105_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNC0xMi0xLTEtMjc0ODYy_1f1f749a-a70e-4999-a0d5-d8cc530836c6"
      unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS0yLTEtMS0yNzQ4NjI_74c324bc-a8b8-4327-878d-e74825189f68"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS00LTEtMS0yNzQ4NjI_2806deb0-0d5c-48fb-bd78-22b61766132a"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS02LTEtMS0yNzQ4NjI_0a32496a-f503-4fc3-8b7a-127d223a05d8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS04LTEtMS0yNzQ4NjI_0f80680f-6892-4ca7-b644-759d34c01edf"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS0xMC0xLTEtMjc0ODYy_83dbcfaa-1bbd-430d-b9e3-06dcdd1a8c5d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i54d199eaa87840c0a4d4f70f7a8421d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNS0xMi0xLTEtMjc0ODYy_e1894d3f-143c-4d71-8d66-609afc9c268d"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy0yLTEtMS0yNzQ4NjI_0f75a962-df21-4327-bfaa-5d4862e82ddc"
      unitRef="usd">17000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy00LTEtMS0yNzQ4NjI_bb4d4b77-bdc4-41ed-b0ab-392d4947ec7d"
      unitRef="usd">774000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy02LTEtMS0yNzQ4NjI_c371e1a6-b710-438b-b728-e7c44cb37024"
      unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy04LTEtMS0yNzQ4NjI_99a3c106-bb70-42fb-84a6-c4ed2c40786e"
      unitRef="usd">439000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy0xMC0xLTEtMjc0ODYy_2b2a0998-af48-4e24-bfda-02e67b991113"
      unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ifb7af46ffb3e46329ea1f12b52941b2a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfNy0xMi0xLTEtMjc0ODYy_43e85479-3b94-4152-8b7c-78d24cfd6c7c"
      unitRef="usd">1213000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC0yLTEtMS0yNzQ4NjI_af5ff988-11c1-40aa-9237-0068cd2d361a"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC00LTEtMS0yNzQ4NjI_9f4d885f-80cb-4bdf-a6a3-3a275d043b70"
      unitRef="usd">205000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC02LTEtMS0yNzQ4NjI_aeffe6e2-d546-472e-8ced-04b62fe8411a"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC04LTEtMS0yNzQ4NjI_0c43fb82-86df-42c3-ba74-8f68af14f4b4"
      unitRef="usd">56000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC0xMC0xLTEtMjc0ODYy_74e35433-ecb6-41c9-9258-3e883be10dad"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3ed5ea9fddae4be1b98b90febc6c39b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOC0xMi0xLTEtMjc0ODYy_7330d13b-656f-4d28-8fa2-333f93a71549"
      unitRef="usd">261000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS0yLTEtMS0yNzQ4NjI_681278d5-e027-439a-96d6-2be10797bf46"
      unitRef="usd">22000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS00LTEtMS0yNzQ4NjI_7374ddad-1bbd-4796-a295-452e281d401e"
      unitRef="usd">1204000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS02LTEtMS0yNzQ4NjI_197f8002-5230-449e-9383-f545d935ab27"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS04LTEtMS0yNzQ4NjI_e30e8b95-32fe-4812-98e0-3a03b0ed7adc"
      unitRef="usd">705000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS0xMC0xLTEtMjc0ODYy_5551e6d6-81ea-401b-b3e3-13dbfe559dd8"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmU3MTlkYWU5MWNjMjQ0ZWE5YWNhY2NkOWFhZTZkNjUxL3RhYmxlcmFuZ2U6ZTcxOWRhZTkxY2MyNDRlYTlhY2FjY2Q5YWFlNmQ2NTFfOS0xMi0xLTEtMjc0ODYy_84bee0de-42d2-4d5c-bbf2-6fd794e452fd"
      unitRef="usd">1908000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTA5OTUxMTYzMDU4Mw_ec83a4de-f3df-4687-b22a-042cf6deb857"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjEyNQ_16a1f23f-fa08-487b-b626-ad5726422140">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6e9f4eec9e644776964e5a8b7a54bd46_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMS0yLTEtMS0yNjkzNjI_8a5f052a-dba0-40b4-9348-1e127cf8905e"
      unitRef="usd">63000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iec2e973c5db44ac4ae316708dcf05f82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMS00LTEtMS0yNjkzNjI_71b3e768-b992-4d31-b2c0-dc242a6ab1eb"
      unitRef="usd">75000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i510d5f78872c4535851a18295b4f79b6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMi0yLTEtMS0yNjkzNjI_b5f690a6-12f9-4601-9f61-230d267f12fd"
      unitRef="usd">936000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic5ee9e4a34394e0981b4f0da01de2965_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMi00LTEtMS0yNjkzNjI_259bb323-1b25-4abd-af07-6ef9e7fd4c9b"
      unitRef="usd">973000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id87e5e8c32c24d6b861c84c1383d9257_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMy0yLTEtMS0yNjkzNjI_5289bd89-a6f3-44f3-b822-750331523241"
      unitRef="usd">1327000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9c3d373c59d041b98c7a3bfed37f67b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfMy00LTEtMS0yNjkzNjI_b1630379-15c1-4e26-9846-e5569d92ffbf"
      unitRef="usd">1245000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfNC0yLTEtMS0yNjkzNjI_aeba9180-bc55-47b7-894f-ae6e28c9800b"
      unitRef="usd">2326000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjIxNDkwYjA2NzdlMjQ3MjVhOTFiMjM5ZGQ1YzIzNGFkL3RhYmxlcmFuZ2U6MjE0OTBiMDY3N2UyNDcyNWE5MWIyMzlkZDVjMjM0YWRfNC00LTEtMS0yNjkzNjI_eb996be0-b505-45c5-880c-89b03ebfe3cc"
      unitRef="usd">2293000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjEyMQ_cf1f6298-015e-4721-a50a-c98c8d7f7caf">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMi0yLTEtMS0yNjkzNjI_f105dece-c9c2-47ea-bf4f-ceb5d2061e31"
      unitRef="usd">1006000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMi00LTEtMS0yNjkzNjI_62a0caf0-114b-450d-bfff-7b01e1fcd76a"
      unitRef="usd">999000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMy0yLTEtMS0yNjkzNjI_9e79c203-cecc-4590-9bdc-46390b4e0197"
      unitRef="usd">1325000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfMy00LTEtMS0yNjkzNjI_678ca2ce-84ae-487c-9209-4acefce9fb7d"
      unitRef="usd">1308000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNC0yLTEtMS0yNjkzNjI_0f2b4b7d-def8-4e66-b2de-d485dbc982ad"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNC00LTEtMS0yNjkzNjI_0db4bf4e-f659-49b8-8b5d-7ff831c1ad7c"
      unitRef="usd">14000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNS0yLTEtMS0yNjkzNjI_056b734d-29b0-4810-8ee3-2f75a361aaeb"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNS00LTEtMS0yNjkzNjI_1b0804bf-ab83-4d1d-998d-773334c1d3fb"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNi0yLTEtMS0yNjkzNjI_3cc7ba34-d35c-498c-9f47-9238f25b0d72"
      unitRef="usd">2350000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOmM3MzRkZGY0ODc2MjRkMGNhZDkzYWUwNmU5NDY3ZjdlL3RhYmxlcmFuZ2U6YzczNGRkZjQ4NzYyNGQwY2FkOTNhZTA2ZTk0NjdmN2VfNi00LTEtMS0yNjkzNjI_a86b7c82-1f37-4df5-beb2-cfe7334470a7"
      unitRef="usd">2326000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjE0NQ_99d65e69-3a9a-41ba-a774-b42eecfa3e50">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;(1) &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6e9f4eec9e644776964e5a8b7a54bd46_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMS0yLTEtMS0yNjkzNjI_6b857f45-89ec-43c8-a050-60a5cffccbfb"
      unitRef="usd">3175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iec2e973c5db44ac4ae316708dcf05f82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMS00LTEtMS0yNjkzNjI_9b5c1bbc-7a6f-4d22-a2e5-75fb8e61c341"
      unitRef="usd">3831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iba2356957a154f63a357aa595e78976a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMi0yLTEtMS0yNjkzNjI_9cbdcb34-7368-42bc-b2e8-ad2fbcfc6ecd"
      unitRef="usd">394000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6343117edb334debb880ca01f650cb9f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMi00LTEtMS0yNjkzNjI_70389aa2-602f-400a-a8d7-446ff8d4c373"
      unitRef="usd">473000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic51b601fb20040c198873c13a12ac3d8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMy0yLTEtMS0yNjkzNjI_283f95e1-7464-4876-a795-72aa976d7fb1"
      unitRef="usd">982000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibfc9e7315e954128826864d8f2720166_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfMy00LTEtMS0yNjkzNjI_89c36bef-3acf-485b-ad38-2f828fc7bec0"
      unitRef="usd">943000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d904395d75449c6b4a29ead472571b4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfNC0yLTEtMS0yNjkzNjI_e575f6fe-527a-4101-9273-891b8a63b693"
      unitRef="usd">4551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d6353ae110f4676995da4b3e2534756_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RhYmxlOjM4MDM0ZmI1MzQ3NjQ2NGNhZjA0ZmE0NmEyZTdhZjg4L3RhYmxlcmFuZ2U6MzgwMzRmYjUzNDc2NDY0Y2FmMDRmYTQ2YTJlN2FmODhfNC00LTEtMS0yNjkzNjI_34aa8253-f40f-4a31-8129-778433601bbb"
      unitRef="usd">5248000000</us-gaap:AssetsFairValueDisclosure>
    <gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTQzNg_c6f896a5-bcd4-4b02-acfa-a0b4ffb1d4ec"
      unitRef="usd">333000000</gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount>
    <gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTQ0Mw_919e288d-ca5a-4f11-a0d6-2207c07d650d"
      unitRef="usd">423000000</gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMTYwMA_4e5aae3c-b921-4585-8c2b-2de1cfb1f70e"
      unitRef="usd">256000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80My9mcmFnOjEwNmExMDIyNjk3ZjQ3ZTg5MGY2MDU0MjE5M2I3ODFhL3RleHRyZWdpb246MTA2YTEwMjI2OTdmNDdlODkwZjYwNTQyMTkzYjc4MWFfMjE5OTAyMzI2MTgwMg_1323ca9e-b5ab-45a4-a9e8-6bd4b498ace2"
      unitRef="usd">96000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjk5Mw_0695c3b0-51f7-433f-8291-27dc94eaa30f">DERIVATIVE FINANCIAL INSTRUMENTS&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held foreign currency exchange contracts with outstanding notional amounts of $2.9 billion as of March&#160;31, 2023 and $3.0 billion as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 25.75pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) recognized in Accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain reclassified from Accumulated other comprehensive income into Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of March&#160;31, 2023 are expected to be reclassified to Product sales within 12 months. There were no discontinuances of cash flow hedges for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the three months ended March 31, 2023 and 2022 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzNTQxMA_a9c84102-932f-4724-8a07-06e064e1e0be">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjI5MQ_777f61db-60c6-4922-ba41-4d99244c1c2d"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjMwNw_f079eaa6-a770-4830-8836-6c8d43e43faf"
      unitRef="usd">3000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjk3Mw_8cb88ae9-0f7c-4f7c-a3a7-3baca6c9b4d6">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 25.75pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Condensed Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 28pt 2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i5635d77dfe96415b8fb073a7a5cea4f6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNC00LTEtMS0yNjkzNjI_76596b10-f186-4995-b465-b52b38b7de66"
      unitRef="usd">30000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ie22760aef3ef40599b18170cf792b16b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNC04LTEtMS0yNjkzNjI_a49867ca-d964-4356-be8a-62444866bd1f"
      unitRef="usd">35000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i711389022cab421e9b3754a803e7423a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNS00LTEtMS0yNjkzNjI_6caff572-4be3-474b-9230-e5c46c0b9a38"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i5acaacfcea4242ec9bbcbe69b9091425_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNS04LTEtMS0yNjkzNjI_ac4199bc-c433-4c11-bb45-495b59759d69"
      unitRef="usd">3000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0206d1fc4e7644e2afbdb52420fef11b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNi00LTEtMS0yNjkzNjI_ddb81187-3f06-41f2-a263-13908e72853d"
      unitRef="usd">31000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0206d1fc4e7644e2afbdb52420fef11b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfNi04LTEtMS0yNjkzNjI_4d919148-8ae0-427a-8371-df9a755c0912"
      unitRef="usd">38000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i725217d7109d45ce87fd002dc195f7c6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOC00LTEtMS0yNjkzNjI_577b622c-3a95-4838-bd14-1792071cee1b"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3c6fdd16179f433088b6dc239a41cdd7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOC04LTEtMS0yNjkzNjI_1cdf8e3e-797c-49f8-a910-6a3a5263f55d"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="idc5853354bfe4cce8964c6ee51f3ad72_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOS00LTEtMS0yNjkzNjI_7f03cb27-5f05-4ddd-ae60-65f7242550d5"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="idc5853354bfe4cce8964c6ee51f3ad72_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfOS04LTEtMS0yNjkzNjI_940e6e62-eec6-40ea-bbbc-742a91ccab05"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTAtNC0xLTEtMjY5MzYy_43ae392b-6252-44b0-ba3d-750a4af37f74"
      unitRef="usd">32000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTAtOC0xLTEtMjY5MzYy_5378021a-5ce6-4bbe-9bdd-bae1cfcc62ba"
      unitRef="usd">49000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTMtNC0xLTEtMjc1NDAx_1859db4c-d5aa-4b8c-9d2b-c70386fa67d0"
      unitRef="usd">24000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTMtOC0xLTEtMjc1NDAx_81c9bf05-bf39-4b21-b19f-e217f1337908"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTQtNC0xLTEtMjc1NDAx_82d30df3-9f50-465a-885d-ccccc41455cc"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTQtOC0xLTEtMjc1NDAx_a7f0a02a-f570-40ba-bec8-8e1dd7e3f973"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTUtNC0xLTEtMjc1NDAx_be46b34d-c546-48e0-8c49-069efccf557a"
      unitRef="usd">7000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjY3NDM2NmFiOGJiMTQ2OGU4ZjQwODhmOTQyOWIxNmRjL3RhYmxlcmFuZ2U6Njc0MzY2YWI4YmIxNDY4ZThmNDA4OGY5NDI5YjE2ZGNfMTUtOC0xLTEtMjc1NDAx_317266c9-d74a-4ff3-b46a-be8fb3bf6b3d"
      unitRef="usd">25000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="idbb59ef088a34337a2c34aded0358835_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNC00LTEtMS0yNjkzNjI_c4843b80-9e0a-41b1-a5c4-673d23d7e94e"
      unitRef="usd">59000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0273ef720045479f9a269b27d3e723bc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNC04LTEtMS0yNjkzNjI_32b8aaaa-30ed-4e6e-b5f5-8830750fbe09"
      unitRef="usd">26000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8b209667eea74724a7b9275aafea9399_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNS00LTEtMS0yNjkzNjI_bbc146c3-206d-44b2-939e-8a16f19bfe88"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2b4ed3db406545adbb4af3cbdee68817_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNS04LTEtMS0yNjkzNjI_65cd4307-6948-4abd-8a4d-73754f9e79a1"
      unitRef="usd">9000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i17f7dcb7986040429aa8c1583d69150a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNi00LTEtMS0yNjkzNjI_70310f96-9718-45ed-a2c3-0a3ac2b8a568"
      unitRef="usd">59000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i17f7dcb7986040429aa8c1583d69150a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfNi04LTEtMS0yNjkzNjI_6dae1954-9f2a-4ea0-aa0c-8543de7ba4ff"
      unitRef="usd">35000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic7080bfe269540189101c2421e6675ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOC00LTEtMS0yNjkzNjI_ac4dcc90-288a-4c76-b015-3f3d76a64fd6"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i73c00e7d8b1e4ef485fcb73e58436bd3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOC04LTEtMS0yNjkzNjI_aa770035-9706-42ed-b2e4-f119ad5866b7"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ib882e81dd83841ac984af47ed8b513e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOS00LTEtMS0yNjkzNjI_309c2964-4c4a-4ea1-adb4-f7c6c73b3eb4"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ib882e81dd83841ac984af47ed8b513e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfOS04LTEtMS0yNjkzNjI_6dcead08-977f-43dc-ba97-69537bc3c9d5"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTAtNC0xLTEtMjY5MzYy_b618ae0a-8d4f-407d-8bb9-24a7ced8f722"
      unitRef="usd">60000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTAtOC0xLTEtMjY5MzYy_2b338e58-a004-4b34-81cb-e34fe7bc385c"
      unitRef="usd">42000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTMtNC0xLTEtMjc1NDE4_a904e35b-f10a-4d84-9c17-cf7b052238b8"
      unitRef="usd">36000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTMtOC0xLTEtMjc1NDE4_a3c7eb51-1c1d-41e3-8406-078ee145239b"
      unitRef="usd">36000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTQtNC0xLTEtMjc1NDE4_0c5c4c89-0069-4eed-a39a-1a9194a59820"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTQtOC0xLTEtMjc1NDE4_416c4ab2-0e12-4840-9b62-9d68b2e8ff4f"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTUtNC0xLTEtMjc1NDE4_78d4bc7b-34e4-461f-8122-00bcf51385e0"
      unitRef="usd">25000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhlZDk4ZjJiODU3NDRkN2FhOGM3MGQ1ZmZkOTE4YmQ0L3RhYmxlcmFuZ2U6OGVkOThmMmI4NTc0NGQ3YWE4YzcwZDVmZmQ5MThiZDRfMTUtOC0xLTEtMjc1NDE4_e85fc7aa-3e60-4017-81a9-61f3ffc2bda5"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMjk2NA_dba4e405-c3e6-46f2-9e80-1ab6bc9d8dd8">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) recognized in Accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain reclassified from Accumulated other comprehensive income into Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNC0yLTEtMS0yNjkzNjI_66a4871c-b467-4451-984f-967da07001e1"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNC00LTEtMS0yNjkzNjI_047d7010-f956-4668-b4fb-827a359fdbfe"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNS0yLTEtMS0yNjkzNjI_9b2c8aca-9df2-4dba-b575-8fe761da5d2b"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNS00LTEtMS0yNjkzNjI_97760705-5db5-4e85-8887-39939a7d2328"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNy0yLTEtMS0yNjkzNjI_41e5effb-bc64-4d37-852f-4279bef0eb32"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RhYmxlOjhmOGIyNTAzYmE2MjQyNGM4MjhhNzM4NmUxNDYzM2Y2L3RhYmxlcmFuZ2U6OGY4YjI1MDNiYTYyNDI0YzgyOGE3Mzg2ZTE0NjMzZjZfNy00LTEtMS0yNjkzNjI_5d7a445a-1207-4e46-b3bf-9c78830ff7e1"
      unitRef="usd">19000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="i1318af24ad124c9e99c5c8711d62dcd7_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzMzUzNw_6d4f57ed-c879-427c-b215-9a355a4695d2">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzMzU1NA_12f0a02d-7d4e-4e22-8e6a-b16fa90c9e32"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF80Ni9mcmFnOjQ5ZTI1OGI5ZTM0MzRhNmQ5NzhkZDUxMjQxYjkwN2JkL3RleHRyZWdpb246NDllMjU4YjllMzQzNGE2ZDk3OGRkNTEyNDFiOTA3YmRfMTA5OTUxMTYzMzU1NA_263f4969-774e-4d33-9a2a-e488cc1d3b55"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzM4NDgyOTA3MDg0MTE_8c8694a6-586d-4048-aad9-e9a309a3376a">ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTSWe enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tmunity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, we closed an agreement to acquire Tmunity Therapeutics, Inc. (&#x201c;Tmunity&#x201d;), a clinical-stage, private biotechnology company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $300&#160;million in cash consideration. As a result, Tmunity became our wholly-owned subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the transaction as an asset acquisition and recorded a $244&#160;million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income during the three months ended March 31, 2023. The remaining purchase price relates to various other assets acquired and liabilities assumed, consisting primarily of deferred tax assets. Under the agreement, the former shareholders of Tmunity and the University of Pennsylvania are eligible to receive a mix of up to approximately $1.0 billion in potential future payments upon achievement of certain development, regulatory and sales-based milestones, as well as royalty payments on sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Collaborations and Other Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Arcellx&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, Inc. (&#x201c;Arcellx&#x201d;) to co-develop and co-commercialize Arcellx&#x2019;s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma, and potential future next-generation autologous and non-autologous products. In conjunction with the collaboration agreement, we recorded a $212 million charge to Acquired in-process research and development expenses on our Condensed Consolidated Statements of Income during the three months ended March 31, 2023, primarily related to an upfront payment, as well as a $115&#160;million equity investment, which is subject to lock-up provisions until July 2024, in Other long-term assets on our Condensed Consolidated Balance Sheets. The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales. Arcellx is eligible to receive performance-based development and regulatory milestone payments of up to $835 million related to CART-ddBCMA, a potential future next-generation autologous product and a potential future non-autologous product, with further commercial milestone payments, profit split payments on co-promote products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts-in to co-promote on the future products. If additional future products are developed, Arcellx would be eligible to receive additional milestone payments, profit split payments on co-promote products and royalties on at least a portion of worldwide net sales, depending on whether Arcellx opts-in to co-promote these additional future products as well.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pionyr&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, we entered into a transaction with Pionyr Immunotherapeutics (&#x201c;Pionyr&#x201d;), a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate agreements, one related to the initial acquisition of a 49.9% equity interest in Pionyr and the other providing us with the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (&#x201c;Pionyr Merger and Option Agreements&#x201d;). The exclusive option had an estimated fair value of $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. In March 2023, we waived our exclusive option to acquire Pionyr and certain other rights under the Pionyr Merger and Option Agreements and recorded a $70 million charge to Other income (expense), net on our Condensed Consolidated Statements of Income. We will retain our equity interest in Pionyr as well as the right, under certain conditions, to review new data as it emerges.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <gild:PaymentsForAssetAcquisitions
      contextRef="i644b5cd4730b4d5982cd086b35235aeb_D20230222-20230222"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzEzMzM_6e60959c-9fc5-4390-ba9c-6a3edbdb1cc3"
      unitRef="usd">300000000</gild:PaymentsForAssetAcquisitions>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i506cbd3ce6ca465992effd4d69548672_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzIxOTkwMjMyNjIzNzA_7399c2ec-a1e6-462f-a85a-f7ec558eedd9"
      unitRef="usd">244000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="ie59389bcaac841308152584683c981e2_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzU0OTc1NTgyOTkzNQ_4cf0f006-5754-4e3a-860d-31123da206ad"
      unitRef="usd">1000000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if7e7f985abe641bf816e52117d2bceef_D20230130-20230130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzgyNDYzMzcyMTk2OTU_845f7972-64cb-4d8c-aa8b-b22bcab42074"
      unitRef="usd">212000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="if7e7f985abe641bf816e52117d2bceef_D20230130-20230130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzM5NTE_15f8faee-0856-46f1-b040-74117dcd3ee9"
      unitRef="usd">115000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:RevenuePerformanceObligationPercentageOfUSProfits
      contextRef="i7994adfb551a4093b62e6cfbc11bfe49_I20230130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzQxODQ_5a68e467-6388-4eba-a0b7-23806bc9e14b"
      unitRef="number">0.50</gild:RevenuePerformanceObligationPercentageOfUSProfits>
    <gild:RevenuePerformanceObligationPercentageOfUSProfits
      contextRef="ie49fa68b1f2d482184e980aaa5e1c250_I20230130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzQxODc_79217ab8-2858-4776-87db-e0515b75d045"
      unitRef="number">0.50</gild:RevenuePerformanceObligationPercentageOfUSProfits>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="i7994adfb551a4093b62e6cfbc11bfe49_I20230130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzc2OTY1ODE0MTIwMDE_2df020fa-0c38-4ebb-bc96-66572ae6227d"
      unitRef="usd">835000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9e1c0e3aad754d999d54e43dd7074379_I20200619"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzgyNDYzMzcyMjA5NzE_1a6e5c99-a74c-4eb5-843e-228a43f429b7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9e1c0e3aad754d999d54e43dd7074379_I20200619"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzU0OTc1NTgyODM5MQ_77e9380d-8dff-40de-919b-265e7be2c86e"
      unitRef="usd">70000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3e84714994f54c519010f82389507cd7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NDk3NTU4MTQ5NDEvZnJhZzo3NDE4NTk5ODFkY2Q0ODg4OWE5YTAxZGI0NjY1MmY0ZC90ZXh0cmVnaW9uOjc0MTg1OTk4MWRjZDQ4ODg5YTlhMDFkYjQ2NjUyZjRkXzgyNDYzMzcyMjEwMjk_08f4f41e-cfdb-4043-8288-570c0875edc7"
      unitRef="usd">70000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjk4Mg_983d6e9e-1de4-4315-818c-f0a96029de61">INTANGIBLE ASSETS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; axicabtagene ciloleucel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Hepcludex &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets &#x2013; IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;amp;D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $546 million and $445 million for the three months ended March 31, 2023 and 2022, respectively, and is primarily included in Cost of goods sold on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No indicators of impairment were noted for the three months ended March 31, 2023 and 2022, except as described under &#x201c;2022 IPR&amp;amp;D Impairment&#x201d; below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 IPR&amp;amp;D Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;amp;D intangible assets related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#x201c;HR+/HER2-&#x201d;) breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#x201c;third-line plus patients&#x201d;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;amp;D intangible asset to $6.1&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Condensed Consolidated Statements of Income during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMzAwOQ_3f3c387b-3a00-4077-b88c-6f8f2744c712">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; axicabtagene ciloleucel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Hepcludex &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets &#x2013; IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;amp;D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMzAxMA_1746b239-f3c8-4f9b-b79a-80a192d13418">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; axicabtagene ciloleucel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Hepcludex &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets &#x2013; IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;amp;D intangible asset of $6.1 billion was reclassified to finite-lived assets in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0yLTEtMS0yNjkzNjI_503c0f3b-184a-4b39-9d0c-8a4ac30c680b"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy00LTEtMS0yNjkzNjI_1c5f6be9-c35f-4388-ab47-7579a58b0df4"
      unitRef="usd">6525000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy02LTEtMS0yNjkzNjI_8de29ff6-de31-4585-9611-ad62fb722603"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5d20ca09d0f5459abd1fc754af94d026_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy04LTEtMS0yNjkzNjI_0f704781-ed11-4fee-a461-386b495ace54"
      unitRef="usd">4195000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xMC0xLTEtMjY5MzYy_cb30e9d9-890e-453e-9a2b-498a5e53be62"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xMi0xLTEtMjY5MzYy_5276a731-d7af-4fb5-b36c-b34060872ff8"
      unitRef="usd">6350000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xNC0xLTEtMjY5MzYy_2e8c9a28-7fe4-48b2-a677-973f82f49c3f"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6461839ec90348219c82e7f40c41cfd5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMy0xNi0xLTEtMjY5MzYy_87a641e0-f9dd-476c-9b95-f64b34aa0916"
      unitRef="usd">4370000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0yLTEtMS0yNjkzNjI_72a96777-974d-41ba-8a41-f48048387daa"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC00LTEtMS0yNjkzNjI_61fbb95b-df96-444b-9e68-dec23c0d527c"
      unitRef="usd">2009000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC02LTEtMS0yNjkzNjI_06aa1a3e-91ce-4a2a-8cf5-a002cc590ffa"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb2f7d6f0f204d2a9fb5e98cf7427d79_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC04LTEtMS0yNjkzNjI_4e68e479-0a49-4d0a-b173-011e0c4b5aca"
      unitRef="usd">5101000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xMC0xLTEtMjY5MzYy_0087d078-fe13-4dd0-82e2-21fe3ee7c12b"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xMi0xLTEtMjY5MzYy_3f384135-713a-454a-8529-483b73c127ac"
      unitRef="usd">1908000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xNC0xLTEtMjY5MzYy_9ffb795f-ad1d-49e4-ba6a-0089bbdfa21b"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia3b6da4b585b4321a7ec80b7967fa580_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNC0xNi0xLTEtMjY5MzYy_afa250f8-1c0c-4b04-b886-15cbeb1f6830"
      unitRef="usd">5202000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0yLTEtMS0yNjkzNjI_18246893-0112-4f66-ba0e-a8d21bd40d95"
      unitRef="usd">11730000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS00LTEtMS0yNjkzNjI_3234a9ad-8caa-4e06-8abe-b02d9a888f70"
      unitRef="usd">1192000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS02LTEtMS0yNjkzNjI_76543005-687d-49b3-b70b-8664f1fe5464"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS04LTEtMS0yNjkzNjI_324d6e02-57c5-4557-b3e2-b287adda9726"
      unitRef="usd">10538000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xMC0xLTEtMjY5MzYy_707bc35a-5b5e-47dc-a5e7-811fc2a8198b"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xMi0xLTEtMjY5MzYy_a9b48719-0e76-4b83-a874-4b351d893a65"
      unitRef="usd">973000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xNC0xLTEtMjY5MzYy_447d0a84-1488-4135-bffb-b832ed8f2060"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3c9a928007a34088ae330d4ec7c5a37b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNS0xNi0xLTEtMjY5MzYy_c3127ce4-2ec7-4d98-a951-0224d09c0b7c"
      unitRef="usd">4657000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0yLTEtMS0yNjkzNjI_4ff38d5f-bd13-4338-bb2d-1b0b9f5a7991"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi00LTEtMS0yNjkzNjI_27394688-a6a8-4728-91bc-46b87098d900"
      unitRef="usd">179000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi02LTEtMS0yNjkzNjI_bb27fc26-538e-484f-8acd-96cc74101548"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb30d25a05de4811a48616e9e844ea50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi04LTEtMS0yNjkzNjI_370549d7-0d9a-4496-81b0-fd4a1aeffcdf"
      unitRef="usd">666000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i30ff5746ef9a40388f4773379f847193_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xMC0xLTEtMjY5MzYy_4b1d86e9-6365-4508-beb3-6ca0b5d0a626"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30ff5746ef9a40388f4773379f847193_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xMi0xLTEtMjY5MzYy_acc3b624-d809-41d5-8527-6b1920e39bf7"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i30ff5746ef9a40388f4773379f847193_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xNC0xLTEtMjY5MzYy_d21e78c6-6387-4a1f-8b45-a007f4b3e397"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i30ff5746ef9a40388f4773379f847193_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNi0xNi0xLTEtMjY5MzYy_241c5d19-8b2c-4c7b-bc22-27641b18f395"
      unitRef="usd">687000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0yLTEtMS0yNjkzNjI_a167f6ab-1ead-4885-8ee1-949bc619a504"
      unitRef="usd">1489000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy00LTEtMS0yNjkzNjI_bbf67abb-c86b-467c-b910-3fd87cd4ddf0"
      unitRef="usd">762000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy02LTEtMS0yNjkzNjI_827145ac-69e3-430b-ab82-ffd2da2158aa"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibd1ddf57d6b34a6583488abad14ff60c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy04LTEtMS0yNjkzNjI_323cd7ab-f8a7-4439-a546-48803e0a4574"
      unitRef="usd">728000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xMC0xLTEtMjY5MzYy_a82b4b3f-f63b-458d-bbeb-ffe89c175dc4"
      unitRef="usd">1489000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xMi0xLTEtMjY5MzYy_8e1b4475-6897-4d34-90af-8b42c693c1e8"
      unitRef="usd">733000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xNC0xLTEtMjY5MzYy_5ad8d79e-ffe1-4de0-9520-9e5163b689b9"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia2b40d58e2714e7ba69b19c7555c6750_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfNy0xNi0xLTEtMjY5MzYy_fbc501cb-e9ac-4941-917c-a1aacf1f98ea"
      unitRef="usd">758000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0yLTEtMS0yNjkzNjI_431b10ec-27ad-4514-8925-0316ed308ad3"
      unitRef="usd">31894000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC00LTEtMS0yNjkzNjI_2d3a2303-5c35-4b33-b047-125e5828371b"
      unitRef="usd">10667000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC02LTEtMS0yNjkzNjI_217bb2aa-4dbf-432d-81bf-a242b886be6d"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC04LTEtMS0yNjkzNjI_d9c2f5b3-6fc6-4f39-8608-9f64ffbbf50d"
      unitRef="usd">21228000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xMC0xLTEtMjY5MzYy_812ca1c0-7349-46f2-8bfe-7b4501e70d3e"
      unitRef="usd">25794000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xMi0xLTEtMjY5MzYy_6ba39272-2d16-401e-836b-9d08db007655"
      unitRef="usd">10121000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xNC0xLTEtMjY5MzYy_671c6634-fa4f-456f-9a5f-efc68e2967ac"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOC0xNi0xLTEtMjY5MzYy_806c1b86-d206-4f41-8c09-68833f2265bc"
      unitRef="usd">15674000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0yLTEtMS0yNjkzNjI_ecdc96f7-3115-4dc4-9025-06fc8131e904"
      unitRef="usd">7120000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS02LTEtMS0yNjkzNjI_95048c05-552a-4e0b-bf4d-9cd1881cf1da"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS04LTEtMS0yNjkzNjI_e3f9e80c-47e4-4554-9f44-0f5125246450"
      unitRef="usd">7120000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i875d511da18240e9bc3567ad24abf2e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0xMC0xLTEtMjY5MzYy_98978918-0821-46b0-93b2-0bca757e5715"
      unitRef="usd">13220000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i875d511da18240e9bc3567ad24abf2e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0xNC0xLTEtMjY5MzYy_fb9471e7-686e-4e76-98ec-57ed114e35f8"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i875d511da18240e9bc3567ad24abf2e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfOS0xNi0xLTEtMjY5MzYy_3ff4e641-1706-4b66-a835-a5308af193f6"
      unitRef="usd">13220000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMi0xLTEtMjY5MzYy_1a1bd0b8-0d28-4059-b5d9-20fbd9bfb9c8"
      unitRef="usd">39014000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtNC0xLTEtMjY5MzYy_90fa29ac-d51b-49a5-87a4-9bca774725c7"
      unitRef="usd">10667000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtNi0xLTEtMjY5MzYy_8ffe3c08-204c-4481-a75c-e19d24136924"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtOC0xLTEtMjY5MzYy_c07de3e2-a6f3-466b-a0d9-acb0459cff94"
      unitRef="usd">28348000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTAtMS0xLTI2OTM2Mg_fc804adc-1cd6-46d3-81a4-e653e9160235"
      unitRef="usd">39014000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTItMS0xLTI2OTM2Mg_216531b3-b470-443d-94d4-88889a6a6bdc"
      unitRef="usd">10121000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTQtMS0xLTI2OTM2Mg_f5dd1374-4ee6-4ddb-a4d6-9b5e615bf8fa"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOjE5NjgxZDJjNmI2YjRmMmJiYTA0YmQzNjZiZTViMTFlL3RhYmxlcmFuZ2U6MTk2ODFkMmM2YjZiNGYyYmJhMDRiZDM2NmJlNWIxMWVfMTAtMTYtMS0xLTI2OTM2Mg_ad022e7c-c2d2-4c25-8bee-5e7a64d27bb2"
      unitRef="usd">28894000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="ie5526c08c2df4105af84704e07402cc8_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMTA5OTUxMTY0MTgzMQ_c125badd-bdea-4931-b962-954605efd0f0"
      unitRef="usd">6100000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="i55e770ea3ec74304b98f2ab1d7526cb1_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMTA5OTUxMTY0MTgzMQ_c1efc07a-d6a8-47d1-9dda-1b5cad80cad7"
      unitRef="usd">-6100000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfNDI0_eabd8333-77da-43f6-958e-ae285208769b"
      unitRef="usd">546000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfNTQ5NzU1ODIyOTk3_251864c0-1ccd-4b15-ae5d-6f0a06f35014"
      unitRef="usd">445000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjk3Mg_9c02674d-3c8c-4894-93b6-03b00ca60aa7">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfMS0yLTEtMS0yNjkzNjI_97fc31c3-682b-4ebd-a36b-9a96a19b898e"
      unitRef="usd">1794000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfMi0yLTEtMS0yNjkzNjI_c31e6569-48f0-4b3b-9bad-d88129942d53"
      unitRef="usd">2392000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfMy0yLTEtMS0yNjkzNjI_ab5d6caf-7035-41c0-af69-dd750ef5f408"
      unitRef="usd">2386000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNC0yLTEtMS0yNjkzNjI_272ddbc0-9f8c-453d-b49f-626c92d3afaa"
      unitRef="usd">2378000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNS0yLTEtMS0yNjkzNjI_a6ae5f80-5979-4aea-b915-3a9ff6de1d47"
      unitRef="usd">2378000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNi0yLTEtMS0yNjkzNjI_adaf61ba-6213-460b-835f-57d0a1b03762"
      unitRef="usd">9900000000</gild:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RhYmxlOmU5YjBlZjFjMmRlMzRmODNiMmQ4NDgzY2EyNTY5MjM1L3RhYmxlcmFuZ2U6ZTliMGVmMWMyZGUzNGY4M2IyZDg0ODNjYTI1NjkyMzVfNy0yLTEtMS0yNjkzNjI_bbb20ff0-5ae8-4760-9a46-aaf6ed2573ac"
      unitRef="usd">21228000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i7c429589ccdf4bfea176e02c0cac635a_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfODUy_64da9105-b508-41d6-8733-5fbee0ea12b8"
      unitRef="usd">8800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="if70af8c6a10b495e9247a23a7f7601b0_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMTU3Mg_a4cfd776-cc97-4543-8cb5-41da4ff83a4f"
      unitRef="usd">6100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <gild:IndefiniteLivedIntangibleAssetMeasurementInput
      contextRef="ib00d0aa9e5e94a278cb25a17dafeb1d9_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjQ3Ng_82a165e6-ac29-459b-9851-e72a2fc2cf97"
      unitRef="number">0.0675</gild:IndefiniteLivedIntangibleAssetMeasurementInput>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i9a2868046c1c40f5b963d0310b6e2c28_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81Mi9mcmFnOjBmMzc4Y2U0MjgwNjQ0NDNhYWYyZDhhZWE0Mzc3ZDFmL3RleHRyZWdpb246MGYzNzhjZTQyODA2NDQ0M2FhZjJkOGFlYTQzNzdkMWZfMjgzMQ_ade40d71-ddc1-4027-812f-b8d75b10a9f6"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzI4_6ef7e1d1-fc39-495d-b370-168847d7bd77">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our trade accounts receivable arises from product sales in the U.S. and Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzIw_2b110234-5516-4903-8a7e-62e2f961c8d3">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMS0yLTEtMS0yNjkzNjI_0a82476f-4830-4ee2-841c-ee9f88f969f7"
      unitRef="usd">4933000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMS00LTEtMS0yNjkzNjI_81e33e93-e01f-498a-8d78-1594cf542ba9"
      unitRef="usd">5464000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMi0yLTEtMS0yNjkzNjI_6bfb05f7-c759-44c0-982a-dcba011c2a8a"
      unitRef="usd">634000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMi00LTEtMS0yNjkzNjI_b35da719-c476-41f6-ae3f-733fa7962e64"
      unitRef="usd">549000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMy0yLTEtMS0yNjkzNjI_f4a7b312-829f-494e-a204-574cc259a36e"
      unitRef="usd">81000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfMy00LTEtMS0yNjkzNjI_ac4a6cab-0129-4b2c-9e90-330c2b50c260"
      unitRef="usd">83000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNC0yLTEtMS0yNjkzNjI_d42ff7b6-35b6-40f1-b9e6-846372906e46"
      unitRef="usd">56000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNC00LTEtMS0yNjkzNjI_8907e12e-d943-4fa8-b4a1-0f31e6dcef17"
      unitRef="usd">55000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNS0yLTEtMS0yNjkzNjI_d3f9cab0-66e4-4670-91d1-9589d61323b9"
      unitRef="usd">4162000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmU1YWExMmMxZDBhNjQ5MDQ5ODY4MzBjOWMwY2YzOGMyL3RhYmxlcmFuZ2U6ZTVhYTEyYzFkMGE2NDkwNDk4NjgzMGM5YzBjZjM4YzJfNS00LTEtMS0yNjkzNjI_2493ed46-3969-4435-908e-a2cf3067904a"
      unitRef="usd">4777000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzM3_38f7980c-772b-4c31-b31c-c358d3dda040">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMS0yLTEtMS0yNjkzNjI_799e9397-546d-4f15-a8b1-e2dba807bb48"
      unitRef="usd">1157000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMS00LTEtMS0yNjkzNjI_a484b391-ae4f-4b09-b3f3-7b1d09addc78"
      unitRef="usd">1177000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMi0yLTEtMS0yNjkzNjI_cd1dd0e7-7b10-49fb-a416-472c5e5e614a"
      unitRef="usd">570000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMi00LTEtMS0yNjkzNjI_b31fc13a-fa69-4ca9-a4ea-6da998a987b5"
      unitRef="usd">577000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMy0yLTEtMS0yNjkzNjI_164325b8-c83f-497d-911c-861fb51d70d4"
      unitRef="usd">1283000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfMy00LTEtMS0yNjkzNjI_f55aa11c-971d-4054-8857-20d145765150"
      unitRef="usd">1066000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNC0yLTEtMS0yNjkzNjI_50491089-ad2d-4aa6-8c6a-962e316eb94f"
      unitRef="usd">3010000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNC00LTEtMS0yNjkzNjI_eaa0fb86-dcfb-46f7-8fb6-0399b50a3840"
      unitRef="usd">2820000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNi0yLTEtMS0yNjkzNjI_2c6d6327-5a9d-417b-a78b-c01fc4c0f7ab"
      unitRef="usd">1576000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNi00LTEtMS0yNjkzNjI_79c783b1-9229-4d7b-a142-7552d6e060e3"
      unitRef="usd">1507000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNy0yLTEtMS0yNjkzNjI_9751622d-a2dd-4007-8002-6c66fb6ca36d"
      unitRef="usd">1434000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfNy00LTEtMS0yNjkzNjI_39f3884b-9876-41ac-811c-7d120fcfadcb"
      unitRef="usd">1313000000</us-gaap:InventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfOC0yLTEtMS0yNjkzNjI_8670b99a-e1b8-40aa-b174-94fc766287a5"
      unitRef="usd">3010000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjVmMGYwMGQxZTg2NDQ0ZWJiZDhiMDhiZjgxOTc3YWE5L3RhYmxlcmFuZ2U6NWYwZjAwZDFlODY0NDRlYmJkOGIwOGJmODE5NzdhYTlfOC00LTEtMS0yNjkzNjI_e737ff3a-7960-48fb-84ab-765842aec10a"
      unitRef="usd">2820000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzE3_382d49a2-806e-4306-979f-c0492215803f">The following table summarizes the components of Other current liabilities:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMS0yLTEtMS0yNjkzNjI_0a9a6966-a9c1-4192-93b3-7a6533a25215"
      unitRef="usd">707000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMS00LTEtMS0yNjkzNjI_fd535fec-ca84-4207-b610-a41b77053931"
      unitRef="usd">1018000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMi0yLTEtMS0yNjkzNjI_4ea1d461-5149-410e-8d09-e0054f515542"
      unitRef="usd">1138000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMi00LTEtMS0yNjkzNjI_4afecc34-2d70-4db0-a4b6-f9db6e561051"
      unitRef="usd">959000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMy0yLTEtMS0yNjkzNjI_51b5eddd-0f45-4bca-bf8a-b4203f190d4e"
      unitRef="usd">444000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfMy00LTEtMS0yNjkzNjI_1373bc93-ede7-4bef-bd19-b695f540e80f"
      unitRef="usd">422000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNS0yLTEtMS0yNjkzNjI_b71c4908-d0dd-4d9e-acfb-cf32f74f6d33"
      unitRef="usd">1851000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNS00LTEtMS0yNjkzNjI_4a097bcd-1660-443a-b380-f97e33c75895"
      unitRef="usd">2182000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNi0yLTEtMS0yNjkzNjI_e4a27bcd-cfdc-4906-b289-9dc9dca8391d"
      unitRef="usd">4140000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOmJkZmMzMmJiZGM5YjRlNTU5ZjZjMzU4YzkxZTI3YjIxL3RhYmxlcmFuZ2U6YmRmYzMyYmJkYzliNGU1NTlmNmMzNThjOTFlMjdiMjFfNi00LTEtMS0yNjkzNjI_990a302e-faef-44f0-8220-fe36fe8949dc"
      unitRef="usd">4580000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RleHRyZWdpb246Yzk3NWFhYTc0YWViNGFlNmI1YTk0ZDZiMWVmYjRhNThfMzg0ODI5MDY5OTA4NA_ca9c2438-d434-4464-9720-5225dd37d50a">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in Accumulated other comprehensive income (loss) by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i263db7dcf6884988a0e0a6b78d1e1a18_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS0yLTEtMS0yOTY1OTE_d22e61f4-db63-4c74-b2ba-425646377f3e"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib52e3a2b0b3f4d21893074364d38ef63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS00LTEtMS0yOTY1OTE_abdc5fb1-523c-44d1-bed2-5a330c9b58d2"
      unitRef="usd">-33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i399115e8a60144f3bb971ed4e82ff382_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS02LTEtMS0yOTY1OTE_15d46502-6329-4756-acd1-c35776b3010a"
      unitRef="usd">33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idca3647effb04f2ea342c2cdf2754864_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMS04LTEtMS0yOTY1OTE_be4d7380-2deb-498d-946f-9d902f8309eb"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi0yLTEtMS0yOTY1OTE_96bccb4c-eaaf-4695-974e-6dd1af8b87b2"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi00LTEtMS0yOTY1OTE_5e3667bd-737f-4d01-9210-2d693d077b83"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi02LTEtMS0yOTY1OTE_285e598f-2ea1-4eaf-8fd3-7cfa76c4646c"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMi04LTEtMS0yOTY1OTE_f3b349db-ad82-402a-ba6b-a22bb6bcf124"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy0yLTEtMS0yOTY1OTE_e7e9434f-15e7-4810-a8a6-2e1615dd4e9c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy00LTEtMS0yOTY1OTE_9b5b3754-28c0-4358-b7dc-e4f5922c36d7"
      unitRef="usd">-1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy02LTEtMS0yOTY1OTE_729d2b94-02ec-4e2c-a09b-d0be7e3a5c42"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfMy04LTEtMS0yOTY1OTE_028d1d06-6e18-4d23-9ff1-fc62158ed1aa"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i08dddc261f6b4ad19aa8eb2be792f2d6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC0yLTEtMS0yOTY1OTE_97e77a04-8e50-4d6d-90d1-83ecfaff8891"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0f9f071b586343ada7322d9d63c7bb55_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC00LTEtMS0yOTY1OTE_b764589c-5e20-4fd9-9a93-8149d6473ad1"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b60d0040a424bceb24d8d30b99e9900_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC02LTEtMS0yOTY1OTE_07780860-f8cc-40b4-a0c1-6a715a1e521a"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNC04LTEtMS0yOTY1OTE_1791dc8b-0e19-4a88-a319-e464c49d9f89"
      unitRef="usd">-22000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad4cdb4878a34e009c969cee15e38f5c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS0yLTEtMS0yOTY1OTE_06e6c3a3-70e1-4026-81ba-1b9fd5589ba4"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6de5de081bec4dd18128468f84151606_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS00LTEtMS0yOTY1OTE_61459e66-a2b1-4d54-a514-f66acc900253"
      unitRef="usd">-24000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b9f2ddd7ebd4003a278244a23a11b71_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS02LTEtMS0yOTY1OTE_8a0276bf-8d85-4da1-8934-59396d13a66d"
      unitRef="usd">7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e727936efcb4ba8ab5f6da9a5878ef5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjY0Y2IxOTc2NTVjZDQyOTRiN2JhYjZmNmE3NGMwNjJiL3RhYmxlcmFuZ2U6NjRjYjE5NzY1NWNkNDI5NGI3YmFiNmY2YTc0YzA2MmJfNS04LTEtMS0yOTY1OTE_9d75cc88-842f-4a8d-bcde-d5d9a9b46c21"
      unitRef="usd">-20000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05fe8e63eff3469cb53503276158f5ce_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS0yLTEtMS0yOTY1OTE_720afee6-5033-4892-be3e-1ecfceeda820"
      unitRef="usd">13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4f13613183647b781938b7084edb764_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS00LTEtMS0yOTY1OTE_a5eaebc4-8e88-456f-bcac-923229575d4d"
      unitRef="usd">-4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica3992c52c804cb987a0221a71af7bf0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS02LTEtMS0yOTY1OTE_1e85cf79-d5a3-4693-8f44-2bd2fe1dcd99"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a853e0354f546ee8636eb887f31fb19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMS04LTEtMS0yOTY1OTE_ba242636-a85a-4a3a-9c4a-1f8fd121c493"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i574633526e804738b0b65a58c499de43_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi0yLTEtMS0yOTY1OTE_46ac8221-09d9-4728-a1ed-063f9057503e"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi00LTEtMS0yOTY1OTE_6f2fc144-6be2-4e91-aa85-6299b1c2e2e1"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi02LTEtMS0yOTY1OTE_78779498-ba97-4eef-925c-635a0b024887"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMi04LTEtMS0yOTY1OTE_8dc0b55a-3a11-4af5-a093-916ad0d8f484"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i574633526e804738b0b65a58c499de43_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy0yLTEtMS0yOTY1OTE_65c2ca42-5c1a-4adb-89bf-a47619d783b5"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy00LTEtMS0yOTY1OTE_53336531-03e2-4e39-876a-98e8477ea199"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy02LTEtMS0yOTY1OTE_06146866-a615-41df-b3e4-8c7856cf4654"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfMy04LTEtMS0yOTY1OTE_7bf2080c-a553-4378-9336-528bf189c451"
      unitRef="usd">20000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i574633526e804738b0b65a58c499de43_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC0yLTEtMS0yOTY1OTE_53821e7d-8ce2-4e9d-8798-b2d25591e892"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib39da7b7ee1d4be6875571039474d351_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC00LTEtMS0yOTY1OTE_5a80b13f-c05e-45e5-a11e-e1ee536660e4"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i00078da76af44b00ac5d30f282d2a8ae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC02LTEtMS0yOTY1OTE_9f6ebf15-f31a-4acc-bfa7-54f74c0212c2"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNC04LTEtMS0yOTY1OTE_751dbdd6-677c-4322-8be4-055c62f1f704"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd1126acbd5f41e5ba02e34d7f3b1994_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS0yLTEtMS0yOTY1OTE_689ec780-bc31-404a-b35b-b85cfb5d0378"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61611069f0d34b499f897eda986a5c12_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS00LTEtMS0yOTY1OTE_62324518-8cec-49c6-ba88-3e94a9cf4bd9"
      unitRef="usd">-23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0b010acb61941da9f9b3702c05299d1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS02LTEtMS0yOTY1OTE_19c01dc1-705c-490c-85be-74b1f6a0ef98"
      unitRef="usd">78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c3b3b01542f435fab6816bf508c9fe0_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81NS9mcmFnOmM5NzVhYWE3NGFlYjRhZTZiNWE5NGQ2YjFlZmI0YTU4L3RhYmxlOjFmMDAzOGNmOTMzNzQyYjE4MmY3NDFmMjc1MDliMzE2L3RhYmxlcmFuZ2U6MWYwMDM4Y2Y5MzM3NDJiMTgyZjc0MWYyNzUwOWIzMTZfNS04LTEtMS0yOTY1OTE_3a93c430-3ebf-457c-9bfe-22ea966e9239"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNzcy_fb30f1fd-0892-424b-8905-a63b595ceeb4">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of March&#160;31, 2023, we were not in violation of any covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, there were no amounts outstanding under our $2.5 billion revolving credit facility maturing in June 2025, and we were in compliance with all covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNzgy_cdef9e19-8657-499a-be70-9eb76d071e72">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03775ab216e04b35b7ed6670a04e0399_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNC02LTEtMS0yNjkzNjI_931defa7-2b56-4e72-95f1-03ff2c09d7a2"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i03775ab216e04b35b7ed6670a04e0399_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNC04LTEtMS0yNjkzNjI_14e7a695-7eaa-4d18-844d-d2a91cb75eea"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if226e46e81434b4fa5ad7d3f0467adc3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNC0xMC0xLTEtMjY5MzYy_edd1bb73-c839-4bf2-8293-be29c8aaab16"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32affe91c7174503bb23d6ad77cb2f0f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNS02LTEtMS0yNjkzNjI_86e205e4-5507-4ebb-bba2-3de784f9a162"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i32affe91c7174503bb23d6ad77cb2f0f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNS04LTEtMS0yNjkzNjI_9506777f-def1-49a4-bc01-04e23ac88ea9"
      unitRef="usd">1499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i89771330d55c448a92e44362a44f16e3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNS0xMC0xLTEtMjY5MzYy_a489c26b-a988-4094-95b0-087d3fded8cd"
      unitRef="usd">1498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idfe06128b3294a28a03f9d23d916dc3c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNi02LTEtMS0yNjkzNjI_9cb64fe1-8d37-438a-bc7c-e3c2c5e99f71"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idfe06128b3294a28a03f9d23d916dc3c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNi04LTEtMS0yNjkzNjI_0c30606e-b5a3-4917-a9b9-6adef9838e71"
      unitRef="usd">1749000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i088891cbdf314ce6b8fcd496558912a3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNi0xMC0xLTEtMjY5MzYy_8dc2c744-5498-481a-a29e-aca8ac12f718"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5cb55cd4308343798ee15ab28060178f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNy02LTEtMS0yNjkzNjI_ccf39663-c6d2-4684-99f9-339d5004505a"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5cb55cd4308343798ee15ab28060178f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNy04LTEtMS0yNjkzNjI_12ab14d1-a573-4d4b-8b27-254ce7674730"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaf624d97eb3d4a40934c3c494fa763f1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfNy0xMC0xLTEtMjY5MzYy_9811d369-3bb7-4d30-a245-dad75325e04c"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i169f8c04a26a42f5a0b60374d9b36c86_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOC02LTEtMS0yNjkzNjI_35d127b6-11f8-4afd-9923-1f8f45cd1a11"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i169f8c04a26a42f5a0b60374d9b36c86_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOC04LTEtMS0yNjkzNjI_a7ca9af2-0550-4c9a-9d35-9eca042a797c"
      unitRef="usd">2742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7e24c0141fe24d3d87e593b121853912_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOC0xMC0xLTEtMjY5MzYy_a5e1756a-2832-4cd2-8ed8-380f776456b6"
      unitRef="usd">2742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibf82b9ef3fed489896bcbd40c4d57784_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOS02LTEtMS0yNjkzNjI_9747caf6-25a5-4d08-86f1-7ca5967a041c"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ibf82b9ef3fed489896bcbd40c4d57784_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOS04LTEtMS0yNjkzNjI_bb17c5e6-4c23-4757-a796-2e6566c83421"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1d81d540e4094ac484768eedff9edef5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfOS0xMC0xLTEtMjY5MzYy_23379c8e-a3dc-4fc2-a86c-330319314c74"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1d8c353412dc437b91aace4b203357c8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTAtNi0xLTEtMjY5MzYy_9063af43-1f5b-40c0-b667-e9ee3212d67e"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1d8c353412dc437b91aace4b203357c8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTAtOC0xLTEtMjY5MzYy_5a15aa22-5fde-4d06-8521-cdaaad8ff6e3"
      unitRef="usd">747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8b148329838748f6809e967fa7b82687_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTAtMTAtMS0xLTI2OTM2Mg_2370a2d3-09b4-4044-a972-b6e0cc83f185"
      unitRef="usd">747000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d46f8e092244b26b34a459dc7f0c882_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTEtNi0xLTEtMjY5MzYy_3546f510-0d8c-432f-80fa-6ba6df6e7410"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3d46f8e092244b26b34a459dc7f0c882_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTEtOC0xLTEtMjY5MzYy_ef4db5c3-0274-4c3b-ba6e-6456c44413c9"
      unitRef="usd">994000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i34c2aeb4935e4346aed2bcc659b68b5a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTEtMTAtMS0xLTI2OTM2Mg_ce08b07e-1b27-499a-8ece-2476d33de80b"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifbcd186911f94c619108ead92cb447d6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTItNi0xLTEtMjY5MzYy_c829bcd1-d5b7-47b2-b7dc-360afe0930fc"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ifbcd186911f94c619108ead92cb447d6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTItOC0xLTEtMjY5MzYy_2bccf8a1-6eaf-426e-adfd-40268e099e8d"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibb9297445f1f41d294ff95f5471d37d7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTItMTAtMS0xLTI2OTM2Mg_ba1e214c-389f-46e5-8779-85932f4a0597"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0f118b76b09d48e4b614386c5bc45cd5_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTMtNi0xLTEtMjY5MzYy_32b8a8d1-660f-4f98-a2ca-e83592d60045"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0f118b76b09d48e4b614386c5bc45cd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTMtOC0xLTEtMjY5MzYy_3531f3fd-ff0a-447c-8c91-cd19e181eda5"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ife4ae268d228410b823829d0e1ed0bef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTMtMTAtMS0xLTI2OTM2Mg_7ba57ff0-ddbf-4e13-b4e2-a84c7d422e60"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie1142e4972ea45ddaafa04ee35493867_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTQtNi0xLTEtMjY5MzYy_24f64431-8dd2-49a7-9af3-7ff96c59437e"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie1142e4972ea45ddaafa04ee35493867_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTQtOC0xLTEtMjY5MzYy_a3cc0128-d663-47af-b8fe-310efea81548"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i63c8bcfa26754f4fa29fad75dea0ebca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTQtMTAtMS0xLTI2OTM2Mg_b10ae50e-6ae4-4fe3-a59e-555faeb5d621"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icdc0d81cbb4140808a9a1e24ab2c3d24_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTUtNi0xLTEtMjY5MzYy_a1dc6749-fcae-452e-82a4-1a2ed8a4fab2"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="icdc0d81cbb4140808a9a1e24ab2c3d24_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTUtOC0xLTEtMjY5MzYy_0a8f2024-e906-436a-a663-b85d9df21579"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i945f98bdf3c64038b9ab71e096b3f268_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTUtMTAtMS0xLTI2OTM2Mg_f1b20715-c693-4ff9-8495-1b4148a4663a"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia87974f636664eaea5bcaeec0ab40f90_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTYtNi0xLTEtMjY5MzYy_29d2adce-65d5-4032-bfd0-12dbbab87bcd"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia87974f636664eaea5bcaeec0ab40f90_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTYtOC0xLTEtMjY5MzYy_9cb23100-9a50-47cb-aa8f-208c067adc70"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1572140a5a8d4e83a9e6933296251621_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTYtMTAtMS0xLTI2OTM2Mg_eb4d86f0-71b5-40a2-b139-b41eb2911242"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95602d00443e4029bb73f9109ee2f243_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTctNi0xLTEtMjY5MzYy_4d8575b2-d1a8-4290-a6e4-ddb4b58131fa"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i95602d00443e4029bb73f9109ee2f243_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTctOC0xLTEtMjY5MzYy_3b044a8e-206c-4010-baf8-97e6eb60ee89"
      unitRef="usd">1734000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7ed4f399902a463ea3fcf0a543273745_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTctMTAtMS0xLTI2OTM2Mg_7c77ebcd-ac2a-4291-bb08-08a3769500ab"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0f7c7fd53cb943fca75d8a9cca2d3665_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTgtNi0xLTEtMjY5MzYy_1823405f-5c48-4b0f-a9af-cee573fe3d13"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0f7c7fd53cb943fca75d8a9cca2d3665_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTgtOC0xLTEtMjY5MzYy_848b7f3b-74f7-45b8-89cf-34945a743d6e"
      unitRef="usd">2221000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iade8a85e37a04d2dbacdbfd5cb15f536_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTgtMTAtMS0xLTI2OTM2Mg_ac581972-a1fd-47cb-8d4b-9ce2153dd8b5"
      unitRef="usd">2221000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i091813ff4b0b4bba8dd45fbd21ee9c90_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTktNi0xLTEtMjY5MzYy_eca73f7f-4d34-4506-a573-50e3acb374da"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i091813ff4b0b4bba8dd45fbd21ee9c90_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTktOC0xLTEtMjY5MzYy_2845f8a2-e357-4ff8-953e-24e8fae33e74"
      unitRef="usd">1728000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ide79ceb5e2244413ba088809663b461f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMTktMTAtMS0xLTI2OTM2Mg_52a42add-2770-41e6-89df-c3da671b7c70"
      unitRef="usd">1728000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if2273e9e92d64f43ac4633c496068250_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjAtNi0xLTEtMjY5MzYy_55b2ce8a-d003-42ae-ab56-6ec936c8892e"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if2273e9e92d64f43ac4633c496068250_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjAtOC0xLTEtMjY5MzYy_2f1cac37-a1c9-4c86-b732-7f188e439d85"
      unitRef="usd">1477000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic6515a317e7e49bb958a7c1cfb861802_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjAtMTAtMS0xLTI2OTM2Mg_586f38e1-2850-406e-8bc6-207cedad8089"
      unitRef="usd">1477000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i018b9520570d4bdb9a852a1dc0a67292_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjEtOC0xLTEtMjY5MzYy_eec084d4-f0c5-4df0-a0b0-6cc4b6a4cbeb"
      unitRef="usd">24092000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifcb2412b199c42529e8362b7502e548d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjEtMTAtMS0xLTI2OTM2Mg_bee8d70e-e4c4-40f9-be58-e7ab0b08f2f3"
      unitRef="usd">24088000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i18c75b45dd0b494a9413038b43d87195_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjItOC0xLTEtMjY5MzYy_56156461-bbb6-47a8-b0ef-299d7673f61b"
      unitRef="usd">1146000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i88176a5b89454f6fb32288e4abf39fd2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjItMTAtMS0xLTI2OTM2Mg_1e2c2117-f242-4cc5-b408-4562624958e5"
      unitRef="usd">1141000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjMtOC0xLTEtMjY5MzYy_4a7aff42-9a3f-4ef0-8c9e-2b9cfc39d0d5"
      unitRef="usd">25238000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjMtMTAtMS0xLTI2OTM2Mg_7017fa11-df5f-44a4-a613-01893ddc8cd4"
      unitRef="usd">25229000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjQtOC0xLTEtMjY5MzYy_7acc8084-7792-4fd0-ab77-d6547f6bce48"
      unitRef="usd">2283000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjQtMTAtMS0xLTI2OTM2Mg_0e9b936b-5b0d-42fd-a626-924dbd85a1eb"
      unitRef="usd">2273000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if8f2633fb3c542d2b3573b60b6456dd2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjUtOC0xLTEtMjY5MzYy_a5a93cd1-636a-4bf4-8f28-7f9f53fb42db"
      unitRef="usd">22956000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id5b99939368b46f298d75ed65a8f6ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RhYmxlOjczMTRiNmZlYTFiMjQ3MDA4YWEzZTM3YjFiZWMyYTczL3RhYmxlcmFuZ2U6NzMxNGI2ZmVhMWIyNDcwMDhhYTNlMzdiMWJlYzJhNzNfMjUtMTAtMS0xLTI2OTM2Mg_d2c87003-59a7-4e38-8360-c4638dccc0ad"
      unitRef="usd">22957000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCredit
      contextRef="i7036db910ef7473694d4dc36eb796a6c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjQy_861280ea-f39b-4b01-a80d-c75284a4d074"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i708772249eff4b8db077ea95cb4df25d_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjQy_e249560f-cacf-4142-8d1f-474d84a32d81"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i708772249eff4b8db077ea95cb4df25d_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjc1_15b1d18b-04d9-4add-bfa0-db31f385769c"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7036db910ef7473694d4dc36eb796a6c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF81OC9mcmFnOmUzZGVjZDY1YWIxNjRjMWRiNDI1MGU4Zjg1MmI3ZmI2L3RleHRyZWdpb246ZTNkZWNkNjVhYjE2NGMxZGI0MjUwZThmODUyYjdmYjZfNjc1_67754358-1ea6-44ed-863b-6bca54aa3298"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMjM4Mzg_1a8204d4-b4af-470f-8495-cf834fb6584e">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. We did not have any material accruals for the matters described below on our Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, sold under the brand name Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#x2019;s patent invalid. In July 2021, the University appealed this decision, and in March 2023, a three-judge panel of the Court of Appeals for the Federal Circuit affirmed the PTAB&#x2019;s decision. The litigation in the U.S. District Court was dismissed in April 2023 after the University represented to the Court that it did not intend to pursue further appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with NuCana plc. (&#x201c;NuCana&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NuCana has obtained European Patent No. 2,955,190 (the &#x201c;EP &#x2019;190 patent&#x201d;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#x201c;EPO&#x201d;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#x2019;190 patent in amended form. The EPO subsequently held an appeal hearing in March 2023 and revoked the EP &#x2019;190 patent, including the amended patent. We had also initiated proceedings to invalidate the U.K. counterparts of the EP &#x2019;190 patent and a related patent, European Patent No. 3,904,365 (the EP &#x2018;365 patent) in the High Court of England &amp;amp; Wales. NuCana had filed counterclaims against us in the High Court of England &amp;amp; Wales alleging patent infringement of the U.K. counterparts and seeking damages and other relief. The U.K. case was heard in early 2023, and the judge issued a judgment in March 2023 invalidating both patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#xfc;sseldorf alleging patent infringement of the German counterpart of the EP &#x2019;190 patent and seeking damages and injunctive relief. In April 2022, we filed an action for grant of a compulsory license before the Federal Patent Court in Germany. In July 2022, the D&#xfc;sseldorf court determined that NuCana&#x2019;s German counterpart of the EP &#x2019;190 patent is infringed and granted an injunction. In August 2022, Gilead filed a notice of appeal regarding the D&#xfc;sseldorf court&#x2019;s decision, and a hearing is scheduled for August 2023. Following the revocation of the EP &#x2019;190 patent by the EPO, we expect the injunction in Germany to be lifted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (&#x201c;TDF&#x201d;) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of three material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and two clinical trial agreements (&#x201c;CTAs&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. A trial for the bifurcated portion of the lawsuit in the Court of Federal Claims was held in June 2022, and in November 2022, the Court determined that the government breached the three MTAs. The Court also made findings of fact relating to the CTAs but declined to issue a decision on breach of the CTAs until after trial in the Delaware District Court. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the Delaware District Court has been set for May 2023. A separate trial at the Court of Federal Claims to determine the damages Gilead is owed based on the government&#x2019;s breach has yet to be set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, we received a letter from Lupin Ltd. (&#x201c;Lupin&#x201d;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen (&#x201c;Janssen&#x201d;), filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. Trial has been scheduled for October 2023. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (&#x201c;Apotex&#x201d;) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Apotex asserting infringement of two additional patents in the same court. Trial has not yet been scheduled in the lawsuits against Apotex.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in March 2022, we received letters from Lupin, Laurus Labs (&#x201c;Laurus&#x201d;) and Cipla Ltd. (&#x201c;Cipla&#x201d;), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of three of the five patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for December 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing was held in November 2022, but a final decision regarding the validity of the claims has not yet been announced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. The original opposing parties have appealed, requesting full revocation. The hearing for the appeal has been scheduled for September 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. The appeal hearing was held in March 2023 and the EPO affirmed the validity of the TAF hemifumarate patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process for sofosbuvir opposition proceedings may take several years . While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for sofosbuvir, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We, along with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and Johnson &amp;amp; Johnson, Inc., have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes. These cases have been coordinated with the class actions. Trial has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#x201c;Cipla Defendants&#x201d;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we, along with BMS and Teva Pharmaceutical Industries Ltd., were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, and Missouri, involve more than 25,000 active plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed while the California First District Court of Appeal considers the merits of plaintiffs&#x2019; theories of liability. The first bellwether trial in California federal court is scheduled to begin in January 2024. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#x2019;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The lawsuit seeks all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice Advocates, LLC (&#x201c;Health Choice&#x201d;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#x2019;s dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. This case was stayed in September 2021 pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above. Health Choice filed a motion to lift the stay, and in April 2023, the trial court granted Health Choice&#x2019;s motion to lift the stay. Gilead has filed a motion to the Texas Court of Appeals requesting reinstatement of the stay until final judgment in the Eastern District of Pennsylvania lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. In June 2022, plaintiffs filed their Motion for Class Certification, and Immunomedics submitted its Opposition in July 2022. The parties have agreed to settle this litigation. A motion seeking preliminary approval of the settlement was granted in February 2023. The court has not yet entered a final order approving the settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <gild:LossContingencyMaterialTransferAgreementsNumber
      contextRef="ic2d94e60ba65414383aad05e7c5d0ac4_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTA5OTUxMTY4MTk4Ng_c444a421-b979-4339-addb-cd5991aab945"
      unitRef="agreement">3</gild:LossContingencyMaterialTransferAgreementsNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTM0Nzg_8d2698f7-337d-4127-9069-470dad603cf3"
      unitRef="patent">3</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <gild:LossContingencyNumberOfPatents
      contextRef="ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTM0ODg_478f41ac-3468-494b-816d-080e67acbffd"
      unitRef="patent">5</gild:LossContingencyNumberOfPatents>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="idcf147879c32413c88dcfab0f196e448_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTQ3OTY_fe7b075e-e1c3-4ec0-84b9-d468bfd49fd4"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ie39ed308edf943f8974b315e8b36ca06_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTkwMjc_26651362-ac3e-4e2e-a3a5-d74755e94c87"
      unitRef="lawsuit">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="ie39ed308edf943f8974b315e8b36ca06_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82MS9mcmFnOjg4MDMyYjNiYzg1NzQ5Zjg5MTMxY2E4ZTA0MmE4OTc5L3RleHRyZWdpb246ODgwMzJiM2JjODU3NDlmODkxMzFjYThlMDQyYTg5NzlfMTk0MDA_839ae9aa-2f4c-482e-8fb1-3f1cb1c62584"
      unitRef="plaintiff">25000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfOTg2_3e984b1f-d403-45b3-9c7c-cc9b58d2e599">EARNINGS PER SHARE&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.866%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in basic earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in diluted earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of diluted earnings per share attributable to Gilead because their effect would have been antidilutive were 3 million and 16 million for the three months ended March 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfOTc1_36c055df-b02d-4b14-ac0b-f7e66496ae5c">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.866%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in basic earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in diluted earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfMy0yLTEtMS0yNjkzNjI_73a15179-f95e-4dc6-8e1e-b4ea722275fa"
      unitRef="usd">1010000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfMy0yLTEtMS0yNjkzNjI_b8035a5d-c6eb-48ae-b374-3ed328f99520"
      unitRef="usd">1010000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfMy00LTEtMS0yNjkzNjI_017bd6a9-ceb0-4e81-a9a0-436ee50682a6"
      unitRef="usd">19000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNC0yLTEtMS0yNjkzNjI_29374399-5c60-450d-981d-f811d8632878"
      unitRef="shares">1248000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNC00LTEtMS0yNjkzNjI_d31ae73c-65cb-47e0-9441-e600520fbf64"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNS0yLTEtMS0yNjkzNjI_cfa562ff-87ed-4e9f-8afd-09553eeeef5b"
      unitRef="shares">13000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNS00LTEtMS0yNjkzNjI_35f910df-949d-4de3-b156-67b041270396"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNi0yLTEtMS0yNjkzNjI_028b07fb-63f6-4165-bfb8-11b4f09011a8"
      unitRef="shares">1261000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfNi00LTEtMS0yNjkzNjI_18df49ba-f0c8-4227-80d1-eabb9c18bcd5"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOC0yLTEtMS0yNjkzNjI_f5cda576-46bf-444e-9655-f627879c6bbe"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOC00LTEtMS0yNjkzNjI_b2880eda-e95e-44a7-98aa-471910d5c0fd"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOS0yLTEtMS0yNjkzNjI_7cf7a139-10c0-4bd3-8c02-632406976621"
      unitRef="usdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RhYmxlOjgwZmZjMTkxOTNlZjQ5NmJiNzA1ODljMzZkNmY0MjRhL3RhYmxlcmFuZ2U6ODBmZmMxOTE5M2VmNDk2YmI3MDU4OWMzNmQ2ZjQyNGFfOS00LTEtMS0yNjkzNjI_3c18f1b5-1bf6-4f24-a962-092aec70f2b6"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfOTE0_5c00fac1-1cdf-4a09-99d2-9166fd8a491d"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF82Ny9mcmFnOjRmYmNhMjI3ZGJmNzRhNjRhNThhMGVkYWZlMzZkYmE4L3RleHRyZWdpb246NGZiY2EyMjdkYmY3NGE2NGE1OGEwZWRhZmUzNmRiYThfMjE5OTAyMzI1NzI4OA_cdf6be10-1dde-4185-800a-ab081c3db611"
      unitRef="shares">16000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTYwMQ_4442dcb4-e188-4fd7-a042-f6f4d7e95d2f">INCOME TAXES &lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Income tax benefit (expense):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 24.3% for the three months ended March 31, 2023 differed from the U.S. federal statutory rate of 21% primarily due to $244 million of non-deductible Acquired in-process research and development expenses recorded in connection with our acquisition of Tmunity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective income tax rate of 107.9% for three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to a decrease in state deferred tax liabilities associated with a partial IPR&amp;amp;D impairment charge of $2.7&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTU5OA_b9b8a7d5-7b8c-451b-932a-088a39b6385b">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Income tax benefit (expense):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfMy0yLTEtMS0yNjkzNjI_d6f00951-b667-4c50-8840-e8a6dfa8fd85"
      unitRef="usd">1300000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfMy00LTEtMS0yNjkzNjI_2cb70953-42d6-4745-9662-bb70970a8ecd"
      unitRef="usd">-152000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNC0yLTEtMS0yNjkzNjI_08a1c297-e921-4239-b84d-6601d71e3221"
      unitRef="usd">316000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNC00LTEtMS0yNjkzNjI_da2f3fec-2076-453b-84c9-89bcbd08387b"
      unitRef="usd">-164000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNS0yLTEtMS0yNjkzNjI_a9cc45d3-aaad-4147-8afa-839cdc483be3"
      unitRef="number">0.243</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RhYmxlOjM4ODEwYTJjNTc2NjRiZWFhOWQwOGQzOTA0MTY1Njg4L3RhYmxlcmFuZ2U6Mzg4MTBhMmM1NzY2NGJlYWE5ZDA4ZDM5MDQxNjU2ODhfNS00LTEtMS0yNjkzNjI_6e867960-a6d3-4cb8-8dc2-1de3ca5e014c"
      unitRef="number">1.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icd6c59c571494a02a71ad883d5631309_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfODc_7d22bb21-90e6-458f-b369-34fea9d98264"
      unitRef="number">0.243</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i506cbd3ce6ca465992effd4d69548672_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMjc0ODc3OTA3MzU4OA_7399c2ec-a1e6-462f-a85a-f7ec558eedd9"
      unitRef="usd">244000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTA5OTUxMTYzMDAzMA_6e867960-a6d3-4cb8-8dc2-1de3ca5e014c"
      unitRef="number">1.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i9df0d41627834bad8a580aa95611df74_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4Y2RjYjE1NzI3NTRiNmM5NDY5OWQwN2JkN2YyZmQ0L3NlYzo3OGNkY2IxNTcyNzU0YjZjOTQ2OTlkMDdiZDdmMmZkNF83MC9mcmFnOjNjY2VlNzlhNzg1MzQxMjI5YWY3NzU1NDY3OWRlYmIwL3RleHRyZWdpb246M2NjZWU3OWE3ODUzNDEyMjlhZjc3NTU0Njc5ZGViYjBfMTA5OTUxMTYzMDQ1Nw_3db38071-fdf4-497e-8318-2abd1c57437f"
      unitRef="usd">2700000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^%6[>>.:HYIR5D8)'V64Y@EDL-BU4ZM3L@?7<IH5ZSA/88QP98SP4<9(K=[
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MRZ?E">XD/[?L5*\7Q[^W1,V8 D5T!:'6>1^&/%Z<J!8WDJ7YH>03DY+%^65
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M WRZ_Q[N5] )RNT/<KS@"-[UBG'!I@+/Z4*>:R:0<G!J0&.T5-QPU%>'-JT
MK1\&M1?_2B]8A!V';K9&M4(G_/RIUO"^'E+\3F [^NNE_GH5>OC 7H"G!&]
MSB"CJK7,J!@)_AMCF%,1@E,AM3X[M D%<B-'ML5J%7IM=[6MK,ICA^YE2??R
M/^@JC 33FL\HZ6U-TF!DKH%GD4SQ$.<"_K*"<Y7'#N=&R;E1F6)=IA.84;6&
M!./YD81JO&="O1/8CMIFJ;;Y80G5?+/UY[6]TWGK$AP^G5;)M_6Q&=5ZD^/!
M'N<JCX*SN]4_4E3SO*UJB.0R,T5I+6?+SGV=-ZR]^1OJZ$4#_@M3_ Y0X9QS
MTB-P1I#>19/V4!4MMC",7.1=:BH-];Q\F-!?"2KK0.LS*<VK83]0_N>$?P!0
M2P,$%     @ SH"C5BF %ZR,"   $4<  !@   !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6S%7&MOVS84_2N$5W0-4-<2];#=)@9:6U2#M4D6)QN&81]4BXF%
MZN%*<MS^^U&R8YD/,U)[NWV)+8<\]XKG\I(ZNM+I)LL_%TM*2_0UB=/BK+<L
MR]7KP:!8+&D2%*^R%4W9?^ZR/ E*=IC?#XI53H.P[I3$ VP8[B )HK0W.:U_
MN\HGI]FZC*.47N6H6"=)D'][1^-L<]8S>X\_7$?WR[+Z83 Y707W=$[+V]55
MSHX&>Y0P2FA:1%F*<GIWUGMKOO8MI^I0M_@CHIOBX#NJ3N53EGVN#L[#LYY1
M>41CNB@KB(!]/- IC>,*B?GQ90?:V]NL.AY^?T0G]<FSD_D4%'2:Q7]&8;D\
MZXUZ**1WP3HNK[/->[H[H=K!1187]5^TV;4U>FBQ+LHLV75F'B11NOT,ONX&
MXJ"#:1WI@'<=L-C!/M+!VG6PA YX>*2#O>M@"QUL]T@'9]?!$5T:'>G@[CJX
MHDO'SF&XZS"LR=J.;DW-+"B#R6F>;5!>M69HU9>:W[HW8R1*JU"<ESG[;\3Z
ME9/IY<7,NYA[,\2^S2\_G,_>WK"#^0W[^.A=W,S1)6%'E]/?WE]^F'G7\^>_
MC+ Y?(.\WV_/;_Y"+V[38!U&)0U/4!_=SF?HQ;,35"R#G!8H2M''*(Y9R!4O
MT;/#P]-!R9RO7!@L=HZ^VSJ*CSAZDY5!K.@VU7:K9O+K8A4LZ%F/3=6"Y@^T
M-YEF2<*FP;S,%I^?_V*ZQAL%\$SOS]N0G34[E2!&5T$4]L]3- U6D=I)[PFL
MQ6*=K.. C2*Z+)<T1\Q#YNZRFO(/%)VGBRRAZ,6'K"A.%/!$#W]-2Y:3&+87
MY&F4WJM&W]=#7&3,A;3,,T9?>L\<*BD;S9('&K#8VP<@W@<@KI'M(\COZ'V4
M5EZQC!('Z8*=)HN3;0"=H*!$,[IXA2SS)<(&-E5QH\57!\!1TJ=;,*<&J]+X
MP\3$CGTZ>#B,#$B+'B08@03S@<"XL+#V86%U#(LVH;#%= _8PZ;A"O1-Y5:F
M0+#<PG9=H9$G-QI9?!.BL.1:6/#'EUOUG7T3;O3L_>C9=1_KR.BQA,'V)06;
M2VS(ZF\G5?:M$]XRBT.:%[\B[\LZ*K^AOZ_9I$9L7=\$>?B/:E1MR D&"3:#
M!/,@P0@DF \$QH62LP\E1SL1+]AV.-JM/_&1]>>=H\B:PJ336NG*.R28!PE&
M%",Q%J:[W*0_5$]W=\^1J^5HNV=8<'N&BJN7**6EBB]7=L$T!,*T)KL2!@GF
MM?">0!KT@< X;H=[;H=:;L^+8EVM?P5:IRQO(YJLXNP;I:BHDCE:K?/%LLKT
M*[9*'FZ=5+1K+75-Y$,YTH55%-*<!PE&(,%\(# N.D;[Z!B!18<J(D82B4-A
M#S/5.M U#SQMSX.T1R#!?" PCNCQGNAQ*Z(?>=[NW=C"3--*RZD)+IZ:_UH3
M7>?_6*92F/^0YCQ(, ()Y@.!<6%A&HU^8W3+ ,K(4.HMAL0@%E+X5&^\Z^QO
M8=$#M4A T7PH-)[J ZG.U%)=7[[U*^$UK#=[;*<75!*4DEQ37IXMB5VMO<[L
MMC#I@9HDH&@^%!I/;R.$F7HE[)H^+M<%RNXJABN1<KN0;^=V3IL%/<_N\R!Y
M,N7K;7;-^:8LC_5=(>N#6O1 T0@HF@^%QL=+HY"9>HGLN^)%&2.6S*KEB/M
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MU)K6-PN 2EG FG%R>=(T@'-R?5$%\LKES=YV/BY92&9S7;D&EM!>=UW7:5S
MELJ/^9HYI(-RNHM=O%W<9 _2!>YR>KH&!]@QI9Q1(RSMMM\?M-+AXODANBE?
MYPY=C*[DOQ,EX5.:@/&10WM>/Y""Q?W^^;\ 4$L#!!0    ( ,Z HU;3<B)U
M8PD  -88   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;-5977/;-A;]
M*Q@UV^G.Z,NRW:2)[1G935MWXCAK.YN'G7V 2$A$ @(L %K6_OH]]X*D*$?V
M-#-]Z4-KD0 N[N>YYS(G:^>_A$*I*!Y*8\/IH(BQ>CV9A*Q0I0QC5RF+E:7S
MI8QX]*M)J+R2.1\JS60VG?XX*:6V@[,3?O?!GYVX.AIMU0<O0EV6TF_.E7'K
MT\'!H'UQHU=%I!>3LY-*KM2MBA^K#QY/DTY*KDME@W96>+4\'<P/7I\?T7[>
M\&^MUJ'W6Y E"^>^T,-E?CJ8DD+*J"R2!(D_]^I"&4."H,8?C<Q!=R4=[/]N
MI?_"ML.6A0SJPIE/.H_%Z>#50.1J*6L3;]SZ-]78<TSR,F<"_U^LT][CHX'(
MZA!=V1R&!J6VZ:]\:/S0._!J^L2!67-@QGJGBUC+GV649R?>K86GW9!&/]A4
M/@WEM*6@W$:/58US\6Q^\:^/E[>7=Y?7[V^'XN+ZW;OY^?7-G)_%_/W/XOKN
MM[<W8GYS,W__Z]NKM^_O;D\F$1?3\4G67'*>+ID]<<FAN'(V%D&\M;G*=\]/
MH'"G]:S5^GSVK, KZ<?B\& H9M/9X3/R#CLO'+*\PR?DG=<!;T(0%ZY<:"M3
MPMA<S$- 8<RS/VH=-+_]SWP1HD<R_7>?'](U1_NOH0)['2J9J=,!*B@H?Z\&
M9]]_=_#C],TS1AQU1AP])_VO"N5??LDG)92-R@MMHT,9=KX,0V%T1@5N5^QM
M<FQ4*YT)I+61"^<Y$H$772P@(^A2&^F%]%[:E0(\Q("2B86(A?:YJ*2/6@4!
MN,(;A0*]!_!4M(^E9*XLE<^T-/I_*<QN*3+E(_!+5-[E=1;3?<V#R/"@<^@5
MQN(.$I]4;4>E4FY@[[TS]TK$M1-0IW1>=?JM"[@"SPF5TNM,5Y+.0A-2'<!+
MEY!O:)/F<] V/E:"=2!AZJ%R0>4";@YZ9?520_DHO Y?DJ)>K:7/ [P"4,])
MM+.-O-8M@.<LHU)H;MK>S>8'M<_.S-2Y$M;9$3"UMKE<&"7J:NE1]K!MPWN'
MI!^BK:"&+A>U#XT,^*;=(Q8;4:?HN2HYN,T9V-?&R1/40EX&\3""8NL61J^:
MD&QE5"YBD:QZG =>K6HCH_,;H*I1P%FKMEI@QP3'@\3*B$ _W[-K*+S;2!,W
M_3>XQM:*3?)NJ>,H%-)S#'M>(\W#_B563L'<R/F#*_GUN(]!0=R5M:4=EU;\
MHA:^1CME*!R*-;QD. DD\F+E%8OM.[$]BV!Z6:D:>0>%+FTV%C]\_]VKV6SZ
MIMG"3P=O_CD4$D*U13:948CHU4-8I^]1$V*AX>*LL,ZXU8;2""F\@>_1NJ #
MLLNJASA"B%23JQ?S&W$WBGPY)339VTG@+/N()I&*%Z!1;A.Q-8:-;*R!F<8(
MD VHE1*:G)KJI#4T56<L)*6ZHP0V1%^PL+80@&SY%;&5.6>,K!"W!XUVK\Q&
MO#B<3BGRAC1'XF4R%)1U0>>-/0@,;$#< VC L+MSH3)9(@UJ3Y5NS&:4+@OU
M F<UXC46G\B*S-7 QKS#*R"@#;)A+(&#R"VH!YM-_F;.YV2_>#$[.NJ4S&#^
M2E&\YZV'M!W!)JYI:CK29P6+Z)=$4YF!(D9*7S@$P5((\2LXPP"8B]N(/TW1
M+BEG'(S,:\YBUKY C !TW.P5-7MQQ?>UO3I!J%=$%^E056,5]47YE-&"(: E
M]>]1&PYEW& K.2'TH@[]C98+;1(L8KTN53Y,P0F,FA )GJD11N@*HJ8\G8SR
MH9'6S[1><M$CD5UJ-I1+"!]V[604YRRV?;3 ;A\XR9;B@[(V;,R]M%HF. 8D
M:4)"F(-X*0)ZB4@]T.ZZXJ+<3;>#\105U:7;%KZ6=:Q]#Z#JBAEMH1%##F"O
MB_7B.NSC''?8?8B&\D>JK<&,Z>]C4*.4X&-CY,)7K>^:PS/O(]C<9Q#U0.#T
MN[1_"IOZ_$"LC%M0']I/!E*S;^YXA%O-VQ:W2'+F1HT_FO8_ZC, )7I'#EZ^
M"8*!@)(P =W7+&!("'8WRO/SBZOYL%>W2L8V$A4TW1(32NJ*T=#3&$/<D=L.
M $-7R(YR _5*.4RLXW'('^.GK",A)94&[:>>VWO5,I@Q>1^U\+FVV=9K>YC#
M#JCN@,K![.\"*L->J2<$80J$)'M$07;R'#8>'!QW-G[5<^&10N,6'0BU/V.*
M)*'&95]&J%T8?Z\#EP$ 7!OQ>VTXSX^&5+FI+(RSJQ$UL1:_GG?$N332 @5O
M:9KKV"9U5&:,4#0ATFZ%MYT9*8BT&3[!<HEP)$[42U_>RW(_.Q2?V8C=XB#O
MMP7 Z%$!;L7'\>VX83=!'$\GQ].QN$8'1D],J(AU3B>6_+S$%BMX:XN1"8&T
MZD-/NQ'1V >KH,K\@0+N:]#MVPA?!\@O7AUN<Z*73#M%+[^I3/OV[CNYMX*'
MJ6*7M>=,ZO'S?40T1:.)3Q^X@7=8*W'G[G"SXV(9"?9"9.U\.Q2MG3?YFH)J
MP3\X#,/=P6%=J ;]4VS V,.(AA?7O[>9,-H.M@6HI9!YSHRFU^ Z);=I3FV]
MRQ-7&U"V)WKK5MS?S4DQ35;/^",!UUA\P/K&<W.M81X09\K%QBV4@9F;:)]'
M<B:UYTIP&!=[W+_KGFE'G_0W)!^X4"B3=^P>I"W49)YU"!"- $S^F[%UJ6DO
M?*/YJI$#H--ZAZ=I6LQ)8[])^M*$'!2&8!HINIX$5U($>U5(\H%V7#Y]1HS;
MI#CZ:?S3/[8X3NY N*!58WK+VA*C9 #G(-5AVQW5 Y0+E$QI_!SVL;\E6&DL
M23AK\_931F_$BCL<MS^=9!AZ(I,;]!$FC4FWW1B(*X5^FS2^9CW$O'-*&Z#4
M'QXK+ K)] JF,ZO$9"&U!YLV-)4NQ8N7VX$F 27E-GECD=CT9K3F+YFTDB02
M-2?=2Y<CVC5_K4%@%_3]B@=];:N:@I7B2Y7;CD@0\HZ*6!SB1,NU>PJ5J"BD
M>0?2N0[$$"GS5S6Z(N"<F4SJ]QV+7$L8G',K_<K^7AAZ<6]#EV*?OA_T5/H3
M;O]JZNHY<LN/4M_7B</\T! @U!*AP[>S()X1F]:8U">+GT[P+;GA#"0KAXV5
MK0,>9:Q7]_3EW.(_J"'I*, 1>L">,-[W47+2^];,V^B+>A \QZ;/SMW;[J/]
M/'VKWFY/7_P1U96VQ+F7.#H=OSP>)*7;A^@J_G*]<#&ZDG\6X.?*TP:L+QVP
MLWF@"[I_RCC[/U!+ P04    " #.@*-6(>%1?S@)  !P%@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6RE6&MOVS@6_2N$)UND6,6VY&?2)$ >?028
M:8,DN_-AL5C0$FUS*I$J2<7)_/H]EY1D.4W2SFZ!QA0?E_=Q[KE7.MYH\]6N
MA7#LH<B5/>FMG2N/!@.;KD7!;5^70F%EJ4W!'1[-:F!+(WCF#Q7Y(!D.IX."
M2]4[/?9SU^;T6%<NETI<&V:KHN#F\5SD>G/2BWO-Q(U<K1U-#$Z/2[X2M\+]
MH[PV>!JT4C)9"&6E5LR(Y4GO+#XZ']-^O^&?4FQL9\S(DH767^GA*COI#4DA
MD8O4D02.GWMQ(?*<!$&-;[7,7GLE'>R.&^D?O.VP9<&MN-#Y[S)SZY/>O,<R
ML>15[F[TYI.H[9F0O%3GUO]EF[!W,NJQM+).%_5A:%!(%7[Y0^V'SH'Y\(4#
M27T@\7J'B[R6E]SQTV.C-\S0;DBC@3?5GX9R4E%0;IW!JL0Y=WKU^>[L\\>K
M\U_?L[/;V_=WM\<#![&T.$AK$>=!1/*"B!'[32NWMNR]RD2V>WX =5J=DD:G
M\^15@;]QTV>C.&+),!F](F_4VCCR\D8OR/NH=;:1><ZXRMB5<ERMY"(7[,Q:
MX2R[E#;-M:V,8/\Z6UAG@)1_/^>&<,OX^5LH>XYLR5-QTD-Z6&'N1>_TS2_Q
M=/CN%1O&K0WCUZ3_7)S^H@AVMQ9LJ7,DIE0KYC@Y)62G_%-8IBO3=1?W[HJ8
M$NZ((4;IN@T2NQ2I*!;"-#,)VY<*>,USI)Y]RSX:;2T[2].JJ'+N1,:04\@8
MQ2XJ8X1*']F=X<IBC7+U+/L#T$?N._89Q/3_G?X@E73B($?V9[411]_9Q=[\
M,D_B^!VS>JGMHKJ7ANVQ>!C-DB$&^]-HDDS>8N3W)>\P&D?QX>3)IM%D^'33
M:#9\^3;^(%.^<* _)5@J<YV+*A4YFT5Q/&3[230<'KYMQ4VB>!@W:W%T.)QW
MU^#VER^Z,SH3^?TCSKUE<1S-1EY$?)AL1<"0R6@.25-:/)R-MDOC:#J9O2S]
MDRC3O,K$ YN/)Y [ZR@]G4[KV4E'W>E\QKZX-1 31^/Y(=N?3:$)C$OF[<QH
MY&<F<W:G'<_9\OM $M[FAV,('T;3Z8SV)W&40$@RB6;U0IR0S2R&8;,QC !I
M/R.IL>7J^N8-+\IWE]Y5<#9BVVC=_(;9>(2;OE^LIX/.\FG^ !.CPV@8CPDP
MC=8 $?XG\V@TGC_=X+5O-Y"Q_WG]G]?[2K$/8F$J%%J?H1'[<'G&5L@22A]>
MED;?0SV]W"(#%9Y55D!EQC,4-58BG9!$%B7)K5FEB-72P!*Y3GF>/V+C/5<I
M).)L(1RW#F=2]NGF[X-/[V^2 [9 IV =2VF789NU9FM^+U#.4^&=+U2F4P.F
M.J#:FC&"!"\?/55SQW)_VFTT;LHD93>4MH_6B0+7A,T25 6=\=!5 ;YV8+4^
MT88V&8;Y8^0W&1$X9!OHIT$BM^Q-^S%;! )C&VY)Y1RK<BE)3?TL&FLUEM)
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M:6PY*\D Y*$4PD5ZH=MPC5".>P)"T&Y.()P^2NE(8T(),26^&O3%TOK H!I
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MY[N/>]C>[F#_:;V[7<26<-UM7)PP-@$C>P4CAR^JL;6!VZ;$\JE\3'Q&4ME
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MVCV@^TI1F$X;IV!L]*O_ %!+ P04    " #.@*-6H9J1Q74$  #5"0  &0
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MQ5PNL'4T2% 83/.MK7FI]-I]WYKK"IG=#5>X(4C#!%A?:%WM7OB [H/GZ?\
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MD>$JPTN;NN6%>(_9;&,GT6[Z-M2?1<8V!KL5=)!*\EGW$<\T#<W2-9K_8M.
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MCL7"JI4?UY;*TO#G7U.:ME$[ =J/%;6/Y<(=4,WODS\!4$L#!!0    ( ,Z
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M'6W?>0R;J_ZC>O/"A)R>\$I3$HS)U#](J9NKYB5$\V#DS%W\1](863IQBJQ
M915H?BRE63_8!=HW08._ 5!+ P04    " #.@*-6VEMUE3$%  "O#@  &0
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M_YW"V$+PUXWCGNTJL7NV2E9/EI=H>1NC;MJ#$72'.(MZ=OOFV*C8@N7.>R1
MNL!M OOFU2@*HW<0XNK0B@0]IWR;JS4V'/D2:JS98Y1W=M'P<Z]^J%/KCO6F
M&R5VR-P4+?]O60QM?W%^>X<3_(?[4@N-*6X)QSV(<%L)7LSB=O3!_&4N-[83
M'()6)FUB8L^T[#D^,SO/XKU=;+!SB:@HGJ[L54F#._;X^T3SMKF-3?PEY&FY
MO\HAAJ4EB=,%B@9'&9Y3E+\>^0<C:W<EF4N#%QPW+?%&295=@-\74IKM@S70
MW%''_P!02P,$%     @ SH"C5J$3[<HU!   HPH  !D   !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&ULE591<^(V$/XK.^Y=YVZ&@BW+&%)@!D@R92:Y9A*N
M?>CT01@!FK,E3I+#I;^^*]FX<$<@?6!MR?H^?;M:+3O8*?W%;#BW\*W(I1D&
M&VNW5YV.R3:\8*:MMESBEY72!;,XU.N.V6K.EAY4Y!T2AMU.P80,1@,_]Z!'
M U7:7$C^H,&41<'TRX3G:C<,HF _\2C6&^LF.J/!EJWY$[>?MP\:1YV&92D*
M+HU0$C1?#8-Q=#6A;KU?\(?@.W/P#LZ3A5)?W&"V' :A$\1SGEG'P/#QS*<\
MSQT1ROA:<P;-E@YX^+YGO_6^HR\+9OA4Y7^*I=T,@UX 2[YB96X?U>XW7ON3
M.+Y,Y<9;V%5KXVX 66FL*FHP*BB$K)[L6QV' T O? 5 :@#QNJN-O,IK9MEH
MH-4.M%N-;.[%N^K1*$Y(=RA/5N-7@3@[NKZ9S&'\Z1JFCS?7LSG<CJ>SN]E\
M=O,$'^9LD7/S<="QN)%;WLEJTDE%2EXAC>%>2;LQ<".7?'F,[Z# 1B79JYR0
MLX3W3+<ACEI 0A*?X8L;KV//%[_F-5]8N!8FRY4I-8>_Q@MC-6;(WZ><K;CH
M:2YW:Z[,EF5\&."U,%P_\V#T\T]1-_SUC%+:**7GV$=/U64!M0(O>LJT?A%R
M#>-"E=*>DGN6\+3<^8;#2N5X0QVU=>=>7U/Q#S=@\7.VWYCYC9T@5>*-4%I[
ME($2#UO#,V)4:6 E)).9!VC-Y)KC3;;F"CX(B7F<YW@ES<?OW8'YRY8[ZLF>
M%F;&E!PPMSG<,UMJ85^JT4Q:C@Y8>*R^Z6S3I C&*N/% N74,P2>N!1*PV=I
M>(9'OL2)K:W6D##J'@V1@+23\#V\@S0)G:7]\P0D_)X@;*?)>XA:M-_WMO<C
M0:49=Z<PWFJ1.R"%N)V&#NCV=/8$\)-Z;I13N.4+7;H<07B"\*2&]UZ#'WF>
M-#)(%\%=%$T01FI[*6P-.,60];W'A*:UO12RWS.KZ@%"V@2%IPA+_Q<T#A'J
M9/?[%'_Q17\/AW$"M-T-WWO@9?!QFL1=!(=>= P7@W4DFH88+K]OK^=_/T";
M#,9MH\,1C2"I_>WZWUORBE*4VJL2 V57]NUY15V8ZKR*J;>7X[R705V84I]7
MA$2U?6M>82K0=N3S*B6]VKX]SHF+<^4W3=/:SI5E.9B*I&Q(I+)8ZPAMA7WB
M'W@L=X(M1.YJCN8YUIDE6 6KTKH_#:U>6&X%8J)61+O>1C7Y$FMU"R0V521I
MD;CG'Z0/=]Q@#9R66F,UA*W2OC7!@I<KN?X%"UKAH<#D$A2670UJD8LU<\M,
M3=@BO=C9-*XWNSO"5JO> 2&M?M+=OZ1PZL^H<] X%%RO?7MD('.UN.HAFMFF
M QM7C<=_RZOV#0]L+:2!G*\0ZJI? +IJB:J!55O?ABR4Q:;&OVZPB^3:+<#O
M*X7QKP=N@Z8O'?T+4$L#!!0    ( ,Z HU8BW4M.[P(  "D'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;)55;4_;,!#^*Z<,32!5Y*4OL*ZMU$('
M? !5+=L^3/O@)I?&PHF#[5#V[W=VVJRP4L$7O]X]]]SY[CQ82_6@,T0#S[DH
M]-#+C"G[OJ_C#'.F3V6)!=VD4N7,T%:M?%TJ9(E3RH4?!4'/SQDOO-' G<W4
M:" K(WB!,P6ZRG.F_DQ0R/70"[WMP9RO,F,/_-&@9"M<H/E>SA3M_ 8EX3D6
MFLL"%*9#;QSV)QTK[P1^<%SKG3583Y92/MC-33+T DL(!<;&(C":GO "A;!
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MCNF+;$QC"0Q'&K)P6=7Y%VF+DTX4GR9=PC-7NN=(AA/=%:(P!GI_Q+E:3TR
MK,]L_0502P,$%     @ SH"C5OB(8_FC'   \5,! !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULM5W];QM)<OU7".40W %WUG3W?#JV@/5'L@OL9A?K
M6P=!D!^XTE@BEA(5DI+/0?[XD!*IKJFNKNX&JWZYD[4USS-5S^1CO9G'-U]7
MZS\V-^.XG?WC=GFW>7MVL]W>OSX_WUS>C+?SS:O5_7BW^R]?5NO;^7;WQ_7U
M^>9^/<ZOG@ZZ79[;JFK/;^>+N[.+-T^_^V5]\6;UL%TN[L9?UK/-P^WM?/WM
MW;A<?7U[9LZ.O_AU<7VSW?_B_.+-_?QZ_#1N?[O_9;W[T_D+RM7B=KS;+%9W
ML_7XY>W9=^;U>]<W^R.>2CXOQJ\;\/-L?RV_KU9_[/_PP]7;LVI_2N-RO-SN
M,>:[_WL<WX_+Y1YJ=R+_<T ]>_E+]P?"GX_H__IT];NK^7V^&=^OEO^QN-K>
MO#WKSV97XY?YPW+[Z^KK]^/ABIY.\'*UW#S][^SKH;8ZFUT^;+:KV\/!NS.X
M7=P]___\'X=.@ -V./0!]G" Q0?4D0/<X0#W=*'/9_9T61_FV_G%F_7JZVR]
MK]ZA[7]XZLW3T;NK6=SMY_AIN][]U\7NN.W%KQ\_?_SWWSY^FOUM]NEYE+/5
ME]F'Q69^?;T>K^=/O=[]YM?Q<;Q[&#>S/W\8M_/%<O.7W1&_??HP^_.?_C+[
MTVQQ-_MIL5SNBC=OSK>[\]JCGU\>SN'=\SG8R#FXV4^KN^W-9O;Q[FJ\FAY_
MOKN>EXNRQXMZ9UG G^;K5S-G_CJSE77$^;S//]PRI^->>NR>\%P$+]K-V7_]
MN"N=_; =;S?_3?7M&;>F<??_Q%]O[N>7X]NSW;_AS;A^',\N_OF?3%O]"W71
M0F"3%M0O+:@Y](N_K[;SY>[?_3.)J$M]/KY].G[_XO-XT;IFU_U'> E$43-4
M+T634VM>3JUA3^VW5Y]>42?$'E7:>R&PR06V+Q?8*M&OE6R!$-BD!=U+"[H3
MZ?=\? .85=<!_8@BUS0T_?J74^O94_OXL-Z]*5.GQ!Y7VGTAL,DE#B^7."@1
M<)!L@1#8I 6F\N^SU8D4/ ! >IFJ&Q 'J:K=^Q1-0@-D@&%/[^?MS;B>_7"W
M'==W3V.:+\ES9%%*)R*%-KUFZZ_9*O'R "S5!B&T:1N\.C'L.W\.,UW N=X:
M3,RPR%3.18CIA8/)40[WZ]75P^5VMIDO(Z?(HA1/1 AM>LU>D9A&BYBBJD4*
M;=H&KUL,JPERB-D&G&M=U6)F$E6-JR/,])K"Y(B*"3-G_S>+R4D>K'@R0FC3
M2_>:Q?1:!!55-5)HTS9X76-8S9!#T('0E8!ZA\L@JIP=:():+SELCN3 !(T+
M3AZN=#92:-.+]X+&&B6*6E&-(X4V;8/7.)85#QD4/0!,W[<;ARA*59DN\AIJ
MO?:P.=H#4S13C/+8Q8/2V(]8KW-LK<574>DCA39M@Y<^EM_&9/"U"<6HP9^2
MB**=&#41NGI%8G,4R?<_?"9/3'1=(H4VO5(O;FRG14=1H2.%-FV#%SJ6W\YD
MT+$/W[L-V$D>+B.L<EW51?CH!8C-$2 [/C+"DX<HGH?&%L5Y2>,JK56ZJ+B1
M0INVP8L;QV]KTK0\ $P(YUHL/(DJV[>199+SHL/EB(YG6L;E)@]2/!&-)8H#
M%H^:QR-K\FBH&.=5C#O5YSD 0,HUML>\)(J:B,_CO+9P.=KBF9:9$I-'+!Z.
MQC[%>?7BM(P@)RIMI-"F;?#2QIUJ!KG0Z+%#P%&J*&(&.2\X'"\XWBW^V,[7
MC]_(TQ+=G4BA32_42Q>G90HY44$CA3:UQ;V@J4^UA>K0\+%MUV%GG*@R3>0#
M3^V%1LT+C2,=&7W)(Y2.0PIM>KU>N=1:EE MJF:DT*9M\&JF/M42JD.WQYH6
M>T)$E>G ?GYZ>N!F$EYE %;&Y26/43P0C;5([:5+K>4(U:(*1@IMV@:O8.I3
M':$Z]'I<A3_V$$6VC;U6>EU1\[H"L#)37?* Q;/16)747KG46IY0+:IKI-"F
M;?"ZIC[5$ZI#M\>:X$ZWL,CTD75[X]5&PZN-]ZO;^^6XGI]_?%P\_4#>^":Z
M*9%"FUZQ%S"-E@W4B.H:*;1I&[RN:4ZU@9K0X'%XJT[4U#%.>JW1\%HCX"2C
M-7FHXIEH[$H:KV(:+<>G$94V4FC3-H#;;T]U?!K"S,%OZ51-9+W>>+G1\'*#
MHF9<</)@Q5/16)(T7LPT6OY/(RIJI-"F;?"BICG5_VE"9\?B-W.J)O:ZZ85&
MPPL-BIR9NI-'+AZ1Q@:E]9JFU;*$6E&A(X4V;8,7.NVIEE!+6$*(J$1)A*>M
MEQXM+ST^C)O+%;W0Y(\L'H#&SJ3U.J;5<H!:454CA39M@U<U[:D.4!N:.W6-
MI291Y&*W&[5>:[2\UCAPD5&8/$#Q+%2>^P$/_J@]^2/[Z(^&EFF]EFE/-7S:
MT,MQP,LY7 519");H]8KC)97&)Z2<67)0Q1/0V-!TGK=TFH9/ZVH;)%"FSZ0
MYF5+=ZKQTQ&6#N8D4>,BMV]T7DITO)3PE,S4DSQ>Z6"DT*97[_5*IV4!=:)R
M1@IMV@8O9[I3+:".L(#PVSA1$[L+L_,2H^,EQK^-=X^K;^3NDC^R> 0:FY'.
MJY5.R_3I1%6,%-JT#5[%=*>:/EWHYS05]B*IHC[V6@D>+.:UQ8&+C*+D 8IG
MH;$/Z;Q:Z;1,GDY4PTBA3=O@-4QWJLG3$8_T&'S3!E741+:6O5<6/:\L/"69
M9\M%5Q]2:-,+]GJEU_)X>E'A(H4V;8,7+OVI'D\?^C<-5I1$31>CI!<3/2\F
M/"4S%26/5SP8C95([_5*KV7T]*)R1@IMV@8O9_I3C9X^-'$"14G4U'V$GUYB
M]+S$^/EJ_+(9R1TE?V3Q"#0V(;U7*[V6J].+JA@IM&D;0.3*J:Y.3SRO$[Q]
M4T4N\M1N[[5%SVN+ Q<91<D#%,]"8P\R>+4R:-DW@ZB&D4*;ML%KF.%4^V8@
MGM5Q^#DSLBCR(6?PRF+@E86G9%Q1\A#%T]!8?@Q>KPQ:7LX@*ERDT*9M\,)E
M.-7+&4*;IL/Q&T3-$+D%>/!B8N#%A*=DIJ+D\8H'H[$2&;Q>&;2,G4%4SDBA
M3=O@Y<QPJK$SA)Z-P8LAOF9Z:EYB#+S$V/V\^'VQO")/2G05(H4VO5"0[:86
M[B:;[J83[P;SW4X/>",<'?Q8&544>P<W%<AWJWB!<20D%U'$0Q2'\TC!H6NV
MX)K5 MXJV80W*3C4"I#Q5IT<\E81?@[6EV11E)T@Y*WBE09@9UQB)D#*AZ*Q
M#S$5B'FKU'+>*MF@-RDXU H0]5:=G/56$3%N 3W#FLARR%0@Z*WB=09@9VY.
M)H]8/A^5O+<*!+Y5:HEOE6SDFQ0<:@4(?:M.3GVKB$=\ JJ&-;&P3)@RFXJ9
M73\\SJ](;SQQ:/$@I.#0M<+(6BW?QTCGV*HH'9ADRV?$YG#2$ _X!*2DBF(O
MH#!A-A4Q^\Q*3GOR".43T=B<&!A;:[1,'R.<9:L39@O3;/F<V"QR$LX/OCF=
M+(J2$TB/5,SL"SD9Z<ECE,]$8W%B8':MT7*"C'"2K4Z4+<RRY5-BL^A).#T!
M.XD@N!@Y@=A(1<R^D#,[H5UTK2(&AS+:@:*Q6@:1D0VT%8-#K0""AP^+S6&J
M#0T@?(<'51/9QQL0-&L22;/'J6QNYNMQ_W5"WVZW#_]+*U$>JGPP*ML5D&)K
MK)9?9&1#;,7@4"N [N$#8K,X&AI"Q@5[4+(JMFH" ;,FD3 ;X2FG37G$\AFI
M+%M BJVQ6O:1D0VY%8-#K0 ZB ^0S:)KZ \%87!441]]407:))$_&R<KHU5Y
MS/(9J2Q<0,BML5H6DY$-OQ6#0]_4 L00'RR;]5TMA'\4[$F)HEB2AP&QM":1
M2QNG:ZYZY?^"XH%)P:&. %7DU"PHV7Q<,3C4"O@U0Z=_SU#H+@7?E4'4Q/:F
M(+?6)()KG_D9279/'%P^"I6-# C"-4[->))-Q!6#0ZT 6HA/F\UB96@J!=_*
M1M28Z LJD">)K-H76G+RE,<H'XG*0@9$X!JGYC7)1N2*P:%6 .G#Q\]FL9-X
MB"A@9U@322HV(+K6)+)K(3D9.<JC%,]$"@Y=-A YM9KM))N5*P:'6@'4#9]#
MFT//FOCB($Q/HB;VV@DR;$TBQ!;2,U=^\I#E U+9QM3PRQ/57"C9_%PQ.-0*
MH'GX;-HLKH8&4[#F)VJB+Z5 A60%V_Y\=[E:KJ[)YY 2".7S4-F\@+1<4ZLY
M4+*YN6)PJ!5 \/"9M%G4#-VEM@ONSB.J:AOYW@P#,FU-5JCMD9Z<%N6!RD>C
MLG !@;FF47.?9'-TQ>!0*X#NX3-J<UC:$/EQ+GB[)ZKL$-OL@XQ;DQ5R"UC*
MB%(>JGPX*LL5$*)K&C4'2C945PP.M0)H'CZP-HNGH;<$OT/]>"6$ Q4+E34-
M_';G'"4">)JK3GG<\DFI[%Y O*YIU'PHV;!=,3C4"J"&^"#;+-(2^7/XD62J
M*/8PDP$QN"8K!_?]N%S._K[CZOR>UJ@\2OE45-8O(&+7-&K.DVS&KAC<M!4@
M9=?P^;597\9.F4J!4TI4V5BRIP'YMR8K !=2E-.I/%CQ>*3@T-4#[=.J^4RM
MK!22@D.M %*(3[C-8BKQ%%,;[/2)*M/%="I(R#59$;F(J8Q6Y>'*!Z2RB0$A
MO*95<Y]DXWG%X% K@ +BHV^SN$HY2^&K*N%11:D*9$E6="ZB:JY<Y;'+AZ6R
MI@%)O:95\Z5D$WS%X% K@##BTW&S>$L\WQ2L H@B$]M7@6Q=DPK7'2_GZ^T#
M?6+\L<6SD()#%PN$3Z?F1\D&]XK!H58 %<2'XN;0L@N]ICYXYR>*VMA-)B!2
MUZ0R=0^TY(0I#U$^$I5M#,CJ-9V: R4;YBL&AUH!= \?E)O%3L)="ME)1.#%
MUE(@9M>D<G8].QDQRH.4#T5E\0+R>TVG9D/))ON*P:%6 'W#I^9F\9/X)J-@
M!T44F9A'"C)W32ITU_,S5X'RB.434EG"@&1?TZNY4;*)OV)PJ!5 ]?!INCED
M[=-?>$35Q-:E((G7)*)X_W/<[+E*/_S$'UL^"95]"\CV-;V:]20;\RL&AUH!
MQ X?H9M%RM!4<N%;/%%EHWM\$,%K$AF\1V)R"I2'*!^*RHX%9/N:7LUED@W_
M%8-#K0!BAP_6S>)G:"!9$]QH0E09&WN/!\&\)I',"_C):% >I'PL*ML4D/AK
M>C6;238+6 QNV@J0!FSXG-T<A@ZA@61LL%DBJF(Y]@;$])I$3B\@:*X(Y1&+
M1R0%AUH Q,V@9C7)A@2+P:%6 .G#!_!FL96PFH+M/5$4R1$W(+W7I.)[UZNK
M<4E_]6;BV/)1J"Q70!ZP&=1,)=EH8#$XU H@>/C8W2Q6AG:1#;ZVF*HR=>RI
M9A#;:U*YO0=B<BJ4AR@?BLIR!>0!FT'-/)+-"Q:#0ZT <H?/XLWB)^$+M2$_
MB2H3>>&T(,K7IJ)\/3_C*C0!4CH6,3ATU09<M9:/9&6#@\7@4"LL:,6I/M(1
M8;*IQ\_=446Q3TD6A/G:5)BOYV>F"$T@ED](8]-B06"PK;1L)2N;(BP&AUK1
M@%:<:BL=$;CH7*HF<@.)!;F^-BO7]\?%XXZENYF-\TWDQ51TTR(&AZZ[ ]>M
M92M9V>A@,3C4BAZTXE1;Z8@P?;H)YY:152[Z<CJ $\S1(Q..,LHT@58^'XV5
MBP61P=9HF4I6-E%8# ZU D@@/J@WAZJ&,)4,_D!/5=DNIDQ!SJ_-ROG%5&5$
M*H]7/B&-C8L%2<+6:)E-5C9A6 P.M0)((#ZX-XNLH8UD:KS,)ZMLY'8G"W)_
M;5;N+R9KKF+EP<O'I;&5L2!FV!HM&\K*A@^+P:%6 ''$9_IF,9>RH?"=)F25
MBS(72):L2.#OWY-I4(F#R\>AL8^Q(&/8&BW[R<J&#8O!35L!PH8MG^&;PTQ+
M/>44:%6BR@TQ 0 B@&U6!/".F9Q"Y3&*IR(%ARX:J!ZKY3A9V:1A,3C4"J!_
M^ #?+((2CE/P30]4E8D3%*B2K/S?9X(RNI1'*9^+RA(&I I;JV4_6=ET83$X
MU H@=/C0WBR*$L:2";:G1-40^[@/(G]M5N3O,T-SQ2@/63XCE9T,R!6V5LN-
MLK+IPF)PJ!5 _?"AO5ET#7VF =^R1Q69*D97$/EK$Y&_/XY7B_OYYG&Q/O^T
M^K+:_/ZP^Y$\31ZH>#)2<.C*@=9Q:H:4;(RP&!QJ!5! ?#IO#DD=$;07R%*B
M*+I!!=&^-A'M2W*44Z@\7OE\5'8Q(#[8.C4[2C9;6 P.M0(H(3ZR-XNJZ9P]
MJL;$/MF#N%^;B/N-,961JCQB^8!4MB\@4]@Z-6M*-FE8# ZU L@@/L WBZNA
MZ12LH8B:2*")!=F_-I']&Z-JKF;EX<N'I;*; 7'#ME;SJ60CB,7@4"N ,N*3
M?7-X6Z>_"(JJ,9$OU+,@%=@F4H$]6\\_C\O[^?:)Q/19RJYGI.#0I0,A5*O9
M4[+1PV)PJ!5 $O&)OED<#8TGUX<L):I<)"3"@D!@FP@$IFG*J58>L'Q$*IL:
MD#IL:S5+2C:-6 P.M0*((C[D-XNMA-E4!4LKH@K>N8I.$$B51$9PE*V,<N4A
MRX>DLJH!,<2V5C.J9'.)Q>"FK0"YQ):/^\WA:Q-:4$/@_1-%?>QC%L@*MHFL
MX"A;<\4KCU\\+RDXU!"@B1HU"TLVJE@,#K4":"0^ 3B+NL3S4"%UPZ(^MLL"
M\<$V$1]\^-J(B/?/'UP^#)5M#<@BMHV:;R6;1BP&AUH!U! ?\IO%R]"1"JU_
MHLC%U@$@(=@F$H)?>,DI5!ZC?"8J"QJ0.VP;-9]*-HM8# ZU H@?/N(WBYZA
M!64#@<H734\/Y /;1#XPI"<C27F4XJE(P:'+!D*G5?.H9".(Q>!0*X#$:4_V
MJ%K"HPKNG2:*8DLID IL$ZG D)^Y(I2'+)^0RDH&! _;5LVEDLT@%H-#K0"Z
MAX_VS2(K$;,7<#7_H2F0"FRS4H&_?_?Y_/L/M SE <K'H;)^ 3G#ME7SI&13
MAL7@4"N Y.'#>[.82:3PN>#S$5D5^X $LG]M5O;O@9V<&.5QRB>CLG,!J<*V
M4S.@9#.'Q>!0*X#LX:-\<TC:A>92'SQT2A7%5OL@!]AFY0![BC*"E$<JGXS*
M=@5D#-M.S8&2C1X6@T.M '*'3_3-(FGH+=F0I$113)&".&";%0?L29JK2GG8
M\C&I[%U [K#MU%PHV3!B,3C4"B"#^(S?+,927_ 4W)%"5<4Y"\1)(B+X\WB[
M7%R1B5*)0\N'H;)P 7G#ME-SFV1SA\7@IJT N<.6C_/-X65/I/*%-TD35;:*
MO>&#-&";2 ,^\))3HSQ"\4RDX- E XW3JSE*L@G$8G"H%4#S\,&^6?0DS*+@
M59,JBI(3Z)!$*K G)Z-#>8SRF:@L6$#2L.W5C"79 &(Q.-0*('#X7-\L>A*/
M.@7LY&K0R0')D8@$]N3,U9\\8/EX5!8N('/8]FH>DVP0L1@<:@60/'R^;Q93
MJ<><@KOWJ:I8?KD%\< V$0_\>;$>YU?DB?%'%L]""@Y=*I T@YJS))LX+ :'
M6@&D#A_DFT/+@7"6@E=0HBB:<P)2@&TB!?B9E)SVY '*!Z*R60')PG90,Y)D
M<X?%X% K@,[AXWRSN!F:1'_#>>5444QZ@BA@FX@"?J$FHSQYB/*)J"Q10+JP
M'=2\)-G083$XU H@;?@LWRQR$J%Z 3>Y&G1R0&PD8H!?N)DK/'F\\NEH;%4<
MB!EVE9:?Y&2SA\7@4"L,:,6I?M(189IEAIA*%D6^]<&!/&"7R ,^W#RR7]6_
M^T"?G>A*10P.7;$#5ZQE(SG9J&$Q.-2*&K3B5!OIB##]N!-PDRB*J$\'XG]=
M(OYWPDU&A"9PRN>BL59Q(%K855J^D9--&Q:#0ZWH0"M.]8V."+2^/%X'5X-.
MK@<GQXL03-"X%$T@E<]%8Y_B0+*PJ[0L)">;,BP&-VT%2!EV?'AO#D4-82$%
MKZ)44>Q5%"3_ND3R+R9IIB9-P!:/20H.]0$H':/E*CG9J&$Q.-0*(('X!-\L
MQH:&4?"BRM:@DP.B)!'^^WG\8_FP)HWXQ*'E@]!8L3B0(^R,EI7D9$.$Q>!0
M*X#FX;-YLS@9VD1-AQ?T5)5I8G>'.I#MZQ+9O@=B<D*41R@?BL:6Q8&T8&>T
M#"0G&R4L!H=: 00/G]";Q4_B^:,&QY-257T5,9 <"/AUB8!?3T]&AO(8Q5.1
M@D,7#<2-U;*2G&R4L!@<:@70-WQ";PY!+6$EA3J4J')5Y#DZ!P)^72+@UQ,T
M5X+R@.4C4MFW@ 1A9[7,)2>;*BP&AUH!E \?UIO%5N()I H[GU15'<O0<2#K
MUV5E_3XQE3X[V46+%!RZ7J!NK):WY&0CA,7@4"N ZN&3>;.X&?I&X3VA5)5U
M$7_)@6!?EQ7L^_PJRJA1'J5\+BJ+%I 7[)R:JR0;("P&AUH!= ^?RYM#41<:
M1FW 4*)HB+W5@U!?EQ7J>R0HHT=YG/*YJ&Q60%RP<VKFDFQPL!@<:@40.WP>
M;Q9%0]^H"SXO$45][.,2"/-U66&^1XKF*E(>M'Q(*EL7$!KLG)K3)!L>+ :'
M6@$$$)_)F\77T$5J<,@#511+R7,@T-<E GV_NWVWV*QN(R^CLLL6*3ATL4#@
M.#5W238;6 QNV@J0#>SXR-T<6M:4NX1O=2*KZMA[/4CL=8G$WB,Q.27*0Q0/
M10H.73/0-[6:ER2;"RP&AUH!% \?MYO%S] G"ME)?+53;&</HGI=(JH7D)-1
MH3Q(^4Q4EBL@_]?5:K:2;!"P&!QJ!1 X?+YN%CU#PZ@-O$ZJ*/9)'H3SND0X
M+^!GK@3E$<LGI+)M ?&_KE;SF&13@,7@4"N [.'#=;/(&KI'=?"IGBAJ8G>2
M@&1>ETCF_7'<SA?K!7UB_+'%LY""0Q<+9$VCYBS))OR*P:%6 +7#!^?FT+(A
M/*/@DSQ15$=I"11((G7W2$M.@/(0Y2-16:Z *%_7J#E)LCF_8G"H%4#L\/&Y
M6>PDOI4I9"=E),78"01((GL7L)-1H#Q(^5!4EBD@TM<U:FZ2;-"O&!QJ!= W
M?'YN%C]#GR@0H&P-.CF@.!+1NX"=N?J31RR?C\J"!<3[NE;-59*-_!6#0ZT
MFH=/TLVA:AL:1@%5V1IT<D"%M!E/*M'G)+M2D8)#5PH$3:MF(LGF^HK!H58
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M(1P1R?C=< ;ME@ZX.]ZR?_+>R<N<&1PK\8/GMA@&YP'DN& K86_4YC,V?KS
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MHG(!]KR4TCPLW/4=7NO\+U!+ P04    " #.@*-6$/]6C+,0    MP  &0
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MQQ<V/[$??P@6[7H8\V7*AO''OKFJNVJZ%]*>4:)D<Y3G<LKKA-*9E.<HA*$
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MBN4^LT8FFTMU#G;2PR:V4E+$0Z5-=)8CGM30=G0.CXIJE$N13B::"0^8"Z<
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M"&O3786 A!$@6$V(TU*(4ZO+-M=6;:G\U'D@NB\^(Y/U9V2H5Y2W\1GY)GC
MHN4+TGD\NIG\YMR0"3YJ4L[:C5T7%23,@X01(%A-R[-2R[.]BI-GD))"PCQ(
M& &"U21UV]6.K?T_)W-V [OJ5-!^D?F!VB10M+H$&YMFU_ZQ^G."?H^?;G1,
MM"2"=LC.;H:D>: T D6KRX$K.?!>A;FB.U#"0M(\4!J!HM6%K2H1KG57/%@K
M^(*F.ILH5YVI=F#<OM /LBOWX@#Y.LW3"IK@IR]EJ#/(O&#U<UVH:E02M/@
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MH[G97"J:N0U+RC/,-9<Y*%R.G*A['@^L?^GPF>-.'XS!9K*0\H>=S-*1X]F
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M8U-5=Z\F1F[*?K>0AKIG.5S3)41E'6A]*:793^P&S2=6^#]02P,$%     @
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M ]3]+6/R8:-GY/R=R/L-4$L#!!0    ( ,Z HU:$@] H90,  &T-   9
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MM-12\JRVSQJ2K=+R>,JD*K;3RTA]#P'7 ]3]!6/RN:$K[N(+*_@+4$L#!!0
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MF2Y_85>/'7B0%-I(7H-M!9R*ZI\\U3[L 2Q/.R"H <%+P.@50%@#PE\%C&K
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MLP/@H;5""R^BV$3>:C8T"-.XE%Q]2Y6?G,YOGA:OU\^+UQMPNWBX?I@MKN_
MXF'Y_/1R?_/PO 078'G,,&!K,/.P$'1-5_B8@\ %MYAR\(J]/0D-YH33=QQF
M!BP"(?E>95P*<#8G$E-/G"NXE^4<G'TY!U\ #< ]]3R%),:V5),)*=FKF/BW
M(W%80_P>\TN G*\ =B"J<)_IW>=DE;C#O+NM0IC$$29QA!$>JL7[F+CXFHW)
M'W?*$"PD\<6?59,\HG:K4<,U?"5V>$4FEEJD@O!W8DU__LGI=WZIFK(AL%P
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M$U$LFL/\EX401=8\O.;1C)=U@'Q_7A3BYY/Z]P&;WX-,_@=02P,$%     @
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MS"I.E=!OB=:I:')]-[B^G)Q_&Z/!=#J^FZ+/:%JL*.)S-):*Z%Q!@BY6:B4
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M890VP+Q?"*&?)W:GKP_VY ]02P,$%     @ SH"C5GA64%S> @  (@@  !D
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M-34N>&ULK95=;]HP%(;_BI554RMMS3?0#B)1&"I2"Q6TV\6T"Q,.8-6Q,]M
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MBN+;46P4S^WXG7&EA[E=KO3G%H0)T/<7G*NWC9GHU0<\^0U02P,$%     @
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MB' MLK) \?U36N16_:9\\,KA03OS_P-02P,$%     @ SH"C5JN*X(.9 @
M*P8  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULK55=;]HP%/TK5E9-
MK;21#Z";NA )2*MF:J<*VNUAVH-);L"J8S/;@?;?[]H)$:THV\->$G_<<WS.
MS?5-O)7J4:\ #'FJN- C;V7,^L+W=;Z"BNJ>7(/ G5*JBAJ<JJ6OUPIHX4 5
M]Z,@./<KRH27Q&[M3B6QK UG NX4T7554?4\ 2ZW(R_T=@LSMEP9N^ G\9HN
M80[F87VG<.9W+ 6K0&@F!5%0CKQQ>#$=V'@7\)W!5N^-B76RD/+13K)BY 56
M$'#(C66@^-K %#BW1"CC=\OI=4=:X/YXQW[EO*.7!=4PE?P'*\QJY'WV2 $E
MK;F9R>TUM'Z&EB^77+LGV;:Q@4?R6AM9M6!44#'1O.E3FX<]0#AX Q"U@.A?
M ?T6T'=&&V7.5DH-36(EMT39:&2S Y<;AT8W3-BO.#<*=QGB3))>3N[)^%M*
MIK/+-+LG5^-I=I/=9Y=S\I&,BX+99%-.,M%4C$W]:0J&,J[/,.0&^8@LR50!
MQN+"##:2;YA8[I:N:,XX,\^X]WHEK8%\K9$@"J(A[C_,4W)Z<D9."!-DPCC'
MTW3L&_1IU?IYZVG2>(K>\'1+58_TPP^6MG\ /CT.3R'OX-%+N(_9[5(<=2F.
M'%__3;Z%P?QIHVHL?T-^NIQE!BK]ZY"YAFUPF,W>Z@N]ICF,/+RV&M0&O.3]
MN_ \^'+(ZG\B>V&\WQGO'V-/QI6LA=$$FX<V5!2V*&I1@,+KORN2O"F)LBD)
M!@<_=W/,N3O&MJ5-$L3^9M_FL8@7V@>=]L%1[;?TB55U1192(=(II9@HK-I#
M ANN,-P[/^H-7VG\2U CT]^[RK:-8BTOF="$0XFHH/=IZ!'5M*9F8N3:W>Z%
M--@KW'"%W1R4#<#]4DJSF]B&T?T?DC]02P,$%     @ SH"C5A!N70,W!
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MQQNWNB=0/J-VVX_5J; Z%['<)J=:"[A:4?&U%8#*4O("<FMCU:X2X->"[YC
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MD2,RBB)FPDL3<LG+,V*"?7 .FK)$':+)_=TY.=@[)'N$<7+%D@0-U,#62,9
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M4]9G:Y=_'#\\\];4W2&?#?]VFKT!4$L! A0#%     @ SH"C5@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #.@*-6<9((A>X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #.@*-6F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,Z
MHU9<R;K9WP4  .,>   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #.@*-6D1]PEY$&  #P&P  &
M        @($B#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ SH"C5KQO>?_I @  C0D  !@              ("!Z10  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,Z HU;Q\S .E04  *P8   8
M              " @0@8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " #.@*-6I#]^C6 $  #,$   &               @('3'0  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ SH"C5N#D=DO^ @
M\P@  !@              ("!:2(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( ,Z HU8I@!>LC @  !%'   8              " @9TE
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #.@*-64X%[
MU-,"  #/!@  &               @(%?+@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ SH"C5B/?L\,N!P  DB   !@
M ("!:#$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,Z
MHU8]?NCD0 4  "H,   9              " @<PX  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ SH"C5J*$/RK$"   :A,  !D
M         ("!0SX  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " #.@*-6(FZ<QUH*  !=&P  &0              @($^1P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,Z HU:;7=LA+@@  " 8
M   9              " @<]1  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ SH"C5E^ >TG&!P  ZQ<  !D              ("!-%H
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #.@*-6TW(B
M=6,)  #6&   &0              @($Q8@  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( ,Z HU8AX5%_. D  ' 6   9
M  " @<MK  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MSH"C5GFBGL,=!0  D@T  !D              ("!.G4  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " #.@*-6PBM8<]4$  !!#   &0
M            @(&.>@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( ,Z HU9+UV%LLQL  %M7   9              " @9I_  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ SH"C5OICOU$] P
M] <  !D              ("!A)L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " #.@*-6H9J1Q74$  #5"0  &0              @('X
MG@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,Z HU8G
M#\O/A @   D4   9              " @:2C  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ SH"C5A1R?R__"   _!0  !D
M     ("!7ZP  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,Z HU;:6W65,04  *\.   9              "
M@:S,  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ SH"C
M5J$3[<HU!   HPH  !D              ("!%-(  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " #.@*-6(MU+3N\"   I!P  &0
M        @(& U@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( ,Z HU9$C1C/HP(  +0%   9              " @:;9  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ SH"C5CMN J,3 P  <PH
M !D              ("!@-P  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " #.@*-6^(AC^:,<  #Q4P$ &0              @('*WP
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,Z HU:F]TWU
M(@,  "P,   9              " @:3\  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ SH"C5F40YU"W @  HP8  !D
M ("!_?\  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #.
M@*-6MM$#G5$"  "Y!0  &0              @('K @$ >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,Z HU80_U:,LQ    "W   9
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M970T,2YX;6Q02P$"% ,4    " #.@*-6_+SK@#$#  !N"0  &0
M    @(%.+ $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M ,Z HU:XH3.3.0,  !\-   9              " @;8O 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ SH"C5H2#T"AE P  ;0T  !D
M             ("!)C,! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " #.@*-6.E.]-X4#   *#P  &0              @('"-@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,Z HU8?Y/A>:@,
M -H,   9              " @7XZ 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ SH"C5BK/1I$O!0  $2$  !D              ("!
M'SX! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #.@*-6
M;O \YR$#  #:!P  &0              @(&%0P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( ,Z HU:K@,1C)P8  %HN   9
M      " @=U& 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ SH"C5O"0WADN!P  &S(  !D              ("!.TT! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #.@*-6G8_!HEH$  #%%P
M&0              @(&@5 $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( ,Z HU8U5\]#_P(  +H)   9              " @3%9 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ SH"C5OOPTMK6
M @  Y <  !D              ("!9UP! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " #.@*-6>%907-X"   B"   &0
M@(%T7P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,Z
MHU9YLVVI[0(  ,P'   9              " @8EB 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ SH"C5@2D=H>7!0  XAT  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( ,Z HU8.9ROSA (  /0%   9
M  " @3=_ 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
MSH"C5K+95)*U @    <  !D              ("!\H$! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " #.@*-63WK]R2$#   H"@  &0
M            @('>A $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( ,Z HU;D2,!94 ,  $84   -              "  3:( 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ SH"C5I>*NQS     $P(   L
M     ( !L8L! %]R96QS+RYR96QS4$L! A0#%     @ SH"C5I/F6Y34!
M$"H   \              ( !FHP! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( ,Z HU8G9=6E# (  (0E   :              "  9N1 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,Z HU;NU>T8Y@$  /4D
M   3              "  =^3 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !' $< :!,  /:5 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>552</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>125</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUES</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS</Role>
      <ShortName>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - OTHER FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</Role>
      <ShortName>OTHER FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - DEBT AND CREDIT FACILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</Role>
      <ShortName>DEBT AND CREDIT FACILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EARNINGSPERSHARE</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/REVENUES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INTANGIBLEASSETSTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INTANGIBLEASSETS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables</Role>
      <ShortName>OTHER FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OTHERFINANCIALINFORMATION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables</Role>
      <ShortName>DEBT AND CREDIT FACILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DEBTANDCREDITFACILITIES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EARNINGSPERSHARETables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/EARNINGSPERSHARE</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/INCOMETAXES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - REVENUES - Summary of Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails</Role>
      <ShortName>REVENUES - Summary of Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - REVENUES - Summary of Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails</Role>
      <ShortName>REVENUES - Summary of Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - REVENUES - Summary of Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails</Role>
      <ShortName>REVENUES - Summary of Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - REVENUES - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails</Role>
      <ShortName>REVENUES - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails</Role>
      <ShortName>AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails</Role>
      <ShortName>ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails</Role>
      <ShortName>DEBT AND CREDIT FACILITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - EARNINGS PER SHARE - Schedule of the Calculation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails</Role>
      <ShortName>EARNINGS PER SHARE - Schedule of the Calculation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EARNINGSPERSHAREAdditionalInformationDetails</Role>
      <ShortName>EARNINGS PER SHARE - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - INCOME TAXES - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESScheduleDetails</Role>
      <ShortName>INCOME TAXES - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 7 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. gild-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="gild-20230331.htm">gild-20230331.htm</File>
    <File>gild-20230331.xsd</File>
    <File>gild-20230331_cal.xml</File>
    <File>gild-20230331_def.xml</File>
    <File>gild-20230331_lab.xml</File>
    <File>gild-20230331_pre.xml</File>
    <File>gildq12023ex10112023employ.htm</File>
    <File>gildq12023ex10222023psuagr.htm</File>
    <File>gildq12023ex10262023psuagr.htm</File>
    <File>gildq12023ex10332023employ.htm</File>
    <File>gildq12023ex1049offerlette.htm</File>
    <File>gildq12023ex1050stockoptio.htm</File>
    <File>gildq12023ex1051rsuagreeme.htm</File>
    <File>gildq12023ex1052rsuagreeme.htm</File>
    <File>gildq12023ex311ceocertific.htm</File>
    <File>gildq12023ex312cfocertific.htm</File>
    <File>gildq12023ex32section906ce.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1179">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1179,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 552,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 540,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 19,
   "keyStandard": 269,
   "memberCustom": 74,
   "memberStandard": 43,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gilead.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - REVENUES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.gilead.com/role/REVENUES",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS",
     "shortName": "ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.gilead.com/role/INTANGIBLEASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - OTHER FINANCIAL INFORMATION",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATION",
     "shortName": "OTHER FINANCIAL INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - DEBT AND CREDIT FACILITIES",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIES",
     "shortName": "DEBT AND CREDIT FACILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - EARNINGS PER SHARE",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.gilead.com/role/EARNINGSPERSHARE",
     "shortName": "EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.gilead.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - REVENUES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.gilead.com/role/REVENUESTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.gilead.com/role/INTANGIBLEASSETSTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables",
     "shortName": "OTHER FINANCIAL INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - DEBT AND CREDIT FACILITIES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables",
     "shortName": "DEBT AND CREDIT FACILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - EARNINGS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.gilead.com/role/EARNINGSPERSHARETables",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.gilead.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i40c694f02592405083bdaf13c4316671_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - REVENUES - Summary of Disaggregation of Revenues (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails",
     "shortName": "REVENUES - Summary of Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i1c91b5b81b3f49cc99ed4d965e15cb05_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "ic87bba42a74544ebb4ed1b2216e3f687_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - REVENUES - Summary of Revenues from Major Customers (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails",
     "shortName": "REVENUES - Summary of Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "ic87bba42a74544ebb4ed1b2216e3f687_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - REVENUES - Summary of Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails",
     "shortName": "REVENUES - Summary of Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - REVENUES - Summary of Contract Balances (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails",
     "shortName": "REVENUES - Summary of Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i825aac04e24b40208c807dce228c07fb_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i4162868d814a43e3aaf697b3f77e900a_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i05b4776cc8f6409e92531b2b339c0031_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i05b4776cc8f6409e92531b2b339c0031_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i6e9f4eec9e644776964e5a8b7a54bd46_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i6e9f4eec9e644776964e5a8b7a54bd46_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
     "shortName": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES - Summary of Classification of Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i6e9f4eec9e644776964e5a8b7a54bd46_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENTS - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
     "shortName": "ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if7e7f985abe641bf816e52117d2bceef_D20230130-20230130",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - INTANGIBLE ASSETS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails",
     "shortName": "INTANGIBLE ASSETS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS - Summary of Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Summary of Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Inventories (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Summary of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accrued and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "id5b99939368b46f298d75ed65a8f6ded_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "OTHER FINANCIAL INFORMATION - Summary of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "if8f2633fb3c542d2b3573b60b6456dd2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LineOfCredit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i708772249eff4b8db077ea95cb4df25d_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
     "shortName": "DEBT AND CREDIT FACILITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LineOfCredit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i708772249eff4b8db077ea95cb4df25d_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "ie7a93ad78ff7434d9928c41e2243dfea_D20220301-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - EARNINGS PER SHARE - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails",
     "shortName": "EARNINGS PER SHARE - Schedule of the Calculation of Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - EARNINGS PER SHARE - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.gilead.com/role/EARNINGSPERSHAREAdditionalInformationDetails",
     "shortName": "EARNINGS PER SHARE - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - INCOME TAXES - Schedule (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.gilead.com/role/INCOMETAXESScheduleDetails",
     "shortName": "INCOME TAXES - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "i9df0d41627834bad8a580aa95611df74_D20220101-20220331",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "iba0cff47492f4decb13158e416e6a4a3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "iba0cff47492f4decb13158e416e6a4a3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20230331.htm",
      "contextRef": "icd6c59c571494a02a71ad883d5631309_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 125,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "0.75% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A250SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.50% Senior Unsecured Notes Due September 2023",
        "label": "2.50% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A250SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A295SeniorUnsecuredNotesDueMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "label": "2.95% Senior Unsecured Notes Due March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due March 2027"
       }
      }
     },
     "localname": "A295SeniorUnsecuredNotesDueMarch2027Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A350SeniorUnsecuredNotesDueFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "label": "3.50% Senior Unsecured Notes Due February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due February 2025"
       }
      }
     },
     "localname": "A350SeniorUnsecuredNotesDueFebruary2025Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A365SeniorUnsecuredNotesDueMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.65% Senior Unsecured Notes Due March 2026",
        "label": "3.65% Senior Unsecured Notes Due March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due March 2026"
       }
      }
     },
     "localname": "A365SeniorUnsecuredNotesDueMarch2026Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A370SeniorUnsecuredNotesDueApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "label": "3.70% Senior Unsecured Notes Due April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due April 2024"
       }
      }
     },
     "localname": "A370SeniorUnsecuredNotesDueApril2024Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A400SeniorUnsecuredNotesDueSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.00% Senior Unsecured Notes Due September 2036",
        "label": "4.00% Senior Unsecured Notes Due September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due September 2036"
       }
      }
     },
     "localname": "A400SeniorUnsecuredNotesDueSeptember2036Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A415SeniorUnsecuredNotesDueMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "label": "4.15% Senior Unsecured Notes Due March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due March 2047"
       }
      }
     },
     "localname": "A415SeniorUnsecuredNotesDueMarch2047Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A450SeniorUnsecuredNotesDueFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "label": "4.50% Senior Unsecured Notes Due February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due February 2045"
       }
      }
     },
     "localname": "A450SeniorUnsecuredNotesDueFebruary2045Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A460SeniorUnsecuredNotesDueSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.60% Senior Unsecured Notes Due September 2035",
        "label": "4.60% Senior Unsecured Notes Due September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due September 2035"
       }
      }
     },
     "localname": "A460SeniorUnsecuredNotesDueSeptember2035Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A475SeniorUnsecuredNotesDueMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "label": "4.75% Senior Unsecured Notes Due March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due March 2046"
       }
      }
     },
     "localname": "A475SeniorUnsecuredNotesDueMarch2046Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A480SeniorUnsecuredNotesDueApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "label": "4.80% Senior Unsecured Notes Due April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due April 2044"
       }
      }
     },
     "localname": "A480SeniorUnsecuredNotesDueApril2044Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A565SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "label": "5.65% Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due December 2041"
       }
      }
     },
     "localname": "A565SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: allowances for cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: allowances for chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcellxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcellx, Inc",
        "label": "Arcellx, Inc [Member]",
        "terseLabel": "Arcellx, Inc"
       }
      }
     },
     "localname": "ArcellxIncMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AxicabtageneciloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "axicabtagene ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset \u2013 axicabtagene ciloleucel"
       }
      }
     },
     "localname": "AxicabtageneciloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Tecartus",
        "label": "Cell Therapy Products, Tecartus [Member]",
        "terseLabel": "Tecartus"
       }
      }
     },
     "localname": "CellTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total Cell Therapy"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Yescarta [Member]",
        "label": "Cell Therapy Products, Yescarta [Member]",
        "terseLabel": "Yescarta"
       }
      }
     },
     "localname": "CellTherapyProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Liability",
        "label": "Contingent Consideration, Liability [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "Credit Facility Due June 2025"
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount",
        "label": "Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments and equity method investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EuropeanPatentClaims2032ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2032 Expiration",
        "label": "European Patent Claims 2032 Expiration [Member]",
        "terseLabel": "European Patent Claims 2032 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2032ExpirationMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement",
        "terseLabel": "Effect of foreign exchange remeasurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsGrossReclassified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "label": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "terseLabel": "Reclassified intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossReclassified",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos, a clinical-stage biotechnology company based in Belgium",
        "label": "Galapagos [Member]",
        "terseLabel": "Galapagos"
       }
      }
     },
     "localname": "GalapagosMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GlobalStrategicCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Strategic Collaboration Agreement",
        "label": "Global Strategic Collaboration Agreement [Member]",
        "terseLabel": "Global Strategic Collaboration Agreement"
       }
      }
     },
     "localname": "GlobalStrategicCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product [Member]",
        "terseLabel": "Total HBV/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]",
        "terseLabel": "Other HBV/HBD"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductOtherMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "terseLabel": "Vemlidy"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "terseLabel": "Viread"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVireadMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepcludexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepcludex",
        "label": "Hepcludex [Member]",
        "verboseLabel": "Intangible asset \u2013 Hepcludex"
       }
      }
     },
     "localname": "HepcludexMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics"
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Process Research And Development Trodelvy For HR+/HER2-",
        "label": "In Process Research And Development Trodelvy For HR+/HER2- [Member]",
        "terseLabel": "In Process Research And Development Trodelvy For HR+/HER2-"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentTrodelvyForHRHER2Member",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Asset, Measurement Input",
        "label": "Indefinite-Lived Intangible Asset, Measurement Input",
        "terseLabel": "Discount rate, measurement input"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetMeasurementInput",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset \u2013 sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Net And Inventory Noncurrent",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LiverDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liver Disease",
        "label": "Liver Disease [Member]",
        "terseLabel": "Total Liver Disease"
       }
      }
     },
     "localname": "LiverDiseaseMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyMaterialTransferAgreementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Material Transfer Agreements, Number",
        "label": "Loss Contingency, Material Transfer Agreements, Number",
        "terseLabel": "Number of material transfer agreements"
       }
      }
     },
     "localname": "LossContingencyMaterialTransferAgreementsNumber",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Appealed, Number",
        "label": "Loss Contingency, Parties Appealed, Number",
        "terseLabel": "Number of parties appealed"
       }
      }
     },
     "localname": "LossContingencyPartiesAppealedNumber",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR GmbH"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OncologyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology Product",
        "label": "Oncology Product [Member]",
        "terseLabel": "Total Oncology"
       }
      }
     },
     "localname": "OncologyProductMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20230331",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHepatitisCVirusProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Hepatitis C Virus Products",
        "label": "Other Hepatitis C Virus Products [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHepatitisCVirusProductsMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total Other"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Asset Acquisitions",
        "label": "Payments For Asset Acquisitions",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PionyrImmunotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Immunotherapeutics Inc",
        "label": "Pionyr Immunotherapeutics Inc [Member]",
        "terseLabel": "Pionyr Immunotherapeutics Inc"
       }
      }
     },
     "localname": "PionyrImmunotherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PotentialFutureMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments, Maximum",
        "label": "Potential Future Milestone Payments, Maximum",
        "terseLabel": "Maximum potential future milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsMaximum",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PreExposureProphylaxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Exposure Prophylaxis",
        "label": "Pre-Exposure Prophylaxis [Member]",
        "terseLabel": "Pre-Exposure Prophylaxis"
       }
      }
     },
     "localname": "PreExposureProphylaxisMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RevenuePerformanceObligationPercentageOfUSProfits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Percentage Of U.S. Profits",
        "label": "Revenue, Performance Obligation, Percentage Of U.S. Profits",
        "terseLabel": "Revenue, performance obligation, percentage of U.S. profits"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPercentageOfUSProfits",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorNotesAndMediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes and Medium Term Notes",
        "label": "Senior Notes and Medium Term Notes [Member]",
        "terseLabel": "Senior Notes and Medium-Term Notes"
       }
      }
     },
     "localname": "SeniorNotesAndMediumTermNotesMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TmunityTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tmunity Therapeutics",
        "label": "Tmunity Therapeutics [Member]",
        "terseLabel": "Tmunity Therapeutics"
       }
      }
     },
     "localname": "TmunityTherapeuticsMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy",
        "label": "Trodelvy [Member]",
        "terseLabel": "Trodelvy",
        "verboseLabel": "Intangible asset \u2013 Trodelvy"
       }
      }
     },
     "localname": "TrodelvyMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_VekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Veklury",
        "label": "Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "VekluryMember",
     "nsuri": "http://www.gilead.com/20230331",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r307",
      "r600",
      "r667",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r421",
      "r527",
      "r550",
      "r574",
      "r575",
      "r596",
      "r610",
      "r616",
      "r664",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r307",
      "r600",
      "r667",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r304",
      "r528",
      "r598",
      "r614",
      "r659",
      "r660",
      "r667",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r304",
      "r528",
      "r598",
      "r614",
      "r659",
      "r660",
      "r667",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r414",
      "r421",
      "r424",
      "r425",
      "r426",
      "r503",
      "r527",
      "r550",
      "r574",
      "r575",
      "r596",
      "r610",
      "r616",
      "r656",
      "r664",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r414",
      "r421",
      "r424",
      "r425",
      "r426",
      "r503",
      "r527",
      "r550",
      "r574",
      "r575",
      "r596",
      "r610",
      "r616",
      "r656",
      "r664",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r206",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r288",
      "r326",
      "r327",
      "r439",
      "r466",
      "r467",
      "r468",
      "r469",
      "r494",
      "r495",
      "r496",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r206",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r288",
      "r326",
      "r327",
      "r439",
      "r466",
      "r467",
      "r468",
      "r469",
      "r494",
      "r495",
      "r496",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Reclassification Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r305",
      "r306",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r599",
      "r615",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r305",
      "r306",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r599",
      "r615",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r218",
      "r308",
      "r309",
      "r578"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r176",
      "r194"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r5",
      "r176",
      "r194"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r180",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Future royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r232",
      "r241",
      "r242",
      "r457",
      "r585",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r232",
      "r241",
      "r242",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r36",
      "r37",
      "r219",
      "r543",
      "r556",
      "r560"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r240",
      "r241",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r33",
      "r37",
      "r135",
      "r496",
      "r551",
      "r552",
      "r628",
      "r629",
      "r630",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r32",
      "r37",
      "r135",
      "r241",
      "r242",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "OTHER FINANCIAL INFORMATION"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r427",
      "r428",
      "r429",
      "r641",
      "r642",
      "r643",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r57",
      "r93"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Repurchases of common stock for employee tax withholding under equity incentive plans"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r113",
      "r114",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r220",
      "r310",
      "r328"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r57",
      "r87",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EARNINGSPERSHAREAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborations and Other Arrangements [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r174",
      "r193",
      "r214",
      "r255",
      "r295",
      "r298",
      "r302",
      "r324",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r453",
      "r458",
      "r483",
      "r613",
      "r662",
      "r663",
      "r682"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r209",
      "r222",
      "r255",
      "r324",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r453",
      "r458",
      "r483",
      "r613",
      "r662",
      "r663",
      "r682"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r71",
      "r313",
      "r540"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r71",
      "r312",
      "r539"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "After ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r71",
      "r314",
      "r541"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "After ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r71",
      "r311",
      "r538"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r449",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r123",
      "r124",
      "r449",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r126",
      "r127",
      "r451"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Liability for MYR GmbH (\u201cMYR\u201d) contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination, Separately Recognized Transactions [Line Items]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Table]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r60"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r167"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r181",
      "r200"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r349",
      "r350",
      "r564",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r641",
      "r642",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 shares authorized; 1,248 and 1,247 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r237",
      "r239",
      "r247",
      "r535",
      "r547"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Gilead, net"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r132",
      "r133",
      "r138",
      "r237",
      "r239",
      "r246",
      "r534",
      "r546"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to noncontrolling interest, net"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r131",
      "r138",
      "r237",
      "r239",
      "r245",
      "r533",
      "r545"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income, net"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r63",
      "r64",
      "r165",
      "r166",
      "r307",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r63",
      "r64",
      "r165",
      "r166",
      "r307",
      "r561",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r63",
      "r64",
      "r165",
      "r166",
      "r307",
      "r563",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r63",
      "r64",
      "r165",
      "r166",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r63",
      "r64",
      "r165",
      "r166",
      "r307",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Contract Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r397",
      "r399",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r397",
      "r398",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Changes in estimates"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue share with Janssen and royalties for licenses of intellectual property"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r668"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r605",
      "r607",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r44",
      "r528"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r62",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r254",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r381",
      "r388",
      "r389",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT AND CREDIT FACILITIES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r175",
      "r177",
      "r191",
      "r258",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r493",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r177",
      "r191",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Short-term and long-term debt, carrying values",
        "verboseLabel": "Total senior unsecured notes"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r21",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r258",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r493",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r22",
      "r106",
      "r107",
      "r108",
      "r109",
      "r168",
      "r169",
      "r171",
      "r190",
      "r258",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r493",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r651"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r320",
      "r339",
      "r589"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r320",
      "r339"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r320",
      "r339",
      "r589"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r320",
      "r339"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r651"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "netLabel": "Available-for-sale debt securities",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r318",
      "r336",
      "r589"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r319",
      "r337"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r335",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r317",
      "r589",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities in a Continuous Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r57",
      "r121",
      "r437",
      "r442",
      "r443",
      "r640"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r57",
      "r98"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r223",
      "r584"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amount (legal offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r28",
      "r30",
      "r224"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r30",
      "r152",
      "r225",
      "r583"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "terseLabel": "Cash collateral received / pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r30",
      "r152",
      "r225",
      "r583"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "terseLabel": "Cash collateral received / pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Time estimate for gains (losses) to be reclassified from AOCI to product sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r149",
      "r675"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Net gain (loss) recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r223",
      "r584"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "verboseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amount (legal offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r28",
      "r30",
      "r224"
     ],
     "calculation": {
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturities of derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r148",
      "r150",
      "r151",
      "r153",
      "r155",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedges:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r410",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Disaggregation of Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r110",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r248",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r288",
      "r468",
      "r469",
      "r536",
      "r548",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Gilead (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r248",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r277",
      "r282",
      "r283",
      "r284",
      "r288",
      "r468",
      "r469",
      "r536",
      "r548",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Gilead (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EARNINGSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://www.gilead.com/role/INCOMETAXESScheduleDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r105",
      "r205",
      "r240",
      "r241",
      "r242",
      "r259",
      "r260",
      "r261",
      "r263",
      "r270",
      "r273",
      "r290",
      "r325",
      "r396",
      "r427",
      "r428",
      "r429",
      "r438",
      "r439",
      "r467",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r496",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r215",
      "r480",
      "r579"
     ],
     "calculation": {
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net unrealized loss on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r83",
      "r192",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r379",
      "r482",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement",
        "verboseLabel": "Market value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r470",
      "r471",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r158",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r379",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r471",
      "r500",
      "r501",
      "r502",
      "r592",
      "r593",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r158",
      "r162",
      "r379",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r473",
      "r474",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r379",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r379",
      "r415",
      "r420",
      "r471",
      "r500",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r379",
      "r415",
      "r420",
      "r471",
      "r501",
      "r592",
      "r593",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r379",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r471",
      "r502",
      "r592",
      "r593",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r159",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in valuation assumptions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r379",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r500",
      "r501",
      "r502",
      "r592",
      "r593",
      "r605",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r470",
      "r471",
      "r473",
      "r474",
      "r476",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r145",
      "r148",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r338",
      "r340",
      "r341",
      "r390",
      "r395",
      "r465",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r589",
      "r647",
      "r648",
      "r649",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r212",
      "r346"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023 (remaining nine months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r348",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r92",
      "r530"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r88",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r92",
      "r529"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofEstimatedFutureAmortizationExpenseDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r669",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "terseLabel": "Discontinuances of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r211",
      "r342",
      "r531",
      "r590",
      "r613",
      "r653",
      "r654"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r143",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r637",
      "r655"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "In-process research and development impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "verboseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r172",
      "r182",
      "r203",
      "r295",
      "r297",
      "r301",
      "r303",
      "r537",
      "r588"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before income taxes",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/INCOMETAXESScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r256",
      "r434",
      "r435",
      "r436",
      "r440",
      "r444",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r257",
      "r272",
      "r273",
      "r294",
      "r432",
      "r441",
      "r445",
      "r549"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/INCOMETAXESScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Non-deductible IPR&amp;D charges"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r251",
      "r321"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net loss from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.",
        "label": "Increase (Decrease) in Income Taxes",
        "terseLabel": "Income tax assets and liabilities, net",
        "verboseLabel": "Reclassification into income tax assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Reclassification out of prepaid expenses and other",
        "negatedTerseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r284",
      "r423"
     ],
     "calculation": {
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r344",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure",
        "terseLabel": "Indefinite-lived intangible assets, fair value"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r89",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails",
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r86",
      "r90"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r170",
      "r184",
      "r243",
      "r293",
      "r492"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r85",
      "r580"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r221",
      "r577",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r626"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r85",
      "r582"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r85",
      "r581"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r173",
      "r187",
      "r204",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r179",
      "r198",
      "r613",
      "r639",
      "r650",
      "r679"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r210",
      "r255",
      "r324",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r454",
      "r458",
      "r459",
      "r483",
      "r613",
      "r662",
      "r682",
      "r683"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r4",
      "r177",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amounts outstanding under revolving credit facilities"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r177",
      "r195",
      "r378",
      "r393",
      "r592",
      "r593"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r22",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails",
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r351",
      "r352",
      "r353",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of class action lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs involved"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents challenged"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "verboseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Equity Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r27",
      "r178",
      "r197",
      "r255",
      "r324",
      "r356",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r483"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r58",
      "r183",
      "r202",
      "r208",
      "r235",
      "r238",
      "r242",
      "r255",
      "r262",
      "r264",
      "r265",
      "r267",
      "r268",
      "r272",
      "r273",
      "r281",
      "r295",
      "r297",
      "r301",
      "r303",
      "r324",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r469",
      "r483",
      "r588",
      "r662"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Gilead",
        "totalLabel": "Net income attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r134",
      "r137",
      "r235",
      "r238",
      "r272",
      "r273",
      "r630"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r129",
      "r396",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives not designated as hedges:"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r295",
      "r297",
      "r301",
      "r303",
      "r588"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r61",
      "r65",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r227",
      "r228",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r37",
      "r40",
      "r241",
      "r485",
      "r487",
      "r491",
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "verboseLabel": "Net unrealized gain (loss), net of tax impact of $(1) and $3, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r226",
      "r230",
      "r460",
      "r461",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Net gain (loss) recognized in Accumulated other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Tax impact of net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r230",
      "r233"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassification to net income, net of tax impact of $3 and $3, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r230",
      "r233",
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Net gain reclassified from Accumulated other comprehensive income into Product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedTerseLabel": "Tax impact of reclassifications to net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r40",
      "r105",
      "r236",
      "r239",
      "r244",
      "r485",
      "r490",
      "r491",
      "r532",
      "r544",
      "r628",
      "r629"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss, net",
        "totalLabel": "Other comprehensive loss, net",
        "verboseLabel": "Net current period other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r34",
      "r38",
      "r82",
      "r234"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassifications to net income, net of tax impact of $0 and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r35",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Tax impact of reclassifications to net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r227",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax impact of $0 and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r35",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Tax impact of net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r631",
      "r632"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock under repurchase programs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payments of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r48",
      "r68",
      "r249"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r251",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Payments to acquire equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSAdditionalInformationDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r627"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r249",
      "r250"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r633",
      "r635"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r47",
      "r68",
      "r249"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales",
        "verboseLabel": "Total product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r208",
      "r235",
      "r238",
      "r252",
      "r255",
      "r262",
      "r272",
      "r273",
      "r295",
      "r297",
      "r301",
      "r303",
      "r324",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r452",
      "r455",
      "r456",
      "r469",
      "r483",
      "r537",
      "r588",
      "r611",
      "r612",
      "r630",
      "r662"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r99",
      "r199",
      "r542",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r37",
      "r40",
      "r241",
      "r485",
      "r489",
      "r491",
      "r628"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification [Line Items]",
        "terseLabel": "Reclassification [Line Items]"
       }
      }
     },
     "localname": "ReclassificationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification [Table]",
        "terseLabel": "Reclassification [Table]"
       }
      }
     },
     "localname": "ReclassificationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r110",
      "r196",
      "r555",
      "r560",
      "r613"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r205",
      "r259",
      "r260",
      "r261",
      "r263",
      "r270",
      "r273",
      "r325",
      "r427",
      "r428",
      "r429",
      "r438",
      "r439",
      "r467",
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r291",
      "r292",
      "r296",
      "r299",
      "r300",
      "r304",
      "r305",
      "r307",
      "r409",
      "r410",
      "r528"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/REVENUESSummaryofDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r307",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r37",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Available-for-Sale Debt Securities from Cost Basis to Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r72",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of the Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Debt Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r146",
      "r150",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Effect of Foreign Currency Exchange Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DERIVATIVEFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of the Calculation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EARNINGSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESSummaryofRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r88",
      "r91",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r88",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r13",
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Summary of Revenues from Major Customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/REVENUESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/INTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DEBTANDCREDITFACILITIESSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Repurchases of common stock for employee tax withholding under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r105",
      "r205",
      "r240",
      "r241",
      "r242",
      "r259",
      "r260",
      "r261",
      "r263",
      "r270",
      "r273",
      "r290",
      "r325",
      "r396",
      "r427",
      "r428",
      "r429",
      "r438",
      "r439",
      "r467",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r496",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r290",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r110",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchases of common stock under repurchase programs (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r6",
      "r7",
      "r105",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock under repurchase programs"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r67",
      "r613",
      "r639",
      "r650",
      "r679"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r129",
      "r130",
      "r136",
      "r205",
      "r206",
      "r241",
      "r259",
      "r260",
      "r261",
      "r263",
      "r270",
      "r325",
      "r396",
      "r427",
      "r428",
      "r429",
      "r438",
      "r439",
      "r467",
      "r485",
      "r486",
      "r491",
      "r496",
      "r552",
      "r553",
      "r639",
      "r650",
      "r679"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.gilead.com/role/OTHERFINANCIALINFORMATIONSummaryofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r315",
      "r316",
      "r390",
      "r395",
      "r465",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r647",
      "r648",
      "r649",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborations and Other Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/ACQUISITIONSCOLLABORATIONSANDOTHERARRANGEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r586",
      "r605",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r586",
      "r605",
      "r607",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AVAILABLEFORSALEDEBTSECURITIESANDEQUITYSECURITIESSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FAIRVALUEMEASUREMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r276",
      "r284"
     ],
     "calculation": {
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in diluted earnings per share attributable to Gilead calculation (in shares)",
        "totalLabel": "Shares used in diluted earnings per share attributable to Gilead calculation"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r275",
      "r284"
     ],
     "calculation": {
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in basic earnings per share attributable to Gilead calculation",
        "verboseLabel": "Shares used in basic earnings per share attributable to Gilead calculation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUnaudited",
      "http://www.gilead.com/role/EARNINGSPERSHAREScheduleoftheCalculationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(ii)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130611-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0000882095-23-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-23-000017-xbrl.zip
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M7ZIFGJHW/&YUGFI-)P$:(.?@I:F@6ZR>#FD=^WI4+U_4S)-=8YUKU=RJ304
M@Z#5%'7(FDK34O:11LO4-//4OI"*&:452 E\V*;<AVDJ1;N7FLLAN=.W0:8#
M"M2DTCAXS"$10J,BY-9(K5F9LB_JD5G+QW@8CSIET SUVD$-L<=Q?N@^[46$
M>DCKURM1-/,(XP0Q1Y[\:X*,B,6';ZW)R I"6D,+J'VBT;JC--3$NU>JP1F:
M!HJA,%EJE"2MHT[M/I'I@((T#;*PY5YS+$#N),US#H&SY 3MD*+)MZ%HYNG[
M8R0E"0\?J$-SYY8E1FCC_SR>'I)SO7PQ,T\_2Z+:6LN)I0)/5L+)AYHA(2V)
MVI%!B],Q\]1X054M+$IUS#8"7$MF9&T)L&O'(X^6+6%FBAV7X:6W6F,D2!BG
MS(IBT)A]JGQY)-6RX6U!.I;D=<P^0[TD;,-J3+W6BXV99PWU _?%9JPU%)-"
M!VXUE00$PU\6C3TVB@F8<TR'M&M@+>IEGBA,&=-)K-XU)% D'K3J6C%##R"R
MAH(@>\*C PK E,:"+;7!JN&.IR(6 FL7BE%SQD,*[:T1WD!!H?7,03N4%#%Z
MM2(A5 WBBZEJ^3_ ^^GFA6_O;BZ<+W92K^P PRNYMR%MHXMR@S@\%Y)@U2/7
M@&2T@H2%6R3)NB,H'2,64Y26 4QH*GJ(PM)#-4EI!;4];I$J!Q0D\4(=4X&4
M(T%N5= 84_>@KHAU*;6X=\.;12*8$WC,,13O  7:&/11BV-5RD!E!64ZUJ4D
MYMG.D1V"%FPE1NA9I=7 P3#%V(;:7,%VCC4JB7D<3^K4<VK-;5H+;EP@&% (
MR:WW-=2/6KV2F*>^#S9 :+4/*0K#IQ52M6FK1ZBU]374][E%)3%/:N*TZSBH
M=@LP=(0RBY4"!04I4EW!@MD7_O3T:KN"@G#S9'LP,58)DABG!561&MDBMLRQ
MZ!I\S-OAQ\HC$36"5N;H+(!86$6UY8ADW'@Q0:N]JZS_R[BY2,JDABX$)>3A
MLJ8^S(L8AX8!R#6M(1%QQ> -QU(@1'-L'5*) \=J#&E:NH(<5U"_9#6J89[:
MC%B**4C 0!"]BH>:(!0$4J8U^ 4K4PWS]..Q HUS=X0"67U(!0UYJ$W1#-;2
M0EARH*IAGD 5J"J;%JU3B8FIA7#L.3@2E:G$XT(H<Z#@H=98IZ86#<!#9VD0
MIT9*%?/P&\KR)=_U4+]I]_SALX\V%^?/5K!\,8O&)#*JH>KP(05R:XA=H;BG
M6-%!5Q"9FH,MZXY#1)>(K+UFZ%-U:.Y%S:8D<:F)< 55?N?@S &E1G#!V*FT
MP)7'' 726VP20)-4',+C, FT2"@!ID*Z)7@4@@Q,P<JP"$E8#+DNI=OGGMF"
MM48L.G&C%KM- ]^B2ANN15#*P]<HS"O8^[YJM3%/;XH<4H#4<HD^_)G(55-.
MVJE1S)A7D(5U.&ICG@RMY"7FX<\@"@R;(R%;-NM:VIBC8 5U@>90&S/53AF#
MWBUXDPS5D;JE#-+$J1+Q"JHBO 7EIW[)F^WFY]I$+T!MS)._:SJ<"U,29W M
MV*WTWAH%"8)KJ'TP!UO6'=L84A0BVK NU$!CYZ"QF79E9PMVM# +4AOS%+/L
M(I0XQ=0$D@D%F!*[FBM,%9=7L/WPUQ!HD5!B(/,VW(Z>.O2&0F/6J*B&@A[#
M"M;75ZHV9M&F8,P:.70?,T<SDL&3TJMA*EC#&LJ/KEIMS-.P ]*@ 4.FQH"=
MF;UK'1/%,#@Q^U)R,_:,,P<4V^@)+7DW*#U"[%5BCUV;)<@%4C]0H[-(*%LI
M/4D.JM6G9G64M8;B%0.R15W;HMA**IW/(DQK:P:UQB;<8?BFU%H+'8)8SR7X
M"K:+W#I55A[5H"I6I#L8@*4B34$ZII:5^[ X1\(L1&3,L^](D).S)Y^ZPW.1
MVH*EJ%Q0<O=^@.Q9)(Z8LG2Q,5DH0C7C7DLIXQ(#WVEY=65B<24*8YY%=XE!
MS8&I)-"@7%.B'&J@X:8"KBVM9U4*8YZ]2! #DB,-^P)#A;+GCDW';%$]<5Q;
MK'2]"F,><T.UBP.4U,+XHV/T@,UB9Z3N\1!GID7B2.P8(R6CG*#F( R2:YG"
M%S;Y'RM3BH_.+_GT^Z]\SJ>^@O63>78[Y]RAFX " 2043C+TQU0"6L 7TU1@
M%PI@?I(NDD$M$ ?D7)I$ ,H2D_2IAT'!7L>_RV?0/#M=#Y5.,02J%JN4"JE%
M5.Y2."7#6"RL+2!_.,!J9$%VS11PS#;.&D/RT$(=<@7#"KH*'(1*F47A2B<O
M->684X#A\9*P,ZDE*]PJ+*4FRU&ES)?SD0,E%;, !D$B,4NJU0QK&Q2JRV?0
MH:J4>0P2M6HUM#;U)=;4AN_D/!4;+S",4EW;]JC# 3;&/$"- U=F"!RD#M7)
MA6J,37M9BC?ST\!>79P\9GY^\^[RQ<@\^^BUU5)-R$( 2H6Z:]&)*1VX4EH(
M1686(_\>%Q=)%&W4F3- +0PVE1 M11!;R9%KQ*5L2M@GS7$ K$&R@H,>4-J0
M%MH$RM 8*78V'=/2LNO5KVX&FJ?1IY;<L;L$)N@5* *2 I0I^EIQ*:&4@YJ!
MYEGA[9$:H07J-)6,X9HH0Q;S2%[3"HBR\AEH'M8 0VQ3Y_H4(=?&HG'\F8;,
MI<RR@D3GA^<O^?3RY9WQJ[>LEQ^>V4K2UN;)<V[8BW14(X-8(X422 99"HGW
M-2S9S,.7=6?'9^ BG!B'6P2A ;E!96]<QP.O2\F.WZ>YZ3_@ZB(I),4YEYR;
M8H.0;,Q3 9/+%)GU4I;M*JU[HIJG*'MNPY'.5(MFT)1Y:./A21$G$EY%U\"5
M3U3SK/4T91XN=Q=+4%.E,2FQI.R<AA<5EU(^\3A1S;BJI!2E"$;)'4B5)K%C
MPPYY+"IA*=7A#]"WJ2XQEY('8!7 I\T67&K/S6%,&7$IOLT^&.]Y\,/8 L0B
MJ71H$M!\>*?#XQA*L69;P<@[H"VQ02H"<7%A!:5&"1I!A*RM05],"N$!*F^C
M,>=)Y=P30TN*F5-GS-0I3%[<\I%;MP9.O9%%[7V,-<C6<<"8:]90<DUM,=5\
M]\Z,SI,+B4V$(?'4K@A<!-RBI!2KYUYQ*=4V[_/7Y]L[5Q>7Y\]\>_$]%#\<
MSS<7YU=;]?&QQWYVYWS[_#]U9F[6?8:[HCYY+!,_'FXNGG[T\M'+YS]8'+KY
M5C\Z^#?\%A_YF3YYQMNG;W^5A_["SZ[\D^WYLQM/ZV^;RR<WWW E,N'J;/.*
MW&=7TQ=_0]=GSA=76__@]3G&PYL3W+QS\WPZPT^/EJ80<_ P+!UT0Q$B#)&@
ME]!:7DJ0\3A:]G^TS"/-N.:<N28'A^"%-6'44HV:CQE^*3M _R6_[_#6-F,F
M_Y/SZ>63>V=ZY/::9X(?YK\8]YBLAPHH#:M ;Z$VXDKN2RFH<N3V?G-[ICUQ
MG66JW $2(;IAGC9=LTK05'M;2C_ ?\GM^_K4+R[.CW+DL$QV''*DU2%$:)CL
MS(:A66_<QVN$@]Q+-]E'6L]-ZWER*AL'C&UJ:9  N)$ER<.'S$0=)>:_W]M7
M(WT#VB>\V7[!IU?^T<LW#_\TSLA;??+RTX'HZ=L@OSGHWMGSJZF(]#@B[HIK
MW_LR'UY<^.6=4[ZX>/OZ?_W\T?;:QW_YN>O5=G.Y^<^WW__$Y>^_BB-,-_.3
MK?_C:C#^Y;^X$=\[].+A])VVF[/'NR?[YFQ0>AS[8[-\\\ZO\1)AD*JP]9(B
MP% ;14(QIB#5II2:P^!O.O)WH?Q-'(+T5$NJ ;JH"!A'<9W*252OB^+OS)3Y
MU<,G'_G[:_D+;#$-N4M-*T /))&3J8YG8EEA4?S]'A ?\<7F!RS^^.)R\VS(
MK,_ZFX^\>7!W<Z&GY].'CY9XH4SNEL$;M&R40'-"<[?"5=4,N/LUDU-,BV#R
M40DOA+_I)*8=*0E"CHED&%X$C05[&^Z<=&9Q$:/#X.]1"2^5OQIBL=R2UM:
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MJI8[DL>8@4J7@)$J"QB :%]'[8U]MKL')XQWQUW7JN8@K"I0"@]YC#"8S%Y
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M$D(1S Q7/#!!GK64GS85\"3RAIE7&B0N;>+<86R]" PGJFF@5MOXK.7]I*F
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M[_-)CAXBKKVO <(UBE4"_Q! 7#IIY+!T2&HA Q9>.&IR#KP/AEODF7HZ.96
MO=G[ %RVU?'/E.H^0)H'ZU]#Q#810E&P GBJ#P2\/;.(N;S1R2@G$UUXLP)H
M#'/7:=G)C/$CR?(#*)1M[[:.1T'+"Q/4IZ]&6Z:P\4@Y&Q'/,G+)6Z2%3=(*
ML$C,,BWCF%<HJ_];+C'*EXUEG%G4<0],M75LVT7\$?UP $ /;P.SB/T_BS]
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MDIN>Y-ZN-Y8;*^O+[\';Y!,EEYOE(:Z_%>&T-T?^4MK7M ZX>(9R9:9^?M6
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M/K#OX]']SVA&:*74 B8^!L 86GZP5&S"N$$IAX!?I\0D,_C\95"K##7@C]K
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M$L"<80FI9"U1#"(THP'FV")(<$H1VMWV6LU+YN5%&_[4UHYJPY^1X4_R&ZH
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MEE*;]&.;] 17D<$F94)"FF."N-8!.1V JV 2%,>)64]*D];F&9:_5)JLG%I
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MSQ_;6SNK.<[K#.@[;JW[\Q;\OG>X"]_Q";=V.E>I.VY]^**\]BH*BCCA$O$
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MB*"\MMSJ:'GBT@ECG9/.1Q.=M^3N#2\N:W)1UMF4=<*)*+6AN6TB5]HA'K5
MUH!(3""!4K@:#+]G@_FBI+7=9.=>9[RHYIU5<[+O!$Z6:Z^1P$HCSG)1W&1!
M25.T*EAK&:[*BHL:[:)SZCRQ$'ZJ^;=RGV-RV.+!UMTLN-^LGP7H(EFD5*14
MI/12I313%(>),A =@L"9% 2#A<56>"$P(TG3NUM3"]6>?B'(7'LRHM<;XTW@
M/C,X@CC6 =D@.&)!>TR2D%)K,+,F0WIGCM4HVELPMDBI2&FAI#3+3OAPC73+
M3CC_G7#2K4$TCLD[C5(0%G'/94YSP4@1;)S&SGC+ZK,5OJ3 F\W!X"07O!F
M^H78;\2CXT[O+.;*YCW_M7%\TO<'=A ;QQW;+3$Y#UO=1BB/4]2)I<BYM\0Y
M%C@-$@NNHZ%I9L]L%;R8)1S#^DD_ARS"4_3"J.3-QEC2U9O>C^7\'L1<W+@S
MX=W99)$;Z36A4F%$"-!_SHD&N',!!>9"I%AEFVX.11[*(<LB\,HBI9I@[B2M
M5()'$@7'22O.B#8: YD4WF%04DWPO #W']LYB=?B;8';V>!VHG2$EY;",O6(
M^)00Q\8@&V) .F%'@O%::+FT(NO4K;UH<L';(J4BI2*E(J6:A/$4[O((W&72
M->:3$8ZXB)RB(=>]DIF\ (VQN>:+(2DQ7#/R\I("?B;\8U4.:,Y5B]W<-+1R
MC-VJLGGQ_B^*9ZSZ^1<@7,@' [$[L'F(!>IF@+JM*:6?54H!A&^15SFV$><L
MW9@4$I9CD:(%'&2 ='-*T"WG>+5FED5*-<';)_:*%:R=!]9.N,2D-@H6 D:,
M,3-BE=H"]!JKK<;&.Z_]T@J=5[VLHL8%;(N4BI2*E(J47HA+K!"7>1"7*:%B
MV%MIHD&"$HZX2QPY&CFB*BJN/:4N9\#5BKF\I'BQ2B60R^N^2H.[6/@E-JR<
MR!0I%2G5GB3,W;NQ&@Y/!L.CV!T.=GJKX:*[<FZLO-D=MU2NR(*[2A8^YL.$
M07L8MV/_6]O'$;OX&'UOOUO=I2(:A5+,0BFV)WTA5"0@%28BSUQ$/#*);.()
M)6*H#%ABIO'2"I%URJDO6E^PN4BI2*E(J4BI)LZ0PG/JQ7,F72<Z.NH4XTA8
MG!#73B#'M$#8R"B4YMA06C>B,Z=8HEN[3$+[V\6]Q[= ^?VOB:Y@Y ET^F.\
M2+*K6L[[JC7Y./UN%'/4CS_3\/J]_;X]&C3^^-?OL  TK%+%^6("O0H)._UH
M!R?]L\HIM.I!R_LQK,+4V_VXUAL,?PYCK-JXJ/:-JMW<61U>K:\)]^O$_WP\
MV_L<CAWE<F]]G\&<P%@_B-W/,%?KNPSN!^^%.?@,XWFW=[BW\X'LO6NEULX'
M ?-"MM8WSK=V]O$70ZWW.AJDB6.("R6093E%33)K,(U24[VTHNDRG2R6W[ C
MZ<)"!"!O',/JK *V?N;I@H*5XXUY9,$_8B#<3PB:$@U7]N59E?=JO4TED\(F
M)F1\,H@329 5Q""CDX^&&.^(6UJ9W)5+'9BZ:FTY.EX$*<U28>1A@MZN =9B
M[]P%5UM7<95;95)T&$DA!>(J8&23B\@+;#&7,2F=[9W)H^("K'55V0*LBR"E
MF4K"S[NG0P'6N1/6_/]V!M=->(XF;>Y_4=1%&CU'RCJ%N)$2.:PD"H1(@Z/
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M<VZRV?T6N\->OYSL+4*TT4T =DF:!;EF0J[=*6XT%3!)A.;8!(S ,-=@EI.
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MMG8:JVMK6Y_@&5OO&N\!%0#=MB\8VGB174\>+JF+^75C/#P9#-OI;/2G=C?
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MF/(LV&C+26'=@&U[,K**)V&(YP()#J8AMTHA%Q)#/GAK(B6YYCV0L7MSL=\
MRQ-U52MZ_(.]$"#BGDG)+/=2NZBB"23(2),/+A0]KI\>3P0B:>()=U(B[3U%
M7!N-G'(&,<*B=TI@9SCPDWL?^!<]KJT>!\Z<,"Y&*A4WRCOI*56,IJ0HC['H
M<0WU>")RA[G$G4@&N9@;<&.1D(F"(J(9\4)Q9FQ:6F%%C9^M&G-' B9"1!R
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M>QF^?I&MA:^EA>\?=^(1*&?C% !6=>)]5B>L,2 ;4,<>G=;,H9_D<BD'\VL
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M\&@OQ5:"*U4"H%I[S>)5 (5-Q6KJ(\ZOPP'J+A[>/IDXV#0BSLROZ:P;BM>
M4C6XCQ[2K!$SB!>3LC8G.?+;(Q3_PLCQT$OP6;P:_'#3AL_6"_WVSZ]@U?B7
MLK>?NI_Z@SSU.V )^H-S>?<-WWGZ<KY8?052?]$__?3)1[_KS^WS3>M^ZMO[
MU LU2[K#..'YW9"]VO.77[SX3F;(;>Y^Q6U+%:DQMS&P8XMD-$9Q:S7V-JN-
M/8#H?%5#_9NA\2\__]/[?_E]_L12%32F4&QM3VI:T^(DA@HQF2* KKGJM,]
M7R_(N?I$EQO2*)A2%RQ#6,N\!<!A@WQ*D/_J1_P&9&U@*G$$MH8!>^[!:\5
M$4B09/0U]C$]NO+?()\6Y!ICYXPMUYXQ"@KW ;R0)C3,N]G?*4&^'Y'1E0T)
M@WC+ 5.+06/Q,(84MEQ&C;*;"UTSQU8B82+IZ("E1,V:?%"#B:STTC;')^3X
M@_L!&52<3& A3 ';C,IN* 'S2)ZR*$&_N96=65\OR 5&F3$8HU= F7E8@]1K
MFAE9;RAQSQ\Z(\A_<^6]_\?W/YH__Q\_D8C2*JX&?UV7QY^"\@S)<0UHY6H
M9?7?W;GU]:),# ;>E6)%C(U%L:BE@4W-1]VFNG.B_-Y]E(UK\@82(LG,KHU+
M4%TS3"+ C,O:'?'F%G97DNM%N1L"S!#LG0I"UK4$6DA3YC'OB3VUY*0H?W@?
M941W\Y(#&]6 D6$FV!U"+M5ZU5('U-U-^YI)]D0SFQ[&V&8@3N:)G>LRMN6B
M8K9)/B7)'Q^"LJGQ#,@A-NBS5#9;\X=:R%.H,=E@J7!S6\ZTYG7)_D)OP8[Z
MQ_W%VE*W'[J]T%7+&5CBE%4-8D:N+H#5:FK:1@.4OM?]3B=GOSWNJ)=Y\S90
M#&4P!AQ1@G=(0;%E,TBC"=_<)KC4L9VWU(U_U20/+'E&FBR)(B(4;]DQD\>D
M,V45W"2?D.3#EOJ4XFC=1G G#9B1@B/4T//:GL'$,R^9!49Z=(FQ23XMR=8R
M#Q'#: V!04 YCM%*RS*:[X$]IR3Y?DS6:E(2CI"S39*[0="T^IF2Y9(!(K+,
MF'RI'CT;Y/.!7)*"5Q\\N"*XBGM/I<8>L^4ZR@;YA" ?-M7KI!A+*0$TSN0:
M/(<9HRDTFG_;1FKF[>8V/]ZONDD^+<G4(7;H;<3"R*UKG'FUIRGD6FAF:7O5
M[X0D/[2K/J.RM35%KQ1=O70MB,R2.6;U7CEA@[32ZTN=:M\LGY#E*>@V\R\;
MF=%BT1HI1S:.W2?=>P7_G"P?MM4IC2AD)10?)<QL>E(M,SBCQHH#ZRR7Z>:6
M+W7N?*-\/I0M4F-/;:9B'9G$4TH#7==.K+3ZAEI,;)1?$^7#MKJL/3)O$L!]
M#:F&%-QC"0TX6:J01QX7&(JY23XMR1U'$^Q& (X@27'BRXV*%"0;;ZC3Y";Y
M-4D^;*OSVH! I) R0L ^6G!C"0J#4K2<[*N=J#.M7U_RI'J.I]]7_VINSVOV
MF?A>#4/_I*7/E:L>C[&&>L>>&]J2ON229QG*T$ON>Z7_?*KW^^/N^V!MO10(
MXG59]8'G(]8@FJQ*G9EIKU/SRJ6.W;PJ+F^19?#?5@$:1LR>ARA6%!Y6AP^3
MHKW% ABW IQ0 0Z[]M):G7?IFL6A$E#%@U>FD$G'VL(U<5C#"A^]V;<5X.H4
M0)K%U#IX,Y]B4(5;:R39M7<?0EL!SJ@ ]W. Z&N 4JF!HWE SSE(IQ8ZMFY=
M1V^K76Z^U,F +0#7(P!5L$RRN\=,R&@:6W%OHX(#)> M "<4@*-+8/0N,+/^
MI#Z+@%IC<"8/M:0,O57BT6]N<:< 6P&."E#=.TH6(D$?W8I0*E)J]@BSMMR+
MGR=4@ ?<!1/R&D%J<"IYU@(1@Q=8*Z"MIF2Q)QRS#.!'S]'9&G!U&L!@:\;6
M3/Q+P>;BN>9<:215BP/W8?]S:L#!E:"]Y-IL%@(E3@V( X*PM) 5C5(K8R8)
M-[>Z)6!+P.$$CQ+,M-\J,V(DU%@J0:)1LM2>8$O *27@X&9H:2W?0@E-O,]2
MH$M0*SV8H?<QB[MT=X;GT8?QM@1<G01TJC6-Y%S<L6E5]BJS@F25TM3;EH!3
M2L#!!B'2>W+GU>AG3>"%$;RG%)Q1ATGKHRX;!.-;H@%?6R2^>1]?W][Y#O!7
MF DP085T9XPXS7B"_=3]U!]HF@7(&3Q"=]_PU>?2?/3\6>N??KF]0C_8/F'W
MEKDP(&5,HW@N;-%YE &FO \3GBXU^)___)97Z->__/E?/O%Y$5?;J$ SSPM8
M<@VBU,,HW5."E)76 :3'C]K>Q<'5*8"+-X/HO;:!8,-11<U[R6TU^(6M "=4
M@+_W"MTI *6:6K02>M'5%V"48  M('8<SDV@K^DW;TMEL 7@S0D 3K2;6Q11
M1?/J,K!EJA2U--O-NLXI /=3@,E];A$M%!L2T&8>('FJ0!H W;I3EM5Y</._
M^;_?K&\T34XN$0@+#[/*GC2F&CNGM*=FG9'_#^XG #C0D2@%*UG6<0$*UEL/
MS4J3E+U6Z3>W*>T28"O X<!S[YHJM*+#4(&,<X,>27WM&^3M%#JC GS;*?3A
M']__XR=HW<R2A]&B!]0!P0C7Y#SM6?IPN#LP /O(T-: ^QH06\S<XTC>$7T=
M&N34DQ?,:>!,#;8&G%(#WCMHP- (4\]# H)9_N<X,X)F(?5!;=1!)8Z9!UQJ
M+,B6@.N1@*I#A6?\UPPXFCN/UBVRMT%")EL"3BD!']Z7@%+<BZ86\*YO=ZL<
MI"J&K@5<>BFU+PG8"K 5X+Y1*!=&DADG6#!-"8A3 M+HV"&."KL0.*<"?'Q?
M :H7LM%Y1OU> R;GL&S"@:QRRTE;'+I.#K\MRX'_PB?Q8,N4<@8[Q"NT3/G@
ML_5ROWT5"\3K:-L_OB)7KV*J33B95=.&T=!+39:X^]KJ'+"['YQ/Q=Z[YVGX
MSS]](EF;=<$ ."\4-I9@RA1Z)RDM"DXEN[G%US[\_.I@7#9CV?"^VEJD)$&;
MZ6IFPERKU]AR0VPV.+*F#>\)X?VV'6'"6TS&U. 4-*65@. R)+F%F8E0=BVC
M]#A+D/BZ1<B&]]3P.N;,D:+Z<#2ITLP%4NXEF\>Z.X^=$M[[D3=KJ@Y: J<J
M 6?B%&Q6%,' S>;56UVD;F[SZ[9 WNR>FMT1BY7N*"J$FJ/UV/K@6F4@E+9M
M0&=D]X/[@3?%+%J!0HFYK?E $K0CATEN \Q*7/#FMO#K'A/<\)X:W@3F))-4
MF]>WN%J?A-),H8<M3\\^YW]&>._MX/_IUQ]^,N:U6V:LT-+"-V</8M%"[5:%
M9?0B-O/FUS[HO_$]-;ZZAH8(-Z.>40U=Q_RK^1>I5<JZ=][.B>][!WP%!(9I
M2"ES0)^/Q(Q"E@)M5D,C&RX#SDZ=KPI?].RMF2*,@3V96<QLK4M.,.+&]Z3X
M?G@?7S%.<=01(LS B]A7MSWQT%%3(<01TVJQL5><KXK>W@NIY<Z0$N86U0E[
MYFH2,1;>F][GI/?C^_0V2@A:6DC><D#.$@Q50E-*-O$%R^7F%M/Y2M_OL+U]
MIMWMAX_V_]?3^6:>_/+IBVXO^B4VM_=3]U//TZ6#X!_Q^<I0MJ=??O,M_F#/
M?_OTLSN1P24RW\A*6-_@'>!ONMR<HFG'+W[W_-EG3^N3W_7/[>73ET]?//G%
MDR^?/O_BQ9,?_>__)3-"OONK7_SF[A&\^^._DC]_VLMV/?DNG_.W/M:4O]^/
M]9\F*/_5V]//[<7\W'[VW\_&LQ?^Q7SXS8=UT?=#/TVO\([>_?S9BZ<K&K[S
MO'\Z+^N7_=UU-X;TT_7SW/]HIZ2O;W!S^Z/\T!7^ 3R;5YVB*JZ!LH.X9,4)
MF$$1=TTH*!W:GN9PNA3UH_HW1]/_?$SO_^7C/W^"&G/!P2%!TX#9, C""(-@
M6>TM)DDWM_E"GLRWU'M]U1PS9<E55X^E@4W;,LD M92%4!BWN>F,'/_5W/0-
MQU$9$%:-*5("M@Y!1TNA9')$9$A]1L9'3XC>')^6XXIH/#A/: F)LO7H'7"L
M9AM5##?'9^3X?CP6BPV;]< 5>,)L(X@RAR&E:&1.$>7F]E(G)3?'Y^.X:\:L
MQ=$LS12[6,FK4Q9*PE[FE\WQ"3G^X'X\1J8:V\B!=)T4X.AA'5D-U>KJ84G
M[#>WL$&^7I!-$@W+9:1*V$D-5"6G$6-VSA;W'LX)0?Z;_^F]^7.\G][_[2=:
M0(MZ#O-:]IE:&P6O4@/T.+P,*%C;1'G7R->+LE:.,S$;/,MD+*7+0*FS5(Z9
MA<5W(Y)SHOS>?93-.7+W%G1-+,4^+%A-&F;IC,E;C=#UYO92#4DWR><CN936
M^BR(M7=&SGU1C>++'U5'W&W%3DKRA_=)GHD56^P6<KL;0MIK,,<:,#?4WJH)
MTPS*EYI!NE$^'\KDX%YG?5QT(ERZ=YI_ ?/:]\*<=:-\2I0_/@3E.,1PQN,"
M,H-RH1*4ALQT.T-J/5$L?'.;SU0JO[9;8-S]<UUN@;]9!'[VF_[IY_;RSCGP
M%MH%\#%V@7M7]CNI]0-WQ]6I==1(F: #>YG?3)<]'>-JYSQS<:)]E/-\:OW;
MHUV@),G#"X4N"68!Y2-HP11J\30:8AI\UT/AT274PX+YO>9=F^17- QH[308
MM)N@$*[13"19N2JU"&.3?$*2#X8!US9*F21/?#U@(P^NV$,$3=HA%8NS@-)'
MCV[=()\6Y(PS]CJ+2LI8:E5'C*[1:L;L0S?(9P3Y?DB&*%X9,%3E'#!)7 Z^
M$H0'\%#F+KQ!OFJ0"6*+DE)-Q$A(UESF/> 6H]2NOD$^(<@'RT">.JRC2ZB4
M:T C"S)J#M0MKQX+,=99K69Y]$+()OF\),MH-4&KA?K,R4@:)@)L$]TU(9WW
MFN8)27[ ,U B>8J6YOUD.(.RSG@\RZ80J7"<]1+8JI,O,/QTLWQ:EHM)F07Q
M:#,:(U+UF($TCF@QF43;+)^2Y8-I0++XZH$35-N,RSU1D.:TMBLDIE'G!96;
M6WFT_V>C?%J4+26S;&.&8\49H%<[K#6")-;Y"Z%NE$^)\L$U -#FA:0>*J,&
M]!Z#FLHB>S2UA&.=DMD9]A6C+"4*^Q#/;.BB5FL18*]]2&<J&^53HGQP#70N
M2FD"G%87?I01@Y=U6J;$[C6KY6*S6LYG6O?:308FJQ^\_%U__N17O_C-6^@4
MH-U8X/M7Z#82DD(?D QA5"-@G#*\%L#<(>_5S-,I].^/3H%YM5*1NR6/-/6Y
MI!S$(P6.Q=9I9."ZNL9NK_45@^Q(YH5=-:(4TAF4,0]!H-XU[@XA9P3Y:!08
MW%P:!%=9DQLY!TT#@J!Z*YF8JVZG]76#S)0(X_Q1)](2A[N7GMR-4LWH>W_Q
ME"#?C\BU F:?P9A1(6 R#>YJ(8[16X.IT WVX:=KYKA6G!6S8)RY-4(EST*Q
MJ0#GAISW$,(S<GSP"43%/%'F *WQS*RY!U^;$M%2;9F;:FN3XS.=E]@@7]JY
MUY"HUCJTH>0D'+T.1-#$T&T??3HCR _8!%KV;M(YL*^IZ(H:#*L%$U45S@4:
M[R+YJE%6&1)KB=%'Q)1$4FX@,TQ7G]D:;)? .5$^N 2@=NH->FB<<D </1B,
M%F*>ES6W,K,LO[G=5?+UDHP=7%QG_N41ZX18?8AR AJ"->^=Q7.2?# )M#(T
M.W.8U,Z@#%V#5,JATH1X.&#2/(/R)OEJ25[3W+4;%NEUIF/DPM: )1M(J]HV
MR:<D^> 1:&5FUQE:@+0Z=WG2H,8Y4.J:$\XB.J[FUF=*KR_46>#NM7,\T4"6
MAZ'\Z-E+^_3OS0 _E.?IGTS4N6ZM(X\DT0A[RNB#9&8KA=8I0,IQYC![3?!L
M6O<_/S_NMHLJD.4<>%:0 27',&.6AGEKMQA;3"QMYBSY4N<-7A67M\CU^.^K
M $B:1\P5 '"UYLC4N<S?UMZ>>-L*<$(%.&S3UQA+Z9F#-)H*T%R"8QX!2^'!
MO5'^:D[DI3IS; 6X'@6 [(4;\R@C8?)HX$.L(A#YE +;"G!&!;B? Z2LSMSJ
M#/HU3P40#-)G(H"YUZ2MX$SM;FY5MP!L ;C?TL=-T7/4F A;R6[L+1=I8#+F
M+;4%X(0"<# &0-0:2746 >P!75</Q90"QE&!1QJ2_>86'^\,V IP=0J0+448
M F,6D<A)S0?'#%#*:$2\&P^<40$><!0,&VGY-%?4MS4'K 6GV@)@;//2FL:^
M^B+O+&!KP'';@S&W@;-2[!5++=ZK5J!4#6*.P[<&G%(##E8$E=&T10V17);1
M%X*43*&3=8@%\Q3U60CL-&!+P"$-6$,11IREHC$6S6(S;RR66C72.O*6@%-*
MP,'#@))X4J[!M:^A"#J"#9L)04[:^M1SBZO_4-P:L#7@<$K .)DEBLO'%#/Y
MK/@UNV?K1AUV&G!.#3C.54!GD-7B!'1J0%SFXM0Q=*SSNLT4(0VYN<UO32GP
MM37BF_?Q]>V=[P!_6!_^I0Q\IZ>^RL^Y7W&_XG[%5WK%!QU/!(?7?D3SDS_8
M\]\^_>SN/>%Z3]^\D:^ZH0!_O]U0[K[A.T]?SO=7OQ6I^<%(_8O?/7_VV=/Z
MY'?]<WOY].73%T_^X\F73Y]_\>+)C_[W_Y(9;]_]U7_\YNX1O/OC)S_[N^>U
M_NE+N__<7_[UN0^T+KE00YH[.4]X>K?9;_H?YKWXY^_D-=O>V5?+'E/N/GJ+
MA+$@Y&YC:(&NE$#!]ACZ$V:/[Q_]9#V5RHUFP5BB!P3-03M;\-Z6,5I%G6YN
MA4_DG-T@7[A17EKM6V0Y004E%9TEX2P9O$>7FNL>V'1&D ^V,,%>F[<2^E@6
M>"8.9E "E6@$HT@:<'/[Z!)P<WQ:CD=J=X,4Y\\:,4OUC)1R&K9&12AO@_<I
M.3Y,>4E=I5,. A8#UC8?,<!JWN(N@#4G6 NZ>PK]]9(<->.R\S-YGW= L6:B
M/$8AJ%W:;L-T1I(/+BUIS3NW%!(MFV9""49#0XD%FB1LYNTB#HU-\FE)IHK1
MYO4F*3"C,6D9U=5,FY3.$?<6RPE)?L!MI06G_LX*6:",@.:KI5K'8-RB 7B7
MI+-,?G0/ZHWR:5%VBK%+'V*S3"Y0?)*]EKI($0!M&R?/B?+!-+6:6M9,,5 M
M*>"P$2:^LUJ>LMQ2RE#9=Z%\S22//%.S[B7VGA#S4)JQF&.+R@RQ[J9JYR3Y
MX'VB1EJE<JB1(*#T.DOE>=%BB6FD&F&4LDY"PF;Y:EGN!2,#58O9,'75QK6)
MTK!(4\AW@GU.E@\>IC)Z:K8&".0T$VR O-J0YU"E6)/89ID\HW**9\JP+]G"
MY6W85'_ZO%O[H?NWO'UJ]J/7&25)R7LC+UEH5IPJ*N8QCSI:P\*O<D#[Q?QY
MYZ.M:V]:USX\[JZ7U6,GSHM5N$]I@^S!"HY@5MJ\?,,*K27 @Z;]> ^@.RG,
MK]5PB9NW5GA^0<JL,'A6EU4FVS 0]BK^"1$^[*L/EC@X6A@1/""7&"QW#8E'
MY;KZYD"^N2TG&CZW.;XPQVVLO5<87CIV<4-/+5JK9>@L-?<PA5-R?#\4-QS5
M"3T44PW8, <=A<(R.[DP8K;)\<6Z)FV0SP=R5VXI@3;LBK&+</*<2:6N!>&T
MYPV>$>3C5)2A);'.@-R,9T!.%L1=YY>A21U2%5S;ZAODJP79^X1S4IR (N(P
M38/3D)2\5>'8W\RBWWCV_ _V<KZ=/[U\9SS]4V_A+_WYLPWXZQ;-#_0VR>P9
M$P75P<N4GH*7UD-N57LIN72VF]MUW 72NYOSJ^4<K%'+I0B-@B3)4\YM7OL9
MJW4-VMB+^Z?D^;#E7K5HS".&E'):(U-*L!FS@\RLJ]M8<^GBKJ&OF60S[6X>
M/9MB:N1>.%7H!BI$A3;)IR3YL.4NT*P,YS O4@U(PX(;6U@-I7*9P@QM;;D_
M^KC81OFT*%<H7,2E1E];4E'4%<J(,Q>W;FG/3#DGRH<==V1*)IT"YX[+/=/"
MO'XC"*W+6&5FW&E-$C@1RA<ZQ?Y=.@M\JY% RM]O(X%_BNH'+W_7GS_YU7_\
MYF>_^N5?IZE<]'W03],KO)-W/W_VXNFZ(=YYWC^UET^_[.^NO@LA_73]'/<_
M4GO1US>XN?U1>:@_P;9%7?A,KT6EG+O%Y*A3I'/LQ-4GY5!Z>D-G ?<*R07$
M^_\>;07LE:J4'DK#'K!H#SJKJN"M:U1HE-82Z(761[;Y\;R4MV&EU,RE=6P4
M75I)4#M;T75^<&]HG)#F@\,@=M ^,(9F:@&16M#"'HK.2TC,ELO:T-@NYNL%
MN7J1+,Z$*6&?83N/&;6)ZNA4,KVAG<D=KB\#^,%Z $Q2H09)+0>L, $GD] Z
MN /-*\ZRP_7U4YZ(;8I]CDD%6<FU-];:N-$Z%EQVN#XAS0\,7^GL'G-H7%-
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MII\-J&Z_P"D5X.]]0W<* ,;&8Y20,HV WCE8+CF8EH)K-"U%7ST6+M6Z?2O
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M#+-,WDT[KA?ECA!%N^B,S#@%W'H>PG4FVJ4G@VWX.R?*!Y> UQ%[-9^5L96
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M3< 7(FO" EGRE63 _/J7M64;8YE&QK*1[>I!UKAW36ME9F56YO_0PW&[C^[
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M1+!*$):%D<$K8O4&X)4 \)]G 9RSE3(@9W66&'ACF2O>L2A2U.A  [9(X+L
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M2*V28!$=<;;3$2VW)22';?/M.FW8>1^U-P11&R+S(I L#58RU"&QK!R4J+-
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MZ+SHAE\3RS_)6IYWI4=O ^G;@3EPR$#J4H][)^:SYZ!09B-:Q=Z[@.WDI<7
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MVYU5\&JY\^R-88I;LMF%1(8B9$9*.Q@5H@!8GDNL\5WCN]O =TX2;"*'+"$
ME]Q%QVV*U2<1ZZGYIN*M%.G-A??8""9D%9ES-0Z !R3M+G"FM.+)(AF\1=U[
M:.Y[OJS,%XWR&N7=:,K+*:I@)$<+'DRR-#HJ%&G01XA9+)PDOU'>]6SDS0<_
M)9$4D9Y@)AI+=BU&%FS2#$-$DR+] 7/OH;YOM&NDUTBOD1[9M<K5)%@R%:.A
M!..-C1F-$""]+% :Z:T8Z<U%B\58O$%$IC *,F]M9!@M9S[RK+Q*-+WEWD-Q
MWX-JI-=(KY'>O7XHH69F=-9H38#)");L7""X<*]X7#BXKFWF73W?S871">#
MA54L6I<9)&48>J<8^$!O! ,^M>V\QGB-\;XZII>L"P6$=UI!S<<51!;9&0GT
M.O&%<W,U->^::&\N\A U!E]0LV)](;)30+1'+*@+!EZR+47F>P_M?<.7E?[G
M&DAO2=F!5IJ@_NACZ ^Z1%@/KC3YSP+7.#6EBJ8LC0["(,_-Z&7NT%K96ME:
MV5IY!:U<9B#[JJ>2.Q8:AU6MZFV]>M;[?2_\J_=+-6LD_Y7>Z)Z)7__1Z7G4
MO3R<UJ>3/@UK5QOM9X3 WP'SX7;:!PK0"QZ%)!L!/"<#P2<5N/9%>9-@X1HT
MOQU,J!F3R:/17N@/NW7XZ&1]/CJ]/$]6>-LK68K1\'X^LCU)P!PD,)$4F0RA
M<(:::R91A12UU"(L+TG/WY#MBFZ%-+):I;Y=Y,2-+*)H%P1R "L*9C1)H;)9
M*\G+PB4I&UG]/+*:3Q,HDW:" PN91P;$7<SEXIDL3IE2LL[Y-I<1:&1U2\DJ
M<^CR7SIA(\2(OD@O5"+^BC'"42*'JR*K1DH7(Z6S&E0,6JDL.#,%:^[2B,R#
M]"R%:)!+'76H!V6L;834".F&$)+,)NF250(7((?HC)!>2:5=B=EETPAI=0AI
M+JS; 6E#*1(#.3 UO9MAGA0D5B3)$BR:<Q4:(35"^NE]NP AB10QZV)J*F'2
M^T/@IOBHO$Q22ZWUHK[I9L[]Q+VG^6!L7C@/MD;G<.,8"+0,$UAF1 AHHRH\
M^F;0-;I:B;Y=9*M<1S F)&5DH8M9QZ.UV6J!)<JHH-'53:"KN3!J966J\H=)
ML(I!UI:Y:#,+]0PD68%<!]WHJM'52O3M(@=Y.7=.I@A! GAKO- DF"V9"S+S
MDA<^U=;,O>N@I?GBG,(&*XUD7BG2HI35S(/WS#MCK-?H32S5X%M6;JI&28V2
MKIJ2N(%LN2JA) [>69>R\UFBB#I%(T6CI%6BI+E(9.>]ECQ)ED( !@8$<P&1
MH3:@G)%9*[=JE'27RI!NY)+'XUP[NK>?AY,. ;W] ?Y82%A+Z[QP5CR=I;"H
M@Q# K70%#)="VQ2<S7+AL(2GT]T\/A4UWE(Y7Y+&WJW/QT9QE:&(8EF2+M2D
M4(54*HY,%!Z\(R790"4QN'1VE):(?741*X.GZ3:!!P= %CYJ!:"5!LS"0UPX
MR=%"B&U;-TM!\ES@$&2I9+"!Z4QV$6!(K*;49Z129BM5B2DO;Y^YH7EUT1R$
M4\'%C-SKFH#;80+ (CE'!\XN',/<T'R-:#XKE[$6H+-<L$)\S,A.3,QI$9E0
MVD9EM,UN>=NP#<TKC&:3LR31G+ES(+&*:!4!(SW7-7E#TZ9_'FKGBXG2E"1;
M)#/" @.?(B,4%U:L1!6]#&!#TZ9O.6)U$<D9!TD:"1;1J5R<CFAKOM#D<-%M
MO8;8*[!_Y^,S0,?H/1F_+FA+%C )682L&1:N<PH\)I4(LW*5:ADUS"X9LSYI
MJZ)U(E@.X(O/'H0ADREQ3F:P72IFF\Z\)"S/!2_H9$P4"IA&*QE JA5#,S(H
MR8!PVI!P;EKS'<!SY-HH'3.A%H$[Y;4#(8VQ->=/3@OG^6EXODX\SY<*)?U)
M<^N8<$A6L)*!>8R&<9M NY@=VN4=AFMX7ET\ZZ","V10*4O*63;>6^>YD5+&
M#$''IE/_3-S.N<:+].B*XZQXG<D.MHG1$T5BF0?NG$@0<-5TZKN45N6H8FXO
M'I7,)<R,^Q]PVO^0.]S5V9A<1>*4A1AMT;BF&\UHSI2,VH),H@#HY&/56$A#
M<5#(YN2+[NM]H_CQY"34IZDL5T5]C^?=Z2YQFWT!IDJ)#$(MIRF#8\E6ZP.S
MU 5O<?1T@_?)AH+/6:/A!:.%9'BP)DKGBDS%:946WK;_,7@W&%\(QG.^=&\(
ML$@FA\)B2']QAGE5 E/*!Q!< **\]_#RV_@-P2N,X'I>3UI9!35$)YQ"'S+]
M9Z%D5Z )Z)N [+,"6F6A",^>26X$ Y,4"\ ]4S4/2;;$S]@$]%V -WJ,D(61
M/!M:$#'H *""Q623DDU KQ2,YQSMH*LG56J6>50,K'',.1E9$B(1/7M-TKH)
MZ-N-8!,2BE2ABP44_0FR!DU)$[DW1N=%]P2;@/Z9%O2\0UZ:4+RT0-B6I8KH
MS'Q,GGF/"@7$Q//RG'@-X*L+\$2K  -/TCL'I(J'C#9$+"K)%)5?N#Q1$]'7
M N0Y;[R7@F>N+(N> P,0CF'.GA4C)%HIDXR.A+1L&+Z]&+8IU5K95EE2LYUU
MC@1V";)$TM,PZBO&<!/22\+VG&?>10>8R7 .@*2 :T?8+H&SD$C[@N"XCM"$
M])T >'&1)^Y5*.#JB2-%"KF2:(02$GP3TBL%Y#E7/22:P4(Z=K DFL&XP()4
MGCDK4(G '7B_8D)ZF8?8I5B3>L6]]3NC*0ZNXLSZ@L5I9IT_KS[-':ZB>!5#
M=&N$@LS6Y:2=AE(@@O;:83V*J,B.=Y[CHINK+5)KB?2_>4YEE)P@9%68T;%F
M54)2X*)!EBS)\BA= JF6>5YIF6CYR;&9C3L;=UY1^A11A)2871&0,7O%C;?1
M^E L%I,:=_X4[IR+$1&B5I5*G&E=D"Q@T"R@\,P;C-)DDRW$9;B@&G4VZFS4
MN9A'T'.A,#HLN@!I--XDG@6D:)PU@3?J_$G4.5=.IBB.RAEF>+8,+/<,2U(L
M>DGO&*]]%$NIWM"XLW%GX\[%SB-(C1AKDF\(P"5WT7&;8G7>Q)JXH''G3^'.
MN<BG&(0V.D<F:@E3L#DQ% $82EF2]60P0+CW4%\^ZVCCSL:=C3L7JVV8H@I&
M<K3@P21+PZ="D09]A)C%PKGE&W<N=[OSG&(\$DB]S)D9K)JG$9DY X7Y#+)+
M]2&R7.;!U,:>C3T;>W[':E=.)_0R%:.A!..-C1F-$""]+% :>_XD]IP+Z O2
M* @R,ZL"9R 5, ]9L.!<R9AJWGNSC%B!1IZ-/!MY+N8M*J%F 776:%)>;$:R
M""5 5IY[Q>/"\96-/)=,GG,1DSI+#AHBD\4E!H$7YF12C"?($('FT,!2RH4T
M]FSLV=ASL4.@R;I00'BG%=34<$%DD9V10*\37SA-7&//);/G7)AJ\DH5YSTK
MB?1/< Z91\.9#5 L1N+5ZFW7RMTB]NSB7/\Y1;HM_4W]#P^/.[=]L$?8B,=+
M_>CEF12(R43MH[8"/""7: 4FYQ2IZ4HH[M]L=!OZ@@OV96?_3$SV\5K>RE@7
M\EX>3O]#W8R'L\<=NMEO@U%\?S/7]2#_Z]GAZY=I/T@P6_*5?+JQO?MZ;^OS
MZY>OU/;&"[W][CU_5=OYF9[OQ$_;71_^*ML[6^KI^AM5N+<R<V9\D0RXJ-4)
M03--TMR[E(01:D8X_>%!3NOU((I3647(-M*"!@@N0-9 >H!7V=N<B2LRD<4^
M3<)T?)!I)="T'R_6/1R_[0^[)>>_ED_O#B;3?CF\<L*U9PE7\O^:M8/8<32K
M,?> P)3']5OW'OZ1/^1!3_8VA_L'IQ**=4OYVQT[P@ZK4O>!<.=V=?96GVXU
MG#Y@]4M7U_GNB@_Z4VI _.YPW'NX_@'[@PI:5D9C]IR8O[>1P[3W/,>#<2<C
M%AD(6-/?[[B4]5O7+V?E41*YWNA@W,.O^CNI_4VUOY.3_M[O?<RTKJ<D/Z>Y
M-]W-O4+,TOM0J672"X>]<?[0SQ]ISGO3,=:Y[U7R_M"?'O9PF'K[1&[=FY/>
MJ'2_W_M"2+U$%[W??8^N-,7W]9O]X714D?>E]&%WM^X9721,D;J3>F4\VJ/K
M]<>)[>.8[G9\)QJ2#_V8)VN]';K;V7=[!U.2]I\SW2;1K(P/:>CI_CA.7^[2
MVQNE/*"N]X=Q<-#UB=A]M[X<[646<$+WKXVF.7^?I\=O[.^/1QAWZYC1:/8^
M[O;C;@\'@]Z$UD"_D*R@'O<[./5PG*DKM5%U]._W<K]FM^RE_CC'Z>"P1[^G
M!AZ]NM^C$?G&''2]G.3CZ\Y:G&E6]D?C*;6J3DKNQKX;Y?'H?1[_,V6:Z7'O
M?P]&T_K9L+OFA.1'O>^D3PL.QU^M@?YD<D _B..<^K0Z]L<9$[T=\C#NUD'X
MZLOTZ3X>UOFE&Q4\&$SIK=&['&<S.!LMNNEN?S(=C:L(K>L NP:.NF'X,C)'
M_5J[(_QSG-SQ^"@5L<])<L>38U6W@X*>'X2*O&F?$'+8P836:.6DLDB"R]XN
MTDO"P]&JZWTD /6'M(9Z?Z=8"24<%@F8A(3HLR<E*SHK1#(RQ6074*R^S,BS
MO$=41*MM:]:,0_'5J54:F/@@'8SWJ &[=TS+VOJ\J9]N5&OA;?WL<'O]C>/2
M.Z$M,]&1QA5C8B%!84X$XW6B?S5I'<*=U9-9-WX](K_<VR6Z^#P:=DQ15TQE
MT3KQ-,D'-,OC*@CJ8ICNXG2V0K"W1U.T=[!WS%U5HA"?TUI;9Y7M\O\>T'0.
MJC B$?3\OW%O_]?_]'X?C +1TK/NRT1I6Z-1.NQ.Q-I?)Z02?<B5NB:D%W12
MY3Z]%=?JY9[TIT3Z)[_KWG[Y-P)T)A,GIU?VWTK"^OMO2D/\2AY^$6='LF\V
M+$?R;U*A\I5 ^ZY 7+)4^X;DFH-__A1W<?@VUZFKXJ73Q:B]3\D &U9"H4$?
MXK"3\L_J&-?5,?F(^[,??'T;4F>H1;D*:V+D62N_;G6/QHA&A58=-;B3D'5H
MIO73P5DY=-:DJZ^/;(9NW+YBYR/V [EF*S?OCR;]3N<>YT%')[]^[*?I[O%&
MR*D?'AFR_,M/,)#%>C#]]D].20+UM1R(N?;E)W&^$&?&[]3C[OBX-?OXEM8D
MJ1CO&19J[ ,<?,3#R;U_?MU%ZM^9(3T[&K-./OR?,*:?GG/C,[,UHVB/UF ]
M4"NY B<R2H^0C,X>G''<_ZU==\/5C^=YV">,OAA.CC"V717$VZ%O5&-@6D_C
MGI!Q.LO$5?N8S(;@X&0(AJ..=5*FE;C7<6TMV?ZV=VP?']'7B59+C-<?'Q/'
MS$ XND4UI6;4,QY]ZEI #/-_+^)MC\*++)S+@8/2Z)3'4F1V*D4>;/E&G*>;
MV_(<#=_N4&^J:7NR3_1UQHWAP1Y+HVYOH%[F9!O4WSE%YNW'K8]OBB4BX#45
MOA.DO$BNF<<46-'*&(LVA<)K[-&:F=O#[(7^8- _4EHN,MNAQ**LXKE&IF6Z
M?_0A)> ^"R%3^=8&=YOM2\WVIZWU-R*J)(SR+-JL&!2H&1:B9RD*8[P/V;E"
MLRW6Y@^(?9GMCE&V<!QW9[O82MSO57AVZV CQ[P7\OBKC^1],MLG^]5.)FHY
MG.V+5(4OXGA\6#FGXY'>1[KV11:2R$F%X"P:G4!%LGFXS%"BLER9H/*BM%$7
MT.:05,2#:ML_.FK4^E[5O=MZ^L9Z EI/I$EX%TQD+F3#H)XY)-/',Q^]D=8+
MLD3MA7Q?(F%&S4U!K@&$"+[$& -$,EUC-&)1:F@S^H,S&B6/-<$*(V73,0!-
M,VJ,9$HK,,[$8J'* U@3<PRQ7,HX8Y"<J]%^UV_Q-QKMBKHEU-UR2SSJYO1M
MW:1X]-5VP$F&I=NAHV\.*\\-9SO%LYV=;D>P/YY,2:7&,>G@==F+'L;_/>C/
MK.$.-*^>=8Z*:LI/#D+=:ZY[YMC;)S6\VV,\\N5U8_CUELK17G6]S,%^_=5_
M_Q^G#/SZ33[.!^,S? S"2#(.DQ. 0&A#+,;;H(HE.Y(?Y4P1WS^ ]5LU+?)D
M\FBT%_K#KGE?IOZKF3^9^,5H^H9&+US"R_MG?4\\W=B$K8U-^<9[#UPF9#9X
M8$2 C@A;().Z&&4+%UJ3"%9\_O! ;V]&S_=/+ZQ(R*'E/C[L8:HHJ@NHVUNJ
MFV/]276*554M]4AKWSURQE0%;I]P,3JV(,D,#$>S> 0+^L$DYB'2ER;=;MN+
MM>=KO2>CT<S=M#$^>-M;3W5'DV3V;/7^4G<E)?_UR<9Z]TS\^H^9A4D-J$OZ
M7WF_VU?[1.MWVA]T^F2WXY33%TC$PUFC)Z/!AYS.V>3Z>E/KFB(73D7F' 4Q
MI*?#9]4L'U.K?\-)?_)B^&7CKI,(]/%H&.E775/O<I##UI]OZ&<>$013!2-I
M*<:P0 N2<?!!%G V@%HP:&'U94?=WRFCP6 T\T5W6[F3@SWJ0[?;W=E1LWWD
M_O#4QL_QOL\WQ</@F&D?]"XC9&E4CMITO*G;Q2#1Z QP?Y(?'#_Y-?4G^P,\
M?- ?=GWL?O3KT0V.=H+K'<Y$'W4WG'W\91MTC<^V0H_R[1W=^>CCM>ZC,S%5
ML\^L7W,>OODQ7Q,_^)ER/W;5OVWLFA/NYK15?OO3,U<])_KV>&T0^^8%,RI^
M-POJ!;[JY[YZ3KSMS,%P/5&E[GO&Q"P'X^XXY]Y6=2-.>H^)JM(""1G;4/_(
M4'?&:X^,TZL=X9\:YKW82/Q"4N9(<YS\8X'1N,#BN5CXZFHOF*H$+I(>=;$N
MW[W!DU<#M._%5I\W?'\W=BMW"..W3/K4L(OLPP$.8_Z).7K;T9:[=7*%ZP#6
MFAA=,=6=YZ56(LB@E(^<JV_MWL^G73\GQ/]E?[H[9Q1/OK:*)U_;T"=;24>.
MP9N]971TX&5+/]W9?;_U.?+MSX\_OOK\;&]K9["[M;'^:?M=>K>]L3O8ED_(
MDGXQ?^#E\WO]]/<_/]-]Z+J_O=O^_=6GIR\??]S:>"RWY19_^OL+]>KEJ\_;
M.[^5K4-^V&7X><X/R1;_O/UN\XWP-G#E"\L\20;%)(:@.(N\:)FTX"[&*S@K
M>'N. C8ZO%MT:(WEP"URR0&TYJXF,:M!N38"%UG/-L\;'=X(.N1GZ=!HZ92R
M>99R H3TS N03!JN,KJLN''W'BJQY'R1UT^'2]&RSZ^TL3#)G=J2/+TO>QU^
MW/-IX%&WXUJ#>T\%$^-D<K"WWT'O>':7VC;3;<%^KW'G!.#61</4VCG;JS6Z
M;^9__D7\XXQ[I)4F6G0U_'*QY!C*:V$@.@#G39"V>(5<I& S/3_7D?2U>*@!
MZO1L67+B&V+B=^P/_QA-)INS^/6T.7R,XVI93IKLN(#LV'X^KTI'K1T/RC%,
ML=8W2IQYD,C0FHP8 8-&DAUSDF-NO^V"?-NJDZV"7NBDB)"C05L2Q 2AQE;)
M;%($D=! QP#RF 'D N6^&_!7$_AS2B-R'J21D16N--G0LA#F'3+K,VA79+2V
MW'LH+IWI\<KAO\RMUUNC%#XNI8;1C,K)6:\O1[SRJ=/A-U YE)=1#K^S?;*0
M9#AGK=P^R; $W7 F&=[V!VG98N'H"/?CHR7][/2*;H+A(H*A/Z\1!@4E!= ,
M.3V B98YG0S30L18A,HADD:XK*W5%=H[O>7@OXAEN 2]\(QEV&A@M6E@3C^T
M& -!G3.G:BZ![(%Y[0)+*2NEB@6;B ;FS^(M;AA>.0.LR';A3]( A^D\U_O2
M]].^][N6?/)ZAVBUA= %9) /0I/)+XJP I*3/EEEDRTNH/9"JT4K[C2?U4\7
M+^>Y\"$*C*8P63<=@$?-7."*@=<64E AQK24&F=7@+&?O'W9&+<Q[M6D^]4A
M9TSTH -(HYPJ8&5,AE<XAJ.@J<:X-X)QYQ3ZR)VI57>9X"DP<$*P$!4R(X1+
MA@2K-O5XGKQT>8J59]QOV@5?)Q,^M:F[&F>;[4*'M-Y\YY]%3EBIE3G/K=?D
M KW^UEZR7',+!AI<:6CY^1/5F^%J_O'8VU5#.I[E2>X.?-3#J:D>S!_M=T>I
M\Z?]/)S,4HO6PW6/1G46:H*D>HBY(JD[?_I\2G^ZH[/5&;#9):.;96W]<E*O
MRW^P/^[7<WR#PY.CJ]-1[V!_=I5ZLUB?'!_DKF]/OB1/.7TI^?>7.G4BMTL>
M=Y(JZF\2D-Z%I2A7?BD^[1(-SO(9]GXY6G__N-\;YNF/+,*_3_-W:_-,G&@U
M!.T3<#PYF)*>1#<\Q,'MR8#]LCH;8Y7RJ8=?#OF>9H4RZ_CXN.,U04M-K?DE
M4>W!>+I[.B\%/YN78G-O[V!("RKUXW$VT.,#^Z<_.CZY?RJ#P.2 U-'_/:!Q
MJMEQ]VK^@,\GN><JK^7.BUJ3XG;9*8FI>GMYNCM*O1$!^>B<_U&"VE,I[P;]
M<L2Q7Y^!KM]?;!0NFGZJN%!**"F'DB%R='7+A)YZ85QVR!=-/[4>X_@@IY-U
M.,N1/%T?IFW2TV<O6M*B<],!;+SG3]??B!1J;+5CO*:N U,L"^@E,];0N]$:
M)?%"-IDJ7CFM24$/ %Q"4$HEZU+Q4#7VN&@:JC:SEYQ9ZX K80.+DHPFD*GF
M%E.^YGTPJ#W-$$W!0[%(-JJ9:+U<%KLEY:U#;P.9?E8*7QE#A%B,T#)!3<]G
M S3BN/H\(F3ZOWV#*LH8 RVO;"T#H8'Y@,"4<4[SF)T*^F)E0V6FN=0V*-=1
MA9=<0R0R"MI%@=^J?-=F=MDS6SAQM<R>R:)))( EXH ::\LMB.B]@RH2KHDX
MUA9*L'(+U&Q:G./CW<1>W9#L=;N(O5-;DK=$R]XX&!_KJ],N"\?>+ M'KEDX
M>B?9(H[DQL>O=/(NF3\.>OV]?1JBSK(G6W[\ME-7+R)'/-;D;!Q,%!$X+71O
M5")YR8/),DKWO8"1.=K9/&G1T[(YG.+P;3\,\OIDDJ>33>I9(:5[2K;SAYP>
M?SJJ(//[:)0^$C@:'9V;5G-G73^ME>1V7GW>_OSJT]:?;[*1)J$JS/',&9#J
MR@+/DKD@8J8931YJS<VU>2?<24+-4U9,S.-:*6%FGXV[/0.V/Q[%/.GRGIV_
MC75BJOWG65<78N-+AK5NKM=ZSVE)UQSI/;O6^[(2>K.ET&5PJTQ56U47\G V
M]?2JL\!J\8KZ,!QU51$B=B4E:'&?6O'4]).[']VURTA.#5T<6NKF,NL/9@D]
M1:JSA*$[8[I/R>-;PJM?KY[I<>=Z(4\_YCP\ZC3-_G&6^KJTCU.G]F=E1&:Y
M"">U7-.DIC;Y?MZ_5LSBJV(6\LQXG7JLK>\(W+J88A#:2JLAF.C!>)]X9]C(
MDN -J'L_L0+&^:,LU+4L[?.5(UB[DKWF!2?U6WO-U].F\T?DBO-MSJH9=4KG
MYK!F!"?S::NK6U$=CH])7DX/O]0_I \?S63ISJS<WTS6?:F8NS(Y-P^/59C'
M'[?W'G_:VMBL[F;U^MV?ZO7.6[WU^RNYM?&";[U[K+?DIGJZ\61W3H7969>O
M=AY_W'I7B]FFO>V--'BZ\?[CZW>O/F[O_'FXM?/^\ROJQ];+)X6N<[C]\4U4
M1BN.F6EA- ,"/G/&(".5TR5PTMF0SQ86U3HEK8,2@D/-THE:2>GJ;FF![+(Y
MFZ-S_:_US3_6?_OC,7OR]!E[OO['X][&X]]V>L\?/WKQ;'-G\_'SWOKV1N_Q
MGR\V=UZ=>G>^7M%W<X=_OVE?=X6^D+S4F=9A!"7!6^T$E[7DFG'@RTVOBGK1
M J%7"]WG<3>G@T%^6D[:]60TKJWZTIXS&7'K=^XP1#]M?7QC=1%):<^,K<G[
M RB&CL"J JTJDTCC]^FNI,5=K CL@Q_2FD^TLQN3^%:Z-2NO(O$MB82E)Y,U
M:QY^[*JMK:VMK:VMK3^EK=HL=-5KS+4LQ0U/MMQ;,(ONK1V)8W_2B2_AJ\&X
M"4FE[5Q:@I96^E(#M7X2,O5H-)DN,%)W+<7TH@/Y^W@TF?1>#,<9!]UXUKPW
MDS:@RQO0FD0HMQ']\1%]?!+=^,7O<_ZYD,:0C2$;0]ZX 6T,>3T,>055(;XS
M6"MW7+>KN#<==Y%8AZ>V0%M]B)80_9J..L<@BPC>9"@!BC+.<PE%@C(>HM'?
M.C Q=]2Y.J9..6[/>(A.Q'^5_B=A:D<1M9M'1TK6:_3!>O4>U$0M],M'XYSZ
MT\K'JW/F^<>\2$=GGM/[+;F]N_5R"[;>O?_T>N?/3]N?=W>W=Q[76#78_OWU
M[I9\MK>U\9:?/?.\_?_9^]:F-I)LV[^BX)YSHT^$D\[WPSU!!&ULCR=&8NS&
M[8N_./()PD+B2,(V_/J[LR0PJ&1; @$ER'E@4*FJLK)RK=SO3=^>[].7W_;/
M#\YV]U[U.CLO8=PO27OO,XSS '\\?GG^\?7^U]V==ZD]IY99JHK7D8"8$QIQ
MGW.>,4G(&(&=,$$DDZO;\GH9HS6KC%YXL?!BDWAQE@EG>-+[T^/3*G"TDD._
MBZ%9K/\SYIJE>_;;]3C>U/T6 SJ/PT&AQ>5HL5X*(C'&.59(1B\0=UXBDU/5
MN!)221FLR;28(W$)_:-08Z'&1TN-RQ3%?&ANS!+A%6XL'+@,!])9#@Q*"^I=
M0@S>'^*:<F29,R I.N,XYCQ*L[%5+X:S='W+0GR%^)I'?(W3E7^D'A>B6X[H
M^"S1,:$T,0JCQ)D'84\DI"/\)B@7@FDOB:]T8%X$O<)WA>\VNBIP$4APC"K*
M+98:TT",P0P+&R.UB_:.+;;!)O'BM_8+_*WBQJ-]T3[?/_ND!2?,<(*LB0R(
M,0ED,&=(F&P>))I+0S>V."E=9 LQ%F)<(3$6XV"C>+$[PXLIQ$ =88AJ8$/0
M@SVRPBCDL.4Q=P-)VA7K8.'&Q\^-RU@''YH<BW7P-B38F14.91!8>4\1O#Z,
M.-9 @HHIA%GRSC"&>9K;!:N8!POS/0+F:YRZ7,R#JV*Z67%/2:6HIPYI1Q.(
M>TPB38U#7!FJDY)<.)S5X%MW@KT_PKOO)E\/%D1YD.L0]ZLJ5O8@]GVN'7S+
M>,K2.WOARKR:4HJEC9SR(*.FDF%J LZ-JD)0)81P_?AQ3J,J)817G(+ZR[%
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MEFHJ'2?,;&S5J\L5^:_PWB/@O36AO<)SR_+<;/H'L2E&[!QB+N9:UCPB&Z)
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M.WBI<G:?6*]Y$3Q3)!(KD5,$PPZN'?Q&-8K*<^X=4YCRC2U=-O#U ?G:8[R
M>CE0UUP'QECF"090.P6@ILDAS0'CGL= /<=*YZ!FSFY=TJ%@^\EOX*4:U1T@
MNNXEH/#"L#$:P2O5B$?*0=,.%F$:I7+&$$+8:KJA%S _V8WZR;;?OD]DSSH.
M.(M:<&40<R9KVX+F.!Z/E Z4^Q2DG[3?IF15[;=+]L)B^'P71]T007:UO=;Q
M8#@^L >Q9?NA94>C.$;Y&6,H^0SW)<^P&$2T)H5@(W>1.*.=P2DZ+STSKBD)
M#84/%^;#W3F%E6P2*1FM$2&>((ZM188RA3"6V@<:F"1V)?UX2@Q$ ^6<9F*\
M@'HY4->K*24>M!8):>Q=+B6>D)66(6:I$@%SYA3.I<3KU71+?%.SL;U^&WCQ
M**P4ZS6/@H65'&6D* @N$5<T(NUC0)@[25/4G.0-O)Z85#;PQH)\[3%>0+T<
MJ.O)")ZSY#3-7>$2XM0S4'\51SI);1/AB>=B:&)5K4 *M)_N_ET<"G< Z+I#
M0?'(!&<,1>]@FR;>@)XM-&)1:P8O%P<;5M+>K&#YR6[3)==@-=B==1DHQG @
MS"$I).S&@6K8B"U%C+%DF%5$<).=@4W*_E]1LL$$B:SAGH.]P=CV[B+#X%?G
M39MK3![^.4Q3*PQ. 9"7[36><(N>NYBB9F\(RPAW03AC##-,:L=EHD8')6*0
MPH*,'V(HWI6UVSKFE(62FE"E@T 1TUS<UEAD9)"(9HE/&>42SW7R;N->N0.8
M/7 82B'=0KIW(H4WDW-+O,\*&;CF"E-,<="ZPC3=7QF)+#4"<4$CU21P3&(5
M[H-7E5Y3F+@P\9-DXO43?XMO<J7D6_--$J.2QI@B01E&G)N(#-,,)<%%,$Q8
M1Q60;Q%_"^D6TGTBXF_Q%=^.9&N^XLAPU Y$6D931%P3BHR.&#&+F<,Q*)N+
M0JC;!WL5JBU4^Y2IMGGR;?'=WP'!UGWW0@@2L]E6DV@1Q\0AQR)#A 67HA F
MY-*_<VJ-%3&V<&OAUK448TMNYCT0[6R@A>8N1AQ BJ6!(IY;+3B7*)(I*,,C
M%S2%;*PUN%XA97V%V2I4X_=Q7GSP;^A^V;IXN,[I,<#);_T#/KQXE&,[/.CV
MJP&9ZX1W=#H:=]/9Y*-N/Z=2/J<T#_K^04V73;C6B4K&DF->Y)?OF%#,2>PD
M%S($6H&:878=U&\ZKY9#]7;.*\V@?C$8C;=[O<%7V_?YX(MA#-UQAOK+;[YW
MFM\IB%'#TQC>P"B'<33^945FO)ZH[\5_OCO[^"&<.,IE>V^;[N^]_-H^>@/W
M",>=G=#;W?G\]>/1_M?.WMNS]M[G\WUXCO:'5PF^*W;WWG]K[^V?PW5Y^^NG
MZ#6S'/";6 Y;EEHA1ZE%F%.?N=EIH7*7LAIX6_;B7>19;OGJ;;1Z\#I@-7ZU
MH]8P^L%!/[^YZ@O=_A=X);F_&1SNC@]A:5W0]<59<-(@M=IVZ \GU,#(LU9>
M1/G(^##..>4KO.C6R1 6UQ# T K#[I?8;[FSEAL.++! RQ_:_D&$N\/_)JNB
ME6N=3L?0'[1L *2/8E[;H=HP1JU)2G/JPFW&AW;<^CHX[06X2_R2N[/E@71'
MHU.X>!H.CEO']C,L/5A2AS&<]F+^8K?ONR>V5V5"7][VQ)Y53[_9^A"!LN#>
MXQ8L^B%\!B//7X-OCP>M4>SUGDU.'<.-JN\!!F*KU_T<X9LPI'[UX61L$9ZD
MUVNY"!/^OZ?=8;QRD=&I/[PV\2ZF?*7\:N"IS_)TP^-TARU[@3*8!QBKLS"Y
MFY?,7!'<-7Z[3@4^2"^,%XIPPRVF5A$;M&9!2$88-I]V*BH@F*#OG+ ,">SE
MW_?@?G_V!O[S4T/MT<NSSMM/1%J2*$M _%@CKA6H-))*9(-05'*0GSCP601J
M.X%Y'0,1;OQH%^)YAVGT/K1WF&DE,TS&5K71PFH^SC _CQ,R\#T[&@%*O:UV
M*EC*@U-8R!<K!\%*1R-8.[-EC3,7Y&^^&.3G',&2A]\J$2&KWZT_;:\BM;\.
M8QR/GE_'P$^F$R9J.LRI_#*10F#">O9D%)]?_/)'Z(Y.>O;L>;=?/79UTA_3
MJTV%FOQV9N2/ZLU,#O_QM1O&AUD*W\0327P:-#J]\_3P9G5H1JJ:')-RDPCR
MP\-X\Z;'!/OQ37]VYL\&2V!Z.5NGP<J%+ON+<-]&E %1%5%<A:N:;V<#3,%U
M>WG[K%E0?O)P/TP_6&@>?,Q[Z_W,A%YH'BK9I74AMCSAB=B)/AX[$)&F<T&O
MS<5-2^,LI]DUVK+TPHX.*R'/YU^RY/8%]BJ0T>ZB1,X*Y_6QV>UN, ./QBPG
MHTD\1F^BY%PI:22/PN86>8*[P.5\#7Y9L]R/M?/'8'L[@GN W+Y_M$T[YZ'7
MAG/:1W\?[NZ]ZK:/VN+CZ[=D__S->>?UJ\^SMC>X'M[=^[/;WMEG'?K^K+,#
M8_T ]_CPYJQ]WOO\<>?O([@&WO_P+K6O1JH??3[/7F1M1<("=/7@+$8<.XX,
MXQJ12*CR21LL0 60J^I_UB _1J&[0G?+TUWT-!K%O B.<^NYC8Q(A77P *.D
MZ6J\$(7N5D-W>);N%'$L*JF1,[G;8V $.>HQ"IYR:J5U)+J-+;6J DGWY45X
MY-VE_CH<#,<(() -I<//<6(C*9VF[K-K'L%!)*6UHIX+)K0@EFAJA.-)&5?$
MO ;Q7K<NYCF1I,%6(D*305QB@DR2!,$K"U2J1"H/JV&WKBQ3JELW%\->Q&@B
MMXPSPR,VF@!X<;"8A$B-%$5V:1*&:[(+%<8Y1ADBC@K$K0O()JR0C,E$E0+W
M!F07$$X;A.&G4+\ZQ[/?B7!2RNPL&AJF5111>T9!C _2:4F\YIXPS8*A0MVU
M</+H@\/NB_7.ZI*+H-JXH VR,C'$.?QPFE*D1'Z?@C+*28X-8[3>_K)4Q7LT
M$#>>!9;M+B9@GNMH>6692Q$^3%(Y?->R2X'XRB!>$VP<D4#.RB B<BWZ2"4R
MFDL4A9 &"#PEEZI<?=ZDPM4KK;1%-ZEHN)A3BFTUT!1?,@96'EQ<]HRF[1F=
M%W6QT$9G#=$8.2] &59.(6UX0C;71-?>:(Q!&:8@%J[*I-6$E('"N(5QF\RX
M]Y.C51CW'ABW)J5'>+7216!<@7,=+2^0UM@#[3K,(JABS/O,N-2LR@#9!,9=
M($DK_^TGU2^J*/)K$=Y3)'&ZJ;* ?S)-*'P^C#WX\I?X/0[[OZ]'VD^?&G\_
MQ3IXO-/QCT^Y$DW.YL5V/E 8/F'7X]^O_CP<?H],/8C(#:/]C&R"P3ZWO:_V
M;+3Q^_5'A.>;F=+9V9@\Y-8_W!!.G7/CF;<U(0-I1;841JN(YXQRHX0FF";*
MK=3<I(V[3EUY\SW!YL4T)R&&/\]R594,HE/;:]MQYL.S'3LNJ2SMMY]\(DG"
M#H,P$3$WP"'("FP1R'X>MIVDO$T+IK)<)E2N0=;*@ODI[JQ:HM.UTSJ>+I[G
MK9*+THCTCJ>;B[)$EL(/OVK6,Z'A)YD=)9%GH95Q\^2-YJV&RZ3TB72<4],7
M,:\N-@-/;"Y?V>ZP];?MG<:2(W1]9CYTQX<Y6;4?6V?1#DMF4 F57S/S^ZSY
MY[MA*)N)IFH1_#59Z;O]N _K_%K%CR=@&#INL_;YN\\?7^_CW1U/VT?O/K=?
M=PX_[H#>].$]7.]]'B=<*_1F#4/[Y_Z\\QK./7K+.^?[9YW7;[_NTU>?=_?@
M?-#+/NY]QITCT,GHWW-C2Q/! N8R@N;E*2ABT2*7>$(^.A$HEB2R*D(#XU7U
M+6R0I;U08Z'&-:/&+"M5HE)AON68KV82E]1B;Q-&A'"'N, !F"\EI!PFD20?
ME+0;6\:8]>&]IY!.M)WMRY<2<6M\" ]T<-A*W2^33THJT:,BO^IU _?M3=[S
M*WC-F09'142\&Z*<$\1KH@+9$#.0";T'HC08&1?@-\D,=CQB8M0DB'=5U<H;
M%&U1D-\TY%^1@ KJ5X;ZNGBDM+<4%$/-;>Y0H#PR%!O$K8_)1Y.<JLJZLI65
M=2TI2\M(0-\%GDL9:!S[MQ"!2C9#DXDPT]^4"?=B?YX(5/AN8;Z;%Y.*$W4<
M. TVD*01CU(B1T-$@6L1G#>:VLQWMVXX6/*4"K)_A>QBY+DAJFM2# X ZL0C
M2E* [&*<1MJ)@%1*FA%/;%"^8:A^.D:<V\DK17%K,JL5(>76=#:GX!\6TBG&
M Z+&X=PV#B,=(T,T*6&9)-;F"EC%#%/0?#=H+H+)#9%<$TR(PQJ#:(*LTPSQ
M0 (R1H-@HAACW), ;[A92%Z1:>4)I$RO)JS@1IDS3RCH8 7S4S:%FS=B^E$>
M7[5?S._25 SV*]M1YD1R,>^5LXRCP(0'55=[9!)7R% &JT,X'!2MDJH%7FU$
MP^V!N!YQ7H60"R$WBY"?<"[U_1%M372W&I1PKRDBB2D0W9- +CJ*?(H@O'.N
ML%4KJE[1%*)=<;?+.\=O+<^$XO^>C - ,!A6N<//89[C,']K8^OE_YYVQV>M
MO^HE'W^5:'DQO2C3^'.B?]U5#>4OW=T,5%=\W@7=I>M_.2=SGKS5CG9TFIL(
MVG%K3F;./70";%]6XOP^K"><+XT[;S\9$Z2(TB!FC46<.(NL4APY3F/TR;(H
M\&0+ZO9A(]C.U ^?T2B$#1XK;JRR5F*J,&%*&1FT*:T"XV3Q7\F\/KZR^%->
M_%_RXF_!*3;WS#P=#O,MG!UU1\_RIW?01G ^7ZY3-C<UZ@X2I)GF)9N[=!9<
M94+R6F7)ELZ"I;-@Z2SX\+-;DN3NL[/@1#_YK@>\^M+I/@'SQE&;MW?:^./Q
M&](^?\LZ1V]I)YLWCK;A,] (CE^>?=P+\/<!KY6*.S_XVCY_=[Q_]/Z\L^,I
M/ _>IZ^.VSOP&8QU?^]?O0[\O;MS.+>IH'1:J,0%TB9ZQ)G7R&*!D<16^)2\
M=]DSR9Z1=6JT5<BND-W=D=VJ^@H6LKMCLJO9<HT3GCCGD;(R(1XH199&@91(
M3D=)/,L-*M@SS<CZD-U]1Y!>UFV\;XC^9QA/+$Q>EG4'XT-0";*%!B3=EAV-
MXG=Y=Z5CDS6]==[@YA0+S:\<L<TY!AAG1W%BB/Z-_,]U0U$)HKL+PG:6,B&-
M4)8(GB2S#'ZUPHBHM%'2WDXZ+9R\."?/"60PW@7O&$>*28TX!79V-((4&FAR
M/GD9?0!.-K<.VB]AKLU%J&2<$:)B<(SQ$)W+Y:HM)DD*[)U)MQ.I"D*706B]
M$3-FVEA+02>D(#5A;)'502'.94HZ<,\4V]CB3[J9X8,)1;N5(-2[[&OX-$6A
MDO.X<%]9XB3PJJ,8<^R)T1HT6<(LH=:SH(LH=%]$.Z?T"M4L@5!*D.*2YR(,
M$EEE0#VEUH*<&E1RH)X:31N4OU@0NFIE)7D3%2,B&L$)U9I*+7G0B2J*B91%
M%+H_A-9$(6T\DRXFQ*P'44@+!WH*TX@F377RRD6/ :'\UJ)0\S*,GT F3VG%
M=6?^@M**ZR>4KX/!G!D1E.#<>.FXI2;:P!45BCB^<))G)?M?9FWN=$>^-\@!
M;L6KL*I-85XMF2B42#)%)*C*T9J8($,50]H0IZUD3IJL'S\3XM9>A09UVRJD
M6DBUR:2J@F2"V4@(3EPJ:8!?+7<L4L&X$@O+T854[X-4:Y(VX]9J>%4H<0R2
MMF4$:4(-4DISQB0FSN6,^6>4KZH@81-(]5KFS6KC;Q>*K?_TB__,F.@62@IB
MC4F;$9MT@5GXD0&3;NJ?&3#G-RO\=5;&]2P.A3FHDD90ZCTH_=X:39CEH/M3
MXQ)54T-IK8WE7=A[9^-SYR^9^<_]Z^=H35!:__DK-W]U8+[9N]7MYQ3)>#7=
MXSB.#P<!CEPV;83?6]M#?SJYTFO;LR?V8#!ZUAK&T4GT^8WWSIYE=F]]/>SZ
MP];7V(H].! G@[(G)[TN_)XS3:YFC9Q4CV]'^?L.5D7\$EO=,?PZ&L.E4[["
M)#UEDHIVEG-+(DS=X+CK1SE)!8Z-XM61;K9VX4&^?Y!'?CG>5G=TF>@2\P/^
M:%("#&X\:'E8N1:^E=.JT.E)ZV0X^-(=Y3C[?&[5JQ#N$>!2HU,W\L/N]'D.
MAC%6-__:'1_F,1X_F\X+X!5.R-?>/CT $.?P;+Y97YT+-3(TC:&)&V?73>;_
M%MF%34Z[>OE#.'T'ZA1R5P_F13,XS0"P 08%HE9>FMU^E>#T'3T9-,/8^J][
M3+H^Z/9"S4JZW0^3C]K5<WYO]?IA\ASO)H^Q<^4I+D7#[6.0*AYW-O;-$QOW
MWIYW#CYYF;215B#G T?<88JL3Q99['A*C@0>_<868W7[Z452T$]V.B?S?^\0
M JT[V687O'E&V3+PN&U_]P*/^X4';G_]9(B)5&O03*RPB"=" !E!(DJQ @$2
M7AX.&UN<_A@>6?P 2:+*'IN(4Q<I9!5-7R1373M$9R6?_,V*CF-5<0(D@C0<
M'%>BRR0QU;K!E[C9VJOD%5N]URF!3P6PGXDCR^31;CX1R>%]'_;'7BZV!/)=
MMS_94W,1I7@WH1P+#/07%+C>PDPGCH$[+^>\5\UT3OD>'/2K3V"1UM/%EQ91
M;E0=85FG[O>U\^BK;MV"7_>_MK<_Y:0T&YE'SE""N- ":4\=HB$2#^)'4A@T
M>2KJE5R^\^N2V[ )"0=.)%6:<0=OWPJ-K35"$A*2XM42H!=+@)8E<(>E-<3N
MWO99^_P-;>\=?&T??"*,,F]-1$[8W!/.<@1_:21=X(X;;7VD&UOF1W5]+I9$
M-A14>^,A:,JM8WC[AZ/61).^GL4]V5E_NN/6]T_X9' <6[_%;R=YN_R?9ZT^
MD-?/-]&_QO#/1/\"8>!-=87-NNWNN@GI"I=/N9+33545O:D9Q"[K1OSW]4(B
M4^,I_GZ*=3"LT_&/3YFQ%-9RT1]HA\A%XJ_-UY6?>?03*Y?VP3LB%%6".^D-
ME\8$K%Q0B:; /W&Y<7'2X?![^OT!+#E [&=D<_G$Y[;WU9Z--GZ_/B\P*3/O
M878*)S.S]0\W_'UKWFCGSS)A][+QSA=TQ.9#ZE _,CG>SYCFS\@=5U?:@:M^
MJ4#[IC\:#T\K5@ U[I\Q'%2EY.#0I [TI6.K*<67.MV+'>*M^+CWANR^?@/_
MMG'[_-UAY_BMZ)P??OZX\_Y;^^CMM_VCS]7]9G>(SDZOUSYZS_>/X-_SM^>=
MUR_IQYW/,(YWGSM[+\\Z.Z^ZL"NP_>-WL$-\%J"$86F$9PXC ?( XHPEI*F!
M&58! !ZM93C-FNTQ=0J^8P/QFE.K<Q0GC0Y^2XF3X&:++^V\?/?F[^V]-W^_
M;+UZT]GNO'BS_>_6F\Y?>^_>MU]V]OZJN59FZW'5+>Z_'L+,D),$K5(P>%3-
M.27.6N4]APV1Y-0;L\85HK+1?' 2)X7?*NLV;-'PA3Y, :BJPRS+PW8Z .7U
M=)3-U\=5";+6L#OZG+74@>]6VVAE\+X\M7)"^+.L%!_:_D%LP?5C*_5._?AT
M>B<7QU]C[%?2P/O-OS9;(9=J&E;;^Q<[[ [@=C/7@[$\:YT,N[E\5>^L.O/E
MZ7  RG4>5A^V"OBL.ZK&]BQ[%@X!N*!TMTYR==[OQ:WF#/.D0G-6:WK5X\"#
M#D['HS&,)KL>0%")8SL\N^I6Z76MZ_8FVD[ER.CU\K_YXMZ.\D5.AH, 3]P:
M@1 Y@NG+5_KQ%,&1KW88JJ67A:?1)D@CK8/8AY?3>U8][=6YOS+2B2_D\KSL
M[!BD! -MN3/X>)CEI\'D00XN->:I'C>8O(%JIN!B0UA*$\%M5-DL6KZJ43S_
M=<^Y;P &A9>:[UL]5;6BNM/BFY/**W/71C6F9WG^<C6QT6EO_*Q:!7F$7W)#
M%%CSFZT_SUI?!\//^4$&?5@!U2B.[1$(E<[V/T\>+#,S"(KYG77'@ZHJV853
M;#I_/D]&]8S5*AG%^#E/8Z][#$^:9Z-ZVO&A'4] $(<G=EB]YSF3?6S/8"V#
M6E-9>^ + *:L4VRV/L#2ZXT&,]?/"["Z/BS&_ [R7%7"6QXHS-3@RK6K(9QD
M\^"XDF3AE8Y[$P>3S4]3=2(XJU[4,.:5]:RZ?)XQ"ZOQVFVZDQ<=O^2SX4-[
M]=FRKR%9F/7\#JMQ7JZLJ<VJ.J5_=M42,%E+E73]'2G?!_];=S-NYG4[N#9?
MU3,=VB\37&;)]\M5Y\;_Y"?+M\W2>;[I=&#5=(9!JS\83Z9K,E?A<LN^<HM*
MR1C::CPGI\-,7HM9QYI/UQF25YZY^UU.R2OY=%2MP GM57[=2V++<W+AU?P5
MFU6OR [SG;+#M5\AOIL+_<$VB])IOR((V_N.Y?SE_&9"',&T5=\'*%?CF/+(
MC0?]0SZ=#/#J_:JB3JDW^#J]<_5@U5([OFS:D9?4S\1(PHBVB7*0#2CW)AH0
M*;U6A 1)@P]J*3'R73R&^89E.&T:<D:NV1M@$?CGX718J<%/38#<VQ:[>W"]
MO?WSSM[;;^WM3]: -$8P18;EW$E%.=(6*X1EQ))'$K$#<9#H68'OPHP BP76
M!:RWQP'U#WE7[H6?2 S?&:_:"*_2,(!Q M$+CP,L^WMP&.L?8Z$S'=$RKBWS
MU$!Q]$:TWWY22B4):@B2V$O$#:7(64X0#\90SCWQ-&QLT4U3-[VZA5Q;]^ ;
M+2OAEBNA_;7S]5/"RH 6G7,;5>YJQC#2FDDDO0Z<1<Z231M;;+/>MV)F)<QW
M9LY2Y=V:5_[RL"V?]N)NFFMH>=._-,7NIE<@=8#"9WO_F1I'+UWC3]CBPMI?
M/VGOM+;1()R41SS_L,PJQ)SU5GKC>)"SY@NIN'<,=E8B'(].:B4TE@%+JX2S
MTCZ:<M<?#KO9XPZJ3Y8CY^H&-A?#KDP9E9X'YU:Z_D1=GB\/3TP)68P\ :$T
M*Q_A<EOM+N&@G]3*/AA62E^NDSV1C)>KSYW'=C44K-*0YHG6SZ;^D>K"<)V3
MP1@^!D2U8DK15PK=Y+''.1)[89GIWBMN&[.I!;M)P6VF-CE>K"STLC6LZ<IK
M6%.RJ?C-2F/?_V#%)N,WNVJ9V%].[&+%W!<L9%[ED.5L+E'YQ18K=OWCB@-D
M8P;W%U[,Y0I#-Z]T]D]JB"\ST[><7S,[O3<HNMV\N?TN[K6VKY7<^5ERY&+/
M_W1G\M_?!92;K-:GWN#@,:V*%]=$Q'L U^.<QCDMG<I2*TOM'I?:K\K//)Y&
M'-\WLM%<I]'S!X'@*D2X<M/%;KK2INGXU\L=!O= :_W5KQTX=]%^Y@Y+>3[<
M7"Y:U_P^6UO<J&S*PTWATHTKEJMY\G /MH132T@F@E(A12,Y$4XGAQ6SR@H?
M+4\+]^#YOHU5BNVED^)U-O)6'[VY,,)V!N._3MU1]..]03O',PP[$]/K]G"8
MR2 ;;1N3<'!#Y\:T$LH^Z^RT:>?X57?W];^Z[7R/U^_YQZ.W7W=W#H_AGF>[
M'V <Q^^.9BNA=(X\W&.?[G]XP_>/X3L[^_SCWN%Q9V>;[[[>A^=[(^"9Z<?7
MG;F54)041CJ"42(Z>TZ-0(Y+^"&H8]JI$*7<V&*K:O-^LS(F$X04JE^H6O,%
MO?=^8.XH'%\X_@>MARA5$MN86$P<"V,<T41AGY2ACDBW/,=?F-S.KO/\Y<>%
MZ^^0ZWFMV3PW6BIO43"Y C03$KFH+9*4<ZZE=('DV(A5M6*[-=>OM+;LDU1X
M%FT1LOJ&3@^]"_ZH9T'IL'(GY1 )8=I@2KUUG))H'%."6XU95)RRA7L@%>W@
M 7>,.2WMI+<I"441=Y$AKKA#!MXCBL)SZ;$SENF-K545GFU0X=@GP8P#!P.:
M))<5>KQ3XXGUUOJ4+264T^B-<]Y%:9S!AG JBF"]5C19%ZP])Z M>>0Y YKT
MA"#GN$#<"">,$B9( X)U@VAR);X$<R%;SP]R;1)8J[8-5^(^Y_O0FN)4N--K
M+- #Y[95S]>:K#'%$A1ASZ.2G$=JDPM. &_C%!,A-[""%%GVWDEZ3J/!$)PF
M1"O$$I:(DY3;,TN&"#-81T6U8+D5Z!KU9FXBNQ2&6D>&*N+D S)539SDP1#0
M"S32-F+$<]\7S11!(1FKA/"@-%!@JENW)GB\7>0?.D#K1YG]BP1IW8NMXJ&O
ML<(@QZ8_ZD--5PD7*^%BZQ$NMHS@=S/);BW<[XH*2E10!)O A8]:I8 Q#9X8
MD90O(59K(,[MS@FQ$DHY2:E'S!J12Q)HY +AB"A#L2*PKHE;@1.E1%@]L@BK
M0HL5+3(O4PA$ EP29PQK[63PE!G+B0]!%6UWK>BQINW"2TPZLHB4R?4Y3-+(
M&H*1M,P**ED2(@ ]-H8?5Z++KK7KY$?:[9-0;A=P9C]IXV3P0@O&!'<I<L"<
M-I)[&:,@B=F@?MDXJTBQ#:#I.:% *F'F'55() Q2; @!V2B!ID$WH9P*@8-8
M72A0@[PGA: *015YLK%$59,G#<=11DE1C+D6)(X6.><\4IR"7.F]=5BL0IZ\
M/Z9:A267ZG66.+^7D9L4@YO68%^HB%Q33+]W<8V[=I,WSLFV=)K6,C/P:+:X
MVS:O+3+XPV]M[;WM<><%_E9M;T?[ LX[^\29C<Q0AR05%''N,'*6!:0$MMPF
MII+B&UN,KD]D0(/(M!!R(>2U(>2B<SPD,>_.$K-@2F-*+!(^@M+A7$3&A0#L
MG'M_>B^ILQM;O%Y_OK'$/%4Z+H9RL?*G]8P;:/=8HVM<>7T,7D\8G.;RT"7X
M:66SM:+8IU_MO,?=$'KQ@;:?BN\ORZIGG\RT)OLRRO'- A+71!@KUUCQ->Z[
M(,.#XNM*Y>!TT5OC:KN XNVLO]QU"#WY[>$-*2"3[U9<_1^@97_VLA>KD>S$
MW*P-?BGR^%+R>/N*H<03^,ZW3T0+$QSW* AK01[7'AEX?<@KS+1,5JJ -[8H
MK\GCM:+9=Y.->X-XNT(=3YPZ+G7[0A\KIH_=6?K0Q!N7XQQ<8@;H@Q+DB$DH
M4J(284P9K!M"'_>=YO&@,MF+W*_4YWY)X]RPMS6,/@(R0NOWUDFO:LC\)/29
M.PL(?KKVU!>7BVKWLBK.WN!=')\.^WG576^ZF+K?8D#G<3@H7+L4U[ZMBVJ:
M!H9#8L@D@1&7PB*M!:SG_!].N!#>;VS]W_^C*:%_/&@0\*/V7!5RN0]R>9>'
ME'G%]VSWN!#+"HFE)L19E7#NNXJ2R*U@L;/(1:^1CB0$%5DRBC616.X@6?X'
M45X/*LMU<OO0RGK=^JT7#T":F]BO%VE;M;;:\8*^CFF/P#GNCKL(('C09;!X
M ,%=3-$OH?F@<_/PELK+Z(*)P6'[P&8+^/?]#$"\FQ8),;ANJBB;VU*;V_NZ
MU.PBEXYQ (?@$G$=,=*>&X2EB<G[)(2R&UMJM4'.*\'<XMOB)?::QN)E)R@[
MP1/:">JQ9F4W>-#=H*;J,**HE-Z@H+A%/"66N_AD?4?#.G )MHJPL45OW=FA
M0=M!I27]/K9P6_@W=+]L73Q<Y_08EJZ?_)VAT>V?5O:\K7_ UV8"VCBMNGS_
M<3(8=?-WG@]CKUKT?TQ;CT_@=^7$B_[=WT^Q#A[O=/SC4X[M\*#;OXA@JC?:
MO']2H7F(1%R^^,G\7?EY>!GY=V(/(G+#:#\CFV"PSVWOJST;;?Q^_1'A^6:F
M='8V)@^Y]0\WA%/GW'CF;4VH "=)L1+,,Z<YI\19J[SGS%MB TWFAQ/--R>A
MBG.O*A7WCA%,B7 \.JF5T%@&+*T2SDJ;0QSSROK^SJOU7'D>3D;Q^<4O?X3N
MZ*1GSYYW^]7T5B?],1W%=*'DJ9AUW^0%,#D\G25C-K5@>:*FBO_TQM,YW,0_
M['#/U*:8G#GW,-XD-SPF&+W1F3\;+"6;PJS+8,4FXS>[ZH-,K.(_/MRLP>:)
MY0M==;G6[-4^0L6$?1K=IGW^MON3)_RQM9[,]I2]V)_6O>/S3O3QV,5ABY%G
M+1!9Z3*-GQM1./3^5X-9ML'PFJR$RTC,[86+$-ZRP.BCG\E__Z!XV6,"UF_=
M?@NNV\L=;A9Q*RQC[WE$J^)%SXY&W02CR1+R/8#K<4YCMHZT*O-(66IEJ3W$
M4ON5Y_C&,]"XM..KQ=9O6FA]]6MG@2N5FZ[HIJ6\>2EOOA[ES6\=3=>L*2R=
MTC>ZP3EA8L):6\894Y9ZQFV( 3.A-9LT=*2$E@([-W&D'?8^[GSF'X_^U=W=
M><\Z.^]@+*\.=U^W6?OU6_(1[K&[]Y+O5V.[[DC;??TW'#N$<;SA,$[<>?V6
M[7^ [Y[[KQ]W_CZ&YQ'MO4,8Z[O<(;U6Y-)SS9G3&)F(+>+$$62%YT@J%B@+
M*AH>-[;$JLHXE%KMCZ56>^'X1\?QF"H6DZ(8<\&52<92:1Q5@45%F?/+<WRI
MV?. 7%^K$\JHTQ;^@QB. ?$H(W(B"03[-U8")Q>QV=BBLBE<?]_%%QZ?PG,'
M47V-9_+9GN^W4',>//%[71*(M*/82*EBM(HKRJURABIA;8K6,&.*=K &.\:<
M$OC.><*E9RCW7\W5-RF"UQF1MD0F8ER*6J^N!/Z:U[A?.V8<7.;]%GJ\4WJD
MCL? @N-8"BYL<"Z7KO4NQ"BU)JH(UFM%DS7!6@H?.,C02!JN$;<N $/R@!13
M@B<3E;%D8^O6-I05TN1*? EKW=)I9>V<'F&V^Y/NED)44L$[9;3$''-JK-6>
M",V"-$1@6V39-2#I[IQV3I@1G(Q$1A$@:1$#RDX,A"VS/EM&A-0KM'272O*%
MH=:&H8HX^8!,51<G@XW$"(Y,HA;Q:#&R%GND!6<A*F=Y2AM;[-:Y;?=>6OVN
M5>O&!&C]J%_HS8I/KTE^]S+76&&08],?]:&FJX2+E7"Q]0@76T;P6[<"NDN(
M=5YAC5V*5,+>CXDV!!-/.2512B5L*(IG\\6YW3DA5M;SX+W!B&H-XIQ7$CE,
M!&*)!26MY"G(%3A12H35(XNP*K18T:)B'N.H@G8D\IBX%@ET7Q:%YDRZP(JV
MNU;T6--VK54*8R:045@B3F- CD:.$B'&!J&E=&H%=;T:%92TUIZ3'RFW3T*W
M+;WF?\[63FL:-0E!,\V)]49SF[B*0-^"L%@B@=:!I>=$ C%L/#62@_S**YLD
M038X8&GEI5?,L>CXZB*!&N0\*015"*J(DXTEJCG.$Q]MP!K$29409\$C9TT.
MS1%,.<^\"6+E96(;Y3N9(^E2O<X"Y\DPCG)!@M ZJ#J +M/NLRF&W])ZO;1>
MOZ]47>&,,<PPJ1V7B1H=E(A!"JN3#+'8D==@9\LMUSNS+=>=)-KF-%T=.&QM
M6 6DG3,HYUMX$&"2HG1C2^+UB0MH$)D60BZ$O#:$7%2.AR3FW5EBIHXQ'85&
M%F..N&,<:>(=BHRGF)4.+?S&%J?K0\Q3I>-B*!<K?U)@NHEFCS6ZQI77-Z>0
M?%-&V91KW&"V5A3YU.C6(17?3[N)35PRDUYB2RG'-PM'7!-AK%QCQ=>X[W(,
M#XJO*W6#4[</F.G:7BOW?AF>9IFI.#OGO-QU"#Q9IJ']'1E2GD@S^_N2Q]LS
MK>)>\D_68!Z9<"B17-0L:(Z,)PKYI!P6E#+M],86JQ>ZN?]F]DV$?:&.!E+'
MI6Y?Z&/%]+%;HP_F572"(.))0)Q$AC3'$F&E8R1<4&9<0^CCOI,\'E0FR\W#
M\U-.>^^UAM%'0$9H_=XZZ>40M/ D])DGWZY^]>3ZXG)1[5[6Q,D]Z\>GP_X3
M:%E_7US[MBZJ82\\]]H@C*5!/.:L?&8L(M80PZTPFN(FMJQO(C$4<FDXN;S+
M0\J\XGNV>UR(987$4A/B.)&>6T<1CH0B#@(<,DY29 *\6!IU2CPUD5A6865;
M,MSK086Z3AQ/S=BMWWKQ ,2ZB2%[D>Y5:ZLF+^CT**W02ROTA]Z]KL=^E3;H
M#[C+O:^+STH'[KQRB/'($9<D(4TH;'K8^20(TR+B1]8&O4$T7K:"LA4\H:V@
M'G56MH,'W0YJ2D_,R?$J=WB($B..B8+MP!H$^P)+R5,7[.J37QYT-ZC4I=_'
M%FZ[53U6QD"W?UJ9\."3T/UR 9K.Z3$L93]3="5(+XP7BG##+:96$1NT9D%(
M1A@VGW8 )0P33%#U"\MPN0Z0O_QA#*<] ,-WJ+SY'BGP&L#Q[\%H]*;_UQC@
MD3_;3:\N8@K^$X>5!:#OXQX,ZL_>P']>S]7?B_]\=_;Q0SAQE,O.3J_7/GK/
M]X_@W_.WYYW7+RF@ L8!:-A[>=;9>=7=W=MF^\>PDH\^T\[VI^ LR#!8( ^+
M%V7&0B9JC(AUTGD3= AZHQ6!(DY@\F%V\QJ UWNQ3(_M\*#;KQ:;F:_V5A]U
M<US4^#FEFY-@QGMF<5JE.!W&5@*V''R%Y=^J%F]K='H,3P 7&57Q6S$E($70
MA5N#T^&5;*CO):URI%<^]H-(K\L5UKI<=J/GK4N(5[B8/WN\ZC5=ZP:; S\G
M(YW2P@3<E3_F9!2?7_SR1^B.3GKV['FW7SUY==(?T^M/N2+?8-:IE>\W.?S'
MUVX8'SXW9E,+EC>]J3ED>N/)4;)9[8<S7#4YILRF4.R'A_$FN>$QP>B-SOSI
M8#<UN^EX'F*LBUUUP:;JJ^BJ:FI?78N.QGN'PQA;;?C>X:CU$C!\W7NY#EWI
M^4(RZWSAX@F]Z;8=^L,6(\_6[@6K:BOX]1/^UNVWX+J]W$ID$</M,@KU(VIB
MGB7(T@'^YI-'E^K]OIJ<_4;GWZVB*7SC"M>NR3!7&GK%&K[0LI<N6WE:O_5
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M_!>I>=\3\O*PJZJ&&9RCF1=4SV;-KZR"F=(^>$>$HDIP)[V!3<X$K%Q0B:;
M/PENE! Z,PW9^/D;)^Q>7F8MJ+]ZF7)S(M[5?]YQTNZ?IR,8S&CT8G#LNOUJ
M?C.)@O1Y.FQ*)B[I /MT]M[S]AXPV [<L_^OPX]PC9SKW=G[+'9W7L&UWN+=
MG0.^^^&EV-_;_O;Q]1M0M_9)^W@??WQA\,?_=XC]\=]]^\&<PGAQ>^^ [.Y]
MYNT/[XX^[KSE<"Z<USMLYVL=O:6=H_=G'X_>??Y_6>W; 34.&*^]<P#GO?RD
MO98PX1()+0/BF&MD;3 H@J2%X?],23O9]&#-@N:<]POJ+<C2E.JH#7<QV22Y
MX I.5DE8:V=3>K=?O'W_YJ\W>V]V.W\]:[W8_?>_M__<?;==_=W:[NRT=O?^
M^?)=:_O=NVT@Z/;+SMY?->5K 9YKNB;VCQGP3Q;BKR?S^N0K!G*+U5KH9#CE
MU&21F"C.D^?)<;.Q]0&TJ9SI,XE\LOY_3[NC;J6]/6OUNCXK9YG:^EFQ!IZ+
M!Q46>SWK!D,[T?+RP8E&-^K"3-@AZ&B7%1XF^A=0;W<86B=V6-'C!2&'^"7V
M!B?Y>]550 /Z_^R]:5-;2;8N_%<4O/?<Z!,O2><\N$X0016VFXH2M%VX'?#%
MD2,("XFCP1A^_5VY)8'0%C9@ 1)D19MFT-X[=V8^SQIR#;"".6FY=3EZZRSY
MP!+/)R!G(ZMN]+SQ#T#'G5"QZDB+OWUH-X9T:B_@?;]UVR F!N?=!@SG%/2A
MJ_&='W<K.[-B]/&O?0MV 5S;&O77F$_[J?K;C4%48Q@;K=W^R$#-KJ7*&(3W
M[K7Z7T<#[<5SVPLYD><,A%.^];B7Q_6T-/I##PK!U9.NGUV]?C_.>\]*B#4
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MSA GJNC(L,EZ2$:0&Z_(6#3EOXQV83Y_S_O]M!M ( RKR/3AU'(#+/-Z3T1
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MM_J^W>T/>W<\BWYMW-?<_Y33\"SW*2@ED?=&(2XX0]J['"T3+$]),_@ZO_S
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MKSDOG))<:..1B!00GX)!QAJ&-*BZ07(%"YF[."THT*+ ?C5@O_QA&H4 'D8
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M<Q"NDZF=3-T:J[R3J8\C4^<8YH'F.S;6D9DNL66#ZH[LZ)8B8^62$_B^KY!
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M,3ZW8T*!'PEP4&;X!=AT?Y4)11UO]IC^KRP^9F&"U1F1Q*?<\B1Q?*/!AXM
M^HJ2DO!EH7G$\&@[?H ]K6T-MNA9OFM8K@OJR OL4 L#XYNEOKC=IE+U)S&7
MYMF)+UZK=8N>=1AK?6Z'S?[]-(N:#Y)_3[B24YT& LLW7=^T52PZ431BJR1P
M'#TP+5W5%??; =,;*M@GC0*9%"G[Z7 8%5AME^\EP3ZCJDN:^!'-#Z+<C],<
MO)<+F/%-G/H_UBLMM.-S(2V^7QK'!\? U2?1EU^7,-='$R2$>7QQ_/.+=FA\
MO=A3CH>'QNF%;TY+B].#R^OC7W]%Q]I?WT$RZ"<',4B('S^/?[W]_N5B$!\?
M?!Q_N;@T3W[%F*EE'/^Z_*821U.P/-8S")H*8#XX8$;(?NCH1NA9IF-0+O*!
M)6FPAT(W-!75\@WL!Z(;NJ&Z/G6H0D(S]#67JB!X*<C@$:"BR$IPA/9/CX^/
M+HX/3R[.I;V3 VG_].3BZ.3/PY/]H\/SF8#"A#R8$@<<1W?//[5>2P]\/]!\
M,#D,PU,=WU #S2.^J7B>@M=4WNQH;IQ7^9Y>DECZD*4^I6B7[5:T@D@CDH%F
M*5+IBF116N92S#;,E5+>E_9%W"*';41AY(,203U4T"QG(P1 >UGDT4#R:)Q>
M]Z7/& /Q4WCZ%XSO^UD))@A:$%)>^H-J8)P1?%,)X(&Y;L6 %*C#@)#\N PH
M_X!((#1R*<HE+P5%-LI2#T-C3.%EE.1I K^.@?H+L$3@"S8YFY*R"7$"#[X5
M3Q24Q3_XH*@:85M$R@A(J3^D07I-KVC6DZ)02M+F#7@&AV%/L950W#NN+V&A
M%):'Q_SL!#<@9L=7AE&"YI0P[B<&ZDM'(3X=4#RV!N14^\4ILPC@7VV\M<T1
M?!15V\>AV#.P3;XVEB8('P"&8)'U!@(6#0JX .8+JP?"Y_O2IR2F.!!NY#K*
M6=0(7\-'P2$!<X(-#K_"=Q7J:<3R#V&%&&.B/T?4%^6B'FUVD=9/U'/"$\VN
M&474N"<)/CF#V$* DUNG,!)2#(X.LS*=(@E4UW"8VN!GW#\+FTD#<D49VNHE
M3E HGX?O<(JP)8R>@3,&>@VX-X>/X2<6 69ULF](S"RN\P&EX,B1A8(U4A6G
M6<@J$Q)"L+&A]6T4,K#7B,DL5K$;7=$_KJ.@&%0G)JT7161;:5XA'FR@+&Y^
MI272IHJ$>)/!-0DOO*1C EZMOP=9M9H1N:2R!^3T0R8A+/85B:_).'_Q^^06
M87]3()V&!M_DZW][V>^OYTT\7VG>I02GE*9"-+"_B&(JKFM0WR8J& .4XAU1
MJA<XX8V(N4G7/!YNV(BOH@*F\Q<P.]\#L?$<9>FLJ2H_3\,T]\JK*-L-A7J4
MX"4<6H\K 7$&\&% P''.<UKTI*/$[TL7@RPM+P=,T+"G."=.OI77H '?3DI*
M/Z9I$04HN$B<7@I=X1=,B4;)(/*B@@M "HZ?7T?ZW^W_#8J&K8N?"8!>IB A
M HF,0)=>@?0+LW0HO3W8X_JY-2\(AD"$H)@6S5!NH;T/B(,7@ZC?PB *>1"A
MN!BFO0-4=NAVPB)09@(B?U#$.ZP(M7A0PN*97&;RN%F6Q/N!,EW64(T?DVB(
MJO"29"PTUBP4!AE$,?J^?"@?3)*PC&,\XDAR@!D[B6&:2XPB+ D\40'HX:["
M-(Y9O&,:*^Q;$/X1& ;XW9@9/&@X@%J4T'PN>BW%-4)OW>>8*./*X&@4*%-V
M8A736GNA<YC-9X+*JKS&OU$1$]35.0,D_QE)KZ)1 ,-U@OH5[,]!E 7,%@5O
MD1,XPZ='P:Q*D8+&E0$EVE& F0$41B_Y^PRV]>LIBW=PRBUS6I'A)/4=A5.S
MIAXS=(&ZP5C %=,$N,*GS.04.^'!%IC-!Y.)$QIR$IJ)(49F*+J_W%I":ZO:
M/ZQP>@&<<M(R1A*;.#4<P5XGK.TTH07)QE) AJ#2..,L2',1:&F DE^ B8-3
MCRA:^S5#U=)X%CP5<^8CV(&(,44LDL2U%KZ%WX&AV%YL1G,8"Z #]E-(>22;
M7 )<\V*"#^]%\&NA[EN=Q$98L9 ;HN-3 C(MRS%NAZ9@E"0 FH+L!J-?W+Q!
MZ27N_I__XVB:\D?S#/M _>-?0%45JP'I?>J?]Z4/7#*<I'W)Z3FJV7-T96(4
M_$>U_\"/.4=5@P$3#2+D_#+#:BG&^EZ6DB >"Q' M2=J@EQ$0X%\07&@Y9\$
M[#<?#?>,.:97L-!*95J]:32&H&E02<7D.B]!Y59T#4ZSD$UL.P=17F3(E/O
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MZSW\=2CHJT4B->9P;A[=X%[GCL04CEKZ"AA5H+QE!=YDD/])LR&&^H59_1[
M>HE'GH-".OCG_VBF]@?HPSA(LW AI//AVFB_DR?F4424?"\3=#5H31;M'?(
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MX4ZVYG9Z$*4_&)J:=$,$F91'0$BP"K3(D0(9PH*L1)''TR,Q\NEY:*$S/9\
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ML:;Q^61P/AX6Y2_2:]%#.Y^'<\I? "'PW42F;"9DI%#7^8!@OY(HJ0ET.N#
MX8).;8H"%K59->*'6I2_[W_HLPFJKRH@B=\;]J[\\'GG--... <ZP1B*/(K1
M?HW"<-$@1E]D C6VS\3Y0 OQ.MOR.1T5;;_A9EK8PP*6GSP=G.<9L=_WTVS4
M4 ?_L"8/Y,UV/&4L9.\,>=S(\@+7;*VMQ6LW86<Y4(L]K SKS[2V(^-QZ_0K
M"%CT!NNA;IH1TWUXS'3JR Y<U];[E?84*\HQD]WGWD^#:-3-:$Y.(5R\(Y:0
M3ZUA1Z39>4$J0#:GRU.$S,DX;\DTX%U28ECU/?&:@ #_;"*^NQ\!64Q*0/91
MP]K3(G >F2.-YZO*P'E:^TWT _9]->Y/;J?76C.O*ZA,L=DTD!OC<ISDIH)R
MU":N3@+;"4/;T(W =36L#**:9NA!2 FKL]84G==9:].-.EK1N:9#W42 3KBU
M>U5.S5%UYMK%YVZ)SQTK)[\NOSF!9KE.:,NZ;@>RH6JV["J6BV7: 0DL1??Q
MVM(;@G+"A%X7.<P+UG*4GX:")CK<WX![>/Z; 3@P5.++NF$YLN$:GNRH5B K
MCD(MF_A>& 8O7H<@!V=17RF7& ^5:GUQRBM\WJ3I#]2,H*I2G_LS3-$VHN?S
MS8<NDT*V$4I1G2*K+7XJPP*<5<*F*&YAG_)2#>9HS"T8N<,8JLM983G&;D1@
MIG/7>/AJ-S0]SP4W>V!R7;'87%4 Q8FPR;:LK27,76QIV\D,&)&ACL13Q1UJ
MZ%6,P?(Z)ROWN))G+C'W((!XG*G:"YSWAN3+NIUBG>;-6B4VPT]D/U[1&S.X
M*]\?6 (64F!<550NXI1I%@%B 49^=3C'TKHXW*:?X9!C660<H$V]0C5[KPU'
MK!]K 9/'&*;20=N'%5-'$W@\0/ H@5V.*(X$)K.AIM-5!;1F;%V,^9>)/Y-Y
MM-TD;C\8B=],VQ,G-[=3M]$D H,-@*XO]W+2K(5O'IK','B3B!SQX@U&>RUV
M$(5T;-"[:'!A\IM<1T..\R7_A->K=VEKRZ6MZ9N?MG9G&MI4VIJN*6[@!X%C
M>:;AV/BNI;N*0VS3M8AF+9VV]NQE"B84X:%&G7@T*UETK=*;[IUZLZ4%Q")F
M)J@TYXV>3"5C6.N@Z;[K?JB"*6V[OJX9JNX[#GQ"/"5478L:AH-))ZH[W9_P
M#C_F X?TGI!BG2=[BS?S43^]^/(MI+:GV":5J>KKLD%]178,SY4#<&Z\,##<
M$&^ O)COR<Y5'9-VTYVVRE0-2T65$X5MTW1Y$R7NADW2 MCDX69M,]Q0YX3'
M+P7Y06O!P\];6JTO\,P>N#!DIVEUB+/(:')9#.K#J:J#P>(=*W@V1TNR57VK
M<,(R:=H@X)Q-O?_,:SUQA)NUFX((62>$$6[2HR #L/<HBM.LKGNJZ$>\4)U_
MBK*(%OPJL?NIZ:N %5<%8>VBXK&4#](,QN##TS@:8M8GQ48/!4C3>,RVUX*5
M:.C.EL%-_R05Q\,S+@X^6LGSVMWAD,!S-+QP ." @[</6,6V>;I#M0R)V_$E
M* $L\6@_7\W@C:7#X[T*'7'3:^)F\/06/$AL@%>=1<**HN&(,'NUL@LY#3:%
M9W5;#%H['^RD&7#"3XQ8AX[V5D":P+IW)&-C#],-,LSO9C$: ".V5\0C+H&,
MW9!AGR?/BMYD$7C,L7P\QE.!\_^6D>?!YOFI<17F?W,\F>G]5SI(<J!.7G0G
M?N/MD7JM' :T!@*,FW&Y0L3A#8@+$)S"(JE/9+@)QOTDE\V"J:WMI,*JNR$>
MYN<\#8 U':!@3+T[^KM=0]EZA'?3K9/#"6-0GJ:-"9$@",@(I,:'YL2+U[)*
M54^[EY7PXE*CV<N_@-LOR26?HUJ<< NK6$1&1#=?D<0\<Y5#E3K'F*] X4UJ
M.D38M+[P*Y)LR0=\1-21"T!6_30:-/BM)G<])N1&0LHOT/+BCF8"DW/SY 76
MP(/U/A9&*C8S') XQ%<#@#X,,BK!M@")F>6\RQ,WKV-@)"8\020.TIABLD96
MU=R)-U'L)X$\(F/XJ1FFC?T!+UV(DISGAE3O7T5!R<\1(YY1UT(Z6[G(9.NQ
MPRB2<$T\5>LWIR;T2&AKBLB7JIWBP3D_<H^RO&A_K+4<D&8%G 'J7+P:ICR+
MA,OP=%3P*T6*EB/0,!/6I&* JSY1%1C@)=I92Y>RT>I35,+S]$=EP1-7V*"4
M$U;.6WGD$P258GRJB8-/+R2?C39/IQWNAC#%,DR25+4,LR?Q(#@GDB(F\R5Z
MXH:7^6*R.4FH12/"^;QD&5U9<SS /BU$:]2&-7OX1,)-\W."YGQ!TQZ:'7NT
M2(CH9C?!G$!N-.84S@[)P=*/\;A#2"$@'C#V0=!5_;VF2)-3$1N]3=@M:B5>
M>C5+*@/1!TP8+W<1*EI* AAS1IJ9_AZ<O3-$.A'D4V;(]')N;B _IFH.K#Z=
M[W&:>5FDE[1@/7/;>0#204V_K>9.MU+X/%-@DMSOT^B&I3[Y/\ VN8J OJ0/
M*99:B\X20B^\!:T"?P&T\!-1]':$FH/U@KU@BKC)96J-QKYJZL;:?#1/0?6E
MV;<GY#/N"&P? V5E$?,DF+I2 WL67Z,@+?/:F9H&>J7Y^?NMO)\@RD=83=6.
M2<T<ZZ!G<3@$,%Z!:&AGY^_!9SA1G1G)DMTQ6X/E<U2T Z-EXR9KLITO.>X)
MFP=HNCKTN<WNP<]N-W9JQ<VX.W_N[#W5".4&)71!KXAH9^K3DJ?L'H&UBKP#
MR\'$GI4TTEMFW_P%MA<F'=[$K+6&PFT?TY^1GTYIJ(+ 1JKBH^8I($#PH1,Z
MYBG,).8D<,L#PH+/%S'A*R.=-T*[T4QOS;8,G=ZVR(YRZ^!7JZU=;6ZNW*>5
M151:^I^;$^TP%\_HKHZ#5^WAB9Y(.TCUG7*W[U9$7I-,]-8-R57*NN0V2]V-
M.(JP<:7W$?%VZ.Z^*@EA,K)!&F&"2+WQO$4(SNG4,=VE@:XX- A=0P\=US8\
M736IX^F63Q1K[HTMRV02PMYYVLO;J#MTN?W0Y<?U\7?_FV99IJI;FDQ\G<H&
MU:A,=&+*@6W8IDE=PW?L%Z]!$LP>N<RU95%R5Z&A*D$_KABC\?%;4:Z_0?Z0
MH#;!>I7]U6-1N1A4!QOT'#Z%48(;(U>+C?,[9@"(H216UL@4Y5"T/@!6H6@&
M_X@"4%W@/&*FD'BM2%,69/E>HODP/P@U%6SBAAZ\6UE_?M78J.VV3J:['4<Y
MMB..,,"#EVI1$,2L2Q*YA=UJF?KD#%>E:]9(6>SFM6?(;\KQP=XW1W<)=0F1
MM=#P9<,!?G-"3Y7U4/4]U;<TTS%>O-;,'@CW.7<N<N7:TJ!M;N":OC8HVG&
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M"23.O3GB-,$U7(Y7W>9-K+()&H]QRCZ-8^D"B(^,[MSD=O!^>T>W"0'+$$+
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MG7WS7))X+(OQ$-@?ZL23+/T.S^<]H#ZQG #^]@M^@1?!%)$D)SZ_AHN1>#'
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M"G]?YD6G/AFR5Z](P:/RMK8FMF:@,/(.R>+?S,=T6=R*Q?Y!R&.TD,2*\@H
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MFR"&A$*"&2<*:<<4RX449> _T;C&!RE6@1$>C'!!L:%AO#07? ZXL8A<(GY
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M-.1V=,BDA#G]:(SM;;V>$Z>.F%.2R["GU7>S%+(.,7IZ08 *RR;[\ZD;OP=
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M#V$0JO+.("9^&COT2+24?B>!T"9[T><3NF4[5HG52=A><RH[$B4-( !!J_%
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MV=!>K)4ND=J&V.,"AJ.$>OM(_FK4ML D;T)AM1%MTFJAK,U5!?#'5-D__0K
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MG>Q%!Y;UC&)WR+#'(;FS)HQ("MX-MTW?R#&T^6@D&1K9!(79?@*3_GX%4C_
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M,>9;NP<C$^RWSJ\4-Y355'><:7 PPN*+S+):<BM:.?GJ<3'!\GO7ARQU -9
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MPA35/"_Z4,)XNT%7.Q(\<W:W6:&U>_#^X^'>K_29_=_W-E&N]>@#-U"[M?R
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M)BFY87DO:<DO7J\_(CWV7W_[_U!+ P04    " #.@*-6_HAK[Q5B   ,+ 0
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M/G(ZB[/#R65RVMY?0[2$:>0\Z$A\3!&]''1P'*!XG*<B6LJ\RZUB3/B &SS
M[ZXYL.K9%5GP0$W1 ZQX@AJ;BN*LF.IW \_-[,-W\]VQ%:C!4F'3YKJ^"Z3F
MOK^J(.M:W75T=%?AE03<F_9%Y#'2) B'((D,3A(;%!"=?6*H-R7:A0YV2^NW
MRMJVHO1UY-I!5N\EL(]SRV<@6+!.1H7.;<QE$V,D>"U(<N"DQK_EKO9EU2T
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ME>J/@5\;9O_^;57^W/5VNE54!_&0%?*XS,*R@892"HRFOKJH# ZX5Q.;N'3
M: )=>U;!0WCZ<H4[Y4@U@>^"8WQ_XUXF.<N9D4BM1D9S73S#1%1I]&B8!S0#
M*MA;N]2@O)Y2'VU7OH9P^VM7W@+4:VI7OHZ.VK4K?X* >],^TT*$Z"71H:3C
M95YFA8M4$JQ <II":&=Q[9;6UVY77EWIZ\BU\W;EVB<;C(_$:2C=V*,B08$G
MFDJ6*#665F_NLI/MRM=2RH/MRM>1:.UVY;\<_'X)YMB/8)'>DC@SO#1A%!S*
MC+WHB8M1$"<416LTZ."7L@]7M"F_]^/[M_4WD'=355@5W\XE1-,WPS]F?O+M
M?+%(7)%(B,I(Q8E43A%GN"<F,<V5X$XN3Q5X5(5+C^A/C;6$?[\N-Y%<A_HL
M^4LCF/C];\/Y?Q>99^@D*HI>8O89T.,H\ZABY,11$!F$R3Z*=?5Z_Z->C'XK
M2+)B]N8RNG<PC<T5^:B*'(2P) 9MT47 15N#?P3M8T14$>FXKGIO/>'%:/7I
M<JN8D+D,ZF<8?VO.%PQS G<0&@P)HG3]R5823X4DEDN?F$%;,*1UE7GK"2]&
MF4^76\76KLN@#E&@4U@P++G(54E+,<(((H-BQ 4\%H(S6EF9J%)Q767>>L*+
M4>;3Y5:Q8>HRJ.-2Z8T_6Z3NX^8NLU$$I$M$.B2;+U,>LZ.:I^1%SGQ=;=Y^
MQ(M1YP:2J]B/=!G5R>3LFT^+'<.[D*21@F250FE!DX@%W#8R5R$Q@=N(6=O:
MO?6$%Z/-I\NM8L?/.:@%HLL0Z;QQQ?'YZ>SL?Z[.@>BI,E&3-$]5\(X2;SPG
M0+5B.2';EIOSK-#JHX]ZWNJM*\F*'3=OH9OG_N+*+R$%B5N%Q8U#:$HOO?#B
M< 4+T>EY\6X[2_?^SW\9&MU 9A7;2,XA'8YC,VH^G]^.I> &$;QA0#05I9^/
M!N*9"B5WQ&GN% NI7:3HWH]_MI&BS855V^-\"Z/1"9+)?SV_.@J:F1_=_?E-
M M/$/)4>?617NMWK5/J.1TJLH F)'!V/[8S>)SV^YW>X@M*:7B5>._IT'V*(
M?C([6Z"S ;P.)A-P("YJW;Q(G'!IT-&V*;:-*C[ZJ)YUWX.R'N/&TR7= P_^
M"Z8%WL*>  NII#<02]&5D[R<:5SA']H8RD&J(.13>7#[4:^.!QM(NO:9<8*0
M8'058TO6&<71B)2,HA&IF"->6N2ETDJ"]ERZ=F?][<]]WKO\!C*JK:X/PV\P
M>3><EKJJ2SA,)^ 173L=/4/V>(O$\8YD 9()EZ1C[<(<=S_[V=IF&XJI>O3X
M[7V> P@N'#.1F$05>@YHY'L#^$?02@.G0IJ6T<;[/K[G5VY3B3=5Q57]SNX*
MT?0#I.%7/_TVG!PWN9F&,_QJX;HYYJC0E@0ZKYT3"3>&3(F0 7_BDA:QY<5.
MF\?U[?UNKI3[=5Q+HAWJ_!K7[S#ZZF=SL N6@U.VC+"4.96!.KE<9'A!6/3.
MEPDH&=96^@//>S%:KR73VB?L13@&$!'*=?KV]^'D;+K O+#;C4XT"4M\1F32
MH]'F5>ERG%&K1G"5P;12^>//>M[JKBS+ZL?R MF;.;*K;]_!:.9O@ET8D,%2
MPZ@N^=\H!\=+*\*(J"4"S6"M6&X8L.I57^_!S_DH[U#$U1,VVF+]'4Y'P[1P
M!^91V>S+?"N)D UZ M9D3_!X"@F<TUJ%NJRX]?R^=X@N%?HDYCQ=&]4MAM:0
MAQ/PB\M6S6Q("L\YE32ZI>BA$C=O* ^96Z><HYI6YL^-QW^GSU-UL;7M9WZJ
M+HY/*2G%<[CT9"B5WI0A5LT(,T)[7!=5IF6.PQ.>_NJY\U1-U#9D?H<_1F>3
MQ18(UJM2@D""+295D,52*ZU.(UCCJ)0.VEVIW_K89QL+>KIP:N>=S>ER*^1\
M\R<W+6[&:42K&ZWB@%"EQGTHE/PJ2 HI;&R"EG=RK1_Y;-7;C5!K9ZG=0KEW
M^F8XO6XQZRV'9*4CP=& ^Q2:V5[H0*A363(NM<CM(@@//*3O 'PW2EFI]PTD
M6ML(O(7K0VF#,!DN%BMP-5(H1JPJDY%TF6E$K4%P7H-5TN(+L+ZF;S_DA6MZ
M XEV$BFZE<6SJ#J021N>'/&>9B)%,,11DXE2(BG#&&<M0X*KGO#"=?Q46=8V
MJXZ:<S\J788ONCLL>ELN/$W#=8PQ$24T(DO B2V-\Y+F"KA!0B[W8%ZAY0<?
M\YQ+(2L+L7*-\]78D9^A^3SQ7[\,HQ_-JWM=H "968*&NR"2N4@"RXY8GUAI
M+ZV]JM'38"6 %]78H(Z8*^[=<U 7W3!N0KKD>1M0%;L;K 32?W>#2HIJNI)R
M[==_)3C 0XHKA^ <DERJ;$H&;KF<H#E0[Y@S^OFI_H$6!WUJ?AWA5M1X;,[P
M_#D?_'8\X#DB=!9(SB!+^DX9+.KQW/%!V9R#=T8]H-XIQ+]];K[]=/F)%QJ^
M_.9:P=?/Z_< KR3X9B.I56Q@4-:T?S9IOE[=1($2&1]8> A$&DC$4^-(!,\%
MCX)&TVIHTB,OY\UG/F<-;B2_3ESC^62-L;\8TK3(J-."4C"11$D15)22A$ C
M09N06UW:I*WC,-WSA.>LPGJB6VE$==EE<]$1LHCHH__O9K)HD%>US^;C3ZG?
M:7/-E2WWVC3),&&1!\E++H3%%Y/[K'U6)0X:[_;:?/QY&XZF',^&L_-_#A-<
M/NG60SY<-<0S/J?LJ" &G?URTX'V "Z%"*=I%#9S'6H/'VH);?/1C.,(Q4\M
MW#@:3O_X%9TG_('_#&P T2IMRMT.4$UDL(DXP1GQ4C*P3N/;ULHL7&M*XVH\
M6YBYU $_[HYPK*2!#KIG'L<OD,Y&<)CO2.+-^>T7\LWY$7PM\\?'GR\/@^F%
M%ZUCB,KJ2%0JU7U":&(C*RV83<"5,:I<J]#".A.@-X?=5R_./AC6MQ9WH7/G
M[67-/3L(0E%#+5&JE+- B9EKQPE/5BG#+-HI-?JDWWWRUF:.]ZWWIIK\*T<^
M/OE3E,(M3 OSM 6HBL&OE4#Z#WYMJJ&F*_'VIGL>*-6J9'=FA(2.A"(AH8,O
M*$\FVB1YJK$A]*SS!Z)>O:A\':G6=K?W$,9PVIRA 85VW6<8OVTF7Q?-(AAN
M95R:,B&D)/3&TGD),J&.Y1R$MX&VRQ%ZX"'].MV5=-!T(,#:#3W?^DD:COWH
M%_"CV9>#<;S$9"Q+0CL\#@-S1%+AB5,1OS)>BC+1,B[WXEY5L7O_ YZ]0FL(
MKO9;^C'^ =-I<Y-;!HR#,FU6<U9NT9TFWLI C,>]*;H0Y?(%Q H]WOWL9Z_"
M#<75P8CN.R[KF_,W,(Y?3OWDC_FIHLI V9P06J)E"*:AQ.6 (#U:C,$*=&%K
MQTL>P_3:C/!.=-4+EQ;H+M^;-OC6L= WXM1M;/T:[=UH]%&Z5%!'!]W;'\4I
M=7"".4]8+-LMXQ'?F1"(IXYZ*B!D4WM>\G;HLL+>WPVVK*.%3D;?/CBP:)%P
M9U)P$ Q1PI23V:%A:YPE27LC0?F8EYM/=SU+:EL)ZG7UN=[TJ"<HHX.(]SVO
MRPG^T_F;$J4NPP314O:E%4I*F;@D%#'<@ ?CM1:U9XX] .>[0;.9ABJFSJZ$
M5H!=OCEMH/5EQES#VAD+YFDJ?(P:&\J_#[OE!L1,97(NXF[*2P]BD8%8R0-1
M*ABE.;X8[1)]=ID:ZULKG3-C';%WP8C+W?(.Q,L#47%*%8N>J%R&RJ;(\$"T
MFD3#@@H6C,S5+^$?AK0#=LE3U;=,BXJR7VF,5$PU>K]W</3[WH??]C_N[QW_
M=H3_^71RG2U3QF[.IGZ</@Q]&([P6:5*Q4_/)I#\[+T?3G[WHS/8( FIZO,W
M3D_J3AK+B4N4:1"1!F,,6L#6&\HI_A X, M@!U61;+:=7'W<Q5/W[GWJX?@(
MXMED4F:UCM.G9CQ9?/O&3X?3#U=I!U$FR1AHPES %T H3FPHZ2A1,6-*.JSR
ME3>?J@O8='.^P'"MHN&T)# @@KTPG7LP ^D4>.XEX3JB7+ATQ/%L";K-.2@/
M3/*'<JN?(J%'0?6_06^/=<M;>EV-=>!AOH,P.RX+G\MF[QN^\\4G>M],2EGA
M]0SE&"=GD.8)L#"=#3SE'D!*XO#0(5)&BDYW!*)Q0Q(A><UM[2#%TY#V3[[*
M*E\>:-R]OCJP*O?_=8:^^37N]]\^#=&]T0RD!V*$MVC.6%>*Q"F!S+/S6C#\
MA=IIK/?@>&D,V5C6'5RK(#UA^'G\%O=7&,?K6M0BB'OD,!"V5+L*2RB4\:[6
M!A)*SV EF C&<YYHKGW0KP?QI;&F2PUU$-M:*8P!+_\O6DM,C+C3E215)XTB
M+AC'HX[2I-JC<U>">6DDJ2/UBEU]%L!NF'</K9TK*7P"W/;P/Z7??R26&T:
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ME_ZRD0@:A&&.!25J)P6VP;7%^&DMA;8@S$;:Z"!WX,9+<_7E+T.8X$.^G'^
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M': ;OF1<207$\ 1H75I*0M(!CP0FI3'1,]&C?]T?S1XIF-I5EJVCKOI79[<
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MGTZJQY/-C$(CG30XQ_P(,RB#2T[&Z0U\AYO)MY*&.!^CY8TPFUUS8R!SE=#
ME@O=2I^(%<80=)@H5]Y'MGE%7H6"VB<A'1-/:DJ_06G=3_9"G(Q+7=""M!>3
M8O-Q7QZ%F^)M8^ &V]_DFJ=RV33"1K?+$4G+N1NEEK@H-#4N<;8YG;">L7TI
MZ&,BV+ :;-#GLTTT=SF]0"/G 0114 )_4:ZIXJ!)!I\I9]&;S6N:FNSC@R;
M!R!*+SD?.@V^>IN3V0SF)_'/V]'L3@\E4X3101)@%(F68M2@ D8A*EK"081$
MN;64Y\J$V8;C4*GQ2AJ>5)9T@VUK$],R"NV"JE&#P'9$AVD/Z*^Q9RC00]S#
MD2$R;50$P!VM#/Q6HMA**T@2W$@..63?*7/^2DGP3&O 4!S81\JU,VY77V]1
MDC^NOF"H]0UNYZ-X?TDUC^A$)TZ$15.'.-"AEG$QR2AHAG^,8N/<?$?2;><2
MP[N0-10PJ2Z]?=L EO]<?@0_@__\C_\'4$L#!!0    ( ,Z HU8]F7YH'_\
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M8&!(PSR&@B09$HI+(C6(3>W8P_.,C2[68H)')2<L2FW9:$DMZ\,>@=6,)#R
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MY=F#:NT2Z.&+W)AQ(U#XNGQ\FNMB1HNX1A*B-.:1+B24"(@P2B%.PEC])*-
MTH0G%-D\W,>G&MN3OAD]W8@*M*R.(:4=")L]]'YPZYD!7"&S?O!/H^&)!3HF
M&I023BN\RP\&=SBF4I?S@A?3)[T=6F?QO?O&ID]<<)W7<C5[4!,VSM4;^8Y4
M95'>Z_+,M[IN>UN7:!(BE D>9#!*A.(5G9>B=IP)%"AGN> 9$9%5*UTO4HV-
M@C:5 O5**R 6:K6E;L5"%_ HJD5M?+;6%7Q?E.VG]7$?3X\+;49O@R]?STRX
MM7)KA<"[K97;T*DY/%XNI%(+-'I=@%8SC]G3/H'VE3?M1:9A,Z9]PKB7*^UU
M\ 'Z6=V4R[XJNL7*3C,DQB4/>(AA*BB&B&42XC2)82J#"$5,AE%@UPS/EV2C
M8_NFN=&L;-M9K;I9K1M<]=C.JG,%#2G\-=:E9QH?KIV5 F35T$I#\DHMK4S6
MY35:6G7*-9):&8YPGM72RF@"AU)\S1G5H@I3??GPIJAG#\O4Z(@I^UP(!L,L
M8A#%/(9Y'!'($BH"'&6YC(Q:F)R::'3\O)#.HJ!;%XS=K.H3G$'.E9=B:I.U
M%=2E EX78!:%[CP!-U ].W< [0K7&:#269^NZ_[ARM 9:+%5;<[D^C,"<?82
M8MLO*\NS.(^5U8N2-(4H%3G$613#1"+!PS1):6;EW^B8:VP\Z1I^<P1),^O3
M$SZ#4.6!E#1O#[H%'C[#<([,-'P@3K?*!T-Q3MQR!C?H;7HEOHJR;N*!EZ<U
MNXV +OE_/-5S_:)I6@+=7%TO3+\;N3;^/HGYC;PCWR8B"A,:80PS+".(U%<.
M8L8(%#) %*5Q(IAE*&]OLAH]>0/'!&^K4^MCR7)UIGO1_#R38$Z^@>+AD;2Y
M'/\0-)NX?P@N@!+F4>A*36)JV4&TOV^$!4.^VBH/R:];2FX?25_LMXM;Z[K1
M*%#78M/ZZM7?W/]_:K\>2FO/5-WGPO@D^E[D'/XUT2?<!U\RO4[HZ.)EK&D1
MHF00Q;/V./Q<Z?+^34C6?$(QRW.* LCR*(&(T@1BH@L>8Q+A( J(L"QSW#G=
MV(S8I;2ZD^A"7$OW:S>ZACY5;YCU?=ZUA&LMZ06@0M&H:#RA?S:MGC6K7E6"
M%_.F4O#%(NC3Y_&6$6"^/)C=DPWKEC12?,_7:':7&[^\^\^G8OZBB6]6JM$6
MX2YQ((5((P[C0)-)EN:0<A+ ((E9&$=,9-BJ ?+!6<;&)JV08"6E8Q31843-
MJ.1LG'IF$'N(K,FA$P)/G'!XCD&IH%/-70;HOOC,7H4;,4CUIUE9:0NF*LK[
MA6<'1WD6D"2 21 (B(((04KR".8AS;CDJ434B@H,YQT;.6R>'VY*Z]BJ\ 3H
M9FS1 Y0]\\<Q%'OPK5F"X[MKX8E97Z=QH1D41WL7&M[N)[Q99Y1HLT=79%D\
M%4&6X1C' A(N)40AQS"/U=XGY#())*69B*UR&$Y/.3866DKH4,/) %\SUO&+
M6L^$LQ?L? &V,.R!>,SQZ2G\^<"$KQH&?1R 4^'0'7<Z>E.:LX-#:9Q,4(&9
MXI8\9$BW*4001U)Q"XY"2:(,<1399)H=G<F*4@;(.KO3<UAZ38ZB:.@P\8%-
MW[Z21:GLGE-:3T+ARPMR=)YA'2"GU-WS?9R\P;[]1KN;^BCF7V>\;>PAQ$:1
M>"E%)()0P$R7XD$9Q9 0967DDL89$:D0"3;MR-$]U=BLBU;"MK:A0V5^ VR[
M^<$O8CT3A#U85LT[S' XHY_'B0D&:_%AINAFUP_#.YS/6ZHGP;_,7LBT:7S6
M>EDO2ZZ+@2S.!;(@"I,T(C +=? 0U86S\SB$E,:QP"3%ZC_+4Y>3DXZ-+-X_
MS14-@VHIL_7!RVF8C8]?O(+7_R&,%A=\.0F<R[F*,1+^3E=.3SGT&8LQ" =.
M6LSO=>F=?OW;(L91GQ8O8^>")$I33!#,&140L9S"/$@8)+$D*)988F3$)L>G
M&!MW-'L.H$2U:;M]$+MNBO"#2,^$H.1;AA4WT2P&@8:FZ-AT'3\7I:':BN^B
MY:M?>)?^W0W!#]XY8,?O+LFW6WIW7NGO&.GS;%JPE_;?=2'C+)$$YX$RE0B5
M$"59"$D042@S2J3DA*9F&2G6,X^-_39<"IL>]?-/D@[C[GZ6=#::@YTF;0)Y
M 5J)P>^+_WLI"FV-5X\'3(?G??4CIDXX3 Z9N@=P+;J\'<O7]MY)LCQ))2(0
M2:;^H6&B3# I82J2$,<L9*$(;+CIX"QCXZ&](%NG+D>' 34CG;-AZIE@K!%R
M*+W<@8"W^LN'YABX"'.'FON5F+LN=GOLEZ4+_U;,OUX]U?/9@Z@:W_(G,9_$
M89@',=?1+3%2EHD@$"<BAG&,TCB,.4KM>@1U338V$EC*"DCC:;=[]CM1-:,
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MFP]/^I-GL?QD$F:YR'F>*%,%AQ!1)J%NM0N#C"=12'.*F5&IP+X$'!O]+'0
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MB6>+:&^7U'83T,TXW#.4/7/Q$L5E9W:-9EN;8^G*]>Z>L #($T^:S#@HWUE
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M1"22$LXMVZ1[EM#F41RFL?KQ[DM-[W3]3.KVZH6R<5GSVS]\'_[0>'/_(;X
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M&*640)31&%*) AA1+E@>A#1)K(K1N8DQ-GI47]G,,HC##7XSNNL?U)Y)KU4
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MOD@]VYOKC*(+L*$B^%/I"#:5!*V6>U'N*SU!H^C%1E;2;YU+[9Z,U,=2^$Y
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M$/U8=-@K!]D#<$A$#D]ZZJ%MV6TC#?ENO.#ZC5O-Y2A5.*UD04'!D YHE%2
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M1#275@&877=#B[2:]<S&XF3'9)MKN3Z =Y-,>!A[61'VBJ"#'G90)'N2R.Y
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M5==N=GWT.I<@FF$@<Y$!7* 24)'G>AU<2E;BHN3<<:6UU_[0^&]'ZMAO!^T
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M2>=47SR A]J:V/_K'[6F8%6K"L2>KD"9*5XEJG8)LA[@+>CFTPF,[3C6X%Y
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M<DBC+(<1)[$4&NQ8Y$X;Y([.IL8GNP*"\TI<L#'R@D?Z[&YZ=8)LN=<-!-W
M9-*("6HY026H,9Y:40/N/BT ";6W[.IJW)VCA=(G^T*;9WKO^BYN/BN+^)9G
M6:I89E(LF93E*9>0<FV<9)1A5F"%TQ1[[O&Z>YX:K1SL+@Y.>=;T(*=0LY=P
M=/^R'Q'G+5TXG,?<P)T<I+E W&>/9@=7^!W9E7Y?:O]E!T?';LNR <_$*O_Q
M--\\GQ09YXSD-!(1%#C3]@]5#+*DR&$L4")RS%G,G/([G>]F:A3U:7.O=P./
M3VPQYXMGH"U.(>O2IIMG[_QP%Q".<RICQ10L(LDAPB9SC2K,];G*DEA;G06U
M]/H)A_$X_C^UG'ML% 1/.U;OC]' %'X"S@ [T6X00F6@.=_)N EH.A4]R3_3
M_6T/1YI7"8Z^RN6\7/U]6=&'%-69V9LG^8EO2MUZ$F51\P)G&4]5+K"V#'D*
MD9(%)/I?*(HB%RR3!;';<CKW/#463G[&T7\%M?1@*WY]#@VT J#1 !@5'-Q#
MG$:CFTX&Q7A@AG&"U\<-QPEG!V^<H? >R2DGS&OMYI[C UFGEXY3@^,YZ_CH
M>>"SX]5 S_IFZ[WJIZ^I?E>X_'HOY>:#&5/]*KY^WGWAIEQ6*?%-;,GKYZ;R
M9UL.5'^W.6N(N*!(8IC&-()(4 DQ5P6D/$M5BK+"U(?T*8\67-2IK3D[%Q,]
M%W>ZSD"C+:C4!:V^,\">][X'6IV;2"R?\XL!7PL[TW@:@SWPXC?J./L7EAML
M"$+7I0LOZ,N4M1L,\(M5\8;KT3=">?58KNA&&I^ID]VUXDS%25Q EM$$HDQE
M$*<%@QE*:)ZHA(K"JKJ>56]36QRVPO8K%-"-<$84)5@QJ%+]3Y51O<HB0A4K
M$A7++,F9VWE0,(S'.18:!66[I3 8<@.O9CO(COQHAW!?L,$D6$!X5U\CAX1;
MJ'T:%&[SD!]/?Y'?Y?))OM.2MLO"/^>;^]97HN7K/,NR/(JA2B(%$<DS2 4F
ML* BB;EB'%/JPM=6O4Z-MQNA@1G5G>GVAY8;;%U_7LLEOS>E8-Q8QFX4[-@F
M.+8#LXX3K ,PD1->@1C)KL]1F<D)AF.&<GNX;[JU=^6JJ?)7'_,5.4YSAA",
M#44A@F-(>)I!DJ X37&2IW:UFJ_V-#5&VI<-R!\F!Y&K0]5%4.W()@A4 Q/,
MOEA#I 6[H'GP?%['_;Q0(JX+ZE[.H'7I <_SSG(E]4;UEU)O(Y:F^;.&.4,)
MCF3"H.01AT@4&#+,,-36BMX%T:Q ;C7IK'J=&CU\+/5_?_[Z,[C;BNV]#[*#
MW?)H,#28 Q/(_F[H>09V<E<.F?HK U@E3AB%.H:SZG/<$S47&$X.QYP>[NNY
MV=A KY]_I?\J5ZWILW[]_$4^&O9;WGV5=W5&P<.8,,02F= D@5+D!419*B$I
MB*$NPB05J4B$D_G27Z2I$=E>]%ZCTKK>+E1Z;;<)CI068.CL^&[< 1F8#/>=
M0MNM&WL^'@GST58GT"HU4EA?7Y2#^Y)Z"_1"3J9] ;SL?=J[93>6%G)^^W:Y
MT<OV*R'T+%@W__DP7\KXEJ*$$H419#$U7JE2$R\E"$J4(L0Q23.N;(BWLY>I
M<6DM*&A$G+4_ ",L^+2TW#]V ]M-B\'@&ICIO)&RIBXK),ZPD3;B?]8V_5_T
M\S41Z1]V_-/=ZBB48J58RQ)V7_8SSSZO2BZE6)N3J2:)^%J;A95G]C;$^!7?
MS+]7)N$M1AE+$Q/Q2YFVQ4P",D:$@DI&1!8B0U1$+K:88_]3(XM*3C>KRA5Q
M.Q-J0!P'9I%6\MI@_:D5WB2M_S.H(P1V&1!V&H2SBSRA"V0$N?8^JL7C"<VQ
M>>/;C'?N]Y,#]FW)D]LLIW$>)QDD(HL@PD)365%$,)*Y*=L4)REW2U[0U=O4
MZ&I[>^2=V;D;7-OK_D"0#7[=?^ZN;;:KKQ0T^?MU2,*E?^_H:^P$\-?5/I,"
MWN(AS^K%#X]TOC($]4D=E]!\OQ125:77%Z;T^FGY5X6++"FR#,I"*6T;H0QB
M)E*(A<D?GT:\R)!35>,>PDR->=XOX:-9!?3V0#<K]<#<5\F-A-[O+LK'ZNA]
MOM77L39OGT&SHZRQAF)@1MNI84ZGSE3VW>D"/QAEAB[S&P#64.5_^X@R;EG@
M *"=E L.T:8;Y:Y7F]LF;^NG55,+J"H>HQ1GG,6:1A61$"6D@$QE!2RD_D 5
M*26)56#>I0ZF1HUMG=PJK68MIE-!GHM =E-;"'B&WQJZ(F--0=?4[Z(5_>P>
MI>C?=G1RL=E1*.*:4NVTO_H]]ZG\]FE5/LKFFIM0Q3$M$BB)$A 50D']&X*<
M8"R15)$LK)*P'#<\M:E;RV8_30] NCX]?54?^MRW$BO@G?XE77O,P8/F1IM[
MYY38GW-G_^X3Z(Z*[$+XY*_&M$XBE#=O69)+G$:$0Y93/14Q9I"EG$.%8Y0Q
MBO3Z:I5ZW+'?J<U4]'.1=48#5_(#HX!+Z+7].'3/]@'1'9@,'(#U"FZW1]@E
MM'T0I$<*; ^*N&-\NS-NW='M]LV-&-ONK.-A9+O[XWY'5?OABHL%U21*%Y_8
M8GY7ARB67^3F:;6\H>O[6\4%HVF,8<ZY7@.B1$&,<0Z3).,"2Y)GL5-V3?NN
MI[8,&)D WPH-5E7R9#U[_@(>%U+<2>%V].0P"'8'3<- ._ :L!>Q71T9S,#7
M)_8OJ7=NFU*ST=H4A?@H-Y6KTT&%ZIV.,[#3TCQ5ZPFJ\=+S!]1UZL.=/+GC
M'.B<R:'C44^5W $Y/D/R:*%G1H\W\S5?E&O-L>M7;%U="MRF/!&(Y1E,4)Y#
M%!<IQ!PED%*92,)9E"7"*R?'F<ZFQFZ[; M@3UKP6RNO;XJ,<SC;T5DH] 8F
M,'_@_'-.=" 2.FO$N:Y>)N]#A](7,S=T/>-YR[?4LU&N-V_KB+#;6/"",BZA
M3%0,D5 "TD0HR 3/L"BB7,;H=BGO3/6C;P[W=X?=6+WOI'[?3SH;\F:NEM(O
M/NX82LOK- ]D1KHA:]%X>P4-][NN\SJ'NKXZ:GW<&ZGSJIU<,EWX6M_]S_NE
M9H5JYVT*HS3I6G;N1#O^V"Y>61ZG<9PSF!-EKIB,%V/!<H@CH;*8ICA%Q&]#
MY"S+U&R(/5M^3Y?J"J;19L\);V^U]+8R^HRCZYYJT-$9;Y,5?&!Z;)^\(0V^
MGW*7Y(4V6-Z07=YQ^3?I4Z]:/NI.-_/UZW_,5T_K[:]O]$C1ZJ/F;E'_+*EH
M(XZ+C) LYU#%B!G/<6UDH5SOSC*4(\H+HI3]1827"%.CVEHVMY+S'L!;W#P,
M#N? W+@5&+P&E;C@+V#W6:5%\WFCQPS4FGB5O?8:!9<RV$./QEAEL8<;%<>J
MV7T [:ZB[=7RB%6U^VA^6&6[5TNAJVYO+4 :,Y50%,'$Y/)#"4G,<9]>9#*<
MTCCA1,9.[OS7NYS:*G*EI'-5[,?7-K<8 #L3/"RL@UO:5XMD#V)4VX,T>"GK
MES&1[0&P+TD=Z,CP9B7%?/..\BK*H'*OC%"B8B6**AS:Y&C5U*-H!&/CX<:B
M0B:Q4PJ=TRZF1C6UA* 5T<E+M0-(.PKI!\_ E.&(C'M\T$7E0P4%G78P;B30
M105/PG\N?]-O:E=AB#?EP^-*WLOENMI-FPJ&?U]J0V8Q_T\I_E8N*H=W.E]^
M*-?K3\L]>EG-UR8YM/YU>?=9[\=+\5%N/JEO],=M+@I,\UC"'!-SK8!2R#*]
M[8U8*@B*.5+*Z2IR*$&G1C-:+O"TU0G<:6W 3PNMSY]G8"FKT)4-_5&%"_'J
MMS]%U3'8GZ*9"2YZE.;<0RXNA^>-^QK8T=L4!G=@DOQT\WYVG#GYG'$U SNE
M0:,U^*5Z"S[4;P&3^KL2[%+HS0!5QLM$*QR.=(<>DD#4/9B8HRX 0X-]O(P,
MWI_OU?1W_3J7J^>]NLVJ(+%*90Q9E.@]KDACX\RM((]83(DLDBRW.CGMZ&-J
M2T"=]V&QK8Q-JT@TUZOI4RAMKZ=[ 33X%74CW3#EKCN4#W97?=K#R/?5%U4\
MO;.^_-7>I:SK>MD?=KD8CK+G91CG-,V%WE(R90ZW!&0L32$A12%IHG"4. 64
MVW<]-3[82W!84T-;_OV#;R(+AV&P(XUAP!V82PXJ6)]".E(^0EO PM>POM;Q
M2Q6QM@2DHXJU;0L>][_5#&Q.^]<?Y(;.M3G47G/E*><89S"+XP(B5E"(8QE!
MG"DB$T882ZQ*XEWK:&H$U4KG<(_8!:/%G6T@<(;>\U5LW8HY ZV@/A>OG>^=
M_?5J(.!&ND3U!]#MCM0"E<Z;T*[GQ[OOM-#BX%;3YOL^\;G1Q2"PKUJ%JGT#
M8?/RRHQF!8XSF B10R2QA$R9?U@BXYSA*(MB^QA=I[ZGQJ/1M>#&K0[ *.$2
M2>HV)A8,/!S2 Y.R(\A><;MN:+O$[@Z&^DB,?A7]^=)Y !S#>+T@[ [E=6MR
MQ'!>+UT/0WK]FO#-Q/V-_G@O]&LX5_.Z-.G'IVJ.X#A-4289S)E@VK26"609
M3V%"69SBC)#(+O7NU9ZFMB8T>::UM.!07%#+ZYJ1^Q+ W90?%+:!"=X;,8_,
MW%?0Z)&=^U++(V?HOJ+@:9;N:P_TC7=9;T/C/LR7\KTFH/5MF@J&B'&!4RB"
MR.3KISA-H,CUN\(PX9GPC&@YT]O4".*@LOA>+.=O1F)0B>P=E'(.;+L#P6 0
M#DP6O=#K$3G2@4KPV)!S?;U0]$>'VI?C.[H>ZE4F[J:ZT^#/;5+=*G_#F=#;
M6QQ1E"F.M>%!,X@B0B!6@L*,9"FC180X<[J$=.Q_:I33B ]X(S\0N_ LWNCB
M5T'.>D3L6&A G ?FI1;B5O1M[=M9FV7D;-A^\!)SKM"%+39GW?M+E)USA>9"
M 3KG9GHX^NWN<>OLMFUT&E=)*GD$69YRB%*<0IHG%%(>,Q4+*9+4JM2115]3
MH[(0OA9=T-KQ5"# 1KG.V(G9),X>H+ZE!1XA_<<N]#2^"UBWRF>]N*X\XD<6
MKY_6VM):KV_*!S9?5MNXK_*1KNA&+IZ_2%[>+8V3V+<57:XU9>D_KW<;!)$B
M)C(<08XS"A'A"#*21K!0>C,F*>=%ZA25U$>8J=%-JPO84V8&=NJ G3Y@7Z$>
MN[E>8VE'7V.-T,#\-NS@.)-@"%0#L60O44:ET1"@'?-LD#8]S[WF:WIWMY)U
M&KEMA<PC'ZTH4XP)A6&:I05$ G.(LSB!:9[C-,,XH=BI+IU5KU.CUCTON4/Y
M]PL#.QZ$6:%O>2 6&M.A#\8N83BH6YP32J$.RJSZ'/? S 6&DX,SIX<]*V<V
MA>R^E:_X?SS-5_*M_G?SO L2>/?]XUSO*R.)TY3"A&O[#XD$0_,1I CE.$I5
MDMEE/7'J=6J\M*WIN"D!K<4&LI(;K+>".U;1M$+?CI>"8SHP+^W#V4@,:I$/
M JO>_0-^?!^P3*8+2J&*8UKU.6Y)3!<83@IA.CWLQTL-UYE:F^<JY6T3-TA"
M$\H(@1*;I. QSR UU2%PEJHB3N(T8DY[5,M^I\9-[9)>59\]7_'1.WV&[5#8
MT=0   ],5(&P=:8J1Z0"D95MKZ/2E2,4QX3E^KCG76157:XJ.'A<?.[50[G:
MS/^SLN.:O*%?Y .=+W7KG]2[^9K3Q?^1='6;I%%.59;"M"ABB'BN-X!)@6%"
M$=-,1R(5N>7][B_3U*BN<B7\:56):D*JE^;(YD$/Z_WZ<DW'P0;,\OIRW&$8
M^DISO[3F<?G-695SF&_TG_95FX&M5F8+6NL%C&(!;SK#H1SJ]C. 1./>B(:#
M\.26-&#3'L$,)OC=D+^F#'-)^YFNJA#XQT=)%U(TOI-<$H72*($T2SA$1&%(
MJU!5)2E7*"8QL:KX9]WCU,BUELK,T,=:7$ ;>1V\YJV@[B;.00 <F!:-N&!/
MWAEH) :MR#,G5U][+!WB#D)C.E*T00!LW8(+7'#J#"FP:FB\0 (7O0["!YP>
M],PI<$_U._.9SL6[<O6-_C V^GV=OL0DQ#-_?4W74IA\)WJ-J-]VCDC!4JD@
M14D"41X;EY=<P1QQGA>"8Q3''E4O?&2QFC?CE\;X(A]U4_=:VK4A=EX^:&L9
MZ*T/_QVH<@7DP^.B?):R2D?UQTY/\%19:\T1YUR_6\O*,?!1M[X&/\UU&Q5(
MCE:WURC;F=F##=I(:0R,@+"2$#1G;(>%QFK]0*667(AJ]$QTQ)Z>>P7( N8X
MZ(%KJ&P'/B*,F_>@!T@G&1#ZM.5[X+J6IK+CJZ5X([_+1?EHWKG&&G_[@R^>
M1)6,OSKPU1;\YU7)JZOT]>8VH4QEIAXC(3G69G/$(8EY 7F4YC+#)G&@4]A&
M#UFF9E"WJE2I_<1.F;9.D>.%49]1LCV?'07[P<]L]V#?TZ,MB 1^VJK27CX)
M$[':: .,.I?7-8^CW-Z@!CO>]9=DY"/?WI"='@/W;[)GK<>]3#:_2FJ\P<6G
MY1=S<69R\&E.GZ__OBS96JZ^FUO^]\O'IXUQ3%J:/+$5S=_0!7]:5#]^*1<+
MO1S\05?B-LXBE7(109KEYH8^E1"30D"2BX+A1.:XL,I8,YK$4R/J713&["!W
M5*LTT#;S5FU0Z6TR?.XT!Y7JX%#W&=C3'OQF] <- +YE+ =[A2R/LJ?T8@Q]
MT#V==\*_0N?0XQ2ZS.=@\KY,K="AX;]8<'3PCCU+$-#UO?F_\1GY3A?&CT2O
MRYO5W%P9F3_HU?GP@[UOUDEJWR_Y2FLDW\CZO_KW>NG6:_B]V2U_H1OY5BEI
M_$,*@J@L*"RRE.AU,4<0HX1"5<0\*B(A*!>WFW)#%W;KXKCB.RV26R4&O!Z0
M&U#+:(QE;LJ:&P.[^D'N]'2LI3#N&V&WS$UWG =>\XPJL[IB_9Y&YOJV51;4
M7S$#?_3AX1,U"J"% ?S4 O'G&=AB 5HP@$$#U' $K#CQ(L,8JIK%N,*/6RGC
M10;FI K'RTCA<7V]=WNN97J_%%)=OD\_"DBNXEGJ=;Q- W_S]%"M[-]E^\DM
MYC%74G"]-)H$+"+B$*<<PUA%@N"$TR0J;%;*<<2=VLIX$N:_I\5>A0>'F]_A
M1]SB"GY2XSBF6Y/6%NS4O>#K9-S3N\;]H-K'3O?]SR?U0CCX$4SJQ1C)"6%:
M+XB;/\-HX]7I##&\%.-Y4HR&Z($;QGB]^B9^O)'&PWIA1/OQO^3S;<$5SB1E
M4#+]#RI(;'*I<YASFE.<)#&)K<H_7.QA:B?)3=K"1LJ*)'X +:=K@L=C(+N7
MZR#P#+S".B/CD<CQ@O8]$C@>MSARXL8+"ITF;+STQ9Y75J^?F^-#L\*^6\G_
M>#)<4I6\Y+$0J2(2TD014]DEAH3F!61Q&I."%9E,K3)^._0YM<F^)R?8"NI5
M4M0&<,<KFC P#DP*7@CZ7X=<QR3TA49'CR]S)7$=@HN7"A:/!@^>TGW2?Y6K
MFP5=KZM9(#.4ISB2L"!$0,01AB2*$YBQC+$D+0I1.+D;.?0]-?KI#,59 _8,
M*OE!I8 ?+3D,C"4]#0/WF*<#?9$.&=IT";/A0YA.>IY*J-(E2!Q"DBXVX4=O
MNQ/ ]1>YJ#R_2UO?YR@3"2)1 2FK/=PE9"FC$',3&JK93LC4P\.]ATC_/SFZ
MN[%EGW&V8\^AAVTBKN[M=<IH/NX!< W$N'TD&96! T!VS,@AFNR15O>TWN!-
M4W(WRZDL6,0@)95_9<0AC:6$21;K?:Y*<9%0Y\RZ%[N;FIE92>N12_<RGG9D
M%PZE@?GL8CG767/P']"GP0Z4D&EU+W<V?F;=JXJ?3:Y[_:E^=_)'YF.; F$_
ML/V5TC/51+&_TV_=+54X%4*EL*!2&W4L2R#)"(<Y*6B2$B$C):TCS7L(,C6F
M^:8'2U(CH=_-J/- N%V"#PGO2VY@+V;MJ+2I\G0 H\](@^)W$3WDX+S$%7/P
M0?*^,O9%UO8RV+G]%[GF]47AT@6N=WM^%N[>R6WE[/U--U,=V^6"TXR@%*JX
M(! I*B#!L8)1E@B4*JKB)'>Q;2]U-+6U9O_FH0[4,))ZG9)>Q-;.S@V!V(C7
M-/9@.1NWUY (9-9>[&94@_::LL>F[-7O^_ILO"E-MJ5;4J110O,4)I+&$*$X
MA3A)*$18, TA9;D=$1PW/+6)W_@A_%9+9SG53]#JGMI],!AX*MNJ[^%]<:AK
M#Z>+IJ&1?2T.Q3]UL3CZNT]-]1]S3MF&WLFEY/.%ENZ)R\6;#Z]O/C2%AHA0
MB6)I#"/!,ST)$8(TXC'46\2""51(SAS*J%_K;FI3<\_FK2HX@7__-YS$\5\!
MW=,$[%1Q*>9]%7J+O6!00 >>YQ<@ S]5XO[9JR#Z50Q=:J"'Q'*D#5IO3!UK
MG-M"U%W6_&HK(U8RM]7HL'BY]5,^G(SB2Y71?S7Y(I((%<W;36F<2!0AF) B
M-YEN*,19SJHBHE(;3Y+;N9XX]CLUED8_Q]E_!;7L8"L\J*0'6GQ0R0^, B[D
M8C\.-DP]"+H#4[8#L%[T;8^P"X\/@O1(A!X4<4=R=\:MF^7MFQN1[IUU/.1]
M]\?=]\ WVK)_M9+TIA3R-J(JHSDB4+\N$42%-L196B"8(:$(XQPC;E5"];CA
MJ5&XD0T8X8"1SGX+? #6]2VP+P0#\ZRE]DX[X'.J>NV #QH:;0=\3OS]'?#9
MOWMZP]59O]O"(4BE,L5$<UK,I-[QIAPR$IN,KBB62B 6(:?J4H?-3VWBO?(H
M3'P$F-VALC\, T^^MMKP #53SNL<RC'KL/%Q?:W.*G;B/G7^6WZS]$.YO#.E
MM-](5ITT-\>>O(ACCI"$C&4$(L8I)!)G,$VI2%%>1#EURC1WOINIS=H/V\+B
M1LY9<_GA=(!\!5>[2=T?K8$G=P74-U>@G"=Z-PZ!)OR%3D:=^-V*'A/ E6_[
M.#FUH3][ET_&'?,D=]CZ,'G88::QUO'JN0E)WB9'T>UMF[U-(Y(4F8A@(9F
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M4%'%$>5NYA@.NX&9I*ZPLO-,W8,1/-:?@K61W,?_UQY=!Q?@05 >R0O8&NU
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M'R%T0R;6L #,BG*4!0Y&2 +9L$B#933XW:**QRNNI_Z&<Y@[B;!G]9]/7:E
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M49'P:J/H72ZM'E+2#)AVTO,+=U8["+U'Z)2JP<+"]"K%T^31FL\&P9?Q.XQ
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M 6B]O5GVEIE[$BPW^8$X&UAFP'TI<76,@8\T0=2+(7,^LUS? 7J5I&:<HNX
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M9EF1>)M6OS>)DDB2J 6;6 (A24#81((AA"/42<[K]SU_@93=,]\W'WA>-N)
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M>UO><^.6=H)"II(G:J+& +@3]#XAI>]W!AT@;S=Q[WKTUJJ]0[H73B6/+NK
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M;#@HH+/LQ#[1MJ7$&SAYUWK*SG1*Z+1D()ZAK2?9H.>"FX)&E%A4G$G7QR"
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ML&3M/J7IHABBS!'PH^%RWQY]^Y)*YZ'SX27^R$D^P^_.,@H;_^[)5I8LQ>"
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M I!=Z.TWE]HQ2/>FR 9 >]=F[TZ(=\P((6W*VH#- >/6+"GX1"181H*U)(7
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MGZ1+2DN957<E3:_3UH_;N%<<5E1.4Z##_36]2O>KN)]4!'CM^.)>E2\ZW7A
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M4=K@$>SL]SSBES^^WZ-D!VU-J@JN1[OPB(/9F^$?<S?]>KT2"DJ 1^1""\E
M2(NNEV8.=*2*2<ZLL&Y#]3]:HL>G<A44]SP.=I%B0U@HY2BC-'5'7X>+WV^X
M$2E$20R![$I+""$)^! 86))X3EQG]_@IYO<Q\?Q2/3Y?ZPX;%:3:$$;>IEF8
MW *=R, 2YP8P-C/H?Z.0C,9?O'(A(!<!H;\I-!ZLT..[LNX0L;T,&P+"+VG\
M=7*]0K/E:.F(U^!Y1HN7C0!'N"@S-5RD&CUMO]ZC])=6Z/'M5G= V%Z&#0'A
M)*8\2RLT1QN8+ ECS34'X24%Z_'H\U8K:40D4H9-@?!@A7[:X'8,A.UEV! 0
MSN;3H<?OW7!1#C"1M80D2JFJ16"[C)Y0MD2Q&!W/F6V*A(=+K 4%]8-!80<I
M-H2%\^G55Q=7ELU9'X46'+*,'D0,$4Q"\Y:9])%R-'=ZXZCBP0IK(4'_8$C8
M7H9] V'%P4VN=O'^YNSZ<G[UW[=G77!$ZJ @+NK(G"7@M&.0B)(T1T1V^.[%
MVWI+K04-\R- HZY46\'(HH8!)77#@A=HT@P:.*X(N<G*E"#:FQ2L"L)ELUY$
M\?SGKX4&^R.A80?Y]0V!DW&8C"87UP_S<FC(O-,T@2*\# %6"1R5OA0%6L6L
MI#ZNEX%\]N/[K>.HE('<77!]J_XPC4;G"%SWY?KVN)O,W>CI]^]O%A*I(\(1
M]'XHGH$J9G!E?+/A).*F"98]'B;W C2V6K[/)E^[*WRR5^FWB*\4W'1^M>+&
M^.24UQF23;R4_W)P/#)@0BL73 SK9KJ_NU2/N-F#HK^'J^VEWB"&_B/-"CLK
M?RN9%+/6 @S!\%RP<FZS\B13:4U8$M)SL2V&'B[58V:\?PSM(/6^,72.+*31
M;:XW&JLE0P==4((.NJ06G#!EEH:2(JDR)VL]W^;AY_;9]J_NR;2#O/I6=>GO
M.WT[G)5*VAORJ8J)!0S757!T^4K<*F<A\R0HMU%8NEX*[.EG]]M%N9(?NZ/(
M^M;XKX?/172),VZI#J CD658&<,@/.$O7DF56&E-OF8&_+F/[]&9V%5;DZJB
M:T?YL_<I#K^XV=?A]&R2)S-_A7]:A>.66L*5 4\6Y?D\H@'+!+CP^!T;%0]K
M7I"NLUR?M16[*_1Y?-22;D-XN>/C]S3ZXN8+YE8[*EEI8BQSATNC=Y7+):#C
M0(.SSN1L<]H8,*^LUV?%16>(J27?OB&S3.TEY& X'\X.?Q].KV8K'E?QE%:1
M1&[ 9>1$.'2(79FX:C(B0G,F<])KP>7[:_59BE$7*I7EVC=,;CEYL^#D]LNW
M:31W]YE;.>?>$$V) L,RRLVR",:67A\"&<O)&/[X:=U+)F:SA7NT-55=EP[%
M_<- Z?=T.1K&59BVN%G(*$$O!;*H,4(S.CO (]C'9*U2TM=%U(/U^W1[N@3#
M5JC;7C,_#OB&T^16!1**&A\EGN4R*H*66E.P63OP*3-CI;5$D<K8N[=\G_Y3
M>]#;5B\_#/(6GL/*11""$/0U2F^)T@J'E*'DB@+57#F4 Y%ZS?JF+5;OTQEK
M#G?;:J5OV/V>_AA=35>F.ADGRX,T\*:XG%X43Q;EY$,RVA(A;%JO).;!Q_93
M-ULY3[B]H/I6\0*:#ZY-[G_G?C1#&0D8T6#$X5.9:(CVTI<:T!0E;A=M8EKS
M;GOM)?NII*U="M&)@)N"S<'EF^%L<KD*7)QA*1I1)K02C_840QC'E0=B91:4
M"<7S>AFB5Q;I>YY9?86^B)D=I-L42MZ73A_3X4HX'+D77%(P,A3AE#%LQ&AD
MQJEDI#"XV39'R<-%^IXVMD>4["#=IE!RWU42(BK-H@7G2 ;!O09+= 8I>92:
M4D;73#6_M$+?0\'VB(]MY=HW.$XGUVXTOU[U9%GU%%ME#S13(80(DBOD)"8&
MIO2:BHK)Q#2"GZ[W\O/59?HQ(_6; E06:,\M1LY6;3I_29.+J?OR>1C<:-%3
MPWJ24J8&,*#B(*@-X&FV8%RD606AG*S1BN9% OHMX>VD'TT=8?>-F'3QF(6;
MW930AC)ID0F+$A$RZU*47NY52/;$66JUJH&8EPCHK^U()<5.:DNY1Z@L.L]/
MKP>_G0U8#L@J]9!S*KWF<>,8X= F.B]-SMY9+5_!Q2R%OU],OOY\\XE+:-Q\
M<8>,N_5ZA$$=I4UVDF#/YN'H:CKY<GO[EB3/2&#!? *A4P1'M(60'.,L<!+T
M6L-#OV,1[J_9GYM15_L[R;)O?W/A#!V/\=/&"]&[T:K24W%"D@X0!$$F@A#@
M/0F ?A(S2A#+-@E&GEFAGV"DOOKKB;&![F0O.%/O;]O;4N5ULC:"XFC:A!"Y
M7"-PH#YX7HK S7KM['9OHOE^HV;GG57>5G<_.U%% ]#Z3L?1HV]A=!6'XXO2
M/AO_%\_=MP'7*<1@"'#-*93=@J>IY*"5-EEJXV5,E=&V!9E-]N/<$B=/&N]W
MJ[0V1Z(]Z>:\ZMY<I/_!_>=DNA) U3[5WU^EBT[5&_*VYU[5PA JF!5 ,HT@
MDJ#@RJL3H;C6,8AD?.VA]GOJ57UO,NIX/IQ?_V,8T\W2;ZX?*N+-]6GZ,IF6
M\6 WOLMR8/Q !1^D40%D+(_+.5=@ BVC6K37/%(B[5J9G^U&VVY+]H_1^7H3
MY+TR]78ONNTYDGS(T2*;DCR71!,#4I;GAJG<Q2@\"5@T4FIJT,^N,6SIZ<K]
M@FOOBI]4TT+/&/KH+E%J#WBX"<J8)T3)4A.<D70,H23XZ!APPJ(.)@H6:T#I
M10+ZRU+MJM%);?'VG:TX0+*'L\G5-"0,KB_2^' R_;+JM4-QWS"ARR2\4C\>
M2J.^E(%8FK/G#D.Q]<JU7EFD/RA4TM^D V'V#8I#-\40Q(U^36XT_WP\#C<\
M:$,C5S9!].78)MR!E0'_I)W@PN0<'D]H>*D9P/,+])>_[  ,-838-Q ^A#\P
M")W<Q[%.VB8M#2A&2S&!5>",\* =VM!@?1"/+[I>P,#3S^XO?]F!^G<470/I
M)?3E0RKN?-' Z7#VQYOK-VD</F.0^\?BY)3"&)<CLA))F<>F"=CLD2F'+I4W
MG+/'M1,[QTK?HZG?B_.^?-5.--8D E?<K :K*F\YM0YH*+N3LH#"\AX<L<01
MGGS6M:<X?H^F?J.EN@CX+KQV4$<#\/I.WF)5ZZ:CM\EKD%R7$\"BXZ:M@:B<
M%DFZD!_/!N@Z7]:GY]P-%C;+D6^AF ;0]LS6/,=_NMB50:@R(!H]05<Z <68
MP48N03.=7-).*5[[5N85<OJ]_FOP$-U*3RU"KC!RLS\S$=':@!N2E:[;/"<P
M@GF0TFNI&$IIO?*472!W1TYKQFQ+E7\/2EO*OP4HW>RY)RS=&&.)BTH:',A<
MAL['0-$8&P5!4R^]25KDM>H?-X'3ZR0U!JEM5?\84A7UT "LGICX!P;^[L9=
MH\^:+>&@22BCA-!W-9IRX%:1P$UFRM=VPM8DK=_7IWT?EEWHKP%8/ME=G]*T
M?,-=)#I(P4BER]/K1/!$\":"Q; )G! T&:N,$M5-W2OT]&OG.@' ]X[1;;7Q
M@]3&('MY,KUTR/6)'PV794A5ZV)>7Z&+FI@->-IS/0RG7$DA- 16&KE*C:X>
MI:7-7E*DW DZ4GN(^9[J89[[[&?U<(:_SO(PQ>/QIVGZ.IQ<S?#GAI,X<"($
M% \%]$DD;K%2@EV*-R@//#D1C8RFOJW;D>H?HQIF$]P]8Q'WJ=DV3N0G'+\?
M.C\<X?%S>'5Y-4).OZ9#-P^??_MR$/\3?Z;X..>3&WT<?G;CBW0\/IK-AY=N
MCA[3^=2-9_B1**9/TV%( QU)E)YH4#E1/$I0)$9* HK)H+2VA(G7WNK4 GME
MMOJ]$NEK-_2)C1_$S5B)[8T;%:-1U<%XZ;.[<"W6XF//3H4BQ N5)1!F0\E^
M)PSV741TZ\"9M%S&_-=Q*DJM^OQCPEW,,M.+POA@2FN14#H$& 69*I$5 L:3
MVM6SK]'S8S@"FV!E'=.WE39:/^('A%@7B4@0>6FV%V1IG\0=:.ZUD]9)XCK(
M5[],T(]QK-;&UG;Z:/- ?'=P?/K[P?O?CCX<'9S]=HJ_?3R_.U46NVCFQG'%
M\K#T4W&S*Z3=S=^YX?1W-[I*.QR:5=>O<+!V)X]*A^_=(L-9&$W*TK,[I#MG
MG<\!LB_WS:(4:A$B01G/">(^QUP[0_P:/;L:P]O/7LK]X%FYGXQ/4[B:3LMS
ML7'\.!E/5U^^<;/A37HW6YVSL 3]:84FP*&/[1UE$ P>#21(9D7M_$8UXOL]
MP*OA[;%E[4>Y#1SQMXR_N;YAL\1A[Z;IOZ[2.%PO+EP%B\9GAVZ*=+P(5D,9
M6P D$\JEH=8RUA5>7R:K$23N%S OP;:2]EH"Y',,K5H8&'2BA5=@<S(@#!'@
M;=2@T*U.-I72)M\5(%\FJQ% UH+"2U"KI)=&H3:[W;&K<3^$,Q43A9B5*^TR
M7&G5%P!C-:ZII>ABUXYRUJ&K$;#5 L,:8-M),RVA[<WU[1]_':8I$O7Y^CU&
MC\L67492GTADH"DI7DSVX+S-0)4H5(4L6>WF(^M1UF]XW=QY6TN'+2'S_FY[
MRM_-OE;<L""0+RVU ,%4 L\]'B<D)F9*%]J\%X/X$H&-6,:*"%G'.%915TM8
M/!Y_N2HMD%%B=-5G*G)!%P^!N2O5)1SW,!,*F%&&.$X-T;6OOE\AIQ&<U0?!
M2W#;42.-@HNM9GBH&(AP%HQ83@\V8.7B77!B0@KNC*I]/_0*.8T<MKV :QN-
M- HNOFK=KKDBZ(^"*VTS,>Y2:.Z1,Y$T<SQ3FVWM.H97R.GW-4F_X-I&(RV!
MZT%TO_!J%_Z$4TSPI#DDDW&'N(BQD%(>@RV;;&0RQM!92OEYDAH!62OAPLY:
M:PF$=]GW4DI\<%E: Z^:V!.IM8E. M4.-Q9#QKQ&SQ9->4R<:9I\[8*#=>AJ
MQ%NK 8270%9+*PT@[5-Y%8&JN;O%?(;+VWG<DM'2];'8<SP77'D81@(PY;U6
M*G!7/4&W 7F-X*X:-B;[450#&+PK/5R#MY10ACZ65#HU(")3X#,I?=$%#Y9J
MQD7UUU ;T-<O"CL#R>.G3UUIK $TWCM!%B[-X<C-EF='S-)IKSCD&%69>1K
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MFK^[&L<5%]$PXK,4H%3A@BKTC25+P+D5N;" NZVR@7R>DK4 J?]' +*BRAH
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MR<30)Y:L]GCQO]>TYZVPL<>TYVT4U0 &MYH='+FCWN<(;BE#D@58BS)45KE
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M7TPU$O <'K#]!><5T-/2<;K7&?R/T>+[$^;G#[F?GSW2SDV N"HI2SKH((,
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M@]".@G-H3ZU2B,DLO,^U;<W072X/FO:?[\O?V$DG\/I)CD6@TOFR39J ]T0
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MHF\ 1"].\%!)*%-ZZS.5OI3R2;3O0@(7VCA+2&:Y=I3R)D>H;*7S;4:H;*.
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M%/[?;].?_PM_],ILX6_NK-4S'QQXBL8A[\1]Q3TP4E94W[B<6B5GRSYPEJ4
M(3@%RU@J"_ \>J(\2?-2'=#K,+G_M6$LS-[JFE:0W="7SY/@T6M+HO8!/#<2
M): L&%;&D:H0.34<(P[=Z89I(_#>3SDOAMG;2*H!)W<'4_CIMHA?YC(H&P5&
MA,NEF4D@US: 2I2C2T>U"PT\XG_::LY.;_V4@P1B!U/OT!;KJ_NU= 8_3F>/
MWY?FE\2A!",E0+PUR B><V-2@.04E\9'JZ/H9+U>^LJ;>[G?4='3/J3>@"4\
M0X4A =\QG/B0?J;Q]$=A[:3LM@HHV,M$9)"Z,"&E!4$H7A$BEIXZ23*ER*VN
M70/]"DEO[DUM/\3UH:C!S=9T@;2/W/CC]>)ZECZ/QFF^F$[2^F#=;(Y&AX4[
M3;6!R"1'KR(Q=#Z-!>I9I(EPHYCI9L&Z??#-Y2QK&+,>=-& 75N3?S%=6N=9
M6CTKG*=0%@2/TOSCS]/1)46K["G3H*4G(!*+X&AV>'R$5B9REQ\#;/^!TUT(
M>W.)@CHVKK[2AK9T9VBJ)]?I:YKEZ>RJ#)>\&W*#?QF*6K^E+_F/<[3C>;3
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M<W55-M',5\D]L\S0E)%10U)9-T)+3BF&,N<H)LZT(;YV_N^ WGIO8[>; _D
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M+)T"M+?+B0 6/)X(\$I3FX1V(9F.*.KZS6XH>DM)[W[$/3B*V,8;^S:0D.M
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M!FS@BF@;&8V]W:*[$MU($K,Z. ^KS?ZSFS?_H/SBW3S][__G_P=02P,$%
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M4TGGU/OD'*4K6%O/&E\#:)?()PJ,#)1S(2?RQ,]!\<TEI%I,=I'Y-F$]ES5
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MJ!^MJ\PF>:XIG[=<.-M'D$$\&\$;[PI8\&=16ZVX1B .,\#--%ILF\ TQ_\
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MCL;!"'RNX.M4=P?8">&?E[YRMXO7&. M!K7S$3IL^V7WGN?;0PN)<32#4K-
M"$C/^?X^",%YWL,F7P\VN4&_X,95+:E2YQ0']F=1ZJHN<U(;%3O5^]I14,KJ
M2$\D?E/16V(@Y;0W4-;7A,H%8WUU+3DW'/#[Q#MG98@+L";SBGN# YDT_XQ
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M)I/;FG)P_<_FRMHY HNXUG[.E,;X#(*>CED>RM?28@ 3>/%[%!D,/-8\LSM
MOYG"E@B< *0X0>2/8I10&$="@GZO+6TR9AU)#! K,Z2OH,EC*9KJBIKW\;GY
M:C21ISSS5K2HYT5!*U0?+Z(T80[Z4,, _-/W11Q0#RC\;YWS7[11=>5S3OIZ
MO4[415$R$;/+;X1WK"'"&XC8@:0;.5#MIJ(K)!8GS+="9[[UVJW;U9F9=9 *
M%.#SD0M9@N'O.+):;AS7O9YZYFQ2NU0GXXYW"J%8\&+J8D+I8<?_=?;^Z/5Q
M\J-W?LN. -LZR<=#L(L%K%1-)B8SRI4:J!QL5$J/HT1OJG?&'7-5 ;*?TD/&
M 4)'@34V<!'.U%9Q>,%KK9[32TF"BD_/,_L "*H%$<DYZX-6] *S(%" 4;*#
M](GISEVJY\J><K988-!\*>2]8C0&[(%/XYP[0J+RM0RPFAP;(?<>.UD=':]Q
MGS>F\W+B4 6<$KD0@I[=#<1Y4YE,0JU$/)YE0MB'&V/$2K8O0B//U[I:Z7G#
MX$4(5>3:D'!F)IE$2UT^GB#:"W.-6#"1D$"/S-(TUZ#'SQ+GUG;PZELO.KQ5
MI9AP<)VNPK?KS#&W35K7]7DS?$JULL*=2!ET'#AN*X1>/V:'04[K9[/  7,D
M>/-53)Z3RI9SZANQHZ7]NY#K4K:0SA55_LAU9Z\XI78+9IL.V*C': N1^5JS
M.^OA@'U*7NBYO<J+TI->O54:W:W7P7X)E^#*V"MMY_>4(6YN':SIEA@#R48,
M1EQ!BX3@IRQ54N)_32LIV'.(T!8.&,,-DA<&@L 7=M?RF2$"6%Q@OY"F'WL8
MTA!U0'UBU<EW*J/+ZU6RC'IH84*?7N)^O+ZB\Z6V7'+I6L/1DDV,!HHU$A?*
M%9[$8-##Y,-4Q[C^>4%GA"ELY-N^XM4N@4V8&K4>\-Z0I8[9%OV4>H8_,\(I
MJ:T -679$@#26R_HOEW+\W<',Y4[;Q$%;#![8LR*]6N=@T2F7J(?HD3^.QO9
MN4:.U))&GPR."E<9;H$&_N/Q)UJ-38$L*<+#162N_F'YB!'2%MUN*666#DN4
M_N5N(R:@2@$;L*R@"A/>*IT:X_<N5Q5BLW.L\H!%%*CA!$FAJW+C^%GQJ('I
MA?&I2PX/!7FEN("&_U-'5Y-C2;4H@OR+J"$B<[]F4FBI86[M"ALI<.!RK\TN
M(:1$TCB#^T!0D$*TOW61H-L3"C=D2W$)U%(^X,B]6MH(&)OAU%;R30GRS3;8
M3'S'NJ.#Q:++/N<'O6ZFB9=)M2Y=I&*.;OXZ-\[DPXA %58/;8\[XM:Q+&XY
MW0(UM5-I2/.>T',V:3VK)3)9V*Z;CD#_Q+V@8UTYUD\OD/[9M2O=92@)HFFT
M^\8U?<:7#>)'NQ79[%_HZ>_CW7;HMZRHPL?TOFL0:P'H3!CT- <1<&9>+KP#
MFSR;G#R6O@J=.Z' %GTT#&?3RN0*Q/:TR%!LQL%+_/VTN!2H4!?Q3*6 C[N(
M6S$9N&1S7,R-A+Y0&K><\]0GVCW*FU*6DL-!Y4[ST O4G7!K>MQ+&6OE82)U
M25U>J*001N&,8'@<^Q6D(MXS J]ST/<N(LOW8-$E%IHPS+@8D7Y!52REL@Y*
M.9I::!4YJ[43^UWQ)K^Y33]ZQ^[S1M%JGL*QP2P$BIKQXKCWD14J]5#XW.^H
M3UP41)Y$29)^A^YF+35I5)J>932WH@Q>C!"Q1;[7-B2#SM2N4QO1HD >[9B+
M^.2#!J"ND_7G90$QGDX">E(MM1FM2SG1.K/21]B/S503M@?:N=B5+1F$XXY-
M.:YGEI(]K0>P7<50EIV,OS4[%\$M0!$9P!->L>!8\DY1;%->(S=]P,@Z_\.7
M4+8:*N^X=$O!;'#Q?V*A0)OP:X&FD#I&[YB47 AQ:.X.@E8'\69T[WW#%@M/
MRKTJ1HA1@?$X4CI*(_60")U0@UI,*@1V46)?RUAQHBMV"]-EOMRE$.X<5;AE
M-BCL]+B669&>:PJSP&S0M&C4E0:N@4OJVLFFTN:V D/N1[8:!F' B3*"?7H#
M.L;9#>4KX]A-TM,,D;G\M5;6% =5JD_UXYE/:Y#1U."E+M%"C]LJ;G8IP_7J
M=0[W-Z>4X8IZ';)_WY4%)2G7ZVT^N[X]>_#]&ENU<CLFZBF/-OW<'X:7X0XL
M5%THDY&8B]N=^@MF$,DVU^B.H:8$R4]OX1__^.;IX4N7C8NED^[F\1<<<#YB
MWP5_1"]\[0 RACV\2]02BB[EG+$P]W[68 FCA6,'R**#+!$7'T//$64J4>-!
M^1!F\?CEN<FT2H? ^+:")QS<&9[P1N7GM3K?C,YO?SMFT*H2XG*?Y3GER\/#
MR#%L36P%?L**F?S#J>C'^3DV:T@R.7'2"J:"=U)G 7BDJ]C%/CU7#"R#8A8F
M]0TM&( JRH-I= @.&_L$E<!2[51(!II-"-V'\Q4UIYU['V=*.L2?OC)ACEQG
M4B.$<_:;(K^&O?5K<[V0?,B;?W@!:T+UBF/KA*-&*!IDJ7AMUHTA3P_Z/HS[
MX&X#^SN\,^SO&&]?6>1FC&T)L8:7*]..?.'=YJ -S! (6,!H6ET.!M0W(:7K
MEO(ZN'N?Q[T*K@$#=-!]D;C-BNI[85"\16(,-;>1F_*%Q8+.!N'T/?_Z>)PT
MW.H&N6M9D60U+8OZG$VC8)2^XLBH*0W'[#EHT^T70_!+3;80^N88NKGSZ%;<
MR;O3S=V3UZ9<PD8CAC-MA/1U15DB$#T-Z8*,7'PV50-MWL<!@SC@P7T<\.L0
M>HLY.OI4!+A7Z3PD3>'@7<<?V8E8:YH@Y*Z=J#%E.,5/D3\M+P@PF5&@ AB:
M40/AY/,G@1JI.[QS^S4S&29'>03Y1( >1>G\^I3ES&G749S$9R1V8$W9+:VB
MY4:('),;W/UU-E;?"K%U=UJJ_RC :4=2#D Y2,F1M1KTG_>::#(_7Z\D>^UC
MBH1LQKYFSB<&LF>??1:FX+#Y)]&*3KC0!R\<:)RR%'(L?4U$Z=8=A6F2-OK;
MJNH"J8X@:[7(TF5%%*W:B8(R(J>-L4@FV5*8XV2G2;OT@,QP8[ 4,'4)#"*1
M,1<1<<,;1'#D,8*GU3^[7>:+H[+XJ$LR,[&4)__H]PGK[4S:DULJQS-<^@UM
MHVQNRR? F^\Y)L'G#?B,:$D!AJ,'^@C":R[*@''6OAK SM206+!A&^*G.DA!
M[[!@WIQV$D,]O&60#"JE0A1@L',0S$NPQXK+_//PQZR:K9,S;T?@X^ZTX3Y*
M\1K7MW3FUV6^;UM8[C'TF$.TN7'7O)$.-1NZ3G--A-^KHBA."YE@UWGB2EA3
M(_OC5:, _TQ7W/J GE\Y\J0WFTNX5(CBL5D9/YM ' [*9)C\ I*TN&B[/<&
M(TPC8M/4D'T2"&]FT!1@;\!59%7L<;SRW!CF7,Z*_)$H"!9A0FR[J6ZH]?M&
M\$%M@4@2IXC3&WK?'Q5@2%(#Y[N&Q5D76K*(I4+)+9"1^ B[V/J&7BU?\C9P
MV[O3%OYDYKP(E&A"OH_W@?:W.1Y53$7P!<0^,</@_%TD(%);BQXM:%7Q3Q[:
MM83JP?RV S,<Z:[7O&B<*]?<'+HO($P\FO,5U\BG"3GE,8S96-+F6308J1[U
M[5Q(>:0Y,RIKH,^/=%Q,A6HGZGN6_5R^=<E7NY*/GOHKV>-\^9N[Q@ZWSC6V
M[.S_:G9\\C;Y<'+V]OCT-/GP\_'[XU]_7"=7BPMC**:K:MN-D+HN -0@A;@1
MQI($U6VTX#8'=;;8$]/OW_@0QGYUZ9@9=J1$OK'0"L&M2XMAX-0PX"+5W'W6
MU2;FVW>X%;$S?Q=+8#I[F"*HYE:_<'^\3(V=9VKQPA!LYA[]Z*6\3BXP8KR"
M7E6A]UU>2J_CKX5HGSP9/C]\CG1; ;%6J7NQD/202/IAE7:_.SP8'CY^OO3K
M_>'!TN]6#?OLZ?#)D^4_#8=]2%/F:</&6*"%?SUX^J"YRB3"7QS./R4'\>:C
M5._L33%?T]7ZZ>3-\='KY/35R?';5\>G@^3D[:N&II:N]%%GI?NXSF#G5CQZ
MS4UA6EF3>Y[\B9:]BO][450F^45/2_4Y.[-!-+ L+X92VJ*U]2])6 +RE/TA
MW'&,C)LTP2F^O#/+W?;C/$/0LNN>Z)U9U?'O[P;)SY3@[-,LN\?WD(31'5%V
M5F>I-;%K#HW%'7_"/#5)Z7"N +& 0!=Q;;;8XD%%XAR]'4%ZQO*X6H2*I,,$
MN<9WOW2$CL_K*/)YA6BTJ_Q8PW8J&F+MZG3%[,0D- S>5VK$"\2?3A4FJ 2U
MBV0O!15 W"^$*P[JW&K,%C:<R!]O?XRC.ZGQ@"+XARQK_(S=O;R&F^3O:#L]
M^CS;Z>&H2!?PGVDUR[[__U!+ P04    " #.@*-6%V:HFQQ'   K]P$ '@
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M^X?FTX:E+I?!-!Q8ZR36[\G7S<Y?RG^7*B-1G/>#9>[_=;OF8/2#FO?B <I
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M$"^Y[??7="3Y>#BX&(4 @^=,=XZ$[6#J,$?X/*<0!_ .# C?S)Q09PD&!?=
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MYX<ME0:.)/$4FW'3O^K3<STP(D'IOR%@KXE0[)!"TQ85F28+1&5BJBD,EX1
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MB<7%Q-HQJ!5L_O&K:<A5OV/>)='N.K\/H\9 T\1<1Q)WN[76PKI=W4\;Y/1
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M0R3JV'S5Q]7T\7%Y=$.[QHE2 K;. "0.2*V6G&)S+VVN-=L(4XWC,C=X.":
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M.-I.Y*42S3[.SO;=O@*$>+O<8EU&L[ZEUZJX,6XF40G%[XY$1$YH"Z1/Q^&
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M/ GR+&SYHT="SYX=3;X\!&OX^2%\\<F",_R^,,C4/>#X(3#(QX?]@Y??ON_
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MK L<@],-3LD!"3]@1BD<*%H[=PF]W_%^ZBTI?()GM>5OKTSR[U[W&/?!3=0
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MVSOEQ$V*Q8[=_DR.6=4,_JZA/%5*INKD;-\SU3RA.O)?\\CTW3H0H%5M:H
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MXC4D-E)/E)V,*=KS1(-RQ0)CPDF0-[9TJC-/UM@/L]R&[?:*VFKWX:INTV&
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M!M/-?GA6=Y;W<O58O+BDL1Z2TO12W?@^A;, E/!UI9(N)X#P1%+<+K"Z$E$
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MDFE/U@4_MHQ@=$(1_?(G(OAAV&'I"/;L[@IW;R,D0-R87AE&CV^_:>.,:BX
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M1[#)B1/8C7.SM/O-@A5KP]=FSLD>9NW8X5_*U\1*!J.6.R.X#>]SA5C]'A8
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MJ@R0[[D9N=0]O;1L6SNYR*14-H:_NC+_0E%6-=?NU),E2Y8+E;-S08!.J1Q
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M;MH;STH<4#05$0ZNCMGA/0R^@,T-!/9MUFTAK2LY2CU93K0C:3===6#S;GD
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M%?R&A<:[/83&X6$^-96)*S7#$;_XOFOVY ^M+6C8PT3]LQ/B@S/VXO/^CG^
M#PO3X$:@ZW5[IJ"F/*/P'M=Z]8,+$>4ZQG;A>&+'8^.LT8H.]M]:[?%+?->O
MH):NK4H%YPT4,<U"AT.)%RB<A$?M'->:VDX[(\WHT!8+A0NX,OCTD@330=5Z
M10W0<P]I3D]7/)FQ4]5#OH.N'*G!6GG'KWB)'W?+8O+GV0JPV[0'A<?>"GNN
M,*1ZZ:EK8[>$^RF!JYCZE(:2-#,:F8CCEB<2*%3O3FG>++7GCN/[O0L\&GCS
MDI0UO'%IXH*?E(?76.O.-$_A(NTZ$_4>[YVYJG++]*I(#0_\2'J>P9F.+_=U
MH ?30WCG>7!__^GAU]CU5^]/1]:VO&[J!FS0M&8F-[(/_9-ZD):<"KK2.!%P
MN6CZG]J'SRGI2]R8NM5Y$YOY-\^VMD;XZ)OHGY&J(.#LT^<X!],V%1<+5Y4X
M.?'P;/1*3W'+GAI\#)Q6JVLO_R^\UG&<_]CNV[G6:V]D3M-<%2/L%,2("KAA
M&UQM8@2.3HRHC2;;VS2H28F1V5@QHJ+V)D;6@?U,QHX8N9/.*$;<HK.)Q4@\
M=;:5,YW1?IU[7;,G \U=U-XABA&>AYH\?/]9B:^V]RBH<B-2NUDV?+,QG,=>
M%Y$^2WV"%I]KXT@M%Z98L*^,?4J=?8RS9NPYB)7\6,ZRY\*V]13(5:%*O0IX
M841S,7VU=B&Q??D2"N!K=[.[:J0*-,B]MG-0,^]JA9T3'7Z%_^+SV&V89N?Z
ME2MJ=@,>FU=K6\C9HO1<&QMBZH \EG.GJV2[N^D'*,C;%,C=!R&B[6["@@8K
M>_H&_ICLXGRO*PI-XC>UB1& ^OR"-_.%([<7?O[2>'R^\V'#G\Y??[9[\ O[
M!TZLTF69?/;9@5?K4\!I3AYIZCP+2[5  17\UI)/4).S+Z@20N'-E/H0*K<<
MK;W7N!HZBXT>.=#PU66/<!ZK]&PYTY4=IOFD2=Y1ZOF9\3B'\3/+SG_R2=.%
MR2W^D_:X\5 ,G'VE8OJJ:+VGE:CG<P]S27J7,-V#Y[T8:4M),_E,5ZT<:4DY
M)$5$C, ;AWBG()C;8#)>SW#Y9G>TLW]CH:K)+>CGZTDJ2>W)IIVL0Y'/B<#P
M C$R"S-]SF!AB@INP^%PS</1R]FT/)P96(*<Q>ODA/*T)%%%1;08Z25&6DFZ
M16C9\RU&7D' F6)!D2$QXFHY&U0)!'/&CS\G//7EXTO7<XW\1,&D7SF8]"JY
MAWXDB_;&0,]B9E$7BNLB2&_?_2.D2)/.$29.?V"+^X_/UKFFWVQ[M'^3$.\4
MR]>U:P7Y6#S,*M0)Y.RGDC"(L@(M;B9&5&%>PA1#$B,N'\B"W&93.3-95" X
M8W7$R MU4[D5>+32M!RI[_+L;J>H,^=G8"2=0P\9+_S@_N[>(3DJQNRH$",]
MN018]D<9\+[N@\Y=4%7J#$+,,-UJI=P9[W8>0*U ^S"B!/X:;,%)^W8 8\5;
M#%X<.+E\QE^L_0XCE5W3A'/E02BPN<:V4"J4YLP47ZU'ZV=8JK\1'CK[LXY8
M5;US:-V=.G>GSO_9U!-TYF@QDEI8BI&5,F3$""L+E'AGV]U688D%38RP<LX=
M6=O372+1%Y'VYD+D6RE$?E-@N3ZIEYCZO.%,\YGZ)@?N*3,U1%><*M<P R3G
M#/??LAOA(;:R2@G8U6JDLL^%<Z1_%J0B_DV2BKCA'.F3X$4E+B?Z"#'B)JH+
M,>(*PAZ$A?:"$G;N0-.W5E30Q4*,L()VJ+B D,-+<O8I4:X:00$19O,2(VV.
M&>L0VCI;D&U(J0^)*DI,3^C$OQ]-S8#\G@8J0?0WR36(8J1I?>,"A"N8R6;&
M:EL8W962,'9^_?H$#1&"V?FX@ED\V*4:+$R;;VP)-AZ,MY]^<9(RMA^_._SR
M,V&S+[9W)ON[)#R5*H!S\(4)Q/QG"E =Y\L%9TA/B/8;$:1D@C6JI*&PUT\A
MYL%M &\D+7L]EHRK<+USQ5X 4.1Z"9]X$K6(0A<ISZ-KR""YR%BEB\+YDI@"
MUR1DC7=G)G#K,VPC3[VFTE;-"0#"Q2!8VGE*YF'T2.\ PI>'8@%E6Z5R&AE!
M0DQQ*%3?=4R@ST2*^W_I7I6>D23 C:#I. UO!,SHZJ8":H^8+4B0RNBL'(V"
MD%I*T-@F6&XM"8E,V[<88=,).5(UZ-!Z0<HR\P!+RF>3%\J]>?*K2P9"OFQO
M?[)+Y3*[&G\''BJNX?71FJBYC./6^A8]#:YJX^5;DJQ7US#]Z'?#GPO?O;71
M<QA//>C3L9ZAMGN@JZ5>A7N?5=;U=]YY*\J57K;TOK!=)\J#]7M6$)D_4UVQ
M,7:E-43V&H'C33+Y0UL4$ +5T$O69:Z+6*T44:'KJB(%:&A$K0T:NI]\X<.'
M,*A_C"8GVH%H11K'<?X>EB]FG.Z4Q]LMK#"O8D[8D:,R6CP/Q0C+F[88:3GC
M3!:(:,.1+ NOK&I];NJVYJJ_K!*![9(.!]F#737GY-=.'%GK.L))\4$51_=Z
M3W^^#XI53T%9%\W,)'0C*5\E1&VH@ S9$.DYW6!P]>PI%?+)Q VLUVU<TCUU
MT% .<^5:*Q0,X%K&="/J6.G3@.I=)&4053!CARH@UZ;F-M^%<?ZP, Y'+1BA
M>G7(@N(2'].>G4T)L)LS*D51+KJG5.>VV4B [:&U_*X_4KGG@,_G:_@?D:-+
M^<45@O-GF/L[4:_H#=B#*=!$@N29C\\P,9>TQ^ZDWOI4?.NS5R*/VB>68>KH
M/VH1DH2?OP*_<%[R.S.W8^S08QT6Z@75++N9G.3WCBJS4Q]2U_7\<L/*7*FB
M&O<Z>!Q;JUI+DX?FX,4P=V(D2$LH3?1<#ZCGWN *7_@NK]"PMJXVA9@STF ?
MF$+'+EK+'?3!&0[0=ML0K4%=!7=E=2X/!=#>H&F-CAE[D$;GYO(==FXPWX&+
MONN&>Y5[J*O_+F9*#>O<;Y2SH_U%3"^\MFD+76<NL+(@L@_Z?4.79^2=+#-G
MAZAED5DS!V4V$\M)HU<>C0V%RF-Q2HI&P!,,[)K79%WF,T%VYMX%.1C5Q*W:
M*7(BE\](+=P24(<>45U=U&W)8B7\56O3:6/IUV@J7E.LTV9=GE;:TB5=FXV"
M1(PCI@<[2)H8@7,%^9&"\P*:B!-F1O!""@ZYWL!#S>ZJ69'S*@<V'-4'SCZ1
M32IQ?(68+M6XP,0(ZR&T%>^V&A7[LBW8'6#('^8IJHBVDJK!SZDB-96W1ELK
MQ>6[#3K/#CD5Y4Z2@8_;,QW9Y,3XW564ZAS'A6NC^M&Y4KT%'; +'VHJBCQC
M:"V71'Y$G6QFG[4N.1)\K-L &\_+?HA\40_SY@KD.=/V!#4S2V@,]:;2]E'R
M+X6V6&PX1EV!YG-8;RI7>+:NWESP]>2A8C#Y>K[0@:Y>RSG3DSY\40]F_9@.
M=K*M^6Q/O:^[JO!:W>E!0=5MH"X2([B'1IM^R\B^QVZ'3?8D79(V!3>MS#RM
MT317^/!?>R)&5Z<2R)Q)W0(<T0+SO(T&E[9OVC_9[SUKL;N2K_O"/M8MQE1A
M/8]26&CN7C&=R?I!.G^V']S?>W*XL_>)24FS44S7#%:=&)D%%8 K!57(,').
M!]KPQ0@KB+-!H -(C+QD1PO:HBQ^(JB(S\-G6X_$"%OJE1P5RM0UE 8-KTK.
M;+Z *128)C!P)(J1F;D6Q$A[(F=@):F5'-X0(ZT@H@,^B21NRX+&6*"B(:C8
M.P7J*6@O1F!!*Y=WYQ(TA:#P%\KU-I6)B0)](VKL"?;N4T29PR^*L "-AS/C
MVE#AKQ2C2G&K\.43$*XG[L\NDC\G1&U+1BDM.+$=Y@[_&G48A@'4HFQ];TXE
M-.4:>R P)?D:"*Z<.I/A)V+ZY[J &#$=\@G@CTI$A.N)<VE648C\T\"EP0:5
MR2J(&$7E%!U*5;.K/MW$0ZU3PDF?Q'-UB<21$EICD\% O!L2)H'SM)0@73VC
MH.]HU6^MJ&F'.8>B%66$2LI_L<Z.41UUQ9V?X9:*JM524\%F.0(+6KYSL. %
M%2/R@(92D*-F"MJGBDJ;6HZIER RZ\H F;@C-% DDHSIBNV+? T:=W5*UF >
M]W+H-Y@H0?$]3GTIC"_:FCQ2!801FZV;_/R9.$1,KZ"IWV@OQP@3M"^R$=9Y
M7L1(/?0PB1&:/7/)[R9&Y@%=KAB9$RV )*0*AX'$2*NM)8L[:+]VIP^S=5.A
MGR/46EK+$< KTF_'EVA:^$I9WD>5M>3OMA3A< ?\CY<RH&4!^HAQ1EJ-[<VH
MDRB6HG6 +3$D7B! Y""\9MV![,>()E'.([Z2!Y%X)&RBXEO3'Z;0?;_7=$9F
M3H5O;4D%R "-# H]%L0=^7&\0F[[S126N"L>\?]5/.(+@TN.Y'A\6DGE/P59
M,*BAR)G$%43</>7DSV>23,+5B)$YX8<R1:88J6O F\5(*\GYP.18'JP@BD5!
M_G%)>?6"AE72!K5V:S&*7LXIY&X&E;3VA3RXO__T#U9QKLFA8!ZQ$Z8D/S&H
M8J'M',B-<Q'5':*.!+/ENALCU3E&" [>>%.3BYF\/BB+X2P4*C2B@WKURYN1
M.G:^81XU=32CDO+)$_1CP@SAMZT-4*F'QA95RZD='M@3S;]M/O,1]M2S0[R6
MVKU)0KI1 4*'1',,MJO,XSD\CZ^O6L^E"2@-)M&,KRY=.L6VS4P,=-UR88I%
MNA)OS)5'Y&CAPCA4=I.+7XR\=T?YK925PE!RA&V!CP4Q N,)A2>@D<-^)*RH
M:L[7E7,*H78E1E9!T D/%67TR#F)!(TM,PA46I(SLXW!E'+DU6I_2^'S0'E=
MFE2S+U49!4V5,G]P@?XY9LH)>N/,>6LTF<FZJS'#V>"> SEZ6JT&3!1>GZ'1
M[U):P;0-^/H0!O4[L\%.):],:;1?7;\T+:,.$@#A0QNBF:V^<*W,MVG?(V?"
M40@F)0C<3+G,%U 0NX&824M>(#'">DE4!W=*\2V659#B)*@("+GAY5CM@KSD
MD@[9I.:*$9?4>3'"+M#2^*W5'@<XR $3]C1O5=4A[/NR@ZH '[6QRJ]MF&$T
M-+0-Q693M+5V9]"7"M-6_>#1T#&A<.J%7JDCM/LFZEW*#>@N6V,,",,_][I9
MC-2P06"YX#&U!UM!;UD00QC:>*=<G72D7K0K-#M_T54+ZC4G6JN'+WYY_4B]
M\0X?6(^4+FMC#2W;E)^>>,1Z><[ ELZ/U*]@B@4(2E?^R26&R(DZ$E3,)G$+
M$?:.:2-QC@:=4 ,%;NV!IEGAK(7TF;BJP$$+,B(%A;M3[55&G$;>0\5(3NBB
MAX(*"M)9&9R""K<P.3'AIO7%XHZ$Z5:*JI6%I:Q-JTMYY9S6(:T2%97UKITO
M>GUUHMXO#.DMA)>$P'HUZMJH.Q-*DX&/M0F!ZZK&54/YF"I 5:'67%0ND!;$
MFL](5/)RUQ/B]HV-,5<Z!%=0;2TY(R^*[)TV W%37.31B%8\ ]<K$(2P:5QE
MBM5'"2+PU.Q.R9X2?).$ K\"-_LJP 1_@+>N;5BZ)=IXJ_&,++Z'.WN/4F'Z
M!-B FG(O_$KI@O0"5^K$OD%4'<P8O\*?WIJP &+GZ#(U-/'X4>;'I//.,0LD
M'B"7'&F9!T0STF'=-.KRP#8)74IW3_$R.H@($X+?!KC0IHGZ89-8)Y-1?D*,
M5$J@UJMD_:0")P50N8*9=W77=L & ;\4N\;'N9Y#1I:L5&J,(C.9]*3\*>I5
MA3=3&#!?=DVC*B(WL=YZA^GU2[1\5;-7SAZ55JD8>3DWJL<YI=4_6'&=-J)$
MG=)T0H\4US[9V$E,&$8^".4FIE/2%BM&W'R4R(DK"JJKUR]J,1(+0K=(BO[U
M:JT8B=>GKQB1M1R(@RC\=V==RR&</9%C0DB"?_-$%B.M(+"[N$B$'&L^.3@D
M^O>HHJUUDB*H>NK.X)'R8.II2T11Y/(C-SZ14HOIA9S_>AE!NHZI)^?GJH<M
M=_O?'>*V$%78D^>%&&D%^8;62'$Q(HN"SXA36"4%Y<1(:@75Y!&'$A8CK*!,
M^4^@OLGD^*E2/^)?S57([XNX9O4QO.\:EG5WR-U>4>\.N=LH*^-]Q4A[)$92
MH?AM,>+>Z6NW4]0N[T",P()BEI("[U,Y6W&?/2M&XO>"<(S2C $QPO9NC;H-
M<B!"@E0I:06&OA,C:I^%*D9B4>CC$+4@[CRJJ#11)W(V*EVFXH1RTB2$51D2
MY9L2F),M1E8Y(:^.O$*,P#F'FN+>:\8.$[AF;>U:;(B;$=L)K(CZ8PJJ#5 J
M9RO^>P%5PU#EWHA,>?D=IP<QZ:Q9CE>IGBQ#5@=$(=]2O)VHA$-43(U"N&<]
MY"8Q^,1 '#,ZT9\4V#H&O9I<FQ:;@B]&L8B!S>%SJ$2.'#_4/P7M13CVULG1
MBB65%I*4%B[UH!$C[^R&:M[?B'YHY8PK:CJ-$[0I.Z*9$B,MJIAR'%""( =L
M>,A9M \[.D=\I!S">DGZXX;%+$9J04F!HB)=E=.2.';DS&+G2TG:HQR%2A!^
MIG:"<%%1GXN159=GVD8]!]?*H9(0M$>A"B4'6[&4LR&+PE5HHH\5(ZTD5(6@
MG;AP=F;FK9>S1U$= C'"]K@1.8:MI)!7K:T59,5+.H.*A7,!Y&C)XM**C1S7
M1:JT(.?4U8*LH KF@@H;S5O<H^AC.9-9$EPJZG-\X)GS@LZAZ$%SN4LQ$@MB
M?DAY77("N.\'V0MBA!XDAXC3HN&\J-I@SH#27A)MI!C9?\VT+F($IO2CMA$C
MKB W= 0Y#LH5:!\XK4^,R-K:5E>J-"%Z,VU%U1# 4SE 5%0(7D4W++2>TS@+
MW310*AW5-WO[6R-LQ9^HR/E1%<%;'?D$'BDCBO!$C*QW1>INJ:A>DMTOARR!
M"]2)D?:.O.;V"GM'7G-[915574O.X4,ZA:"0X)"G1XS0,L>8*8ZT!P5H<9MI
ME0B1T,#_9F<K&>Y,UI0Z9\C95#B+OW*9HZC/-=UI;$%T3-JF"L)$X-1H4RH+
M3.QT$UV+38/P)_(]=/[OU(':>VWGP.17^@RZ2K1M@(6K2C5WK@RJ=F<T!BY]
MNT&"U493F7]W%%A4G43;%8U<]+J@&E(%OL& GZ@W>D7Q4I6*XA(_,^HH>!^<
M-V #A-R>*KBN7!619N6;\-U<\0H[B1BU:/QG@%,#)PSW/]W2>L]47HJPJJIQ
MGAN(K^-6>^C;W+WQXX.6.VQO?[*[CYW:N,3,=8 /8:?-X=*4<7% Q8SO;=PX
M=3&Z^F!K?8N>!E>U\?(M:=2??S_USS?;,?RY\-V3&SV'\=2#/AWK601_H*NE
M7H7-U]<XTW+;G]!D^\QW7IZV69[O\%D7)C(^T-1S'*_XUWNFQL;]:WORH9G?
M4\$7%S_9Z-2=)\WYX>;CJ8]Q<".5)<MK@Y=)^GHM17-^[\^PPB31EXDRJP0E
MB8H+B<NQ-&H3"J@J;47EB:[/?S$B<ZJ=MH)X@@15#D#CB6PG.?YJJDLK:?'*
MV9IUB78+@1QR0%R,X&@D!G*(=%6:$W&T+9.QG0S>C=-Z;2R'ME@H'9+]'0U;
MP&@;5Q4?<2.E6WQ"90JZFLUE#_/<Q?PU?D*&.K,AKI]J7>S!D JJ $O\&E2+
M3?*YSO2W86A*I^J<U_9^?&%#["3;_E WE4N.A+!P;87="Q[G'+D24C4A%9=.
M/=QYI!AFU#L-WE'%$O42KQNQ?V/65I4J=%@,R,39VS#L$EV<HO&;G1C&SD=J
MVD;NVLK4)O+@CKCWLP>D/Z?Q)9GG;L4^F+XH]RC1@^N"WY _JMI:#JHOM+6@
M#9%6Y[H,NR0.F[G'/7'<-D'IHH FIA+WY$'&55:V<E19F@.-7K'76Q"T)ATR
MW:[\;$N5>H5S@3R>:4NN=(B*:BO1WKO>V$=XB-%\61=58'<R^[2M2\>EA\Z=
M[*:5F<LR!F5A#(=GOABY!3%T]/J;' >EN/P[,>+28>=:.?O4L994!>:A($].
M"3/\3,[*%400)8F,_CC!6![<?[JS_>10SO+=V=K94:]^:TU<J1-;H.YLT'QZ
M4VG[2#G?&>*$WOK1N5*]!1V<5;C!J;SPE9ZZ,WCTY?V!%SOUR97R'>4*M;I2
M+\!BDV.8W%C"?9YDG;\5C5R&3WE8@*74[ Y,-6: VS2W][)[42U 5W$QPC$@
M -U(G9G /M[*S.BRT/KD6R2/0N7L?$S*,V45ZBGYCE?K:U2#0XU=(@G <@F8
MF+HS00RAFM'W?>>;60]FU.P,'G,MQV1K JBE\Z<T)#M;Y+\E1[(G8@50#UM;
M00C)W[XT 51HH# S ^4C[N_DKK"07/]@O<,_J3DUE 2+HB>E 7YP?^_)81KC
MSDVRNYW<))W;>F'PE25[K9WOG2%BAE12/45!D*1NE8H16)#;-VUX8L1M4;.2
M(ZTDT\'"N9S#QS6""$C2%I5B34F;$R.ZI/1*BAB*$5:KWUI\SFQ%1@O9BV(D
MAS-<R!/UCX;Q-&B_09<M-%SG;$TQ#HM,[BG,T516,)M!P9X1_KJ+19/1];4"
MH8XBPY?H<!K(ETW$/E@^'5C":(0VFC)R3$/RH9%)LK[J#-UWT16GZDWKBX4.
MR46D'I*_;&?K\-6[-V_XU^W#1RD<[[#'T!BF%U$S7$/)6:TEWP/CW&SB-P+5
M-O3!]OY?>E,6M+<X.<,H?T?WG[Q]IVI];NJV'HFCKVOT2I2J7%*E6UJ;<HY;
M079?DW<0,0(+"VT'.B?$2*OEF'Y/]_\B1E9!64627#656X)7=X-[*V4M*L?I
M$XTW!1!+*!D./6QX;0(YKSH=9*+(<MGXLB@HB$>Y(13GHQ MY8=\M59>']XF
M4E%!!339OL3!V=O:?GCZ2(S8%*W'<5Z88K%&$21K/BZ4I-4^]"A0T/R-AW'4
MYW*28]\Z'/$CRI(@N1F\, "[K+\(FC+. D%Y2L!%XVF/G'E7J^WQ_M;:[9*I
MIX.NM,>])+33#U P#<_ ^1+D5,@09K:)@HO4.A9R_(=$!B5&6$'*/6_;^=P3
M(S2><PR'PR.?3D Q<O<'NAB)^R#1723@EHHJR%PAPTV,L*)*3RG=&4>;7*AY
MYR+[ZIOM?2)N4@UEM),W2?U$"/$2HD8CHU3&H@5;)RX1#W/M&>3/QWN/0^^Y
M;SNNEI3S[M7/L%P'Z5][0XCQQ/@2%F@A5ZMU*GV",PSRI+]:MU9 <[3'V(]Z
M!#[C,E#V(3M-E[*C?G7^E# 'E&4!-J3N'"0Z)-Z:Q+N3_E"Z:2HCJ$2MH,-%
M4FGI;J'(F<C+A9R9/ 4B0!<CKB0_%)'BVP^MI"K:@OAW)-DW']QT<D$A$R-[
M5CS%R#M4L,4(G8M:$"?=__Q=G71FA1CYCVJ\K] C8@F8J.-*FSJP3;;0MJP2
M9]\[*.=+4YR.T"9&,\N7XS?:QY4Z6K.].C\BRW5[_'1_?[R[^]UXZ]G3W:_5
M#)64%"\J_B<IA=I&$RM!"J8@'T< 2E.2= IU[E Q @NBF])%X7PI:CJ+*NPI
MR1PFOB4YFQ1: &)D+9Q-($LYPRL(4B5IC\J\Z^\* WCFAFS9O^MT2L[P_EHM
M\Q]<YH8?A,XI_R&QOZ,\E0L4(Q<SF!VYH7K7UC45$W%MQ*L(1] 7<5D3"GHW
M]UH2F/M7V*Q].\LD>8*,Q1H@IC01K6JHIYP(IS8P)B'JV8P0_Q[.#"PO(% Z
M&DK*-,ALA51%9P'J3'M#I8KZ>85[!Q!)A'41F ]B1(6+"-)Q#D5+1!H##@HJ
MDX.ZOV]S86?*NQH[; C5T.$KJ,X1;56\N+DH3P7G)E-94CT>S12,3,Q(-W;0
MF-*$PD/&@2BA]@5WV)0J"Q$;)=%-WFDNMU!429H+KF,JF44+N]MJQ,A.6ZH8
M8>GH$"2LG($5Y\<M 541,Q44AQ'DN:9ZD&*$K2 2G%Q[.;M5SH46(Z\@JUC2
MH<M!"3;?UTYL,I\U.48H$Z+@TI-]E0JJ#,&7<[:$ ;3K3R1MZJ"8,I0,: \$
M_*)>23X%[*!BI:80ER"(#UG28LD:JAAYDX+:R,)TXA7:W%4ONY6B<I'V3ED5
M%*"6M$DGC>;.RWLK95VKI&)$'JK>S%/(:<HC#N%T<YW_&*CK?&VOI:_4G'*D
M/SMP__S[J7_^T7MR(_?V)[O[*$CC EL/!QXJ3=&\PZ4IX^* B(;N;=PX=3&Z
M^F!K?8N>!E>U\?(M'VW'\.?"=T]N]!S&4P_Z=,SY[0>Z6NI5V'Q]C8+FMC^A
M8?_,=U[NM2S/=_BLR_UHZCG:4O&O]TR-C?O7]N1#,[^G@B\N?K+1J3M/FO/#
MS<=3'^,@1JH"-\9Y-;<'$<YC_GHM17-^[VLNN/B>9NS-5%L\$I3,4$A,Q^IH
M,,0(+,@GMW*M'!K/OJBK&(E1P1$C:Z&#'("_\V)$!:Z8/9[J(.@(&BH:HYZ0
M:D 4?(&0"=M30=&18 U,%H*E+5S%+%=1GQ/V6)*')@.O>_#CW+L0QFW#I:/U
M*21H)'90PJF201C:8I&ZZFM%9%-!:Z;E"I&,42X"%@<USTV@<FF9UPSG3:';
M #WY=#C%S@BB9D$JQ6[RY.>)<+%73JU;5E#.^9-,+#<S5!/<4-5WU($;;R R
M7S=.E.AUB>L1"/.ZP2F7[\:+\:I,%N7I#JY-CL-DO)Q^IQIW*SG(]Q=RE*U@
MYISP,(7*+1E@+D9T7?1[A1B9[\"AMU36K#*(D7>AY: '0_2FB)6<P44E;6&F
M)@JR$R4=O%Q(I^6Z8RXEG.4J9/\)=9T5=944V%3'&HTM'^EU:T[GOA149WIM
MEGOVY+H@#F6TUTEA&E[96^['@X:KDT'3R%(YL82*8_#@T=P#\$N[2M#')R='
M?25HLEX[:NJ (I9H_\>>VEKW-PNCP>CYIR?JZ$Z#N96R@J^-E161$X3"267J
M^QU7EJF9#Q(Q\GK I2PITBQM(1,*V-B6])*R)8=L+B_!BA&J,SV;@2>O?1R6
MCV!'=[I*%=K#K*VJU5?LH1<SL*+83'45Y(!#1)T\R503([ @C--,T@;EVCLS
M]S;*"@3O\,Z:0HS(KWJK3X[(E9EGLBTQ,O]"M[&W4I 'Y^$/SM?J9/SL4:Z2
MMU[?Y,JMUY OSHIV[%<^,UI!K4TU4:]M<NS.C ]1E9JYV89NDB;945.& 9'A
M9*& $(BNL'1%2Q>%A!R"$/6T,F&161[9%QV3Q35P=<-Z:G[%5E?R=%.!C V$
MPF6,E*1 8$W!#^LR!*GQKC8!3>\.D:2M6E+WX"Q,3)9<)E,-DCHGZB2JG,$;
MN!MICGAF .RL]QY[)JA;$Q4B+TY<DAMQEH*RRFQ%Q 6J=B7N<*ENR](;[%$[
MN)(F:OJ.2V\F/X>83KP8#GL+C8>0"JN>P43QFD:C.R]L7L=AX=JJ3-U5%-!$
MI567]*8VUWG*YQML8RF-SMFP, W->(85XTCQ=74;6UW13.=M-R< =B4?USZH
M].R).F*:2YP$58K\^4_%!NEM%*7#A1@:*.C,$S/*#=[FY!C7@MRZ1 3[X/[^
MLT,Q$H/A<U-2'(KQ$.+.)#'RHJXB1M8.+B!G-DM:N2#/9314:,4(+0B-3HX@
MKN-))@1I6Z-D6>"93/^BQ:YR)A.:G^49EQ.Q+IHB&T_96&(;JJ\1L&&7U%K.
M4<>F.%KA>@Z);[$ON<#H4BYK@ 8]_TLN$?QB7=G@VGZO0Z80T<PF\J$-$5_Y
MA5UA[R71Y"8OE""C2^ Q)V@Z T[G@KQ?8B0FM]@3BF+(&>1TW A2S4M)-I>@
MLT@@(3^%;"7-9=*N! VR*(QG0F3/*6#5-H( &*$M" \Q:^5  Z>Z.)U[UTHB
M?A$DJP?<IT%2R<5B <4I5<J0HVUI25!F.<,JR1!$8Q_FCI!3@G1*8O(+,UU$
M1XP$C:PZFH1P$R,L!17(U\'1&6.S7^MKA<R>R!F76HRH9^#E1/1ZXA<Q$DM"
MGDDJ?2E)"?3TNQAIB8,8/*&_Q8B\R4]]"\3>NB9TU#?.WXY0U_4D/IK-M/%R
M1OC!_=VGMP'L?CUI?P0+7M\&G]-UUV]K ]P&>:^+[)]K:_Z]9ARLG#NE@VJI
M/?,6+IWG+#?&'%+&54Z5&M[8)V]5SL['A+!6.;SRNV;OQXM\W3R&[IVQ!7BH
M5J,_LQ0/[N_AT/!/]1*'#"KU.@_8RS7P\\\H62?-MR3'U#\_?O6:I_#Q @^D
M>IW3\'7+=G5IMQ]Z)^F5E<2I2O9TE;,? =6L_?69].<3-[V_A((T)RI<R*1@
M=!4MPKG5L?7 ,BJE-N8S3/&6A7H/%8ZW^IW_;F<'_:SKOF^&_]WU#>T0\<J^
M4>J_6POJZ4CM;.WL_%[?;/;0E]SA_J^#EA]R\S5$'T]=N<)_%K&NGO\O4$L#
M!!0    ( ,Z HU;J1[,U$#4  $!K 0 >    9VEL9'$Q,C R,V5X,3 U,'-T
M;V-K;W!T:6\N:'1M[7U;=]M&MN;[_ H<]YP^TBR*UL67V$YG+<56$O4XLL=6
MDCE/LXI$4:P8!-@H0#+[U\^^5:$* "G)MD**=J_NMB2"A;KM^][?_OX_7KUY
M>?[?;T^2:37+DK>__?CZ]&7R8._APS^.7CY\^.K\5?++^:^ODT?#_8/DO%2Y
M-94I<I4]?'AR]B!Y,*VJ^?.'#Z^NKH971\.BO'AX_NXA#O7H85845@_3*GWP
MP_?X%_A_K=(?_L?W_[&WE[PJQO5,YU4R+K6J=)K4UN07R1^IMA^2O3UYZF4Q
M7Y3F8EHEA_N'1\D?1?G!7"K^O#)5IG]PXWS_D'___B&]Y/M1D2Y^^#XUEXE)
M__' 3)Z.GXQ&Z=/][YZ,'SU[?/2=UI,C?7AP\.PH??I(/_U_!S#)A_ X?\=6
MBTS_X\',Y'M3C>]__O1P7KVX,FDU?7ZPO_^?#Z+G*OVQVE.9N<B?TVSATTF1
M5S"+$D;E'SN#+_F2^WA<9$7Y_&_[])\7^,G>1,U,MGC^7^=FIFURIJ^2=\5,
MY?\UL' L>U:79L(/6O-O_?S@ &9,OU[)$F"<S.3:+>G@$-=Q\G]_.?WQ]#PY
MV!\^WH\GNVK*8]AS77[Q.1_>:,X_G[X^.7Z5O']Y>G+V\N3](#D]>SF\R4:O
M==9PA0^3D__SV^GY?^.$3\[.3W\_2=Z^/C[;\*F_H&FD>ER4"HG_>9VGNL2G
MX"A>O_GQ^'7R_OS-R_^=O'E[?OKF+#G^^=W)R:^POF3IPF:JO #BJHHY3R%8
MZ)^UK<QDL7$K?7?R\O3\^/7[FQQ6O(8;\ $#[\F9R]SYPA_UWLYC3T!__=M?
MS%6: OO?R_2D>G[X:'CT"/?A?*I! LSF*E\D,V7R"OYGDPK^^K/)@,LG[\=&
MYV-M@0'DXV'"!/:OVE0+_ -LJ+G4R=M,Y<F.XB]:-=,PUB(9Z01^A%U/!_3!
MW__VW>'A_HL[W@,:\;FIX):,;\ Q<.KK.Y4'/]"F'+S8329%2;LTK\LY"/6D
MF"3SLK@T>&B)<5L-6UPDJJI*-:X&2:GQO!*5I\FL@(]!RB<:J,.,,IV<S.99
ML=!X=*],J<=545IZ]&61VSJK5%[9Y1R]EWNLGX1^W!P2>LST8VSR<U:,5):\
MKXKQA^3-'+E:<GQ1:DW:UTZ%S\CE/]ZLVR^37"<!5)X"8)?T1SVN454%*K U
MW%"X[@.ZM/ A<"?B)D@"8U66BZ2HJY!F+! -LQIB2$ 9XR+/X>;C@5R9:DJ?
M";O#UQX\?6&3BQ+? ^0&7RGX\. %-(HJ*S,V<_S<Z@I)%,88Z:RXPE/=4([&
M%U#K3>!J]XZ_O-PP_O)2S>G@_XW77I<SF^0%7%:X?.65 2F1Z@F,DN)=)S;3
ML)VI L&,EW2F50ZCVN *T]-,);<\H?7KCP]^.'OSQR Y_^7DW<E/;]Z=K/.:
M#Y*[>7O;K%S".>$(U[EZ8:3KW(($Z$"/%LS#4;M9ZX:P]%CK?HCD<C(@R4$#
M3T5DU?."Z7Y29/ [ZI5K%?S(SM:Z6:A7@(:0DKO-_OUOC[][<6-N&/'J1\/'
MO0SRKY=J_1SSX"^2:KWV?BS5#INM6N+M<.K8FSNDIIO=T&$2F,<;Q.: R#V!
MJ[72\%F1@WJJJAJ,RT5D *V;"X)),)XJT)#L5)5D&:Q;5LZ ^](.K75KB-(:
M&VG3S9AU[I4S8@:)K4=_@AGII.LWJ=E(S;95$=H@PT]R3J\U@"#N]9_?'9^=
M)^_?GKP\_>GTY8W\T=&T5[NC9?&CHJJ*V?,GI!94"GUV\L"H*(%*]V#1F9I;
M_=S]\"(U=IZIQ7.3T]3I2R_BX5"\7FIT7*A,ID:SY(^;^-IPGV-L%4RT2MV;
MY>,A??2P2KN?'>T/GST^6/KQ_G#Y9ZN&??)D^-VC9S<:]B%-F:<-.V-!.O_C
MP=$#]P71-YX?SC\F!_'50A6DLSG%?./B(&?H0O<JD-:Q:BK[<S^6WL]$7FFX
MXFJ:G.MLUOC?OY+390WWE:JV[US_66>+Y/#Q@.)$7]FQGA>@VB1G]6P$"I8G
MWN0]Z9];=]*/OAL\.=P/M.L^#?<K.?F3C[H<HS?V;6G&>IM.^7\^V1\^?9S,
MX4;327]E!_N[MA6ZR=Z/ISJML[OEUZ0EKN.0WS?6S1J#'RN.X:TJU46IYE.;
M/%JG[46FSV9NT>/UAD$:GW-R9;(LN03"H=T:P6Q!E]7,(<G&458<T"P4DQVS
M"RK#?Z(,"89Y+X)%/-:FI %S Z1C%89^^>E&EZ+7[1@8[,EPZ7#_JE4)5AHH
M*1A!TVI2D3.D+.J+J;C&:S1E5[YI@):N5N-I,E96=[P#C=(N >:7L($FKXO:
M)N]U>0DBPK^21KD4+I/"V&V3^2MAM"<?YX;_NO5Z\5&/7OR0#/D>3X$,\N31
M\#N,.12<&?R\U)G";*"EV;+B"]AOOJ)&MLCJ:OE7_GH/3/]6'73<)DM=*N'_
M3\OF4ESHO1$0]X<]HN_G*KM2"_O@5FG'U[QSE3/GQ;T.%1W>HU"1\/9S7<Z
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MHV$7^4\3B7+A71+NZ,Y#'BFQ6.9P ]982SW/U!B>8[$//!F^6LQ8_]D#G<:
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MCA<)_AV(;RI<25"_%-^5/L>)<_*H9I &U+5D]P2[/**AJ+ ,!8!V7K)X8,X
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M<*QR0>*8(R# V/6J9ZL)D7^!?VV1L-D<@#,0-D\(Z\WT'9N@"0/_*0D7!=0
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M!^F6Q,@[K=[,[^.N-5MQJ?/-N=1>207M<JK+%1I"WA\9\H(76_9DNFD!"HH
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M!S^TREFX+F5Y8O/R@#&R>EN3/("OL+HIOSC#XR2_P)8.228G3KK.5'!<ZBR
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M<F^Z00YB@\(LZ4]Z4N%,PB8M*MA L!M'M*?@0Q >=-AQATY4GB^CK"K]+5W
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M$ZQL=+[?3V8ZKI*O*Q"W=C@\*;"]+;;&VE"7N5K,BNC!5HUV=.&&.46/MA\
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M<?J'1T]/:^45[X@=.L0Z_+"KML/&2W42G#0L"R(+QYDM#:,"@WR4MAFA-9.
M&0N3CC]G^:5*88"-?)%LJ!*V*'?_IK)R:PYPJ+#*Z5MPZ[G.+S79Q"#4#'?
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M#\TN#*C2X#PY,I*2.<IT,ZD=3#<[X[1G>>A>UAN+-Q<TV'W2FE[2&%^H<":
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M&RG*12:E(DC\U?%4%(J2L[EVIYXL6;)<B(Z!ZQIT2E4-PGF!E 5>Q>SNK/4
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MS*VX=,-)X;VR)9E-X;^"@X#_6&:EB7[1LUQ]SLP,: _T054(E1:\6_<KB4A
MF7*$V@?SB":.<(C/;\WK[OIR7B"+VJ8K>FO>ZNR?;T?1SX1<=DC)]O+=)V5T
MIPWOM.%G:<.WI^\NSE^>OSU]<]$^0'>*\)6&4Z!FT85.X+X[*3S_8KIPW8KV
MRM/! /GZ .B?"TP7D3T8CW@UNKB&?#"4P18:=G1[MA@I&S/F@!AXK+9!)P?
MT-V\Q-BX!WGJQZ($E'W:SZ#4:=G>.[2R)*=!EL3G\5Z3^6ABR@A*C'SE.EXQ
M2(D3&J:>S362W^)79RHFG)BK=Z<0FE<3RLW"N :M2@N-U2&&B[H:RQ 0D4\K
M7*B 82A)_$14<TI]V/2-]_-?,=#VJ#_0=G^<Q4OXSZR<)R_^!U!+ P04
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MS:I\!H9(E(VC69Y=FQCM#&.G&J8XBU19YFI4#J)<XWI%*HVC:08?@V42:=B
M9ICHZ'PZ2[*YQJ4[,[D>E5E>T*6G65I42:G2LN@7LANSMW]8L+=-$;W719F;
M$9IL'\IL]#'Z+35E='*5:TWVW$Z)5ZWEUG2#7(O]";.D/^E1A3,)>[2H8/_
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MTQ>OHF57;J9B5"][B1[#FY#'N Y'H7MU#_?_FA7M-!.#F3HZJJ>JQU;.<?U
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MS4P>:#2/'>G$'B7\^!W/2PB26O*!.PQ>[&9R"4&8NU^*M+7P"U^N>WD(BOZ
MW0@C&&D=%[O+5-!LJ\!8(XEQN(_3]>BU!R>^\TIN,/[XZ4-UTT-UT]>I;KJX
MO^JFBXN_!DZ[%:[1NI7@DC46>-3$S\!>]<#SI&NG*&;JG <_:!D_J NCB>$R
M:Z[TA7F6"BN$9;P-,T4,H#"8 ;=%5F]:0[F.T9D>'!/-5"*<KG.<=1@(QP4V
MFIA_8!;+!1;E(3?EK)('"6L!8ADKVGK++NN8_3R6$3V/7R)#/9QW,(,?'H!,
M<O!=%%ZA@%HO5<(> 6R;5>YIF%9VT;T"'Y+C+A#JXRUJZ][BB*EHKT90]!'A
MX74M4OL-HZU8*:531WBUVQ$;U!4Q7V25N9 \)9&IR03=[R&MZJ&]-R*MNC9U
M7Z$P[HA9^,T: FS#" 3\$/NBQ]H%0PBLH*XE,R3H" ^1$?(,V?C\DX/O3FKE
M%6]+6=?:%=FCEQ_T3780<RGR@3. U35DXCB[I6%58'2/\C78K'V4@!T+DXX_
M9_F52F& C421[*@2Q!OW=Z9Z=6L/<(RPRNE;<.NISJ\T&<4@;@QWYX!=![]<
MPT\6E4U7%SJA>]4]#?AW:A4 TA4'CH\-2H<*T&[;6N?R;(, $2'Z:^7M:K>%
MUV/],!&_2FL=/K56F72 S,D'RKQ06&>JW!=?84MR#E;C5_$V*(-0/4U4,FZ8
M6XA@P+9+8VKY'.WPB 2-@=EL!!/F66I&A-/;;6?5"7LOC+<U-+9VC)I^40 1
M# &.72S2-@R[&KQOS8AANR)AOH_68"G\)1G$BS&86W'4UC #?QMW_[H[<RNF
MI*<(3*"7T*+H2Z37/-)-E)&-E)!EC'CB!'LMU3V'+NJX^B":V 9$]"V4%&.*
MZ/OGW,E$+&<@D2@H>8H!9VA3I<TVIX$H]5-M]3BY;[J'E_>JA&L97-R*T]ZE
ML0\:I5&I)G<666IA('F&LX3%/#>IO3"%*V$>$7#-00TD(,II+L'&O,Y,W*HT
M4*W9>8A9WX_>OFS,?$]3A7#'>_%1HG@R].T&>15JSS#+C*A"N$&C/Q 7B(AG
MFNLR:U;RPWTM&;:%Y%EVI*W8%&OI/^(I%0K-#L\P&Q*-&-D9(!T8)L*Y9*QC
M1-+J:)C%<XQ<DL2IP.3)\5Y"=MW8*RS%G"BQNTX(L=W^I."U=)_#KP7E#0NV
M+.PPHZ7PPSY2;@%[5]ZRJ^P7><#JTY%[K>]T^'#EU4*1H>:FII@HO[Z; K8\
M?=J2A\J0FDH".40,%5 A]0B=ER'J(3W&L&WAKP-<'3QU6UW?YQOD^K8LX@<B
MA^US>P/W;_0QS6ZH=2:#N#%:=@5"**&HE 1);=\%3Q+E36<JI+816A\"?6+J
MV'9I(:2S7SB*?UC+7N_G3&6T4NR&[?9.$8!2?=1MYAY>"Q2F[1Z_N2Q)6!N?
M=^9W9O9OW$<Q=9AT4F#4J".9-]IH>/=A>[]*P(RG4G*GH<8R.A+U[2$:CEAP
MEYRB<V1<?%L8N2%>CM.!!"*:K7"I7^!J<"D$GNBDI;%ET]J5;1 9C;G#0?M(
MM"Q$_R:4!)WBTJ280Y_!:)$<JN0\@K!@P=+!*Q=RM.PYJ#M>R#GKF!Y*DJ<2
MP9 R&1@$K[\/30^;V6IN9C2HD==YPUGROMAT9#RH74C"L,MI^X4W\@I/K.%A
M(U/81#=OY'QI6P2VTD.^T"LC?,@7W@F;,-%^%VH_M%DP>K$=(. > ZY=F1!Z
M@(<X-;A!&7R" 0".I*1HO\*K2N48?%YGB2Q$VX%=Z RZ'M+M,\NPF[AB.QWL
M?8:Z=TK!4**V)04^930AC\$FF<R(Z%E*]4E:$-1M7%HM7+A-$S( ^8YRIT"B
MP#A!:#!2[G,"ADU=[BI'B;(0H\2.@)!Z7Q>>TMFUH?!<BRQ!!T8&R5/ %?[=
M<[1P\-MA;:YAY-?S%FUF@F+R@U:T!4,IR#7-CO>_A8S*\[?=-_'O[?5=0((E
M,4,;#@TRS5Z4\;,BC'7O>!QZAGBVD0.FU6,D3'J,@L)7@#6 (9@C^\5!6'=8
M^.]$8<GPO9PJ5M$,_&V7]O!2-U(HVRYFW7'5IS4EDM/,F"+;#<MAQ>JRP*+V
M<JRO;<^+XX_X%PV3M-(TK[7U!]A4#9VO&E#7'FC0Z+PHJ%\6BK_X&IO(.'(+
M[,J58$2*+5&D? OL89>)B?4(RX?1B*3P38-IA.+G")_,TBNX;04W0C#%PA$&
M9<GMF&I(JX,OPRTL!(_L*=D>60Z#A,\+2U"/0(JKA2/J*2(:<( 6E*1ETJ*D
M@,3\+)&ICUFDQ"?6O+<2&PLPN%@3V>1PPVHS[R:-H^V\&$G3N'YH/$S\QDS-
M[5LO3&MNA6I;OSS$Q7BI0UH5.O:@X%UZR\*S2;TA3QK&IOV=ZG1,-,RSCSK?
MBS6H'PGNB@=MRM*6Y8NB65!W_GPGW@U*S]NLO@.\TW2&^ 'R^]#HPE@N#<Z3
M(P.I@B2\ K/^P72S*TY[EH?N81>P'G=&@]TEK>FE_O&%"F<"**'+2P4^0$#P
MH:3\78QY+J) C2B('T(!I 3,,RJ(N ^LQU')0I9G%+\F5 6DSVZ?9P)W<6RL
MJ#\3L'RB71$:''U->I)OB<358RWC8 ?;.[PCV$Q7*(/"MR!;Q+[D\FB&GVUP
M'H3WG5ZH9N^C*>%6GZB5,-S!87N^A0FY\WR%5!LE352&81@_/I!-HPQ> NOW
MKC(8K0L4V@!"F+6PKAJ'4.H1RVGSE9H5X0C9L_PAN"P3,R3:KR13MI:EQGL>
M.5FL\J%*=;'WZZ=$SZ,3]MZ.#@Z.MD.@KF$.[R+,VKF$JCB02QY,3P#>8B8%
M/ .M@O)Z*XV520I/0BCZ"@F>MKA21>V?#N==P+ PE@X^;;_A15(STH;D!!&^
MC>50-5D.'0L-FGDT4_4\"![:'>8.Q=#?8$A+ I-E)M8(,1Y6U-6M<LAI@.[V
MAT3$.N^K.R@T]BPH43!J3)B&A48!OSZ\1ZYKR"W<<%QAY*>I#VQEQ&W^"_>N
M\ETX%GS\/=*"++YO%(8XO*%Y+Q)B:FHD31,^TU&O@9HQSQ&B3/[G<NJN9@"Z
MJ[;8"IFV;NU*^L,?2\8P.K&9?IT;L58Q#K-T7(YV=X7;MQ$44.5#L-V'J#\$
MV^\R74&]34]@Z#:9,ZCI3IBVP=^>C9(>AMN4KKC,7EMDSE,>^.Z&!SU&YSXX
M!YY4547#XFA@D?LT\W:(R_'ZB,LG^P?'37F)T?[EP_N$N6//@E:YWGB(-I]6
M4^(YKTAI!MN!]FM1D\Y[W_2O0S,DZ&HQ59_HMM[U=(TPV+1LF3!7XA@71M@Q
MQ[<[\;5==QSX"<T8F]!"!VG/A89JYCXZ/SMTG-#8:!/!>W2*ID&W;\F4T%3F
MIV' HCFB0NN/]7#(_.'X(AXO"Y8S%D5,C[1T:^1B[7ESV;Y[(ZDSPVHO3!/5
MA07M!6>#-'$FD(].\,8TCSS^Q!XHP%:<YJOU.<U+-JX(8=F-9F)^-%5]"H I
MB',GT#L?R6Y3RM]/0]V+"NG 6-C@+=YK)P3V<K2@L=.P2=INPP^3M*](%!$Q
MCL_?LM41-H;.27%+!+#-7I H4(,!>\%B9I<@#50+.QD:E0LL_;(MM'^C]4AP
M&(,L$@EOO\8JI.J2@QFH_K A1SALPYA2HB0@4YC>V4.A6$:-SYV304=<%&1E
MD=EX: L9/!!JI*$>9P(+N.M2^?T%>D8ECG-3L*FVHVQ(M\4NQWXW-[F'$'?Y
MX[:PD*SY<KBO$MA_J7!(A75T2T1*?$# @N'?36+<Z166C0S\I=8J@[;#$O>-
M($%[OE*M]N@UI>(\69:EM;W1K"9RM25>+Y*&\ SL2=YM4Q+^'N7 \>'1X<ZU
MTR?$.K"=T/@7&P2-?Z/5M:9U.N$0W8IKPG]L]'["C>:RP=<J-\C.8HV8CH/?
M*%5N-!?M$[)HJOL]1U394H]A]IS[@791R+%Z0:0=SF;=><L6N6@B$!J[B"CW
MN"\%*]S3W[5-VFI#772_021]!\,3[/?O$@WP%1OA!KC N[; C7B9@RJAFA>%
M$F?SNQ$8K[,'L][%$E*7Q8YYQ^;C)D2UI>I.GSVFXRQWI%D<Q0+]KS63(Q8V
MYD_U4(B3UGE!GF_G4=@)N98*="*"&V$U6ZK@XUBW[^"WWNM_YFZ;;'.HYYE
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M;+_ [3-P**L44;/U0P:V[G2L0?IRO 6_9LD!WV:$Y4VQJH)0G.$8!U)L*V@
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M,A\,(T!OK@2A@Z.%Y<1:W )9U!T09+@1J_ !4(I'*E-N225CW[($9A]I'\2
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MSL\0N\C%C@N,QX08<!!<H0E.I/@55MA#@H6'V.>*%0;ELADF60:X#'5C@>!
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M;&0M,C R,S S,S$N>'-D4$L! A0#%     @ SH"C5AZK?&3>*0  4;,! !4
M             ( !D^<" &=I;&0M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( ,Z HU;^B&OO%6(   PL!  5              "  :01 P!G:6QD+3(P
M,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    " #.@*-6/9E^:!__  #YCPH %0
M            @ 'L<P, 9VEL9"TR,#(S,#,S,5]L86(N>&UL4$L! A0#%
M  @ SH"C5GZTTQ,WG   K?$& !4              ( !/G,$ &=I;&0M,C R
M,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( ,Z HU:F'QPCB3,  (54 0 >
M          "  :@/!0!G:6QD<3$R,#(S97@Q,#$Q,C R,V5M<&QO>2YH=&U0
M2P$"% ,4    " #.@*-6%V:HFQQ'   K]P$ '@              @ %M0P4
M9VEL9'$Q,C R,V5X,3 R,C(P,C-P<W5A9W(N:'1M4$L! A0#%     @ SH"C
M5@_ZIIT22   &0X" !X              ( !Q8H% &=I;&1Q,3(P,C-E>#$P
M,C8R,#(S<'-U86=R+FAT;5!+ 0(4 Q0    ( ,Z HU9 ']&^"SP  *J% 0 >
M              "  1/3!0!G:6QD<3$R,#(S97@Q,#,S,C R,V5M<&QO>2YH
M=&U02P$"% ,4    " #.@*-6D74[X]\F  !YM ( '@              @ %:
M#P8 9VEL9'$Q,C R,V5X,3 T.6]F9F5R;&5T=&4N:'1M4$L! A0#%     @
MSH"C5NI'LS40-0  0&L! !X              ( !=38& &=I;&1Q,3(P,C-E
M>#$P-3!S=&]C:V]P=&EO+FAT;5!+ 0(4 Q0    ( ,Z HU9&A3$O:3T  (*<
M 0 >              "  <%K!@!G:6QD<3$R,#(S97@Q,#4Q<G-U86=R965M
M92YH=&U02P$"% ,4    " #.@*-6Z<QRRU<]  !UG@$ '@
M@ %FJ08 9VEL9'$Q,C R,V5X,3 U,G)S=6%G<F5E;64N:'1M4$L! A0#%
M  @ SH"C5ILVD]*^!P  P!\  !X              ( !^>8& &=I;&1Q,3(P
M,C-E>#,Q,6-E;V-E<G1I9FEC+FAT;5!+ 0(4 Q0    ( ,Z HU;;7U/UFP<
M .D=   >              "  ?/N!@!G:6QD<3$R,#(S97@S,3)C9F]C97)T
M:69I8RYH=&U02P$"% ,4    " #.@*-6D(C [*4%  !Y%@  '@
M    @ '*]@8 9VEL9'$Q,C R,V5X,S)S96-T:6]N.3 V8V4N:'1M4$L%!@
0   1 !$ S@0  *O\!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
